<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Nov 14 02:19:07 UTC 2024 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:orka="http://www.orukatx.com/20240930" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"><b>As
filed with the Securities and Exchange Commission on November 14, 2024 </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>Registration
No. 333-</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 2pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>UNITED
STATES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>WASHINGTON,
D.C. 20549 </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>FORM&#160;<ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-22658">S-1</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>REGISTRATION
STATEMENT</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><i>UNDER</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><i>THE
SECURITIES ACT OF 1933</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-80"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Oruka
Therapeutics, Inc.</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(Exact
name of registrant as specified in its charter)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;<span style="font-size: 10pt">&#160;</span></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center; width: 49%"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-102"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>36-3855489</b></span></td></tr> <tr style="font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State or other jurisdiction of<br/> incorporation or organization)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S. Employer<br/> Identification No.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>855
Oak Grove Avenue</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Suite
100</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Menlo
Park, CA 94025</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(650)&#160;606-7910</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(Address,
including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Paul
Quinlan</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>General
Counsel and Corporate Secretary</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Oruka
Therapeutics, Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>855
Oak Grove Avenue</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Suite
100</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Menlo
Park, CA 94025</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(650)&#160;606-7910</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(Name,
address, including zip code, and telephone number, including area code, of agent for service)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><i>Copies
to:</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Ryan
A. Murr </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Branden
C. Berns </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Gibson,
Dunn &amp; Crutcher LLP </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>One
Embarcadero Center, Suite 2600 </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>San
Francisco, CA 94111 </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(415)
393-8373</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Approximate
date of commencement of proposed sale to the public</b>: From time to time after the effective date of this Registration Statement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">If any of
the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities
Act of 1933, check the following box.&#8194;&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">If this form
is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box
and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">If this form
is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">If this form
is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; width: 41%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-299"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="ixv-312"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-328"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.&#8194;&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>The Registrant
hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant
shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance
with Section 8(a) of the Securities Act of 1933, as amended, or until this registration statement shall become effective on such date
as the Commission, acting pursuant to said Section 8(a), may determine. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1pt solid; border-bottom: Black 2pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>The
information in this prospectus is not complete and may be changed. The selling stockholders named in this prospectus may not sell these
securities until the registration statement filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) is effective. This
prospectus is not an offer to sell these securities, and it is not soliciting an offer to buy these securities, in any jurisdiction where
the offer or sale is not permitted. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>SUBJECT
TO COMPLETION, DATED NOVEMBER 13, 2024</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>PRELIMINARY
PROSPECTUS </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_001.jpg"/>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Oruka
Therapeutics, Inc.</b></span> </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>8,719,000
Shares</b></span> </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Common
Stock </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Offered
by the Selling Stockholders </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">This prospectus
relates to the proposed resale or other disposition by the selling stockholders identified herein (the &#8220;Selling Stockholders&#8221;)
of up to (i) 5,600,000 shares (the &#8220;Private Placement Common Shares&#8221;) of our common stock, par value $0.001 per share (&#8220;Common
Stock&#8221;), (ii) 2,439,000 shares of Common Stock (the &#8220;Private Placement Conversion Shares&#8221;) issuable upon the conversion
of 2,439 shares (the &#8220;Private Placement Preferred Shares&#8221;) of Series A preferred stock, par value $0.001 (the &#8220;Series
A Preferred Stock&#8221;) and (iii) 680,000 shares of Common Stock issuable upon the exercise of pre-funded warrants (the &#8220;Pre-Funded
Warrants&#8221;). Subject to receiving the requisite stockholder approval and certain beneficial ownership limitations set by each holder
of Series A Preferred Stock, each share of Series A Preferred Stock will automatically convert into an aggregate of 1,000 shares of Common
Stock. The shares of Common Stock registered by this prospectus are referred to herein as the &#8220;Resale Shares.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Private
Placement Common Shares, Private Placement Preferred Shares and Pre-Funded Warrants were issued and sold to accredited investors in a
private placement (the &#8220;September 2024 PIPE&#8221;), which closed on September 13, 2024. We are not selling any Resale Shares under
this prospectus and will not receive any of the proceeds from the sale or other disposition of Resale Shares by the Selling Stockholders.
Upon any exercise of the Pre-Funded Warrants by payment of cash, however, we will receive the nominal cash exercise price paid by the
holders of the Pre-Funded Warrants. We intend to use those proceeds, if any, for general corporate purposes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Selling
Stockholders may sell the Resale Shares on any national securities exchange or quotation service on which the securities may be listed
or quoted at the time of sale, on the over-the-counter market, in one or more transactions otherwise than on these exchanges or systems,
such as privately negotiated transactions, or using a combination of these methods, and at fixed prices, at prevailing market prices
at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. See the disclosure under the heading
&#8220;Plan of Distribution&#8221; elsewhere in this prospectus for more information about how the Selling Stockholders may sell or otherwise
dispose of their Resale Shares hereunder.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Selling
Stockholders may sell any, all or none of the securities offered by this prospectus and we do not know when or in what amount the Selling
Stockholders may sell their Resale Shares hereunder following the effective date of the registration statement of which this prospectus
forms a part. Discounts, concessions, commissions and similar selling expenses attributable to the sale of the Resale Shares will be
borne by the Selling Stockholder. We will pay certain fees and expenses (other than discounts, concessions, commissions and similar selling
expenses) incident to the registration of the Resale Shares with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">You should
carefully read this prospectus and any applicable prospectus supplement before you invest in any of the securities being offered.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Common Stock is traded on The Nasdaq Global Market under the symbol
&#8220;ORKA.&#8221; On November 12, 2024, the last reported sale price for our Common Stock was $26.10 per share.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>An investment
in our securities involves a high degree of risk. You should carefully consider the information under the <span style="font-size: 10pt">heading
&#8220;<span style="text-decoration: none">Risk Factors</span>&#8221; beginning on page 6 of this prospectus and any applicable
prospectus supplement. </span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>We are
a &#8220;smaller reporting company&#8221; as defined by Rule 12b-2 of the Exchange Act and are subject to reduced public company reporting
requirements. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Neither
the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>The
date of this prospectus is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024 </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>TABLE
OF CONTENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; width: 91%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 9%"><span style="font-size: 10pt"><b>PAGE</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_001"><span style="font-size: 10pt">ABOUT THIS PROSPECTUS</span></a></td>
    <td style="text-align: center">ii</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_002"><span style="font-size: 10pt">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</span></a></td>
    <td style="text-align: center">iii</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_003"><span style="font-size: 10pt">PROSPECTUS SUMMARY</span></a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_004"><span style="font-size: 10pt">RISK FACTOR SUMMARY</span></a></td>
    <td style="text-align: center">4</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_005"><span style="font-size: 10pt">RISK FACTORS</span></a></td>
    <td style="text-align: center">6</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_006"><span style="font-size: 10pt">USE OF PROCEEDS</span></a></td>
    <td style="text-align: center">35</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_007"><span style="font-size: 10pt">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></td>
    <td style="text-align: center">36</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_008"><span style="font-size: 10pt">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></a></td>
    <td style="text-align: center">49</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_009"><span style="font-size: 10pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></td>
    <td style="text-align: center">49</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_010"><span style="font-size: 10pt">BUSINESS</span></a></td>
    <td style="text-align: center">50</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_011"><span style="font-size: 10pt">MANAGEMENT</span></a></td>
    <td style="text-align: center">84</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_012"><span style="font-size: 10pt">EXECUTIVE COMPENSATION</span></a></td>
    <td style="text-align: center">90</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_013"><span style="font-size: 10pt">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></a></td>
    <td style="text-align: center">96</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_014"><span style="font-size: 10pt">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</span></a></td>
    <td style="text-align: center">98</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_015"><span style="font-size: 10pt">SELLING STOCKHOLDERS</span></a></td>
    <td style="text-align: center">102</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_016"><span style="font-size: 10pt">PLAN OF DISTRIBUTION</span></a></td>
    <td style="text-align: center">111</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_017"><span style="font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</span></a></td>
    <td style="text-align: center">113</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_018"><span style="font-size: 10pt">LEGAL MATTERS</span></a></td>
    <td style="text-align: center">117</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_019"><span style="font-size: 10pt">EXPERTS</span></a></td>
    <td style="text-align: center">118</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_020"><span style="font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</span></a></td>
    <td style="text-align: center">119</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_021"><span style="font-size: 10pt">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-1</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ABOUT
THIS PROSPECTUS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">This prospectus
is part of a registration statement that we filed with the SEC using a &#8220;shelf&#8221; registration process. Under this shelf registration
process, the Selling Stockholders may, from time to time, sell the securities described in this prospectus in one or more offerings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">This prospectus
contains information that you should consider when making your investment decision. Neither we, nor the Selling Stockholders, have authorized
anyone to give any information or to make any representation other than those contained in this prospectus. The Selling Stockholders
are offering to sell, and seeking offers to buy, our securities only in jurisdictions where it is lawful to do so. We have not authorized
anyone to provide you with different information. This prospectus and any accompanying prospectus supplement do not constitute an offer
to sell or the solicitation of an offer to buy any securities other than the securities described in any accompanying prospectus supplement
or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is
unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement and any related free writing
prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may
have changed materially since those dates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In this prospectus,
unless the context otherwise requires, the terms &#8220;Oruka,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221;
and &#8220;our&#8221; refer to Oruka Therapeutics, Inc., a Delaware corporation, and its consolidated subsidiaries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">This prospectus
contains trade names, trademarks and service marks of others, which are the property of their respective owners. Solely for convenience,
trademarks and trade names referred to in this prospectus may appear without the &#174; or TM symbols.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">All references
to &#8220;our product candidates,&#8221; &#8220;our programs,&#8221; &#8220;our portfolio&#8221; and &#8220;our pipeline&#8221; in this
prospectus refer to the research programs with respect to which we have exercised the option to acquire intellectual property license
rights to or have the option to acquire intellectual property license rights to pursuant to those certain antibody discovery and option
agreements, each dated March 6, 2024 and subsequently amended and restated on March 28, 2024, by and among Oruka, Paragon Therapeutics,
Inc. (&#8220;Paragon&#8221;) and Paruka Holding LLC (&#8220;Paruka&#8221;) (the &#8220;Paragon Option Agreements&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>CAUTIONARY
STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">This prospectus
contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). These forward-looking
statements involve a number of risks and uncertainties. We caution readers that any forward-looking statement is not a guarantee of future
performance and that actual results could differ materially from those contained in the forward-looking statement. These statements are
based on current expectations of future events.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">All statements,
other than statements of historical facts contained in this prospectus, including, without limitation, statements regarding: stockholder
approval of the conversion rights of the Series A Preferred Stock; our ability to achieve the expected benefits or opportunities and
related timing with respect to the Merger (as defined below), our future results of operations and financial position, business strategy,
the length of time that we believe our existing cash resources will fund our operations, our market size, our potential growth opportunities,
our preclinical and future clinical development activities, the efficacy and safety profile of our product candidates, the potential
therapeutic benefits and economic value of our product candidates, the timing and results of preclinical studies and clinical trials,
the expected impact of macroeconomic conditions, including inflation, increasing interest rates and volatile market conditions, current
or potential bank failures, as well as global events, including ongoing military conflict between Russia and Ukraine, conflict in the
Middle East, and geopolitical tensions in China on our operations, and the receipt and timing of potential regulatory designations, approvals
and commercialization of product candidates. Forward-looking statements generally relate to future events or our future financial or
operating performance. Forward-looking statements generally relate to future events or our future financial or operating performance.
The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221;
&#8220;anticipate,&#8221; &#8220;predict,&#8221; &#8220;target,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221;
&#8220;should,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; and similar expressions that convey uncertainty
of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain
these identifying words.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">These forward-looking
statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing
environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the
impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements we may make. Factors that might cause such a difference are disclosed
in the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results
of Operations.&#8221; You should evaluate all forward-looking statements made in this prospectus in the context of these risks and uncertainties.
We caution you that the risks, uncertainties and other factors referred to in this prospectus may not contain all of the risks, uncertainties
and other factors that may affect our future results and operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In addition,
statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements
are based on information available to us as of the date of this prospectus. While we believe that such information provides a reasonable
basis for these statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have
conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors
are cautioned not to unduly rely on these statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">All subsequent
written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety
by the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly any revisions
to these forward-looking statements to reflect events or circumstances after the date of this prospectus or to reflect the occurrence
of unanticipated events, except as may be required under applicable U.S. securities laws. If we do update one or more forward-looking
statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="font-family: Times New Roman, Times, Serif; padding: 5; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<a id="a_003"></a><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>PROSPECTUS
SUMMARY </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>This summary
may not contain all the information that you should consider before investing in securities. You should read the entire prospectus carefully,
including the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations,&#8221; and our consolidated financial statements and the related notes included elsewhere in this prospectus,
before making an investment decision. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Company
Overview </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Our
mission is to offer patients suffering from chronic skin diseases like psoriasis (&#8220;PsO&#8221;) the greatest possible freedom from
their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. We are advancing
a proprietary portfolio of antibodies that were engineered by Paragon and target the core mechanisms underlying PsO and other dermatologic
and inflammatory diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Our co-lead program,
ORKA-002, is designed to target interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis (&#8220;PsA&#8221;),
and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology
with the aim to increase exposure and decrease dosing frequency. We believe that our focused strategy, differentiated portfolio, and
deep expertise position us to set a new treatment standard in large inflammatory and immunology (&#8220;I&amp;I&#8221;) markets with
continued unmet need.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our principal
executive offices are located at 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025, and our telephone number is (650) 606-7910. Our
website address is www.orukatx.com. Information contained on, or accessible through, our website is not incorporated by reference in
this prospectus. We make our periodic and current reports available on our website, free of charge, as soon as reasonably practicable
after such material is electronically filed with, or furnished to, the SEC. No portion of our website is incorporated by reference into
this prospectus. We file our annual, quarterly and special reports, proxy statements and other information with the SEC. Our filings
with the SEC are also available to the public on the SEC&#8217;s website at http://www.sec.gov. Our Common Stock is traded on The Nasdaq
Global Market under the symbol &#8220;ORKA.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Business
Combination of ARCA and Pre-Merger Oruka and Pre-Closing Financing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April&#160;3, 2024, we (formerly known as ARCA biopharma, Inc.)
(prior to the Closing Date, unless context otherwise requires, &#8220;ARCA&#8221; and, after the Closing Date, the &#8220;Company&#8221;
or &#8220;Oruka&#8221;) entered into the Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), by and
among ARCA, Atlas Merger Sub Corp, a Delaware corporation and wholly owned subsidiary of ARCA (&#8220;First Merger Sub&#8221;), Atlas
Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of ARCA (&#8220;Second Merger Sub&#8221;), and Oruka
Therapeutics, a private Delaware corporation (&#8220;Pre-Merger Oruka&#8221;) prior to the consummation of the Merger (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On August
29, 2024 (the &#8220;Closing Date&#8221;), we consummated that previously announced business combination (the &#8220;Closing&#8221;)
pursuant to the Merger Agreement to create a new public company focused on advancing Pre-Merger Oruka&#8217;s pipeline of antibody therapies.
On the Closing Date, First Merger Sub merged with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the
surviving corporation of the merger (the &#8220;First Merger&#8221;), and Oruka merged with and into Second Merger Sub, with Second Merger
Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;).
In connection with the completion of the Merger, we changed our name from &#8220;ARCA biopharma, Inc.&#8221; to &#8220;Oruka Therapeutics,
Inc.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"></p>
</div><div>
</div><!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="font-family: Times New Roman, Times, Serif; padding: 5; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Immediately
prior to the execution and delivery of the Merger Agreement, certain new and existing investors of Oruka (the &#8220;Financing Investors&#8221;)
entered into a subscription agreement with Oruka (the &#8220;Subscription Agreement&#8221;), pursuant to which, and on the terms and
subject to the conditions of which, immediately prior to the Closing, the Financing Investors purchased 39,873,706 shares of Pre-Merger
Oruka common stock and 9,664,208 Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $275.0 million (which includes
the issuance of 4,764,032 shares of Pre-Merger Oruka Common Stock on the conversion of Convertible Note, along with the accrued interest
through the conversion date), immediately prior to the Closing and before the effect of the Reverse Stock Split (as defined below) (the
&#8220;Pre-Closing Financing&#8221;). At the Closing, the shares of Pre-Merger Oruka common stock and Pre-Merger Oruka pre-funded warrants
issued in the Pre-Closing Financing were converted into shares of Common Stock in accordance with the Exchange Ratio (as defined herein).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
connection with the consummation of the Merger, on the Closing Date (prior to the Reverse Stock Split (as defined below)):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.4pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pre-Merger
Oruka issued to the Financing Investors an aggregate of 39,873,706 shares of Pre-Merger Oruka common stock and 9,664,208 Pre-Merger Oruka
pre-funded warrants for gross proceeds of approximately $275.0 million (which includes the issuance of 4,764,032 shares of Pre-Merger
Oruka Common Stock on the conversion of Convertible Note, along with the accrued interest through the conversion date); and</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.4pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
of the then-outstanding (i) 9,460,019 shares of Pre-Merger Oruka common stock, (ii) 20,000,000 shares of Series A convertible preferred
stock of Pre-Merger Oruka (&#8220;Pre-Merger Oruka Series A Preferred Stock&#8221;), (iii) 2,063,669 options exercisable for shares of
Pre-Merger Oruka common stock, (iv) 5,345,336 Pre-Merger Oruka employee warrants and (v) the Pre-Closing Financing Pre-Merger Oruka common
stock and pre-funded warrants were automatically converted into the right to receive the number of Common Stock, Series B Preferred Stock
or warrants in lieu thereof equal to the exchange ratio calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;),
except for the preferred stock, which was converted at the Exchange Ratio divided by 1,000.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Following
the consummation of the Merger, we effected a 1-for-12 reverse stock split of our Common Stock (the &#8220;Reverse Stock Split&#8221;),
which became effective on September 3, 2024. Our Common Stock commenced trading on a post-Reverse Stock Split, post-Merger basis at the
open of trading on September 3, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Private
Placement of Common Stock, Preferred Stock and Pre-Funded Warrants </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
September 13, 2024, we completed the Private Placement of Private Placement Common Shares, Private Placement Conversion Shares and Pre-Funded
Warrants pursuant to the Securities Purchase Agreement dated September 11, 2024 (the &#8220;SPA&#8221;) with the Selling Stockholders.
The Selling Stockholders purchased (i) an aggregate of 5,600,000 shares of the Common Stock, at a price per share of $23.00, (ii) an
aggregate of 2,439 shares of Series A Preferred Stock, at a price per share of $23,000.00, and (iii) Pre-Funded Warrants to purchase
an aggregate of 680,000 shares of Common Stock at a purchase price of $22.999 per Pre-Funded Warrant, which represents the per share
purchase price of the Private Placement Common Shares less the $0.001 per share exercise price for each Pre-Funded Warrant, for an aggregate
purchase price of approximately $200.5 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Subject
to stockholder approval and certain beneficial ownership limitations, each share of Series A Preferred Stock is convertible into 1,000
shares of Common Stock. Shares of Series A Preferred Stock shall not be convertible if the conversion would result in a holder, together
with its affiliates, beneficially owning more than 9.99% of our outstanding shares of Common Stock as of the applicable conversion date,
which may be increased at the holders&#8217; option (not to exceed 19.99%), effective in accordance with the terms of our Certificate
of Designation of Series A Convertible Preferred Stock (&#8220;Series A Certificate of Designation&#8221;). We filed a definitive proxy
statement with the SEC on October 18, 2024 to solicit such stockholder approval at a special meeting of stockholders to be held on November
14, 2024. Except as otherwise required by law (e.g., voting on a change to the authorized shares of Series A Preferred Stock or the rights
of such shares as required by the General Corporation Law of Delaware (the &#8220;DGCL&#8221;)) and as specified in the Series A Certificate
of Designation, the Series A Preferred Stock does not have voting rights. The Pre-Funded Warrants will be exercisable at any time after
the date of issuance. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would
beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.
A holder of Pre-Funded Warrants may increase or decrease this percentage to a percentage not in excess of 19.99% by providing at least
61 days&#8217; prior notice to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The sale
of Private Placement Common Shares, Private Placement Conversion Shares and Pre-Funded Warrants was not registered under the Securities
Act, and such sale was intended to be exempt from registration pursuant to Section 4(a)(2) of the Securities Act as a transaction by
an issuer not involving a public offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Corporation
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On August
29, 2024, we completed the Merger, in connection with which Second Merger Sub changed its corporate name to &#8220;Oruka Therapeutics
Operating Company, LLC&#8221; and ARCA changed its name to &#8220;Oruka Therapeutics, Inc.&#8221; Our principal executive offices are
located at 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025, and our telephone number is (650) 606-7910.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
</div><div>
</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="font-family: Times New Roman, Times, Serif; padding: 5; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>The
Offering </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    Offered by the Selling Securityholders </span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
    to (i) 5,600,000 shares of Common Stock, (ii) 2,439,000 shares of Common Stock issuable upon the conversion of 2,439 shares of Series
    A Preferred Stock and (iii) 680,000 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terms
    of the Offering </span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    selling securityholders will determine when and how they will dispose of the shares of Common Stock, shares of Common Stock issuable
    upon conversion of Series A Preferred Stock and shares of Common Stock issuable upon the exercise of Pre-Funded Warrants registered
    under this prospectus for resale. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 0pt; width: 30%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    Outstanding </span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 70%; padding-left: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of September 30, 2024, there were 34,998,550 of our Common Stock, 2,439 shares of our Series A Preferred Stock and 137,138 shares
    of our Series B Non-Voting Convertible Preferred Stock, par value $0.001 per share (&#8220;Series B Preferred Stock&#8221;), outstanding.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of Proceeds </span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will not receive any proceeds from the sale of the Resale Shares offered by the Selling Stockholders under this prospectus. The net
    proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders. Upon any exercise
    of the Pre-Funded Warrants by payment of cash, however, we will receive the nominal cash exercise price paid by the holders of the
    Pre-Funded Warrants. See the section titled &#8220;Use of Proceeds.&#8221; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 0pt; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    Factors </span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 70%; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    the section titled &#8220;Risk Factors&#8221; and other information included in this prospectus for a discussion of factors that
    you should consider carefully before deciding to invest in our securities. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Markets and Ticker Symbols </span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Common Stock is listed on The Nasdaq Global Market under the symbol &#8220;ORKA.&#8221; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The number
of issued and outstanding shares of Common Stock does not include the following, as of September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,439,000
shares of Common Stock issuable upon the conversion of 2,439 shares of Series A Preferred Stock;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,428,149
shares of Common Stock issuable upon the conversion of 137,138 shares of Series B Preferred Stock;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,522,207
shares of Common Stock issuable upon the exercise of 5,522,207 pre-funded warrants to acquire shares of Common Stock with an exercise
price of $0.01 per share;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">680,000
shares of Common Stock issuable upon the exercise of 680,000 pre-funded warrants to acquire shares of Common Stock with an exercise price
of $0.001 per share;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,287,760
shares of Common Stock issuable upon the exercise of stock options outstanding under the 2024 Equity Incentive Plan and the 2024 Stock
Incentive Plan with a weighted-average exercise price of 7.97 per share;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,054,358
shares of Common Stock issuable upon the exercise of 3,054,358 warrants to acquire shares of Common Stock with a weighted-average exercise
price of $7.80 per share;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,526,324
shares of Common Stock reserved for issuance under our 2024 Stock Incentive Plan; and</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.3pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">463,489
shares of Common Stock reserved for issuance under the ESPP.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">For additional
information concerning the offering, see the section titled &#8220;<i>Plan of Distribution</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
</div><div>
</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<a id="a_004"></a><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>RISK
FACTOR SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The following
summarizes the principal factors that make an investment in the Company speculative or risky, all of which are more fully described in
the Risk Factors section below. This summary should be read in conjunction with the Risk Factors section and should not be relied upon
as an exhaustive summary of the material risks facing our business. The occurrence of any of these risks could harm our business, financial
condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking
statements we have made in this prospectus and those we may make from time to time. You should consider all the risk factors described
in our public filings when evaluating our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Our Financial Condition and Capital Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a preclinical stage biopharmaceutical company with a limited operating history on which to assess our business; we have not initiated,
conducted or completed any clinical trials, and have no products approved for commercial sale.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have historically incurred losses and we anticipate that we will continue to incur losses for the foreseeable future.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never generated revenue from product sales and may never be profitable.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to raise the capital that we need to support our business plans.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raising
additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies
or product candidates.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Clinical Development and Regulatory Approval</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug
development and obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are substantially dependent on the success of our two most advanced programs, ORKA-001 and ORKA-002, and our anticipated clinical trials
of such programs may not be successful.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to meet requirements for the chemistry, manufacturing and control of our programs.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face competition from entities that have developed or may develop programs for the diseases addressed by product candidates developed
by us.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States Food and Drug Administration (&#8220;FDA&#8221;) and comparable foreign regulatory approval processes are lengthy and time
consuming and we may not be able to obtain or may be delayed in obtaining regulatory approvals for our product candidates.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval, we will be subject to ongoing regulatory obligations.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may fail to achieve our projected development goals in the time frames we announce and expect.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to obtain and protect our patents and other proprietary rights is uncertain.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may fail in obtaining or maintaining necessary rights to our programs.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be subject to patent infringement claims or may need to file such claims.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
patents and our ability to protect our products may be impaired by changes to patent laws.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
patent protection could be reduced or eliminated for non-compliance with legal requirements.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may fail to identify or interpret relevant third-party patents.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may become subject to claims challenging the inventorship or ownership of our intellectual property.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
terms may be inadequate to protect our competitive position of our programs.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
technology licensed from various third-parties may be subject to retained rights.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Our Reliance on Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely on agreements with third parties to develop our product candidates. If we are unable to maintain collaborations or licensing
arrangements, or if our collaborations or licensing arrangements are not successful, our business could be negatively impacted.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties we rely on for the execution of nonclinical studies and clinical trials may fail to carry out their contractual duties.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be unable to use third-party manufacturing sites, our third-party manufacturers may encounter difficulties in production or we may
need to switch or create third-party manufacturer redundancies.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Other
Risk Factors - Risks Related to Employee Matters, Managing Growth, Other Risks Related to Our Business, and Owning Our Common Stock </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.05pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is dependent on key personnel and we will be harmed if we cannot recruit and retain highly qualified personnel to successfully
implement our business strategy.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties
in managing this growth.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete
achieve the forecasted growth, our business may not grow at similar rates, or at all.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
disruptions of information technology systems or breaches of data security could adversely affect our business.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in and failures to comply with United States and foreign privacy and data protection laws, regulations and standards may adversely affect
our business, operations and consolidated financial performance.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may become exposed to costly and damaging liability claims and our insurance may not cover all damages from such claims.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business could be adversely affected by macroeconomic conditions.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate paying any dividends in the foreseeable future.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
sales of shares by existing stockholders could cause our stock price to decline.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
sales and issuances of equity and debt could result in additional dilution to our stockholders and could cause our stock price to decline.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;<b>&#160;</b></span></p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>RISK
FACTORS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Our Financial Condition and Capital Requirements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are a preclinical stage biopharmaceutical company with a limited operating history on which to assess our business; we have not initiated,
conducted or completed any clinical trials, have no products approved for commercial sale, have historically incurred losses, and we
anticipate that we will continue to incur significant losses for the foreseeable future. Moreover, we have never generated revenue from
product sales and may never be profitable.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are a preclinical stage biopharmaceutical company with a limited operating history. We will need to raise substantial additional capital
to continue to fund our operations in the future. We have based our estimates on assumptions that may prove to be wrong, and could exhaust
our available financial resources sooner than it currently anticipates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have devoted substantially all of our financial resources to identify, acquire, and develop our product candidates, organizing and staffing
our company, and providing general and administrative support for our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Biopharmaceutical
product development is a highly speculative undertaking and involves a substantial degree of risk. We expect our losses to increase as
our product candidates enter advanced clinical trials. It may be several&#160;years, if ever, before we complete pivotal clinical trials
or have a product candidate approved for commercialization. We expect to invest significant funds into the research and development of
our current programs to determine the potential to advance product candidates to regulatory approval. If we obtain regulatory approval
to market a product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive
approval, and our ability to achieve sufficient market acceptance, pricing, coverage and adequate reimbursement from third-party&#160;payors,
and adequate market share for our product candidates in those markets. Even if we obtain adequate market share for our product candidates,
we may never become profitable despite obtaining such market share and acceptance of our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
expect to continue to incur significant expenses and increasing operating losses for the foreseeable future and our expenses will increase
substantially if and as we:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
the preclinical development and initiate the clinical development of our product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -18.45pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
efforts to discover and develop new product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -18.45pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
the manufacturing of our product candidates or increase volumes manufactured by third parties;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -18.45pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance
our product candidates into larger, more expensive clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -18.45pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate
additional preclinical studies or clinical trials for our product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -18.45pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
regulatory and marketing approvals and reimbursement for our product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -18.45pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
a sales, marketing, and distribution infrastructure to commercialize any products for which it may obtain marketing approval and market
for ourselves;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -18.45pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
milestone, royalty, or other payments under third-party&#160;license agreements;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -18.45pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
to maintain, protect, and expand our intellectual property portfolio; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -18.45pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">experience
any delays or encounter issues with the development and potential regulatory approval of our clinical and product candidates such as
safety issues, manufacturing delays, clinical trial accrual delays, longer&#160;follow-up&#160;for planned studies or trials, additional
major studies or trials, or supportive trials necessary to support marketing approval.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have no significant experience as a company in initiating, conducting or completing clinical trials. In part because of this lack of
experience, we cannot be certain that our planned clinical trials will begin or be completed on time, if at all. In addition, we have
not yet demonstrated an ability to obtain marketing approvals, manufacture a commercial-scale&#160;product or arrange for a third party
to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently,
any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.
Further, the net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a&#160;period-to-period&#160;comparison
of our results of operations may not be a good indication of our future performance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
will need to continue to raise additional capital in order to fund our operations. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, we had $410.9 million of cash. We have incurred significant net losses since our inception. We anticipate that
we will continue to incur significant losses for the foreseeable future. Since February&#160;6, 2024 (inception), we have incurred significant
operating losses. For the period from February&#160;6, 2024 (inception) to September 30, 2024, we reported a net loss of $57.9&#160;million
and net cash used from operating activities of $39.0&#160;million. We will need to raise additional capital to continue to fund our operations
and service our debt obligations in the future. Until such time, if ever, as we can generate substantial revenue from the sale of our
product candidates, we expect to finance our cash needs through a combination of equity offerings, debt financings and licensing, development
or collaboration agreements. If we are unable to raise additional capital when needed, that may raise substantial doubt about our ability
to continue as a going concern. We expect that our existing cash as of $410.9 million as of September 30, 2024 will be sufficient to
fund our operating expenses and capital expenditure requirements for at least 12 months from the date these condensed consolidated financial
statements were issued.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Developing
our product candidates and operating our company requires a substantial amount of capital. We expect our research and development expenses
to increase in connection with our ongoing activities, particularly as we advance our product candidates through clinical trials. We
may need to raise additional capital to fund our operations and such funding may not be available to us on acceptable terms, or at all,
and such funding may become even more difficult to obtain. Competition for additional capital among biotechnology companies may be particularly
intense during this period of economic instability. We may be unable to raise capital through public offerings of our common stock and
may need to turn to alternative financing arrangements. Such arrangements, if we pursue them, could involve issuances of one or more
types of securities, including common stock, preferred stock, convertible debt, warrants to acquire common stock or other securities.
These securities could be issued at or below the then prevailing market price for our common stock. In addition, if we issue debt securities,
the holders of the debt would have a claim to our assets that would be superior to the rights of stockholders until the principal, accrued
and unpaid interest and any premium or make-whole&#160;has been paid. Interest on any newly-issued&#160;debt securities and/or newly-incurred&#160;borrowings
would increase our operating costs and reduce our net income (or increase our net loss), and these impacts may be material. If the issuance
of new securities results in diminished rights to holders of our common stock, the market price of our common stock could be materially
and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
do not currently have any products approved for sale and do not generate any revenue from product sales. Accordingly, we expect to rely
primarily on equity and/or debt financings to fund our continued operations. Our ability to raise additional funds will depend, in part,
on the success of our preclinical studies and clinical trials and other product development activities, regulatory events, our ability
to identify and enter into licensing or other strategic arrangements, and other events or conditions that may affect our value or prospects,
as well as factors related to financial, economic and market conditions, many of which are beyond our control. There can be no assurances
that sufficient funds will be available to us when required or on acceptable terms, if at all.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
we are unable to raise additional capital when required or on acceptable terms, we may be required to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significantly
delay, scale back, or discontinue the development or commercialization of our product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    strategic partnerships, or amend existing partnerships, for research and development programs at an earlier stage than otherwise
    would be desirable or that we otherwise would have sought to develop independently, or on terms that are less favorable than might
    otherwise be available in the future;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dispose
    of technology assets, or relinquish or license on unfavorable terms, our rights to technologies or any of our product candidates
    that we otherwise would seek to develop or commercialize ourselves;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursue
    the sale of the company to a third party at a price that may result in a loss on investment for our stockholders; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">file
    for bankruptcy or cease operations altogether (and face any related legal proceedings).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Any
of these events could have a material adverse effect on our business, operating results, and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Even
if we are successful in raising new capital, we could be limited in the amount of capital we raise due to investor demand restrictions
placed on the amount of capital we raise, or other reasons.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Raising
additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
the extent that we raise additional capital through the sale of equity securities or convertible debt securities, the ownership interest
of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect
the rights of holders of our common stock. Debt financing and preferred equity financing, if available, may involve agreements that include
covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures,
or declaring dividends.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third
parties, we may be required to relinquish valuable rights to our research programs or product candidates or grant licenses on terms that
may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements with third
parties when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts
or grant rights to third parties to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
the extent that we raise additional capital through the sale of equity, including pursuant to any sales under convertible debt or other
securities convertible into equity, the ownership interest of our stockholders will be diluted, and the terms of these new securities
may include liquidation or other preferences that adversely affect the rights of our stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
September 2024, we entered into a Securities Purchase Agreement with certain new institutional and accredited investors, whereby the
investors purchased an aggregate of 5,600,000 shares of Company Common Stock, 2,439 shares of Company Series A Preferred Stock and pre-funded
warrants to purchase an aggregate of 680,000 shares of common stock for an aggregate purchase price of approximately $200.5 million.
Each share of Company Series A Preferred Stock is convertible into 1,000 shares of Company Common Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Debt
financing, if available, would likely involve agreements that include covenants limiting or restricting our ability to take specific
actions, such as incurring additional debt, making capital expenditures, making additional product acquisitions, or declaring dividends.
If we raise additional funds through strategic collaborations or licensing arrangements with third parties, we may have to relinquish
valuable rights to our product candidates or future revenue streams or grant licenses on terms that are not favorable to us. We cannot
assure you that we will be able to obtain additional funding if and when necessary to fund our entire portfolio of product candidates
to meet our projected plans. If we are unable to obtain funding on a timely basis, we may be required to delay or discontinue one or
more of our development programs or be unable to expand our operations or otherwise capitalize on potential business opportunities, which
could materially harm our business, financial condition, and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Clinical Development, Regulatory Approval and Commercialization</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
face competition from entities that have developed or may develop programs for the diseases addressed by product candidates developed
by us.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
development and commercialization of drugs is highly competitive. Product candidates developed by us, if approved, will face significant
competition and our failure to effectively compete may prevent us from achieving significant market penetration. We compete with a variety
of biopharmaceutical companies as well as academic institutions, governmental agencies, and public and private research institutions,
among others. Many of the companies with which we are currently competing or will compete against in the future have significantly greater
financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trials, regulatory approvals,
and marketing than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources
being concentrated among a smaller number of our competitors. Smaller or early-stage&#160;companies may also prove to be significant
competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with
us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, recruiting participants
for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
competitors have developed, are developing or will develop programs and processes competitive with our programs and processes. Competitive
therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments. Our
success will depend partially on our ability to develop and commercialize products that have a competitive safety, efficacy, dosing and/or
presentation profile. Our commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective,
have a more attractive dosing profile or presentation or are less expensive than the products we develop, or if our competitors develop
competing products or if biosimilars enter the market more quickly than we do and are able to gain market acceptance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
programs are in preclinical stages of development and may fail in development or suffer delays. We depend on the successful initiation
and completion of clinical trials for our product candidates to advance our product development plans.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have no products on the market, and all of our programs are in preclinical stages of development and have not been tested in humans.
As a result, we expect it will be many&#160;years before we can obtain regulatory approval for and commercialize any product candidate,
if ever. We have not yet demonstrated our ability to initiate or complete any clinical trials, obtain regulatory approvals, manufacture
a clinical or commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities
necessary for successful product commercialization. We must initiate and complete clinical trials that demonstrate the safety and efficacy
of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, and can take years to complete
and is uncertain as to outcome. A failure of one or more of our clinical trials can occur at any stage of testing. The outcome of preclinical
testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial
do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and
analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical
trials have nonetheless failed to obtain marketing approval for their products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may experience a number of unforeseen events during clinical trials, including the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
product candidates may have undesirable side effects or unexpected characteristics, causing us or our investigators to suspend or terminate
the trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    supply of our clinical trial materials or other materials necessary to conduct clinical trials of our product candidates may be insufficient,
    delayed, does not meet agreed-upon specifications, or are otherwise inadequate for use in clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators
    or institutional review boards (&#8220;IRBs&#8221;), the FDA or ethics committees may not authorize us or our investigators to commence
    a clinical trial or conduct a clinical trial at a prospective trial site; clinical trials of any product candidates may fail to show
    safety or efficacy, produce negative or inconclusive results, and we may decide, or regulators may require it, to conduct additional
    preclinical studies or clinical trials or we may decide to abandon product development programs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and/or contract research
    organizations (&#8220;CROs&#8221;);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    trial sites deviating from trial protocol or dropping out of a trial; we may elect to, or regulators, IRBs or ethics committees may
    require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance
    with regulatory requirements or a finding that the participants in our trials are being exposed to unacceptable health risks;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of subjects required for clinical trials of any product candidates may be larger than we anticipate, especially if regulatory
    bodies require completion of&#160;non-inferiority&#160;or superiority trials; enrollment in these clinical trials may be slower than
    we anticipate or subjects may drop out of these clinical trials or fail to return for post-treatment&#160;follow-up&#160;at a higher
    rate than we anticipate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    third-party&#160;contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely
    manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical
    trial sites or investigators;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of clinical trials of any of our programs may be greater than we anticipate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reports
    from clinical testing of other therapies may raise safety or efficacy concerns about our programs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product
    candidates as well as data emerging from other therapies in the same class as our product candidates; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or other regulatory authorities may require us to submit additional data such as long-term&#160;toxicology studies, or impose
    other requirements before permitting us to initiate a clinical trial.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Commencing
clinical trials in the United&#160;States is subject to acceptance by the FDA of an investigational new drug application (&#8220;IND&#8221;),
biologics license application (&#8220;BLA&#8221;) or similar application and finalizing the trial design based on discussions with the
FDA and other regulatory authorities. In the event that the FDA requires us to complete additional preclinical studies or it is required
to satisfy other FDA requests prior to commencing clinical trials, the start of our first clinical trials may be delayed. If our clinical
trials do not produce favorable results, our ability to obtain regulatory approval for our product candidates may be adversely impacted.
Moreover, the combined data from our trials maybe inconclusive or may not be sufficient to ultimately gain marketing approval from the
FDA or other regulatory authorities. There are equivalent processes and risks applicable to clinical trial applications in other countries,
including countries in the European Union (&#8220;EU&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, because of the competitive landscape for&#160;immunology and inflammation (commonly referred to as &#8220;I&amp;I&#8221;) indications,
we may also face competition for clinical trial enrollment. Clinical trial enrollment will depend on many factors, including if potential
clinical trial participants choose to undergo treatment with approved products or enroll in competitors&#8217; ongoing clinical trials
for programs that are under development for the same indications as our programs. An increase in the number of approved products for
the indications we are targeting with our programs may further exacerbate this competition. Our inability to enroll a sufficient number
of participants could, among other things, delay our development timeline, which may further harm our competitive position.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a product
candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, our product candidates.
Our inability to complete development of, or commercialize our product candidates, or significant delays in doing so, could have a material
and adverse effect on our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are substantially dependent on the success of our two most advanced programs, ORKA-001 and ORKA-002, and our anticipated clinical trials
of such programs may not be successful.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
future success is substantially dependent on our ability to develop and timely obtain marketing approval for, and then successfully commercialize,
our two most advanced programs, ORKA-001&#160;and ORKA-002. We are investing a majority of our efforts and financial resources into the
research and development of these programs. We anticipate initiating a Phase&#160;1 clinical trial in healthy volunteers of ORKA-001&#160;in
the first quarter of 2025 and of ORKA-002&#160;in the second half of 2025, each subject to the filing of an IND or foreign equivalent
and regulatory approval. The success of our programs is dependent on observing a longer half-life&#160;of our product candidates in humans
than other extended half-life&#160;monoclonal antibodies (&#8220;mAbs&#8221;) currently marketed and in development as we believe this
longer half-life&#160;has the potential to result in a more favorable dosing schedule for our product candidates, assuming they successfully
complete clinical development and obtain marketing approval. This is based in part on the assumption that the longer half-life&#160;we
have observed in&#160;non-human&#160;primates (&#8220;NHPs&#8221;) will translate into an extended half-life&#160;of our product candidates
in humans. To the extent we do not observe this extended half-life&#160;in humans, it would significantly and adversely affect the clinical
and commercial potential of our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
programs will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, product development,
marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues
from product sales.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
success of our product candidates will depend on a variety of factors. We do not have complete control over many of these factors, including
certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights
and the manufacturing, marketing, distribution and sales efforts of any current or future collaborator.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
we do not achieve our projected development goals in the time frames we announce and expect, the development and potential commercialization
of our product candidates may be delayed and our expenses may increase and, as a result, our business may be materially harmed and our
stock price may decline.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">From
time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product
development goals, which it sometimes refers to as milestones. These milestones may include the commencement or completion of scientific
studies and clinical trials, such as the expected timing for the anticipated commencement of our Phase&#160;1 studies, clinical trials
in psoriasis (&#8220;PsO&#8221;) and other target indications, as well as the submission of regulatory filings. From time to time, we
may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions.
The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control.
If we do not meet these milestones as publicly announced, or at all, the development and potential commercialization of our product candidates
may be delayed or never achieved and, as a result, our business may be materially harmed and our stock price may decline. Additionally,
delays relative to our projected timelines are likely to cause overall expenses to increase, which may require us to raise additional
capital sooner than expected and prior to achieving targeted development milestones.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Any
drug delivery device that we may use to deliver our product candidates may have its own regulatory, development, supply and other risks.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
expect to deliver our product candidates via a drug delivery device, such as an injector or other delivery system. There may be unforeseen
technical complications related to the development activities required to bring such a product to market, including primary container
compatibility and/or dose volume requirements. Our product candidates may not be approved or may be substantially delayed in receiving
approval if the devices that we choose to develop do not gain and/or maintain their own regulatory approvals or clearances. Where approval
of the drug product and device is sought under a single application, the increased complexity of the review process may delay approval.
In addition, some drug delivery devices are provided by single-source&#160;unaffiliated third-party&#160;companies. We may be dependent
on the sustained cooperation and effort of those third-party&#160;companies both to supply the devices and, in some cases, to conduct
the studies required for approval or other regulatory clearance of the devices. Even if approval is obtained, we may also be dependent
on those third-party&#160;companies continuing to maintain such approvals or clearances once they have been received. Failure of third-party&#160;companies
to supply the devices on time and in accordance with the agreed-upon specifications, to successfully complete studies on the devices
in a timely manner, or to obtain or maintain required approvals or clearances of the devices could result in increased development costs,
delays in or failure to obtain regulatory approval and delays in product candidates reaching patients.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
approach to the discovery and development of our programs is unproven, and we may not be successful in our efforts to build a pipeline
of programs with commercial value.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
approach to the discovery and development of the research programs with respect to which we have the option to acquire intellectual property
license rights to pursuant to those certain antibody discovery and option agreements by and among the Company, Paragon Therapeutics,
Inc. and Paruka Holding, LLC (the &#8220;Option Agreements&#8221;) and leverages clinically validated mechanisms of action and incorporates
advanced antibody engineering to optimize half-life&#160;and other properties designed to overcome limitations of existing therapies.
Our programs are purposefully designed to improve upon existing product candidates and products while maintaining the same, well-established&#160;mechanisms
of action. However, the scientific research that forms the basis of our efforts to develop programs using half-life&#160;extension technologies
is ongoing and may not result in viable programs. There is limited clinical data available on product candidates utilizing half-life&#160;extension
technologies, especially in&#160;I&amp;I indications, demonstrating whether they are safe or effective for long-term&#160;treatment in
humans. The long-term&#160;safety and efficacy of these technologies and the extended half-life&#160;and exposure profile of our programs
compared to currently approved products is unknown.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may ultimately discover that utilizing half-life&#160;extension technologies for our specific targets and indications and any programs
resulting therefrom does not possess certain properties required for therapeutic effectiveness. We currently have only preclinical data
regarding the increased half-life&#160;properties of our programs and the same results may not be seen in humans. In addition, programs
using half-life&#160;extension technologies may demonstrate different chemical and pharmacological properties in participants than they
do in laboratory studies. This technology and any programs resulting therefrom may not demonstrate the same chemical and pharmacological
properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, we may in the future seek to discover and develop programs that are based on novel targets and technologies that are unproven.
If our discovery activities fail to identify novel targets or technologies for drug discovery, or such targets prove to be unsuitable
for treating human disease, we may not be able to develop viable additional programs. We and our existing or future collaborators may
never receive approval to market and commercialize any product candidate. Even if we or an existing or future collaborator obtains regulatory
approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired
or may require labeling that includes significant use or distribution restrictions or safety warnings. If the products resulting from
the research programs with respect to which we have the option to acquire intellectual property license rights to pursuant to the Option
Agreements prove to be ineffective, unsafe or commercially unviable, such programs would have little, if any, value, which would have
a material and adverse effect on our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Preclinical
and clinical development involves a lengthy and expensive process that is subject to delays and uncertain outcomes, and results of earlier
studies and trials may not be predictive of future clinical trial results. If our preclinical studies and clinical trials are not sufficient
to support regulatory approval of any of our product candidates, we may incur additional costs or experience delays in completing, or
ultimately be unable to complete, the development of such product candidate.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Before
obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies
and then conduct extensive clinical trials to demonstrate the safety and efficacy of such product candidate in humans. Our clinical trials
may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or
clinical trial process.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
a failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early-stage&#160;clinical
trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to
varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical
studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. In addition, we expect
to rely on participants to provide feedback on measures such as measures of quality of life, which are subjective and inherently difficult
to evaluate. These measures can be influenced by factors outside of our control, and can vary widely from&#160;day-to-day&#160;for a
particular participant, and from participant to participant and from site to site within a clinical trial.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
cannot be sure that the FDA will agree with our clinical development plan. We plan to use the data from our planned Phase&#160;1 trials
of our ORKA-001&#160;and ORKA-002&#160;programs in healthy volunteers to support Phase&#160;2 trials in PsO and potentially other&#160;I&amp;I
indications. If the FDA requires us to conduct additional trials or enroll additional participants, our development timelines may be
delayed. We cannot be sure that submission of an IND, BLA or similar application will result in the FDA or comparable foreign regulatory
authorities, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues
may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Events that may prevent successful or
timely initiation or completion of clinical trials include: inability to generate sufficient preclinical, toxicology or other&#160;<i>in
vivo&#160;</i>or&#160;<i>in vitro&#160;</i>data to support the initiation or continuation of clinical trials; delays in reaching a consensus
with regulatory authorities on study design or implementation of the clinical trials; delays or failure in obtaining regulatory authorization
to commence a trial; delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which
can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; delays in identifying,
recruiting and training suitable clinical investigators; delays in obtaining required IRB approval at each clinical trial site; delays
in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our product candidates for use
in clinical trials or the inability to do any of the foregoing; failure by our CROs, other third parties or us to adhere to clinical
trial protocols; failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s current Good Clinical
Practice requirements (&#8220;GCPs&#8221;) or applicable regulatory guidelines in other countries; changes to the clinical trial protocols;
clinical sites deviating from trial protocol or dropping out of a trial; changes in regulatory requirements and guidance that require
amending or submitting new clinical protocols; selection of clinical endpoints that require prolonged periods of observation or analyses
of resulting data; transfer of manufacturing processes to facilities operated by a contract manufacturing organization (&#8220;CMO&#8221;)
and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; and third parties being unwilling
or unable to satisfy their contractual obligations to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
could also encounter delays if a clinical trial is suspended or terminated by it, by the IRBs of the institutions in which such clinical
trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial or by the FDA or comparable foreign
regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct
the clinical trial in accordance with regulatory requirements or our clinical trial protocols, inspection of the clinical trial operations
or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety
issues or adverse side effects, failure to demonstrate a benefit from the programs, changes in governmental regulations or administrative
actions or lack of adequate funding to continue the clinical trial. If we are required to conduct additional clinical trials or other
testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials
of our product candidates, if the results of these trials are not positive or are only moderately positive or if there are safety concerns,
our business and results of operations may be adversely affected and we may need to adjust or abandon our business plans and we may incur
significant additional costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
we encounter difficulties enrolling participants in our future clinical trials, our clinical development activities could be delayed
or otherwise adversely affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may experience difficulties in patient participant enrollment in our clinical trials for a variety of reasons. The timely completion
of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of participants
who remain in the trial until conclusion. The enrollment of participants in future trials for any of our programs will depend on many
factors, including if participants choose to enroll in clinical trials, rather than using approved products, or if our competitors have
ongoing clinical trials for programs that are under development for the same indications as our programs, and participants instead enroll
in such clinical trials. Even if we are able to enroll a sufficient number of participants for our clinical trials, it may have difficulty
maintaining participants in our clinical trials. Our inability to enroll or maintain a sufficient number of participants would result
in significant delays in completing clinical trials and increased development costs or may require us to abandon one or more clinical
trials altogether.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Preliminary,
&#8220;topline&#8221; or interim data from our clinical trials may change as more participant data becomes available and are subject
to audit and verification procedures.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">From
time to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which are based
on a preliminary analysis of then-available&#160;data, and the results and related findings and conclusions are subject to change following
a more comprehensive review of the data. We also make assumptions, estimations, calculations and conclusions as part of our analyses
of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary or topline results
that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results,
once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Any
preliminary or topline data should be viewed with caution until the final data are available. From time to time, we may also disclose
interim data from our preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical
outcomes may materially change as participant enrollment continues and more participant data become available or as participants from
our clinical trials continue other treatments. Further, others, including regulatory agencies, may not accept or agree with our assumptions,
estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the
value of the particular product candidate, the approvability or commercialization of the particular product candidate and our company
in general. In addition, the information we choose to publicly disclose regarding a particular preclinical study or clinical trial is
based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate
information to include in our disclosure. If the preliminary, topline or interim data that we report differ from actual results, or if
others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize,
our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
clinical trials may reveal significant adverse events or undesirable side effects not seen in our preclinical studies and may result
in a safety profile that could halt clinical development, inhibit regulatory approval or limit commercial potential or market acceptance
of any of our product candidates.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Results
of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects, adverse events or unexpected characteristics.
While preclinical studies in NHPs conducted with respect to our programs have not shown any such characteristics to date, we have not
yet initiated any clinical trials in humans. If significant adverse events or other side effects are observed in any of our future clinical
trials, we may have difficulty recruiting participants to such trials, participants may drop out of the trials, or we may be required
to abandon the trials or our development efforts of one or more programs altogether. We, the FDA or other applicable regulatory authorities,
or an IRB, may suspend any clinical trials of any program at any time for various reasons, including a belief that subjects or patients
in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential products developed in the biotechnology
industry that initially showed therapeutic promise in early-stage&#160;studies and trials have later been found to cause side effects
that prevented their further development. However, other potential products have shown side effects in preclinical studies, which side
effects do not present themselves in clinical trials in humans. Even if the side effects do not preclude the product candidate from obtaining
or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to their tolerability
versus other therapies. In addition, an extended half-life&#160;could prolong the duration of undesirable side effects, which could also
inhibit market acceptance. Treatment-emergent&#160;adverse events could also affect participant recruitment or the ability of enrolled
subjects to complete our clinical trials or could result in potential product liability claims. Potential side effects associated with
our product candidates may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from our
product candidates may not be normally encountered in the general patient population and by medical personnel. Any of these occurrences
could harm our business, financial condition, results of operations and prospects significantly.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, even if we successfully advance our product candidates or any future product candidates through clinical trials, such trials
will only include a limited number of participants and limited duration of exposure to our product candidates. As a result, we cannot
be assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of participants are
exposed to the product candidate after approval. Further, any clinical trials may not be sufficient to determine the effect and safety
consequences of using our product candidates over a multi-year&#160;period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
any of the foregoing events occur or if one or more of the research programs with respect to which we have the option to acquire intellectual
property license rights to pursuant to the Option Agreements prove to be unsafe, our entire pipeline could be affected, which would have
a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may expend our limited resources to pursue a particular program and fail to capitalize on programs that may be more profitable or for
which there is a greater likelihood of success.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Because
we have limited financial and managerial resources, we focus our research and development efforts on certain selected programs. For example,
we are initially focused on our most advanced programs, ORKA-001&#160;and ORKA-002. As a result, we may forgo or delay pursuit of opportunities
with other programs that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to
capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development
programs for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial
potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration,
licensing or other royalty arrangements in cases in which we would have been more advantageous for us to retain sole development and
commercialization rights to such product candidate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Any
approved products resulting from our current programs or any future program may not achieve adequate market acceptance among clinicians,
patients, healthcare third-party payors and others in the medical community necessary for commercial success and we may not generate
any future revenue from the sale or licensing of such products.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Even
if regulatory approval is obtained for a product candidate resulting from one of our current or future programs, they may not gain market
acceptance among physicians, patients, healthcare payors or the medical community. We may not generate or sustain revenue from sales
of the product due to factors such as whether the product can be sold at a competitive cost and whether it will otherwise be accepted
in the market. There are several approved products and product candidates in later stages of development for the treatment of PsO.&#160;However,
our programs incorporate advanced antibody engineering to optimize the half-life&#160;and formulation of antibodies; to date, no such
antibody has been approved by the FDA for the treatment of PsO.&#160;Market participants with significant influence over acceptance of
new treatments, such as clinicians and third-party&#160;payors, may not adopt a biologic that incorporates half-life&#160;extension for
our targeted indications, and we may not be able to convince the medical community and third-party&#160;payors to accept and use, or
to provide favorable reimbursement for, any programs developed by us or our existing or future collaborators. An extended half-life&#160;may
make it more difficult for patients to change treatments and there is a perception that half-life&#160;extension could exacerbate side
effects, each of which may adversely affect our ability to gain market acceptance. Market acceptance of our product candidates will depend
on many factors, including factors that are not within our control.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Sales
of medical products also depend on the willingness of clinicians to prescribe the treatment. We cannot predict whether clinicians, clinicians&#8217;
organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that our product is safe,
therapeutically effective, cost effective or less burdensome as compared with competing treatments. If any of our product candidates
is approved but does not achieve an adequate level of acceptance by such parties, we may not generate or derive sufficient revenue from
that product candidate and may not become or remain profitable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Certain
of our programs may compete with our other programs, which could negatively impact our business and reduce our future revenue.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are developing product candidates for the same indication, PsO, and may in the future develop our programs for other&#160;I&amp;I indications.
Each such program targets a different mechanism of action. However, developing multiple programs for a single indication may negatively
impact our business if the programs compete with each other. For example, if multiple programs are conducting clinical trials at the
same time, they could compete for the enrollment of participants. In addition, if multiple product candidates are approved for the same
indication, they may compete for market share, which could limit our future revenue.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may conduct clinical trials for programs at sites outside the United&#160;States, and the FDA may not accept data from trials conducted
in such locations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may choose to conduct one or more of our future clinical trials outside the United&#160;States. Although the FDA may accept data from
clinical trials conducted outside the United&#160;States, acceptance of this data is subject to conditions imposed by the FDA.&#160;For
example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles.
The trial population must also adequately represent the U.S.&#160;population, and the data must be applicable to the U.S.&#160;population
and U.S.&#160;medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject
to the applicable local laws, FDA acceptance of the data will depend upon the determination that the trials also complied with all applicable
U.S.&#160;laws and regulations. If the FDA does not accept the data from any trial that we conduct outside the United&#160;States, it
would likely result in the need for additional trials, which would be costly and time-consuming&#160;and would delay or permanently halt
our development of the applicable product candidates. Even if the FDA accepted such data, it could require us to modify our planned clinical
trials to receive clearance to initiate such trials in the United&#160;States or to continue such trials once initiated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Further,
conducting clinical trials outside of the U.S. presents additional risks that may delay completion of our clinical trials. These risks
include the failure of enrolled participants in foreign countries to adhere to clinical protocol as a result of differences in healthcare
services or cultural customs that could restrict or limit our ability to conduct our clinical trials, the administrative burdens of conducting
clinical trials under multiple sets of foreign regulations, potential restrictions on data generated from the clinical trial, foreign
exchange fluctuations, diminished protection of intellectual property in some countries, as well as political and economic risks relevant
to foreign countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Government Regulation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>The
regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently
unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates,
we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue
will be materially impaired.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
process of obtaining regulatory approvals, both in the United&#160;States and abroad, is unpredictable, expensive and typically takes
many&#160;years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety
of factors, including the type, complexity and novelty of the product candidates involved. Before obtaining regulatory approvals for
the commercial sale of our product candidates, including our most advanced programs, ORKA-001&#160;and ORKA-002, we must demonstrate
through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective
for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process
to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, our product candidates may not be effective,
may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that
may preclude our obtaining marketing approval. The FDA and comparable foreign regulatory authorities have substantial discretion in the
approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional
preclinical, clinical or other data. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for
many reasons, including: the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical
trials; we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate
is safe and effective for our proposed indication; the results of clinical trials may not meet the level of statistical significance
required by the FDA or comparable foreign regulatory authorities for approval; serious and unexpected drug-related&#160;side effects
may be experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates; we may be
unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh our safety risks; the FDA or comparable foreign
regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; the data collected from
clinical trials of our product candidates may not be acceptable or sufficient to support the submission of a BLA or other submission
or to obtain regulatory approval in the United&#160;States or elsewhere, and we may be required to conduct additional clinical trials;
the FDA or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of
our product candidates; the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities
of third-party&#160;manufacturers with which we contract for clinical and commercial supplies; and the approval policies or regulations
of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient
for approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Of
the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes
and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our
failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations
and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than
we request, including failing to approve the most commercially promising indications, may grant approval contingent on the performance
of costly post-marketing&#160;clinical trials, or may approve a product candidate with a label that does not include the labeling claims
necessary or desirable for the successful commercialization of that product candidate. If we are not able to obtain, or if there are
delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed
in commercializing, our product candidates and our ability to generate revenue will be materially impaired.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may not be able to meet requirements for the chemistry, manufacturing and control of our programs.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
order to receive approval of our products by the FDA and comparable foreign regulatory authorities, we must show that we and our CMO
partners are able to characterize, control and manufacture our drug products safely and in accordance with regulatory requirements. This
includes manufacturing the active ingredient, developing an acceptable formulation, manufacturing the drug product, performing tests
to adequately characterize the formulated product, documenting a repeatable manufacturing process, and demonstrating that our drug products
meet stability requirements. Meeting these chemistry, manufacturing and control requirements is a complex task that requires specialized
expertise. If we are not able to meet the chemistry, manufacturing and control requirements, we may not be successful in getting our
products approved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
product candidates for which we intend to seek approval as biologics may face competition sooner than anticipated.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Patient Protection and Affordable Act, as amended by the Healthcare and Education Reconciliation Act (the &#8220;ACA&#8221;), includes
a subtitle called the Biologics Price Competition and Innovation Act&#160;of&#160;2009 (&#8220;BPCIA&#8221;), which created an abbreviated
approval pathway for biological products that are biosimilar to or interchangeable with an&#160;FDA-licensed&#160;reference biological
product. Under the BPCIA, an application for a highly similar or &#8220;biosimilar&#8221; product may not be submitted to the FDA until
four&#160;years following the date that the reference product was first approved by the FDA.&#160;In addition, the approval of a biosimilar
product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first approved. During
this&#160;12-year&#160;period of exclusivity, another company may still market a competing version of the reference product if the FDA
approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled&#160;clinical
trials to demonstrate the safety, purity and potency of their product.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe that any of our product candidates approved as biologics under a BLA should qualify for the&#160;12-year&#160;period of exclusivity.
However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not
consider our product candidates to be reference products for competing products, potentially creating the opportunity for competition
sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject
of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference products in a
way that is similar to traditional generic substitution for&#160;non-biological&#160;products is not yet clear, and will depend on a
number of marketplace and regulatory factors that are still developing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Even
if we receive regulatory approval of our product candidates, we will be subject to extensive ongoing regulatory obligations and continued
regulatory review and may result in restrictions on the use of the product, which may result in significant additional expense and we
may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Any
regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities
and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions
for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval&#160;study or risk management
requirements. For example, the FDA may require a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) in order to approve our
product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional
elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition,
if the FDA or comparable foreign regulatory authorities approve our product candidates, our product candidates and the activities associated
with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling,
storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the FDA
and other regulatory agencies in the United&#160;States and by comparable foreign regulatory authorities. These requirements include
submissions of safety and other post-marketing&#160;information and reports, registration, as well as&#160;on-going&#160;compliance with
current CGMPs and GCPs for any clinical trials that we conduct following approval. In addition, manufacturers of drug products and their
facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance
with CGMPs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
we or a regulatory authority discover previously unknown problems with a product, such as adverse events of unanticipated severity or
frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that
product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing,
restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials, restrictions
on the manufacturing process, warning or untitled letters, civil and criminal penalties, injunctions, product seizures, detentions or
import bans, voluntary or mandatory publicity requirements and imposition of restrictions on operations, including costly new manufacturing
requirements. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates
and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may face difficulties from healthcare legislative reform measures.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Existing
regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval
of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation
or administrative action, either in the United&#160;States or abroad. If we are slow or unable to adapt to changes in existing requirements
or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval
that we may have obtained and we may not achieve or sustain profitability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors,
patient organizations and customers will be subject to applicable healthcare regulatory laws, including conflicts of interest rules,
which could expose us to penalties.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party&#160;payors,
patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These
laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we
research, market, sell and distribute our product candidates, if approved. Principal investigators for our clinical trials may serve
as scientific advisors or consultants to us or may be affiliated with our other service providers, including CROs or site management
organizations, and from time to time may receive cash compensation in connection with such services. If these relationships and any related
compensation result in perceived or actual conflicts of interest, the integrity of the data generated at the applicable clinical trial
site or in the applicable trial may be questioned or jeopardized.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Ensuring
that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations
will involve substantial costs. If our operations are found to be in violation of any of these laws or any other governmental laws and
regulations that may apply to it, we may be subject to significant penalties, including civil, criminal and administrative penalties,
damages, fines, exclusion from government-funded&#160;healthcare programs, integrity oversight and reporting obligations to resolve allegations
of&#160;non-compliance,&#160;disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the
curtailment or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming&#160;and
may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought
against us, our business may be impaired.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Even
if we are able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement
policies, we may not be able to offer such product candidates at competitive prices which would seriously harm our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
intend to seek approval to market our product candidates in the United&#160;States and in selected foreign jurisdictions. If we obtain
approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions.
Our ability to successfully commercialize any product candidates that we may develop will depend in part on the extent to which reimbursement
for these product candidates and related treatments will be available from government health administration authorities, private health
insurers and other organizations. Government authorities and other third-party&#160;payors, such as private health insurers and health
maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Government authorities and
other third-party&#160;payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications.
These entities may create preferential access policies for a competitor&#8217;s product, including a branded or generic/biosimilar product,
over our products in an attempt to reduce their costs, which may reduce our commercial opportunity. Additionally, if any of our product
candidates are approved and we are found to have improperly promoted off-label&#160;uses of those product candidates, we may become subject
to significant liability, which would materially adversely affect our business and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are subject to U.S.&#160;and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering
laws and regulations. We can face criminal liability and other serious consequences for violations, which can harm our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are subject to export control and import laws and regulations, including the U.S.&#160;Export Administration Regulations, U.S.&#160;Customs
regulations, various economic and trade sanctions regulations administered by the U.S.&#160;Treasury Department&#8217;s Office of Foreign
Assets Controls, the U.S.&#160;Foreign Corrupt Practices Act&#160;of&#160;1977, as amended, the U.S.&#160;domestic bribery statute contained
in 18 U.S.C. &#167; 201, the U.S.&#160;Travel Act, the USA PATRIOT Act, and other state and national anti-bribery&#160;and anti-money&#160;laundering
laws in the countries in which we conduct activities. Anti-corruption&#160;laws are interpreted broadly and prohibit companies and their
employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly,
improper payments or anything else of value to or from recipients in the public or private sector. We may engage third parties to sell
our products outside the United&#160;States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations,
and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated&#160;hospitals,
universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors,
and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws
and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or
import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Governments
outside the United&#160;States tend to impose strict price controls, which may adversely affect our revenue, if any.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
some countries, particularly member states of the EU (&#8220;EU Member States&#8221;), the pricing of prescription drugs is subject to
governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt
of marketing approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices
and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further
complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used
by various EU Member States and parallel distribution, or arbitrage between&#160;low-priced&#160;and high-priced&#160;EU Member States,
can further reduce prices. To obtain coverage and reimbursement or pricing approvals in some countries, we or current or future collaborators
may be required to conduct a clinical trial or other studies that compare the cost-effectiveness&#160;of our product candidates to other
available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party&#160;payors
or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries.
If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at
unsatisfactory levels, our business, financial condition, results of operations or prospects could be materially and adversely affected.
Brexit could lead to legal uncertainty and potentially divergent national laws and regulations, including those related to the pricing
of prescription pharmaceuticals, as the United Kingdom (&#8220;UK&#8221;) determines which EU laws to replicate or replace. If the UK
were to significantly alter its regulations affecting the pricing of prescription pharmaceuticals, we could face significant new costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>A
breakthrough therapy, fast track, or other expedited designation for our product candidates may not lead to a faster development or regulatory
review or approval process, and it does not increase the likelihood that those product candidates will receive marketing approval.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may seek a breakthrough therapy, fast track, or other designation for appropriate product candidates. Designations such as these are
within the discretion of the FDA, or other comparable regulatory authorities. The receipt of a designation for a product candidate may
not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures
and does not assure ultimate approval by the FDA.&#160;In addition, even if one or more of our product candidates qualifies under one
of FDA&#8217;s designation programs, the FDA may later decide that the products no longer meet the conditions for qualification or decide
that the time period for FDA review or approval will not be shortened.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Our Intellectual Property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
ability to obtain and protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive
advantage.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
rely upon a combination of patents, trademarks, trade secret protection, confidentiality agreements and the Option Agreements to protect
the intellectual property related to our programs and technologies and to prevent third parties from competing unfairly with it. Our
success depends in large part on our ability to obtain and maintain patent protection for our platform technologies, programs and their
uses, as well as our ability to operate without infringing on or violating the proprietary rights of others. Paragon has filed provisional
patent applications and intends to file one or more additional provisional patent applications directed to antibodies that target IL-23,
including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA-001.
In addition, Paragon has filed provisional patent applications and intends to file one or more additional provisional patent applications
directed to antibodies that target IL-17, including applications covering composition of matter, pharmaceutical formulations, and methods
of using such antibodies, including ORKA-002. However, we may not be able to protect our intellectual property rights throughout the
world and the legal systems in certain countries may not favor enforcement or protection of patents, trade secrets and other intellectual
property. Filing, prosecuting and defending patents on programs worldwide would be expensive and our intellectual property rights in
some foreign jurisdictions can be less extensive than those in the United&#160;States; the reverse may also occur. As such, we may not
have patents in all countries or all major markets and may not be able to obtain patents in all jurisdictions even if we apply for them.
Our competitors may operate in countries where we do not have patent protection and can freely use our technologies and discoveries in
such countries to the extent such technologies and discoveries are publicly known or disclosed in countries where we do have patent protection
or pending patent applications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
pending and future patent applications may not result in patents being issued. Any issued patents may not afford sufficient protection
of our programs or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed,
designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products
or programs. Even if these patents are granted, they may be difficult to enforce. Further, any issued patents that we may license or
own covering our programs could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies
in the United&#160;States or abroad, including the United&#160;States Patent and Trademark Office (&#8220;USPTO&#8221;). Further, if
we encounter delays in our clinical trials or delays in obtaining regulatory approval, the period of time during which we could market
our product candidates under patent protection would be reduced. Thus, the patents that we may own and license may not afford us any
meaningful competitive advantage.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to seeking patents for some of our technology and programs, we may also rely on trade secrets, including unpatented&#160;know-how,&#160;technology
and other proprietary information, to maintain our competitive position. Any disclosure, either intentional or unintentional, by our
employees, the employees of third parties with whom we share our facilities or third-party&#160;consultants and vendors that we engage
to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity
breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements,
thus eroding our competitive position in our market. In order to protect our proprietary technology and processes, we rely in part on
confidentiality agreements with our collaborators, employees, consultants, outside scientific collaborators and sponsored researchers
and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate
remedy in the event of unauthorized disclosure of confidential information. We may need to share our proprietary information, including
trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft
of trade secrets, including through direct intrusion by private parties or state actors and those affiliated with or controlled by state
actors. In addition, while we undertake efforts to protect our trade secrets and other confidential information from disclosure, others
may independently discover trade secrets and proprietary information, and in such cases, we may not be able to assert any trade secret
rights against such party. Costly and time-consuming&#160;litigation could be necessary to enforce and determine the scope of our proprietary
rights and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Lastly,
if our trademarks and trade names are not registered or adequately protected, then we may not be able to build name recognition in our
markets of interest and our business may be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may not be successful in obtaining or maintaining necessary rights to our programs through acquisitions and&#160;in-licenses.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Because
our development programs currently do and may in the future require the use of proprietary rights held by third parties, the growth of
our business may depend in part on our ability to acquire,&#160;in-license,&#160;or use these third-party&#160;proprietary rights. We
may be unable to acquire or&#160;in-license&#160;any compositions, methods of use, processes or other third-party&#160;intellectual property
rights from third parties that we identify as necessary for our programs. The licensing and acquisition of third-party&#160;intellectual
property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party&#160;intellectual
property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due
to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive
us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party&#160;intellectual
property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully
obtain rights to required third-party&#160;intellectual property rights or maintain the existing intellectual property rights we do obtain,
we may have to abandon development of the relevant program, which could have a material adverse effect on our business, financial condition,
results of operations, and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">While
we plan to obtain the right to control prosecution, maintenance and enforcement of the patents relating to our programs, there may be
times when the filing and prosecution activities for patents and patent applications relating to our programs are controlled by our current
and future licensors or collaboration partners. If any of our current and future licensors or collaboration partners fail to prosecute,
maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by
payment of all applicable fees for patents covering our product candidates, we could lose our rights to the intellectual property or
our exclusivity with respect to those rights, our ability to develop and commercialize those product candidates may be adversely affected
and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the
right to control patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely
affected or prejudiced by actions or inactions of our licensees, our future licensors and our counsel that took place prior to the date
upon which we assumed control over patent prosecution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
future licensors may rely on third-party&#160;consultants or collaborators or on funds from third parties such that our future licensors
are not the sole and exclusive owners of the patents we&#160;in-license.&#160;If other third parties have ownership rights to our future&#160;in-licensed&#160;patents,
they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This
could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">It
is possible that we may be unable to obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain
a license, it may be&#160;non-exclusive,&#160;thereby giving our competitors access to the same technologies licensed to us. In that
event, we may be required to expend significant time and resources to redesign our technology, programs, or the methods for manufacturing
them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are
unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial
condition, results of operations, and prospects significantly. We cannot provide any assurances that third-party&#160;patents do not
exist which might be enforced against our current technology, manufacturing methods, programs, or future methods or products resulting
in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part
to pay royalties and/or other forms of compensation to third parties, which could be significant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Disputes
may arise between us and our future licensors regarding intellectual property subject to a license agreement, including: the scope of
rights granted under the license agreement and other interpretation-related&#160;issues; whether and the extent to which our technology
and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; our right to sublicense
patents and other rights to third parties; our right to transfer or assign the license; the inventorship and ownership of inventions
and&#160;know-how&#160;resulting from the joint creation or use of intellectual property by our future licensors and us and our partners;
and the priority of invention of patented technology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may be subject to patent infringement claims or may need to file claims to protect our intellectual property, which could result in substantial
costs and liability and prevent us from commercializing our potential products.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Because
the intellectual property landscape in the biotechnology industry is rapidly evolving and interdisciplinary, it is difficult to conclusively
assess our freedom to operate and guarantee that we can operate without infringing on or violating third-party&#160;rights. If certain
of our product candidates are ultimately granted regulatory approval, patent rights held by third parties, if found to be valid and enforceable,
could be alleged to render one or more of our product candidates infringing. If a third party successfully brings a claim against us,
we may be required to pay substantial damages, be forced to abandon any affected product candidate and/or seek a license from the patent
holder. In addition, any intellectual property claims (e.g., patent infringement or trade secret theft) brought against us, whether or
not successful, may cause us to incur significant legal expenses and divert the attention of our management and key personnel from other
business concerns. We cannot be certain that patents owned or licensed by us will not be challenged by others in the course of litigation.
Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because
they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation
could have a material adverse effect on our ability to raise funds.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Competitors
may infringe or otherwise violate our patents, trademarks, copyrights or other intellectual property. To counter infringement or other
violations, we may be required to file claims, which can be expensive and time-consuming. Any such claims could provoke these parties
to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights. In
addition, in a patent infringement proceeding, a court or administrative body may decide that one or more of the patents we assert is
invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to prevent the other party from
using the technology at issue on the grounds that our patents do not cover the technology. Similarly, if we assert trademark infringement
claims, a court or administrative body may determine that the marks we have asserted are invalid or unenforceable or that the party against
whom we have asserted trademark infringement has superior rights to the marks in question. In such a case, we could ultimately be forced
to cease use of such marks. In any intellectual property litigation, even if we are successful, any award of monetary damages or other
remedy we receive may not be commercially valuable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Further,
we may be required to protect our patents through procedures created to attack the validity of a patent at the USPTO.&#160;An adverse
determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which
could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary
standard in U.S.&#160;federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO
proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim
if first presented in a district court action.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, if our programs are found to infringe the intellectual property rights of third parties, these third parties may assert infringement
claims against our future licensees and other parties with whom we have business relationships and we may be required to indemnify those
parties for any damages they suffer as a result of these claims, which may require us to initiate or defend protracted and costly litigation
on behalf of licensees and other parties regardless of the merits of such claims. If any of these claims succeed, we may be forced to
pay damages on behalf of those parties or may be required to obtain licenses for the products they use.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings
relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure
during this type of litigation or other proceedings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent
contractors have wrongfully used or disclosed confidential information of third parties.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
is common in the biotechnology industry, in addition to our employees, we engage the services of consultants to assist us in the development
of our programs. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or
may be currently providing consulting services to, other biotechnology or pharmaceutical companies including our competitors or potential
competitors. We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged
trade secrets or other confidential information of former employers or competitors. Although we try to ensure that our employees and
consultants do not use the intellectual property, proprietary information,&#160;know-how&#160;or trade secrets of others in their work
for us, we may become subject to claims that we caused an employee to breach the terms of his or her&#160;non-competition&#160;or&#160;non-solicitation&#160;agreement,
or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information
of a former employer or competitor.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">While
we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and
could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court
could prohibit us from using technologies or features that are essential to our programs, if such technologies or features are found
to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation
or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators,
engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results
of operations and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial
costs and be a distraction to management.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Changes
to patent laws in the United&#160;States and other jurisdictions could diminish the value of patents in general, thereby impairing our
ability to protect our products.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Changes
in either the patent laws or interpretation of patent laws in the United&#160;States, including patent reform legislation such as the
Leahy-Smith&#160;America Invents Act (the &#8220;Leahy-Smith&#160;Act&#8221;) could increase the uncertainties and costs surrounding
the prosecution of our owned and&#160;in-licensed&#160;patent applications and the maintenance, enforcement or defense of our owned and&#160;in-licensed&#160;issued
patents. The Leahy-Smith&#160;Act includes a number of significant changes to United&#160;States patent law. These changes include provisions
that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective&#160;avenues for
competitors to challenge the validity of patents, and enable third-party&#160;submission of prior art to the USPTO during patent prosecution
and additional procedures to attack the validity of a patent at USPTO-administered&#160;post-grant&#160;proceedings, including post-grant&#160;review,
inter partes review and derivation proceedings. Assuming that other requirements for patentability are met, prior to March&#160;2013,
in the United&#160;States, the first to invent the claimed invention was entitled to the patent, while outside the United&#160;States,
the first to file a patent application was entitled to the patent. After March&#160;2013, under the Leahy-Smith&#160;Act, the United&#160;States
transitioned to a&#160;first-to-file&#160;system in which, assuming that the other statutory requirements for patentability are met,
the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was
the first to invent the claimed invention. As such, the Leahy-Smith&#160;Act and its implementation could increase the uncertainties
and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could
have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly
uncertain. U.S.&#160;Supreme Court and U.S.&#160;Court of Appeals for the Federal Circuit rulings have narrowed the scope of patent protection
available in certain circumstances and weakened the rights of patent owners in certain situations, including in the antibody arts. For
example, the United&#160;States Supreme Court in&#160;<i>Amgen, Inc. v. Sanofi</i>&#160;(<i>Amgen</i>) recently held that Amgen&#8217;s
patent claims to a class of antibodies functionally defined by their ability to bind a particular antigen were invalid for lack of enablement
where the patent specification provided twenty-six&#160;exemplary antibodies, but the claimed class of antibodies covered a &#8220;vast
number&#8221; of additional antibodies not disclosed in the specification. The Court stated that if patent claims are directed to an
entire class of compositions of matter, then the patent specification must enable a person skilled in the art to make and use the entire
class of compositions. This decision makes it unlikely that we will be granted U.S.&#160;patents with composition of matter claims directed
to antibodies functionally defined by their ability to bind a particular antigen. Even if we are granted claims directed to functionally
defined antibodies, it is possible that a third party may challenge our patents, when issued, relying on the reasoning in&#160;<i>Amgen</i>&#160;or
other recent precedential court decisions. Additionally, there have been proposals for additional changes to the patent laws of the United&#160;States
and other countries that, if adopted, could impact our ability to enforce our proprietary technology. This combination of events has
created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S.&#160;Congress,
the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material
adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Geopolitical
instability in the United&#160;States and in foreign countries could increase the uncertainties and costs surrounding the prosecution
or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. For example, the United&#160;States&#8217;
and foreign governments&#8217; actions related to Russia&#8217;s invasion of Ukraine may limit or prevent filing, prosecution and maintenance
of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result
in abandonment or lapse of patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such
an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government
in March&#160;2022 allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality
in, are registered in, or have predominately primary place of business or profit-making&#160;activities in the United&#160;States and
other countries that Russia has deemed unfriendly without consent or compensation. Consequently, we would not be able to prevent third
parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia.
Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may
be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, a European Unified Patent Court (&#8220;UPC&#8221;) entered into force on June&#160;1, 2023. The UPC is a common patent court
that hears patent infringement and revocation proceedings effective for EU Member States. This could enable third parties to seek revocation
of a European patent in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which
the European patent is validated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Although
we do not currently own any European patents or applications, if we obtain such patents and applications in the future, any such revocation
and loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology
and products. Moreover, the controlling laws and regulations of the UPC will develop over time, and may adversely affect our ability
to enforce or defend the validity of any European patents we may obtain. We may decide to opt out from the UPC any future European patent
applications that we may file and any patents we may obtain. If certain formalities and requirements are not met, however, such European
patents and patent applications could be challenged for&#160;non-compliance&#160;and brought under the jurisdiction of the UPC.&#160;We
cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, if we decide
to opt out of the UPC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Obtaining
and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for&#160;non-compliance&#160;with these
requirements.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Periodic
maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be
paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO
and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other
similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late
fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment
or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.&#160;Non-compliance&#160;events
that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official
actions within prescribed time limits,&#160;non-payment&#160;of fees and failure to properly legalize and submit formal documents. If
we fail to maintain the patents and patent applications covering our programs, our competitive position would be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent,
which might adversely affect our ability to develop and market our products.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims
or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party&#160;patent
and pending application in the United&#160;States and abroad that is relevant to or necessary for the commercialization of our product
candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in
a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application
may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party&#160;patent or may incorrectly
predict whether a third-party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration
date of any patent in the United&#160;States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly
interpret relevant patents may negatively impact our ability to develop and market our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, because some patent applications in the United&#160;States may be maintained in secrecy until the patents are issued, patent
applications in the United&#160;States and many foreign jurisdictions are typically not published until 18&#160;months after filing,
and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent
applications for technology covered by our issued patents or our pending applications, or that we were the first to invent the technology.
Our competitors may have filed, and may in the future file, patent applications covering products or technology similar to ours. Any
such patent application may have priority over our patent applications or patents, which could require us to obtain rights to issued
patents covering such technologies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual
property as an inventor or&#160;co-inventor.&#160;The failure to name the proper inventors on a patent application can result in the
patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different
individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter
of the patent, conflicting obligations of third parties involved in developing our programs or as a result of questions regarding&#160;co-ownership&#160;of
potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership.
Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we
fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as
exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our
business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
future licensors may rely on third-party&#160;consultants or collaborators or on funds from third parties, such as the U.S.&#160;government,
such that our licensors would not be the sole and exclusive owners of any patents we&#160;in-license.&#160;If other third parties have
ownership rights or other rights to our&#160;in-licensed&#160;patents, they may be able to license such patents to our competitors, and
our competitors could market competing products and technology. This could have a material adverse effect on our competitive position,
business, financial conditions, results of operations, and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Patent
terms may be inadequate to protect the competitive position of our product candidates for an adequate amount of time.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Patents
have a limited lifespan. In the United&#160;States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
20&#160;years from its earliest United&#160;States&#160;non-provisional&#160;filing date. Various extensions may be available, but the
life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent
life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time
required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might
expire before or shortly after such product candidates are commercialized. As a result, our owned and licensed patent portfolio may not
provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
technology licensed from various third parties may be subject to retained rights.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
future licensors may retain certain rights under the relevant agreements with us, including the right to use the underlying technology
for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make
customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors
limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology
in the event of misuse.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Our Reliance on Third Parties</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
currently rely on licensing arrangements with Paragon through the Option Agreements. If we are unable to maintain collaborations or licensing
arrangements, or if our collaborations or licensing arrangements are not successful, our business could be negatively impacted.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
currently rely on our licensing arrangements with Paragon through the Option Agreements for a substantial portion of our discovery capabilities
and&#160;in-licenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Collaborations
or licensing arrangements that we enter into may not be successful, and any success will depend heavily on the efforts and activities
of such collaborators or licensors. If any of our current or future collaborators or licensors experience delays in performance of, or
fails to perform our obligations under their agreement with us, disagrees with our interpretation of the terms of such agreement or terminates
their agreement with us, the research programs with respect to which we have the option to acquire intellectual property license rights
to pursuant to the Option Agreements and development timeline could be adversely affected. If we fail to comply with any of the obligations
under our collaborations or license agreements, including payment terms and diligence terms, our collaborators or licensors may have
the right to terminate such agreements, in which event we may lose intellectual property rights and may not be able to develop, manufacture,
market or sell the products covered by our agreements or may face other penalties under our agreements. Our collaborators and licensors
may also fail to properly maintain or defend the intellectual property we have licensed from them, if required by our agreement with
them, or even infringe upon, our intellectual property rights, leading to the potential invalidation of our intellectual property or
subjecting us to litigation or arbitration, any of which would be time-consuming&#160;and expensive and could harm our ability to commercialize
our product candidates. In addition, collaborators could independently develop, or develop with third parties, products that compete
directly or indirectly with our programs and products if the collaborators believe that the competitive products are more likely to be
successfully developed or can be commercialized under terms that are more economically attractive than ours.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
part of our strategy, we plan to evaluate additional opportunities to enhance our capabilities and expand our development pipeline or
provide development or commercialization capabilities that complement ours. We may not realize the benefits of such collaborations, alliances
or licensing arrangements. Any of these relationships may require us to incur&#160;non-recurring&#160;and other charges, increase our
near and long-term&#160;expenditures, issue securities that dilute our existing stockholders or disrupt our management and business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may face significant competition in attracting appropriate collaborators, and more established companies may also be pursuing strategies
to license or acquire third-party&#160;intellectual property rights that we consider attractive. These companies may have a competitive
advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition,
companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a definitive agreement
for a collaboration will depend upon, among other things, our assessment of the collaborator&#8217;s resources and expertise, the terms
and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Collaborations
are complex and time-consuming&#160;to negotiate, document and execute. In addition, consolidation among large pharmaceutical and biotechnology
companies has reduced the number of potential future collaborators. We may not be able to negotiate additional collaborations on a timely
basis, on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake
the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them
to market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
currently rely, and plan to rely in the future, on third parties to conduct and support our preclinical studies and clinical trials.
If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be
able to obtain regulatory approval of or commercialize our product candidates.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have utilized and plan to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions,
CROs, contract testing labs, CMOs and strategic partners, to supply, conduct and support our preclinical studies and clinical trials
under agreements with us. We will rely heavily on these third parties over the course of our preclinical studies and clinical trials,
and we control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion
of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials
than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our
studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance
on these third parties does not relieve us of our regulatory responsibilities. We and our third-party&#160;contractors and CROs are required
to comply with GCP regulations, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities
for all of our programs in clinical development. If we or any of these third parties fail to comply with applicable GCP regulations,
the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities
may require us to perform additional clinical trials before approving our marketing applications or refuse to approve our marketing applications.
We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical
trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced under cGMP regulations.
Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.
Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws
and regulations or healthcare privacy and security laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Any
third parties conducting our clinical trials will not be our employees and, except for remedies available to us under our agreements
with such third parties, we cannot control whether they devote sufficient time and resources to our programs. These third parties may
be involved in mergers, acquisitions or similar transactions and may have relationships with other commercial entities, including our
competitors, for whom they may also be conducting clinical trials or other product development activities, which could negatively affect
their performance on our behalf and the timing thereof and could lead to products that compete directly or indirectly with our product
candidates. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines,
if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere
to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated
and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, we currently rely on foreign CROs and CMOs, including WuXi Biologics (Hong&#160;Kong) Limited and its affiliates (&#8220;WuXi
Biologics&#8221;) and will likely continue to rely on foreign CROs and CMOs in the future. WuXi is a subsidiary or affiliate of WuXi
Biologics, which is identified in the proposed U.S. legislation known as the BIOSECURE Act as a biotechnology &#8220;company of concern.&#8221;
The current version of the BIOSECURE Act introduced in the House of Representatives would prohibit federal agencies from entering into
procurement contracts with, as well as providing grants and loans to, an entity that uses biotechnology equipment or services from a
biotechnology company of concern, and includes a grandfathering provision allowing biotechnology equipment and services provided or produced
by named &#8220;biotechnology companies of concern&#8221; under a contract or agreement entered into before the effective date until
January 1, 2032. The pathway and timing for the BIOSECURE Act or its provisions to become law are uncertain, although the bill was passed
in the House of Representatives on September 9, 2024. Depending on whether the BIOSECURE Act becomes law, what the final language of
the BIOSECURE Act includes, and how the law is interpreted by U.S. federal agencies, we could be potentially restricted from pursuing
U.S. federal government business or grants in the future if we continue to use WuXi or other parties identified as &#8220;biotechnology
companies of concern&#8221; beyond the grandfathering period. Foreign CMOs may be subject to U.S.&#160;legislation, including the proposed
BIOSECURE bill, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material
available to us, delay the procurement or supply of such material or have an adverse effect on our ability to secure significant commitments
from governments to purchase our potential therapies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">For
example, the biopharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government
policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on our collaborators in China
which could have an adverse effect on our business, financial condition, results of operations and prospects. Evolving changes in China&#8217;s
public health, economic, political, and social conditions and the uncertainty around China&#8217;s relationship with other governments,
such as the United&#160;States and the UK, could also negatively impact our ability to manufacture our product candidates for our planned
clinical trials or have an adverse effect on our ability to secure government funding, which could adversely affect our financial condition
and cause it to delay our clinical development programs. Furthermore, if the BIOSECURE bill is passed and one or more of our collaborators
in China, including WuXi Biologics, is deemed to be a biotechnology company of concern, our operations and financial condition may be
negatively impacted as a result of any delays or increased costs arising from the trade restrictions and other foreign regulatory requirements
affecting such collaborators. In addition, while we have established relationships with CROs and CMOs outside of China, moving to those
suppliers in the event of a geopolitical instability affecting our collaborators in China could introduce delays into the development
program.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
currently rely and expect to rely in the future on the use of manufacturing suites in third-party facilities or on third parties to manufacture
our product candidates, and we may rely on third parties to produce and process our products, if approved. Our business could be adversely
affected if we are unable to use third-party manufacturing suites or if the third-party manufacturers encounter difficulties in production.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
do not currently own any facility that may be used as our clinical or commercial manufacturing and processing facility and must currently
rely on CMOs to manufacture our product candidates. We have not yet caused any product candidates to be manufactured on a commercial
scale and may not be able to do so for any of our product candidates, if approved. We currently have a sole source relationship for our
supply of the ORKA-001&#160;and ORKA-002&#160;programs. If there should be any disruption in such supply arrangement, including any adverse
events affecting our sole supplier, it could have a negative effect on the clinical development of our programs and other operations
while we work to identify and qualify an alternate supply source. We may not control the manufacturing process of, and may be completely
dependent on, our contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the
FDA or comparable foreign regulatory authorities for the manufacture of our product candidates. Beyond periodic audits, we have limited
control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a
comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws
any approval in the future, we may need to find alternative manufacturing facilities, which would require the incurrence of significant
additional costs, delays, and materially adversely affect our ability to develop, obtain regulatory approval for or market our product
candidates, if approved. Similarly, our failure, or the failure of our CMOs, to comply with applicable regulations could result in sanctions
being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation,
seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly
and adversely affect supplies of our product candidates or drugs and harm our business and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Moreover,
our CMOs may experience manufacturing difficulties due to resource constraints, supply chain issues, or as a result of labor disputes
or unstable political environments. If any CMOs on which we will rely fail to manufacture quantities of our product candidates at quality
levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows us to achieve
profitability, our business, financial condition and prospects could be materially and adversely affected. In addition, our CMOs are
responsible for transporting&#160;temperature-controlled&#160;materials that can be inadvertently degraded during transport due to several
factors, rendering certain batches unsuitable for trial use for failure to meet, among others, our integrity and purity specifications.
We and any of our CMOs may also face product seizure or detention or refusal to permit the import or export of products. Our business
could be materially adversely affected by business disruptions to our third-party&#160;providers that could materially adversely affect
our anticipated timelines, potential future revenue and financial condition and increase our costs and expenses. Each of these risks
could delay or prevent the completion of our preclinical studies and clinical trials or the approval of any of our product candidates
by the FDA, result in higher costs or adversely impact commercialization of our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Employee Matters, Managing Growth and Other Risks Related to Our Business</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>In
order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties
in managing this growth.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of
preclinical and clinical drug development, technical operations, clinical operations, regulatory affairs and, potentially, sales and
marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial
personnel and systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial
resources and the limited experience of our management team working together in managing a company with such anticipated growth, we may
not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining
highly qualified personnel, we may not be able to successfully implement our business strategy.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are a preclinical stage biotechnology company with a limited operating history. We have been and will continue to be highly dependent
on the research and development, clinical and business development expertise of our executive officers, as well as the other principal
members of our management, scientific and clinical team. Any of our management team members may terminate their employment with us at
any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Attracting
and retaining qualified personnel will also be critical to our success, including with respect to any strategic transaction that we may
pursue. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development
and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing
executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals
in our industry with the breadth of skills and experience required to successfully develop, facilitate regulatory approval of and commercialize
product candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these
key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel.
We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our discovery
and nonclinical and clinical development and commercialization strategy. Our consultants and advisors may be employed by employers other
than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.
If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
future growth may depend, in part, on our ability to operate in foreign markets, where it would be subject to additional regulatory burdens
and other risks and uncertainties.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets for which we
may rely on collaboration with third parties. We are not permitted to market or promote any of our product candidates before we receive
regulatory approval from the applicable foreign regulatory authority, and may never receive such regulatory approval for any of our product
candidates. To obtain separate regulatory approval in many other countries, we must comply with numerous and varying regulatory requirements
of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and
distribution of our product candidates, and we cannot predict success in these jurisdictions. If we fail to comply with the regulatory
requirements in international markets and receive applicable marketing approvals, our target market will be reduced and our ability to
realize the full market potential of our product candidates will be harmed and our business will be adversely affected. Moreover, even
if we obtain approval of our product candidates and ultimately commercializes our product candidates in foreign markets, we would be
subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting
and legal requirements and reduced protection of intellectual property rights in some foreign countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete
achieve the forecasted growth, our business may not grow at similar rates, or at all.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which
may not prove to be accurate. Our estimates and forecasts relating to size and expected growth of our target market may prove to be inaccurate.
Even if the markets in which we compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or
at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many
risks and uncertainties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted
price for the product, the ability to obtain coverage and reimbursement and whether we own the commercial rights for that territory.
If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is
narrower than we expect or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not
generate significant revenue from sales of such products, even if approved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors
may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators,
CROs, CMOs, suppliers and vendors acting for or on our behalf may engage in misconduct or other improper activities. We have adopted
a code of conduct and ethics, but it is not always possible to identify and deter misconduct by these parties and the precautions we
take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us
from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
internal information technology systems, or those of any of our CROs, manufacturers, other contractors or consultants, third-party service
providers, or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper
access to, use of, or destruction of our proprietary or confidential data, employee data or personal data, which could result in additional
costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the ordinary course of our business, we and the third parties upon which we rely collect, receive, store, process, generate, use, transfer,
disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) proprietary, confidential, and sensitive
data, including personal data, intellectual property, trade secrets, and other sensitive data (collectively, sensitive information).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Despite
the implementation of security measures in an effort to protect systems that store our information, given their size and complexity and
the increasing amounts of information maintained on our internal information technology systems and those of our third-party&#160;CROs,
other contractors (including sites performing our clinical trials), third-party&#160;service providers and supply chain companies, and
consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system
malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent
or intentional actions by our employees, contractors, consultants, business partners and/or other third parties, or from cyber-attacks&#160;by
malicious third parties, which may compromise our system infrastructure or lead to the loss, destruction, alteration or dissemination
of, or damage to, our data.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Some
actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state&#160;actors for
geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts,
we, and the third parties upon which we rely, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks,
that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services.
In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations,
ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion
payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for
example, applicable laws or regulations prohibiting such payments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
the extent that any disruption or security breach were to result in loss, destruction, unavailability, alteration or dissemination of,
or damage to, our data or applications, or for it to be believed or reported that any of these occurred, we could incur liability and
reputational damage and the development and commercialization of our product candidates could be delayed. Further, our insurance policies
may not be adequate to compensate us for the potential losses arising from any such disruption in, or failure or security breach of,
our systems or third-party&#160;systems where information important to our business operations or commercial development is stored.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
fully-remote&#160;workforce may create additional risks for our information technology systems and data because our employees work remotely
and utilize network connections, computers, and devices working at home, while in transit and in public locations. Additionally, business
transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems
could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">While
we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will
be effective. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and
techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred.
Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.
Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures
are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
rely on third-party&#160;service providers and technologies to operate critical business systems to process sensitive information in
a variety of contexts. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties
may not have adequate information security measures in place. If our third-party&#160;service providers experience a security incident
or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party&#160;service
providers fail to satisfy their privacy or security-related&#160;obligations to it, any award may be insufficient to cover our damages,
or we may be unable to recover such award. In addition, supply-chain&#160;attacks have increased in frequency and severity, and we cannot
guarantee that third parties&#8217; infrastructure in our supply chain or our third-party&#160;partners&#8217; supply chains have not
been compromised.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may
experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections);
additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation
(including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions
in our operations (including availability of data); financial loss; management distraction; delays; and other similar harms. Security
incidents and attendant consequences may cause stakeholders (including investors and potential customers) to stop supporting our platform,
deter new customers from products, and negatively impact our ability to grow and operate our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in
our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.
We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out
of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or
that such coverage will pay future claims.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection,
and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which
could include civil or criminal penalties), fines and sanctions, private litigation and/or adverse publicity and could negatively affect
our operating results and business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
and third parties who we work with are or may become subject to numerous domestic and foreign laws, regulations, and standards relating
to privacy, data protection, and data security, the scope of which is changing, subject to differing applications and interpretations,
and may be inconsistent among countries, or conflict with other rules. We are or may become subject to the terms of contractual obligations
related to privacy, data protection and data security. Our obligations may also change or expand as our business grows. The actual or
perceived failure by us or third parties related to us to comply with such laws, regulations and obligations could increase our compliance
and operational costs, expose us to regulatory scrutiny, actions, fines and penalties, result in reputational harm, lead to a loss of
customers, result in litigation and liability, and otherwise cause a material adverse effect on our business, financial condition, and
results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur
costs that could have a material adverse effect on the success of our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the
handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations may involve the use of hazardous and
flammable materials, including chemicals and biological and radioactive materials. In addition, we may incur substantial costs in order
to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations
may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result
in substantial fines, penalties or other sanctions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
rules dealing with U.S.&#160;federal, state and local income taxation are constantly under review by persons involved in the legislative
process and by the Internal Revenue Service and the U.S.&#160;Treasury Department. Changes to tax laws (which may have retroactive application)
could adversely affect our stockholders or us. We continue to assess the impact of various tax reform proposals and modifications to
existing tax treaties in all jurisdictions where we have operations or employees to determine the potential effect on our business and
any assumptions we make about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms
of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted. For example, the
United&#160;States enacted the Inflation Reduction Act&#160;of&#160;2022, which implements, among other changes, a 1% excise tax on certain
stock buybacks. In addition, beginning in 2022, the Tax Cuts and&#160;Jobs Act&#160;eliminated the previously available option to deduct
research and development expenditures and requires taxpayers to amortize them generally over five&#160;years for research activities
conducted in the United&#160;States and over 15&#160;years for research activities conducted outside the United&#160;States. The U.S.&#160;Congress
is considering legislation that would restore the current deductibility of research and development expenditures; however, there is no
assurance that the current provision will be repealed or otherwise modified. Such changes, among others, may adversely affect our effective
tax rate, results of operation and general business condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that we believe
will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able
to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and
company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new product candidates or products
resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business.
There is no assurance that, following any such acquisition, we will achieve the synergies expected in order to justify the transaction,
which could result in a material adverse effect on our business and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
maintain our cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions
could adversely affect our ability to pay our operational expenses or make other payments.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
cash held in&#160;non-interest-bearing&#160;and interest-bearing&#160;accounts exceeds the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)
insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance
limitations. For example, the FDIC took control of Silicon Valley Bank on March&#160;10, 2023. The Federal Reserve subsequently announced
that account holders would be made whole. We currently hold a small portion of our cash and cash equivalents at Silicon Valley Bank.
However, the FDIC may not make all account holders whole in the event of future bank failures. In addition, even if account holders are
ultimately made whole with respect to a future bank failure, account holders&#8217; access to their accounts and assets held in their
accounts may be substantially delayed. Any material loss that we may experience in the future or inability for a material time period
to access our cash and cash equivalents could have an adverse effect on our ability to pay our operational expenses or make other payments,
which could adversely affect our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>General
Risk Factors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
estimates&#160;of market&#160;opportunity&#160;and forecasts&#160;of market&#160;growth may&#160;prove&#160;to be inaccurate,&#160;and
even if the markets&#160;in which we compete&#160;achieve&#160;the forecasted&#160;growth, our business&#160;may&#160;not grow at similar&#160;rates,
or at all.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which
may not prove to be accurate. Our estimates and forecasts relating to size and expected growth of our target market may prove to be inaccurate.
Even if the markets in which we compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or
at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many
risks and uncertainties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted
price for the product, the ability to obtain coverage and reimbursement and whether we own the commercial rights for that territory.
If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is
narrower than we expect or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not
generate significant revenue from sales of such products, even if approved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may become exposed to costly and damaging liability claims, either when testing a product candidate in the clinical or at the commercial
stage, and our product liability insurance may not cover all damages from such claims.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing,
marketing, and use of pharmaceutical products. While we currently have no products that have been approved for commercial sale, the future
use of a product candidate in clinical trials, and the sale of any approved products in the future, may expose us to liability claims.
These claims may be made by patients that use the product, healthcare providers, pharmaceutical companies, or others selling such product.
Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially and adversely affect the
market for our products or any prospects for commercialization of our products. Although we intend to obtain product liability insurance
for our future clinical trials, it is possible that any liabilities could exceed our insurance coverage or that in the future we may
not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability
that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess
of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Litigation
costs and the outcome of litigation could have a material adverse effect on our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">From
time to time&#160;we&#160;may&#160;be&#160;subject&#160;to&#160;litigation&#160;claims through the ordinary course of our business operations
regarding, but not limited to, employment matters, security of patient and employee personal information, contractual relations with
collaborators and intellectual property rights. Litigation to defend ourselves against claims by third parties, or to enforce any rights
that we may have against third parties, may continue to be necessary, which could result in substantial costs and diversion of our resources,
causing a material adverse effect on our business, financial condition, results of operations or cash flows.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
business could be adversely affected by economic downturns, inflation, fluctuation in interest rates, natural disasters, public health
crises, political crises, geopolitical events, or other macroeconomic conditions, which could have a material and adverse effect on our
results of operations and financial condition.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things,
diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases
in inflation rates, fluctuation in interest rates, and uncertainty about economic stability. For example, the&#160;COVID-19&#160;pandemic
resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. The Federal Reserve previously
raised interest rates multiple times in response to concerns about inflation and it may raise them again. Fluctuation in interest rates,
coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending.
Similarly, the ongoing military conflict between Russia and Ukraine and in the Middle East and rising tensions with China have created
extreme volatility in the global capital markets and may have further global economic consequences, including disruptions of the global
supply chain. Any such volatility and disruptions may adversely affect our business or the third parties on whom we rely. If the equity
and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing
more costly, more dilutive, or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates
can adversely affect us by increasing our costs, including materials, operational, labor and employee benefit costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating
or expanding clinical trials and manufacturing sufficient quantities of materials. Any one or a combination of these events could have
a material and adverse effect on our results of operations and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Owning Our Stock</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>The
market price of our common stock may continue to be volatile.</i></b></span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
market price of our common stock may be subject to significant fluctuations. Some of the factors that may cause the market price of our
common stock to fluctuate include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timing
and results of clinical trials and preclinical studies of our product candidates, or those of our competitors or our existing or future
collaborators;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to meet or exceed financial and development projections that we may provide to the public;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of significant or potential equity or debt sales by us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to meet or exceed the financial and development projections of the investment community;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to achieve the perceived benefits of our recent merger as rapidly or to the extent anticipated by financial or industry analysts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions
    taken by regulatory agencies with respect to our product candidates, clinical studies, manufacturing process or sales and marketing
    terms;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection
    for our technologies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    or departures of key personnel, including scientific or management personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    lawsuits, including patent or stockholder litigation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions
    regarding our business and stock;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the market valuations of similar companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    market, macroeconomic or geopolitical conditions or market conditions in the pharmaceutical and biotechnology sectors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    of securities by us or our securityholders in the future;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    we fail to raise an adequate amount of capital to fund our operations or continued development of our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading
    volume of our common stock;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or
    capital commitments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    publicity relating to precision medicine product candidates, including with respect to other products in such markets;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    introduction of technological innovations or new therapies that compete with our products; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">period-to-period
    fluctuations in our financial results.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Moreover,
the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual
companies. These broad market fluctuations may also adversely affect the trading price of our common stock. In addition, a recession,
depression or other sustained adverse market event could materially and adversely affect our business and the value of our common stock.
In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted
class action securities litigation against such companies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
market volatility may lead to increased shareholder activism if we experience a market valuation that activists believe is not reflective
of our intrinsic value. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of
our board of directors could have an adverse effect on our operating results, financial condition and cash flows.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
certificate of incorporation and bylaws, as well as provisions under Delaware law, could make an acquisition of the company more difficult
and may prevent attempts by our stockholders to replace or remove management.</i></b></span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Provisions
in our certificate of incorporation and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of the
company that stockholders may consider favorable, including transactions in which our common stockholders might otherwise receive a premium
price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of
our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible
for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace
or remove current management by making it more difficult for stockholders to replace members of our board of directors. Among other things,
these provisions:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    a classified board of directors such that all members of the board are not elected at one time;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allow
    the authorized number of our directors to be changed only by resolution of our board of directors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
    the manner in which stockholders can remove directors from the board;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on
    at stockholder meetings;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written
    consent;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
    who may call a special meeting of stockholders;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorize
    our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221;
    that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not
    been approved by our board of directors; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    the approval of the holders of at least 66 2/3% of the votes that all stockholders would be entitled to cast to amend or repeal certain
    provisions of our charter or bylaws.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Moreover,
because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law (&#8220;DGCL&#8221;),
which prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Although we believe
these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with
our board of directors, they would apply even if the offer may be considered beneficial by some stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
governing documents provide that, unless we consent in writing to the selection of an alternative forum, certain designated courts will
be the sole and exclusive forum for certain legal actions between us and our stockholders, which could limit our stockholders&#8217;
ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
governing documents provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware
is the sole and exclusive forum for state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action
asserting a claim of or based on a breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees
or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, the certificate of incorporation
or the bylaws, (iv) any action to interpret, apply, enforce or determine the validity of the certificate of incorporation or bylaws,
or (v) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery
having personal jurisdiction over the indispensable parties named as defendants therein, which for purposes of this risk factor refers
to herein as the &#8220;Delaware Forum Provision.&#8221; Our governing documents further provide that, unless we consent in writing to
an alternative forum, the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting
a cause of action arising under the Securities Act, which for purposes of this risk factor refers to herein as the &#8220;Federal Forum
Provision.&#8221; Neither the Delaware Forum Provision nor the Federal Forum Provision will apply to any causes of action arising under
the Exchange Act. In addition, any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will
be deemed to have notice of and consented to the foregoing Delaware Forum Provision and Federal Forum Provision; provided, however, that
stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations
thereunder.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Delaware Forum Provision and the Federal Forum Provision may impose additional litigation costs on our stockholders in pursuing any such
claims, particularly if such stockholders do not reside in or near the State of Delaware. Additionally, these forum selection clauses
may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors,
officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action,
if successful, might benefit our stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Future
sales of shares by existing stockholders could cause our stock price to decline.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
our stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after legal restrictions
on resale lapse, the trading price of our common stock could decline. In addition, shares of our common stock that are subject to our
outstanding options will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements
and Rules 144 and 701 under the Securities Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
do not anticipate that we will pay any cash dividends in the foreseeable future</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
do not anticipate that we will pay any cash dividends in the foreseeable future. The current expectation is that we will retain our future
earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock
will be your sole source of gain, if any, for the foreseeable future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted
to our stockholders for approval.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
executive officers, directors and principal stockholders beneficially own a significant percentage of our outstanding common stock. As
a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters
submitted to our stockholders for approval, as well as our management and affairs. For example, these stockholders, if they choose to
act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of
all or substantially all of our assets. This concentration of voting power could delay or prevent our acquisition on terms that other
stockholders may desire.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
equity research analysts do not publish research or reports, or publish unfavorable research or reports about us, our business or our
market, our stock price and trading volume could decline.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and
our business. Equity research analysts may elect to not provide research coverage of our common stock, and such lack of research coverage
may adversely affect the market price of our common stock. If we do have equity research analyst coverage, we will not have any control
over the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or more equity
research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases
coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our
stock price or trading volume to decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>USE
OF PROCEEDS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are not selling any securities under this prospectus and we will not receive any proceeds from the sale of the Resale Shares covered
hereby. The net proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders.
Some of the shares of Common Stock offered hereby are issuable upon the exercise of the Pre-Funded Warrants. Upon exercise of such Pre-Funded
Warrants for cash, we will receive the nominal cash exercise price paid by the holders of the Pre-Funded Warrants. We intend to use those
proceeds, if any, for general corporate purposes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Subject
to limited exceptions, the Selling Stockholders will pay any underwriting discounts and commissions and expenses incurred by the Selling
Stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Stockholders in disposing
of any of the Resale Shares. We will bear the costs, fees and expenses incurred in effecting the registration of the Resale Shares covered
by this prospectus, including all registration and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our independent
registered public accounting firm. &#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>




</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>You
should read the following discussion of our financial condition and results of operations in conjunction with the consolidated financial
statements and the related notes thereto and other financial information included elsewhere in this prospectus. This discussion contains
forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance
that involve risks, uncertainties and assumptions. Our actual results could differ materially from those discussed in these forward-looking
statements as a result of various factors. Factors that could cause or contribute to these differences include, but are not limited to,
those discussed below and elsewhere in this prospectus, particularly in the section titled &#8220;Risk Factors.&#8221; Please also see
the section titled &#8220;Cautionary Statement Concerning Forward-Looking Statements.&#8221; As used in this prospectus, unless the context
suggests otherwise, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, &#8220;the Company&#8221;, or &#8220;Oruka&#8221; refers to
Oruka Therapeutics, Inc. and its subsidiaries, including Oruka Therapeutics Operating Company, LLC. </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are a biotechnology company focused on developing novel monoclonal antibody therapeutics for psoriasis (&#8220;PsO&#8221;) and other
inflammatory and immunology (&#8220;I&amp;I&#8221;) indications. Our name is derived from <i>or</i>, for &#8220;skin,&#8221; and <i>arukah</i>,
for &#8220;restoration&#8221;&#160;and reflects our mission to deliver therapies for chronic skin diseases that provide patients the
greatest possible freedom from their condition. Our strategy is to apply antibody engineering and format innovations to validated modes
of action, which we believe will enable us to improve meaningfully upon the efficacy and dosing regimens of standard-of-care medicines
while significantly intending to reduce technical and biological risk. Our programs aim to treat and potentially modify disease by targeting
mechanisms with proven efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells.
Our lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (&#8220;IL-23p19&#8221;) for the treatment of PsO.
Our co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (&#8220;IL-17A/F&#8221;) for the treatment of
PsO, psoriatic arthritis (&#8220;PsA&#8221;), and other conditions. These programs each bind their respective targets at high affinity
and incorporate half-life extension technology with the aim to increase exposure and decrease dosing frequency. We believe that our focused
strategy, differentiated portfolio, and deep expertise position us to set a new treatment standard in large&#160;I&amp;I markets with
continued unmet need.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Since
our inception in February&#160;2024, we have devoted substantially all of our resources to raising capital, organizing and staffing the
company, business and scientific planning, conducting discovery and research activities, establishing arrangements with third parties
for the manufacture of our programs and component materials, and providing general and administrative support for these operations. We
do not have any programs approved for sale and have not generated any revenue from product sales. To date, we have funded our operations
primarily with proceeds from the issuance of convertible preferred stock, common stock, convertible note, pre-funded warrants, and the
proceeds from the reverse recapitalization and merger with ARCA biopharma, Inc., our Pre-Closing Financing and subsequent PIPE Financing
(as defined and further described in &#8220;<i>Recent developments&#8221; </i>below).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Since
our inception, we have incurred significant losses and negative cash flows from our operations. Our ability to generate product revenue
sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of any programs
we may develop. We generated net losses of $28.6 million for the three months ended September 30, 2024 and $57.9 million for the period
from February&#160;6, 2024 (inception) to September&#160;30, 2024. For the period from February 6 (inception) to September 30, 2024,
we have used net cash of $39.0 million for our operating activities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
had cash and cash equivalents of $410.9 million as of September 30, 2024. We expect that our existing cash and cash equivalents will
be sufficient to fund our operating plans for at least twelve months from the date of filing of this prospectus. We expect to continue
to incur substantial losses for the foreseeable future, and our transition to profitability will depend upon successful development,
approval and commercialization of our product candidates and upon achievement of sufficient revenues to support our cost structure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ORKA-001</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ORKA-001
is a high affinity, extended half-life monoclonal antibody (&#8220;mAb&#8221;) designed to target IL-23p19. IL-23 is a pro-inflammatory
cytokine that plays a critical role in the proliferation and development of T helper 17 (&#8220;Th17&#8221;) cells, which are the primary
drivers of several autoimmune and inflammatory disorders, including PsO.&#160;IL-23 is composed of two subunits: a p40 subunit that is
shared with IL-12 and a p19 subunit that is specific to IL-23. First-generation IL-23 antibodies bound p40 and inhibited both IL-12 and
IL-23 signaling, while more recent IL-23 antibodies targeting the p19 subunit have shown improved efficacy and safety. Based on preclinical
evidence, we believe that ORKA-001 could achieve higher response rates than established therapies in PsO while requiring less frequent
dosing and maintaining the favorable safety profile of therapies targeting IL-23p19.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ORKA-001
is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain to modify the pH-dependent
binding to the neonatal Fc receptor. As a result, it has a pharmacokinetic profile that has the potential to support a SQ injection as
infrequently as once or twice a year. In addition, emerging evidence suggests that IL-23 blockade can modify the disease biology of PsO,
possibly leading to durable remissions and preventing the development of PsA.&#160;We believe that the expected characteristics of ORKA-001
increase its potential to deliver these disease-modifying benefits.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
plan to initiate a Phase 1 trial of ORKA-001 in the first quarter of 2025. We expect to share interim data from the first-in-human trial
in healthy volunteers, including initial pharmacokinetic data, in the second half of 2025 and initial efficacy data in PsO patients in
the second half of 2026.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ORKA-002</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ORKA-002
is a high affinity, extended half-life mAb designed to target IL-17A and IL-17F (&#8220;IL-17A/F&#8221;).&#160;IL-17 inhibition has become
central to the treatment of psoriatic diseases, including PsO and PsA, and has also shown efficacy in other&#160;I&amp;I indications,
such as hidradenitis suppurativa and axial spondyloarthritis.&#160;More recently, the importance of inhibiting the IL-17F isoform along
with IL-17A has become appreciated, and dual blockade with the recently approved therapy Bimzelx<sup>&#174;</sup> (bimekizumab) has led
to higher response rates in patients than blockade of IL-17A alone. ORKA-002 is designed to bind IL-17A/F at similar epitopes, or binding
sites, and affinity ranges as bimekizumab, but incorporates half-life extension technology that could enable more convenient dosing intervals.
We plan to initiate a Phase&#160;1 trial of ORKA-002 in the third quarter of 2025. We expect to share interim data from the first-in-human
trial in healthy volunteers, including initial pharmacokinetic data, in the first half of 2026.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
view ORKA-002 and ORKA-001 as highly complementary. Patients with moderate-to-severe PsO that have purely skin manifestations are most
often treated with IL-23 inhibitors due to the high efficacy and tolerability of this mechanism. However, for patients who also have
joint involvement, or signs and symptoms of PsA, an IL-17 inhibitor is typically used due to its efficacy in addressing both skin and
joint symptoms. In addition, IL-17 inhibitors are often used in patients with highly resistant skin symptoms that do not adequately resolve
through treatment with an IL-23 inhibitor. Together, ORKA-001 and ORKA-002 provide the potential to offer a highly compelling product
profile for most patients with PsO and/or PsA, as well as the opportunity to address additional&#160;I&amp;I indications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Additional
Pipeline Program</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have a third mAb program, ORKA-003, designed to target an undisclosed pathway. Our strategy as a company is to remain highly focused
on&#160;I&amp;I diseases, and specifically on inflammatory dermatology conditions. Our third program provides the potential for indication
expansion beyond PsO and may create combination opportunities with our more advanced programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Recent
Developments</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>The
Merger</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
August 29, 2024, we consummated the previously announced business combination (&#8220;Closing&#8221;) pursuant to that certain Agreement
and Plan of Merger and Reorganization, dated April 3, 2024 (the &#8220;Merger Agreement&#8221;), by and among ARCA, Atlas Merger Sub
Corp, a wholly owned subsidiary of ARCA (&#8220;First Merger Sub&#8221;), Atlas Merger Sub II, LLC, a wholly owned subsidiary of ARCA
(&#8220;Second Merger Sub&#8221;) and Oruka Therapeutics, Inc. (&#8220;Pre-Merger Oruka&#8221;), pursuant to which, among other matters,
Pre-Merger Oruka merged with and into First Merger Sub, with Pre-Merger Oruka continuing as a wholly owned subsidiary of ARCA and the
surviving corporation of the merger (&#8220;First Merger&#8221;) and following that, Pre-Merger Oruka then merged with and into Second
Merger Sub, with Second Merger Sub being the surviving entity of the second merger (the &#8220;Second Merger&#8221; and together with
the First Merger, the &#8220;Merger&#8221;). Following consummation of the Merger, we effected a 1-for-12 reverse stock split (the &#8220;Reverse
Stock Split&#8221;) of the common stock, par value $0.001 per share, of the Company (&#8220;Company Common Stock&#8221;), which became
effective on September 3, 2024. The Company Common Stock commenced trading on a post-Reverse Stock Split, post-Merger basis at the opening
of trading on September 3, 2024. Second Merger Sub changed its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221;
and ARCA changed its name to &#8220;Oruka Therapeutics, Inc.&#8221; We are led by the pre-reverse capitalization Pre-Merger Oruka management
team and remains focused on developing biologics to optimize the treatment of inflammatory skin diseases.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pre-Closing
Financing</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Immediately
prior to the execution and delivery of the Merger Agreement on April 3, 2024, certain new and existing investors of Pre-Merger Oruka
entered into a subscription agreement with Pre-Merger Oruka (the &#8220;Subscription Agreement&#8221;), pursuant to which, and on the
terms and subject to the conditions of which, immediately prior to the Closing, those investors purchased shares of common stock of Pre-Merger
Oruka (&#8220;Pre-Merger Oruka Common Stock&#8221;) and Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $275.0
million (which includes $25.0 million of proceeds previously received from the issuance of the Convertible Note (refer to Note 6 in our
condensed consolidated financial statements included in this prospectus for additional details) and accrued interest on such note which
converted to shares of Pre-Merger Oruka Common Stock) (the &#8220;Pre-Closing Financing&#8221;). We incurred transaction costs of $20.5
million which was recorded as a reduction to additional paid-in capital in the unaudited condensed consolidated financial statements.
At the Closing, the shares of Pre-Merger Oruka Common Stock and Pre-Merger Oruka pre-funded warrants issued pursuant to the Subscription
Agreement were converted into shares of Company Common Stock and pre-funded warrants of Company Common Stock in accordance with the Exchange
Ratio (defined below).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with an Exchange Ratio determined
by terms of the Merger Agreement and upon the effective time of the First Merger (the &#8220;First Effective Time&#8221;), (i) each then-issued
and outstanding share of Pre-Merger Oruka Common Stock including outstanding and unvested Pre-Merger Oruka restricted stock and shares
of Pre-Merger Oruka Common Stock issued in connection with the Subscription Agreement, were converted into the right to receive a number
of shares of Company Common Stock, equal to the exchange ratio of 6.8569 shares of Company Common Stock (the &#8220;Exchange Ratio&#8221;),
which were subject to the same vesting provisions as those immediately prior to the Merger, (ii) each share of Pre-Merger Oruka Series
A convertible preferred stock, par value $0.0001 (&#8220;Pre-Merger Oruka Series A Preferred Stock&#8221;), outstanding immediately prior
to the First Effective Time was converted into the right to receive a number of shares of ARCA Series B non-voting convertible preferred
stock, par value $0.001 per share, which are convertible into shares of Company Common Stock at a conversion ratio of approximately 83.3332:1,
(iii) each outstanding option to purchase Pre-Merger Oruka Common Stock was converted into an option to purchase shares of Company Common
Stock, (iv) each outstanding warrant to purchase shares of Pre-Merger Oruka Common Stock was converted into a warrant to purchase shares
of Company Common Stock, and (v) each share of Company Common Stock issued and outstanding at the First Effective Time remain issued and
outstanding in accordance with its terms and such shares Subsequent to the close of the merger, the common stock shares were then, subject
to the reverse stock split of 1-for-12 effected on September 3, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
part of the Pre-Closing Financing and the Closing, the investors in the Pre-Closing Financing received 22,784,139 shares of Company Common
Stock in exchange for 39,873,706 shares of Pre-Merger Oruka Common Stock (which includes the issuance of 2,722,207 shares of Company
Common Stock in exchange for 4,764,032 shares of Pre-Merger Oruka Common Stock on the conversion of Convertible Note along with the accrued
interest through the conversion date) and 5,522,207 Company pre-funded warrants in exchange for 9,664,208 Pre-Merger pre-funded warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Pre-Merger Oruka
was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the fact that, immediately
following the Merger: (i) Pre-Merger Oruka stockholders own a substantial majority of the voting rights in the combined company; (ii)
Pre-Merger Oruka&#8217;s largest stockholders retain the largest interest in the combined company; (iii) Pre-Merger Oruka designated
a majority of the initial members of the board of directors of the combined company; and (iv) Pre-Merger Oruka&#8217;s executive management
team became the management team of the combined company. Accordingly, for accounting purposes: (i) the Merger was treated as the equivalent
of Pre-Merger Oruka issuing stock to acquire the net assets of ARCA; and (ii) the reported historical operating results of the combined
company prior to the Merger are those of Pre-Merger Oruka. Additional information regarding the Merger is included in Note 3 to the condensed
consolidated financial statements included in this prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Reverse
Stock Split</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
September 3, 2024, we effected the Reverse Stock Split, a 1-for-12 reverse stock split of Company Common Stock. The par value per share
and the number of authorized shares were not adjusted as a result of the Reverse Stock Split. The shares of Company Common Stock underlying
outstanding stock options, common stock warrants and other equity instruments were proportionately reduced and the respective exercise
prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. All references
to common stock, options to purchase common stock, outstanding common stock warrants, common stock share data, per share data, and related
information contained in the condensed consolidated financial statements have been retrospectively adjusted to reflect the effect of
the Reverse Stock Split for all periods presented, unless otherwise specifically indicated or the context otherwise requires.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>PIPE
Financing</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 11, 2024, we entered into a Securities
Purchase Agreement for a private placement (the &#8220;PIPE Financing&#8221;) with certain institutional and accredited investors. The
closing of the PIPE Financing occurred on September 13, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the Securities Purchase Agreement,
the investors purchased an aggregate of 5,600,000 shares of Company Common Stock at a purchase price of $23.00 per share, an aggregate
of 2,439 shares of the Company&#8217;s Series A non-voting convertible preferred stock, par value $0.001 per share (&#8220;Company Series
A Preferred Stock&#8221;), at a purchase price of $23,000.00 per share (each Company Series A Preferred Stock is convertible into 1,000
shares of Company Common Stock), and pre-funded warrants to purchase an aggregate of 680,000 shares of Company Common Stock at a purchase
price of $22.999 per pre-funded warrant, for aggregate net proceeds of approximately $188.7 million (net of issuance costs of $11.8 million).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Components
of Results of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Revenue</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
date, we have not generated revenue from any sources, including product sales, and do not expect to generate any revenue from the sale
of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory
approval, we may generate revenue in the future from product sales or payments from future collaboration or license agreements that we
may enter into with third parties, or any combination thereof. We cannot predict if, when, or to what extent we will generate revenue
from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product
candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Operating
Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Research
and Development</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Research
and development expenses consist primarily of costs incurred in connection with the development and research of our programs. These expenses
include costs of funding research performed by third parties, including Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;), that conduct
research and development activities on our behalf, expenses incurred in connection with continuing our current research programs and
discovery-phase development of any programs we may identify, including under future agreements with third parties, such as consultants
and contractors, personnel-related expenses, including salaries, bonuses, employee benefits, stock-based compensation expense, and allocated
human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation
for our leased office space.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
expense research and development costs as incurred. Our primary focus since inception has been the identification and development of
our pipeline programs. Our research and development expenses primarily consist of external costs, such as fees paid to Paragon under
the Option Agreements. We separately track the amount of costs incurred under the Option Agreements with Paragon between ORKA-001 and
ORKA-002. See &#8220;&#8212;&#160;<i>Contractual Obligations and Commitments</i>&#8221; below for further details on the Option Agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
expect our research and development expenses to increase substantially for the foreseeable future as we advance our product candidates
into and through preclinical studies and clinical trials, pursue regulatory approval of our product candidates and expand our pipeline
of product candidates.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>General
and Administrative</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">General
and administrative expenses consist primarily of personnel-related expenses, including salaries, bonuses, employee benefits, and stock-based
compensation, for our executive and other administrative personnel. Other significant general and administrative expenses include legal
services, including intellectual property and corporate matters; professional fees for accounting, auditing, tax, insurance, and allocated
human resource costs, information technology costs, and facility-related costs, including rent, utilities, maintenance, and depreciation
for our leased office space.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
expect our general and administrative expenses will increase substantially for the foreseeable future as we anticipate an increase in
our personnel headcount to support the expansion of research and development activities, as well as to support our operations generally.
We also expect to continue to incur significant expenses associated with being a public company, including costs related to accounting,
audit, legal, regulatory, and tax-related&#160;services associated with maintaining compliance with applicable Nasdaq and SEC requirements;
additional director and officer insurance costs; and investor and public relations costs. We also expect to incur additional intellectual
property-related expenses as we file patent applications to protect innovations arising from our research and development activities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Other
Income (Expense), Net</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Other
income (expense), net includes interest expense on the convertible note from a related party, interest income, and foreign currency transactions
gains and losses. Interest expense relates to a convertible note (the &#8220;Convertible Note&#8221;) issued to Fairmount Healthcare
Fund&#160;II, L.P. (&#8220;Fairmount&#8221;) in March&#160;2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Income
Taxes</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">No
provision for income taxes was recorded for the three months ended September 30, 2024 and for the period from February&#160;6, 2024 (inception)
through September&#160;30, 2024. Deferred tax assets generated from our net operating losses have been fully reserved as we believe it
is not more likely than not that the benefit will be realized due to its cumulative losses generated to date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Results
of Operations for the Three Months Ended September 30, 2024</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes our results of operations and comprehensive loss for the period presented (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Three&#160;Months<br/>
    Ended&#160;<br/> September&#160;30,<br/> 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating
    expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development<sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,691</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative<sup>(2)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,758</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">29,449</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(29,449</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other
    income (expense)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Interest
    income</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,330</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense<sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(504</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total
    other income, net</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">826</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss and comprehensive loss</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(28,623</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $13,537 for the three months ended September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $71 for the three months ended September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $504 for the three months ended September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes our research and development expenses for the period presented (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended&#160;<br/> September&#160;30, <br/> 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">External research
    and development costs by selected target:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORKA-001<sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,761</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORKA-002<sup>(2)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,147</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other
    research and development costs:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personnel-related
    (including stock-based compensation)<sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,076</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other<sup>(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">707</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total
    research and development expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,691</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $2,316 for the three months ended September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $3,824 for the three months ended September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $7,251 for the three months ended September 30, 2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $146 for the three months ended September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Research
and development expenses were $25.7&#160;million for the three months ended September 30, 2024 and consisted primarily of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.3&#160;million
    of research and development expense due to Paragon for services rendered under the Option Agreements for ORKA-001, including $1.5
    million of milestone payment due to Paragon upon exercise of option to enter into a license agreement and achievement of development
    candidate for IL-23;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$9.4
    million of research and development expenses on chemistry, manufacturing, and development costs for ORKA-001, including $3.2 million
    of toxicology testing for ORKA-001 with a third-party contract research organization;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3.8&#160;million
    of research and development expense due to Paragon for services rendered under the Option Agreements for ORKA-002;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$9.1
    million of personnel-related costs related to salaries, benefits and other compensation-related costs, and stock-based compensation
    expense of $7.8 million, including $7.3 million for stock-based compensation related to Paruka Holding LLC (&#8220;Paruka&#8221;)
    warrants; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.7
    million of other research expenses and allocated human resource costs, information technology costs, and facility-related costs,
    including rent, maintenance, utilities, and depreciation for our leased office space.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>General
and Administrative Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes our general and administrative expenses for the period presented (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended&#160;<br/> September&#160;30, <br/> 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Personnel-related
    (including stock-based compensation)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,435</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Professional
    and consulting fees</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">701</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    fees related to patent<sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">116</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">506</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total
    general and administrative expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,758</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $71 for the three months ended September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">General
and administrative expenses were $3.8&#160;million for the three months ended September 30, 2024 and consisted primarily of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.4&#160;million
    of personnel-related costs related to salaries, benefits and other compensation-related costs, including stock-based compensation
    of $1.2&#160;million;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.7&#160;million
    of professional and consulting fees associated with accounting, audit, and legal fees to support our business activity and operations
    of a public company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.1&#160;million
of legal fees due to Paragon associated with patent related activities; and</span></td>
</tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;
</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.5
million of other business expense and allocated human resource costs, information technology costs, and facility-related costs, including
rent, maintenance, utilities, and depreciation for our leased office space.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Total
Other Income (Expense), Net</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Interest
income from money market funds was $1.3 million for the three months ended September 30, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Interest
expense was $0.5 million for the three months ended September 30, 2024 relating to the Convertible Note from Fairmount.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Results
of Operations for the Period of February 6, 2024 (Inception) to September 30, 2024</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes our results of operations and comprehensive loss for the period presented (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period&#160;from<br/>
    February&#160;6,<br/> 2024<br/> (Inception)&#160;to<br/> September&#160;30,<br/> 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Operating expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development<sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">49,557</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative<sup>(2)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,248</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">57,805</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(57,805</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other
    income (expense)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Interest
    income</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,330</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense<sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,468</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total
    other expense, net</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(138</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss and comprehensive loss</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(57,943</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $33,967 for the period from February&#160;6, 2024 (inception) to September&#160;30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $1,339 for the period from February&#160;6, 2024 (inception) to September&#160;30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $1,468 for the period from February&#160;6, 2024 (inception) to September&#160;30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
                                            and Development Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes our research and development expenses for the period presented (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Period&#160;from
    <br/> February&#160;6, <br/> 2024<br/> (Inception)&#160;to<br/> September&#160;30, <br/> 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">External research
    and development costs by selected target:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORKA-001<sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,939</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORKA-002<sup>(2)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,987</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other
    research and development costs:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personnel-related
    (including stock-based compensation)<sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,684</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other<sup>(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">947</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total
    research and development expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">49,557</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $15,478 for the period from February&#160;6, 2024 (inception) to September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $10,662 for the period from February&#160;6, 2024 (inception) to September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $7,681 for the period from February&#160;6, 2024 (inception) to September 30, 2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $146 for the period from February&#160;6, 2024 (inception) to September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Research
and development expenses were $49.6&#160;million for the period from February&#160;6, 2024 (inception) to September 30, 2024 and consisted
primarily of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$15.5&#160;million
    of research and development expense due to Paragon for services rendered under the Option Agreements for ORKA-001, including $1.5
    million of milestone payment due to Paragon upon exercise of option to enter into a license agreement and achievement of development
    candidate for IL-23, and $5.9 million of research and development expense due to Paragon incurred through March 31, 2024 upon completion
    of IL-23 selection process;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$11.4
    million of research and development expense on chemistry, manufacturing, and development costs for ORKA-001, including $3.4 million
    in toxicology testing for ORKA-001 with a third-party contract research organization;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$11.0&#160;million
    of research and development expense primarily due to Paragon for services rendered under the Option Agreements for ORKA-002;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$10.7&#160;million
    of personnel-related costs related to salaries, benefits, and other compensation-related costs, and stock-based compensation expense
    of $8.3&#160;million, including $7.7 million for stock-based compensation related to Paruka warrants; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.9
    million of other research expense and allocated human resource costs, information technology costs, and facility-related costs, including
    rent, maintenance, utilities, and depreciation for our leased office space.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>General
and Administrative Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes our general and administrative expenses for the period presented (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period&#160;from
    <br/> February&#160;6, <br/> 2024<br/> (Inception)&#160;to<br/> September 30, <br/> 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personnel-related
    (including stock-based compensation)<sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,590</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Professional
    and consulting fees</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,330</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    fees related to patent<sup>(2)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">606</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other<sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">722</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total
    general and administrative expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,248</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $609 for the period from February&#160;6, 2024 (inception) to September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $550 for the period from February&#160;6, 2024 (inception) to September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $180 for the period from February&#160;6, 2024 (inception) to September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">General
and administrative expenses were $8.2&#160;million for the period from February&#160;6, 2024 (inception) to September 30, 2024 and consisted
primarily of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$4.6&#160;million
    of personnel-related costs related to recruiting costs, salaries, benefits and other compensation-related costs, including stock-based
    compensation of $1.5&#160;million and $0.6 million of personnel-related costs are amounts due to Paragon related to recruiting costs
    for hiring our executive team, legal, and finance and accounting functions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.3&#160;million
    of professional and consulting fees associated with accounting, audit, and legal fees associated with becoming a public company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.6&#160;million
    of legal fees due to Paragon associated with patent related activities; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.7
    million of other business expenses and allocated human resource costs, information technology costs, and facility-related costs,
    including rent, maintenance, utilities, and depreciation for our leased office space, including $0.2&#160;million of other business
    expenses due to Paragon.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>Total
Other Income (Expense), Net</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Interest
income from money market funds was $1.3 million for the period from February 6, 2024 (inception) to September 30, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Interest
expense was $1.5 million for the period from February 6, 2024 (inception) to September 30, 2024 relating to the Convertible Note from
Fairmount.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Liquidity
and Capital Resources</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, we had $410.9 million of cash and cash equivalents.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since our inception, we have incurred significant
operating losses and negative cash flow from operations. We expect to incur significant expenses and operating losses for the foreseeable
future as we continue the pre-clinical and clinical development of our programs and continue our early-stage research activities. We have
not yet commercialized any products and we do not expect to generate revenue from sales of products for several&#160;years, if at all.
As of September 30, 2024, we had funded our operations primarily with proceeds from issuances of convertible preferred stock, common stock,
convertible note, and pre-funded warrants. In March&#160;2024, we received $3.0&#160;million in gross proceeds from the issuance of Pre-Merger
Oruka Series&#160;A Preferred Stock and $25.0&#160;million in gross proceeds from the issuance of the Convertible Note, both of which
were related party transactions. In August 2024, we raised approximately $228.0 million in net proceeds from Pre-Closing Financing and
received $4.9 million in cash from ARCA upon consummation of the Merger. In September 2024, we received approximately $188.7 million in
net proceeds from the issuance of common stock, Company Series A Preferred Stock, and pre-funded warrants in connection with the PIPE
Financing.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
primary use of cash is to fund the development of our product candidates, and advance our pipeline. This includes both the research and
development costs and the general and administrative expenses required to support those operations. Since we are a clinical stage biotechnology
company, we have incurred significant operating losses since our inception and we anticipate such losses, in absolute dollar terms, to
increase as we continue to pursue clinical development of our product candidates, prepare for the potential commercialization of our
product candidates, and expand our development efforts in our pipeline of nonclinical candidates. We expect that our existing cash and
cash equivalents will be sufficient to fund our operating plans for at least twelve months from the date of filing of this prospectus.
We will need to secure additional financing in the future to fund additional research and development, and before a commercial drug can
be produced, marketed and sold. If we are unable to obtain additional financing or generate license or product revenue, the lack of liquidity
could have a material adverse effect on our company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Cash
Flows</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes our cash flows for the period presented (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period&#160;from
    <br/> February&#160;6, <br/> 2024<br/> (Inception)&#160;to September&#160;30, <br/> 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash used in operating activities</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(39,019</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash used in investing activities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(171</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">450,065</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Net
    increase in cash and cash equivalents</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">410,875</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Operating
Activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">From
February&#160;6, 2024 (inception) to September&#160;30, 2024, net cash used in operating activities was $39.0 million, which was primarily
attributable to a net loss of $57.9 million, offset by non-cash charges of $11.3 million and net cash provided by changes in operating
activities of $7.6 million. Non-cash charges primarily consisted of a $9.8 million increase in stock-based compensation expense (primarily
from Paruka Warrant Obligation) and $1.5 million of non-cash interest expense. Net cash provided by changes in our operating activities
primarily consisted of a $1.6 million increase in accounts payable, $1.7 million increase in accrued expenses and other current liabilities,
$6.4 million increase in related parties accounts payable and other current liabilities, partially offset by a $2.0 million increase
in prepaid expenses and other current assets. The increase in amounts due to related parties, accounts payable, and accrued expenses
and other current liabilities was primarily due to an increase in our business activity, as well as vendor invoicing and payments. The
increase in prepaid expenses and other current assets was primarily due to prepaid research and development expenses with our contract
research organization.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Investing
Activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">From
February&#160;6, 2024 (inception) to September&#160;30, 2024, net cash used in investing activities was $0.2 million, which was attributable
to purchases of property and equipment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Financing
Activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">From
February&#160;6, 2024 (inception) to September&#160;30, 2024, net cash provided by financing activities was $450.1 million, consisting
of $2.9&#160;million of net proceeds from the issuance of Series&#160;B Preferred&#160;Stock, $25.0&#160;million of net proceeds from
the issuance of the Convertible Note, $228.1 million of net proceeds from the Pre-Closing Financing, $189.1 million of net proceeds from
the PIPE Financing, and $4.9 million of cash acquired in connection with the reverse recapitalization.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Contractual
Obligations and Commitments</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
enter into contracts in the normal course of business with contract research organizations (&#8220;CROs&#8221;)&#160;for clinical trials,
with contract manufacturing organizations (&#8220;CMOs&#8221;) for&#160;clinical supplies manufacturing and with other vendors for preclinical
studies, supplies and other services and products for operating purposes. These contracts generally provide for termination on&#160;notice
or may have a potential termination fee if a purchase order is cancelled within a specified time, and therefore are cancelable contracts.
We do not expect any such contract terminations and did not have any non-cancellable obligations under these agreements as of September
30, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Option
Agreements</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
March&#160;2024, we entered into antibody discovery and option agreements with Paragon and Paruka (the &#8220;Option Agreements&#8221;).
Under the terms of the Option Agreements, Paragon identifies, evaluates and develops antibodies directed against certain mutually agreed
therapeutic targets of interest to us. The Option Agreements include two selected targets, IL-23 (&#8220;ORKA-001&#8221;) and IL-17 A/F
(&#8220;ORKA-002&#8221;). Under the Option Agreements, we have the exclusive options to, on a research program-by-research program basis,
be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title and interest in and to the intellectual property resulting
from the applicable research program to develop, manufacture and commercialize the antibodies and products directed to the selected targets
(each, an &#8220;Option&#8221;), with the exception of pursuing ORKA-001 for the treatment of inflammatory bowel disease. If we exercise
our options, we will be required to make non-refundable milestone payments to Paragon of up to $12.0&#160;million under each respective
agreement upon the achievement of certain clinical development milestones, up to $10.0&#160;million under each respective agreement upon
the achievement of certain regulatory milestones as well as tiered royalty payments in the low-to-mid single-digits beginning on the
first commercial sale. From time to time, we can choose to add additional targets to the collaboration by mutual agreement with Paragon.
During the three months ended September 30, 2024, we exercised our option for ORKA-001 and recorded a $1.5 million milestone payment
related to the achievement of development candidate as research and development expense in our condensed consolidated statements of operations
and comprehensive loss for the three months ended September 30, 2024. As of September 30, 2024, this amount is included under related
party accounts payable and other current liabilities on the condensed consolidated balance sheet.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
exclusive Option with respect to each research program for a particular target initiated by the parties (&#8220;Research Program&#8221;)
is exercisable at our sole discretion at any time during the period beginning on the initiation of activities under the associated Research
Program and ending a specified number of&#160;days following (i) with respect to any Research Program other than ORKA-001, the delivery
of the data package from Paragon related to the results of the Research Plan activities, or (ii) with respect to ORKA-001, the completion
of the IL-23 antibody selection process described in the agreement (the &#8220;Option Period&#8221;). There is no payment due upon exercise
of an Option pursuant to the Option Agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Unless
terminated earlier, the Option Agreements shall continue in force on a Research Program-by-Research Program basis until the earlier of:
(i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by us; (ii)&#160;the
expiration of the 30-day period after we exercise our Option with respect to such Research Program, subject to mutually agreed extension,
during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii) the expiration of the applicable
research term (the &#8220;Term&#8221;). Upon the expiration of the Term for all then-existing Research Programs, under the Option Agreements,
the Option Agreements will automatically expire in its entirety. We may terminate the Option Agreements or any Research Program at any
time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon, provided that we must pay certain unpaid fees due
to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with its activities
under any terminated Research Program. Paragon may terminate the Option Agreements or a Research Program immediately upon written notice
to us if, as a result of any action or failure to act by us or our affiliates, such Research Program or all material activities under
the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of months. Each party
has the right to terminate the Option Agreements or any Research Program upon (i)&#160;30&#160;days&#8217; prior written notice of the
other party&#8217;s material breach that remains uncured for the 30-day period and (ii)&#160;the other party&#8217;s bankruptcy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the Option Agreements, on a research
program-by-research program basis following the finalization of the research plan for each respective research program, we were required
to pay Paragon a one-time, nonrefundable research initiation fee of $0.8&#160;million related to the ORKA-001 program. This amount was
recognized as a research and development expense during the period from February&#160;6, 2024 (inception) to September 30, 2024. In June
2024, pursuant to the Option Agreements with Paragon, we completed the selection process of our development candidate for IL-23 antibody
for ORKA-001 program. We were responsible for 50% of the development costs incurred through the completion of the IL-23 selection process.
We received the rights to at least one selected IL-23 antibody in June 2024. During the three months ended September 30, 2024, we exercised
our option for ORKA-001 and recorded a $1.5 million milestone payment related to the achievement of development candidate as research
and development expense in our condensed consolidated statements of operations and comprehensive loss for each of the three months ended
September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024. Our share of development costs incurred
during the three months ended September 30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024 was $0.8 million
and $13.2 million, respectively, which were recorded as research and development expenses during the respective periods. An amount of
$2.3 million is included in related party accounts payable and other current liabilities as of September 30, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We were also required to reimburse Paragon $3.3&#160;million
for development costs related to ORKA-002 incurred by Paragon through December&#160;31, 2023 and certain other development costs incurred
by Paragon between January&#160;1, 2024 and March&#160;6, 2024 as stipulated by the Option Agreements. This amount was recognized as a
research and development expense during the period from February&#160;6, 2024 (inception) to September 30, 2024. We are also responsible
for the development costs incurred by Paragon from January&#160;1, 2024 through the completion of the IL-17 selection process. We recognized
an amount of $0.8&#160;million payable to Paragon for the research initiation fee related to ORKA-002 following the finalization of the
ORKA-002 research plan. This was recognized as research and development expenses in the period from February 6, 2024 (inception) to September
30, 2024. We accounted for development costs of $3.8 million and $6.6 million during the three months ended September 30, 3024 and for
the period from February 6, 2024 (inception) to September 30, 2024, respectively, as research and development expenses during the respective
periods. An amount of $3.8 million is included in related party accounts payable and other current liabilities as of September 30, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
part of the Option Agreements, on each of December 31, 2024 and December 31, 2025, we will grant warrants to purchase a number of shares
equal to 1.00% of outstanding shares as of the date of the grant on a fully diluted basis with an exercise price equal to the fair market
value of the underlying shares on the grant date. The warrants are liability-classified and after the initial recognition, the liability
is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated statement of operations
and comprehensive loss as stock-based compensation expenses under research and development expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
expense the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified
within research and development expenses in the accompanying condensed consolidated statement of operations and comprehensive loss.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise
in-process research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination
because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent
a group of similar identifiable assets. The research initiation fee represents a one-time cost on a research program-by-research program
basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts
paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of on-going development cost,
monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior
to the effective date of the Option Agreements that is associated with services being rendered under the related Research Programs are
recognized as research and development expense when incurred.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">For
the three months ended September 30, 2024 and the period from February&#160;6, 2024 (inception) to September 30, 2024, we recognized
$13.4 million and $33.8 million of expenses, respectively, in connection with services provided by Paragon and Paruka under the Option
Agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Note&#160;Payable
with Related Party</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
March&#160;2024, we entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;)
with Fairmount, whereby we issued the Convertible Note, with an initial principal amount of $25.0 million that, at the time of issuance,
could be converted into Pre-Merger Oruka Series&#160;A Preferred Stock (or a series&#160;of preferred shares that is identical in respect
to the shares of preferred shares issued in its next equity financing) or shares of Pre-Merger Oruka Common Stock in exchange for aggregate
proceeds of $25.0&#160;million. The Convertible Note accrued interest at a rate of 12.0% per annum. At issuance, the Convertible Note
required all unpaid interest and principal to mature on December&#160;31, 2025 (the &#8220;Maturity Date&#8221;) and prepayment was not
permitted without prior written consent of Fairmount. At issuance, the principal payment along with the accrued interest on the Convertible
Note was due in full on the Maturity Date. Pursuant to the Purchase Agreement, we had the right to sell and issue additional convertible
notes up to an aggregate principal amount equal to $30.0 million, in addition to the $25.0 million initial principal amount of the Convertible
Note.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Immediately
prior to the completion of the Merger, the Convertible Note was converted into shares of Pre-Merger Oruka Common Stock based on the aggregate
principal amount of $25.0 million, plus unpaid accrued interest of $1.5 million divided by the conversion price, which was determined
based upon the Company&#8217;s fully-diluted capitalization immediately prior to the Merger. At the effective time of the Merger, the
Pre-Merger Oruka Common Stock issued upon the conversion of the Convertible Note (including accrued interest) automatically converted
into shares of Company Common Stock. 2,722,207 shares of Company Common Stock were issued on conversion of the Convertible Note and accrued
interest. As of September 30, 2024, there is no note payable to a related party.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Critical
Accounting Policies and Significant Judgments and Estimates</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
management&#8217;s discussion and analysis of its financial condition and results of operations is based on its financial statements,
which have been prepared in accordance with U.S. GAAP.&#160;The preparation of these condensed consolidated financial statements requires
us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets
and liabilities at the date of the financial statements, as well as the reported revenues recognized and expenses incurred during the
reporting periods. Our estimates are based on its historical experience and on various other factors that we believe are reasonable under
the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are
not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">While
our significant accounting policies are described in more detail in Note&#160;2 to our consolidated financial statements appearing elsewhere
in this prospectus, we believe the following accounting policies used in the preparation of our financial statements require the most
significant judgments and estimates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Accrued
Research and Development Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses.
This process involves estimating the level of service performed and the associated cost incurred for the services when we have not yet
been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed,
on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our
accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known to us at that time.
At each period end, we corroborate the accuracy of these estimates with the service providers and make adjustments, if necessary. Estimated
accrued research and development expenses include those related to fees paid to vendors in connection with discovery development activities
and any research organizations in connection with studies and testing. Although we do not expect our estimates to be materially different
from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing
of services performed may vary and may result in reporting amounts that are too high or too low in any particular period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock-Based
Compensation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
measure stock options granted to employees and non-employees based on the estimated fair values of the awards as of the grant date using
the Black-Scholes option-pricing model. The model requires management to make a number of assumptions, including common stock fair value,
expected volatility, expected term, risk-free interest rate and expected dividend yield. For restricted stock awards and restricted stock
units, the estimated fair value is the fair market value of the underlying stock on the grant date. We expense the fair value of our
equity-based compensation awards on a straight-line basis over the requisite service period, which is the period in which the related
services are received. We account for award forfeitures as they occur. The expense for stock-based awards with performance conditions
is recognized when it is probable that a performance condition is met during the vesting period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Determination
of Fair Value of Common Stock</i>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
public trading market for Company Common Stock has been established in connection with the completion of this Merger. As such, it is
no longer necessary for our board of directors to estimate the fair value of our stock-based awards in connection with its accounting
for granted stock-based awards or other such awards we may grant, as the fair value of Company Common Stock and share-based awards is
determined based on the quoted market price of Company Common Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Prior
to the merger, Pre-Merger Oruka&#8217;s common stock valuations were prepared using a hybrid method, including an option pricing method
(&#8220;OPM&#8221;). The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise
prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under
this method, the common stock has value only if the funds available for distribution to stockholders exceed the value of the preferred
stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method is a probability-weighted
expected return method (&#8220;PWERM&#8221;), where the equity value in one or more of the scenarios is calculated using an OPM. The
PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of future values for the Company,
assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns
considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock
under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to
arrive at an indication of value for the common stock. A discount for lack of marketability of the common stock is then applied to arrive
at an indication of value for the common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
assumptions underlying these valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application
of management&#8217;s judgment. As a result, if Pre-Merger Oruka had used significantly different assumptions or estimates, the fair
value of Pre-Merger Oruka&#8217;s incentive shares and its stock-based compensation expense could have been materially different.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Recently
Issued Accounting Pronouncements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">See
Note 2 to the condensed consolidated financial statements included in this prospectus for more information regarding recently issued
accounting pronouncements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Off-Balance
Sheet Arrangements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, we did not have any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>(a)</i></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><i>Dismissal
                                            of Independent Registered Public Accounting Firm </i></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">KPMG
LLP (&#8220;KPMG&#8221;) served as the independent registered public accounting firm of ARCA prior to the consummation of the Merger.
On August 30, 2024, KPMG was dismissed as the independent registered public accounting firm of the Company. The decision to dismiss KPMG
was approved by the Audit Committee (the &#8220;Audit Committee&#8221;) of the Board of Directors of the Company (the &#8220;Board&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
reports of KPMG on the consolidated financial statements of the Company for the fiscal years ended December&#160;31, 2023 and 2022 did
not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting
principles.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the Company&#8217;s two most recent fiscal years and the subsequent period from January&#160;1, 2024 to August 30, 2024, there were (i)&#160;no
disagreements (as defined in Item 304(a)(1)(iv) of Regulation&#160;S-K&#160;and the related instructions thereto) with KPMG on any matter
of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement, if not resolved
to the satisfaction of KPMG, would have caused it to make reference to the subject matter of the disagreement in connection with its
report and (ii)&#160;no reportable events (as described in Item 304(a)(1)(v) of Regulation&#160;S-K).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Company provided KPMG with a copy of the disclosures made in this section and requested KPMG to furnish the Company with a letter addressed
to the SEC stating whether it agrees with the statements made by the Company and, if not, stating the respects in which it does not agree.
A copy of KPMG&#8217;s letter to the SEC dated September 5, 2024 regarding these statements was filed as Exhibit 16.1 to the Company&#8217;s
Current Report on Form 8-K filed on September 5, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; "><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>(b)</i></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><i>Appointment
                                            of New Independent Registered Public Accounting Firm</i></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">PricewaterhouseCoopers
LLP (&#8220;PwC&#8221;) served as the independent registered public accounting firm of Oruka prior to the consummation of the Merger.
On August 30, 2024, following the consummation of the Merger, the Audit Committee engaged PwC as the independent registered public accounting
firm of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
ARCA&#8217;s two most recent fiscal years and the subsequent period from January 1, 2024 to August 30, 2024, neither ARCA nor anyone
on its behalf consulted PwC regarding: (i) the application of accounting principles to a specified transaction, either completed or proposed,
or the type of audit opinion that might be rendered on ARCA&#8217;s financial statements, and neither a written report nor oral advice
was provided to the ARCA that PwC concluded was an important factor considered by ARCA in reaching a decision as to any accounting, auditing
or financial reporting issue; or (ii) any matter that was the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation
S-K and the related instructions thereto) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;<b>&#160;</b></span></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are a smaller reporting company, as defined by Rule 12b-2 under the Exchange Act and in Item 10(f)(1) of Regulation S-K, and are not
required to provide the information under this item.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>BUSINESS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Company
Overview </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are a biotechnology company focused on developing novel monoclonal antibody therapeutics for PsO and other I&amp;I indications. Our name
is derived from <i>or</i>, for &#8220;skin,&#8221; and <i>arukah</i>, for &#8220;restoration&#8221; and reflects the company&#8217;s
mission to deliver therapies for chronic skin diseases that provide patients the most possible freedom from their condition. Our strategy
is to apply antibody engineering and format innovations to validated modes of action, which we believe will enable us to improve meaningfully
upon the efficacy and dosing regimens of standard-of-care medicines while significantly reducing technical and biological risk. Our programs
aim to treat and potentially modify disease by targeting mechanisms with proven efficacy and safety involved in disease pathology and
the activity of pathogenic tissue-resident memory T cells (&#8220;TRMs&#8221;). Our lead program, ORKA-001, is designed to target the
p19 subunit of interleukin-23 (&#8220;IL-23p19&#8221;) for the treatment of PsO. Our co-lead program, ORKA-002, is designed to target
interleukin-17A and interleukin-17F (&#8220;IL-17A/F&#8221;) for the treatment of PsO, PsA, and other conditions. These programs each
bind their respective targets at high affinity and incorporate half-life extension technology with the aim to increase exposure and decrease
dosing frequency. We believe that our focused strategy, differentiated portfolio, and deep expertise position us to set a new treatment
standard in large I&amp;I markets with continued unmet need.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Our Pipeline
</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_002.jpg" style="width: 623px; height: 195px"/>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>ORKA-001</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ORKA-001
is a high affinity, extended half-life monoclonal antibody (&#8220;mAb&#8221;) designed to target IL-23p19. IL-23 is a pro-inflammatory
cytokine that plays a critical role in the proliferation and development of T helper 17 (&#8220;Th17&#8221;) cells, which are the primary
drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit that is shared
with IL-12 and a p19 subunit that is specific to IL-23. First-generation IL-23 antibodies bound p40 and inhibited both IL-12 and IL-23
signaling, while more recent IL-23 antibodies targeting the p19 subunit have shown improved efficacy and safety. Based on preclinical
evidence, we believe that ORKA-001 could achieve higher response rates than established therapies in PsO while requiring less frequent
dosing and maintaining the favorable safety profile of therapies targeting IL-23p19. ORKA-001 is engineered with YTE half-life extension
technology, a specific three amino acid change in the fragment crystallizable (&#8220;Fc&#8221;) domain to modify the pH-dependent binding
to the neonatal Fc receptor (&#8220;FcRn&#8221;). As a result, it has a pharmacokinetic profile designed to support a subcutaneous (&#8220;SQ&#8221;)
injection as infrequently as once or twice a year. In addition, emerging evidence suggests that IL-23 blockade can modify the disease
biology of PsO, possibly leading to durable remissions and preventing the development of PsA.&#160;We believe that the expected characteristics
of ORKA-001 increase its potential to deliver these disease-modifying benefits.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
plan to initiate a Phase 1 trial of ORKA-001 in the first quarter of 2025. We expect to share interim data from the first-in-human trial
in healthy volunteers, including initial pharmacokinetic data, in the second half of 2025 and initial efficacy on psoriasis patients
in the second half of 2026. Based on recent precedent for PsO, we anticipate that the entire development program from first-in-human
to biologics license application (&#8220;BLA&#8221;) filing could take as little as six to seven&#160;years based on the averages for
recently approved medicines. However, we have no control over the length of time needed for FDA review, and this timeline could vary.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ORKA-002</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ORKA-002
is a high affinity, extended half-life mAb designed to target IL-17A and IL-17F (&#8220;IL-17A/F&#8221;). IL-17 inhibition has become
central to the treatment of psoriatic diseases, including PsO and PsA, and has also shown efficacy in other&#160;I&amp;I indications,
such as hidradenitis suppurativa (&#8220;HS&#8221;) and axial spondyloarthritis (&#8220;axSpA&#8221;). More recently, the importance
of inhibiting the IL-17F isoform along with IL-17A has become appreciated, and dual blockade with the recently approved therapy Bimzelx
(bimekizumab) has led to higher response rates in patients than blockade of IL-17A alone. ORKA-002 is designed to bind IL-17A/F at similar
epitopes, or binding sites, and affinity ranges as bimekizumab, but incorporates half-life extension technology that could enable more
convenient dosing intervals. We plan to initiate a Phase&#160;1 trial of ORKA-002 in the third quarter of 2025. We expect to share interim
data from the first-in-human trial in healthy volunteers, including initial pharmacokinetic data, in the first half of 2026.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
view ORKA-002 and ORKA-001 as highly complementary. Patients with moderate-to-severe PsO that have purely skin manifestations are most
often treated with IL-23 inhibitors due to the high efficacy and tolerability of this mechanism. However, for patients who also have
joint involvement, or signs and symptoms of PsA, an IL-17 inhibitor is typically used due to its efficacy in addressing both skin and
joint symptoms. In addition, IL-17 inhibitors are often used in patients with highly resistant skin symptoms that do not adequately resolve
through treatment with an IL-23 inhibitor. Together, ORKA-001 and ORKA-002 provide the potential to offer a highly compelling product
profile for most patients with PsO and/or PsA, as well as the opportunity to address additional I&amp;I indications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Additional
Pipeline Programs</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have a third mAb program, ORKA-003, designed to target an undisclosed pathway. Our strategy as a company is to remain highly focused
on&#160;I&amp;I diseases, and specifically on inflammatory dermatology conditions. Our third program provides the potential for indication
expansion beyond PsO and may create combination opportunities with our more advanced programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Our Team,
Investors, and Paragon Collaboration</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pre-Merger
Oruka was founded in February&#160;2024 by leading healthcare investor Fairmount Funds Management LLC (&#8220;Fairmount&#8221;). Fairmount
Funds Management has launched other successful biotechnology companies leveraging antibody technologies generated by Paragon, including
Apogee Therapeutics and Spyre Therapeutics. We are led by a management team with significant experience in developing novel treatments
for patients at biopharmaceutical companies such as CRISPR Therapeutics, Celgene, Novartis, CymaBay Therapeutics and Protagonist Therapeutics.
Together, our team has a proven track record of building successful biotech organizations in high-growth environments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
hold options to acquire intellectual property rights with respect to certain research programs, including ORKA-001 and ORKA-002, from
Paragon. Following the exercise of the Options (defined below) under the Paragon Option Agreements and execution of the respective license
agreements, we will have exclusive worldwide development and commercialization rights to our programs, with IL-23 rights for all indications
outside of inflammatory bowel disease (&#8220;IBD&#8221;), pursuant to such agreements, as applicable. Fairmount Funds Management founded
Paragon in 2021 as the firm&#8217;s discovery engine for biologics that potentially overcome limitations of existing therapies. Paragon
leverages a dedicated in-house team of scientific experts in antibody development, as well as its partnership with FairJourney Biologics,
to generate unique therapeutic concepts and enable their rapid proof-of-concept validation. We consider Paragon to be a related party.
See the section titled &#8220;<i>Certain Relationships and Related Transactions</i>&#8221; for additional information.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Our Strategy</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
achieve our goal of developing leading therapeutic antibodies for patients with inflammatory skin diseases, we are applying antibody
engineering to validated modes of action. We believe this approach will enable us to improve meaningfully upon the efficacy and convenience
of standard-of-care medicines while significantly reducing technical and biological risk. The key elements of our strategy include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employ
                                            advanced antibody engineering to build biologics that could significantly improve upon existing
                                            therapies:&#160;&#160;&#160;&#160;</i></b>We and our collaborators at Paragon have optimized
                                            a variety of parameters using a suite of antibody technologies to develop candidates with
                                            the potential to improve upon existing therapies. These parameters include extending half-life
                                            to increase exposure and reduce dosing frequency, enhancing affinity and specificity to maximize
                                            potency and safety, and optimizing developability to ensure consistency and enable convenient,
                                            high-dose formulations. Together, we believe these features have the potential to translate
                                            into more efficacious and convenient medicines for patients.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Target
                                            validated mechanisms of action:&#160;&#160;&#160;&#160;</i></b>Our initial targets, IL-23p19
                                            and IL-17A/F, have established efficacy and safety for the treatment of PsO, PsA, and other
                                            indications. The FDA has approved four biologics in the IL-23 class, including three targeting
                                            IL-23p19, and four biologics in the IL-17 class, including one targeting IL-17A/F.&#160;While
                                            these therapies have advanced the standard of care in PsO and PsA, they have not addressed
                                            these diseases completely, and a significant fraction of patients do not achieve complete
                                            skin clearance. By applying our advanced antibody engineering to these validated targets,
                                            we believe we can maximize our chances of developing superior medicines for patients. In
                                            addition, the reduced technical and biological risk of these validated mechanisms may allow
                                            us to progress our programs more efficiently and rapidly.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leverage
                                            insights from earlier entrants to optimize our approach:&#160;&#160;&#160;&#160;</i></b>We
                                            benefit from a large body of clinical evidence generated by prior therapies targeting IL-23
                                            and IL-17. We continue to extract and apply learnings from this precedent to our programs,
                                            including in development candidate selection, clinical trial design, dosing regimens, formulations
                                            and presentations, regulatory pathway, and indication prioritization. For instance, based
                                            on correlations between affinity and efficacy, we have designed ORKA-001 and ORKA-002 to
                                            bind to similar epitopes and at similar or greater affinities as the leading antibodies in
                                            each class: risankizumab and bimekizumab, respectively, with the aim of maximizing efficacy.
                                            Also, by understanding the exposure-response relationships for efficacy and safety for other
                                            therapies, we plan to select dose levels and regimens that could maximize efficacy and maintenance
                                            of response while maintaining safety.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pursue
                                            opportunities with strong prospects of yielding meaningful new medicines as a &#8220;base
                                            case&#8221; and the potential to shift the treatment paradigm entirely as an &#8220;upside
                                            case&#8221;:&#160;&#160;&#160;&#160;</i></b>Our strategy seeks to maximize the potential
                                            for our programs to reach a base case product profile that could meaningfully advance the
                                            standard of care&#160;&#8212;&#160;for instance, for ORKA-001, SQ dosing one or twice a year
                                            with equal or greater efficacy compared to today&#8217;s standard of care. At the same time,
                                            we aim to deliver an upside case that dramatically improves outcomes for patients&#160;&#8212;&#160;for
                                            instance, significantly increasing rates of complete skin clearance via higher antibody exposures
                                            or offering patients durable remissions free from therapy by introducing patient-specific
                                            dosing intervals.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Build
                                            a preeminent biotechnology company focused on chronic skin disease and other&#160;I&amp;I
                                            indications:&#160;&#160;&#160;&#160;</i></b>We are assembling a team of exceptional people
                                            and helping them reach their full potential and flourish so that together we can bring forward
                                            meaningful new medicines for patients.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe that pursuing the focused strategy outlined above will help us to succeed in our mission of offering patients living with PsO,
PsA, and other dermatologic and inflammatory diseases the greatest possible freedom from their condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Targeting
IL-23 and IL-17 to Treat Multiple&#160;I&amp;I Indications</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
programs benefit from significant advances in the understanding of the biology of&#160;I&amp;I diseases over the past four decades. ORKA-001
and ORKA-002 are designed to target two key cytokines that play a related role in multiple indications. IL-23 is an upstream regulator
of Th17 cells, a pro-inflammatory subset of T helper cells characterized by their production of IL-17. IL-23 has a critical role in maintaining
Th17 cells in the tissue as well as activating these cells to secrete IL-17, which acts downstream to trigger inflammation and other
disease symptoms. Th17 cells are involved in PsO, PsA, HS, axSpA, and many other diseases. They play a particularly central role in PsO
and PsA. The diagram below depicting the immunopathogenesis of PsO provides an example of how Th17 cells can mediate disease and how
blocking IL-23 or IL-17 can break the inflammatory cycle that drives disease.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Immunopathogenesis
of PsO and the role of IL-23 and IL-17</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_003.jpg" style="width: 700px; height: 394px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">PsO
develops when environmental triggers and a genetic predisposition combine to cause activation of an inflammatory cycle in the skin that
leads to the formation of plaques and other disease manifestations. This process begins with the aberrant activation of the dendritic
cells (&#8220;DCs&#8221;), specifically those producing IL-23 and other cytokines like IL-1&#946;, IL-21, TNF-&#945;, and IL-12. These
cytokines induce the differentiation of Th17 cells, as well as other cell types, such as T helper type 1 (&#8220;Th1&#8221;) cells that
produce IFN&#947; and TNF-&#945; and T helper type 22 (&#8220;Th22&#8221;) cells that produce IL-22. IL-23 plays a key role in the
differentiation and activation of Th17 cells to secrete IL-17, as well as Th22 cells to produce IL-22. IL-17 and these other cytokines
induce keratinocyte hyperproliferation leading to plaque formation and a feedforward inflammatory response, with changes in gene expression
in keratinocytes, the production of antimicrobial peptides, and neutrophil recruitment driving further inflammation. While many cytokines
and cell types contribute to the pathogenesis of PsO, the IL-23/IL-17 axis plays an important role, as supported by the success of therapies
targeting this axis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">While
the successful treatment of PsO&#160;&#8212;&#160;for instance, with mAbs targeting IL-23 or IL-17 &#8212;&#160;can result in lesional
skin returning to an apparently normal state, disease tends to recur at previously affected sites following cessation of therapy, suggesting
a mechanism of &#8220;immunological memory&#8221; that predisposes individuals to recurrence in the same locations. Evidence suggests
that pathogenic TRMs play a critical role in this memory. TRMs may arise from the Th17 cells and other cells that drove disease in the
first place and remain in their resident tissue, in this case the epidermis and dermis, for long periods of time. Upon a disease trigger,
these TRMs can actively produce proinflammatory cytokines, causing disease recurrence. IL-23 appears to play an important role in maintaining
and potentiating TRMs, as indicated by the depletion of TRMs following treatment with an IL-23 inhibitor but not an IL-17 inhibitor,
which may explain the longer remissions observed with IL-23 inhibitors following withdrawal of therapy. This type of data has raised
the prospect that efficient IL-23 blockade could modify the disease biology of PsO, possibly leading to durable remissions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
scientific discoveries that refined our understanding of the immunopathogenesis of PsO have led to waves of therapeutic advances, ultimately
leading to today&#8217;s standard of care. Before the 1980s, PsO was not even thought of as an immunologic disease, but rather a disease
of keratinocyte dysfunction, leading to treatments such as phototherapy, methotrexate, and retinoids. The discovery in the 1980s that
PsO results from immune dysfunction led to the use of broad immunosuppressants like cyclosporine. From 1990 to 2008, it was believed
that Th1 cells were the predominant mediators of the disease, which led to the use of biologics targeting TNF-&#945; such as Enbrel
(etanercept) and Humira (adalimumab). Finally, the revelation that PsO is driven principally by Th17 cells resulted in the development
of the primary therapies used today, which target IL-23 and IL-17. This increasingly refined understanding of the disease has narrowed
the standard of care from broad immunosuppressive agents (such as cyclosporine) to more specific immunomodulators (TNF-&#945; inhibitors)
to precise biologic therapies targeting the key cytokines involved in disease pathology (IL-23 and IL-17 inhibitors), with each new therapeutic
class raising the bar on both safety and efficacy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Biologic
therapies, especially mAbs, are now mainstays in the treatment of a wide variety of&#160;I&amp;I diseases, including PsO and PsA.&#160;Therapies
that have improved upon efficacy and/or reduced dosing frequency have achieved the most commercial success, even when launching many&#160;years
after other biologics. Enbrel was first approved for PsO in 2004 with a weekly maintenance dosing schedule. Four&#160;years later, Humira
was approved for PsO with an every-other-week (Q2W) dosing schedule. Stelara (ustekinumab) was approved a year later with similar Phase&#160;3
data to Humira, but with a significantly improved dosing schedule of every twelve&#160;weeks (Q12W). Several drugs for PsO have been
approved since 2009 that demonstrated higher efficacy in their pivotal studies compared to Stelara, but with more burdensome dosing schedules,
including Tremfya (guselkumab), which has a dosing schedule of every eight&#160;weeks (Q8W), and Cosentyx (secukinumab) and Taltz (ixekizumab),
which have dosing schedules of every four&#160;weeks (Q4W). While these therapies have all become generally successful products, the
most commercially successful drug in the PsO market today is Skyrizi (risankizumab), which combines Stelara&#8217;s Q12W dosing schedule
with improvements in efficacy, as evidenced by a higher psoriasis area severity index (PASI) score of PASI 90 and PASI 100 rates in clinical
trials. In addition, Bimzelx (bimekizumab), approved by the FDA in 2023, has shown evidence of efficacy that exceeds even Skyrizi, though
with a less convenient Q8W dosing schedule. Although many biologics have entered the PsO market over the past two decades, new entrants
have had significant commercial success when they have improved upon efficacy and/or dosing frequency, and room remains to improve in
both areas to set a new standard for the treatment of PsO.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Biologics
have raised the bar on the standard of care in PsO, but leave room for improvement</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_004.jpg" style="width: 650px; height: 267px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
biology driving PsO and PsA is well understood today, and the standard of care has progressed dramatically. We believe that it is unlikely
that a novel mechanism will emerge that is as safe and efficacious as targeting the IL-23/IL-17 axis. Therefore, we believe that innovation
now should be focused on optimizing the product profile that can be offered to patients. While much effort is being directed toward daily
oral formats to inhibit this axis, oral medicines have yet to match the efficacy of biologics. We believe that a better biologic with
a longer dosing interval and the potential for improved efficacy will present a more attractive product profile for most patients.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Overview
of Psoriasis (PsO)</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">PsO
is a chronic autoimmune skin disorder that affects an estimated 125&#160;million people worldwide with steadily increasing prevalence,
estimated to be around&#160;2&#160;&#8211;&#160;3% of the population currently, according to the World Psoriasis Day consortium. It is
the largest pharmaceutical market within dermatology, with annual sales of approximately $25&#160;billion in 2022, which is estimated
to grow to $32&#160;billion by 2028. The most common form of PsO is plaque psoriasis. Patients with chronic plaque psoriasis have well-demarcated,
erythematous plaques with overlying, coarse, silvery-scaled patches. These plaques can occur anywhere on the body, though are typically
found on the scalp, extensor areas of the knees and elbows, and gluteal cleft. Involvement of the palms, soles, or nails, and intertriginous
areas, including the genitals, can also occur and can be particularly difficult to treat. Between one-quarter and one-half of PsO patients
have moderate disease, defined as having 3% to 10% of the body surface area (&#8220;BSA&#8221;) involved, or severe disease, defined
as having more than 10% BSA involvement. The chronic inflammation in PsO is associated with multiple comorbidities, including PsA, obesity,
metabolic syndrome, hypertension, diabetes, and atherosclerotic cardiovascular disease.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
discussed earlier, PsO is a complex immune-mediated disease driven primarily by Th17 cells and the cytokines IL-23 and IL-17. The interplay
of environmental and behavioral risk factors and genetics is believed to trigger PsO.&#160;Multiple lines of evidence support a genetic
component to the disease, including the observation that approximately 40% of patients with PsO and PsA have a family history of the
disease and the identification of multiple susceptibility loci, many containing genes related to the regulation of the immune system,
in genome-wide association studies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Current
PsO Treatments and Limitations</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">While
patients with mild PsO typically rely on topical corticosteroids or oral therapies like Otezla (apremilast), these agents often do not
provide an adequate response for patients with moderate-to-severe PsO.&#160;As a result, the American Academy of Dermatology-National
Psoriasis Foundation recommends biologics as first-line therapy for moderate-to-severe PsO.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Several
classes of biologic therapies have been approved for PsO over the past 20&#160;years, resulting in progressively more complete symptom
relief. Efficacy in PsO is typically measured via the PASI scoring system. The first biologics approved for PsO were tumor necrosis alpha
(&#8220;TNF-&#945;&#8221;) inhibitors such as Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab), which achieved a
90%&#160;improvement in PASI score (&#8220;PASI 90&#8221;) at 16&#160;weeks in around&#160;25&#160;&#8211;&#160;50% of patients and a
100% improvement in PASI score (&#8220;PASI 100&#8221;) in&#160;around 5&#160;&#8211;&#160;20% of patients. Stelara (ustekinumab), which
targets the p40 subunit of IL-23 that is shared with IL-12, was approved next and achieved efficacy on par with Humira. IL-17 inhibitors
Cosentyx (secukinumab), Taltz (ixekizumab), and Siliq (brodalumab) followed and achieved responses of PASI 90 in around&#160;70% of patients
and PASI 100 in&#160;around 40% of patients with some risk of certain side effects such as oral candidiasis. Most recently, IL-23p19
inhibitors such as Ilumya (tildrakizumab), Tremfya (guselkumab), and Skyrizi (risankizumab) have achieved responses of PASI 90 in&#160;around
70&#160;&#8211;&#160;80% of patients and PASI 100 in around 30&#160;&#8211;&#160;50% of patients with highly tolerable profiles. Finally,
IL-17A/F inhibitors such as Bimzelx (bimekizumab) have recently shown even higher response rates than IL-23 inhibitors, but with slightly
less tolerable profiles.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Treatment
expectations in PsO have evolved progressively with this continued innovation. A 75% improvement in PASI score was previously thought
to be an adequate depth of response, and weekly SQ dosing was viewed as acceptable. With each subsequent generation of innovation, patient
and caregiver expectations have advanced. Today, Skyrizi (risankizumab) is widely viewed as the leader in PsO biologic therapy. In Phase&#160;3
clinical trials, 43% and 58% of patients achieved PASI 100 at 16 and 52&#160;weeks, respectively, with SQ maintenance dosing every three&#160;months.
Most recently, Bimzelx (bimekizumab) has shown evidence of efficacy that exceeds even Skyrizi, achieving a 64% PASI 100 rate at 16&#160;weeks
in Phase&#160;3 trials. However, the increased efficacy comes with a less convenient Q8W dosing schedule and an increased risk of certain
side effects, most notably oral candidiasis. While agents like Skyrizi and Bimzelx reflect the remarkable advancement in PsO treatment,
there remains significant unmet need. Approximately half of moderate-to-severe PsO patients do not achieve full skin clarity, and while
early signs are present, the promise of disease modifying therapy remains unrealized. In addition, a continued desire for more convenient
dosing options has driven significant interest in orally delivered medicines targeting these same pathways. However, oral therapies have
yet to match the efficacy and safety profile of biologics. We believe that ORKA-001 and ORKA-002 could represent the next step in biologic
innovation in PsO, with the potential for higher rates of complete skin clearance, more durable remissions, and markedly more convenient
dosing regimens.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Overview
of Psoriatic Arthritis (PsA)</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">PsA
is a chronic inflammatory condition that affects both the skin and joints, and often coexists with PsO.&#160;Around a quarter to a third
of patients with moderate-to-severe PsO also have PsA.&#160;Most individuals develop PsO before being diagnosed with PsA, with a median
gap of seven to eight&#160;years between the diagnosis of skin and joint disease, though in up to 30% of patients with PsA, joint symptoms
appear before or simultaneously with skin manifestations. Patients with PsA present with joint pain, stiffness, and swelling affecting
the peripheral joints, axial skeleton, or both. Enthesitis, dactylitis, nail lesions, fatigue, and ocular inflammation all occur commonly.
PsA can lead to irreversible joint damage, including bony fusion across a joint (ankylosis). The pathogenesis of PsA is likely to be
closely related to the mechanisms that underlie PsO.&#160;Like PsO, the exact cause of PsA remains unknown, but environmental triggers,
including infection and trauma, and genetic factors play a role.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Current
PsA Treatments and Limitations</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Effective
treatment of PsA requires a coordinated approach to address the unique combination of disease manifestations each patient has, which
can include peripheral and axial arthritis, enthesitis, dactylitis, and skin and nail involvement. Many patients with milder disease
symptoms will start with nonsteroidal anti-inflammatory drugs (&#8220;NSAIDs&#8221;) and/or local treatments to address specific disease
manifestations. However, those with more moderate or severe disease and/or multidomain involvement will typically receive a biologic
therapy targeting TNF-&#945; or IL-17, or less commonly an oral Janus kinase (&#8220;JAK&#8221;) inhibitor. Comorbid conditions can
also influence treatment selection. For example, an IL-17 inhibitor would be preferred for a patient with significant skin involvement,
but not for patients with IBD or ocular symptoms, where a TNF-&#945; inhibitor would be preferred. The most common endpoint used to
measure the efficacy of TNF-&#945; or IL-17 inhibitors in PsA is ACR response, or the proportion of patients achieving a specified percent
improvement in American College of Rheumatology (&#8220;ACR&#8221;) score, which measures peripheral joint disease. Approved TNF-&#945;
inhibitors, including Humira (adalimumab) and Cimzia (certolizumab), achieved a placebo-adjusted ACR50 response of around&#160;30&#160;&#8211;&#160;35%
at 24&#160;weeks with Q2W dosing. Approved IL-17 inhibitors, including Cosentyx (secukinumab) and Taltz (ixekizumab), achieved a slightly
lower placebo-adjusted ACR50 response of around&#160;25&#160;&#8211;&#160;30% at 24&#160;weeks, but with more convenient Q4W dosing.
Bimzelx (bimekizumab) which was recently approved in the United&#160;States for PsA achieved a placebo-adjusted ACR50 response of approximately
35% at 16&#160;weeks with Q4W dosing. A significant fraction of patients with PsA still do not achieve a satisfactory response with available
therapies, and even the most convenient regimens require monthly SQ dosing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Overview
of additional opportunities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to PsO and PsA, inhibition of IL-23 or IL-17 has demonstrated efficacy in a number of additional&#160;I&amp;I indications, including
HS and axSpA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">HS
is a chronic inflammatory skin disease characterized by lesions that include deep-seated nodules and abscesses, draining tracts, and
fibrotic scars that occur most commonly in intertriginous areas, such as the armpits and groin. Due to the associated pain, sensitive
locations, drainage, odor, and scarring, this condition can have a particularly negative psychosocial impact on affected individuals.
HS is believed to be underdiagnosed and could have a prevalence well above 1% worldwide. Treatment varies depending on severity and can
include topical and systemic antibiotics, hormone therapy, immune modulators, and surgery. Humira (adalimumab) was the only FDA-approved
medication for the treatment of moderate-to-severe HS from its approval in 2015 until the approval of Cosentyx (secukinumab) in October&#160;2023.
However, now multiple other biologics, including Bimzelx (bimekizumab), are advancing through development and have demonstrated encouraging
data in clinical trials, though a significant fraction of patients still do not achieve adequate responses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">axSpA
is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints that comprise the axial skeleton. The disease
causes severe pain, stiffness, and fatigue, and can have additional clinical manifestations like uveitis, enthesitis, peripheral arthritis,
and PsO.&#160;Patients with axSpA may develop further structural damage in their spine, which can lead to the fusion of vertebra (spinal
ankylosis), which has a massive negative impact on mobility, physical function, and quality of life. The overall prevalence of axSpA
is estimated to be around 1% in the United&#160;States. Treatment of axSpA starts with physical therapy and NSAIDs. If patients do not
have an adequate response to NSAIDs, a TNF-&#945; inhibitor is typically used, followed by an IL-17 inhibitor, such as Cosentyx (secukinumab),
Taltz (ixekizumab), or Bimzelx (bimekizumab), or less frequently a JAK inhibitor. Patients often need to cycle through therapies over
time due to inadequate responses or loss of response.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Our Solution:
Half-Life Extension and Antibody Engineering Technologies</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
antibody engineering campaigns are designed to optimize multiple attributes in parallel: binding affinity, potency in a variety of assays,
developability, and consistently extended serum half-life in non-human primates (&#8220;NHPs&#8221;). Half-life extension is possible
by modifying the pH-dependent binding affinity of the antibody Fc domain for FcRn. A primary mechanism of elimination of antibodies from
the serum is through pinocytosis and degradation in the lysosomes of cells. Throughout this process, antibodies can be recycled back
into the serum by binding to FcRn while they are in endosomes. The interior of the endosome is acidic, and therefore the efficiency of
this recycling process depends on the ability of the antibody Fc domain to bind to FcRn at low pH.&#160;If this low pH binding is efficient
enough, antibody recycling can be favored over degradation, potentially resulting in a much longer serum half-life.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Antibody
engineers have discovered methods of modifying the Fc domain to optimize the efficiency of recycling via FcRn binding. Several engineering
strategies have been identified over the past two decades, with the so-called &#8220;YTE&#8221; mutations (M252Y/S254T/T256E) and &#8220;LS&#8221;
mutations (M428L/N434S) being the most frequently used. Importantly, while these strategies have been known for some time, it was only
relatively recently that enough clinical precedent was established to provide confidence in how these mutations perform in humans. Two
products incorporating YTE modification were approved in 2023 by the FDA, Beyfortus (nirsevimab) and Evusheld (tixagevimab and cilgavimab),
and several more candidates are in clinical trials. Two products using LS mutations were approved in 2021 and 2022, Xevudy (sotrovima)
and Ultomiris (ravulizumab), respectively, and several more candidates are in clinical trials. Based on clinical data in humans, antibodies
with YTE mutations typically have a half-life that is two to four times longer than wildtype antibodies. In addition, preclinical data
in NHPs can be used to predict the approximate half-life in humans, with the human half-life equaling around two to four&#160;times the
NHP half-life.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Clinical
experience with YTE-modified mAbs predicts significant half-life extension over wildtype mAbs</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_005.jpg" style="width: 446px; height: 368px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">While
this increasing body of clinical precedent serves to validate half-life extension, we do not yet have clinical data showing that the
introduction of these amino acid substitutions in our programs leads to a longer serum half-life. However, we aim to establish this favorable
pharmacokinetic profile early in the clinical development of our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ORKA-001</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Summary</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ORKA-001
is a high affinity, extended half-life mAb designed to target the p19 subunit of IL-23. Based on preclinical data generated to date,
we believe ORKA-001 has the potential to become the leading IL-23 inhibitor and achieve an optimal product profile in PsO consisting
of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>One
to two maintenance doses per year.&#160;&#160;&#160;&#160;</i></b>Standard-of-care therapies targeting IL-23 require maintenance dosing
every eight to twelve&#160;weeks. We engineered the Fc portion of ORKA-001 to include YTE mutations to increase the half-life of ORKA-001
in circulation, which may enable dosing every six to twelve&#160;months&#160;&#8212;&#160;a dosing interval made feasible by half-life
extension technology. In preclinical studies, serum levels from&#160;NHPs indicated an elimination half-life of over 30&#160;days following
SQ administration of ORKA-001. Based on published scientific literature on other antibodies incorporating YTE mutations and pharmacokinetic
modeling, we anticipate this half-life in NHPs to translate to a half-life in humans that could allow subcutaneous dosing every six to
twelve&#160;months while maintaining high antibody exposures.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Higher
PASI 100.&#160;&#160;&#160;&#160;</i></b>ORKA-001 benefits from the robust validation of IL-23 inhibition in PsO by multiple approved
therapies, such as Skyrizi (risankizumab) and Tremfya (guselkumab), while leveraging insights from these therapies to improve upon their
clinical profile. ORKA-001 is designed to bind a similar epitope to the market-leading anti-IL-23 antibody, Skyrizi, with similar or
greater affinity and could achieve much higher exposures in patients due to half-life extension and higher dosing. Skyrizi and Tremfya
both have a robust exposure-response relationship, with higher drug exposures leading to higher response rates. Published data indicates
that these therapies have not saturated this exposure-response relationship, and ORKA-001 could lead to higher response rates, including
higher rates of complete skin clearance, or PASI 100, through increased exposure, even while having more convenient dosing with as few
as one or two maintenance doses per year.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Validated
IL-23p19 safety profile.&#160;&#160;&#160;&#160;</i></b>Existing commercially approved antibodies targeting IL-23 provide a robust precedent
for the safety of IL-23 inhibition. Across thousands of patients dosed in dermatology and IBD indications, no correlations have been
observed at the patient level between exposure and safety. While we are not pursuing IBD, the approved Skyrizi regimens for Crohn&#8217;s
disease and ulcerative colitis supports the safety of high peak exposures. Peak Skyrizi exposures during the&#160;IV induction phase
in Crohn&#8217;s disease and ulcerative colitis are multiple times higher than the peak ORKA-001 exposures at dose levels we currently
plan to evaluate in PsO.&#160;In addition, an exposure-response analysis for Skyrizi in ulcerative colitis showed no relationship between
exposures and evaluated safety endpoints in the 12-week induction or 52-week maintenance periods. In this assessment, the top quartile
of average exposures were significantly higher than the highest anticipated exposures with ORKA-001 in the same periods.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Potential
to offer longer term remission to some patients.&#160;&#160;&#160;&#160;</i></b>Emerging evidence suggests that IL-23 blockade can modify
the disease biology of PsO, possibly leading to durable remissions and preventing the development of PsA.&#160;Dr.&#160;Andrew Blauvelt,
chair of our Scientific Advisory Board, pioneered some of this work by using two- and four-times the approved dose levels of risankizumab
to achieve best-in-indication response rates. This study, called KNOCKOUT, showed a robust depletion of TRMs following high dose IL-23
inhibition, which could lead to longer-lasting remissions in some patients. Additional evidence from a study of guselkumab, called GUIDE,
showed that intervention early in the disease course can lead to longer treatment-free remissions. In addition, retrospective claims
data suggests that treatment with an IL-23 inhibitor could help prevent progression to PsA, though this finding has yet to be confirmed
by a prospective clinical trial. Given the high antibody exposures expected with ORKA-001, we believe that ORKA-001 could lead to durable
remissions for some patients, especially those with short disease duration. We plan to pursue patient-specific dosing intervals to provide
each patient the greatest possible freedom from their disease.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe that this target profile for ORKA-001 could offer improved freedom from disease to many patients affected by PsO and represent
a step forward in the standard of care.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Preclinical
Data</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
evaluated ORKA-001 in numerous preclinical studies for several key features:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Potency
that matches or exceeds Skyrizi (risankizumab) in vitro</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have tested the potency of ORKA-001 <i>in vitro</i>&#160;in multiple assays, including assays evaluating the inhibition of IL-17 release
from human peripheral mononuclear blood cells, in comparison to risankizumab generated recombinantly based on amino acid sequences from
patent filings. Based on the results of these experiments, we believe ORKA-001 binds a similar epitope as risankizumab with similar potency.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ORKA-001
binds to a similar epitope as risankizumab with similar potency</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;<img alt="" src="image_006.jpg" style="width: 592px; height: 253px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Significant
half-life extension in NHPs that could enable a maintenance dosing interval of once or twice a year in humans</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
assessed ORKA-001 in NHPs in comparison to risankizumab generated recombinantly based on amino acid sequences from patent filings. ORKA-001
had a significantly longer half-life, reaching over 30&#160;days with SQ administration. Based on clinical experience with YTE-modified
mAbs and pharmacokinetic modeling, we believe that this half-life extension could enable dosing once or twice per year, as shown in the
figure below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>The incorporation
of YTE mutations significantly extends half-life in NHPs, which could enable once or twice yearly dosing</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;<img alt="" src="image_007.jpg" style="width: 619px; height: 267px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to enabling less frequent dosing, an extended half-life would increase the exposure of ORKA-001, which has the potential to
increase efficacy. Based on published literature, Skyrizi (risankizumab) demonstrates a clear relationship between antibody exposure
and efficacy, with higher average serum antibody concentration correlating with higher PASI 90 and PASI 100 rates short-term (at 16&#160;weeks)
and long-term (at 52&#160;weeks), as shown for PASI 100 in the figure below. In addition, the KNOCKOUT study, which evaluated two- and
four-times higher doses of Skyrizi than the approved regimen, yielded some of the highest PASI 100 rates observed to date, reaching 67%
at 16&#160;weeks. Based on our pharmacokinetic modeling, ORKA-001 could achieve four-fold higher average exposures than the approved
Skyrizi regimen over the first 16&#160;weeks and over two-fold higher average exposures at steady-state, exceeding even the exposures
in KNOCKOUT.&#160;Based on the exposure-response relationship observed with other IL-23 inhibiting antibodies, we believe that these
increased exposures could result in higher efficacy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ORKA-001
is projected to extend the exposure-response relationship established by studies of Skyrizi</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_008.jpg" style="width: 613px; height: 246px"/><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Safety
in vitro and in vivo</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have evaluated ORKA-001 in several&#160;<i>in vitro</i>&#160;and&#160;<i>in vivo</i>&#160;preclinical studies to assess safety. In addition,
we have initiated a robust nonclinical program to characterize the toxicology, toxicokinetics, and anti-drug antibody profile of ORKA-001
in NHPs, including a single-dose non-GLP dose-range finding study and one-month and six-month GLP toxicology studies. Collectively, this
nonclinical program is designed to support the initiation of clinical trials. In addition, ORKA-001 benefits from the favorable safety
precedent for IL-23 inhibition provided by the existing commercially approved IL-23-targeted antibodies across several indications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Characteristics
that support ease of manufacturing and potentially enable high-concentration formulations</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Finally,
we have assessed a variety of attributes essential for manufacturability and high-concentration formulation, including viscosity, solubility,
and stability, among others. ORKA-001 shows evidence of desirable properties across these characteristics, which we believe will enhance
our ability to manufacture ORKA-001 successfully and consistently and to deliver high doses of ORKA-001 subcutaneously using convenient,
low-volume presentations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Clinical
Development Plans</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Based
on these potential advantages and preclinical data, we are advancing ORKA-001 towards a Phase&#160;1 clinical trial in the first quarter
of 2025. This trial will encompass a Phase&#160;1a single-ascending dose portion in healthy volunteers, followed by a Phase&#160;1b,
multiple-dose portion in patients with moderate-to-severe PsO.&#160;Following completion of Phase&#160;1b, patients will become eligible
for an open-label extension study. Initial data from the Phase&#160;1a cohort has the potential to provide key validation of both early
safety and pharmacokinetics, including half-life, to support extended dosing intervals. Initial data from the Phase&#160;1b cohort has
the potential to provide preliminary efficacy data in patients with PsO.&#160;Pending the results from the Phase&#160;1 clinical trial,
we plan to initiate a Phase&#160;2 clinical trial in PsO in 2026. Several aspects of PsO facilitate clinical development, including well-established,
reproducible endpoints based on PASI scores, low placebo rates, particularly with PASI 90 and PASI 100, a rapid efficacy readout at 16&#160;weeks,
and potentially rapid enrollment due to the large patient population. We have not yet submitted an IND with the FDA for our Phase 1 clinical
trial for ORKA-001.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ORKA-002</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Summary</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ORKA-002
is a high affinity, extended half-life mAb designed to target IL-17A/F.&#160;Dual inhibition of both IL-17A and IL-17F has shown superior
efficacy compared to IL-17A inhibition alone in PsO and other indications, as shown by the performance of Bimzelx (bimekizumab) compared
to Cosentyx (secukinumab) and Taltz (ixekizumab) in Phase&#160;3 trials. These therapies all utilize Q4W maintenance dosing in PsO and
PsA, except Bimzelx, where Q8W maintenance dosing in PsO patients &lt;120 kg is recommended.&#160;By binding IL-17A/F at similar epitopes
and affinity ranges as Bimzelx while incorporating half-life extension technology to potentially enable dosing two to three times a year
in PsO and PsA, we believe that ORKA-002 could become the leading therapy in the IL-17 class.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Preclinical
Data</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
preclinical program we are conducting for ORKA-002 mirrors that for ORKA-001 and spans potency, pharmacokinetics, safety, and manufacturing
characteristics. Based on the results of these experiments, we believe ORKA-002 has the potential for comparable potency to bimekizumab,
but with a significantly longer half-life, which we believe could support dosing two or three times per year based on extrapolation from
clinical precedent and pharmacokinetic modeling.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Clinical
Development Plans</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
plan to initiate a Phase&#160;1 trial of ORKA-002 in the third quarter of 2025. As with ORKA-001, initial data on ORKA-002 in healthy
volunteers has the potential to provide key validation of both early safety and pharmacokinetics to support extended dosing intervals.
Though clinical development of ORKA-002 will initially focus on one lead indication, we plan to evaluate ORKA-002 in a range of indications
over time. We see ORKA-002 as highly complementary to ORKA-001, with the potential to provide an optimal therapy for the approximately
one-quarter to one-third of moderate-to-severe PsO patients who have PsA, as well as for PsO patients with highly resistant skin symptoms
that do not respond adequately to an IL-23 inhibitor. Furthermore, ORKA-002 could address indications beyond PsO, including PsA with
limited skin involvement, HS, axSpA, and additional&#160;I&amp;I diseases. We have not yet submitted an IND with the FDA for our Phase
1 clinical trial for ORKA-002.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Additional
Pipeline Programs</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have a third mAb program, ORKA-003, that targets an undisclosed pathway. A core tenet of our strategy is to remain highly focused on&#160;I&amp;I
diseases, and specifically on inflammatory dermatology conditions. ORKA-003 provides the potential for indication expansion beyond PsO
as well as combination opportunities with our more advanced programs. In the future, we may add additional programs to our portfolio
beyond ORKA-001, ORKA-002, and ORKA-003 that fit our strategic focus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Intellectual
Property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
strive to protect the proprietary programs and technologies that we believe are important to our business, including seeking and maintaining
patent protection intended to cover the composition of matter of our programs, their methods of use and manufacture, related technologies,
diagnostics, and other inventions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Paragon
has filed provisional patent applications, and may file additional provisional patent applications directed to antibodies that target
IL-23, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including
ORKA-001. In addition, Paragon has filed provisional patent applications, and may file additional provisional patent applications directed
to antibodies that target IL-17, including applications covering composition of matter, pharmaceutical formulations, and methods of using
such antibodies, including ORKA-002. We have exercised our option to acquire exclusive rights to ORKA-001 and the corresponding IL-23
patent applications but have not yet entered into the corresponding license agreement. We have not yet exercised our option to acquire
exclusive rights to any IL-17 patent applications, but retain the right to do so. If the provisional patent applications are pursued
non-provisionally and mature into one or more issued patents covering ORKA-001 or ORKA-002, we would expect those patents to expire in
2045, absent any applicable patent term adjustments or extensions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Commercial</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Should
any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United&#160;States
and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the full
commercial value of our programs. Given our stage of development, we have not yet established a commercial organization or distribution
capabilities. We have exercised our option to acquire exclusive worldwide rights to develop and commercialize ORKA-001 but have not entered
into the corresponding license agreement. We also currently hold an exclusive Option (as defined below) to acquire worldwide development
and commercialization rights to ORKA-002.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Manufacturing</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
do not currently own or operate facilities for product manufacturing, testing, storage, and distribution. We have contracted and expect
to continue to contract with third parties for the manufacture and distribution of our product candidates. Because we rely on contract
manufacturers, we employ personnel with extensive technical, manufacturing, analytical and quality experience. Our team has deep knowledge
and understanding of the regulations that govern manufacturing, documentation, quality assurance, and quality control of drug supply
that are required to support our regulatory filings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Competition</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
biotechnology and biopharmaceutical industries are characterized by continuing technological advancement and significant competition.
While we believe that our programs, technology, development experience and scientific knowledge provide us with competitive advantages,
we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and
private research institutions, among others. Any product candidates that we successfully develop and commercialize will compete with
existing therapies and new therapies that may become available in the future. Many of the companies with which we are currently competing
or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing,
preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers
and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller
number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific
and management personnel, establishing clinical trial sites, patient enrollment for clinical trials as well as in acquiring technologies
complementary to, or necessary for, our programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Key
competitive factors affecting the success of all our product candidates that we develop, if approved, are likely to be efficacy, safety,
convenience, presentation, price, the level of generic competition, and the availability of reimbursement from government and other third-party
payors. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval
for our products, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Specifically,
there are several companies developing or marketing treatments that may be approved for the same indications and/or diseases as our two
most advanced programs, ORKA-001 and ORKA-002, including major pharmaceutical companies. We do not yet have clinical data for any of
our programs and there can be no assurance that our programs will have similar or comparable results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">There
are several approved biologic therapies for the treatment of moderate-to-severe PsO.&#160;These include mAbs targeting IL-23, such as
Skyrizi (risankizumab) from AbbVie, Tremfya (guselkumab) from Janssen, and Ilumya (tildrakizumab) from Sun Pharma, also marketed as Ilumetri
by Almirall in Europe, which all target the p19 subunit, and Stelara (ustekinumab) from Janssen, which targets the p40 subunit; mAbs
targeting IL-17, such as Bimzelx (bimekizumab) from UCB, which targets IL-17A/F, Cosentyx (secukinumab) from Novartis and Taltz (ixekizumab)
from Eli Lilly, which both target IL-17A, and Siliq (brodalumab) from Ortho Dermatologics, also marketed as Kyntheum by LEO Pharma in
Europe, which targets IL-17 receptor A; and biologics targeting TNF-&#945;, such as Humira (adalimumab) from AbbVie, Enbrel (etanercept)
from Amgen, and Remicade (infliximab) from Janssen, and various biosimilar versions of each. In addition, there are several approved
oral medicines in these indications, including the phosphodiesterase-4 (PDE4) inhibitor Otezla (apremilast) from Amgen and the tyrosine
kinase 2 (TYK2) inhibitor Sotyktu (deucravacitinib) from Bristol-Myers Squibb. Many of these therapies also are approved or in development
for PsA, HS, axSpA, and other&#160;I&amp;I indications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, we are aware of several product candidates in clinical development for moderate-to-severe PsO, along with PsA, HS, axSpA, and
other indications. These include the biologics picankibart from Innovent Biologics targeting IL-23p19 and sonelokimab from MoonLake Immunotherapeutics
targeting IL-17A/F.&#160;Also, there are several oral agents in development, including JNJ-2113 from Janssen targeting the IL-23 receptor,
DC-806 and DC-853 from Eli Lilly targeting IL-17A, and TAK-279 from Takeda and ESK-001 from Alumis, both targeting TYK2.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>License
Agreements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Paragon
Therapeutics</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
March&#160;6, 2024, we entered into the Paragon Option Agreements. Under the terms of each agreement, Paragon identifies, evaluates,
and develops antibodies directed against certain mutually agreed therapeutic targets of interest to us. Each Paragon Option Agreement
initially included one of two selected targets: IL-23 and IL-17A/F.&#160;Under the Paragon Option Agreements, we have the exclusive option
to, on a research program-by-research program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title,
and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize
the antibodies and products directed to the selected target(s)&#160;(each, an &#8220;Option&#8221;). In the case of IL-23, our Option
excludes the therapeutic area of IBD.&#160;From time to time, we can choose to add additional targets to the collaboration by mutual
agreement with Paragon and Paruka. In September 2024 we exercised the Option to acquire the rights to ORKA-001 but have not yet entered
into the corresponding license agreement. As of the date hereof, we have not exercised the IL-17A/F Option.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of the Paragon Option Agreements, we initiated certain research programs with Paragon that generally focus on a particular
target (each, a &#8220;Research Program&#8221;). Each Research Program is aimed at discovering, generating, identifying, and/or characterizing
antibodies directed to the respective target. For each Research Program, we established or may establish in the future a research plan
with Paragon that sets forth the activities that will be conducted, and the associated research budget (each, a &#8220;Research Plan&#8221;).
Our exclusive option with respect to each Research Program is exercisable at our sole discretion at any time during the period beginning
on the initiation of activities under the associated Research Program and ending a specified number of&#160;days following (i)&#160;with
respect to any Research Program other than ORKA-001, the delivery of the data package from Paragon related to the results of the Research
Plan activities or (ii)&#160;with respect to ORKA-001, the completion of the IL-23 antibody selection process described in the agreement
(the &#8220;Option Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Paragon Option Agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Unless
terminated earlier, each Paragon Option Agreement shall continue in force on a Research Program-by-Research Program basis until the earlier
of: (i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by us; (ii)&#160;the
expiration of the 30-day period after we exercise our Option with respect to a Research Program, subject to mutually agreed extension,
during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii)&#160;the expiration of the
applicable Research Term (as defined under each Paragon Option Agreement) (the &#8220;Term&#8221;). We may terminate any Paragon Option
Agreement or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon, provided
that we must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred
by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate any Paragon Option Agreement
or a Research Program immediately upon written notice to us if, as a result of any action or failure to act by us or our affiliates,
such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed
for a certain consecutive number of&#160;months. Each party has the right to terminate the Paragon Option Agreements or any Research
Program upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the
30-day period and (ii)&#160;the other party&#8217;s bankruptcy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of the date of filing of this prospectus, we have exercised the Option with respect to ORKA-001 but have not yet entered into the corresponding
license agreement. We have not yet exercised the Option with respect to ORKA-002. For each of these agreements, once we enter into the
corresponding license agreements, we will be required to make non-refundable milestone payments to Paragon of up to $12.0&#160;million
for each program upon the achievement of certain clinical development milestones, up to $10.0&#160;million for each program upon the
achievement of certain regulatory milestones, as well as tiered royalty payments in the low-to-mid single-digits beginning on the first
commercial sale in each program.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Additionally,
as part of the Paragon Option Agreements, on each of December&#160;31, 2024 and December&#160;31, 2025, we will grant Paruka warrants
to purchase a number of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully-diluted basis, with an exercise
price equal to the fair market value of the underlying shares on the grant date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Option Agreements, on a research program-by-research program basis following the finalization of the research plan for each respective
research program, the Company was required to pay Paragon a one-time, nonrefundable research initiation fee of $0.8&#160;million related
to the ORKA-001 program. This amount was recognized as a research and development expense during the period from February&#160;6 (inception)
to September 30, 2024. In June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process of its
development candidate for IL-23 antibody for ORKA-001 program. The Company was responsible for 50% of the development costs incurred
through the completion of the IL-23 selection process. The Company received the rights to at least one selected IL-23 antibody in June
2024. During the three months ended September 30, 2024, the Company exercised its option for ORKA-001 and recorded a $1.5 million milestone
payment related to the achievement of development candidate as research and development expense in the Company&#8217;s condensed consolidated
statements of operations and comprehensive loss for each of the three months ended September 30, 2024 and for the period from February
6, 2024 (inception) to September 30, 2024. The Company&#8217;s share of development costs incurred during the three months ended September
30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024 was $0.8 million and $13.2 million, respectively,
which were recorded as research and development expenses during the respective periods. An amount of $2.3 million is included in related
party accounts payable and other current liabilities as of September 30, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Company was also required to reimburse Paragon $3.3&#160;million for development costs related to ORKA-002 incurred by Paragon through
December&#160;31, 2023 and certain other development costs incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024 as
stipulated by the Option Agreements. This amount was recognized as a research and development expense during the period from February&#160;6
(inception) to September 30, 2024. The Company is also responsible for the development costs incurred by Paragon from January&#160;1,
2024 through the completion of the IL-17 selection process. The Company recognized an amount of $0.8&#160;million payable to Paragon
for the research initiation fee related to ORKA-002 following the finalization of the ORKA-002 research plan. This was recognized as
research and development expenses in the period from February 6 (inception) to September 30, 2024. The Company accounted for development
costs of $3.8 million and $6.6 million during the three months ended September 30, 3024 and for the period from February 6, 2024 (inception)
to September 30, 2024, respectively, as research and development expenses during the respective periods. An amount of $3.8 million is
included in related party accounts payable and other current liabilities as of September 30, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">For
the three months ended September 30, 2024 and the period from February&#160;6, 2024 (inception) to September 30, 2024, we recognized
$13.4 million and $33.8 million of expenses, respectively in connection with services provided by Paragon and Paruka under the Paragon
Option Agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Government
Regulation </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among
other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging,
storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting
of biologics such as those we are developing. We, along with our third-party contractors, will be required to navigate the various preclinical,
clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies
or seek approval or licensure of our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>United
States Biologics Regulation </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the United States, biological products are subject to regulation under the FDCA, the Public Health Service Act (&#8220;PHSA&#8221;) and
other federal, state, local, and foreign statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance
with appropriate federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources.
Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or following
approval may subject an applicant to administrative action and judicial sanctions. The process required by the FDA before biologic product
candidates may be marketed in the United States generally involves the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices (&#8220;GLP&#8221;)
regulation;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes
are made;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
by an independent IRB, or ethics committee at each clinical site before the trial is commenced;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacture
of the proposed biologic candidate in accordance with current Good Manufacturing Practices (&#8220;cGMPs&#8221;);</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
of adequate and well-controlled human clinical trials in accordance with current GCP requirements to establish the safety, purity and
potency of the proposed biologic product candidate for its intended purpose;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparation
of and submission to the FDA of a BLA, after completion of all pivotal clinical trials;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
completion of an FDA Advisory Committee review, if applicable;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
determination by the FDA within 60 days of its receipt of a BLA to file the application for review;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to
assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s
continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
review and approval of a BLA to permit commercial marketing of the product for particular indications for use in the United States.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Preclinical
and Clinical Development </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Prior
to beginning any clinical trial with a product candidate, in the United States, we must submit an IND to the FDA. An IND is a request
for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is
on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes
results of animal and <i>in vitro</i> studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics
of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the
investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective
30 days after receipt by the FDA, unless the FDA, within the 30-day period, raises safety concerns or questions about the proposed clinical
trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or
questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical
trial.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to the IND submission process, supervision of human gene transfer trials includes evaluation and assessment by an institutional
biosafety committee (&#8220;IBC&#8221;), a local institutional committee that reviews and oversees research utilizing recombinant or
synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to
public health or the environment and such review may result in some delay before initiation of a clinical trial.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Clinical
trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in
accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation
in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the
parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND
must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore,
an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and
its informed consent form before the clinical trial begins at that site, and must monitor the study until completed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Regulatory
authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects
are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include
oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board,
which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from
the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such
as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials
and clinical study results to public registries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">For
purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
1. The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition.
These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product
in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
2. The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the
preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase
2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
3. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically
significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial
sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an
adequate basis for product approval.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain
more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical
trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the
product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements.
The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things,
must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity
and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate
that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted
under an IND, all IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor
must ensure that the study complies with certain FDA regulatory requirements in order to use the study as support for an IND or application
for marketing approval or licensure, including that the study was conducted in accordance with GCP, including review and approval by
an independent ethics committee and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate
the data from the study through an onsite inspection if the FDA deems such inspection necessary. The GCP requirements encompass both
ethical and data integrity standards for clinical studies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>BLA Submission
and Review </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Assuming
successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development,
nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or
more indications. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including
negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry,
manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to
test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored
by investigators. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption
applies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, under the Pediatric Research Equity Act (&#8220;PREA&#8221;), a BLA or supplement to a BLA must contain data to assess the
safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and
to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Food and Drug
Administration Safety and Innovation Act requires that a sponsor who is planning to submit a marketing application for a biological product
that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial
pediatric study plan within sixty days after an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise
required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Within
60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before
the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time
of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once
a BLA has been accepted for filing, the FDA&#8217;s goal is to review standard applications within ten months after the filing date,
or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and
priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews
a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed,
packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory
committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee,
but it considers such recommendations carefully when making decisions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Before
approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve
an application unless it determines that the manufacturing processes and facilities are in compliance with GMP requirements and adequate
to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically
inspect one or more clinical sites to assure compliance with cGCPs. If the FDA determines that the application, manufacturing process
or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional
testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the
application does not satisfy the regulatory criteria for approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">After
the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance
will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing
of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies
that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate
to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted
product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant
might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay
or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require
post-marketing testing and surveillance to monitor safety or efficacy of a product.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the
indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a REMS to ensure the benefits of
the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and
to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician
communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls
and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre-&#8201;and post-marketing requirements
is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market
studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may
limit further marketing of the product based on the results of these post-marketing studies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Expedited
Development and Review Programs </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended
to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible
for fast track designation if they are intended to treat a serious or life-threatening disease or condition and data demonstrate the
potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product
and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for more frequent interactions
with the review team during product development and, once a BLA is submitted, the product may be eligible for priority review. A fast
track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before
the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees
to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission
of the first section of the BLA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation
to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates
that the product, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing
therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.
The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as
early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior
managers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Any
marketing application for a biologic submitted to the FDA for approval, including a product with a fast track designation and/or breakthrough
therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as
priority review and accelerated approval. A product is eligible for priority review if there is evidence it has the potential to provide
a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition. For original BLAs, priority review
designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date (as
compared to ten months under standard review).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Additionally,
products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated
approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit,
or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict
an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of
the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally
require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect
on irreversible morbidity or mortality or other clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022 the FDA may require,
as appropriate, that such studies be underway prior to approval or within a specific time period after the date of approval for a product
granted accelerated approval. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor
fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the
FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the
timing of the commercial launch of the product.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Fast
track designation, breakthrough therapy designation and priority review do not change the standards for approval but may expedite the
development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product
no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Post-Approval
Requirements </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Any
products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including,
among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and
distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new
indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements,
under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors
are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections
by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon
us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance
of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of
any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly,
manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with
cGMPs and other aspects of regulatory compliance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product
reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity
or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved
labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition
of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
warning letters or holds on post-approval clinical studies;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
seizure or detention, or refusal of the FDA to permit the import or export of products;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consent
decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mandated
modification of promotional materials and labeling and the issuance of corrective information;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety
information about the product; or</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
or the imposition of civil or criminal penalties.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating
to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label.
The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with
these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil
and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling
and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians
may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the
behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject
of off-label use of their products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Biosimilars
and Reference Product Exclusivity </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
ACA includes a subtitle called the BPCIA, which created an abbreviated approval pathway for biological products that are highly similar,
or &#8220;biosimilar,&#8221; to or interchangeable with an FDA-approved reference biological product. The FDA has issued several guidance
documents outlining an approach to review and approval of biosimilars.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Biosimilarity,
which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of
safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability
requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the
same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual,
the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety
risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable
with an FDA-approved reference biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness
for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product.
Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which
such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked
out by the FDA. In September 2021, the FDA issued two guidance documents intended to inform prospective applicants and facilitate the
development of proposed biosimilars and interchangeable biosimilars, as well as to describe the FDA&#8217;s interpretation of certain
statutory requirements added by the BPCIA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference
product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12
years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may
still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s
own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its
product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it
is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which
are governed by state pharmacy law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
reference biologic is granted twelve years of exclusivity from the time of first licensure of the reference product. The first biologic
product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity
against other biologics submitted under the abbreviated approval pathway for the lesser of (i) one year after the first commercial marketing,
(ii) 18 months after approval if there is no legal challenge, (iii) 18 months after the resolution in the applicant&#8217;s favor of
a lawsuit challenging the biologics&#8217; patents if an application has been submitted, or (iv) 42 months after the application has
been approved if a lawsuit is ongoing within the 42-month period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months
to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection
or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written
Request&#8221; for such a study. The BPCIA is complex and continues to be interpreted and implemented by the FDA. In July 2018, the FDA
announced an action plan to encourage the development and efficient review of biosimilars, including the establishment of a new office
within the agency that will focus on therapeutic biologics and biosimilars. On December 20, 2020, Congress amended the PHSA as part of
the COVID-19 relief bill to further simplify the biosimilar review process by making it optional to show that conditions of use proposed
in labeling have been previously approved for the reference product, which used to be a requirement of the application. In addition,
government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which
may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation,
and impact of the BPCIA is subject to significant uncertainty.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
discussed below, the IRA is a significant new law that intends to foster generic and biosimilar competition and to lower drug and biologic
costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Other
Healthcare Laws and Compliance Requirements </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pharmaceutical
companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states
and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the federal Anti-Kickback Statute
(&#8220;AKS&#8221;); the federal False Claims Act (&#8220;FCA&#8221;); the Health Insurance Portability and Accountability Act of 1996
(&#8220;HIPAA&#8221;) and similar foreign, federal and state fraud, abuse and transparency laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
AKS prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration,
to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which
payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and purchasers on
the other. The government often takes the position that to violate the AKS, only one purpose of the remuneration need be to induce referrals,
even if there are other legitimate purposes for the remuneration. There are a number of statutory exceptions and regulatory safe harbors
protecting some common activities from AKS prosecution, but they are drawn narrowly and practices that involve remuneration, such as
consulting agreements, that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny
if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for protection under
a statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception
or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated
on a case-by-case basis based on a cumulative review of all of its facts and circumstances. A person or entity does not need to have
actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Civil
and criminal false claims laws, including the FCA, and civil monetary penalty laws, which can be enforced through civil whistleblower
or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims
for payment of federal government funds, including in federal healthcare programs, that are false or fraudulent. Pharmaceutical and other
healthcare companies have been prosecuted under these laws for engaging in a variety of different types of conduct that &#8220;caused&#8221;
the submission of false claims to federal healthcare programs. Under the AKS, for example, a claim resulting from a violation of the
AKS is deemed to be a false or fraudulent claim for purposes of the FCA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">HIPAA
created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit
program, including private third-party payors, and making false statements relating to healthcare matters. A person or entity does not
need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate the statute in order
to have committed a violation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
FDCA addresses, among other things, the design, production, labeling, promotion, manufacturing, and testing of drugs, biologics and medical
devices, and prohibits such acts as the introduction into interstate commerce of adulterated or misbranded drugs or devices. The PHSA
also prohibits the introduction into interstate commerce of unlicensed or mislabeled biological products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which
payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually
report to the Centers for Medicaid &amp; Medicare Services (&#8220;CMS&#8221;) information related to payments or other transfers of
value to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists,
certified nurse anesthetists, certified nurse-midwives, and teaching hospitals, as well as ownership and investment interests held by
physicians and their immediate family members. Beginning on January 1, 2023, California Assembly Bill 1278 requires California physicians
and surgeons to notify patients of the Open Payments database established under the federal Physician Payments Sunshine Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are also subject to additional similar U.S. state and foreign law equivalents of each of the above federal laws, which, in some cases,
differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If our operations
are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to penalties, including,
without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs,
such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations
to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits
and the curtailment or restructuring of our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Data Privacy
and Security </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Numerous
state, federal, and foreign laws govern the collection, dissemination, use, access to, confidentiality, and security of personal information,
including health-related information. In the United States, numerous federal and state laws and regulations, including state data breach
notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, govern the
collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations
of our partners. For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;),
and their respective implementing regulations imposes data privacy, security, and breach notification obligations on certain health care
providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates and their covered
subcontractors that perform certain services that involve using, disclosing, creating, receiving, maintaining, or transmitting individually
identifiable protected health information (&#8220;PHI&#8221;) for or on behalf of such covered entities. These requirements imposed by
HIPAA and the HITECH Act on covered entities and business associates include entering into agreements that require business associates
protect PHI provided by the covered entity against improper use or disclosure, among other things; following certain standards for the
privacy of PHI, which limit the disclosure of a patient&#8217;s past, present, or future physical or mental health or condition or information
about a patient&#8217;s receipt of health care if the information identifies, or could reasonably be used to identify, the individual;
ensuring the confidentiality, integrity, and availability of all PHI created, received, maintained, or transmitted in electronic form,
to identify and protect against reasonably anticipated threats or impermissible uses or disclosures to the security and integrity of
such PHI; and reporting of breaches of PHI to individuals and regulators. Entities that are found to be in violation of HIPAA may be
subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations
if required to enter into a resolution agreement and corrective action plan with the U.S. Department of Health and Human Services (&#8220;HHS&#8221;)
to settle allegations of HIPAA non-compliance. A covered entity or business associate is also liable for civil money penalties for a
violation that is based on an act or omission of any of its agents, which may include a downstream business associate, as determined
according to the federal common law of agency. HITECH also increased the civil and criminal penalties applicable to covered entities
and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts
to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. To the extent that we submit
electronic healthcare claims and payment transactions that do not comply with the electronic data transmission standards established
under HIPAA and HITECH, payments to us may be delayed or denied.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Even
when HIPAA does not apply, according to the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep
consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section
5(a) of the Federal Trade Commission Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, certain state laws, such as the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;), as amended by the California
Privacy Rights Act of 2020 (&#8220;CPRA&#8221;), govern the privacy and security of personal information, including health-related information
in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and
may not have the same effect, thus complicating compliance efforts. The CCPA/CPRA applies to personal data of consumers, business representatives,
and employees, and imposes obligations on certain businesses that do business in California, including to provide specific disclosures
in privacy notices, rights to California residents in relation to their personal information. Health information falls under the CCPA/CPRA&#8217;s
definition of personal information where it identifies, relates to, describes, or is reasonably capable of being associated with or could
reasonably be linked with a particular consumer or household - unless it is subject to HIPAA - and is included under a new category of
personal information, &#8220;sensitive personal information,&#8221; which is offered greater protection. Failure to comply with these
laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and
security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts,
and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on
data processing. Additionally, our use of artificial intelligence and machine learning may be subject to laws and evolving regulations
regarding the use of artificial intelligence/machine learning, controlling for data bias, and antidiscrimination.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the CPRA expands the CCPA&#8217;s requirements, including by adding a new right for individuals to correct their personal information
and establishing a new regulatory agency to implement and enforce the law. Other states, such as Virginia, Colorado, Connecticut and
Utah, have also passed comprehensive privacy laws, and similar laws are being considered in several other states, as well as at the federal
and local levels. While the laws in these states, like the CCPA, also exempt some data processed in the context of clinical trials, such
developments further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties upon whom
we rely.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Coverage
and Reimbursement </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Significant
uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory
approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors,
such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the
level of reimbursement, if any, for such product by third-party payors. Decisions regarding whether to cover any of our product candidates,
if approved, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Further, no uniform
policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor
to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates,
but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process
is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product
candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained
in the first instance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Third-party
payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing
the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety
and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with
existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement
for any product or a decision by a third-party not to cover a product could reduce physician usage and patient demand for the product.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">For
products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult
because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment
or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic
tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or
biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products,
will apply to companion diagnostics.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including
price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. The IRA provides CMS
with significant new authorities intended to curb drug costs and to encourage market competition. For the first time, CMS will be able
to directly negotiate prescription drug prices and to cap out-of-pocket costs. Each year, CMS will select and negotiate a preset number
of high-spend drugs and biologics that are covered under Medicare Part B and Part D that do not have generic or biosimilar competition.
On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations. These price negotiations
will begin in 2023, although the Medicare drug price negotiation program is currently subject to legal challenges. The IRA also provides
a new &#8220;inflation rebate&#8221; covering Medicare patients that took effect in 2023 and is intended to counter certain price increases
in prescriptions drugs. The inflation rebate provision will require drug manufacturers to pay a rebate to the federal government if the
price for a drug or biologic under Medicare Part B and Part D increases faster than the rate of inflation. To support biosimilar competition,
beginning in October 2022, qualifying biosimilars may receive a Medicare Part B payment increase for a period of five years. Separately,
if a biologic drug for which no biosimilar exists delays a biosimilar&#8217;s market entry beyond two years, CMS will be authorized to
subject the biologics manufacturer to price negotiations intended to ensure fair competition. Notwithstanding these provisions, the IRA&#8217;s
impact on commercialization and competition remains largely uncertain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Healthcare
Reform </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system.
There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving
quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been
significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement
of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental
control of drug pricing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
ACA, which was enacted in March 2010, substantially changed the way healthcare is financed by both governmental and private insurers
in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import
to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs,
a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled,
infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health
care programs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect
there will be additional challenges and amendments to the ACA in the future. For example, the IRA, among other things, extends enhanced
subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the
&#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket
cost and creating a new manufacturer discount program.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Other
legislative changes have been proposed and adopted since the ACA was enacted, including automatic aggregate reductions of Medicare payments
to providers of on average 2% per fiscal year as part of the federal budget sequestration under the Budget Control Act of 2011. These
reductions went into effect in April 2013 and, due to subsequent legislative amendments, will remain in effect until 2032 unless additional
action is taken by Congress.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the Bipartisan Budget Act of 2018, among other things, amended the Medicare Act (as amended by the ACA) to increase the point-of-sale
discounts that manufacturers must agree to offer under the Medicare Part D coverage discount program from 50% to 70% off negotiated prices
of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient
drugs being covered under Medicare Part D.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Moreover,
there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products,
which has resulted in several Congressional inquiries and proposed and enacted federal and state measures designed to, among other things,
reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between pricing and manufacturer
patient programs, and reform government program reimbursement methodologies for drug products. For example, in May 2019, CMS adopted
a final rule allowing Medicare Advantage Plans the option to use step therapy for Part B drugs, permitting Medicare Part D plans to apply
certain utilization controls to new starts of five of the six protected class drugs, and requiring the Explanation of Benefits for Part
D beneficiaries to disclose drug price increases and lower cost therapeutic alternatives, which went into effect on January 1, 2021.
In response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three
new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility,
and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further,
on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in
rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft
Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product
as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised,
it is uncertain if that will continue under the new framework.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Notwithstanding
the IRA, continued legislative and enforcement interest exists in the United States with respect to specialty drug pricing practices.
Specifically, we expect regulators to continue pushing for transparency to drug pricing, reducing the cost of prescription drugs under
Medicare, reviewing the relationship between pricing and manufacturer patient programs, and reforming government program reimbursement
methodologies for drugs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Other
Government Regulation Outside of the United States </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other
things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage,
record keeping, distribution, reporting, export and import, advertising, marketing and other promotional practices involving biological
products as well as authorization, approval as well as post-approval monitoring and reporting of our products. Because biologically sourced
raw materials are subject to unique contamination risks, their use may be restricted in some countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries
prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United
States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement
of human clinical trials. </span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
requirements and process governing the conduct of clinical trials, including requirements to conduct additional clinical trials, product
licensing, safety reporting, post-authorization requirements, marketing and promotion, interactions with healthcare professionals, pricing
and reimbursement may vary widely from country to country. No action can be taken to market any product in a country until an appropriate
approval application has been approved by the regulatory authorities in that country. The current approval process varies from country
to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price
of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved
by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially
unfeasible in such countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Regulation
in the European Union </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>European
Data Laws </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
collection and use of personal health data and other personal data in the EU is governed by the provisions of the European General Data
Protection Regulation (EU) 2016/679 (&#8220;GDPR&#8221;), which came into force in May 2018, and related data protection laws in individual
EU Member States. The GDPR imposes a number of strict obligations and restrictions on the ability to process, including collecting, analyzing
and transferring, personal data of individuals, in particular with respect to health data from clinical trials and adverse event reporting.
The GDPR includes requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal
data relates), the information provided to the individuals prior to processing their personal data, the notification obligations to the
national data protection authorities, and the security and confidentiality of the personal data. EU Member States may also impose additional
requirements in relation to health, genetic and biometric data through their national legislation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the GDPR imposes specific restrictions on the transfer of personal data to countries outside of the European Economic Area
(&#8220;EEA&#8221;) that are not considered by the European Commission (&#8220;EC&#8221;) to provide an adequate level of data protection.
Appropriate safeguards are required to enable such transfers. Among the appropriate safeguards that can be used, the data exporter may
use the standard contractual clauses (&#8220;SCCs&#8221;). With regard to the transfer of data from the EEA to the United States, on
July 10, 2023, the EC adopted its adequacy decision for the EU-US Data Privacy Framework. On the basis of the new adequacy decision,
personal data can flow from the EEA to U.S. companies participating in the framework.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Failure
to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant
monetary fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever
is greater, other administrative penalties and a number of criminal offenses (punishable by uncapped fines) for organizations and, in
certain cases, their directors and officers, as well as civil liability claims from individuals whose personal data was processed. Data
protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data
protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing
personal data in the EU. Guidance developed at both the EU level and at the national level in individual EU Member States concerning
implementation and compliance practices are often updated or otherwise revised.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
there is a growing trend towards the required public disclosure of clinical trial data in the EU, which adds to the complexity of obligations
relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trials
Regulation No. 536/2014 (&#8220;CTR&#8221;), European Medical Agency (&#8220;EMA&#8221;) disclosure initiatives and voluntary commitments
by industry. Failure to comply with these obligations could lead to government enforcement actions and significant penalties against
us, harm to our reputation, and adversely impact our business and operating results. The uncertainty regarding the interplay between
different regulatory frameworks, such as the CTR and the GDPR, further adds to the complexity that we face with regard to data protection
regulation.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">With
regard to the transfer of personal data from the EEA to the UK, personal data may now freely flow from the EEA to the UK since the UK
is deemed to have an adequate data protection level.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">However,
the adequacy decisions include a &#8216;sunset clause&#8217; which entails that the decisions will automatically expire four years after
their entry into force. Additionally, following the UK&#8217;s withdrawal from the EU and the EEA, companies also have to comply with
the UK&#8217;s data protection laws (including the UK GDPR (as defined in section 3(10) (as supplemented by section 205(4)) of the Data
Protection Act 2018 (the &#8220;DPA 2018&#8221;)), the DPA 2018, and related data protection laws in the UK). Separate from the fines
that can be imposed by the GDPR, the UK regime has the ability to fine up to the greater of &#163;17.5 million or 4% of global turnover.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Following
the UK&#8217;s withdrawal from the EU and the EEA, companies are subject to specific transfer rules under the UK regime; personal data
may flow freely from the UK to the EEA, since the EEA is deemed to have an adequate data protection level for purposes of the UK regime.
These UK international transfer rules broadly mirror the GDPR rules. On February 2, 2022, the UK Secretary of State laid before the UK
Parliament the international data transfer agreement (&#8220;IDTA&#8221;) and the international data transfer addendum to the EC&#8217;s
standard contractual clauses for international data transfers (Addendum) and a document setting out transitional provisions. The IDTA
and Addendum came into force on March 21, 2022 and replaced the old SCCs for the purposes of the UK regime. However, the transitional
provisions, adopted with the IDTA and the Addendum, provide that contracts concluded on or before September 21, 2022 on the basis of
any old SCCs continue to provide appropriate safeguards for the purpose of the UK regime until March 21, 2024, provided that the processing
operations that are the subject matter of the contract remain unchanged and reliance on those clauses ensures that the transfer of personal
data is subject to appropriate safeguards.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">With
regard to the transfer of personal data from the UK to the United States, the UK government has adopted an adequacy decision for the
United States, the UK-US Data Bridge, which came into force on October 12, 2023. The UK-US Data Bridge recognizes the United States as
offering an adequate level of data protection where the transfer is to a U.S. company participating in the EU-US Data Privacy Framework
and the UK Extension.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Drug and
Biologic Development Process </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Regardless
of where they are conducted, all clinical trials included in applications for marketing authorization (&#8220;MA&#8221;) for human medicines
in the EU/EEA must have been carried out in accordance with EU regulations. This means that clinical trials conducted in the EU/EEA have
to comply with EU clinical trial legislation but also that clinical trials conducted outside the EU/EEA have to comply with ethical principles
equivalent to those set out in the EEA, including adhering to international good clinical practice and the Declaration of Helsinki. The
conduct of clinical trials in the EU is governed by the CTR, which entered into force on January 31, 2022. The CTR replaced the Clinical
Trials Directive 2001/20/EC, (&#8220;Clinical Trials Directive&#8221;) and introduced a complete overhaul of the existing regulation
of clinical trials for medicinal products in the EU.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the former regime, which will expire after a transition period of three years as outlined below in more detail, before a clinical trial
can be initiated it must be approved in each EU member state where there is a site at which the clinical trial is to be conducted. The
approval must be obtained from two separate entities: the National Competent Authority (&#8220;NCA&#8221;) and one or more Ethics Committees.
NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent
Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU member state before
the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications
must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious
adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees
of the EU member state where they occur.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
more unified procedure will apply under the new CTR. A sponsor will be able to submit a single application for approval of a clinical
trial through a centralized EU clinical trials portal (the &#8220;CTIS&#8221;). One national regulatory authority (the reporting EU member
state proposed by the applicant) will take the lead in validating and evaluating the application and consult and coordinate with the
other concerned EU Member States. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal.
If an approval is issued, the sponsor may start the clinical trial in all concerned EU Member States. However, a concerned EU member
state may in limited circumstances declare an &#8220;opt-out&#8221; from an approval and prevent the clinical trial from being conducted
in such member state. The CTR also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency
requirements such as mandatory submission of a summary of the clinical trial results to the EU Database. The CTR foresees a three-year
transition period. EU Member States will work in CTIS immediately after the system has gone live. Since January 31, 2023, submission
of initial clinical trial applications via CTIS is mandatory, and by January 31, 2025, all ongoing trials approved under the former Clinical
Trials Directive will need to comply with the CTR and have to be transitioned to CTIS. On July 19, 2023, the EC published guidance concerning
the steps to be taken in this transition. This guidance provides, among other things, that (i) documentation which was previously assessed
will not be reassessed, (ii) templates that were developed and endorsed by the EU Clinical Trials Expert Group to provide compliance
with the CTR do not need to be updated and (iii) there is no need to retrospectively create a site suitability form, which are only necessary
for new trial sites.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
both the former regime and the new CTR, national laws, regulations, and the applicable GCP and GLP standards must also be respected during
the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human
Use guidelines on Good Clinical Practice and the ethical principles that have their origin in the Declaration of Helsinki.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the development of a medicinal product, the EMA and national regulators within the EU provide the opportunity for dialogue and guidance
on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee
for Medicinal Products for Human Use (&#8220;CHMP&#8221;) on the recommendation of the Scientific Advice Working Party. A fee is incurred
with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically
provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and
clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future Marketing
Authorization Application (&#8220;MAA&#8221;) of the product concerned.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Drug Marketing
Authorization </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the EEA, after completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining
a MA. To obtain a MA of a drug under European Union regulatory systems, an applicant can submit an MAA through, amongst others, a centralized
or decentralized procedure.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
be used or sold in the UK, a drug must have an effective MA obtained by a centralized application through EMA or a national application.
National applications are governed by the Human Medicines Regulations (SI 2012/1916). Applications are made electronically through the
Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) Submissions Portal. The process from application to authorizations
generally takes up to 210 days, excluding time taken to provide any additional information or data required by the MHRA.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
August 30, 2023, the MHRA published detailed guidance on its recently announced new International Reliance Procedure (&#8220;IRP&#8221;)
for MAAs. The IRP applies since January 1, 2024 and replaces existing EU reliance procedures to apply for authorizations from seven international
regulators (e.g. Health Canada, Swiss Medic, FDA, EMA, among others). The IRP allows medicinal products approved in other jurisdictions
that meet certain criteria to undergo a fast-tracked MHRA review to obtain and/or update a MA in the UK or Great Britain.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicants
can submit initial MAAs to the IRP but the procedure can also be used throughout the lifecycle of a product for post-authorization procedures
including line extensions, variations and renewals. </span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Centralized
Authorization Procedure </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
centralized procedure provides for the grant of a single MA that is issued by the EC following the scientific assessment of the application
by the EMA that is valid for all EU Member States as well as in the three additional member states of the EEA. The centralized procedure
is compulsory for certain types of medicinal products, including for medicines developed by means of certain biotechnological processes,
products designated as orphan medicinal products, advanced therapy medicinal products (&#8220;ATMP&#8221;) and medicinal products with
a new active substance indicated for the treatment of certain diseases (AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune
and viral diseases). For medicinal products containing a new active substance not yet authorized in the EEA before May 20, 2004 and indicated
for the treatment of other diseases, medicinal products that constitute significant therapeutic, scientific or technical innovations
or for which the grant of a MA through the centralized procedure would be in the interest of public health at EU level, an applicant
may voluntarily submit an application for a MA through the centralized procedure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the centralized procedure, the CHMP established at the EMA, is responsible for conducting the initial assessment of a drug. The CHMP
is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions
to an existing MA. Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMA&#8217;s CHMP is, in principle,
210 days from receipt of a valid MAA. However, this timeline excludes clock stops, when additional written or oral information is to
be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more, unless
the application is eligible for an accelerated assessment. Accelerated evaluation might be granted by the CHMP in exceptional cases,
when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation.
Upon request, the CHMP can reduce the time frame to 150 days if the applicant provides sufficient justification for an accelerated assessment.
The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements.
This opinion is then transmitted to the EC, which has the ultimate authority for granting MA within 67 days after receipt of the CHMP
opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Decentralized
Authorization Procedure </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Medicines
that fall outside the mandatory scope of the centralized procedure have three routes to authorization: (i) they can be authorized under
the centralized procedure if they concern a significant therapeutic, scientific or technical innovation, or if their authorization would
be in the interest of public health; (ii) they can be authorized under a decentralized procedure where an applicant applies for simultaneous
authorization in more than one EU member state; or (iii) they can be authorized in an EU member state in accordance with that state&#8217;s
national procedures and then be authorized in other EU countries by a procedure whereby the countries concerned agree to recognize the
validity of the original, national MA (mutual recognition procedure).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
decentralized procedure permits companies to file identical MA applications for a medicinal product to the competent authorities in various
EU Member States simultaneously if such medicinal product has not received marketing approval in any EU Member State before. This procedure
is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The competent authority
of a single EU Member State, the reference member state, is appointed to review the application and provide an assessment report. The
competent authorities of the other EU Member States, the concerned member states, are subsequently required to grant a MA for their territories
on the basis of this assessment. The only exception to this is where the competent authority of an EU Member State considers that there
are concerns of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually
be referred to the EC, whose decision is binding for all EU Member States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Risk Management
Plan </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">All
new MAAs must include a Risk Management Plan (&#8220;RMP&#8221;) describing the risk management system that the company will put in place
and documenting measures to prevent or minimize the risks associated with the product. RMPs are continually modified and updated throughout
the lifetime of the medicine as new information becomes available. An updated RMP must be submitted: (i) at the request of EMA or a national
competent authority, or (ii) whenever the risk-management system is modified, especially as the result of new information being received
that may lead to a significant change to the benefit-risk profile or as a result of an important pharmacovigilance or risk-minimization
milestone being reached. The regulatory authorities may also impose specific obligations as a condition of the MA. Since October 20,
2023, all RMPs for centrally authorized products are published by the EMA, subject only to limited redactions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>MA Validity
Period </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">MAs
have an initial duration of five years. After these five years, the authorization may subsequently be renewed on the basis of a reevaluation
of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority
decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five-year renewal. Applications for
renewal must be made to the EMA at least nine months before the five-year period expires.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Additionally,
the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw
materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing,
manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Any
authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market
of the authorizing member state within three years after authorization ceases to be valid.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">For
the UK, the period of three years during which the drug has not been marketed in Great Britain will be restarted from the date of conversion
to a Great Britain MA. Conversion refers to the procedure by which, as of January 1, 2021, MAs granted on the basis of a centralized
procedure in the EU are only valid in Northern Ireland but not in Great Britain, whereas, prior EU authorizations have all been automatically
converted into UK MAs effective in Great Britain only.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
the other hand, for the EU, in the case the drug has been marketed in the UK, the placing on the UK market before the end of the period
starting when the UK left the EU on January 31, 2020 and ending on December 31, 2020 (the &#8220;Brexit Transition Period&#8221;) will
be taken into account. If, after the end of the Brexit Transition Period, the drug is not placed on any other market of the remaining
EU Member States, the three-year period will start running from the last date the drug was placed on the UK market before the end of
the Brexit Transition Period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Advanced
Therapy Medicinal Products </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the EU, medicinal products, including ATMPs are subject to extensive pre- and post-market regulation by regulatory authorities at both
the EU and national levels. ATMPs comprise gene therapy products, somatic cell therapy products and tissue engineered products, which
are genes, cells or tissues that have undergone substantial manipulation and that are administered to human beings in order to cure,
diagnose or prevent diseases or regenerate, repair or replace a human tissue. Pursuant to the ATMP Regulation, the Committee on Advanced
Therapies (&#8220;CAT&#8221;) is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CHMP and CAT are also responsible
for providing guidelines on ATMPs. These guidelines provide additional guidance on the factors that the EMA will consider in relation
to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs. Although
such guidelines are not legally binding, compliance with them is often necessary to gain and maintain approval for product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to the mandatory RMP, the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual
product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can
be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where
the product is used.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Exceptional
Circumstances/Conditional Approval </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Similar
to accelerated approval regulations in the United States, conditional MAs can be granted in the EU in exceptional circumstances. A conditional
MA can be granted for medicinal products where, although comprehensive clinical data referring to the safety and efficacy of the medicinal
product have not been supplied, a number of criteria are fulfilled: (i) the benefit/risk balance of the product is positive, (ii) it
is likely that the applicant will be in a position to provide the comprehensive clinical data, (iii) unmet medical needs will be fulfilled
by the grant of the MA and (iv) the benefit to public health of the immediate availability on the market of the medicinal product concerned
outweighs the risk inherent in the fact that additional data are still required. A conditional MA must be renewed annually.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Data and
Market Exclusivity </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
in the United States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect
of postponing the entry into the marketplace of a competitor&#8217;s generic, hybrid or biosimilar product (even if the pharmaceutical
product has already received a MA) and prohibiting another applicant from relying on the MA holder&#8217;s pharmacological, toxicological
and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the
market. New Chemical Entities (&#8220;NCEs&#8221;) approved in the EU qualify for eight years of data exclusivity and 10 years of marketing
exclusivity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">An
additional non-cumulative one-year period of marketing exclusivity is possible if during the data exclusivity period (the first eight
years of the 10-year marketing exclusivity period), the MA holder obtains an authorization for one or more new therapeutic indications
that are deemed to bring a significant clinical benefit compared to existing therapies.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
data exclusivity period begins on the date of the product&#8217;s first MA in the EU. After eight years, a generic product application
may be submitted and generic companies may rely on the MA holder&#8217;s data. However, a generic product cannot launch until two years
later (or a total of 10 years after the first MA in the EU of the innovator product), or three years later (or a total of 11 years after
the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant clinical benefit within
the eight-year data exclusivity period. Additionally, another non-cumulative one-year period of data exclusivity can be added to the
eight years of data exclusivity where an application is made for a new indication for a well-established substance, provided that significant
pre-clinical or clinical studies were carried out in relation to the new indication.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Another
year of data exclusivity may be added to the eight years, where a change of classification of a pharmaceutical product has been authorized
on the basis of significant pre-trial tests or clinical trials (when examining an application by another applicant for or holder of MA
for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for
one year after the initial change was authorized).</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Products
may not be granted data exclusivity since there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities
to include an NCE. Even if a compound is considered to be an NCE and the MA applicant is able to gain the prescribed period of data exclusivity,
another company nevertheless could also market another version of the medicinal product if such company can complete a full MAA with
their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its product.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 26, 2023, the EC submitted a proposal for the reform of the European pharmaceutical legislation. The current draft envisages e.g.,
a shortening of the periods of data exclusivity, however, there is currently neither a final version of this draft nor a date for its
entry into force. </span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Orphan
Designation and Exclusivity </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
criteria for designating an orphan medicinal product in the EU are similar in principle to those in the U.S. The EMA grants orphan drug
designation if the medicinal product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating
condition affecting no more than five in 10,000 persons in the EU (prevalence criterion). In addition, orphan drug designation can be
granted if, for economic reasons, the medicinal product would be unlikely to be developed without incentives and if there is no other
satisfactory method approved in the EU of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed
medicinal product is a significant benefit to patients affected by the condition. An application for orphan drug designation (which is
not a MA, as not all orphan-designated medicines reach the authorization application stage) must be submitted first before an application
for MA of the medicinal product is submitted. The applicant will receive a fee reduction for the MAA if the orphan drug designation has
been granted, but not if the designation is still pending at the time the MA is submitted, and sponsors must submit an annual report
to EMA summarizing the status of development of the medicine. Orphan drug designation does not convey any advantage in, or shorten the
duration of, the regulatory review and approval process. Designated orphan medicines are eligible for conditional MA.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
EMA&#8217;s Committee for Orphan Medicinal Products reassesses the orphan drug designation of a product in parallel with the review for
a MA; for a product to benefit from market exclusivity it must maintain its orphan drug designation at the time of MA review by the EMA
and approval by the EC. Additionally, any MA granted for an orphan medicinal product must only cover the therapeutic indication(s) that
are covered by the orphan drug designation. Upon the grant of a MA, orphan drug designation provides up to ten years of market exclusivity
in the orphan indication.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the 10-year period of market exclusivity, with a limited number of exceptions, the regulatory authorities of the EU Member States and
the EMA may not accept applications for MA, accept an application to extend an existing MA or grant a MA for other similar medicinal
products for the same therapeutic indication. A similar medicinal product is defined as a medicinal product containing a similar active
substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic
indication. An orphan medicinal product can also obtain an additional two years of market exclusivity for an orphan-designated condition
when the results of specific studies are reflected in the Summary of Product Characteristics (&#8220;SmPC&#8221;) addressing the pediatric
population and completed in accordance with a fully compliant Pediatric Investigation Plan (&#8220;PIP&#8221;). No extension to any supplementary
protection certificate can be granted on the basis of pediatric studies for orphan indications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer
meets the criteria for orphan designation, i.e. the condition prevalence or financial returns criteria under Article 3 of Regulation
(EC) No. 141/2000 on orphan medicinal products. When the period of orphan market exclusivity for an indication ends, the orphan drug
designation for that indication expires as well. Orphan exclusivity runs in parallel with normal rules on data exclusivity and market
protection. Additionally, a MA may be granted to a similar medicinal product (orphan or not) for the same or overlapping indication subject
to certain requirements.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the UK, following the post-Brexit transition period, a system for incentivizing the development of orphan medicines was introduced. Overall,
the requirements for orphan designation largely replicate the requirements in the EU and the benefit of market exclusivity has been retained.
Products with an orphan designation in the EU can be considered for an orphan MA in Great Britain, but a UK-wide orphan MA can only be
considered in the absence of an active EU orphan designation. The MHRA will review applications for orphan designation at the time of
a MA, and will offer incentives, such as market exclusivity and full or partial refunds for MA fees to encourage the development of medicines
in rare diseases. </span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Pediatric
Development </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the EU, companies developing a new medicinal product are obligated to study their product in children and must therefore submit a PIP
together with a request for agreement to the EMA. The EMA issues a decision on the PIP based on an opinion of the EMA&#8217;s Pediatric
Committee. Companies must conduct pediatric clinical trials in accordance with the PIP approved by the EMA, unless a deferral (e.g. until
enough information to demonstrate its effectiveness and safety in adults is available) or waiver (e.g. because the relevant disease or
condition occurs only in adults) has been granted by the EMA. The MAA for the medicinal product must include the results of all pediatric
clinical trials performed and details of all information collected in compliance with the approved PIP, unless a waiver or a deferral
has been granted, in which case the pediatric clinical trials may be completed at a later date. Medicinal products that are granted an
MA on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six-month extension
of the protection under a supplementary protection certificate (if any is in effect at the time of approval), or, in the case of orphan
medicinal products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and
is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required
when a MA holder wants to add a new indication, medicinal form or route of administration for a medicine that is already authorized and
covered by intellectual property rights.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the UK, the MHRA has published guidance on the procedures for UK PIPs which, where possible, mirror the submission format and requirements
of the EU system. EU PIPs remain applicable for Northern Ireland and EU PIPs agreed by the EMA prior to January 1, 2021 have been adopted
as UK PIPs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>PRIME
Designation </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few
or no therapies currently exist. The Priority Medicines (&#8220;PRIME&#8221;) scheme is intended to encourage drug development in areas
of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized
procedure. Products from small-and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies
on the basis of compelling non-clinical data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of
product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent
discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier
has been submitted. Importantly, once a candidate medicine has been selected for the PRIME scheme, a dedicated contact point and rapporteur
from the CHMP or CAT are appointed facilitating increased understanding of the product at EMA&#8217;s Committee level. A kick-off meeting
with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts to provide guidance on the
overall development plan and regulatory strategy. PRIME eligibility does not change the standards for product approval, and there is
no assurance that any such designation or eligibility will result in expedited review or approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Post-Approval
Regulation </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Similar
to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the
EMA, the EC and/or the competent regulatory authorities of the EU Member States. This oversight applies both before and after grant of
manufacturing licenses and MAs. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations,
pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting
of medicinal products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Failure
by us or by any of our third-party partners, including suppliers, manufacturers and distributors to comply with EU laws and the related
national laws of individual EU Member States governing the conduct of clinical trials, manufacturing approval, MA of medicinal products
and marketing of such products, both before and after grant of MA, statutory health insurance, bribery and anti-corruption or other applicable
regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to
authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or
variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions,
injunctions, suspension of licenses, fines and criminal penalties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
holder of MA for a medicinal product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines,
which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">These
pharmacovigilance rules can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks
and benefits of marketed medicinal products and to engage in ongoing assessments of those risks and benefits, including the possible
requirement to conduct additional clinical studies or post-authorization safety studies to obtain further information on a medicine&#8217;s
safety, or to measure the effectiveness of risk-management measures, which may be time consuming and expensive and could impact our profitability.
MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who
is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission
of Periodic Safety Update Reports (&#8220;PSURs&#8221;) in relation to medicinal products for which they hold MAs. The EMA reviews PSURs
for medicinal products authorized through the centralized procedure. If the EMA has concerns that the risk benefit profile of a product
has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The agency can advise
that the MA holder be obliged to conduct post-authorization Phase 4 safety studies. If the EC agrees with the opinion, it can adopt a
decision varying the existing MA. Failure by the MA holder to fulfill the obligations for which the EC&#8217;s decision provides can
undermine the ongoing validity of the MA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">More
generally, non-compliance with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the MA for the product
or imposition of financial penalties or other enforcement measures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
manufacturing process for pharmaceutical products in the EU is highly regulated and regulators may shut down manufacturing facilities
that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization
holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC,
Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice (&#8220;GMP&#8221;).
These requirements include compliance with EU GMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients,
including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical
ingredients into the EU. Similarly, the distribution of pharmaceutical products into and within the EU is subject to compliance with
the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted
by the competent authorities of the EU Member States. The manufacturer or importer must have a qualified person who is responsible for
certifying that each batch of product has been manufactured in accordance with GMP, before releasing the product for commercial distribution
in the EU or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for
compliance with GMP.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Sales
and Marketing Regulations </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
advertising and promotion of our products is also subject to EU laws concerning promotion of medicinal products, interactions with physicians,
misleading and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU Member
States may apply to the advertising and promotion of medicinal products and may differ from one country to another. These laws require
that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s SmPC as approved by the
competent regulatory authorities. The SmPC is the document that provides information to physicians concerning the safe and effective
use of the medicinal product. It forms an intrinsic and integral part of the MA granted for the medicinal product. Promotion of a medicinal
product that does not comply with the SmPC is considered to constitute off-label promotion. All advertising and promotional activities
for the product must be consistent with the approved SmPC and therefore all off-label promotion is prohibited. Direct-to-consumer advertising
of prescription-only medicines is also prohibited in the EU. Violations of the rules governing the promotion of medicinal products in
the EU could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising
and promotion of our products to the general public and may also impose limitations on its promotional activities with healthcare professionals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">EU
regulation with regards to dispensing, sale and purchase of medicines has generally been preserved in the UK following Brexit, through
the Human Medicines Regulations 2012. However, organizations wishing to sell medicines online need to register with the MHRA. Following
Brexit, the requirements to display the common logo no longer apply to UK-based online sellers, except for those established in Northern
Ireland.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Anti-Corruption
Legislation </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation
codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU Member States. The provision
of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order
or use of medicinal products is prohibited in the EU. The provision of benefits or advantages to physicians is also governed by the national
anti-bribery laws of the EU Member States. Violation of these laws could result in substantial fines and imprisonment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Payments
made to physicians in certain EU Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the
subject of prior notification and approval by the physician&#8217;s employer, his/her regulatory professional organization, and/or the
competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional
codes of conduct, applicable in the individual EU Member States. Failure to comply with these requirements could result in reputational
risk, public reprimands, administrative penalties, fines or imprisonment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the UK, the pharmaceutical sector is recognized as being particularly vulnerable to corrupt practices, some of which fall within the
scope of the Bribery Act 2010. Due to the Bribery Act 2010&#8217;s far-reaching territorial application, the potential penalized act
does not have to occur in the UK to become within its scope. If the act or omission does not take place in the UK, but the person&#8217;s
act or omission would constitute an offense if carried out there and the person has a close connection with the UK, an offense will still
have been committed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Bribery Act 2010 is comprised of four offenses that cover (i) individuals, companies and partnerships that give, promise or offer bribes,
(ii) individuals, companies and partnerships that request, agree to receive or accept bribes, (iii) individuals, companies and partnerships
that bribe foreign public officials, and (iv) companies and partnerships that fail to prevent persons acting on their behalf from paying
bribes. The penalties imposed under the Bribery Act 2010 depend on the offence committed, harm and culpability and penalties range from
unlimited fines to imprisonment for a maximum term of ten years and in some cases both.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Regulations
in the UK and Other Markets </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
UK formally left the EU on January 31, 2020 and EU laws now only apply to the UK in respect of Northern Ireland as laid out in the Protocol
on Ireland and Northern Ireland and as amended by the Windsor Framework sets out a long-term set of arrangements for the supply of medicines
into Northern Ireland. The EU and the UK agreed on a trade and cooperation agreement (&#8220;TCA&#8221;), which includes provisions affecting
the life sciences sector (including on customs and tariffs). There are some specific provisions concerning pharmaceuticals, including
the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP issued documents. The TCA does
not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
UK government has adopted the Medicines and Medical Devices Act 2021 (the &#8220;MMDA&#8221;) to enable the UK&#8217;s regulatory frameworks
to be updated following the UK&#8217;s departure from the EU. The MMDA introduces regulation-making, delegated powers covering the fields
of human medicines, clinical trials of human medicines, veterinary medicines and medical devices. The MHRA has since been consulting
on future regulations for medicines and medical devices in the UK.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">For
other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct
of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials
must be conducted in accordance with GCPs and the applicable regulatory requirements and the ethical principles that have their origin
in the Declaration of Helsinki.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">If
we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical
trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Employees
and Human Capital Resources</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of November 13, 2024, we had 27 full-time employees. We also engage temporary employees and consultants to augment our existing workforce.
None of our employees are represented by a labor union or covered under a collective bargaining agreement. We consider our relationship
with our employees to be good.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
recognize that attracting, motivating, and retaining talent at all levels is vital to continuing our success. We invest in our employees
through high-quality benefits, professional development opportunities, and various health and wellness initiatives and offer competitive
compensation packages (base salary and incentive plans), ensuring fairness in internal compensation practices. The principal purposes
of our incentive plans (bonus and equity) are to align with the long-term interests of our stakeholders and stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Properties
and Facilities </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
maintain a corporate office at 855 Oak Grove Ave., Suite 100, Menlo Park, California. The lease for this office commenced on June 15,
2024 with an initial term of 39.5 months.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Legal
Proceedings </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">From
time to time, we may become involved in legal proceedings. We are not currently a party to or aware of any proceedings that we believe
will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.
Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources
and other factors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>MANAGEMENT</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>Executive
Officers and Directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table and discussion sets forth the names, ages as of November 13, 2024, positions and biographical and other information of
the individuals who currently serve as directors and executive officers of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; white-space: nowrap; width: 33%; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 10%; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 55%; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Executive
    Officers:</i></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence
    Klein</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer and Director</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arjun
    Agarwal </span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior
    Vice President, Finance and Treasurer </span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joana
    Goncalves&#160;&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Medical Officer </span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Quinlan </span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    Counsel and Corporate Secretary</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Non-Employee
    Directors:</i></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Samarth
    Kulkarni <sup>(2)(3)&#160;&#160;</sup></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chair
    and Director</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kristine
    Ball <sup>(1)(3)&#160;&#160;</sup></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carl
    Dambkowski <sup>(1) </sup></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Harwin <sup>(2)(3) </sup></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    </span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cameron
    Turtle <sup>(1)(2)&#160;&#160;</sup>&#160;&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Member
                                            of the Audit Committee.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(2)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Member
                                            of the Compensation Committee.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Member
                                            of the Nominating and Governance Committee (the &#8220;Governance Committee&#8221;).</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Each
executive officer serves at the discretion of the of the Board and holds office until their successor is duly appointed and qualified
or until their earlier resignation or removal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Executive
Officers</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Lawrence
Klein, Ph.D.</i></b> Dr.&#160;Klein has served as Chief Executive Officer and as a member of the board of directors of the Company since
the Closing and of Pre-Merger Oruka from February 2024 through the Closing. Prior to joining Pre-Merger Oruka, Dr.&#160;Klein was a Partner
at Versant Venture Management, LLC, a healthcare and biotechnology venture capital firm, from January&#160;2023 to February&#160;2024,
where he invested in and helped to grow early-stage&#160;biotechnology companies. Prior to Versant, Dr.&#160;Klein served in various
positions at CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, including Chief Operating Officer from January&#160;2020
to October&#160;2022, Chief Business Officer from January&#160;2019 to January&#160;2020, Senior Vice President, Business Development
and Strategy from November&#160;2017 to December&#160;2018 and as Vice President, Strategy from February&#160;2016 to November&#160;2017,
where he helped to initiate and execute on several transformative partnerships, establish the strategic direction of the company, oversee
important pipeline programs and led several functions, including program and portfolio management. Before joining CRISPR, Dr.&#160;Klein
was an Associate Partner at McKinsey&#160;&amp; Company, a global management consulting firm, from October&#160;2014 to February&#160;2016.
Dr.&#160;Klein served as a member of the board of directors of Dyne Therapeutics, Inc. (Nasdaq: DYN) from September&#160;2019 to May&#160;2023
and of Jasper Therapeutics, Inc. (Nasdaq: JSPR) from September&#160;2021 to June&#160;2023. Dr.&#160;Klein received his B.S. in biochemistry
and physics from the University of Wisconsin-Madison&#160;and his Ph.D. in biophysics from Stanford University.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe Dr. Klein is qualified to serve as a member of the Board because of his business development, operational and senior management
experience in the biotechnology industry and his academic expertise and accomplishments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Arjun
Agarwal.</i>&#160;</b>Mr.&#160;Agarwal has served as the Senior Vice President of Finance of the Company since the Closing and of Pre-Merger
Oruka from March&#160;2024 through the Closing, where he is responsible for overseeing the company&#8217;s finance and accounting functions.
Prior to joining Pre-Merger Oruka, Mr.&#160;Agarwal served as VP of Finance at Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology
company, from June&#160;2021 to March&#160;2024, including through multiple financings and the company&#8217;s successful transition
to become a publicly traded entity. Before joining Jasper, Mr.&#160;Agarwal served as Vice President, Corporate Controller at Protagonist
Therapeutics, Inc. (Nasdaq: PTGX), a biotechnology company, from August&#160;2019 to June&#160;2021, where he was responsible for overseeing
the company&#8217;s finance and accounting functions. Prior to joining Protagonist, Mr.&#160;Agarwal served in various roles of increasing
responsibility at McKesson Corporation (NYSE:&#160;MCK),&#160;an international healthcare services company, from 2009 to 2019. Prior
to McKesson, Mr.&#160;Agarwal worked at PricewaterhouseCoopers LLP, where he managed a portfolio of audit clients. He is a graduate of
Sydenham College of Commerce and Economics at Mumbai University, India. He is a Certified Public Accountant (CPA) and a Chartered Accountant
accredited by the Institute of Chartered Accountants of India.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Joana
Goncalves, MBChB. </i></b>Dr.&#160;Goncalves has served as the Chief Medical Officer of the Company since the Closing and of Pre-Merger
Oruka from April&#160;2024 through the Closing. Prior to joining Pre-Merger Oruka, Dr.&#160;Goncalves served as Chief Medical Officer
of Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company, from October&#160;2018 to April&#160;2024, where she was responsible
for representing Cara Therapeutics in interactions with regulatory agencies, the investor and scientific communities and the board of
directors, building multifunctional terms and developing the clinical development strategy in dermatological conditions. Prior to Cara,
Dr.&#160;Goncalves held various positions at Celgene Corporation, a pharmaceutical company, which was later acquired by Bristol-Myers&#160;Squibb
Company, from April&#160;2014 to October&#160;2018, where she most recently served as Vice President, Medical Affairs for Dermatology
and Neurology and was instrumental in planning and executing medical support activities for a number of programs, including OTEZLA&#174;
for psoriasis. Prior to Celgene, Dr.&#160;Goncalves served as Vice President, Medical Strategy and Scientific Affairs at LEO Pharma Inc.,
the U.S.&#160;subsidiary of LEO Pharma A/S, a global healthcare company specializing in dermatology and critical care, from February&#160;2012
to April&#160;2014. She began her pharmaceutical career at Novartis Pharmaceuticals, working on a range of products across various therapeutic
areas from 2001 to 2012. Dr.&#160;Goncalves received her MBChB from the University of Cape Town, South Africa.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Paul
Quinlan. </i></b>Mr.&#160;Quinlan has served as General Counsel and Corporate Secretary of the Company since the Closing and of Pre-Merger
Oruka since April&#160;2024 through the Closing. Prior to joining Pre-Merger Oruka, Mr.&#160;Quinlan served as General Counsel, Chief
Compliance Officer and Corporate Secretary of CymaBay Therapeutics, Inc., a biopharmaceutical company, from October&#160;2020 to March&#160;2024,
where he was responsible for the general supervision of the company&#8217;s legal affairs. From December&#160;2017 to February&#160;2020,
he served as General Counsel and Corporate Secretary of CymaBay, where he was responsible for the general supervision of the company&#8217;s
legal affairs. Prior to CymaBay, Mr.&#160;Quinlan served as General Counsel and Secretary, from 2010 to January&#160;2018, and Chief
Legal Officer from 2016 to January&#160;2018, of TerraVia Holdings, Inc., a biotechnology company, where he was responsible for the general
supervision of the company&#8217;s legal affairs. Prior to joining TerraVia, Mr.&#160;Quinlan served as General Counsel of Metabolex,
Inc., a biopharmaceutical company, from 2005 to 2010. Prior to joining Metabolex, Mr.&#160;Quinlan held various positions at Maxygen,
Inc., a biopharmaceutical company, from 2000 to 2005. Prior to Maxygen, Mr.&#160;Quinlan practiced law at Cooley LLP and Cravath, Swaine,&#160;&amp;
Moore LLP.&#160;Mr.&#160;Quinlan received a law degree from Columbia Law School and an M.Sc. in Medical Biophysics from the University
of Toronto.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Non-Employee
Directors </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Kristine
Ball. </i></b>Ms. Ball has served as a member of the board of directors of the Company since the Closing and of Pre-Merger Oruka since
May&#160;2024 through the Closing. Ms.&#160;Ball has served as President and Chief Executive Officer of Antiva Biosciences, Inc., a private
biopharmaceutical company, since April&#160;2023. Prior to Antiva, Ms. Ball served as Chief Executive Officer of Soteria Biotherapeutics,
Inc., a private biotechnology company, from September&#160;2020 to August&#160;2022. Prior to joining Soteria, Ms. Ball served as Senior
Vice President, Corporate Strategy and Chief Financial Officer of Menlo Therapeutics, Inc., a Nasdaq-listed&#160;biopharmaceutical company,
which later became VYNE Therapeutics Inc. (Nasdaq: VYNE), from September&#160;2017 to March&#160;2020, where she was responsible for
leading all non-R&amp;D functions, including strategic planning, corporate development, commercial, human resources, legal, finance and
information technology. Prior to joining Menlo, Ms. Ball served as Chief Financial Officer and Senior Vice President of Relypsa, Inc.,
a Nasdaq-listed&#160;pharmaceutical company, which was later acquired by Galenica Group, from November&#160;2012 to October&#160;2016.
Prior to Relypsa, Ms. Ball held various other finance roles in the life sciences industry, including Senior Vice President of Finance&#160;&amp;
Administration and Chief Financial Officer of KAI Pharmaceuticals, Inc., a biopharmaceutical company, and Vice President of Finance at
Exelixis, Inc. (Nasdaq: EXEL), a biotechnology company. Prior to that, Ms. Ball served as a senior manager in life sciences audit practice
of Ernst&#160;&amp; Young LLP. Ms.&#160;Ball has previously served on the boards of directors of Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical
company, from 2020 to 2024, Soteria from 2020 to 2022 and Forty Seven, Inc., a Nasdaq-listed&#160;biotechnology company, which was later
acquired by Gilead Sciences, Inc., from 2018 to 2020. Ms. Ball received a B.S. from Babson College.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe Ms. Ball is qualified to serve as a member of the Board because of her experience as an executive officer and director of life
sciences companies and her background in finance, corporate development and strategic planning.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Carl
Dambkowski, M.D.</i></b> Dr.&#160;Dambkowski has served as a member of the board of directors of the Company since the Closing and of
Pre-Merger Oruka from February&#160;2024 through the Closing. Dr.&#160;Dambkowski has served as the Chief Medical Officer of Apogee Therapeutics,
Inc. (Nasdaq: APGE), a biotechnology company, since September&#160;2022. Prior to joining Apogee, Dr.&#160;Dambkowski served as a strategic
and clinical leader for a variety of companies, including as Chief Medical Officer of QED Therapeutics, Inc., a private biotechnology
company, from July&#160;2021 to September&#160;2022; Chief Strategy Officer and EVP of Operations of Origin Biosciences, Inc., a private
bioecology company, from March&#160;2018 to June&#160;2021; and Chief Medical Officer of Navire Pharma, Inc., a private biotechnology
company, from January&#160;2020 to September&#160;2022, where he served as the clinical lead starting prior to IND for BBP-398&#160;through
the out licensing of the compound to Bristol-Myers&#160;Squibb based on initial clinical data and for low-dose&#160;infigratinib in achondroplasia
through initial proof-of-concept&#160;data. He was part of the core team that brought TRUSELTIQ<sup>&#174;</sup>&#160;(infigratinib) and
NULIBRY<sup>&#174;</sup>&#160;(fosdenopterin) through regulatory review and FDA approval at QED Therapeutics and Origin Biosciences, respectively.
From July&#160;2016 to March&#160;2018, Dr.&#160;Dambkowski was an associate at McKinsey&#160;&amp; Company, a global management consulting
firm, where he advised biotech and pharmaceutical companies across the world on a range of research and development activities. Dr.&#160;Dambkowski
co-founded&#160;Novonate, Inc., a private medical device company focused on building life-saving&#160;devices for neonates, in January&#160;2015.
Dr.&#160;Dambkowski has coauthored numerous peer-reviewed&#160;publications and scientific abstracts and is a named inventor on multiple
published and granted patents. Dr.&#160;Dambkowski was trained as a physician at Stanford University, where he also received his M.D.
with a concentration in bioengineering. He also received a B.A. (with honors) from Stanford University and an M.A. from Columbia University.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe Dr. Dambkowski is qualified to serve as a member of the Board because of his significant experience and innovations in the biotechnology
industry and his academic expertise and accomplishments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Peter
Harwin.</i></b> Mr.&#160;Harwin has served as a member of the board of directors of the Company since the Closing and of Pre-Merger Oruka
from February&#160;2024 through the Closing. Mr.&#160;Harwin is a Managing Member at Fairmount Funds Management, a healthcare investment
firm he co-founded&#160;in April&#160;2016. Prior to Fairmount Funds Management, Mr.&#160;Harwin was a member of the investment team
at Boxer Capital, LLC, an investment fund that was part of the Tavistock Group, based in San Diego. Mr.&#160;Harwin also serves as chairman
of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT) and is a member of the board of directors of Apogee Therapeutics,
Inc. (Nasdaq: APGE), Viridian Therapeutics, Inc. (Nasdaq: VRDN) and Spyre Therapeutics, Inc. (Nasdaq: SYRE). Mr.&#160;Harwin received
a B.B.A. from Emory University.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe Mr. Harwin is qualified to serve as a member of the Board because his experience serving as a director of biotechnology companies
and as a manager of funds specializing in the area of life sciences.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Samarth
Kulkarni, Ph.D. </i></b>Dr.&#160;Kulkarni has served as a member of the board of directors of the Company since the Closing and of Pre-Merger
Oruka from February&#160;2024 through the Closing. Dr.&#160;Kulkarni has served as the Chief Executive Officer of CRISPR Therapeutics
AG (Nasdaq: CRSP), a biopharmaceutical company, since December&#160;2017, where he has also served as a member and chair of the board
of directors since June&#160;2018 and September&#160;2023, respectively. Previously, Dr.&#160;Kulkarni served as CRISPR&#8217;s President
and Chief Business Officer from May&#160;2017 to November&#160;2017 and as Chief Business Officer from August&#160;2015. Prior to joining
CRISPR, Dr.&#160;Kulkarni was at McKinsey&#160;&amp; Company, a global management consulting firm, from 2006 to 2015, with various titles,
his most recent being Partner within the Pharmaceuticals and Biotechnology practice. Dr.&#160;Kulkarni has also served as a member of
the boards of directors of Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology company, since 2019, including as lead
independent director since September&#160;2023, Repare Therapeutics Inc. (Nasdaq: RPTX), a precision oncology company, since November&#160;2019
and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a biotechnology company, since February&#160;2021. Dr.&#160;Kulkarni received a Ph.D.
in Bioengineering and Nanotechnology from the University of Washington and a B.&#160;Tech. from the Indian Institute of Technology. Dr.&#160;Kulkarni
has authored several publications in leading scientific and business journals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe that Dr. Kulkarni is qualified to serve as a member of the Board because of his experience as a consultant and an executive in
the biopharmaceutical industry and his academic expertise and accomplishments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Cameron
Turtle, D.Phil.</i></b> Dr.&#160;Turtle has served as a member of the board of directors of the Company since the Closing and of Pre-Merger
Oruka from February&#160;2024 through the Closing. Dr.&#160;Turtle has served as Chief Executive Officer and a member of the board of
directors of Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) (Nasdaq: SYRE), a biotechnology company, since November&#160;2023
and, before that, as Chief Operating Officer from June&#160;2023 to November&#160;2023. Prior to joining Spyre, Dr.&#160;Turtle was an
advisor to Spyre Therapeutics, Inc., a private biotechnology company, from May&#160;2023 to June&#160;2023. Previously, he served as
Venture Partner at Foresite Labs, a life sciences investment firm, from July&#160;2022 to May&#160;2023; Chief Strategy Officer of BridgeBio
Pharma (Nasdaq: BBIO), a biotechnology company, from January&#160;2021 to April&#160;2022; and Chief Business Officer of Eidos Therapeutics
(Nasdaq: EIDX), a biopharmaceutical company, from November&#160;2018 to January&#160;2021, where he led business development, investor
relations, and multiple operational functions as the company advanced an investigational medicine for a form of heart failure. Prior
to joining BridgeBio and Eidos, he was a consultant at McKinsey&#160;&amp; Company, a global management consulting firm, where he worked
with pharmaceutical and medical device companies on topics including M&amp;A, growth strategy, clinical trial strategy, and sales force
optimization. Dr.&#160;Turtle received his B.S. with honors in Bioengineering from the University of Washington and his D.Phil. in Cardiovascular
Medicine from the University of Oxford, St. John&#8217;s College. He is the recipient of several awards, including a Rhodes Scholarship,
Goldwater Scholarship, Forbes 30 Under&#160;30, San Francisco Business Times 40 Under&#160;40, and the Biocom Life Sciences Catalyst
Award.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe Dr. Turtle is qualified to serve as a member of the Board because of his experience as a leader in building, financing, and shaping
biopharmaceutical organizations from preclinical development to late-stage clinical trials and commercialization.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Family
Relationships </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">There
are no family relationships among any of our directors or executive officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Board
Structure and Related Matters</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Board
Structure</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
business and affairs are managed under the direction of our Board. Our Board currently consists of six members. Each of our current directors
will continue to serve until the election and qualification of their successor, or their earlier death, resignation or removal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
authorized number of directors is determined from time to time solely by resolution of the Board. Our certificate of incorporation and
bylaws provide that our directors may be removed only for cause by the affirmative vote of at least 66 2/3% of the voting power of the
common stock outstanding and entitled to vote thereon. In addition, only our Board is authorized to fill vacancies and any additional
directorships resulting from an increase in the authorized number of directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
certificate of incorporation establishes a classified Board consisting of three classes of directors with staggered three-year terms.
Only one class of directors is elected at each annual meeting of our stockholders to succeed the directors of the same class whose terms
are then expiring, with the other classes continuing for the remainder of their respective three-year terms. The terms of the directors
will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the years
2025 for Class I directors, 2026 for Class II directors, and 2027 for Class III directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Our
                                            Class I directors are Dr. Dambkowski and Mr. Harwin.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Our
                                            Class II directors are Dr. Klein and Dr. Turtle.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Our
                                            Class III directors are Ms. Ball and Dr. Kulkarni.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Director
Independence </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
Board has reviewed the independence of all directors in light of each director&#8217;s (or any family member&#8217;s, if applicable)
affiliations with the Company and members of management, as well as significant holdings of our securities and all other facts and circumstances
that the Board has deemed relevant in determining the independence of each director. The Board has determined that each of the directors
other than Lawrence Klein, our current President and Chief Executive Officer, including Kristine Ball, Carl Dambkowski, Peter Harwin,
Samarth Kulkarni and Cameron Turtle, qualify as &#8220;independent directors&#8221; as defined by the Nasdaq listing rules.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Nasdaq
listing rules have objective tests and a subjective test for determining who is an &#8220;independent director.&#8221; The subjective
test states that an independent director must be a person who lacks a relationship that, in the opinion of the Board, would interfere
with the exercise of independent judgment in carrying out the responsibilities of a director. The Board has not established categorical
standards or guidelines to make these subjective determinations but considers all relevant facts and circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Board
Leadership Structure</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
Board has designated Dr. Kulkarni to serve as Chair of the Board. Although our bylaws do not require that we separate the Chief Executive
Officer and Chair positions, our Board believes that having the positions be separate is the appropriate leadership structure for us
at this time, as it helps facilitate independent Board oversight of management and allows the Chief Executive Officer to focus on strategy
execution and managing the business while the Chair focuses on corporate governance and managing the Board.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
Board recognizes that, depending on future circumstances, other leadership models, such as combining the roles of Chief Executive Officer
and Chair, might be appropriate. Accordingly, our Board may periodically review its leadership structure. At any time when a non-independent
director is serving as Chair, the independent directors will designate a lead independent director to preside at all meetings of the
Board at which the Chair is not present, preside over executive sessions of the independent directors (which occur regularly throughout
each year), serve as a liaison between the Chair and independent directors, and perform such additional duties as our Board may otherwise
determine and delegate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>Role
of Our Board in Risk Oversight </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
face a number of risks, including those described under the section titled &#8220;Risk Factors&#8221;. Our Board believes that risk management
is an important part of establishing, updating and executing on our business strategy. Our Board, both as a whole and at the committee
level, has oversight responsibility relating to risks that could affect the strategy, business objectives, compliance, operations and
the financial condition and performance of the Company. Our Board focuses its oversight on the most significant risks facing the Company
and on its processes to identify, prioritize, assess, manage and mitigate those risks. Our Board and its committees receive regular reports
from members of our senior management on material risks to the Company, including strategic, operational, financial, legal and regulatory
risks. While our Board has an oversight role, management is principally tasked with direct responsibility for managing and assessing
risks and the implementation of processes and controls to mitigate their effects on the Company. Our Board believes its administration
of its risk oversight function has not significantly impacted its selection of the current leadership structure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Board
Committees</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
currently have an Audit Committee, a Compensation Committee, and a Governance Committee. We believe that the functioning and composition
of these committees complies with the requirements of Nasdaq listing rules and SEC rules and regulations. Each committee has the responsibilities
described below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Audit
Committee </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Audit Committee currently comprises Ms. Ball, Dr. Dambkowski, and Dr. Turtle, each of whom qualifies as an independent director for Audit
Committee purposes, as defined under the rules of the SEC and the applicable Nasdaq listing rules and has sufficient knowledge in financial
and auditing matters to serve the Audit Committee. Ms. Ball chairs the Audit Committee and is an &#8220;audit committee financial expert&#8221;
as defined in Item 407(d)(5)(ii) of Regulation S-K promulgated under the Securities Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
primary responsibilities of the Audit Committee are to oversee our accounting and financial reporting processes, including the audits
of the financial statements, and the internal and external audit processes. The Audit Committee also oversees the system of internal
controls established by management and our compliance with legal and regulatory requirements. The Audit Committee is also responsible
for the review, consideration and approval or ratification of related party transactions. The Audit Committee further oversees the independent
auditors, including their independence and objectivity. The Audit Committee is empowered to retain outside legal counsel and other advisors
as it deems necessary or appropriate to assist it in fulfilling its responsibilities and to approve the fees and other retention terms
of the advisors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Compensation
Committee</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Compensation Committee currently comprises Mr. Harwin, Dr. Kulkarni and Dr. Turtle, each of whom qualifies as an independent director
for Compensation Committee purposes, as defined under the rules of the SEC and the applicable Nasdaq listing rules. Dr. Turtle chairs
the Compensation Committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
primary responsibility of the Compensation Committee is to periodically review and approve the compensation and other benefits of our
senior officers and directors. This includes reviewing and approving corporate goals and objectives relevant to the compensation of our
Chief Executive Officer and other executive officers, evaluating the performance of these officers in light of the goals and objectives
and setting or recommending to the Board the officers&#8217; compensation. The Compensation Committee also administers and makes recommendations
to the Board regarding equity incentive plans that are subject to the Board&#8217;s approval, in addition to approving the grant of equity
awards under those plans.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Governance
Committee</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Governance Committee currently comprises Ms. Ball, Dr. Kulkarni and Mr. Harwin, each of whom qualifies as an independent director, as
defined under applicable Nasdaq listing rules. Mr. Harwin chairs the Governance Committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Governance Committee is responsible for engaging in succession planning for our Board, developing and recommending to the Board criteria
for identifying and evaluating qualified director candidates and making recommendations to the Board regarding candidates for election
or reelection to the Board at each annual stockholders&#8217; meeting. In addition, the Governance Committee is responsible for overseeing
corporate governance matters. The Governance Committee is also responsible for overseeing the structure, composition and functioning
of the Board and its committees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>Compensation
Committee Interlocks and Insider Participation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">None
of the members of our Compensation Committee has at any time been an officer or employee of the Company. None of our executive officers
currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity
that has one or more executive officers serving on our Board or Compensation Committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>Code
of Conduct and Ethics </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Board has adopted a Code of Conduct and Ethics that establishes the standards of ethical conduct applicable to all our directors, officers
and employees. The full text of our Code of Conduct and Ethics is posted on our website at https://ir.orukatx.com/corporate-governance.
It addresses, among other matters, compliance with laws and policies, conflicts of interest, corporate opportunities, regulatory reporting,
external communications, confidentiality requirements, insider trading, proper use of assets and how to report compliance concerns. Any
amendments to the Code of Conduct and Ethics, or any waivers of its requirements, will be posted on our website to the extent required
by applicable rules. The Audit Committee is responsible for applying and interpreting our Code of Conduct and Ethics in situations where
questions are presented to it. Information contained on, or that can be accessed through, our website is not incorporated by reference
into this prospectus, and you should not consider information on our website to be part of this prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>EXECUTIVE
COMPENSATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">All
of the information contained in the sections below generally relates to ARCA compensation for fiscal years 2023 and 2022 and was included
in the definitive proxy statement/prospectus filed on Form S-4 with the SEC and declared effective on July 24, 2024 (the &#8220;Proxy
Statement/Prospectus&#8221;). Such information has not been adjusted to reflect the effects of the Reverse Stock Split. Since the date
of the Proxy Statement/Prospectus, there have been several changes to our senior management, including the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
                                            A. Keuer&#8217;s resignation as our President and Chief Operating Officer, effective as of
                                            August 29, 2024, and termination of employment, effective as of September 1, 2024.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
                                            Jeffrey Dekker&#8217;s resignation as our Chief Financial Officer, effective as of August
                                            29, 2024, and termination of employment, effective as of September 1, 2024. Mr. Dekker has
                                            entered into a consulting agreement with us, effective as of August 30, 2024, to provide
                                            transition services through August 30, 2025, unless terminated earlier in accordance with
                                            the agreement.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence
                                            Klein&#8217;s appointment as our President and Chief Executive Officer, effective as of August
                                            29, 2024. </span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arjun
                                            Agarwal&#8217;s appointment as our Senior Vice President, Finance and Treasurer, effective
                                            as of August 29, 2024.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joana
                                            Goncalves&#8217;s appointment as our Chief Medical Officer, effective as of August 29, 2024.
                                            </span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
                                            Quinlan&#8217;s appointment as our General Counsel and Corporate Secretary, effective as
                                            of August 29, 2024.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ARCA Executive
Compensation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table shows for the fiscal&#160;years ended December&#160;31, 2023 and December&#160;31, 2022, compensation awarded to, paid
to, or earned by ARCA&#8217;s principal executive officer and its two most highly compensated executive officers as of December&#160;31,
2023, collectively, the ARCA named executive officers:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><b>Summary
Compensation Table</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Name
    and Principal Position</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary
    <br/> ($)<sup>(1)</sup></b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus
    <br/> ($)<sup>(2)</sup></b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Stock
    <br/> Awards <br/> ($)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All&#160;Other
    <br/> Compensation <br/> ($)<sup>(3)</sup></b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total
    <br/> ($)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 28%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Michael
    R.&#160;Bristow</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">345,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,800</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">358,800</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Former
    President and<br/>
 Chief Executive Officer<sup>(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">345,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,800</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">358,800</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Thomas
    A.&#160;Keuer</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">340,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,802</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">400,802</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">President
    and Chief Operating Officer</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">340,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">88,400</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,593</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">448,993</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">C.&#160;Jeffrey
    Dekker</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">270,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,072</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">323,072</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Chief
    Financial Officer</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            amounts reported under &#8220;Salary&#8221; in the above table represent the actual amounts
                                            paid during the calendar year. Because ARCA&#8217;s actual pay dates do not always coincide
                                            with the first and last&#160;days of the year, these amounts may differ from the base salary
                                            amounts authorized by ARCA&#8217;s board of directors.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            amounts reported under &#8220;Bonus&#8221; in the above table represent retention bonuses
                                            paid to each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker in December&#160;2023. These
                                            amounts were previously reported as &#8220;All Other Compensation&#8221; in ARCA&#8217;s
                                            Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2023.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Represents
                                            401(k)&#160;Company match in the amount of $13,800 for Michael R.&#160;Bristow in each of
                                            2023 and 2022, $15,000 and $13,600 for Thomas A.&#160;Keuer in 2023 and 2022, and $11,579
                                            for C.&#160;Jeffrey Dekker in 2023, Health Savings Account contributions by ARCA in the amount
                                            of $850 for Thomas A.&#160;Keuer in 2022, and $3,960 for C.&#160;Jeffrey Dekker in 2023,
                                            group term life premiums in the amount of $9,602 and $4,989 for Thomas A.&#160;Keuer in 2023
                                            and 2022, and $2,533 for C.&#160;Jeffrey Dekker in 2023, and cell phone reimbursements in
                                            the amount of $1,200 and $1,154 for Thomas A.&#160;Keuer in 2023 and 2022.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Dr.&#160;Bristow
                                            and ARCA mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment effective April&#160;3,
                                            2024.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Narrative
Disclosure to Summary Compensation Table</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Employment
Agreements or Arrangements</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Michael
R.&#160;Bristow, M.D., Ph.D.</i>&#160;&#160;&#160;&#160;Dr.&#160;Bristow served as ARCA&#8217;s President and Chief Executive Officer
under an Employment and Retention Agreement dated as of June&#160;4, 2008, as amended. Pursuant to such employment agreement, Dr.&#160;Bristow
was permitted to continue his academic work for the University of Colorado Health Sciences Center and for the Cardiovascular Institute,
so long as it did not interfere with his duties as President and Chief Executive Officer of ARCA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
connection with Dr.&#160;Bristow&#8217;s separation on April&#160;3, 2024, ARCA and Dr.&#160;Bristow entered into a separation agreement
(the &#8220;Separation Agreement&#8221;) pursuant to which ARCA paid Dr.&#160;Bristow a lump sum amount equal to $370,000, less applicable
tax withholding, which consisted of (i)&#160;12&#160;months of Dr.&#160;Bristow&#8217;s base salary as of the last date of his employment
and (ii)&#160;a $25,000 cash payment. The separation payments were conditioned on Dr.&#160;Bristow not revoking the Separation Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ARCA
and Dr.&#160;Bristow also entered into a consulting agreement, effective April&#160;3, 2024 (the &#8220;Consulting Agreement&#8221;),
pursuant to which Dr.&#160;Bristow provided certain consulting services to ARCA through the earlier of (i)&#160;the completion of services
under the Consulting Agreement, (ii)&#160;a termination in accordance with the terms of the Consulting Agreement, and (iii)&#160;a change
of control of ARCA (as defined in ARCA&#8217;s 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;)). During the consulting term,
Dr.&#160;Bristow continued to vest in his outstanding equity awards.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Thomas
A.&#160;Keuer.</i>&#160;&#160;&#160;&#160;Mr.&#160;Keuer served as ARCA&#8217;s President and Chief Operating Officer until August 29,
2024 under an Amended and Restated Employment Agreement that was effective as of January&#160;1, 2015. The potential severance payments
and benefits available under Mr. Keuer&#8217;s employment agreement as in effect on December 31, 2023 are set forth in Item 11 of ARCA&#8217;s
Annual Report on Form 10-K for the fiscal year ended December 31, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
December&#160;8, 2022, the Compensation Committee approved a retention bonus of $100,000 for Mr.&#160;Keuer, subject to continued employment
with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions. On November&#160;29, 2023, the
Compensation Committee approved the amendment of the retention bonus letter between ARCA and Mr.&#160;Keuer to (i)&#160;increase the
aggregate amount of the retention bonus by 50%, to $150,000, and (ii)&#160;in order to assist with tax obligations associated with the
vesting of certain ARCA restricted stock unit awards, provided that $35,000 of&#160;Mr.&#160;Keuer&#8217;s retention bonus was paid on
December&#160;8, 2023. On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of the retention bonus letter
between ARCA and Mr.&#160;Keuer to increase the aggregate amount of the retention bonus by 33.33% to $200,000.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
connection with Mr. Keuer&#8217;s termination of employment, which was considered to be without &#8220;cause&#8221; related to a change
in control for purposes of his employment agreement, ARCA agreed to pay Mr.&#160;Keuer, in exchange for his execution of a legal release
of claims, a severance payment equivalent to (i)&#160;12&#160;months of his base salary, (ii)&#160;the unpaid portion of his retention
bonus noted above equal to $165,000, and (iii)&#160;reimbursement to cover out-of-pocket costs to continue group health insurance benefits
under COBRA for 12&#160;months.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>C.&#160;Jeffrey
Dekker.</i>&#160;&#160;&#160;&#160;Mr.&#160;Dekker served as ARCA&#8217;s Chief Financial Officer until August 29, 2024 under an Employment
Agreement that was effective as of May&#160;10, 2021. Mr.&#160;Dekker served as ARCA&#8217;s Secretary since April&#160;2023 until August
29, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
his employment agreement, Mr.&#160;Dekker was entitled to receive an annual base salary of $270,000, subject to annual increases if approved
by ARCA&#8217;s board of directors or Compensation Committee and was eligible to receive an annual target bonus of 35% of his base salary
as determined by ARCA&#8217;s board of directors or Compensation Committee in its sole discretion. The potential severance payments and
benefits available under Mr. Dekker&#8217;s employment agreement as in effect on December 31, 2023 are set forth in Item 11 of ARCA&#8217;s
Annual Report on Form 10-K for the fiscal year ended December 31, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
December&#160;8, 2022, the Compensation Committee approved a retention bonus of $100,000 for Mr.&#160;Dekker, subject to continued employment
with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions. On November&#160;29, 2023, the
Compensation Committee approved the amendment of the retention bonus letter between ARCA and Mr.&#160;Dekker to (i)&#160;increase the
aggregate amount of the retention bonus by 50%, to $150,000, and (ii)&#160;in order to assist with tax obligations associated with the
vesting of certain ARCA restricted stock unit awards, provided that $35,000 of&#160;Mr.&#160;Dekker&#8217;s retention bonus was paid
on December&#160;8, 2023. On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of the retention bonus
letter between ARCA and Mr.&#160;Dekker to increase the aggregate amount of the retention bonus by 33.33% to $200,000.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
connection with Mr. Dekker&#8217;s termination of employment, which was considered to be without &#8220;cause&#8221; related to a change
in control for purposes of his employment agreement, ARCA agreed to pay Mr.&#160;Dekker, in exchange for his execution of a legal release
of claims, a severance payment equivalent to (i)&#160;12&#160;months of his base salary, (ii)&#160;the unpaid portion of his retention
bonus noted above equal to $165,000, and (iii)&#160;reimbursement to cover out-of-pocket costs to continue group health insurance benefits
under COBRA for 12&#160;months.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;<span style="font-variant: small-caps"><b>&#160;</b></span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><b>Outstanding
Equity Awards at Fiscal Year End</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table shows for the fiscal year ended December&#160;31, 2023, certain information regarding outstanding equity awards at fiscal
year-end for ARCA named executive officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Option
    Awards</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Name</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number&#160;of
    <br/> Securities <br/> Underlying <br/> Unexercised<br/> Options<br/> (#) <br/> Exercisable</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number&#160;of
    <br/> Securities <br/> Underlying <br/> Unexercised<br/> Options<br/> (#) <br/> Unexercisable</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Option
    <br/> Exercise<br/> Price<br/> ($)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Option<br/>
    Expiration<br/> Date</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Michael
    R.&#160;Bristow, Former President and Chief Executive Officer</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">408</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">245.70</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2/26/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">205</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">84.42</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2/11/2025</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,511</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">59.40</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">6/8/2026</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,333</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45.00</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2/15/2027</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">142,500</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,500</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.27</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/21/2030</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63,334</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,666</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(2)(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.29</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/14/2031</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Thomas
    A.&#160;Keuer, President and Chief Operating Officer</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">83</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">245.70</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2/26/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">108</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">84.42</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2/11/2025</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">866</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">59.40</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">6/8/2026</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,400</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45.00</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2/15/2027</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">52,500</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,500</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.27</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/21/2030</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23,334</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,666</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(2)(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.29</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/14/2031</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">C.&#160;Jeffrey
    Dekker, Secretary, Chief Financial Officer</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,521</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,479</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(3)(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.06</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">5/10/2031</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,800</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,900</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(2)(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.29</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/14/2031</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Options
                                            vest in 48 monthly installments measured from December&#160;21, 2020.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options
                                            vest in 36 monthly installments measured from December&#160;14, 2021.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options
                                            vested 25% after one year, then in 36 monthly installments measured from May&#160;10, 2021.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">In
                                            the event of a change in control of ARCA, 50% of the unvested shares subject to this award
                                            shall become fully and immediately vested upon the closing date of such change in control,
                                            provided, however, that on the earlier of (i)&#160;the one-year anniversary of the closing
                                            date or (ii)&#160;involuntary termination, any options that remain unvested on such earlier
                                            date shall become fully and immediately vested.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><b>ARCA
Director Compensation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">All
of the information contained in the sections below generally relates to compensation for our fiscal year 2023 and was included in the
Proxy Statement/Prospectus. Such information has not been adjusted to reflect the effects of the Reverse Stock Split. Since the date
of the Proxy Statement/Prospectus, there have been several changes to the composition of our Board, including the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Linda
                                            Grais, Anders Hove, Robert Conway, James Flynn and Jacob Ma-Weaver resigned from our Board,
                                            effective as of August 29, 2024.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence
                                            Klein, Kristine Ball, Carl Dambkowski, Peter Harwin, Samarth Kulkarni and Cameron Turtle
                                            were appointed to our Board, effective as of August 29, 2024.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table shows for the fiscal year ended December&#160;31, 2023, certain information with respect to the compensation of all non-employee
directors of ARCA:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><b>Director
Compensation</b></span><b><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-top: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Name</b></span></p></td><td style="border-top: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-top: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Fees&#160;Earned
    <br/> or&#160;Paid&#160;in <br/> Cash&#160;<br/> ($)</span></td><td style="border-top: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-top: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-top: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option
    <br/> Awards <br/> ($)<sup>(2)</sup></b></span></td><td style="border-top: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-top: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-top: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total&#160;<br/>
    ($)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Linda
    Grais<sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">162,500</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">162,500</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raymond
    L.&#160;Woosley<sup>(4)(10)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">55,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">55,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    E.&#160;Conway<sup>(5)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">195,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">195,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan
    J.&#160;Mitchell<sup>(6)(10)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">52,500</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">52,500</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anders
    Hove<sup>(7)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacob
    Ma-Weaver<sup>(8)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">130,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">130,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Flynn<sup>(9)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dr.&#160;Bristow,
                                            ARCA&#8217;s former President and Chief Executive Officer, was also a director during the
                                            year ended December&#160;31, 2023, but did not receive any additional compensation for his
                                            service as a director. Dr.&#160;Bristow&#8217;s compensation as an executive officer is set
                                            forth above under &#8220;Executive Compensation&#160;&#8212;&#160;Summary Compensation Table.&#8221;</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            amounts reported under &#8220;Option Awards&#8221; in the above table reflect the grant date
                                            fair value of these awards as determined in accordance with Financial Accounting Standards
                                            Board Accounting Standards Codification Topic&#160;718, Compensation&#160;&#8212;&#160;Stock
                                            Compensation, excluding the effects of estimated forfeitures. The value of stock option awards
                                            was estimated using the Black-Scholes option-pricing model. The valuation assumptions used
                                            in the valuation of option grants may be found in Note&#160;8 to ARCA&#8217;s financial statements
                                            included in this annual report on Form&#160;10-K for the year ended December&#160;31, 2023.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31,
                                            2023, for Dr.&#160;Grais was 19,458, all of which were fully vested. Includes $52,500 for
                                            Special Committee compensation for 2022 approved and paid in 2023, as discussed below and
                                            $52,500 for 2023 approved and paid in 2024.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31,
                                            2023, for Dr.&#160;Woosley was 19,458, all of which were fully vested.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(5)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31,
                                            2023, for Mr.&#160;Conway, Chairman of ARCA&#8217;s board of directors, was 19,458, all of
                                            which were fully vested. Includes $52,500 for Special Committee compensation for 2022 approved
                                            and paid in 2023, as discussed below and $52,500 for 2023 approved and paid in 2024.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(6)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31,
                                            2023, for Mr.&#160;Mitchell was 19,577, all of which were fully vested.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(7)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31,
                                            2023, for Dr.&#160;Hove was 18,999, all of which were fully vested. Includes $52,500 for
                                            Special Committee compensation for 2022 approved and paid in 2023, as discussed below and
                                            $52,500 for 2023 approved and paid in 2024.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(8)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31,
                                            2023, for Mr.&#160;Ma-Weaver was 18,000, of which 12,000 shares were fully vested. Includes
                                            $37,500 for Special Committee compensation for 2022 approved and paid in 2023, as discussed
                                            below and $52,500 for 2023 approved and paid in 2024.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(9)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31,
                                            2023, for Mr.&#160;Flynn was 12,000, of which 4,000 shares were vested.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(10)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">These
                                            directors resigned from ARCA&#8217;s board of directors effective February&#160;2, 2024.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
2021, ARCA revised its compensation plan for non-employee directors to provide that non-employee directors will be compensated for their
service on ARCA&#8217;s board of directors, as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Each
                                            non-employee director will receive an annual retainer fee of $40,000;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">As
                                            additional compensation for their services, each non-employee director will receive (i),
                                            upon joining ARCA&#8217;s board of directors, an initial option grant to purchase 12,000
                                            shares of ARCA&#8217;s Common Stock under the 2020 Plan, (ii), in 2021 the members of the
                                            board of directors received a one-time retention option grant to purchase 12,000 shares of
                                            ARCA&#8217;s Common Stock under the 2020 Plan, and (iii), on an annual basis as of the date
                                            of ARCA&#8217;s annual stockholder meeting, an annual option grant to purchase 6,000 shares
                                            of ARCA&#8217;s Common Stock under the 2020 Plan; provided that such non-employee director
                                            has served on ARCA&#8217;s board of directors for at least six&#160;months prior to the date
                                            of grant (unless such six-month period is modified by recommendation of the Nominating and
                                            Corporate Governance Committee and approved by the Compensation Committee);</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            Chairman of ARCA&#8217;s board of directors will receive an additional annual retainer fee
                                            of $30,000;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">ARCA&#8217;s
                                            Audit Committee chair will receive an additional annual retainer fee of $15,000;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            chairs of ARCA&#8217;s Compensation Committee and Nominating and Corporate Governance Committee
                                            will each receive an additional annual retainer fee of $10,000;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Each
                                            non-chair member of ARCA&#8217;s Audit Committee will receive an additional annual retainer
                                            fee of $7,500; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Each
                                            non-chair member of ARCA&#8217;s Compensation Committee and Nominating and Corporate Governance
                                            Committees will receive an additional annual retainer fee of $5,000.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
January&#160;30, 2024, ARCA approved paying compensation to its existing non-employee directors, pursuant to ARCA&#8217;s Director Compensation
Policy, by granting to Dr.&#160;Linda Grais, Dr.&#160;Anders Hove, Mr.&#160;Robert Conway, Mr.&#160;Daniel Mitchell, Dr.&#160;Raymond
Woosley, Mr.&#160;James Flynn and Mr.&#160;Jacob Ma-Weaver options to purchase 6,000 shares of common stock at an exercise price of $1.64
per share, the closing price of ARCA&#8217;s common stock on January&#160;30, 2024. The options are subject to the terms and conditions
of the 2020 Plan and ARCA&#8217;s standard forms of Stock Option Agreement and Option Grant Notice for the 2020 Plan. The options vest
in 12 equal monthly installments beginning on January&#160;30, 2024, assuming Dr.&#160;Grais&#8217;, Dr.&#160;Hove&#8217;s, Mr.&#160;Conway&#8217;s,
Mr.&#160;Mitchell&#8217;s, Dr.&#160;Woosley&#8217;s, Mr.&#160;Flynn&#8217;s and Mr.&#160;Ma-Weaver&#8217;s continued service on the Board
for such periods.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
2022, ARCA&#8217;s board of directors established a Special Committee to evaluate strategic options for maximizing stockholder value.
The Special Committee includes ARCA board Chairman Robert E.&#160;Conway (chair), and board members Linda Grais, M.D., Anders Hove, M.D.
and Jacob Ma-Weaver. In December&#160;2023, based on the recommendation of the Nominating and Corporate Governance Committee, the board
determined that each member of the Special Committee will be paid $7,500 per month for each month of substantive service on the Special
Committee. In December&#160;2023, payments for 2022 service were made to the members of the Special Committee of $52,500 to each of Robert
E.&#160;Conway, Linda Grais, M.D., Anders Hove, M.D. and $37,500 to Jacob Ma-Weaver (joined the Committee in June&#160;2022). Payments
for 2023 service were paid in 2024 to the members of the Special Committee consisting of $52,500 to each of Robert E.&#160;Conway, Linda
Grais, M.D., Anders Hove, M.D. and Jacob Ma-Weaver. Payments for 2024 service through April&#160;2024 were paid in 2024 to the members
of the Special Committee consisting of $30,000 to each of Robert E.&#160;Conway, Linda Grais, M.D., Anders Hove, M.D. and Jacob Ma-Weaver.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>2024
Director Compensation Program</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
September 17, 2024, our Board approved an updated director compensation program for non-employee members of our Board that provides for
the following annual cash retainers:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Annual
    Cash Retainer</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Annual
    Board Chair Retainer</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">30,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Audit
    Committee Retainers:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 16.5pt"><span style="font-family: Times New Roman, Times, Serif">Chair</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 16.5pt"><span style="font-family: Times New Roman, Times, Serif">Non-Chair
    Member</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,500</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Compensation
    Committee Retainers:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 16.5pt"><span style="font-family: Times New Roman, Times, Serif">Chair</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 16.5pt"><span style="font-family: Times New Roman, Times, Serif">Non-Chair
    Member</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Nominating
    and Corporate Governance Committee Retainers</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 16.5pt"><span style="font-family: Times New Roman, Times, Serif">Chair</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 16.5pt"><span style="font-family: Times New Roman, Times, Serif">Non-Chair
    Member</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
connection with the Company&#8217;s annual meeting of stockholders, each member of the Board will receive an annual grant of stock options
to purchase 17,500 shares of common stock, which will vest in equal monthly installments over 12 months so long as such director joined
the Board prior to January 1 of the year in which such annual meeting occurs. In addition, in connection with a non-employee director&#8217;s
initial appointment to the Board, they will receive an initial grant of stock options to purchase 35,000 shares of common stock, which
will vest in equal monthly installments over 36 months.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">All
members of the Board are also reimbursed for reasonable and documented out-of-pocket travel and lodging expenses incurred in connection
with attending meetings and activities of the Board and its committees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>ARCA
EQUITY COMPENSATION PLAN INFORMATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table sets forth information as of December&#160;31, 2023, for all of ARCA&#8217;s equity compensation plans and has not been
adjusted to reflect the effects of the Reverse Stock Split:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Plan
    Category</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number&#160;of
    <br/> Securities <br/> to&#160;be&#160;Issued&#160;Upon <br/> Exercise&#160;of <br/> Outstanding <br/> Options&#160;or&#160;Upon <br/>
    Vesting&#160;of <br/> Restricted&#160;Stock <br/> Units<br/> (a)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> Average <br/> Exercise <br/> Price&#160;of <br/> Outstanding <br/> Options<br/> ($)<br/> (b)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number&#160;of<br/>

    Securities <br/> Remaining <br/> Available&#160;for <br/> Future&#160;Issuance <br/> Under&#160;Equity <br/> Compensation <br/>
    Plans&#160;(Excluding <br/> Securities <br/> Reflected&#160;in<br/> Column(a)) <br/> (c)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Equity
    compensation plans approved by security holders</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">616,707</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.76</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">459,718</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Equity
    compensation plans not approved by security holders</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">616,707</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.76</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">459,718</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
December&#160;10, 2020, ARCA stockholders approved the 2020 Plan at ARCA&#8217;s 2020 annual meeting of stockholders. The 2020 Plan is
the successor to the Amended and Restated ARCA biopharma, Inc. 2013 Equity Incentive Plan (the &#8220;2013 Plan&#8221;). A description
of the 2020 Plan is set forth in Note&#160;8 to ARCA&#8217;s financial statements included in the Proxy Statement/Prospectus. The 2020
Plan only has options outstanding as of December&#160;31, 2023; no warrants or rights are outstanding under this plan; therefore, all
values in the above table relate solely to the outstanding options.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
September&#160;17, 2013, ARCA stockholders approved the 2013 Plan at ARCA&#8217;s 2013 annual meeting of stockholders. On June&#160;9,
2016, ARCA stockholders approved an amendment to the 2013 Plan (as amended, the &#8220;Amended 2013 Plan&#8221;). A description of the
2013 Plan and the Amended 2013 Plan is set forth in Note&#160;8 to ARCA&#8217;s financial statements included in the Proxy Statement/Prospectus.
The Amended 2013 Plan only has options outstanding as of December&#160;31, 2023; no warrants or rights are outstanding under this plan;
therefore, all values in the above table relate solely to the outstanding options.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Compensation
Risks</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ARCA
believes its approach to goal setting, setting of targets with payouts at multiple levels of performance, and evaluation of performance
results assist in mitigating excessive risk-taking that could harm the value or reward poor judgment by its executives. ARCA believes
several features of its programs reflect sound risk management practices. ARCA believes it has allocated compensation among base salary
and short and long-term compensation target opportunities in such a way as to not encourage excessive risk-taking. The multi-year vesting
of equity awards properly accounts for the time horizon of risk. Furthermore, ARCA&#8217;s Compensation Committee assesses and monitors
whether any of ARCA&#8217;s compensation policies and programs has the potential to encourage excessive risk-taking on an annual basis.</span></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND<br/>
 RELATED STOCKHOLDER MATTERS </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The following
table sets forth information, to the extent known by us or ascertainable from public filings, with respect to the beneficial ownership
of our Common Stock as of November 1, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
person or group of affiliated persons, who is known by us to be the beneficial owner of more than 5% of Common Stock;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
of our directors;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
of our named executive officers; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
of our current directors and executive officers as a group.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The column
entitled &#8220;Percentage of Shares Outstanding Beneficially Owned&#8221; is based on a total of 34,998,550 shares of our Common Stock
outstanding as of November 1, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Beneficial
ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect
to the Common Stock. Shares of Common Stock subject to options that are currently exercisable or exercisable within 60 days of the date
of this table are considered outstanding and beneficially owned by the person holding the options for the purpose of calculating the
percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Due to the conversion
limitations on the Series A Preferred Stock, shares of underlying common stock have been excluded from beneficial ownership set forth
below. Except as otherwise noted, the persons and entities in this table have sole voting and investing power with respect to all of
the shares of Common Stock beneficially owned by them, subject to community property laws, where applicable. Except as otherwise indicated
in the table below, addresses of named beneficial owners are in care of Oruka Therapeutics, Inc., 855 Oak Grove Ave., Suite 100, Menlo
Park, CA 94025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Name
    of Beneficial Owner</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number&#160;of
    <br/> Shares <br/> Beneficially <br/> Owned</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Percentage
    <br/> of&#160;Shares <br/> Outstanding <br/> Beneficially <br/> Owned</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities
    affiliated with Fairmount Funds Management LLC<sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,941,690</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19.99</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FMR
    LLC<sup>(2)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,682,300</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13.38</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities
    affiliated with Venrock Healthcare Capital Partners<sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,541,941</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.99</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities
    affiliated with RTW Investments, LP<sup>(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,963,147</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.61</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Named
    Executive Officers and Directors:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence
    Klein<sup>(5)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">852,338</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.44</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Arjun
    Agarwal</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Joana
    Goncalves</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Paul
    Quinlan</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    R. Bristow<sup>(6)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">399</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    A. Keuer<sup>(7)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,394&#8194;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
    Jeffrey Dekker<sup>(8)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,333</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cameron
    Turtle<sup>(9)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85,233&#8194;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Samarth
    Kulkarni</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Harwin<sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,941,690</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19.99</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Carl
    Dambkowski</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Kristine
    Ball</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    executive officers and directors as a group (9&#160;persons)<sup>(10)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,879,261</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22.67</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
                                            than 1%.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
                                            of (i) (A) 638,614 shares of common stock, (B) 316,025 shares of common stock issuable upon
                                            the exercise of pre-funded warrants and (C) 4,413,743 shares of common stock issuable upon
                                            conversion of 52,965 shares of Series B Preferred Stock held by Fairmount Healthcare Fund
                                            II L.P. (&#8220;Fairmount Fund II&#8221;) and (ii) 2,573,308 shares of common stock held
                                            by Fairmount Healthcare Co-Invest III L.P. (&#8220;Fairmount Fund III&#8221;). Excludes (i)
                                            4,981,639 shares of common stock issuable upon the exercise of the pre-funded warrants, (ii)
                                            7,014,406 shares of common stock issuable upon the conversion of 84,173 shares of Series
                                            B Preferred Stock and (iii) 160,000 shares of common stock issuable upon the conversion of
                                            160 shares of Series A Preferred Stock owned by Fairmount Fund II. The pre-funded warrants
                                            and Series A Preferred Stock are subject to a beneficial ownership limitation of 9.99% and
                                            the shares of Series B Preferred Stock are subject to a beneficial ownership limitation of
                                            19.99%, which such limitations restrict Fairmount Funds Management LLC (&#8220;Fairmount&#8221;)
                                            and its affiliates from exercising that portion of the warrants and converting those shares
                                            of preferred stock that would result in Fairmount and its affiliates owning, after exercise
                                            or conversion, a number of shares of common stock in excess of the applicable ownership limitation.
                                            At such time as Fairmount and its affiliates beneficially own 9.0% or less of the shares
                                            of common stock, the beneficial ownership limitation applicable to the shares of Series B
                                            Preferred Stock will automatically reduce to 9.99%. Fairmount serves as investment manager
                                            for Fairmount Fund II and Fairmount Fund III. Fairmount Fund II and Fairmount Fund III have
                                            delegated to Fairmount the sole power to vote and the sole power to dispose of all securities
                                            held in Fairmount Fund II and Fairmount Fund III&#8217;s portfolios. Because Fairmount Fund
                                            II and Fairmount Fund III have divested themselves of voting and investment power over the
                                            securities they hold and may not revoke that delegation on less than 61 days&#8217; notice,
                                            Fairmount Fund II and Fairmount Fund III disclaim beneficial ownership of the securities
                                            they hold. The general partner of Fairmount is Fairmount Funds Management GP LLC (&#8220;Fairmount
                                            GP&#8221;). As managing members of Fairmount GP, Peter Harwin and Tomas Kiselak may be deemed
                                            to have voting and investment power over the shares held by Fairmount Fund II and Fairmount
                                            Fund III. Fairmount, Fairmount GP, Peter Harwin and Tomas Kiselak disclaim beneficial ownership
                                            of such shares, except to the extent of any pecuniary interest therein. The address of the
                                            entities and individuals listed is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA
                                            19428.</span></p></td></tr>
</table><div>
</div><p style="margin: 0; font-family: Times New Roman, Times, Serif"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    of the shares listed in the table above are owned by funds or accounts managed by direct or indirect subsidiaries of FMR LLC, all
    of which shares are beneficially owned, or may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates,
    and other companies. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson
    family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of
    FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered
    into a shareholders&#8217; voting agreement under which all Series B voting common shares will be voted in accordance with the majority
    vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217;
    voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group
    with respect to FMR LLC. The address of FMR LLC is 245 Summer Street, Boston, MA 02210.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 2,350,074 shares of common stock and 351,506 shares of common stock issuable upon the exercise of pre-funded warrants held
    by Venrock Healthcare Capital Partners EG, L.P. (&#8220;VHCPEG&#8221;), (ii) 668,656 shares of common stock and 95,284 shares of
    common stock issuable upon the exercise of pre-funded warrants held by Venrock Healthcare Capital Partners III, L.P. (&#8220;VHCP3&#8221;),
    and (iii) 66,890 shares of common stock and 9,531 shares of common stock issuable upon the exercise of pre-funded warrants held by
    VHCP Co-Investment Holdings III, LLC (&#8220;VHCPCo3&#8221;). Excludes (i) 54,474, 12,504 and 1,244 shares of common stock issuable
    upon the exercise of the pre-funded warrants held by VHCPEG, VHCP3 and VHCPCo3, respectively, and (ii) 157,000, 39,000 and 4,000
    shares of common stock issuable upon the conversion of Series A Preferred Stock held by VHCPEG, VHCP3 and VHCPCo3, respectively.
    The pre-funded warrants and Series A Preferred Stock are subject to a beneficial ownership limitation of 9.99%, which such limitations
    restrict Venrock Healthcare Capital Partners and its affiliates from exercising that portion of the warrants or Series A Preferred
    Stock that would result in Venrock Healthcare Capital Partners and its affiliates owning, after exercise, a number of shares of common
    stock in excess of the applicable ownership limitation. VHCP Management III, LLC (&#8220;VHCPM3&#8221;) is the sole general partner
    of VHCP3 and the sole manager of VHCPCo3. VHCP Management EG, LLC (&#8220;VHCPM EG&#8221;) is the sole general partner of VHCPEG.
    As voting members of VHCPM3 and VHCPM EG, Dr. Bong Koh and Nimish Shah may be deemed beneficial owners of any securities beneficially
    owned by VHCPM3 and VHCPM EG. The principal business address of each of these persons and entities is 7 Bryant Park, 23rd Floor,
    New York, NY 10018.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 1,963,147 shares of common stock held in the aggregate by RTW Master Fund, Ltd. (&#8220;RTW Master Fund&#8221;), RTW Innovation
    Master Fund, Ltd. (&#8220;RTW Innovation Master Fund&#8221;), and RTW Biotech Opportunities Operating Ltd. (&#8220;RTW Biotech&#8221;
    and together with RTW Master Fund and RTW Innovation Fund, the &#8220;RTW Funds&#8221;). Excludes 95,000 shares of common stock issuable
    upon the conversion of Series A Preferred Stock held in the aggregate by the RTW Funds. The Series A Preferred Stock is subject to
    a beneficial ownership limitation of 9.99%, which such limitations restrict the RTW Funds and its affiliates from exercising that
    portion of the Series A Preferred Stock that would result in the RTW Funds and its affiliates owning, after exercise, a number of
    shares of common stock in excess of the applicable ownership limitation. RTW Investments, LP (&#8220;RTW&#8221;), in its capacity
    as the investment manager of the RTW Funds, has the power to vote and the power to direct the disposition of the shares held by the
    RTW Funds. Accordingly, RTW may be deemed to be the beneficial owner of such securities. Roderick Wong, M.D., as the Managing Partner
    of RTW, has the power to direct the vote and disposition of the securities held by RTW. Dr. Wong disclaims beneficial ownership of
    the shares held by the RTW Funds, except to the extent of his pecuniary interest therein. The principal business address of RTW Investments,
    LP is 40 10th Avenue, Floor 7, New York, NY 10014, and the address of Dr. Wong and each of the RTW Funds is c/o RTW Investments,
    LP, 40 10th Avenue, Floor 7, New York, NY 10014.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    852,338 shares of restricted voting common stock.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    (i) 92 shares owned by Investocor Trust, of which Dr. Bristow is the sole trustee and (ii) 117 shares owned by NFS as Custodian for
    Michael Bristow&#8217;s IRA. Dr. Bristow and ARCA mutually agreed to conclude Dr. Bristow&#8217;s employment effective April 3, 2024.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Keuer resigned as named executive officer at the Closing and his last day of employment was September 1, 2024, which termination
    was considered to be without &#8220;cause&#8221; related to a change in control for purposes of his employment agreement with ARCA.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Dekker resigned as named executive officer at the Closing and his last day of employment was September 1, 2024, which termination
    was considered to be without &#8220;cause&#8221; related to a change in control for purposes of his employment agreement with ARCA.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            85,233 shares of restricted voting common stock held by the Turtle Family Trust, for which
                                            Mr. Turtle serves as Trustee.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
                                            notes (1), (5) and (9) above.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As discussed
in the &#8220;Certain Relationships and Related Party Transactions of the Combined Company&#8221; section of the Proxy Statement/Prospectus,
the following is a description of each transaction involving (1) the Company since the Closing, including proposed transactions, (2)
Pre-Merger Oruka since February 6, 2024 (its inception) through the Closing, and (3) ARCA, beginning on January 1, 2022, and in which:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Company, Pre-Merger Oruka, or ARCA has been, or is to be, a participant;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
amount involved exceeded or will exceed the lesser of $120,000 and 1% of the average of either the Company&#8217;s, Pre-Merger Oruka&#8217;s,
or ARCA&#8217;s assets (as the case may be); and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
which the directors, executive officers, former directors, former executive officers, director nominees and holders of more than 5% of
capital stock of the Company, Pre-Merger Oruka, or ARCA (as the case may be), or other persons as may be required to be disclosed pursuant
to Item 404 of Regulation S-K, had or will have a direct or indirect material interest.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Other than
the compensation agreements and other arrangements disclosed above under the heading &#8220;Executive Compensation,&#8221; and the transactions
described below, since the filing date of the Proxy Statement/Prospectus, there were no transactions or series of similar transactions
to which ARCA, Pre-Merger Oruka, or the Company were a party in which the amount involved exceed $120,000 (or, if less, 1% of the average
of ARCA, Pre-Merger Oruka, or the Company&#8217;s total asset amounts (as the case may be)) and in which any director, executive officer,
holder of 5% or more of any class of ARCA&#8217;s, Pre-Merger Oruka&#8217;s or the Company&#8217;s capital stock (as the case may be)
or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had a direct or indirect material
interest.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>ARCA
Transactions </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Transactions
With ARCA&#8217;s Former President and Chief Executive Officer</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ARCA
previously entered into unrestricted research grants with its former President and Chief Executive Officer&#8217;s academic research
laboratory at the University of Colorado. Funding of any unrestricted research grants was contingent upon ARCA&#8217;s financial condition,
and could be deferred or terminated at ARCA&#8217;s discretion. There was no expense under these arrangements for the three&#160;months
ended March&#160;31, 2024. Total expense under these arrangements for the three&#160;months ended March&#160;31, 2023 was $108,000. Total
expense under these arrangements for the&#160;years ended December&#160;31, 2023 and 2022 was $(91,000) and $432,000, respectively. In
December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements.
In April&#160;2024, the President and Chief Executive Officer resigned.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Cooperation
Agreement</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ARCA
was a party to a Cooperation Agreement (the &#8220;Cooperation Agreement&#8221;) with Cable Car Capital LLC, The Funicular Fund, LP,
Funicular Funds, LP and Jacob Ma-Weaver&#160;(collectively, &#8220;Cable Car&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Cooperation Agreement, ARCA&#8217;s board of directors appointed Mr.&#160;Ma-Weaver&#160;as a Class&#160;III director with a term
expiring at ARCA&#8217;s 2024 annual meeting of stockholders, effective June&#160;15, 2022 and appointed Mr.&#160;Ma-Weaver&#160;to the
Special Committee of ARCA&#8217;s board of directors (the &#8220;First Director Appointment&#8221;). Mr. Ma-Weaver resigned from ARCA&#8217;s
board of directors immediately prior to the Closing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Additionally,
under the terms of the Cooperation Agreement, ARCA and Cable Car initiated a process and subsequently identified a mutually acceptable
second independent director, Mr.&#160;James Flynn, to join ARCA&#8217;s board of directors. Mr.&#160;Flynn was elected as director at
the 2022 annual meeting of stockholders. Mr. Flynn resigned from ARCA&#8217;s board of directors immediately prior to the Closing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the terms of the Cooperation Agreement, Cable Car agreed to abide by customary standstill restrictions from the date of the Cooperation
Agreement until the earlier to occur of (i)&#160;the 180<sup>th</sup>&#160;day after the First Director Appointment is no longer serving
as a director of ARCA and (ii)&#160;the 90<sup>th</sup>&#160;day prior to the 2023 Annual Meeting (such period, the &#8220;Cooperation
Period&#8221;), including that Cable Car would not, among other things, (i)&#160;seek additional representation, or the removal of an
existing director, on ARCA&#8217;s board of directors, (ii)&#160;engage in any solicitation of proxies, or (iii)&#160;initiate, propose
or otherwise solicit, including any solicitations of the type contemplated by Rule&#160;14a-2(b)&#160;promulgated under the Securities
Exchange&#160;Act&#160;of&#160;1934 of ARCA&#8217;s stockholders for the approval of, any stockholder proposal. The Cooperation Period
expired on November&#160;1, 2023, the 90<sup>th&#160;</sup>day prior to the 2023 Annual Meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ARCA
and Cable Car also agreed to customary mutual non-disparagement&#160;obligations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pre-Merger
Oruka Transactions </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Private
Placements of Securities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pre-Merger
Oruka Series&#160;A Preferred Stock and Convertible Note&#160;Financing</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On March&#160;6,
2024, Oruka entered into a Convertible Note Purchase Agreement with Fairmount Healthcare Fund II, L.P. (&#8220;Fairmount Fund II&#8221;),
whereby Oruka issued and sold to Fairmount Fund II (i)&#160;an aggregate of 20,000,000 shares of Pre-Merger Oruka Series A Preferred
Stock at a purchase price of $0.15 per share and (ii)&#160;a convertible note (the &#8220;Convertible Note&#8221;) with an initial principal
amount of $25.0 million at an interest rate of 12% per annum, for aggregate gross proceeds of $28&#160;million. Fairmount Fund II contributed
the aggregate principal amount of $25.0 million and all accrued interest under the Convertible Note (unpaid accrued interest of $1.5
million divided by the conversion price of $66.62 ($5.55 prior to the impact of the Reverse Stock Split) per share) in exchange for Pre-Merger
Oruka Common Stock and Pre-Merger Oruka pre-funded warrants in connection with the Pre-Closing Financing (as defined below), immediately
prior to the completion of the Merger. Fairmount Funds Management (&#8220;Fairmount&#8221;) is the investment manager of Fairmount Fund
II. Peter Harwin, one of our directors, is a managing member of Fairmount.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pre-Merger
Oruka Pre-Closing Financing</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
April&#160;3, 2024, in connection with the execution of the Merger Agreement, Pre-Merger Oruka entered into the Subscription
Agreement to consummate the Pre-Closing Financing. Pursuant to the Subscription Agreement, the Financing Investors purchased
39,873,706 shares of Pre-Merger Oruka common stock and 9,664,208 Pre-Merger Oruka pre-funded warrants for gross proceeds of
approximately $275.0 million (which includes $25.0 million of proceeds previously received from the issuance of the Convertible Note
and accrued interest on such note which converted to 4,764,032 shares of Pre-Merger Oruka common stock), immediately prior to the
Closing and before the effect of the Reverse Stock Split. Three of the investors or their affiliates were beneficial
holders of more than 5% of Pre-Merger Oruka&#8217;s capital stock, and the table below sets forth the number of shares of Pre-Merger
Oruka common stock and Pre-Merger Oruka pre-funded warrants purchased by such holders at the closing of the Pre-Closing
Financing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Participant</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Shares
    of <br/> Pre-Merger Oruka <br/> Common<br/>
 Stock</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Pre-funded
    <br/> Warrants of <br/> Pre-Merger Oruka</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total
    <br/> Purchase <br/> Price</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Entities
    affiliated with Fairmount</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,139,797</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,271,241</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">79,907,282</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Entities
    affiliated with Venrock Healthcare Capital Partners</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,011,172</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">392,967</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">29,996,067</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Entities
    affiliated with FMR LLC</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,503,445</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,999,974</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Includes
                                            $25.0 million of proceeds previously received by Pre-Merger Oruka from the issuance of the
                                            Convertible Note and accrued interest on such note, with the remainder of the purchase price
                                            paid in cash.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Company
Transactions </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>September
2024 Private Placement </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 11, 2024, the Company entered into the SPA with the
Selling Stockholders to consummate the Private Placement. Pursuant to the SPA, the Selling Stockholders purchased (i) an aggregate of
5,600,000 shares of Common Stock, at a price per share of $23.00, (ii) an aggregate of 2,439 shares of Series A Preferred Stock (each
Series A Preferred Stock is convertible into 1,000 shares of Company Common Stock), at a price per share of $23,000.00, and (iii) pre-funded
warrants to purchase an aggregate of 680,000 shares of Common Stock at a purchase price of $22.999 per pre-funded warrant, which represents
the per share purchase price of the Private Placement Common Shares less the $0.001 per share exercise price for each pre-funded warrant,
for an aggregate purchase price of approximately $200.5 million. Subject to receiving the requisite stockholder approval and certain beneficial
ownership limitations set by each holder of Series A Preferred Stock, each share of Series A Preferred Stock will automatically convert
into an aggregate of 1,000 shares of Common Stock. Three of the Selling Stockholders or their affiliates were beneficial holders of more
than 5% of the Company&#8217;s capital stock, and the table below sets forth the number of shares of Common Stock, Series A Preferred
Stock and pre-funded warrants purchased by such holders at the closing of the Private Placement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Participant</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Shares
    of <br/> Common Stock</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Series
    A Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Pre-Funded
    Warrants</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total
    <br/> Purchase <br/> Price</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Entities
    affiliated with FMR LLC</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,105,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">830</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">67,505,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Entities
    affiliated with Venrock Healthcare Capital Partners</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">300,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,949,700</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Entities
    affiliated with Fairmount</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">275,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">160</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,005,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Our Relationship
with Paragon and Paruka</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We are party
to a number of agreements with Paragon and Paruka. Paragon and Paruka beneficially own more than 5% of our capital stock through their
joint holdings of our Common Stock. Fairmount beneficially owns more than 5% of our capital, one of Fairmount&#8217;s employees serves
on our Board, and Fairmount beneficially owns more than 5% of Paragon. Fairmount appointed Paragon&#8217;s board of directors and has
the contractual right to approve the appointment of any executive officers of Paragon, but is not the beneficial owner of Paragon&#8217;s
securities. Paruka is an entity formed by Paragon as a vehicle to hold equity in our Company in order to share profits with certain employees
of Paragon.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In March&#160;2024, Pre-Merger Oruka entered into
the Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paragon identifies, evaluates and develops antibodies
directed against certain mutually agreed therapeutic targets of interest to us. The Option Agreements include two selected targets, IL-23
(ORKA-001) and IL-17A/F (ORKA-002). Under the Option Agreements, we have the exclusive options to, on a research program-by-research program
basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title and interest in and to the intellectual property
resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed to the
selected targets (each, an &#8220;Option&#8221;), with the exception of pursuing ORKA-001 for the treatment of inflammatory bowel disease.
If we exercise our options, we will be required to make non-refundable milestone payments to Paragon of up to $12.0 million under each
respective agreement upon the achievement of certain clinical development milestones, up to $10.0 million under each respective agreement
upon the achievement of certain regulatory milestones as well as tiered royalty payments in the low-to-mid single-digits beginning on
the first commercial sale. From time to time, we can choose to add additional targets to the collaboration by mutual agreement with Paragon.
During the three months ended September 30, 2024, we exercised our option for ORKA-001 and recorded a $1.5 million milestone payment related
to the achievement of development candidate as research and development expense in our condensed consolidated statements of operations
and comprehensive loss for the three months ended September 30, 2024. As of September 30, 2024, this amount is included under related
party accounts payable and other current liabilities on the condensed consolidated balance sheet.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our exclusive Option with respect to each research
program for a particular target initiated by the parties (&#8220;Research Program&#8221;) is exercisable at our sole discretion at any
time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of&#160;days
following (i) with respect to any Research Program other than ORKA-001, the delivery of the data package from Paragon related to the results
of the Research Plan activities, or (ii) with respect to ORKA-001, the completion of the IL-23 antibody selection process described in
the agreement (the &#8220;Option Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Option Agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless terminated earlier, the Option Agreements shall continue in
force on a Research Program-by-Research Program basis until the earlier of: (i)&#160;the end of the Option Period for such Research Program,
as applicable, if such Option is not exercised by us; (ii)&#160;the expiration of the 30-day period after we exercise our Option with
respect to such Research Program, subject to mutually agreed extension, during the Option Period and the parties are unable to finalize
and execute a license agreement, and (iii) the expiration of the applicable research term (the &#8220;Term&#8221;). Upon the expiration
of the Term for all then-existing Research Programs, under the Option Agreements, the Option Agreements will automatically expire in its
entirety. We may terminate the Option Agreements or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior
written notice to Paragon, provided that we must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable
obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate
the Option Agreements or a Research Program immediately upon written notice to us if, as a result of any action or failure to act by us
or our affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or
otherwise delayed for a certain consecutive number of months. Each party has the right to terminate the Option Agreements or any Research
Program upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the
30-day period and (ii)&#160;the other party&#8217;s bankruptcy.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the Option Agreements, on a research
program-by-research program basis following the finalization of the Research Plan for each respective research program, we were required
to pay Paragon a one-time nonrefundable research initiation fee of $0.8 million related to the ORKA-001 program. This amount was recognized
as a research and development expense during the period from February 6, 2024 (inception) to September 30, 2024. In June 2024, pursuant
to the Option Agreements with Paragon, we completed the selection process of our development candidate for IL-23 antibody for the ORKA-001
program. We were responsible for 50% of the development costs incurred through the completion of the IL-23 selection process. We received
the rights to at least one selected IL-23 antibody in June 2024. During the three months ended September 30, 2024, we exercised our option
for ORKA-001 and recorded a $1.5 million milestone payment related to the achievement of development candidate as research and development
expense in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss for each of the three months ended
September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024. Our share of development costs incurred
during the three months ended September 30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024 was $0.8 million
and $13.2 million, respectively, which were recorded as research and development expenses during the respective periods. An amount of
$2.3 million is included in related party accounts payable and other current liabilities as of September 30, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We were also required to reimburse Paragon $3.3
million for development costs related to ORKA-002 incurred by Paragon through December 31, 2023 and certain other development costs incurred
by Paragon between January 1, 2024 and March 6, 2024 as stipulated by the Option Agreements. This amount was recognized as a research
and development expense during the period from February 6, 2024 (inception) to September 30, 2024. We are also responsible for the development
costs incurred by Paragon from January 1, 2024 through the completion of the IL-17 selection process. We recognized an amount of $0.8
million payable to Paragon for the research initiation fee related to ORKA-002 following the finalization of the ORKA-002 research plan.
This was recognized as research and development expenses in the period from February 6, 2024 (inception) to September 30, 2024. We accounted
for development costs of $3.8 million and $6.6 million during the three months ended September 30, 3024 and for the period from February
6, 2024 (inception) to September 30, 2024, respectively, as research and development expenses during the respective periods. An amount
of $3.8 million is included in related party accounts payable and other current liabilities as of September 30, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As part of the Option Agreements, on each of December
31, 2024 and December 31, 2025, we will grant warrants to purchase a number of shares equal to 1.00% of outstanding shares as of the date
of the grant on a fully diluted basis with an exercise price equal to the fair market value of the underlying shares on the grant date.
The warrants are liability-classified and after the initial recognition, the liability is adjusted to fair value at the end of each reporting
period, with changes in fair value recorded in the consolidated statement of operations and comprehensive loss as stock-based compensation
expenses under research and development expenses.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Indemnification
Agreements and Insurance</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We have entered
into an indemnification agreement with each of the directors and officers and purchased directors&#8217; and officers&#8217; liability
insurance. The indemnification agreements require us to indemnify our directors and officers to the fullest extent permitted under Delaware
law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Review,
Approval or Ratification of Transactions with Related Parties </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Prior to
the Closing, Pre-Merger Oruka did not have a formal policy regarding approval of transactions with related parties. All disclosable transactions
with related parties which occurred prior to the Closing were approved by the directors not interested in such transactions, pursuant
to Section 144(a)(1) of the DGCL.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The Company&#8217;s
Board has adopted a written related person transactions policy. Under this policy, our executive officers, directors, nominees for election
as a director, beneficial owners of more than 5% of our Common Stock, and any members of the immediate family of and any entity affiliated
with any of the foregoing persons, are not permitted to enter into a material related person transaction with us without the review and
approval of our Audit Committee, or a committee composed solely of independent directors in the event it is inappropriate for our Audit
Committee to review such transaction due to a conflict of interest. The policy provides that, subject to limited exceptions, any transaction,
arrangement or relationship or series of similar transactions, arrangements or relationships in which (1) the aggregate amount involved
since the beginning of the Company&#8217;s last completed fiscal year exceeds or is expected to exceed $120,000, (2) the Company or any
of our subsidiaries is a participant, and (3) any related person has or will have a direct or indirect interest, will be presented to
our Audit Committee for review, consideration and approval. In approving or rejecting any such proposal, our Audit Committee will consider
the material facts and other factors it deems appropriate, including, but not limited to, whether the transaction is on terms no less
favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the
related person&#8217;s interest in the transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SELLING
STOCKHOLDERS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">This prospectus
covers the resale or other disposition from time to time by the Selling Stockholders identified in the table below of up to an aggregate
of 8,719,000 shares of our Common Stock. The Selling Stockholders may from time to time offer and sell any or all of the Resale Shares
set forth below pursuant to this prospectus and any accompanying prospectus supplement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On September
11, 2024, we entered into the SPA, pursuant to which we sold an aggregate of (i) 5,600,000 shares of our Common Stock, (ii) 2,439 shares
of our Series A Preferred Stock, which will automatically convert into 1,000 shares of Common Stock, subject to stockholder approval
and certain beneficial ownership limitations set by each holder, pursuant to the Series A Certificate of Designation, and (iii) Pre-Funded
Warrants to purchase an aggregate of 680,000 shares of Common Stock at a purchase price of $22.999 per Pre-Funded Warrant, which represents
the per share purchase price of the Private Placement Common Shares less the $0.001 per share exercise price for each Pre-Funded Warrant,
for an aggregate purchase price of approximately $200.5 million. This prospectus covers the resale or other disposition by the Selling
Stockholders or their pledgees, donees, transferees or other successors-in-interest that receive their shares after the date of this
prospectus of up to the total number of shares of Common Stock, shares of Common Stock issuable upon the conversion of the Series A Preferred
Stock, and shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants sold to the Selling Stockholders pursuant to
the SPA. This prospectus covers the resale or other disposition by the Selling Stockholders or their transferees of up to the total number
of Private Placement Common Shares, Private Placement Preferred Shares and Pre-Funded Warrants issued to the Selling Stockholders upon
conversion of the Private Placement Preferred Shares and exercise of the Pre-Funded Warrants issued pursuant to the SPA. Throughout this
prospectus, when we refer to the &#8220;Selling Stockholders,&#8221; we are referring to the purchasers under the SPA listed in the table
below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We are registering
the Resale Shares to permit the Selling Stockholders and their pledgees, donees, transferees or other successors-in interest that receive
their shares after the date of this prospectus to resell or otherwise dispose of the shares in the manner contemplated under &#8220;Plan
of Distribution&#8221; herein.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Except as
otherwise disclosed herein, the Selling Stockholders do not have, and within the past three years have not had, any position, office
or other material relationship with us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The following
table sets forth the names of the Selling Stockholders, the number of shares of our Common Stock owned by the Selling Stockholders, the
number of shares of our Common Stock that may be offered under this prospectus and the number of shares of our Common Stock that will
be owned after this offering by the Selling Stockholders assuming all of the shares registered for resale hereby are sold.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The Selling
Stockholders may sell some, all or none of their Resale Shares. We do not know how long the Selling Stockholders will hold the Resale
Shares before selling them, and we currently have no agreements, arrangements or understandings with the Selling Stockholders regarding
the sale or other disposition of any of the Resale Shares. The Resale Shares covered hereby may be offered from time to time by the Selling
Stockholders, provided that Resale Shares issued upon conversion of Series A Preferred Stock may only be offered after such shares of
Series A Preferred Stock are converted to Common Stock pursuant to the terms of the Series A Certificate of Designation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The information
set forth below is based upon information obtained from the Selling Stockholders and upon information in our possession regarding the
issuance of the Private Placement Common Shares, Private Placement Preferred Shares and shares of Common Stock issuable upon the exercise
of the Pre-Funded Warrants in connection with the September 2024 PIPE. The percentages of Common Stock owned after the offering by each
Selling Stockholder below are based on 34,998,550 shares of Common Stock outstanding as of November 1, 2024, and, for each Selling Stockholder,
assumes the conversion of only the Series A Preferred Stock and exercise of only the Pre-Funded Warrants owned by such Selling Stockholder
but not the Series A Preferred Stock or Pre-Funded Warrants owned by any other Selling Stockholder. The numbers of shares of Common Stock
beneficially owned before and after the offering presented in the table below do not give effect to any Beneficial Ownership Limitations
with respect to the Series A Preferred Stock or Pre-Funded Warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-indent: 0pt; padding-left: 0pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Name
    of Selling Stockholders(1)</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common<br/>
    Stock<br/> Beneficially<br/> Owned<br/> Before the<br/> Offering (2)</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common<br/>
    Stock that<br/> May<br/> Be Offered<br/> Pursuant to<br/> Prospectus</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock<br/> Beneficially<br/> Owned After the<br/> Offering (2)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Number</b></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Percentage<br/>
                                            (%)</b></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; width: 54%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Securities Fund: Fidelity Small Cap Growth Fund (3)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">555,043</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">179,838</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">375,205</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.07</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Securities Fund: Fidelity Small Cap Growth K6 Fund (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">225,831</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">86,378</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">139,453</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Advisor Series VII:&#160;&#160;Fidelity Advisor Biotechnology Fund (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">609,300</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">197,572</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">411,728</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.18</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Select Portfolios:&#160;&#160;Biotechnology Portfolio (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">704,983</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">704,883</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Advisor Series VII:&#160;&#160;Fidelity Advisor Health Care Fund (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">629,688</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">67,978</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">561,710</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Select Portfolios:&#160;&#160;Health Care Portfolio (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">999,710</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">110,356</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">889,354</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.45</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Variable
    Insurance Products Fund IV: VIP Health Care Portfolio (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">159,859</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,109</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">134,750</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Mt. Vernon Street Trust: Fidelity Series Growth Company Fund (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">78,239</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">78,239</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Mt. Vernon Street Trust: Fidelity Growth Company Fund (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">297,445</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">297,445</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Growth Company Commingled Pool (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">400,267</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">400,267</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Mt. Vernon Street Trust: Fidelity Growth Company K6 Fund (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">92,707</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">92,707</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Capital Trust: Fidelity Stock Selector Small Cap Fund (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">283,456</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">283,456</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Securities Fund: Fidelity Series Small Cap Opportunities Fund (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">410,772</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">410,772</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Braidwell
    Partners Master Fund LP (4)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,777,426</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,630,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">147,426</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities
    Associated with Venrock Healthcare Capital Partners (5)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,541,941</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">650,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,891,941</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.50</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="padding: 0; font-family: Times New Roman, Times, Serif; text-indent: 0; text-align: left"><p style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities
                                            associated with Fairmount Funds Management LLC (6)</span></p></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">7,941,690</span></p></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">435,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,506,690</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18.90</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">AI
    Biotechnology LLC (7)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,791,052</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">350,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,441,052</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.12</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities
    associated with Blackstone Alternative Asset Management Associates LLC (8)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">590,174</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">350,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">240,174</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Point72
    Associates, LLC (9)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">618,671</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">340,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">278,671</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities
    Associated with Frazier Life Sciences (10)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">583,327</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">326,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">257,327</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities
    Associated with Paradigm BioCapital Advisors LP (11)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">819,660</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">305,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">514,660</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.47</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities
    associated with RTW Investments, LP (12)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,058,147</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">285,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,773,147</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.07</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities
    Associated with T. Rowe Price Associates, Inc. (13)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,244,191</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">215,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,029,191</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.94</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">SR
    One Capital Opportunities Fund I, LP (14)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">430,330</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">173,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">257,330</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities
    associated with Janus Henderson Investors US LLC (15)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">335,456</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">185,456</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commodore
    Capital Master LP (16)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,419,714</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,269,714</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.62</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Kalehua
    Capital Partners LP (17)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Avidity
    Private Master Fund I LP (18)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">701,363</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">110,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">591,363</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.69</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adage
    Capital Partners LP (19)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Affinity
    Healthcare Fund, LP (20)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">284,836</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">239,836</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Allostery
    Master Fund, LP (21)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
                                            than 1%</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            our knowledge, unless otherwise indicated, all persons named in the table above have sole
                                            voting and investment power with respect to their shares of Common Stock. Unless an address
                                            is provided below, the address for the holder is 855 Oak Grove Ave., Suite 100, Menlo Park,
                                            CA 94025.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Beneficial
                                                                                                                                                                                                                                                         ownership&#8221; is a term broadly defined by the SEC in Rule 13d-3 under the Exchange Act, and includes more than the typical form
                                                                                                                                                                                                                                                         of stock ownership, that is, stock held in the person&#8217;s name. The term also includes what is referred to as &#8220;indirect
                                                                                                                                                                                                                                                         ownership,&#8221; meaning ownership of shares as to which a person has or shares investment power. Notwithstanding the foregoing,
                                                                                                                                                                                                                                                         the beneficial ownership amounts assume the sale of all Common Stock that may be offered pursuant to this prospectus without taking
                                                                                                                                                                                                                                                         into account certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series
                                                                                                                                                                                                                                                         A Preferred Stock into shares of Common Stock (i) prior to the affirmative vote of the holders of a majority of the then outstanding
                                                                                                                                                                                                                                                         shares of the Series A Preferred Stock, or (ii) if, as a result of such conversion, such holder, together with its affiliates, would
                                                                                                                                                                                                                                                         beneficially own more than a specified percentage (established by the holder not to exceed 19.99%) (the &#8220;Beneficial Ownership
                                                                                                                                                                                                                                                         Limitation&#8221;) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such
                                                                                                                                                                                                                                                         conversion.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
                                            funds and accounts are managed by direct or indirect subsidiaries of FMR LLC.&#160;&#160;Abigail
                                            P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC.&#160;&#160;Members
                                            of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly
                                            or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting
                                            power of FMR LLC. The Johnson family group and all other Series B shareholders have entered
                                            into a shareholders&#8217; voting agreement under which all Series B voting common shares
                                            will be voted in accordance with the majority vote of Series B voting common shares. Accordingly,
                                            through their ownership of voting common shares and the execution of the shareholders&#8217;
                                            voting agreement, members of the Johnson family may be deemed, under the Investment Company
                                            Act of 1940, to form a controlling group with respect to FMR LLC.&#160;&#160;The address
                                            of these funds and accounts is 245 Summer Street, Boston, MA 02210.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 250,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Braidwell Partners Master Fund LP (&#8220;Braidwell Partners&#8221;), (ii) 1,147,426
                                            shares of Common Stock held by Braidwell Partners and (iii) 380,000 shares of Common Stock
                                            issuable upon the exercise of the Pre-Funded Warrants held by Braidwell Partners. Braidwell
                                            LP (the &#8220;Braidwell Investment Manager&#8221;) is the investment manager of Braidwell
                                            Partners. Braidwell GP LLC (the &#8220;Braidwell GP&#8221;) is the general partner of Braidwell
                                            Partners. Braidwell Management LLC (the &#8220;Braidwell IM GP&#8221;) is the general partner
                                            of the Braidwell Investment Manager and the managing member of the Braidwell GP. Messrs.
                                            Alexander T. Karnal and Brian J. Kreiter (together with Braidwell Partners, the Braidwell
                                            Investment Manager, the Braidwell GP and the Braidwell IM GP, the &#8220;Braidwell Parties&#8221;)
                                            together own, directly or indirectly, the Braidwell Investment Manager, the Braidwell GP
                                            and the Braidwell IM GP. The address of Braidwell Partners is c/o Maples Corporate Services
                                            Limited, P.O Box 309, Ugland House, Grand Cayman, KY1-1104 Cayman Islands. The principal
                                            address of the Braidwell Investment Manager, the Braidwell GP and the Co-Founders is One
                                            Harbor Point, 2200 Atlantic Street, 4th Floor, Stamford, Connecticut 06902. The Braidwell
                                            Parties may be deemed to have shared voting and dispositive power with respect to the shares
                                            of Common Stock held by Braidwell Partners. Each of the Braidwell Parties disclaims beneficial
                                            ownership of such shares except to the extent of any pecuniary interest therein.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consists of
                                            (i) 2,350,074 shares of common stock and 351,506 shares of common stock issuable upon the
                                            exercise of pre-funded warrants held by Venrock Healthcare Capital Partners EG, L.P. (&#8220;VHCPEG&#8221;),
                                            (ii) 668,656 shares of common stock and 95,284 shares of common stock issuable upon the exercise
                                            of pre-funded warrants held by Venrock Healthcare Capital Partners III, L.P. (&#8220;VHCP3&#8221;),
                                            and (iii) 66,890 shares of common stock and 9,531 shares of common stock issuable upon the
                                            exercise of pre-funded warrants held by VHCP Co-Investment Holdings III, LLC (&#8220;VHCPCo3&#8221;).
                                            Excludes (i) 54,474, 12,504 and 1,244 shares of common stock issuable upon the exercise of
                                            the pre-funded warrants held by VHCPEG, VHCP3 and VHCPCo3, respectively, and (ii) 157,000,
                                            39,000 and 4,000 shares of common stock issuable upon the conversion of Series A Preferred
                                            Stock held by VHCPEG, VHCP3 and VHCPCo3, respectively. The pre-funded warrants and Series
                                            A Preferred Stock are subject to a beneficial ownership limitation of 9.99%, which such limitations
                                            restrict Venrock Healthcare Capital Partners and its affiliates from exercising that portion
                                            of the warrants or Series A Preferred Stock that would result in Venrock Healthcare Capital
                                            Partners and its affiliates owning, after exercise, a number of shares of common stock in
                                            excess of the applicable ownership limitation. VHCP Management III, LLC (&#8220;VHCPM3&#8221;)
                                            is the sole general partner of VHCP3 and the sole manager of VHCPCo3. VHCP Management EG,
                                            LLC (&#8220;VHCPM EG&#8221;) is the sole general partner of VHCPEG. As voting members of
                                            VHCPM3 and VHCPM EG, Dr. Bong Koh and Nimish Shah may be deemed beneficial owners of any
                                            securities beneficially owned by VHCPM3 and VHCPM EG. The principal business address of each
                                            of these persons and entities is 7 Bryant Park, 23rd Floor, New York, NY 10018.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consists of
                                            (i) (A) 638,614 shares of common stock, (B) 316,025 shares of common stock issuable upon
                                            the exercise of pre-funded warrants and (C) 4,413,743 shares of common stock issuable upon
                                            conversion of 52,965 shares of Series B Preferred Stock held by Fairmount Healthcare Fund
                                            II L.P. (&#8220;Fairmount Fund II&#8221;) and (ii) 2,573,308 shares of common stock held
                                            by Fairmount Healthcare Co-Invest III L.P. (&#8220;Fairmount Fund III&#8221;). Excludes (i)
                                            4,981,639 shares of common stock issuable upon the exercise of the pre-funded warrants, (ii)
                                            7,014,406 shares of common stock issuable upon the conversion of 84,173 shares of Series
                                            B Preferred Stock and (iii) 160,000 shares of common stock issuable upon the conversion of
                                            160 shares of Series A Preferred Stock owned by Fairmount Fund II. The pre-funded warrants
                                            and Series A Preferred Stock are subject to a beneficial ownership limitation of 9.99% and
                                            the shares of Series B Preferred Stock are subject to a beneficial ownership limitation of
                                            19.99%, which such limitations restrict Fairmount Funds Management LLC (&#8220;Fairmount&#8221;)
                                            and its affiliates from exercising that portion of the warrants and converting those shares
                                            of preferred stock that would result in Fairmount and its affiliates owning, after exercise
                                            or conversion, a number of shares of common stock in excess of the applicable ownership limitation.
                                            At such time as Fairmount and its affiliates beneficially own 9.0% or less of the shares
                                            of common stock, the beneficial ownership limitation applicable to the shares of Series B
                                            Preferred Stock will automatically reduce to 9.99%. Fairmount serves as investment manager
                                            for Fairmount Fund II and Fairmount Fund III. Fairmount Fund II and Fairmount Fund III have
                                            delegated to Fairmount the sole power to vote and the sole power to dispose of all securities
                                            held in Fairmount Fund II and Fairmount Fund III&#8217;s portfolios. Because Fairmount Fund
                                            II and Fairmount Fund III have divested themselves of voting and investment power over the
                                            securities they hold and may not revoke that delegation on less than 61 days&#8217; notice,
                                            Fairmount Fund II and Fairmount Fund III disclaim beneficial ownership of the securities
                                            they hold. The general partner of Fairmount is Fairmount Funds Management GP LLC (&#8220;Fairmount
                                            GP&#8221;). As managing members of Fairmount GP, Peter Harwin and Tomas Kiselak may be deemed
                                            to have voting and investment power over the shares held by Fairmount Fund II and Fairmount
                                            Fund III. Fairmount, Fairmount GP, Peter Harwin and Tomas Kiselak disclaim beneficial ownership
                                            of such shares, except to the extent of any pecuniary interest therein. The address of the
                                            entities and individuals listed is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA
                                            19428.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 1,441,052 shares of Common Stock purchased pursuant to a Subscription Agreement, dated
                                            August 3, 2024, among the Company and the purchasers thereto (including AI Biotechnology
                                            LLC) (ii) 125,000 shares of Common Stock issuable upon the conversion of Series A Preferred
                                            Stock held by AI Biotechnology LLC and (ii) 225,000 shares of Common Stock held by AI Biotechnology
                                            LLC. Access Industries Holdings LLC, or AIH, directly controls all of the outstanding voting
                                            interest in AI Biotechnology LLC. Access Industries Management, LLC, or AIM, controls AIH.
                                            Len Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH.
                                            Each of Len Blavatnik, AIM and AIH may be deemed to have voting and investment power over
                                            the shares held by AI Biotechnology LLC and disclaims beneficial ownership of such shares.
                                            The address of each of AI Biotechnology LLC, AIM, AIH and Len Blavatnik is c/o Access Industries,
                                            Inc., 40 West 57th Street, 28th Floor, New York, NY 10019.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 72,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Spruce Street Aggregator L.P. (&#8220;Spruce Street Fund&#8221;), (ii) 130,078 shares
                                            of Common Stock held by Spruce Street Fund, (iii) 53,000 shares of Common Stock issuable
                                            upon the conversion of Series A Preferred Stock held by Blackstone Annex Master Fund L.P.
                                            (&#8220;Annex Fund&#8221;), and (iv) 335,096 shares of Common Stock held by Annex Fund. Blackstone
                                            Alternative Asset Management Associates LLC is the general partner of Annex Fund and Spruce
                                            Street Fund. Blackstone Holdings II L.P. is the sole member of Blackstone Alternative Asset
                                            Management Associates LLC. Blackstone Holdings I/II GP L.L.C. is the general partner of Blackstone
                                            Holdings II L.P. Blackstone Inc. is the sole member of Blackstone Holdings I/II GP L.L.C.
                                            Blackstone Group Management L.L.C. is the sole holder of the Series II preferred stock of
                                            Blackstone Inc. Blackstone Group Management L.L.C. is wholly owned by its senior managing
                                            directors and controlled by its founder, Stephen A. Schwarzman. Each of such Blackstone entities
                                            and Mr. Schwarzman may be deemed to beneficially own the securities beneficially owned by
                                            the Annex Fund and the Aggregator Fund directly or indirectly controlled by it or him, but
                                            each (other than each of the Annex Fund and the Aggregator Fund to the extent of their respective
                                            direct holdings) disclaims beneficial ownership of such securities. The address of each of
                                            the entities listed is c/o Blackstone Inc., 345 Park Avenue, New York, New York 10154.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 115,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Point72 Associates, LLC (&#8220;Point72 Associates&#8221;) and (ii) 503,671 shares
                                            of Common Stock held by Point72 Associates. Pursuant to an investment management agreement,
                                            Point72 Asset Management, L.P. maintains investment and voting power with respect to the
                                            securities held by certain investment funds it manages, including Point72 Associates. Point72
                                            Capital Advisors, Inc. is the general partner of Point72 Asset Management, L.P. Mr. Steven
                                            A. Cohen controls each of Point72 Asset Management, L.P. and Point72 Capital Advisors, Inc.
                                            By reason of the provisions of Rule 13d-3 of the Exchange Act, each of Point72 Asset Management,
                                            L.P., Point72 Capital Advisors, Inc., and Mr. Cohen may be deemed to beneficially own the
                                            securities held by Point72 Associates reflected herein. Each of Point72 Asset Management,
                                            L.P., Point72 Capital Advisors, Inc., and Mr. Cohen disclaims beneficial ownership of any
                                            such securities. The address for Point72 Associates is c/o Point72 Asset Management, L.P.,
                                            72 Cummings Point Road, Stamford, CT 06902.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 1,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Frazier Life Sciences X, L.P. (&#8220;FLS X&#8221;), (ii) 23,785 shares of Common
                                            Stock held by FLS X, (iii) 1,000 shares of Common Stock issuable upon the conversion of Series
                                            A Preferred Stock held by Frazier Life Sciences XI, L.P. (&#8220;FLS XI&#8221;), (iv) 40,967
                                            shares of Common Stock held by FLS XI, (v) 81,000 shares of Common Stock issuable upon the
                                            conversion of Series A Preferred Stock held Frazier Life Sciences Public Fund, L.P. (&#8220;FLS
                                            Public Fund&#8221;), (vi) 297,560 shares of Common Stock held by FLS Public Fund, (vii) 23,000
                                            shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by Frazier
                                            Life Sciences Public Overage Fund, L.P. (&#8220;FLS Overage Fund&#8221;) and (viii) 115,015
                                            shares of Common Stock held by FLS Overage Fund. FHMLSP, L.P. is the general partner of FLS
                                            Public Fund and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Albert Cha, James N.
                                            Topper, Patrick J. Heron and James Brush are the managing directors of FHMLSP, L.L.C. and
                                            therefore share voting and investment power over the shares held by FLS Public Fund. Dr.
                                            Cha, Dr. Topper, Mr. Heron and Dr. Brush disclaim beneficial ownership of the shares held
                                            by FLS Public Fund except to the extent of their pecuniary interests in such shares, if any.
                                            FHMLSP Overage, L.P., is the general partner of FLS Overage Fund and FHMLSP Overage, L.L.C.
                                            is the general partner of FHMLSP Overage, L.P. Dr. Cha, Dr. Topper, Mr. Heron and Dr. Brush
                                            are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power
                                            over the shares held by FLS Overage Fund. Dr. Cha, Dr. Topper, Mr. Heron and Dr. Brush disclaim
                                            beneficial ownership of the shares held by FLS Overage Fund except to the extent of their
                                            pecuniary interests in such shares, if any. FHMLS X, L.P. is the general partner of FLS X,
                                            and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Mr. Heron and Dr. Topper are
                                            the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares
                                            held by FLS X. Dr. Topper and Mr. Heron disclaim beneficial ownership of the shares held
                                            by FLS X except to the extent of their pecuniary interests in such shares, if any. FHMLS
                                            XI, L.P. is the general partner of FLS XI, and FHMLS XI, L.L.C. is the general partner of
                                            FHMLS XI, L.P. Mr. Heron, Dr. Topper and Daniel Estes are the members of FHMLS XI, L.L.C.
                                            and therefore share voting and investment power over the shares held by FLS XI. Dr. Topper,
                                            Mr. Heron and Mr. Estes disclaim beneficial ownership of the shares held by FLS XI except
                                            to the extent of their pecuniary interests in such shares, if any. The principal business
                                            address of the above referenced entities and persons is 1001 Page Mill Rd., Building 4, Ste.
                                            B, Palo Alto, CA 94304.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 86,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Paradigm BioCapital International Fund Ltd. (&#8220;Paradigm Fund&#8221;), (ii) 617,323
                                            shares of Common Stock held by Paradigm Fund, (iii) 14,000 shares of Common Stock issuable
                                            upon the conversion of Series A Preferred Stock held by Paradigm BioCapital Advisors LP (&#8220;Paradigm
                                            Advisor&#8221;), as discretionary investment manager on behalf of a separate account client
                                            solely with respect to the assets for which Paradigm Advisor acts as its investment manager
                                            (the &#8220;Separate Account&#8221;), and (iv) 102,337 shares of Common Stock held by Paradigm
                                            Advisor, as discretionary investment manager on behalf of the Separate Account. The shares
                                            of Common Stock may be deemed to be indirectly beneficially owned by each of Paradigm Advisor,
                                            Paradigm BioCapital Advisors GP LLC (&#8220;Paradigm Advisor GP&#8221;), and Senai Asefaw,
                                            M.D. Paradigm Advisor GP is the general partner of Paradigm Advisor, and Senai Asefaw, M.D.
                                            is the managing member of Paradigm Advisor GP. Paradigm Advisor is the investment manager
                                            of Paradigm Fund. Paradigm Advisor, Paradigm Advisor GP, and Senai Asefaw, M.D. may be deemed
                                            to have full investment and voting discretion over the shares of Common Stock held by Paradigm
                                            Fund and the Separate Account. The business address for each person and entity named in this
                                            footnote is 767 Third Avenue, 17th Floor, New York, NY 10017.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 95,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock&#160;&#160;and
                                            (ii) 1,963,147 shares of Common Stock, in each case of (i) and (ii) as held in the aggregate
                                            by RTW Master Fund, Ltd. RTW Innovation Master Fund, Ltd., and RTW Biotech Opportunities
                                            Operating Ltd, (collectively, the &#8220;RTW Funds&#8221;). RTW Investments, LP (&#8220;RTW&#8221;),
                                            in its capacity as the investment manager of the RTW Funds, has the power to vote and the
                                            power to direct the disposition of the shares held by the RTW Funds. Accordingly, RTW may
                                            be deemed to be the beneficial owner of such securities. Roderick Wong, M.D., as the Managing
                                            Partner of RTW, has the power to direct the vote and disposition of the securities held by
                                            RTW. Dr. Wong disclaims beneficial ownership of the shares held by the RTW Funds, except
                                            to the extent of his pecuniary interest therein. The address and principal office of RTW
                                            Investments, LP is 40 10th Avenue, Floor 7, New York, NY 10014, and the address of Dr. Wong
                                            and each of the RTW Funds is c/o RTW Investments, LP, 40 10th Avenue, Floor 7, New York,
                                            NY 10014.&#160;&#160;The shares of Common Stock issuable upon conversion of the shares of
                                            Series A Preferred Stock held by the RTW Funds are subject to a Beneficial Ownership Limitation
                                            of 9.99%.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 62,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by T. Rowe Price Health Sciences Fund, Inc., (ii) 1,125,095 shares of Common Stock held
                                            by T. Rowe Price Health Sciences Fund, Inc., (iii) 3,000 shares of Common Stock issuable
                                            upon the conversion of Series A Preferred Stock held by T. Rowe Price Health Sciences Portfolio,
                                            and (iv) 54,096 shares of Common Stock held by T. Rowe Price Health Sciences Portfolio. T.
                                            Rowe Price Associates, Inc. (&#8220;TRPA&#8221;), as investment adviser, has dispositive
                                            and voting power with respect to the shares held by these funds and accounts. For purposes
                                            of the Securities Exchange Act of 1934, TRPA may be deemed to be the beneficial owner of
                                            these aforementioned shares; however, TRPA expressly disclaims that it is, in fact, the beneficial
                                            owner of such securities. TRPA is a wholly owned subsidiary of T. Rowe Price Group, Inc.,
                                            which is a publicly traded financial services holding company. The principal business address
                                            of TRPA is 100 East Pratt Street, Baltimore, MD 21202.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 55,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by SR One Capital Opportunities Fund I, LP (&#8220;Opportunities Fund&#8221;) and (ii)
                                            375,330 shares of Common Stock held by Opportunities Fund. SR One Capital Opportunities Partners
                                            I, LP (&#8220;SR One Partners&#8221;) is the general partner of Opportunities Fund. SR One
                                            Capital Management, LLC (&#8220;SR One Management&#8221;) is the general partner of SR One
                                            Partners. Simeon George, M.D. is the manager of SR One Management. SR One Partners, SR One
                                            Management, and Simeon George share voting and investment power with respect to the shares
                                            directly held by Opportunities Fund. All indirect holders of the above referenced shares
                                            disclaim beneficial ownership of all applicable shares except to the extent of their pecuniary
                                            interest therein. The address of these persons and funds is 985 Old Eagle School Road, Suite
                                            511, Wayne, Pennsylvania 19087.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 30,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Janus Henderson Biotech Innovation Master Fund Limited, (ii) 258,149 shares of Common
                                            Stock held by Janus Henderson Biotech Innovation Master Fund Limited, (iii) 20,000 shares
                                            of Common Stock issuable upon the conversion of Series A Preferred Stock held by Janus Henderson
                                            Biotech Innovation Master Fund II Limited, and (iv) 27,307 shares of Common Stock held by
                                            Janus Henderson Biotech Innovation Master Fund II Limited. Such shares may be deemed to be
                                            beneficially owned by Janus Henderson Investors US LLC (&#8220;Janus&#8221;), an investment
                                            adviser registered under the Investment Advisers Act of 1940, who acts as investment adviser
                                            for Janus Henderson Biotech Innovation Master Fund Limited and Janus Henderson Biotech Innovation
                                            Master Fund II Limited (the &#8220;Janus Funds&#8221;) and has the ability to make decisions
                                            with respect to the voting and deposition of the shares subject to the oversight of the board
                                            of directors of the Janus Funds. Under the terms of its management contract with the Janus
                                            Funds, Janus has overall responsibility for directing the investments of the Janus Funds
                                            in accordance with the Janus Funds&#8217; investment objective, policies and limitations.
                                            The Janus Funds have one or more portfolio managers appointed by and serving at the pleasure
                                            of Janus who make decisions with respect to the disposition of the shares of common stock
                                            offered hereby. The address for Janus is 151 Detroit Street, Denver, CO 80206.&#160;&#160;The
                                            portfolio managers for the Janus Fund are Andrew Acker, Daniel S. Lyons and Agustin Mohedas.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 50,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Commodore Capital Master LP and (ii) 1,369,714 shares of Common Stock held by Commodore
                                            Capital Master LP. Commodore Capital LP is the investment manager to Commodore Capital Master
                                            LP and may be deemed to beneficially own the shares held by Commodore Capital Master LP.
                                            Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital LP
                                            and exercise investment discretion with respect to these shares. Commodore Capital LP and
                                            Commodore Capital Master LP have shared voting and dispositive power with respect to these
                                            shares. The address of Commodore Capital LP and Commodore Capital Master LP is 444 Madison
                                            Avenue, 35th Floor, New York, NY 10022.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 50,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Kalehua Capital Partners LP and (ii) 100,000 shares of Common Stock held by Kalehua
                                            Capital Partners LP. Kalehua Capital Partners LP is a buyout fund managed by Kalehua Capital
                                            Management LLC. Tai-Li Chang is the sole member of Kalehua Capital Management LLC. The address
                                            of these persons and funds is 3819 Maple Avenue, Dallas, Texas 75219.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            &#160;(i) 20,000 shares of Common Stock issuable upon the conversion of Series A Preferred
                                            Stock held by Avidity Private Master Fund I LP and (ii) 681,363 shares of Common Stock held
                                            by Avidity Private Master Fund I LP, which is a Cayman exempted limited partnership. The
                                            general partner of Avidity Private Master Fund I LP is Avidity Capital Partners Fund (GP)
                                            LP, a Delaware limited partnership, whose general partner is Avidity Capital Partners (GP)
                                            LLC, a Delaware limited liability company. Avidity Partners Management LP is the investment
                                            manager of Avidity Private Master Fund I LP. Avidity Partners Management (GP) LLC is the
                                            general partner of Avidity Partners Management LP. David Witzke and Michael Gregory are the
                                            managing members of Avidity Capital Partners (GP) LLC and Avidity Partners Management (GP)
                                            LLC. Each of the entities and individuals referenced in this paragraph may be deemed to beneficially
                                            own the shares held by the Avidity entities. Certain affiliates of the Avidity entities,
                                            which are not selling stockholders, may also own shares. The address of Avidity Private Master
                                            Fund I LP is 2828 N. Harwood Street, Suite 1220, Dallas, Texas 75201.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            &#160;(i) 25,000 shares of Common Stock issuable upon the conversion of Series A Preferred
                                            Stock held by Adage Capital Partners LP (&#8220;Adage&#8221;) and (ii) 175,000 shares of
                                            Common Stock held by Adage. Bob Atchinson and Phillip Gross are the managing members of Adage
                                            Capital Advisors, L.L.C., which is the managing member of Adage Capital Partners GP, L.L.C.,
                                            which is the general partner of Adage, and each such person or entity, as the case may be,
                                            has shared voting and/or investment power over the securities held by Adage Capital Partners,
                                            LP and may be deemed the beneficial owner of such shares, and each such person or entity,
                                            as the case may be, disclaims beneficial ownership of such securities except to the extent
                                            of their respective pecuniary interest therein. The address of these funds and persons is
                                            200 Clarendon St., 52<sup>nd</sup> Floor, Boston, MA 02116.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 10,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Affinity Healthcare Fund, LP (&#8220;Affinity Fund&#8221;) and (ii) 274,836 shares
                                            of Common Stock held by Affinity Fund. Affinity Asset Advisors, LLC (the &#8220;Advisor&#8221;)
                                            is the investment manager of Affinity Healthcare Fund, LP (the &#8220;Fund&#8221;) and exercises
                                            investment discretion with regard to the shares of Common Stock owned by the Fund. The Fund
                                            and the Advisor have the shared power to vote or to direct the vote and to dispose or direct
                                            the disposition of such shares of Common Stock of the Issuer owned by the Fund.&#160;&#160;The
                                            Advisor may be deemed to be the beneficial owner of such shares of Common Stock of the Issuer
                                            owned by the Fund by virtue of its position as investment manager of the Fund. The principal
                                            business address of each of the Fund and the Advisor is 767 Third Avenue, 15th Floor, New
                                            York, NY 10017.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 8,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Allostery Master Fund, LP (&#8220;Allostry Master Fund&#8221;) and (ii) 12,000 shares
                                            of Common Stock held by Allostry Master Fund. Allostery Funds GP LLC (&#8220;Allostery Funds
                                            GP&#8221;) may be deemed the beneficial owner of the shares held by Allostery Master Fund
                                            because it is the general partner of Allostery Master Fund. Allostery Investments LP (&#8220;Allostery
                                            Investments&#8221;) may be deemed the beneficial owner of the shares held by Allostery Master
                                            Fund because it is the investment manager of Allostery Master Fund. Allostery Investments
                                            GP LLC (the &#8220;Investments GP&#8221;) may be deemed the beneficial owner of the shares
                                            beneficially held by Allostery Investments because it is the general partner of Allostery
                                            Investments. Christopher Staral and David Modest may be deemed the beneficial owners of the
                                            shares beneficially held by each of Investments GP and Allostery Funds GP by virtue of their
                                            positions as managing members of Investments GP and Allostery Funds GP. The address of Allostery
                                            Master Fund is c/o Maples Corporate Services Limited, Ugland House, South Church Street,
                                            Grand Cayman KY1-1104, Cayman Islands.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Relationship
with the Selling Stockholders </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In addition
to the SPA, in connection with the Private Placement, we entered into the RRA (as defined below) on September 13, 2024 with the Selling
Stockholders. Certain of the September 2024 investors were, immediately prior to the closing of the September 2024 PIPE, or became holders
of more than 5% of our Common Stock and were parties to the Pre-Closing Financing. See &#8220;<i>Security Ownership of Certain Beneficial
Owners and Management and Related Stockholder Matters.</i>&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Registration
Rights Agreement</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On September
13, 2024, we entered into a registration rights agreement (the &#8220;RRA&#8221;) with the Private Placement investors. Pursuant to the
RRA, we agreed to file a resale registration statement to register the Registrable Securities (as defined in the RRA) (the &#8220;Registration
Statement&#8221;). This registration statement is being filed to satisfy our obligations under the RRA. We have agreed to use our commercially
reasonable efforts to cause this Registration Statement to be declared effective by the SEC as soon as practicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We have also
agreed, among other things, to indemnify the Selling Stockholders and each of their respective officers, directors, members, employees,
partners, managers, stockholders, affiliates, investment advisors and agents, each person who controls any such Selling Stockholder and
the officers, directors, members, employees, partners, managers, stockholders, affiliates, investment advisors and agents of each such
controlling person from certain liabilities and pay all fees and expenses (excluding any legal fees of the selling holder(s), and any
underwriting discounts and selling commissions) incident to our obligations under the RRA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>PLAN
OF DISTRIBUTION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We are registering
the Resale Shares issued to the Selling Stockholders to permit the sale, transfer or other disposition of these shares by the Selling
Stockholders or their donees, pledgees, transferees or other successors-in-interest from time to time after the date of this prospectus.
We will not receive any of the proceeds from the sale by the Selling Stockholders of the Resale Shares. We will, or will procure to,
bear all fees and expenses incident to our obligation to register the Resale Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The Selling
Stockholders may sell all or a portion of the Resale Shares beneficially owned by them and offered hereby from time to time, and in the
case of the Private Placement Conversion Shares, may only be offered after such shares are converted to Common Stock pursuant to the
terms of the Series A Certificate of Designation, directly or through one or more underwriters, broker-dealers or agents. If the Resale
Shares are sold through underwriters or broker-dealers, the Selling Stockholders will be responsible for underwriting discounts (it being
understood that the Selling Stockholders shall not be deemed to be underwriters solely as a result of their participation in this offering)
or commissions or agent&#8217;s commissions. The Resale Shares may be sold on any national securities exchange or quotation service on
which the securities may be listed or quoted at the time of sale, in the over-the-counter market or in transactions otherwise than on
these exchanges or systems or in the over-the-counter market and in one or more transactions at fixed prices, at prevailing market prices
at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions,
which may involve crosses or block transactions. The Selling Stockholders may use any one or more of the following methods when selling
Resale Shares:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">ordinary
brokerage transactions and transactions in which the broker-dealer solicits purchasers;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">block
trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal
to facilitate the transaction;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">to
or through underwriters or purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">an
exchange distribution in accordance with the rules of the applicable exchange;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">privately
negotiated transactions;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">settlement
of short sales entered into after the effective date of the registration statement of which this prospectus is a part;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">broker-dealers
may agree with the Selling Stockholders to sell a specified number of such shares at a stipulated price per share;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">through
the writing or settlement of options or other hedging transactions, whether such options are listed on an options exchange or otherwise;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">a
combination of any such methods of sale; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">any
other method permitted pursuant to applicable law.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The Selling
Stockholders also may resell all or a portion of the Resale Shares in open market transactions in reliance upon Rule 144, as permitted
by that rule, or Section 4(a)(1) under the Securities Act, if available, rather than under this prospectus, provided that they meet the
criteria and conform to the requirements of those provisions. The Selling Stockholders also may dispose of the Resales Shares through
distributions to members, partners, stockholders or other equityholders of the Selling Stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Broker-dealers
engaged by the Selling Stockholders may arrange for other broker-dealers to participate in sales. If the Selling Stockholders effect
such transactions by selling Resale Shares to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or
agents may receive commissions in the form of discounts, concessions or commissions from the Selling Stockholders or commissions from
purchasers of the Resale Shares for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts
to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction will not be in excess
of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown
in compliance with FINRA IM-2121.01.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In connection
with sales of the Resale Shares or otherwise, the Selling Stockholders may enter into hedging transactions with broker-dealers or other
financial institutions, which may in turn engage in short sales of the Resale Shares in the course of hedging in positions they assume.
The Selling Stockholders may also sell Resale Shares short and if such short sale takes place after the date that this registration statement
is declared effective by the SEC, the Selling Stockholders may deliver Resale Shares covered by this prospectus to close out short positions
and to return borrowed Resale Shares in connection with such short sales. The Selling Stockholders may also loan or pledge Resale Shares
to broker-dealers that in turn may sell such shares, to the extent permitted by applicable law. The Selling Stockholders may also enter
into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities
which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such
broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
Notwithstanding the foregoing, the Selling Stockholders have been advised that they may not use Resale Shares the resale of which has
been registered on this registration statement to cover short sales of our Common Stock made prior to the date the registration statement,
of which this prospectus forms a part, has been declared effective by the SEC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The Selling
Stockholders may, from time to time, pledge or grant a security interest in some or all of the Resale Shares owned by them and, if they
default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the Resale Shares from time
to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities
Act, amending, if necessary, the list of Selling Stockholders to include the pledgee, transferee or other successors in interest as Selling
Stockholders under this prospectus. The Selling Stockholders also may transfer and donate the Resale Shares in other circumstances in
which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this
prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The Selling
Stockholders and any broker-dealer or agents participating in the distribution of the Resale Shares may be deemed to be &#8220;underwriters&#8221;
within the meaning of Section 2(11) of the Securities Act in connection with such sales. In such event, any commissions paid, or any
discounts or concessions allowed to, any such broker-dealer or agent and any profit on the resale of the shares purchased by them may
be deemed to be underwriting commissions or discounts under the Securities Act. Selling Stockholders who are &#8220;underwriters&#8221;
within the meaning of Section 2(11) of the Securities Act will be subject to the applicable prospectus delivery requirements of the Securities
Act including Rule 172 thereunder and may be subject to certain statutory liabilities of, including but not limited to, Sections 11,
12 and 17 of the Securities Act and Rule 10b-5 under the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Each Selling
Stockholder has informed us that it is not a registered broker-dealer and does not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the Resale Shares. Upon us being notified in writing by a Selling Stockholder that
any material arrangement has been entered into with a broker-dealer for the sale of Common Stock through a block trade, special offering,
exchange distribution or secondary distribution or a purchase by a broker or dealer, a supplement to this prospectus will be filed, if
required, pursuant to Rule 424(b) under the Securities Act, disclosing (i) the name of each such Selling Stockholder and of the participating
broker-dealer(s), (ii) the number of Resale Shares involved, (iii) the price at which such the Resale Shares were sold, (iv) the commissions
paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not conduct any
investigation to verify the information set out in this prospectus, and (vi) other facts material to the transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under the
securities laws of some U.S. states, the Resale Shares may be sold in such states only through registered or licensed brokers or dealers.
In addition, in some U.S. states the Resale Shares may not be sold unless such shares have been registered or qualified for sale in such
state or an exemption from registration or qualification is available and is complied with.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">There can
be no assurance that any Selling Stockholder will sell any or all of the Resale Shares registered pursuant to the shelf registration
statement, of which this prospectus forms a part.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Each Selling
Stockholder and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act and
the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which
may limit the timing of purchases and sales of any of the Resale Shares by the Selling Stockholder and any other participating person.
To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the Resale Shares to
engage in market-making activities with respect to the Resale Shares. All of the foregoing may affect the marketability of the Resale
Shares and the ability of any person or entity to engage in market-making activities with respect to the Resale Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We will pay
all expenses of the registration of the Resale Shares pursuant to the September 2024 RRA, including, without limitation, SEC filing fees
and expenses of compliance with state securities or &#8220;blue sky&#8221; laws; provided, however, that each Selling Stockholder will
pay all underwriting discounts and selling commissions, if any and any related legal expenses incurred by it. We will indemnify the Selling
Stockholders against certain liabilities, including some liabilities under the Securities Act, in accordance with the September 2024
RRA, or the Selling Stockholders will be entitled to contribution. We may be indemnified by the Selling Stockholders against certain
civil liabilities set forth in the September 2024 RRA, including liabilities under the Securities Act, that may arise from any written
information furnished to us by the Selling Stockholders specifically for use in this prospectus, in accordance with the related registration
rights agreements, or we may be entitled to contribution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>DESCRIPTION
OF CAPITAL STOCK</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>General
</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The following
description summarizes the material terms of our capital stock, as well as other material terms of our amended and restated certificate
of incorporation (&#8220;Certificate of Incorporation&#8221;) and amended and restated bylaws (&#8220;Bylaws&#8221;) and certain provisions
of Delaware law. This summary does not purport to be complete and is qualified in its entirety by the provisions of our Certificate of
Incorporation and Bylaws, copies of which are filed as exhibits to our Current Report on Form 8-K filed on September 5, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our authorized
capital stock consists of 545,000,000 shares of Common Stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001
par value per share (&#8220;Preferred Stock&#8221;), of which 2,439 shares have been designated as Series A Preferred Stock, $0.001 par
value per share, and 251,504 shares have been designated as Series B Preferred Stock, $0.001 par value per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As of November
1, 2024, there were 34,998,550 shares of our Common Stock, 2,439 shares of Series A Preferred Stock and 137,138 shares of Series B Preferred
Stock outstanding.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Common
Stock </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our Certificate
of Incorporation authorizes the issuance of up to 545,000,000 shares of Common Stock. All outstanding shares of Common Stock are validly
issued, fully paid and nonassessable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Dividend
rights </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Subject to
preferences that may apply to any shares of Preferred Stock outstanding at the time, the holders of our Common Stock are entitled to
receive dividends out of funds legally available if our Board, in its discretion, determines to issue dividends and then only at the
times and in the amounts that our Board may determine.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Voting
rights </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to our Bylaws, holders of our Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders.
We have not provided for cumulative voting for the election of directors in our Certificate of Incorporation. Accordingly, pursuant to
our Certificate of Incorporation, holders of a majority of the shares of our Common Stock are able to elect all of our directors. Our
Certificate of Incorporation establishes a classified Board, divided into three classes with staggered three-year terms. Only one class
of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their
respective three-year terms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>No preemptive
or similar rights </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our Common
Stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Right
to receive liquidation distributions </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Upon our
liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably
among the holders of our Common Stock and any participating Preferred Stock outstanding at that time, subject to prior satisfaction of
all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding
shares of Preferred Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Preferred
Stock </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under the
terms of our Certificate of Incorporation, our Board is authorized, subject to limitations prescribed by Delaware law, to issue up to
5,000,000 shares of Preferred Stock in one or more series, to establish from time to time the number of shares to be included in each
series and to fix the designation, powers, preferences and rights of the shares of each series and any of their qualifications, limitations
or restrictions, in each case without further vote or action by our stockholders. Subject to any certificates of designation, the Board
can also increase or decrease the number of shares of any series of Preferred Stock, but not below the number of shares of that series
then outstanding, without any further vote or action by our stockholders. Our Board may authorize the issuance of Preferred Stock with
voting or conversion rights that could adversely affect the voting power or other rights of the holders of our Common Stock. The issuance
of Preferred Stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other
things, have the effect of delaying, deferring or preventing a change in control of our company and might adversely affect the market
price of our Common Stock and the voting and other rights of the holders of our Common Stock. We issued shares of our Series A Preferred
Stock and shares of our Series B Preferred Stock in connection with the Private Placement and the Merger, respectively, and have no current
plan to issue any additional shares of Preferred Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Series
A Preferred Stock </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Holders of
Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal to, on an as-if-converted-to-common-stock
basis, and in the same form as dividends actually paid on shares of our Common Stock. Except as provided in the Series A Certificate
of Designation or as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares
of Series A Preferred Stock are outstanding, we will not, without the affirmative vote of the holders of a majority of the then outstanding
shares of the Series A Preferred Stock: (i) alter or change adversely the powers, preferences or rights given to the Series A Preferred
Stock, (ii) alter or amend the Series A Certificate of Designation, or (iii) amend or repeal any provision of, or add any provision to,
our Certificate of Incorporation or its Bylaws in any manner that adversely affects any rights of the holders of Series A Preferred Stock,
or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred
Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for
the benefit of the Series A Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the
Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise. The Series A Preferred
Stock shall rank on parity with the Common Stock and Series B Preferred Stock upon any liquidation, dissolution or winding-up of the
Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Series
B Preferred Stock </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Certain holders
of our Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal to, on an as-if-converted-to-common-stock
basis, and in the same form as dividends actually paid on shares of our Common Stock. Except as provided in the Series B Certificate
of Designation or as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares
of Series B Preferred Stock are outstanding, we will not, without the affirmative vote of the holders of a majority of the then outstanding
shares of the Series B Preferred Stock: (a) (i) alter or change adversely the powers, preferences or rights given to the Series B Preferred
Stock, (ii) alter or amend the Series B Certificate of Designation, or (iii) amend or repeal any provision of, or add any provision to,
our Certificate of Incorporation or Bylaws in a manner that adversely affects any rights of the holders of the Series B Preferred Stock,
or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred
Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for
the benefit of the Series B Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the
Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (b) issue further
shares of Series B Preferred Stock beyond those contemplated for issuance in the Merger Agreement or increase or decrease (other than
by conversion) the number of authorized shares of Series B Preferred Stock, (c) at any time while at least 30% of the originally issued
Series B Preferred Stock remains issued and outstanding, consummate either: (x) any Fundamental Transaction (as defined in the Series
B Certificate of Designation) or (y) any merger or consolidation of the Company with or into another entity or any stock sale to, or
other business combination in which the stockholders of the Company immediately before such transaction do not hold at least a majority
of our capital stock immediately after such transaction, or (d) enter into any agreement with respect to any of the foregoing. The Series
B Preferred Stock shall rank on parity with the Common Stock as to the distribution of assets upon any liquidation, dissolution, or winding-up
of the Company. Each share of Series B Preferred Stock is convertible at the option of the holder, at any time, and without the payment
of additional consideration by the holder. As of September 30, 2024, each outstanding share of Series B Preferred Stock was convertible
into common stock at a ratio of approximately 83.3332:1.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Registration
Rights </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Holders of
our Series A Preferred Stock are entitled to certain rights with respect to the registration of such securities as further provided under
the heading &#8220;<i>Selling Stockholders - Registration Rights Agreement</i>.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Anti-Takeover
Provisions </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The provisions
of Delaware law, our Certificate of Incorporation and our Bylaws could have the effect of delaying, deferring or discouraging another
person from acquiring control of our company. These provisions, which are summarized below, may have the effect of discouraging takeover
bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our Board. We believe
that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the
disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their
terms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Delaware
law </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We are subject
to the provisions of Section 203 of the DGCL regulating corporate takeovers. In general, Section 203 prohibits a publicly-held Delaware
corporation from engaging in a business combination with an interested stockholder for a period of three years following the date on
which the person became an interested stockholder unless:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">prior
to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction
which resulted in the stockholder becoming an interested stockholder;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">upon
completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at
least 85% of the voting stock of the corporation outstanding upon consummation of the transaction, excluding for purposes of determining
the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (1) shares owned by persons who
are directors and also officers and (2) shares owned by employee stock plans in which employee participants do not have the right to
determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">at
or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized
at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding
voting stock which is not owned by the interested stockholder.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Section 203
defines a &#8220;business combination&#8221; to include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">any
merger or consolidation involving the corporation and the interested stockholder;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">any
sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">subject
to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested
stockholder;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">any
transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of
the corporation beneficially owned by the interested stockholder; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">the
receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided
by or through the corporation.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In general,
Section 203 defines an &#8220;interested stockholder&#8221; as an entity or person who, together with the person&#8217;s affiliates and
associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15%
or more of the outstanding voting stock of the corporation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Certificate
of Incorporation and Bylaw Provisions </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Our Certificate
of Incorporation and our Bylaws include a number of provisions that could deter hostile takeovers or delay or prevent changes in control
of our company, including the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b><i>Board
of Directors vacancies</i></b>. Our Certificate of Incorporation and Bylaws require that the Board, and not stockholders, fill any directorships
that become vacant or are created by an increase in the authorized number of directors by the affirmative vote of a majority of the remaining
directors or by the sole remaining director. In addition, pursuant to our bylaws, the number of directors constituting our Board is permitted
to be set only by a resolution adopted by a majority vote of the entire Board. These provisions prevent a stockholder from increasing
the size of our Board and then gaining control of the Board by filling the resulting vacancies with its own nominees. This makes it more
difficult to change the composition of the Board but promotes continuity of management.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b><i>Classified
board</i></b>. Our Certificate of Incorporation provides that our Board is classified into three classes of directors, each with staggered
three-year terms. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is
more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stockholder
action; special meetings of stockholders</i></b>. Our Certificate of Incorporation and Bylaws provide that our stockholders may not take
action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling
a majority of our capital stock would not be able to amend our Bylaws or remove directors without holding a meeting of our stockholders
called in accordance with our Bylaws. Further, our Bylaws provide that special meetings of stockholders may be called only by the Board,
thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force
consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal
of directors.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b><i>Advance
notice requirements for stockholder proposals and director nominations</i></b>. Our Bylaws provide advance notice procedures for stockholders
seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual
meeting of stockholders. Our Bylaws also specify certain requirements regarding the form and content of a stockholder&#8217;s notice.
These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations
for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions might
also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors
or otherwise attempting to obtain control of our company.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>No
cumulative voting</i></b>. The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors
unless a corporation&#8217;s certificate of incorporation provides otherwise. Our Certificate of Incorporation and Bylaws do not provide
for cumulative voting.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b><i>Directors
removed only for cause</i></b>. Our Bylaws provide that stockholders may remove directors only for cause, and only by the affirmative
vote of the holders of at least 66 2/3% of the voting power of the stock outstanding and entitled to vote generally in the election of
directors.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b><i>Amendment
of charter provisions</i></b>. Any amendment of the above provisions in our Certificate of Incorporation requires approval by holders
of at least two-thirds of our outstanding Common Stock.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b><i>Issuance
of Preferred Stock</i></b>. Our Board has the authority, without further action by the stockholders, to issue up to 5,000,000 shares
of Preferred Stock with rights and preferences, including voting rights, designated from time to time by our Board. The existence of
authorized but unissued shares of Preferred Stock enables our Board to render more difficult or to discourage an attempt to obtain control
of us by merger, tender offer, proxy contest or other means.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b><i>Choice
of forum</i></b>. Our Certificate of Incorporation and Bylaws provide that the Court of Chancery of the State of Delaware is the sole
and exclusive forum for any complaint asserting any internal corporate claims. In addition, our Bylaws also provide that the federal
district courts of the United States are the exclusive forum for the resolution of any complaint asserting a cause of action arising
under the Securities Act. These choice of forum provisions do not apply to claims brought to enforce a duty or liability created by the
Exchange Act.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Transfer
Agent and Registrar </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The transfer
agent and registrar for our Common Stock, Class A Preferred Stock and Class B Preferred Stock is Computershare Trust Company, N.A. The
transfer agent&#8217;s address is 150 Royall Street, Suite 101, Canton, MA 02021, and its telephone number is (800) 344-5128.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Exchange
Listing </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Our Common
Stock is listed on The Nasdaq Global Market under the symbol &#8220;ORKA.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>LEGAL
MATTERS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Certain legal
matters, including the legality of the securities offered, has been passed upon for us by Gibson, Dunn &amp; Crutcher LLP, San Francisco,
California. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in
the applicable prospectus supplement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>EXPERTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
financial statement as of February 6, 2024 included in this Prospectus has been so included
in reliance on the report (which contains an explanatory paragraph relating to the Company&#8217;s ability to continue as a going concern as
described in Note 1 to the financial statement) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given
on the authority of said firm as experts in auditing and accounting.<span style="clear: both; display: block;"><br/></span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>WHERE
YOU CAN FIND MORE INFORMATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">We are subject
to the informational requirements of the Exchange Act and are required to file annual, quarterly and other reports, proxy statements
and other information with the SEC. The SEC maintains an Internet website (http://www.sec.gov) that contains reports, proxy and information
statements, and various other information about us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Information
about us is also available at our website at http://www.orukatx.com. You may access these materials free of charge as soon as reasonably
practicable after they are electronically filed with, or furnished to, the SEC. However, the information on our website is not a part
of this prospectus and is not incorporated by reference into this prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">We have filed
a registration statement on Form S-1 with the SEC relating to the securities covered by this prospectus. This prospectus is a part of
the registration statement and does not contain all of the information in the registration statement. Whenever a reference is made in
this prospectus to a contract or other document of ours, please be aware that the reference is only a summary and that you should refer
to the exhibits that are part of the registration statement for a copy of the contract or other document. You may review a copy of the
registration statement through the SEC&#8217;s website or our website.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ORUKA
THERAPEUTICS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>INDEX
TO  FINANCIAL STATEMENT</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>As of February 6, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 90%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#aaaa_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm</span></a></td>
    <td style="padding-left: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#aaaa_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Sheet as of February&#160;6, 2024</span></a></td>
    <td style="padding-left: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#aaaa_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Financial Statement</span></a></td>
    <td style="padding-left: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; width: 90%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif">Period from February 6, 2024 (Inception) to September 30, 2024</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#b_013"><span style="font-size: 10pt">Condensed
    Consolidated Balance Sheets</span></a></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-10</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#b_014"><span style="font-size: 10pt">Condensed
    Consolidated Statements of Operations and Comprehensive Loss</span></a></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-11</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#b_015"><span style="font-size: 10pt">Condensed
    Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></a></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-12</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#b_016"><span style="font-size: 10pt">Condensed
    Consolidated Statement of Cash Flows</span></a></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-13</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#b_017"><span style="font-size: 10pt">Notes
    to Condensed Consolidated Financial Statements</span></a></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-14</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p><div>



</div><!-- Field: Page; Sequence: 125; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="aaaa_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Board of Directors and Stockholders of Oruka Therapeutics, Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Opinion on the Financial Statement &#8212; Balance Sheet</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying balance sheet of Oruka Therapeutics,
Inc. (the &#8220;Company&#8221;) as of February 6, 2024, including the related notes (collectively referred to as the &#8220;financial
statement&#8221;). In our opinion, the financial statement presents fairly, in all material respects, the financial position of the Company
as of February 6, 2024 in conformity with accounting principles generally accepted in the United States of America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Substantial Doubt about the Company&#8217;s Ability to Continue
as a Going Concern</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying financial statement has been prepared assuming that
the Company will continue as a going concern. As discussed in Note 1 to the financial statement, the Company has not generated any revenue
from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception,
which raises substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are
also described in Note 1. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Basis for Opinion</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The financial statement is the responsibility of the Company&#8217;s
management. Our responsibility is to express an opinion on the Company&#8217;s financial statement based on our audit. We are a public
accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent
with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted our audit of this financial statement in accordance with
the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement is free of material misstatement,
whether due to error or fraud.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audit included performing procedures to assess the risks of material
misstatement of the financial statement, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statement. Our audit also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation
of the financial statement. We believe that our audit provides a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Critical Audit Matters</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Critical audit matters are matters arising from the current period
audit of the financial statement that were communicated or required to be communicated to the audit committee and that (i) relate to accounts
or disclosures that are material to the financial statement and (ii) involved our especially challenging, subjective, or complex judgments.
We determined there are no critical audit matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ PricewaterhouseCoopers LLP</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boston, Massachusetts</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 13, 2024, except for the effects of the reverse stock split discussed
in Note 1 to the financial statement, as to which the date is September 5, 2024, and except for the effects of the reverse merger exchange
ratio discussed in Note 1 to the financial statement, as to which the date is November 13, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="aaaa_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ORUKA THERAPEUTICS, INC.<br/>
BALANCE SHEET<br/>
(In thousands, except share amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">February 6, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 18.25pt">Subscription receivable</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="orka:SubscriptionReceivables" scale="3" unitRef="usd" id="ixv-22659">1</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 27.25pt">Total assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-22660">1</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9.25pt">Commitments and contingencies (Note 5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9.25pt">STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 18.25pt">Series A convertible preferred stock, $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22661">0.001</ix:nonFraction> par value, <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22662">20,000,000</ix:nonFraction> shares authorized, <span style="-sec-ix-hidden: hidden-fact-2"><span style="-sec-ix-hidden: hidden-fact-3">no</span></span> shares issued and outstanding as of February 6, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 18.25pt">Common stock, $<ix:nonFraction contextRef="c1" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22663">0.001</ix:nonFraction> par value, <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22664">65,000,000</ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-22665"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-22666">3,197,975</ix:nonFraction></ix:nonFraction> issued and outstanding as of February 6, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-22667">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 18.25pt">Additional paid-in capital</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" sign="-" unitRef="usd" id="ixv-22668">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 27.25pt">Total stockholders&#8217; equity</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22669">1</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
this financial statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="aaaa_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ORUKA THERAPEUTICS, INC.<br/>
NOTES TO FINANCIAL STATEMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c65" continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c65_cont_1" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="ixv-15142"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. Nature of the Business and Basis of Presentation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Background and Basis of Presentation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Oruka Therapeutics, Inc. (&#8220;Oruka&#8221; or
the &#8220;Company&#8221;) was established and incorporated under the laws of the state of Delaware on February 6, 2024. Oruka was founded
by Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;). The Company currently operates as a virtual company, and thus, does not maintain
a corporate headquarters or other significant facilities. Oruka was formed to develop biologics to optimize the treatment of inflammatory
skin diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company is subject to risks and uncertainties
common to early-stage companies in the biopharmaceutical industry, including, but not limited to, completing preclinical and clinical
trials, obtaining regulatory approval for product candidates, development by competitors of new technological innovations, dependence
on key personnel, the ability to attract and retain qualified employees, reliance on third-party organizations, protection of proprietary
technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the ability to
raise additional capital to fund operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company&#8217;s potential products will require
approval from the U.S. Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales. There
can be no assurance that the Company&#8217;s potential products will receive all the required approvals. In addition, there can be no
assurance that the Company&#8217;s potential products, if approved, will be accepted in the marketplace, nor can there be any assurance
that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that
such products will be successfully marketed, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The financial statement and accompanying notes have
been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Liquidity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The accompanying financial statement has been prepared
on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of
liabilities in the normal course of business. As of February 6, 2024, the Company had no cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company will devote substantially all of its
resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning, raising capital,
and providing general and administrative support for these operations. Current and future programs will require significant research and
development efforts, including preclinical and clinical trials and regulatory approvals to commercialization. These efforts require significant
amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&#8217;s development efforts are successful,
it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company obtains regulatory approval
for any of its product candidates and starts to generate revenue, it expects to incur significant expenses related to developing its internal
commercialization capability to support product sales, marketing, and distribution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">As a result, the Company will need substantial additional
funding to support its operating activities as it advances its potential product candidates through development, seeks regulatory approval
and prepares for and, if any of its product candidates are approved, proceeds to commercialization. Until such time as the Company can
generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination
of equity offerings and debt financings. Adequate funding may not be available to the Company on acceptable terms, or at all.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><ix:continuation id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c65_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">If the Company is unable to obtain additional funding,
the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its planned
operations, which may have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and ability
to operate as a going concern. The financial statement does not include any adjustments that may result if the Company is not able to
continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company has not generated any revenue from product
sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In March 2024, the Company received $<ix:nonFraction contextRef="c66" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="6" unitRef="usd" id="ixv-22670">3.0</ix:nonFraction> million
in proceeds from the sale of Series A convertible preferred stock and $<ix:nonFraction contextRef="c38" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="6" unitRef="usd" id="ixv-22671">25.0</ix:nonFraction> million in proceeds from the sale of an unsecured convertible
promissory note, both of which were related party transactions (see Note 7 <i>Subsequent Events</i>).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">ARCA biopharma, Inc., a Delaware corporation (&#8220;ARCA&#8221;),
and the Company entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) on April 3, 2024,
pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement,
Atlas Merger Sub Corp, a Delaware corporation (&#8220;First Merger Sub&#8221;), will merge with and into Oruka, with Oruka continuing
as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Oruka will merge
with and into Atlas Merger Sub II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and together with First
Merger Sub, &#8220;Merger Subs&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221;
and, together with the First Merger, the &#8220;Merger&#8221;). In connection with the Merger, Second Merger Sub will change its corporate
name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221;
ARCA following the Merger is referred to herein as the &#8220;combined company.&#8221; The combined company will be led by Oruka&#8217;s
management team and will remain focused on developing biologics to optimize the treatment of inflammatory skin diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Concurrent with the execution of the Merger Agreement,
the Company entered into a subscription agreement with certain investors to which the Company agreed to issue and sell to investors in
a private placement financing (the &#8220;Private Placement&#8221;) shares and pre-funded warrants of the Company&#8217;s common stock
at an estimated purchase price of $<ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-22672">9.71</ix:nonFraction> ($<ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-22673">5.55</ix:nonFraction> prior to impact of reverse stock split and reverse merger exchange ratio) per share of
common stock and estimated purchase price of $<ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-22674">9.70</ix:nonFraction> ($<ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-22675">5.54</ix:nonFraction> prior to the impact of the reverse stock split and reverse merger exchange ratio)
per warrant for gross proceeds of approximately $<ix:nonFraction contextRef="c69" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" unitRef="usd" id="ixv-22676">275.0</ix:nonFraction> million, which will precede the closing of the Merger Agreement. Shares of the
Company&#8217;s common stock and pre-funded warrants to purchase shares of the Company&#8217;s common stock issued pursuant to the Private
Placement will be converted into the right to receive shares of ARCA common stock and pre-funded warrants to purchase ARCA common stock,
respectively, in accordance with the exchange ratio at the effective time of the close of the transaction. The proceeds from the Private
Placement are expected to advance the Company&#8217;s pipeline, business development activities, working capital, and other general corporate
purposes.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">However, the agreements are subject to the satisfaction
of customary closing conditions, and there are no assurances that such conditions will be achieved nor that such financing or other strategic
transactions will be available on acceptable terms, or at all. If the Merger Agreement is terminated under certain circumstances, ARCA
could be required to pay Oruka a termination fee of $<ix:nonFraction contextRef="c70" decimals="-5" format="ixt:num-dot-decimal" name="orka:TerminationFee" scale="6" unitRef="usd" id="ixv-22677">0.4</ix:nonFraction> million or Oruka could be required to pay ARCA a termination fee of $<ix:nonFraction contextRef="c65" decimals="-5" format="ixt:num-dot-decimal" name="orka:TerminationFee" scale="6" unitRef="usd" id="ixv-22678">0.4</ix:nonFraction> million.
Based on its expectation of continuing operating losses for the foreseeable future, as of May 13, 2024, the date the Company&#8217;s financial
statement is available to be issued, the Company has concluded there is substantial doubt about its ability to continue as a going concern
for at least twelve months from the date the financial statement is available to be issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In connection with the Merger Agreement discussed
above, the Company effected a one-for-twelve reverse stock split of the Company&#8217;s issued and outstanding shares of common stock
on September 3, 2024 without any change in the par value per share. Unless otherwise stated, all information related to the Company&#8217;s
common stock, common stock warrants, restricted stock awards, and stock options, as well as the per share amounts, have been retroactively
adjusted to give effect for the one-for-twelve reverse stock split and reverse merger exchange ratio of <ix:nonFraction contextRef="c65" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" unitRef="pure" id="ixv-22679">6.8569</ix:nonFraction> as calculated in accordance
with the Merger Agreement for all periods presented.</p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c65" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-15216"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2. Summary of Significant Accounting Policies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c65" continuedAt="orka_SubscriptionReceivablePolicyTextBlock-c65_cont_1" escape="true" name="orka:SubscriptionReceivablePolicyTextBlock" id="ixv-15221"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Subscription receivable</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<ix:continuation id="orka_SubscriptionReceivablePolicyTextBlock-c65_cont_1"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company accounts for any notes received in exchange
for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement
is available to be issued.</p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c65" escape="true" name="orka:CommonStockTextBlock" id="ixv-15231"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>3. Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">As of February 6, 2024, the Company has the authority
to issue a total of <ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22680">65,000,000</ix:nonFraction> shares of common stock at a par value of $<ix:nonFraction contextRef="c71" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22681">0.001</ix:nonFraction>. As of February 6, 2024, <ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-22682"><ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-22683">3,197,975</ix:nonFraction></ix:nonFraction> shares of common stock
were issued and outstanding for a nominal consideration, which was received in March 2024, prior to the date the financial statement is
available to be issued. Each share of common stock entitles the holder to one vote for each share of common stock held of record by such
holder on all matters on which stockholders generally are entitled to vote. The holders of common stock are entitled to receive dividends,
if any, as declared by the Company&#8217;s Board of Directors. Upon dissolution, liquidation or winding up of the Company, the holders
of shares of common stock, subject to the rights of the holders of any outstanding series of preferred stock, shall be entitled to receive
the assets of the Company available for distribution to its stockholders ratably in proportion to the number of shares held.</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c65" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-15239"><p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><b>4. Related Party Transactions</b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company issued <ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-22684">3,197,975</ix:nonFraction> shares of common stock,
through a series of contribution agreements, to Paragon, Paruka Holding, LLC (&#8220;Paruka&#8221;), an entity formed by Paragon as a
vehicle to hold equity in the Company, and Oruka Advisors LLC (&#8220;Oruka Advisors&#8221;), an entity formed by Paragon as a vehicle
to hold equity in the Company, as part of its common stock subscription agreement with such entities. As of February 6, 2024, Paragon,
Paruka and Oruka Advisors each beneficially own approximately <ix:nonFraction contextRef="c72" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-22685">44.7</ix:nonFraction>%, <ix:nonFraction contextRef="c73" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-22686">44.7</ix:nonFraction>% and <ix:nonFraction contextRef="c74" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-22687">10.6</ix:nonFraction>%, respectively, of the Company through their common
stock holdings.</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c65" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-15248"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>5. Commitments and Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company may be subject to legal proceedings
that arise in the ordinary course of business. As of February 6, 2024, there were no material proceedings to which the Company was a party,
nor did the Company have knowledge of any proceedings threatened against it.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c65" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-15257"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>6. Stock-Based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On February 6, 2024, the Company&#8217;s Board of
Directors approved the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;), under which the Company may grant stock options, restricted
stock awards, restricted stock units, or other stock-based awards to its employees, officers, directors, consultants, and advisors. The
Company reserved <ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-22688">213,085</ix:nonFraction> shares of its common stock for issuance under the 2024 Plan. As of February 6, 2024, no awards had been issued
under the plan.</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c65" continuedAt="_SubsequentEventsTextBlock-c65_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-15266"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>7. Subsequent Events</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company evaluated all events subsequent to February
6, 2024, through May 13, 2024, the date on which the financial statement was available to be issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c65_cont_2" id="_SubsequentEventsTextBlock-c65_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock-Based Compensation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In February 2024, the Company&#8217;s Board of Directors
authorized and granted <ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitRef="shares" id="ixv-22689">1,184,749</ix:nonFraction> restricted stock awards at a price of $<ix:nonFraction contextRef="c76" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22690">0.0001</ix:nonFraction> per share to employees of the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In March 2024, the Company&#8217;s Board of Directors
authorized and granted <ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitRef="shares" id="ixv-22691">1,022,804</ix:nonFraction> restricted stock awards at a price of $<ix:nonFraction contextRef="c77" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22692">0.0001</ix:nonFraction> per share to consultants and a director of the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March 5, 2024, the Company&#8217;s Board of Directors
approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from
<ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-22693">213,085</ix:nonFraction> to <ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-22694">498,789</ix:nonFraction>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March 22, 2024, the Company granted options for
the purchase of an aggregate <ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-22695">399,222</ix:nonFraction> shares of common stock, at an exercise price of $5.16 per share.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On May 7, 2024, the Company&#8217;s Board of Directors
approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from
<ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-22696">498,789</ix:nonFraction> to <ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-22697">1,179,193</ix:nonFraction>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On May 7, 2024, the Company granted options for
the purchase of an aggregate <ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-22698">779,971</ix:nonFraction> shares of common stock, at an exercise price of $6.84 per share.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Antibody Discovery and Option Agreements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March 6, 2024, the Company entered into an Antibody
Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March 28, 2024, whereby the Company
was granted an exclusive, worldwide option, on a research program-by-research program basis, to all of Paragon&#8217;s right, title and
interest in and to the intellectual property (&#8220;ORKA-001&#8221;) resulting from the applicable research program to develop, manufacture
and commercialize products directed at the selected target (&#8220;IL-23&#8221;), with the exception of pursuing ORKA-001 for the treatment
of inflammatory bowel disease. Upon signing of the Antibody Discovery and Option Agreement for ORKA-001, a one-time, non-refundable research
initiation fee of $<ix:nonFraction contextRef="c84" decimals="-5" format="ixt:num-dot-decimal" name="orka:ResearchInitiationFee" scale="6" unitRef="usd" id="ixv-22699">0.8</ix:nonFraction> million was due to Paragon. This amount was recognized as a research and development expense during the period
ended March 31, 2024, and paid to Paragon in April 2024. The Company is also responsible for <ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="orka:DevelopmentCostsPercentage" scale="-2" unitRef="pure" id="ixv-22700">50</ix:nonFraction>% of the development costs incurred prior
to March 31, 2024, provided that the Company receives rights to at least one selected IL-23 antibody. As of the date this financial statement
is available to be issued, the Company has not received rights to a selected IL-23 antibody and has not paid or accrued the $<ix:nonFraction contextRef="c85" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="6" unitRef="usd" id="ixv-22701">5.9</ix:nonFraction> million
of development costs incurred prior to March 31, 2024. The Company will be responsible for <ix:nonFraction contextRef="c86" decimals="2" format="ixt:num-dot-decimal" name="orka:DevelopmentCostsPercentage" scale="-2" unitRef="pure" id="ixv-22702">50</ix:nonFraction>% of the ORKA-001 development costs incurred
from and after March 31, 2024, through the completion of the IL-23 selection process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March 6, 2024, the Company also entered into
an Antibody Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March 28, 2024, whereby
the Company was granted an exclusive, worldwide option, on a research program-by-research program basis, to all of Paragon&#8217;s right,
title and interest in and to the intellectual property (&#8220;ORKA-002&#8221;) resulting from the applicable research program to develop,
manufacture and commercialize products directed at the selected target (&#8220;IL-17&#8221;). The Company was also required to reimburse
Paragon $<ix:nonFraction contextRef="c87" decimals="-5" format="ixt:num-dot-decimal" name="orka:ReimburseOfDevelopmentCosts" scale="6" unitRef="usd" id="ixv-22703">3.3</ix:nonFraction> million for development costs related to ORKA-002 incurred by Paragon through December 31, 2023 and certain other development
costs related to ORKA-002 incurred by Paragon between January 1, 2024 and March 6, 2024. This amount was recognized as a research and
development expenses during the period from February 6 (inception) to March 31, 2024 and accounts payable as of March 31, 2024. The Company
paid $<ix:nonFraction contextRef="c88" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="6" unitRef="usd" id="ixv-22704">3.3</ix:nonFraction> million to Paragon in April 2024. The Company is also responsible for the development costs incurred by Paragon from January
1, 2024 to March 31, 2024 of $<ix:nonFraction contextRef="c89" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" unitRef="usd" id="ixv-22705">0.9</ix:nonFraction> million, which was recognized as a research and development expense in the period from February 6 (inception)
to March 31, 2024. The Company will be required to pay Paragon $<ix:nonFraction contextRef="c90" decimals="-5" format="ixt:num-dot-decimal" name="orka:ResearchInitiationFee" scale="6" unitRef="usd" id="ixv-22706">0.8</ix:nonFraction> million for the research initiation fee related to ORKA-002 within
30 days following finalization of the ORKA-002 research plan as well as for subsequent development costs related to ORKA-002.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">As of the date of issuance of the Company&#8217;s
financial statement, the Company has not exercised its options with respect to ORKA-001 or ORKA-002. For each of these agreements, if
the Company exercises its options, it will be required to make non-refundable milestone payments to Paragon of up to $<ix:nonFraction contextRef="c91" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-22707">12.0</ix:nonFraction> million upon
the achievement of certain clinical development milestones, up to $<ix:nonFraction contextRef="c92" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-22708">10.0</ix:nonFraction> million upon the achievement of certain regulatory milestones,
as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial sale.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c65_cont_3" id="_SubsequentEventsTextBlock-c65_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Additionally, as part of the Antibody Discovery
and Option Agreements, on each of December 31, 2024 and December 31, 2025, the Company will grant Paruka warrants to purchase a number
of shares equal to <ix:nonFraction contextRef="c93" decimals="4" format="ixt:num-dot-decimal" name="orka:PercentageOfWarrantPurchare" scale="-2" unitRef="pure" id="ixv-22709">1.00</ix:nonFraction>% of the then outstanding shares of the Company&#8217;s common stock as of the date of the grant on a fully-diluted
basis, with an exercise price equal to the fair market value of the underlying shares on the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Series A Preferred Stock</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March 6, 2024, the Company issued <ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-22710">20,000,000</ix:nonFraction>
shares of Series A convertible preferred stock to Fairmount Healthcare Fund II, L.P. (&#8220;Fairmount&#8221;), a related party of the
Company, at a purchase price of $<ix:nonFraction contextRef="c94" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22711">0.15</ix:nonFraction> per share for gross proceeds of $<ix:nonFraction contextRef="c95" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" unitRef="usd" id="ixv-22712">3.0</ix:nonFraction> million. The Company incurred less than $<ix:nonFraction contextRef="c95" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" unitRef="usd" id="ixv-22713">0.1</ix:nonFraction> million of issuance
costs in connection with this transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The holders of Series A convertible preferred stock
are entitled to vote, together with the holders of common stock, on all matters submitted to stockholders for a vote. Each holder of outstanding
shares of Series A convertible preferred stock is entitled to the number of votes equal to the number of shares of common stock into which
the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote
on such matter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Each share of Series A convertible preferred stock
is convertible at the option of the holder, at any time, and without the payment of additional consideration by the holder. In addition,
each share of Series A convertible preferred stock will be automatically converted into shares of common stock at the applicable conversion
ratio then in effect upon either (i) the closing of a firm-commitment underwritten public offering of the Company&#8217;s common stock
at a price of at least $<ix:nonFraction contextRef="c96" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22714">12.00</ix:nonFraction> per share resulting in at least $<ix:nonFraction contextRef="c84" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd" id="ixv-22715">50.0</ix:nonFraction> million of gross proceeds to the Company, or (ii) the vote or written
consent of the holders of a majority of the Preferred Stock, voting as a single class.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The conversion ratio of Series A convertible preferred
stock is determined by dividing the Original Issue Price by the Conversion Price in effect at the time of conversion. The Original Issue
Price is $<ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22716">0.15</ix:nonFraction> per share for Series A convertible preferred stock (in each case subject to appropriate adjustment in the event of any
stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company&#8217;s certificate
of incorporation, as amended and restated). The Conversion Price is approximately $<ix:nonFraction contextRef="c98" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-22717">0.26</ix:nonFraction> per share for Series A convertible preferred stock
and each outstanding share of Series A Preferred Stock was convertible into common stock at a <ix:nonFraction contextRef="c94" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-22718">0.5712</ix:nonFraction> conversion ratio.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company may not declare, pay or set aside any
dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock) unless
the holders of the Series A convertible preferred stock then outstanding first receive, or simultaneously receive, a dividend on each
outstanding share of Series A convertible preferred stock in an amount at least equal to (i) in the case of a dividend being distributed
to common stock or any class or series that is convertible into common stock, the equivalent dividend on an as-converted basis or (ii)
in the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend rate on Series
A convertible preferred stock calculated based on the respective Original Issue Price of Series A convertible preferred stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In the event of any voluntary or involuntary liquidation,
dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares
of Series A convertible preferred stock then outstanding are entitled to be paid out of the assets or funds of the Company available for
distribution to stockholders before any payment is made to the holders of common stock. The holders of Series A convertible preferred
stock are entitled to an amount equal to the greater of (i) the applicable Original Issue Price per share of Series A convertible preferred
stock, plus any declared but unpaid dividends thereon, or (ii) the amount per share that would have been payable had all shares of Series
A convertible preferred stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed
Liquidation Event. If upon any such liquidation event, the assets or funds of the Company available for distribution to stockholders are
insufficient to pay the full amount to which they are entitled, then the holders of shares of Series A convertible preferred stock will
share ratably in any distribution of the assets or funds available for distribution in proportion to the respective amounts which would
otherwise be payable if it were paid in full.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c65_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Unless the holders of a majority in voting power
of the then outstanding shares of Series A convertible preferred stock elect otherwise, a Deemed Liquidation Event shall include a merger
or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the
surviving or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all of the
Company&#8217;s assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Series A convertible preferred stock does not have
redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Convertible Notes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March 6, 2024, the Company entered into a Series
A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Fairmount, whereby the Company issued
a convertible note (the &#8220;Convertible Note&#8221;), with an initial principal amount of $<ix:nonFraction contextRef="c99" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" unitRef="usd" id="ixv-22719">25.0</ix:nonFraction> million, that can be converted into
Series A preferred stock (or a Series of preferred shares that is identical in respect to the shares of preferred shares issued in its
next equity financing) or shares of the Company&#8217;s common stock in exchange for proceeds of $<ix:nonFraction contextRef="c100" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" unitRef="usd" id="ixv-22720">25.0</ix:nonFraction> million. The Convertible Note will
automatically convert into shares of the Company&#8217;s common stock upon the closing of a corporate transaction, including the reverse
recapitalization transaction, and is otherwise due and payable at the request of the holder at any time. The Convertible Note accrues
interest at a rate of <ix:nonFraction contextRef="c100" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-22721">12.0</ix:nonFraction>% per annum. All unpaid interest and principal are scheduled to mature on December 31, 2025. Prepayment is not
permitted without prior written consent of Fairmount. Pursuant to the Purchase Agreement, the Company has the right to sell and issue
additional convertible notes up to an aggregate principal amount equal to $<ix:nonFraction contextRef="c101" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" unitRef="usd" id="ixv-22722">30.0</ix:nonFraction> million, in addition to the $<ix:nonFraction contextRef="c102" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" unitRef="usd" id="ixv-22723">25.0</ix:nonFraction> million of initial principal
amount of the Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Oak Grove Lease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On April 12, 2024, the Company entered into a lease
agreement with Oak Grove LP (&#8220;Oak Grove Lease&#8221;) for office space located in Menlo Park, California. The lease commencement
date is June 15, 2024 with an initial term of <ix:nonNumeric contextRef="c103" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-22724">39.5</ix:nonNumeric> months. The total lease payment is expected to be $<ix:nonFraction contextRef="c104" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="6" unitRef="usd" id="ixv-22725">1.4</ix:nonFraction> million over the initial lease
term.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c65" escape="true" name="us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" id="ixv-15380"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>8. Events subsequent to the reissuance of the financial statement
(unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In connection with the reissuance of the financial
statement, the Company has evaluated subsequent events through November 13, 2024, the date the financial statement was available to be
reissued.</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><div><a id="b_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ORUKA
THERAPEUTICS, INC.<br/>
CONDENSED CONSOLIDATED BALANCE SHEETS<br/>
(UNAUDITED)<br/>
(In thousands, except share and per share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">February&#160;6,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-22726">410,875</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Subscription receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="orka:SubscriptionReceivables" scale="3" unitRef="usd" id="ixv-22727">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-22728">2,074</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-22729">412,949</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-22730">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-22731">160</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-22732">938</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-22733">43</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-22734">414,090</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-22735">1</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-22736">2,145</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-22737">1,710</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Operating lease liability, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-22738">146</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Related party common stock warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" unitRef="usd" id="ixv-22739">7,681</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Related party accounts payable and other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-22740">6,357</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-22741">18,039</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liability, non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-22742">842</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-22743">18,881</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Commitment and contingencies (Note 11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 10pt; text-align: left; text-indent: -10pt">Series&#160;A convertible preferred stock, $<ix:nonFraction contextRef="c7" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22744"><ix:nonFraction contextRef="c8" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22745">0.0001</ix:nonFraction></ix:nonFraction> par value; <span style="-sec-ix-hidden: hidden-fact-22"><span style="-sec-ix-hidden: hidden-fact-24">no</span></span> shares and <ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" unitRef="shares" id="ixv-22746"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" unitRef="shares" id="ixv-22747">20,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of September&#160;30, 2024 and February&#160;6, 2024, respectively; <span style="-sec-ix-hidden: hidden-fact-23"><span style="-sec-ix-hidden: hidden-fact-25">no</span></span>&#160;shares issued and outstanding as of September 30, 2024 and February&#160;6, 2024; liquidation preference of $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" unitRef="usd" id="ixv-22748"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" unitRef="usd" id="ixv-22749">0</ix:nonFraction></ix:nonFraction> as of September 30, 2024 and February&#160;6, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0 0 0 10pt; text-align: left; text-indent: -10pt">Series A non-voting convertible preferred stock, $<ix:nonFraction contextRef="c9" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22750"><ix:nonFraction contextRef="c10" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22751">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" unitRef="shares" id="ixv-22752"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" unitRef="shares" id="ixv-22753">2,439</ix:nonFraction></ix:nonFraction> and <span style="-sec-ix-hidden: hidden-fact-28"><span style="-sec-ix-hidden: hidden-fact-29">no</span></span> shares authorized as of September 30, 2024 and February 6, 2024, respectively; <ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" unitRef="shares" id="ixv-22754">2,439</ix:nonFraction> and <span style="-sec-ix-hidden: hidden-fact-27">no</span> shares issued and outstanding as of September 30, 2024 and February 6, 2024, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" unitRef="usd" id="ixv-22755">52,841</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Series B non-voting convertible preferred stock, $<ix:nonFraction contextRef="c11" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22756"><ix:nonFraction contextRef="c12" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22757">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22758">251,504</ix:nonFraction> and <span style="-sec-ix-hidden: hidden-fact-32"><span style="-sec-ix-hidden: hidden-fact-33">no</span></span> shares authorized as of September 30, 2024 and February 6, 2024, respectively; <ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-22759"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-22760">137,138</ix:nonFraction></ix:nonFraction> and <span style="-sec-ix-hidden: hidden-fact-31">no</span> shares issued and outstanding as of September 30, 2024 and February 6, 2024, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="3" unitRef="usd" id="ixv-22761">2,931</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Common stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22762">0.001</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22763">0.001</ix:nonFraction> par value as of September 30, 2024 and February 6, 2024, respectively; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22764">545,000,000</ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22765">65,000,000</ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-22766"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-22767">34,998,550</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-22768"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-22769">3,197,975</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2024 and February 6, 2024, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-22770">35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-22771">397,345</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-22772">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-22773">57,943</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total stockholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22774">342,368</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22775">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total liabilities, convertible preferred stock and stockholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-22776">414,090</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-22777">1</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these condensed consolidated financial statements.<span style="clear: both; display: block;"><br/></span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="b_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ORUKA
THERAPEUTICS, INC.<br/>
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS<br/>
(UNAUDITED)<br/>
(In thousands, except share and per share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> September&#160;30, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period&#160;from <br/> February&#160;6,<br/> 2024 <br/> (Inception)&#160;to<br/> September 30, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating expenses</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt"><span style="font-size: 10pt">Research and development<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">25,691</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">49,557</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-size: 10pt">General and administrative<sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">3,758</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" id="ix_3_fact" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">8,248</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-22782">29,449</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-22783">57,805</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22784">29,449</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22785">57,805</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-22786">1,330</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-22787">1,330</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-size: 10pt">Interest expense<sup>(3)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:InterestExpenseNonoperating" scale="3" unitRef="usd">504</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:InterestExpenseNonoperating" scale="3" unitRef="usd">1,468</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total other income (expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-22790">826</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-22791">138</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net loss and comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22792">28,623</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22793">57,943</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net loss per share attributable to common stockholders, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c13" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-22794"><ix:nonFraction contextRef="c13" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-22795">1.46</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-22796"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-22797">6.08</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c14" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-22798"><ix:nonFraction contextRef="c14" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-22799">1,461.10</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c15" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-22800"><ix:nonFraction contextRef="c15" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-22801">6,077.25</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net&#160;loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c16" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-22802"><ix:nonFraction contextRef="c16" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-22803">121.76</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c17" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-22804"><ix:nonFraction contextRef="c17" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-22805">506.44</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22806"><ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22807">15,013,655</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22808"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22809">7,765,381</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted-average shares used in computing net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22810"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22811">477</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22812"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22813">184</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Weighted-average shares used in computing net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22814"><ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22815">49,191</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22816"><ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22817">19,015</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes related party amount of $13,537 for the three months ended September 30, 2024 and $33,967 for the period from February 6, 2024 (inception) to September 30, 2024</span></ix:footnote></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes related party amount of $71 for the three months ended September 30, 2024 and $1,339 for the period from February 6, 2024 (inception) to September 30, 2024</span></ix:footnote></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes related party amount of $504 for the three months ended September 30, 2024 and $1,468 for the period from February 6, 2024 (inception) to September 30, 2024</span></ix:footnote></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="b_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ORUKA
THERAPEUTICS, INC.<br/>
CONDENSED&#160;CONSOLIDATED STATEMENTS&#160;OF&#160;CONVERTIBLE PREFERRED&#160;STOCK&#160;AND&#160;STOCKHOLDERS&#8217;&#160;EQUITY (DEFICIT)<br/>
(UNAUDITED)<br/>
(In thousands, except share data)</b></span></p><div>

</div><p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-align: center; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Series
    A<br/>
    Convertible Preferred Stock</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Series
    A<br/>
    Non-Voting<br/>
    Convertible Preferred&#160;Stock</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Series
    B<br/>
    Non-Voting<br/>
    Convertible Preferred&#160;Stock</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Common
    Stock</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Additional
    <br/>
    Paid-in</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Accumulated</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Total
    <br/>
    Stockholders&#8217;<br/>
    Equity</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-align: center; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Shares</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Amount</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Shares</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Amount</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Shares</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Amount</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Shares</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Amount</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Capital</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Deficit</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>(Deficit)</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Balances
    as of February&#160;6, 2024 (inception)</b></span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-36; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-37; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-38; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-22818">3,197,975</ix:nonFraction></span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22819">3</ix:nonFraction></span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-22820">2</ix:nonFraction>)</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-39; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22821">1</ix:nonFraction></span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common stock</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-41; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-22822">2,207,553</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-22823">2</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" sign="-" unitRef="usd" id="ixv-22824">2</ix:nonFraction>)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance of Series&#160;A convertible preferred stock, net of issuance costs of $<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" scale="3" unitRef="usd" id="ixv-22825">69</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c25" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-22826">20,000,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd" id="ixv-22827">2,931</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock-based
    compensation expense</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-22828">17</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-22829">17</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net loss</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22830">7,077</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22831">7,077</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Balances
    as of March&#160;31, 2024</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c32" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-22832">20,000,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22833">2,931</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c35" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-22834">5,405,528</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22835">5</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22836">13</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-22837">7,077</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-22838">7,059</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock-based
    compensation expense</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-22839">321</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-22840">321</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net loss</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22841">22,243</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22842">22,243</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Balances
    as of June 30, 2024</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c46" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-22843">20,000,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22844">2,931</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c49" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-22845">5,405,528</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22846">5</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22847">334</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-22848">29,320</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-22849">28,981</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Exchange
    of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c53" decimals="INF" format="ixt:num-dot-decimal" name="orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" scale="0" sign="-" unitRef="shares" id="ixv-22850">20,000,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" scale="3" sign="-" unitRef="usd" id="ixv-22851">2,931</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c55" decimals="INF" format="ixt:num-dot-decimal" name="orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" scale="0" unitRef="shares" id="ixv-22852">137,138</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" scale="3" unitRef="usd" id="ixv-22853">2,931</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" scale="3" unitRef="usd" id="ixv-22854">2,931</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Conversion
    of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares" id="ixv-22855">2,722,207</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" unitRef="usd" id="ixv-22856">3</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" unitRef="usd" id="ixv-22857">26,445</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" unitRef="usd" id="ixv-22858">26,448</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common stock and pre-funded warrants in the Pre-Closing Financing,</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="INF" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" scale="0" unitRef="shares" id="ixv-22859">20,061,932</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" scale="3" unitRef="usd" id="ixv-22860">20</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" scale="3" unitRef="usd" id="ixv-22861">248,437</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" scale="3" unitRef="usd" id="ixv-22862">248,457</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    costs of Pre-Closing Financing and reverse recapitalization</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" scale="3" sign="-" unitRef="usd" id="ixv-22863">20,480</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-91; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" scale="3" sign="-" unitRef="usd" id="ixv-22864">20,480</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="INF" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" scale="0" unitRef="shares" id="ixv-22865">1,208,883</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" scale="3" unitRef="usd" id="ixv-22866">1</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" scale="3" unitRef="usd" id="ixv-22867">4,999</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" scale="3" unitRef="usd" id="ixv-22868">5,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c54" decimals="INF" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" scale="0" unitRef="shares" id="ixv-22869">2,439</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" scale="3" unitRef="usd" id="ixv-22870">56,097</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="INF" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" scale="0" unitRef="shares" id="ixv-22871">5,600,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" scale="3" unitRef="usd" id="ixv-22872">6</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" scale="3" unitRef="usd" id="ixv-22873">144,433</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" scale="3" unitRef="usd" id="ixv-22874">144,439</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    cost of PIPE Financing</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceCostOfPIPEFinancing" scale="3" sign="-" unitRef="usd" id="ixv-22875">3,256</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceCostOfPIPEFinancing" scale="3" sign="-" unitRef="usd" id="ixv-22876">8,573</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceCostOfPIPEFinancing" scale="3" sign="-" unitRef="usd" id="ixv-22877">8,573</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock-based
    compensation expense</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-22878">1,750</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-22879">1,750</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net loss</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-100; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-101; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-102; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-103; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22880">28,623</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22881">28,623</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Balances
    as of September 30, 2024</b></span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-104; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c60" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-22882">2,439</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22883">52,841</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c61" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-22884">137,138</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22885">2,931</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c62" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-22886">34,998,550</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22887">35</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22888">397,345</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-22889">57,943</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22890">342,368</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  </table><div>
</div><p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="b_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ORUKA
THERAPEUTICS, INC.<br/>
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS<br/>
(UNAUDITED)<br/>
(In thousands)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Period&#160;from <br/>
February&#160;6, <br/>
2024 <br/>
(Inception) to <br/>
September&#160;30, <br/>
2024</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><b>Cash flows from operating activities:</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Net loss</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22891">57,943</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 27pt; text-indent: -0.25in"><span style="font-size: 10pt">Depreciation expense</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-22892">11</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 27pt; text-indent: -0.25in"><span style="font-size: 10pt">Stock-based compensation expense</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-22893">9,769</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 27pt; text-indent: -0.25in"><span style="font-size: 10pt">Non-cash interest expense</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashExpense" scale="3" unitRef="usd" id="ixv-22894">1,468</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 27pt; text-indent: -0.25in"><span style="font-size: 10pt">Non-cash lease expense</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd" id="ixv-22895">65</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 27pt; text-indent: -0.25in"><span style="font-size: 10pt">Changes in operating assets and liabilities:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 45pt; text-indent: -0.25in"><span style="font-size: 10pt">Prepaid expenses and other current assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="3" unitRef="usd" id="ixv-22896">1,980</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 45pt; text-indent: -0.25in"><span style="font-size: 10pt">Other non-current assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" unitRef="usd" id="ixv-22897">43</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 45pt; text-indent: -0.25in"><span style="font-size: 10pt">Accounts payable</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitRef="usd" id="ixv-22898">1,621</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 45pt; text-indent: -0.25in"><span style="font-size: 10pt">Accrued expenses and other current liabilities</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" unitRef="usd" id="ixv-22899">1,650</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 45pt; text-indent: -0.25in"><span style="font-size: 10pt">Operating lease liability</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-22900">6</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 45pt; text-indent: -0.25in"><span style="font-size: 10pt">Related party accounts payable and other current liabilities</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="3" unitRef="usd" id="ixv-22901">6,357</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 0.5in; text-indent: -0.25in"><span style="font-size: 10pt">Net cash used in operating activities</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-22902">39,019</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt"><b>Cash flows from investing activities:</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-size: 10pt">Purchases of property and equipment</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-22903">171</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.5in; text-indent: -0.25in"><span style="font-size: 10pt">Net cash used in investing activities</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-22904">171</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt"><b>Cash flows from financing activities:</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid" scale="3" unitRef="usd" id="ixv-22905">2,931</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Proceeds from issuance of notes payable to related parties, net of issuance costs paid</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromNotesPayable" scale="3" unitRef="usd" id="ixv-22906">24,980</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Proceeds from the Pre-Closing Financing, net</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="3" unitRef="usd" id="ixv-22907">228,127</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Proceeds from the PIPE Financing, net</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" unitRef="usd" id="ixv-22908">189,087</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Cash acquired in connection with the reverse recapitalization</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:CashAssumedInConnectionWithTheReverseRecapitalization" scale="3" unitRef="usd" id="ixv-22909">4,940</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 0.5in; text-indent: -0.25in"><span style="font-size: 10pt">Net cash provided by financing activities</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-22910">450,065</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt"><b>Net increase in cash and cash equivalents</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" unitRef="usd" id="ixv-22911">410,875</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Cash at beginning of period</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-105; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Cash and cash equivalents at end of period</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-22912">410,875</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt"><b>Supplemental disclosure of non-cash operating and financing activities:</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Operating lease liability arising from obtaining operating right-of-use asset</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-22913">982</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Assets acquired in connection with the reverse recapitalization</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" scale="3" unitRef="usd" id="ixv-22914">114</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Other liabilities assumed in connection with the reverse recapitalization</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" scale="3" unitRef="usd" id="ixv-22915">54</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Pre-Closing Financing and reverse recapitalization issuance costs included in accounts payable</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable" scale="3" unitRef="usd" id="ixv-22916">150</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">PIPE Financing issuance costs included in accounts payable</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable" scale="3" unitRef="usd" id="ixv-22917">374</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">PIPE Financing issuance costs included in accrued expenses and other current liabilities</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties" scale="3" unitRef="usd" id="ixv-22918">6</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Non-cash accrued interest on convertible note converted to common stock</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" scale="3" unitRef="usd" id="ixv-22919">1,468</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Non-cash exchange of Pre-Merger Oruka Series A Preferred Stock for Company Series B Convertible Preferred Stock</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" unitRef="usd" id="ixv-22920">2,931</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these condensed consolidated financial statements.<span style="clear: both; display: block;"><br/></span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="b_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ORUKA
THERAPEUTICS, INC.<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(UNAUDITED)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_1" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="ixv-18338"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>1.
Nature of the Business and Basis of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Background
and Basis of Presentation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Oruka
Therapeutics, Inc., together with its subsidiaries (collectively, the &#8220;Company&#8221;), formerly known as ARCA biopharma, Inc.
(&#8220;ARCA&#8221;), is an early-stage biotechnology company that is the result of the reverse recapitalization discussed below. Prior
to the reverse recapitalization, the private company Oruka Therapeutics, Inc. (&#8220;Pre-Merger Oruka&#8221;) was established and incorporated
under the laws of the state of Delaware on February&#160;6, 2024 (referred to in the Notes as the inception of the Company). The Company
is headquartered in Menlo Park, California. The Company is focused on developing biologics to optimize the treatment of inflammatory
skin diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">These
condensed consolidated financial statements reflect, in the opinion of management, all adjustments of a normal and recurring nature that
are necessary for a fair statement of the Company&#8217;s financial position as of September 30, 2024, and its results of operations
for the three months ended September 30, 2024 and from February 6, 2024 (inception) to September 30, 2024, and cash flows for the period
from February 6, 2024 (inception) to September 30, 2024. The condensed balance sheet as of February 6, 2024, included in the condensed
consolidated balance sheets was derived from the Company&#8217;s audited financial statements. The condensed consolidated financial statements
and accompanying notes are prepared in accordance with United States (&#8220;U.S.&#8221;) generally accepted accounting principles (&#8220;GAAP&#8221;)
for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;)
and therefore do not include all information and disclosures normally included in the annual consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
results for the three months ended September 30, 2024 and the period from February 6, 2024 (inception) to September 30, 2024 are not
necessarily indicative of results expected for the full fiscal year or any subsequent interim period. The condensed consolidated financial
statements include the financial statements of its wholly-owned subsidiaries. All significant intercompany balances and transactions
have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Reverse
Recapitalization and Pre-Closing&#160;Financing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">On
August 29, 2024, the Company consummated the previously announced business combination (&#8220;Closing&#8221;) pursuant to that certain
Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the &#8220;Merger Agreement&#8221;), by and among ARCA, Atlas Merger
Sub Corp, a wholly owned subsidiary of ARCA (&#8220;First Merger Sub&#8221;), Atlas Merger Sub II, LLC, a wholly owned subsidiary of
ARCA (&#8220;Second Merger Sub&#8221;) and Pre-Merger Oruka, pursuant to which, among other matters, Pre-Merger Oruka merged with and
into First Merger Sub, with Pre-Merger Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger
(&#8220;First Merger&#8221;) and following that, Pre-Merger Oruka then merged with and into Second Merger Sub, with Second Merger Sub
being the surviving entity of the second merger (the &#8220;Second Merger&#8221; and together with the First Merger, the &#8220;Merger&#8221;).
Following consummation of the Merger, the Company effected a 1-for-12 reverse stock split (the &#8220;Reverse Stock Split&#8221;) of
the common stock, par value $<ix:nonFraction contextRef="c105" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22921">0.001</ix:nonFraction> per share, of the Company (&#8220;Company Common Stock&#8221;), which became effective on September
3, 2024. The Company Common Stock commenced trading on a post-Reverse Stock Split, post-Merger basis at the opening of trading on September
3, 2024. Second Merger Sub changed its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA changed its
name to &#8220;Oruka Therapeutics, Inc.&#8221; The Company is led by the Pre-Merger Oruka management team and remains focused on developing
biologics to optimize the treatment of inflammatory skin diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Immediately
prior to the execution and delivery of the Merger Agreement on April 3, 2024, certain new and existing investors of Pre-Merger Oruka
entered into a subscription agreement with Pre-Merger Oruka (the &#8220;Subscription Agreement&#8221;), pursuant to which, and on the
terms and subject to the conditions of which, immediately prior to the Closing, those investors purchased shares of common stock of Pre-Merger
Oruka (&#8220;Pre-Merger Oruka Common Stock&#8221;) and Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $<ix:nonFraction contextRef="c106" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="6" unitRef="usd" id="ixv-22922">275.0</ix:nonFraction>
million (which includes $<ix:nonFraction contextRef="c107" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" unitRef="usd" id="ixv-22923">25.0</ix:nonFraction> million of proceeds previously received from the issuance of the Convertible Note (as defined in Note 6)
and accrued interest on such note which converted to shares of Pre-Merger Oruka Common Stock) (the &#8220;Pre-Closing Financing&#8221;).
The Company incurred transaction costs of $<ix:nonFraction contextRef="c108" decimals="-5" format="ixt:num-dot-decimal" name="orka:AdditionalPaidInCapitalTransacationCost" scale="6" unitRef="usd" id="ixv-22924">20.5</ix:nonFraction> million which was recorded as a reduction to additional paid-in capital in the unaudited
condensed consolidated financial statements. At the Closing, the shares of Pre-Merger Oruka Common Stock and Pre-Merger Oruka pre-funded
warrants issued pursuant to the Subscription Agreement were converted into shares of Company Common Stock and pre-funded warrants of
Company Common Stock in accordance with the Exchange Ratio (defined below).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_2" id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In accordance with an Exchange Ratio determined
by terms of the Merger Agreement and upon the effective time of the First Merger (the &#8220;First Effective Time&#8221;), (i) each then-issued
and outstanding share of Pre-Merger Oruka Common Stock including outstanding and unvested Pre-Merger Oruka restricted stock and shares
of Pre-Merger Oruka Common Stock issued in connection with the Subscription Agreement, were converted into the right to receive a number
of shares of Company Common Stock, equal to the Exchange Ratio of <ix:nonFraction contextRef="c109" decimals="4" format="ixt:num-dot-decimal" name="orka:ExchangeRatio" scale="0" unitRef="pure" id="ixv-22925">6.8569</ix:nonFraction> shares of Company Common Stock, which were subject to the same
vesting provisions as those immediately prior to the Merger, (ii) each share of Pre-Merger Oruka Series A convertible preferred stock,
par value $<ix:nonFraction contextRef="c110" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22926">0.0001</ix:nonFraction> (&#8220;Pre-Merger Oruka Series A Preferred Stock&#8221;), outstanding immediately prior to the First Effective Time
was converted into the right to receive a number of shares of ARCA Series B non-voting convertible preferred stock, par value $<ix:nonFraction contextRef="c111" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22927">0.001</ix:nonFraction> per
share (&#8220;Company Series B Preferred Stock&#8221;), which are convertible into shares of Company Common Stock, at a conversion ratio
of approximately 83:3332:1 (iii) each outstanding option to purchase Pre-Merger Oruka Common Stock was converted into an option to purchase
shares of Company Common Stock, (iv) each outstanding warrant to purchase shares of Pre-Merger Oruka Common Stock was converted into a
warrant to purchase shares of Company Common Stock, and (v) each share of Company Common Stock issued and outstanding at the First Effective
Time remain issued and outstanding in accordance with its terms and such shares. Subsequent to the close of the merger, the common stock
shares were then, subject to the reverse stock split of 1-for-12 effected on September 3, 2024. Net loss per share for periods prior to
the close of the reverse recapitalization has been revised to reflect the exchange ratio. After applying the exchange ratio and the reverse
stock split, net loss per share for the periods from February 6, 2024 (inception) to March 31, 2024 and for three months ended June 30,
2024 and from February 6, 2024 (inception) to June 30, 2024 are $(<ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-22928">2.21</ix:nonFraction>), $(<ix:nonFraction contextRef="c113" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-22929">6.96</ix:nonFraction>), and $(<ix:nonFraction contextRef="c114" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-22930">9.17</ix:nonFraction>), respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
part of the Pre-Closing Financing and the Closing, investors in the Pre-Closing Financing received <ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-22931">22,784,139</ix:nonFraction> shares of Company Common
Stock in exchange for <ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="orka:CommomStockExchange" scale="0" unitRef="shares" id="ixv-22932">39,873,706</ix:nonFraction> shares of Pre-Merger Oruka Common Stock (which includes the issuance of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" unitRef="shares" id="ixv-22933">2,722,207</ix:nonFraction> shares of Company
Common Stock in exchange for <ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="orka:CommomStockExchange" scale="0" unitRef="shares" id="ixv-22934">4,764,032</ix:nonFraction> shares of Pre-Merger Oruka Common Stock on the conversion of Convertible Note along with the accrued
interest through the conversion date) and <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="orka:PreFundedWarrantsOfCommonStockShares" scale="0" unitRef="shares" id="ixv-22935">5,522,207</ix:nonFraction> Company pre-funded warrants in exchange for <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightUnissued" scale="0" unitRef="shares" id="ixv-22936">9,664,208</ix:nonFraction> Pre-Merger pre-funded warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Merger was accounted for as a reverse recapitalization
in accordance with U.S. GAAP. Under this method of accounting, Pre-Merger Oruka was deemed to be the accounting acquirer for financial
reporting purposes. This determination was primarily based on the fact that, immediately following the Merger: (i) Pre-Merger Oruka stockholders
own a substantial majority of the voting rights in the combined company; (ii) Pre-Merger Oruka&#8217;s largest stockholders retain the
largest interest in the combined company; (iii) Pre-Merger Oruka designated a majority of the initial members of the board of directors
of the combined company; and (iv) Pre-Merger Oruka&#8217;s executive management team became the management team of the combined company.
Accordingly, for accounting purposes: (i) the Merger was treated as the equivalent of Pre-Merger Oruka issuing stock to acquire the net
assets of ARCA, and (ii) the reported historical operating results of the combined company prior to the Merger are those of Pre-Merger
Oruka. Additional information regarding the Merger is included in Note 3.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">On
September 3, 2024, the Company effected the Reverse Stock Split, a 1-for-12 reverse stock split of Company Common Stock. The par value
per share and the number of authorized shares were not adjusted as a result of the Reverse Stock Split. The shares of Company Common
Stock underlying outstanding stock options, common stock warrants and other equity instruments were proportionately reduced and the respective
exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.
All references to common stock, options to purchase common stock, outstanding common stock warrants, common stock share data, per share
data, and related information contained in the condensed consolidated financial statements have been retrospectively adjusted to reflect
the effect of the Reverse Stock Split for all periods presented, unless otherwise specifically indicated or the context otherwise requires.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>PIPE
Financing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On September 11, 2024, the Company entered into
a Securities Purchase Agreement for a private placement (the &#8220;PIPE Financing&#8221;) with certain institutional and accredited investors.
The closing of the PIPE Financing occurred on September 13, 2024.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Pursuant to the Securities Purchase Agreement, the
investors purchased an aggregate of <ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="orka:NumberOfSharesPurchased" scale="0" unitRef="shares" id="ixv-22937">5,600,000</ix:nonFraction> shares of Company Common Stock at a purchase price of $<ix:nonFraction contextRef="c117" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22938">23.00</ix:nonFraction> per share, an aggregate of
<ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-22939">2,439</ix:nonFraction> shares of the Company&#8217;s Series A non-voting convertible preferred stock, par value $<ix:nonFraction contextRef="c117" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22940">0.001</ix:nonFraction> per share (&#8220;Company Series
A Preferred Stock&#8221;), at a purchase price of $<ix:nonFraction contextRef="c119" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SupplementalDeferredPurchasePrice" scale="0" unitRef="usd" id="ixv-22941">23,000.00</ix:nonFraction> per share (each Company Series A Preferred Stock is convertible into <ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" unitRef="shares" id="ixv-22942">1,000</ix:nonFraction>
shares of Company Common Stock), and pre-funded warrants to purchase an aggregate of <ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-22943">680,000</ix:nonFraction> shares of Company Common Stock at a purchase
price of $<ix:nonFraction contextRef="c122" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22944">22.999</ix:nonFraction> per pre-funded warrant, for aggregate net proceeds of approximately $<ix:nonFraction contextRef="c123" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="6" unitRef="usd" id="ixv-22945">188.7</ix:nonFraction> million (net of issuance costs of $<ix:nonFraction contextRef="c123" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="6" unitRef="usd" id="ixv-22946">11.8</ix:nonFraction> million).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Liquidity
and Going Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Since
its inception, the Company has devoted substantially all of its resources to advancing the development of its portfolio of programs,
organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations.
Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and
regulatory approvals to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever,
the Company expects to finance its operating activities through a combination of equity offerings and debt financings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative
cash flows from operations since inception. The Company has incurred a net loss of $<ix:nonFraction contextRef="c13" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" sign="-" unitRef="usd" id="ixv-22947">28.6</ix:nonFraction> million for the three months ended September
30, 2024 and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" sign="-" unitRef="usd" id="ixv-22948">57.9</ix:nonFraction>&#160;million during the period from February&#160;6, 2024 (inception) to September 30, 2024. For the period from February
6, 2024 (inception) to September 30, 2024, the Company used net cash of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="6" unitRef="usd" id="ixv-22949">39.0</ix:nonFraction> million for its operating activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, the Company had cash and cash equivalents of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" unitRef="usd" id="ixv-22950">410.9</ix:nonFraction> million. The Company&#8217;s management expects that the existing
cash and cash equivalents will be sufficient to fund the Company&#8217;s operating plans for at least twelve months from the date these
condensed consolidated financial statements were issued. The Company expects that its research and development and general and administrative
costs will continue to increase significantly, including in connection with conducting future pre-clinical activities and clinical trials
and manufacturing for its existing product candidates and any future product candidates to support commercialization and providing general
and administrative support for its operations, including the costs associated with operating as a public company. The Company&#8217;s
ability to access capital when needed is not assured and, if capital is not available to the Company when, and in the amounts needed,
the Company may be required to significantly curtail, delay or discontinue one or more of its research or development programs or the
commercialization of any product candidate, or be unable to expand its operations or otherwise capitalize on the Company&#8217;s business
opportunities, as desired, which could materially harm the Company&#8217;s business, financial condition and results of operations.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-18468"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>2.
Summary of Significant Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-18476"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Use
of Estimates</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
preparation of the Company&#8217;s condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management
to make estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent
liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the
reporting periods. Significant estimates and assumptions reflected within these condensed consolidated financial statements include but
are not limited to research and development expenses and related prepaid or accrued costs and the valuation of stock-based compensation
awards and related expenses. The Company bases its estimates on known trends and other market-specific or other relevant factors that
it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in
circumstances, facts, and experience. Actual results could differ materially from those estimates or assumptions.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-18490"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Concentrations
of Credit Risk and Other Risks and Uncertainties</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s cash and cash equivalents are maintained with financial institutions in the United&#160;States of America. Cash balances
are held at financial institutions and account balances may exceed federally insured limits. To date, the Company has not experienced
any losses on its cash and cash equivalents and periodically evaluates the creditworthiness of its financial institutions.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_3" id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company manages credit risk associated with its investment portfolio through its investment policy, which limits investments to high-quality
issuers and limits the amount of its portfolio that can be invested in a single issuer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company is dependent on third-party organizations to research, develop, manufacture, and process its product candidates for its development
programs, including its two most advanced programs, ORKA-001 and ORKA-002. The Company expects to continue to be dependent on a small
number of manufacturers to supply it with its requirements for all products. The Company&#8217;s research and development programs could
be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#8217;s
research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) (see Note&#160;10).</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-18528"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Cash
and Cash Equivalents</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The cash equivalents were comprised of investments in money market funds.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DebtPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtPolicyTextBlock" id="ixv-18542"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Debt
Issuance Costs</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DebtPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Debt
issuance costs incurred in connection with the Convertible Note (see Note&#160;6) are recorded as a reduction of the carrying value of
the notes payable liability on the Company&#8217;s balance sheet and are amortized to interest expense over the term of the loan using
the effective interest method.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="orka_SubscriptionReceivablePolicyTextBlock-c0_cont_1" escape="true" name="orka:SubscriptionReceivablePolicyTextBlock" id="ixv-18555"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Subscription
Receivable</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="orka_SubscriptionReceivablePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable
is paid prior to the date the financial statement is available to be issued.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-18569"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Fair
Value Measurements</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Certain
assets and liabilities are carried at fair value under U.S.&#160;GAAP.&#160;Fair value is defined as the exchange price that would be
received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are
to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered
observable and the last is considered unobservable:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 24pt"/><td style="width: 24pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#160;1
&#8212;&#160;Quoted prices in active markets that are identical assets or liabilities.</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 24pt"/><td style="width: 24pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#160;2&#160;&#8212;&#160;Observable
inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in
markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated
by observable market data.</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 24pt"/><td style="width: 24pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#160;3&#160;&#8212;&#160;Unobservable
inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities,
including pricing models, discounted cash flow methodologies, and similar techniques.</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note
4). The carrying values of the Company&#8217;s prepaid expenses and other current assets, accounts payable and accrued expenses and other
current liabilities approximate their fair values due to their relatively short maturity period.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-18616"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Property
and Equipment</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-18625"><span style="font-family: Times New Roman, Times, Serif">Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:</span></ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c0_cont_1"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
Useful&#160;Life</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman, Times, Serif; width: 83%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c124" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22951">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c125" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22952">5</ix:nonNumeric> years</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    and office equipment</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c126" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22953">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c127" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22954">5</ix:nonNumeric> years</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_1" escape="true" name="orka:ClassificationOfConvertiblePreferredStockPolicyTextBlock" id="ixv-18679"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Classification
of Convertible Preferred Stock</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_2" id="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Prior to the reverse recapitalization, the Company
had classified its Pre-Merger Oruka Series A Preferred Stock outside of stockholders&#8217; equity (deficit) on the Company&#8217;s condensed
consolidated balance sheet because the holders of such stock have certain liquidation rights in the event of a deemed liquidation event
that, in certain situations, is not solely within the control of the Company and would require the redemption of the then-outstanding
convertible preferred stock.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_3" id="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Upon the closing of the Merger, the Company converted
its Pre-Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and has classified the Company Series B Preferred Stock
within stockholders&#8217; equity (deficit) on its condensed consolidated balance sheet because the Company Series B Preferred Stock is
not redeemable or puttable to the Company by the holder under any circumstances.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In connection with the PIPE Financing (see Note
1) the Company issued Company Series A Preferred Stock, and has classified the Company Series A Preferred Stock outside of stockholders&#8217;
equity (deficit) on the Company&#8217;s condensed consolidated balance sheet because the holders of such stock have certain rights (see
Note 7) that, in certain situations, is not solely within the control of the Company and would require the redemption of the then-outstanding
convertible preferred stock.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="orka_NotePayableToRelatedPartyPolicyTextBlock-c0_cont_1" escape="true" name="orka:NotePayableToRelatedPartyPolicyTextBlock" id="ixv-18697"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Note&#160;Payable to Related Party</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="orka_NotePayableToRelatedPartyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company accounted for the Convertible Note (as
defined in Note 6) at amortized cost. The Company considered if optional conversion features are required to be bifurcated and separately
accounted for as a derivative. Costs related to the issuance of the Convertible Note were recorded as a debt discount, amortized over
the term of the Convertible Note (see&#160;Note&#160;6) and were accounted as interest expense in other income (expenses) within the condensed
consolidated statements of operations and comprehensive loss using the effective interest method. At the effective time of the Merger,
shares of Pre-Merger Oruka Common Stock issued pursuant to the conversion of the Convertible Note (including accrued interest) automatically
converted into shares of Company Common Stock (see Note 1).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c0" continuedAt="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock-c0_cont_1" escape="true" name="orka:ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" id="ixv-18707"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development Contract Costs Accruals</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock-c0_cont_2" id="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company records the costs associated with research
studies and manufacturing development as incurred. These costs are a significant component of the Company&#8217;s research and development
expenses, with a substantial portion of the Company&#8217;s ongoing research and development activities conducted by third-party service
providers, including contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;),
and the Company&#8217;s related-party Paragon (see Note&#160;10).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company accrues for expenses resulting from
obligations under its two antibody discovery and option agreements (the &#8220;Option Agreements&#8221;) (see Note 10), by and among Paragon,
Paruka Holding LLC (&#8220;Paruka&#8221;), an entity formed by Paragon as a vehicle to hold equity in the Company, and the Company as
well as agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials
or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to
agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted
amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers
as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual
balance in each reporting period. If advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will
be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result
in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations. As of September
30, 2024, the Company has not experienced any material deviations between accrued and actual research and development expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p></ix:continuation></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-18741"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Leases</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">At
the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies
a lease as either an operating or finance lease and recognizes a right-of-use (&#8220;ROU&#8221;) asset and a current and non-current
lease liability, as applicable, in the balance sheet if the lease has a term greater than <ix:nonNumeric contextRef="c3" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-22955">one year</ix:nonNumeric>. Lease terms may include options to
extend or terminate the lease when it is reasonably certain that the Company will exercise its option.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_3" id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">At
the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future
minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit
rate, if it is readily determinable, or the risk-free discount rate for a period comparable with that of the lease term. For operating
leases, lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, lease expense
includes amortization expense of the ROU asset recognized on a straight-line basis over the lease term and interest expense recognized
on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments,
incentives received or initial direct costs. As of September 30, 2024, the Company has one operating lease and no finance leases.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for lease and non-lease components related to operating leases as a single lease component. The Company has elected
that costs associated with leases having an initial term of 12 months or less are recognized in the condensed consolidated statement
of operations and comprehensive loss on a straight-line basis over the lease term and are not recorded on its condensed consolidated
balance sheets. Variable lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office
space related expenses.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-18763"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Segment
Reporting</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions.
The Company&#8217;s chief executive officer, who is the chief operating decision maker (the &#8220;CODM&#8221;), reviews the Company&#8217;s
financial information on an aggregated basis for purposes of evaluating financial performance and allocating resources.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-18775"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development Costs</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_2" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Research
and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock-based compensation,
employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated
human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Nonrefundable
advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid
expenses on the accompanying condensed consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered
or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable
advance payments represent a one-time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of
period end, the payment is expensed immediately.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="ixv-18794"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>General
and Administrative Expenses</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">General and administrative expenses consist primarily
of salaries and bonuses, stock-based compensation, employee benefits, finance and administration costs, patent and intellectual property
costs, professional fees, as well as allocated human resource costs, information technology costs, and facility-related costs, including
rent, maintenance, utilities and depreciation.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="ixv-18807"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Commitments
and Contingencies</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities.
The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the
loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the
balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but
not probable; however, it discloses the range of reasonably possible losses. As of September 30, 2024, no liabilities were recorded for
loss contingencies (see Note&#160;11).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-18839"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock-Based
Compensation</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company measures all stock-based awards granted to employees, directors, and non-employees in the form of stock options to purchase shares
of its common stock, based on the fair value of the awards on the date of grant using the Black-Scholes option-pricing model. The Company
measures restricted common stock awards (&#8220;RSAs&#8221;) using the difference, if any, between the purchase price per share of the
award and the fair value of the Company&#8217;s common stock at the date of grant.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company grants stock options, restricted stock awards, and warrants that are subject to service or performance-based vesting conditions.
Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line
method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards
to non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for
the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each
reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation
expense until it is probable that the performance-based vesting condition will be achieved.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company has issued stock options, warrants,
and RSAs with service-based and performance-based vesting conditions.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_5" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan (&#8220;ESPP&#8221;),
based on the fair value of the common stock estimated using the closing price of the Company&#8217;s common stock as reported on the
date of offering, less the purchase discount percentage provided for in the plan.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company classifies stock-based compensation expense in its condensed consolidated statement of operations and comprehensive loss in the
same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments
are classified.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-18872"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Net Loss per Share Attributable to Stockholders</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Basic and diluted net loss attributable to stockholders
per share is presented in conformity with the two-class method required for participating securities (Pre-Merger Oruka Series A Preferred
Stock). Basic earnings per share is computed by dividing net income available to each class of shares by the weighted-average number of
shares of common stock and participating securities outstanding during the period. Pre-funded warrants were included as the exercise price
is negligible and these warrants are fully vested and exercisable. Company Series A Preferred Stock and Company Series B Preferred Stock
share the same characteristics as Common Stock and have no substantive preference attributed to them and, accordingly, have been considered
as classes of Common Stock in the computation of net loss per share regardless of their legal form.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Net loss is allocated to common stock based on
its proportional ownership on an as-converted basis. Net loss is not allocated to participating securities as they do not have an obligation
to fund losses. The weighted-average number of shares outstanding of common stock reflects changes in ownership over the periods presented.
See Note 7&#8212; Convertible Preferred Stock and Stockholders&#8217; Equity.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_4" id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Diluted net loss per share is computed by dividing
the net loss attributable to stockholders adjusted for income (expenses), net of tax, related to any diluted securities, by the weighted-average
number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of this calculation, stock
options to purchase common stock, employee warrants to purchase common stock, and unvested RSAs are considered potential dilutive common
shares.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company generated a net loss for the periods presented. Accordingly,
basic and diluted net loss per share is the same because the inclusion of the potentially dilutive securities would be anti-dilutive.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-18893"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Income
Taxes</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#8217;s tax
returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis
of assets and liabilities using enacted tax rates in effect for the&#160;years in which the differences are expected to reverse. Changes
in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred
tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence,
that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established
through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for uncertainty in income taxes recognized in the condensed consolidated financial statements by applying a two-step
process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood
that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to
be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the condensed consolidated financial
statements. The amount of the benefit that may be recognized is the largest amount that has a greater than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-22956">50</ix:nonFraction>% likelihood of being realized
upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits,
that are considered appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or
penalties related to uncertain tax positions as of September 30, 2024.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-18926"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Recently
Issued Accounting Pronouncements</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In November&#160;2023, the Financial Accounting
Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, <i>Segment Reporting</i> (<i>Topic&#160;280</i>)<i>:
Improvements to Reportable Segment Disclosures</i> (&#8220;ASU&#160;2023-07&#8221;), which enhances the segment disclosure requirements
for public entities on an annual and interim basis. Under this proposal, public entities will be required to disclose significant segment
expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss. Additionally, current
annual disclosures about a reportable segment&#8217;s profit or loss and assets will be required on an interim basis. Entities will also
be required to disclose information about the CODM&#8217;s title and position at the Company along with an explanation of how the CODM
uses the reported measures of segment profit or loss in their assessment of segment performance and deciding how to allocate resources.
Finally, ASU&#160;2023-07 requires all segment disclosures for public entities that have only a single reportable segment. The amendments
in ASU&#160;2023-07 are effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years
beginning after December&#160;15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of
this ASU on its consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In December&#160;2023, the FASB issued ASU&#160;2023-09,
<i>Income Taxes (Topic&#160;740): Improvements to Income Tax Disclosures</i>. This ASU expands disclosures in an entity&#8217;s income
tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.&#160;and foreign jurisdictions. This update is effective
beginning with the Company&#8217;s 2025 fiscal year annual reporting period. The Company is currently evaluating the impact of the adoption
of this ASU on its consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In November 2024, the FASB issued ASU 2024-03, <i>Income
Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement
Expenses</i>. This ASU requires more detailed disclosures, on an annual and interim basis, about specified categories of expenses (including
employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement.
This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December
15, 2027. Early adoption is permitted. This ASU may be applied either prospectively or retrospectively. The Company is currently evaluating
the impact of the adoption of this ASU on its consolidated financial statements.</p></ix:continuation></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="ixv-18952"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>3. Reverse
Recapitalization and Pre-Closing Financing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
described within the <i>Reverse Recapitalization and Pre-Closing Financing </i>section in Note 1, on August 29, 2024, the reverse recapitalization
between Pre-Merger Oruka and ARCA was consummated. The Merger was accounted for as a reverse recapitalization in accordance with U.S.
GAAP. At the effective time of the Merger, substantially all of the assets of ARCA consisted of cash and cash equivalents and other nominal
non-operating assets and liabilities. No goodwill or intangible assets were recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="ixv-18965"><span style="font-family: Times New Roman, Times, Serif">As
part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands):</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" unitRef="usd" id="ixv-22957">4,940</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="3" unitRef="usd" id="ixv-22958">114</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="orka:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" scale="3" unitRef="usd" id="ixv-22959">54</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Net assets acquired</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" unitRef="usd" id="ixv-22960">5,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-19017"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>4.
Fair Value Measurements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueAssetsMeasuredOnRecurringBasisTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="ixv-19025"><span style="font-family: Times New Roman, Times, Serif">The
following tables present the Company&#8217;s fair value hierarchy for financial assets measured as of September 30, 2024 (in thousands):</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:continuation id="_FairValueAssetsMeasuredOnRecurringBasisTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Fair Value Measurements as of September 30, 2024</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Level 1</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Level 2</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Level 3</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Total</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Financial assets:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 52%; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-size: 10pt">Money market funds</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c128" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-22961">403,322</ix:nonFraction></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-106; font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-107; font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c131" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-22962">403,322</ix:nonFraction></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">Total financial assets</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c132" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-22963">403,322</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-108; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-109; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-22964">403,322</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">There
were no transfers between Level&#160;1, Level&#160;2, or Level&#160;3 during the period from February 6, 2024 (inception) to September
30, 2024.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="ixv-19141"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>5. Accrued
Expenses and Other Current Liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAccruedLiabilitiesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="ixv-19148"><span style="font-family: Times New Roman, Times, Serif">Accrued
expenses and other current liabilities consisted of the following (in thousands):</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfAccruedLiabilitiesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September&#160;30,<br/>
                                            2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    employee compensation and benefits</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" unitRef="usd" id="ixv-22965">933</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    professional and consulting</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" unitRef="usd" id="ixv-22966">204</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    research and development</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="orka:AccruedResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-22967">573</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" unitRef="usd" id="ixv-22968">1,710</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-19215"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>6.
Note&#160;Payable with Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
March&#160;2024, the Company entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;)
with Fairmount Healthcare Fund&#160;II, L.P. (&#8220;Fairmount&#8221;), whereby the Company issued a convertible note (the &#8220;Convertible
Note&#8221;), with an initial principal amount of $<ix:nonFraction contextRef="c135" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" unitRef="usd" id="ixv-22969">25.0</ix:nonFraction> million that, at the time of issuance, could be converted into Pre-Merger Oruka
Series&#160;A Preferred Stock (or a series&#160;of preferred shares that is identical in respect to the shares of preferred shares issued
in its next equity financing) or shares of Pre-Merger Oruka Common Stock in exchange for aggregate proceeds of $<ix:nonFraction contextRef="c136" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" unitRef="usd" id="ixv-22970">25.0</ix:nonFraction>&#160;million. The
Convertible Note accrued interest at a rate of <ix:nonFraction contextRef="c137" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-22971">12.0</ix:nonFraction>% per annum. At issuance, the Convertible Note required all unpaid interest and principal
to mature on <ix:nonNumeric contextRef="c66" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-22972">December&#160;31, 2025</ix:nonNumeric> (the &#8220;Maturity Date&#8221;) and prepayment was not permitted without prior written consent
of Fairmount. At issuance, the principal payment along with the accrued interest on the Convertible Note was due in full on the Maturity
Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company assessed all terms and features of the Convertible Note in order to identify any potential embedded features that would require
bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the embedded features. The Company
determined that the share settled redemption feature was clearly and closely related to the debt host and did not require separate accounting.
The Company determined that the conversion options of the Convertible Note were not clearly and closely associated with a debt host.
However, these features did not meet the definition of a derivative under ASC&#160;815, <i>Derivatives and Hedging</i>, and as a result,
did not require separate accounting as a derivative liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company paid debt issuance costs of less than $<ix:nonFraction contextRef="c138" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" unitRef="usd" id="ixv-22973">0.1</ix:nonFraction>&#160;million in relation to the Convertible Note. The debt issuance costs were reflected
as a reduction of the carrying value of Convertible Note on the condensed consolidated balance sheet and were being amortized as interest
expense over the term of the Convertible Note using the effective interest method. For the three months ended September 30, 2024 and
the period from February&#160;6, 2024 (inception) to September 30, 2024, the Company recognized interest expenses related to the Convertible
Note of $<ix:nonFraction contextRef="c138" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" unitRef="usd" id="ixv-22974">0.5</ix:nonFraction> million and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" unitRef="usd" id="ixv-22975">1.5</ix:nonFraction> million, respectively, which includes non-cash interest expense related to the amortization of debt issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Immediately prior to the completion of the Merger
(see Note 1), the Convertible Note was converted into shares of Pre-Merger Oruka Common Stock based on the aggregate principal amount
of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" unitRef="usd" id="ixv-22976">25.0</ix:nonFraction> million, plus unpaid accrued interest of $<ix:nonFraction contextRef="c139" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="6" unitRef="usd" id="ixv-22977">1.5</ix:nonFraction> million divided by the conversion price which was determined based upon the Company&#8217;s
fully-diluted capitalization immediately prior to the Merger. At the effective time of the Merger, the Pre-Merger Oruka Common Stock issued
upon the conversion of the Convertible Note (including accrued interest) automatically converted into <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-22978">2,722,207</ix:nonFraction> shares of Company Common
Stock. As of September 30, 2024, the Convertible Note is not outstanding.</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PreferredStockTextBlock-c0_cont_1" escape="true" name="us-gaap:PreferredStockTextBlock" id="ixv-19252"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>7.
Convertible Preferred Stock and Stockholders&#8217; Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pre-Funded
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
August 2024, pursuant to the Subscription Agreement and immediately prior to the Closing, certain new and current investors purchased
pre-funded&#160;warrants, which, at the effective time of the Merger, were exercisable for <ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-22979">5,522,207</ix:nonFraction> shares of Company Common Stock at
a purchase price of approximately $<ix:nonFraction contextRef="c141" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-22980">9.70</ix:nonFraction> per warrant. After the Merger, there are <ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-22981">5,522,207</ix:nonFraction> pre-funded warrants outstanding and are exercisable
for <ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares" id="ixv-22982">5,522,207</ix:nonFraction> shares of the Company Common Stock at an exercise price of $<ix:nonFraction contextRef="c143" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-22983">0.01</ix:nonFraction> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
September 2024, in connection with the PIPE Financing, the Company issued and sold <ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-22984">680,000</ix:nonFraction> pre-funded warrants, at a purchase price of
$<ix:nonFraction contextRef="c145" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22985">22.999</ix:nonFraction> per warrant, exercisable for <ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-22986">680,000</ix:nonFraction> shares of Company Common Stock at an exercise price of $<ix:nonFraction contextRef="c146" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-22987">0.001</ix:nonFraction> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
pre-funded warrants were recorded as a component of stockholders&#8217; equity within additional paid-in-capital and have <span style="-sec-ix-hidden: hidden-fact-110">no</span> expiration
date. As of September 30, 2024, <span style="-sec-ix-hidden: hidden-fact-111">none</span> of the pre-funded warrants have been exercised and <ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-22988">6,202,207</ix:nonFraction> pre-funded warrants remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Employee
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
July 2024, Pre-Merger Oruka entered into a Subscription Agreement that provided for, among other things, the issuance of warrants to
certain of Pre-Merger Oruka&#8217;s employees, directors, and service providers immediately prior to the closing of the Merger. During
the three months ended September 30, 2024, <ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-22989">3,054,358</ix:nonFraction> employee warrants were issued at an exercise price of $<ix:nonFraction contextRef="c148" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-22990">7.80</ix:nonFraction> per warrant. These employee
warrants vest over a period of <ix:nonNumeric contextRef="c149" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="ixv-22991">four years</ix:nonNumeric>. Per the terms of the Employee Warrant Agreement, the holders of the Company&#8217;s employee
warrants shall not have any of the rights or privileges of a stockholder of the Company in respect of any shares purchasable upon the
exercise of the warrant or any portion thereof unless and until a certificate or certificates representing such shares have been issued
or a book entry representing such shares has been made and such shares have been deposited with the appropriate registered book-entry
custodian. The Company recognizes compensation cost related to employee warrants on a straight-line basis over the requisite service
period, which is the period in which the related services are received. As of September 30, 2024, <span style="-sec-ix-hidden: hidden-fact-112">none</span> of the employee warrants have
been exercised and <ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-22992">3,054,358</ix:nonFraction> employee warrants remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Convertible
Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In March&#160;2024, Pre-Merger Oruka issued and
sold an aggregate of <ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-22993">20,000,000</ix:nonFraction> shares of Pre-Merger Oruka Series&#160;A Preferred Stock to Fairmount (see Note 13), at a purchase price
of approximately $<ix:nonFraction contextRef="c151" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22994">0.15</ix:nonFraction> per share, for aggregate gross proceeds of $<ix:nonFraction contextRef="c152" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" unitRef="usd" id="ixv-22995">3.0</ix:nonFraction>&#160;million. Pre-Merger Oruka incurred less than $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" unitRef="usd" id="ixv-22996">0.1</ix:nonFraction>&#160;million
of issuance costs in connection with this transaction. Upon the issuance of the Pre-Merger Oruka Series&#160;A Preferred Stock, the Company
assessed the embedded conversion and liquidation features of the securities as described below and determined that such features did not
require the Company to separately account for these features.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
August 2024, upon the closing of the Merger, the Company converted the Pre-Merger Oruka Series A Preferred Stock to <ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-22997">137,138</ix:nonFraction> shares of
Company Series B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
September 2024, in connection with the PIPE Financing, the Company issued and sold an aggregate of <ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-22998">2,439</ix:nonFraction> shares of the Company Series
A Preferred Stock at a purchase price of $<ix:nonFraction contextRef="c154" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22999">23,000.00</ix:nonFraction> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock" id="ixv-19312"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, convertible preferred stock consisted of the following (in thousands, except share data):</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Preferred&#160;Stock<br/> Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Preferred&#160;Stock<br/> Issued and<br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Carrying<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common&#160;Stock<br/> Issuable Upon<br/> Conversion</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Series A Non-Voting Preferred Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c60" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23000">2,439</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c60" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-23001">2,439</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="3" unitRef="usd" id="ixv-23002">52,841</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockLiquidationPreferenceValue" scale="3" unitRef="usd" id="ixv-23003">2,439,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Series B Non-Voting Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c157" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23004">251,504</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c157" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-23005">137,138</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c157" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="3" unitRef="usd" id="ixv-23006">2,931</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c157" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockLiquidationPreferenceValue" scale="3" unitRef="usd" id="ixv-23007">11,428,149</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_PreferredStockTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Pursuant to the Certificate of Designation of Preferences,
Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the &#8220;Series A Certificate of Designation&#8221;)
filed in connection with the PIPE Financing, holders of Company Series A Preferred Stock are entitled to receive dividends on shares of
Company Series A Preferred Stock equal to, on an as-if-converted-to-Company Common Stock basis, and in the same form as, dividends actually
paid on shares of Company Common Stock. Except as provided in the Series A Certificate of Designation or as otherwise required by law,
the Company Series A Preferred Stock does not have voting rights. The Company Series A Preferred Stock shall rank on parity with the Company
Common Stock and Company Series B Preferred Stock upon any liquidation, dissolution or winding-up of the Company. Subject to the terms
and limitations contained in the Series A Certificate of Designation, the Company Series A Preferred Stock issued in the PIPE Financing
will not become convertible until the Company&#8217;s stockholders approve the conversion of the Company Series A Preferred Stock into
shares of Company Common Stock in accordance with the listing rules of the Nasdaq Stock Market (the &#8220;Stockholder Approval&#8221;),
which resulted in the Company Series A Preferred Stock being classified outside of stockholders&#8217; equity (deficit) on the Company&#8217;s
condensed consolidated balance sheet.. Following the Stockholder Approval, each share of Company Series A Preferred Stock will automatically
convert into 1,000 shares of Company Common Stock, subject to certain limitations, including that shares of Company Series A Preferred
Stock shall not be convertible if the conversion would result in a holder, together with its affiliates, beneficially owning more than
<ix:nonFraction contextRef="c155" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" unitRef="pure" id="ixv-23008">9.99</ix:nonFraction>% of the Company&#8217;s outstanding shares of Company Common Stock as of the applicable conversion date, which may be increased at
the holders&#8217; option (not to exceed <ix:nonFraction contextRef="c156" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" unitRef="pure" id="ixv-23009">19.99</ix:nonFraction>%), effective in accordance with the terms of the Series A Certificate of Designation. If,
at any time after the earlier of Stockholder Approval or six months after the initial issuance of the Series A non-voting preferred stock,
the Company fails to deliver to a holder such certificate or certificates, the Company shall, at the request of the holder, pay an amount
equal to the closing price of Company&#8217;s common stock on the trading day immediately prior to the date on which notice to conversion
is received by the Company (the &#8220;Fair Value&#8221;) of such undelivered shares, with such payment to be made within two business
days from the date of request by the holder, whereupon the Company&#8217;s obligations to deliver such shares underlying the notice of
conversion shall be extinguished upon payment in full of the Fair Value of such undelivered shares; provided, however that such request
shall be presumed to have been made by such holder if Stockholder Approval shall not have been obtained prior to the date on which the
notice of conversion is delivered to the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock (the
&#8220;Series B Certificate of Designation&#8221;) filed in connection with the Merger, holders of Company Series B Preferred Stock are
entitled to receive dividends on shares of Company Series B Preferred Stock equal to, on an as-if-converted-to-Company Common Stock basis,
and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series B Certificate of
Designation or as otherwise required by law, the Company Series B Preferred Stock does not have voting rights. The Company Series B Preferred
Stock shall rank on parity with the Company Common Stock as to the distribution of assets upon any liquidation, dissolution, or winding-up
of the Company. Each share of Company Series B Preferred Stock is convertible at the option of the holder, at any time, and without the
payment of additional consideration by the holder. As of September 30, 2024, each outstanding share of Company Series B Preferred Stock
was convertible into common stock at a ratio of approximately 83.3332:1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, the Certificate of Incorporation provides for <ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23010">545,000,000</ix:nonFraction> authorized shares of Company Common Stock. As of September
30, 2024, <ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-23011">34,988,550</ix:nonFraction> shares of Company Common Stock were issued and outstanding, including <ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-23012">2,207,553</ix:nonFraction> shares of RSAs issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" id="ixv-23013">As
of September 30, 2024, the Company had common stock reserved for future issuance as follows:</ix:nonNumeric>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September&#160;30,<br/>
                                            2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares
    issuable on conversion of Company Series A Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c158" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-23014">2,439,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares
    issuable on conversion of Company Series B Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c159" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-23015">11,428,149</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Shares issuable upon
    exercise of pre-funded warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="orka:SharesIssuableUponExerciseOfPrefundedWarrants" scale="0" unitRef="shares" id="ixv-23016">6,202,207</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    and issued stock options</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-23017">1,287,760</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    and issued employee warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-23018">3,054,358</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares
    available for grant under 2024 Stock Incentive Plan</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c160" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-23019">4,526,324</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Shares
    available for grant under 2024 Employee Stock Purchase Plan</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c161" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-23020">463,489</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total
    shares of common stock reserved</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c161" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-23021">29,401,287</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-19525"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>8.
Stock-Based Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>2024
Equity Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
2024 Equity Incentive Plan (&#8220;2024 Plan&#8221;) was adopted by the board of directors of Pre-Merger Oruka on February&#160;6, 2024.
The 2024 Plan provided for Pre-Merger Oruka to grant stock options, restricted stock awards, restricted stock units, and other stock-based
awards to employees, officers, directors, consultants, and advisors. Equity Incentive Stock options granted under the 2024 Plan generally
vest over four&#160;years, subject to the participant&#8217;s continued service, and expire after ten&#160;years, although stock options
have been granted with vesting terms less than four&#160;years. As of September 30, 2024, there are no shares of common stock available
for issuance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>2024
Stock Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">On
August 22, 2024, the 2024 Stock Incentive Plan (&#8220;2024 Stock Plan&#8221;) was approved by the Company&#8217;s stockholders and on
August 29, 2024, the board of directors of the Company (the &#8220;Board&#8221;) ratified the 2024 Stock Plan. The 2024 Stock Plan allows
for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stockholder-based awards
and incentive bonuses. The 2024 Stock Plan is administered by the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;)
or another committee designated by the Board to administer the Plan. The initial share pool under the 2024 Stock Plan is <ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-23022">4,634,891</ix:nonFraction> shares
of Company Common Stock and as of September 30, 2024, there are <ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-23023">4,526,324</ix:nonFraction> shares available in the pool. The shares that may be issued
under the 2024 Stock Plan will be automatically increased on January 1 of each year beginning in 2025 and ending with a final increase
on January 1, 2034 in an amount equal to <ix:nonFraction contextRef="c164" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" unitRef="pure" id="ixv-23024">5</ix:nonFraction>% of the diluted stock (including Company Common Stock, preferred stock and unexercised pre-funded
warrants) on the preceding December 31, unless a lower, or no, increase is determined by the Compensation Committee. Current or prospective
employees, officers, non-employee directors, and other independent service providers of the Company and its subsidiaries are eligible
to participate in the 2024 Stock Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>2024
Employee Stock Purchase Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
2024 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was approved by the board of directors of ARCA on July 20, 2024, and by ARCA&#8217;s
stockholders on August 22, 2024. The ESPP became effective on August 29, 2024, at which time <ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" unitRef="shares" id="ixv-23025">463,489</ix:nonFraction> shares were reserved for issuance.
The shares that may be issued under the ESPP will be automatically increased on January 1 of each year beginning in 2025 and ending with
a final increase on January 1, 2034 in an amount equal to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" unitRef="pure" id="ixv-23026">1</ix:nonFraction>% of the diluted stock (including Company Common Stock, preferred stock and
unexercised pre-funded warrants) on the preceding December 31, unless a lower, or no, increase is determined by the Compensation Committee.
As of September 30, 2024, no shares have been issued out of the ESPP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock
Option Valuation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock-c0_cont_1" escape="true" name="orka:ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock" id="ixv-19592"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the three months ended
September 30, 2024 and for the period from February&#160;6, 2024 (inception) to September 30, 2024:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three<br/> Months Ended <br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period from <br/> February&#160;6,<br/> 2024 <br/> (Inception)<br/> to <br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (in&#160;years)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonNumeric contextRef="c176" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-19636"><span style="font-family: Times New Roman, Times, Serif">6.1</span></ix:nonNumeric></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonNumeric contextRef="c177" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-19645"><span style="font-family: Times New Roman, Times, Serif">6.1</span></ix:nonNumeric></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c176" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-23027">97.3</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c177" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-23028">101.0</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c176" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-23029">3.5</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c177" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-23030">4.3</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-113; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-114; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-19715"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February&#160;6, 2024
(inception) through September 30, 2024:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Stock Options</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Exercise<br/> Price Per<br/> Share</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term (in&#160;Years)</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/> Intrinsic<br/> Value (in&#160;Thousands)</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance as of February&#160;6, 2024 (inception)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-115; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-116; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-117; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-118; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; width: 52%; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-23031">1,287,760</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-23032">7.97</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-23033">1,287,760</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-23034">7.97</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-19935"><span style="font-family: Times New Roman, Times, Serif">9.6</span></ix:nonNumeric></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd" id="ixv-23035">21,507</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested and expected to vest, September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-23036">1,287,760</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-23037">7.97</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-19971"><span style="font-family: Times New Roman, Times, Serif">9.6</span></ix:nonNumeric></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" unitRef="usd" id="ixv-23038">21,507</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable, September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-124; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-126; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
weighted average grant-date fair value per share of stock options granted during the period from February&#160;6, 2024 (inception) to
September 30, 2024 was $<ix:nonFraction contextRef="c166" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-23039">6.44</ix:nonFraction> per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying
Company Common Stock and the exercise price of outstanding, in-the-money employee stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Restricted
Stock Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
February 2024 and March&#160;2024, the Company issued <ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-23040">2,207,553</ix:nonFraction> shares of RSAs to certain employees, directors, and consultants at a
price of $<ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" scale="0" unitRef="usdPershares" id="ixv-23041">0.0001</ix:nonFraction> per share, the then par value of Pre-Merger Oruka Common Stock. Such RSAs have service-based vesting conditions only
and vest over a four-year period, during which time all unvested shares are subject to forfeiture in the event the holder&#8217;s service
with the Company voluntarily or involuntarily terminates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="ixv-20052"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the RSAs activity for the period from February&#160;6, 2024 (inception) through September 30, 2024:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of<br/> RSAs</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/>
                                            Average<br/> Grant Date<br/> Fair Value</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Unvested balance
    as of February&#160;6, 2024 (inception)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-127; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-128; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; width: 76%; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c179" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-23042">2,207,553</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-129; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Unvested
    balance as of September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c180" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares" id="ixv-23043">2,207,553</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-130; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Option
Agreements and Paruka Warrant Obligation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In March&#160;2024, the Company entered into antibody
discovery and option agreements with Paragon and Paruka (the &#8220;Option Agreements&#8221;). Under the terms of Option Agreements, Paragon
identifies, evaluates, and develops antibodies directed against certain mutually agreed therapeutic targets of interest to the Company,
and the Company has the exclusive option to, on a research program-by-research program basis, be granted an exclusive, worldwide license
to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable research program
to develop, manufacture and commercialize the antibodies and products directed to the selected target(s). Paruka will be entitled to grants
of warrants to purchase a number of shares equal to <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="orka:SharesOutstandingPercentage" scale="-2" unitRef="pure" id="ixv-23044">1.00</ix:nonFraction>% of then outstanding shares of the Company&#8217;s stock, on a fully diluted
basis, on December&#160;31, 2024 and December&#160;31, 2025, at the fair market value determined by the Board (the &#8220;Paruka Warrant
Obligation&#8221;). The grant dates for the issuance of warrants are expected to be December&#160;31, 2024 and December&#160;31, 2025
as all terms of the award, including number of shares and exercise price, will be known by all parties. The service inception period for
the grant precedes the grant date, with the full award being vested as of the grant date with no post-grant date service requirement.
Accordingly, the warrants expected to be granted to Paruka were accounted for as a liability on the condensed balance sheet and, after
the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded
in the statement of operations and comprehensive loss as stock-based compensation expenses under research and development expenses. As
of September 30, 2024, the estimated fair value of warrants to be granted on December 31, 2024 was $<ix:nonFraction contextRef="c168" decimals="-5" format="ixt:num-dot-decimal" name="orka:EstimatedFairValueOfWarrantsToBeGranted" scale="6" unitRef="usd" id="ixv-23045">11.0</ix:nonFraction> million. For the three months
ended September 30, 2024 and the period from February 6, 2024 (inception) to September 30, 2024, $<ix:nonFraction contextRef="c169" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd" id="ixv-23046">7.3</ix:nonFraction> million and $<ix:nonFraction contextRef="c170" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd" id="ixv-23047">7.7</ix:nonFraction> million were recognized
as stock-based compensation expenses related to the Paruka Warrant Obligation, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Employee
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">As stated above, on July 3, 2024, the Subscription
Agreement was amended and restated, among other things, for employee warrants to be issued to certain Pre-Merger Oruka&#8217;s employees,
directors, and service providers, immediately prior to the closing of the Merger. Pursuant to this amendment, during the three months
ended September 30, 2024, the Company issued <ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-23048">3,054,358</ix:nonFraction> employee warrants at an exercise price of $<ix:nonFraction contextRef="c148" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-23049">7.80</ix:nonFraction> per warrant, which are accounted
as equity in the condensed consolidated financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" continuedAt="orka_ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock-c0_cont_1" escape="true" name="orka:ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock" id="ixv-23050">The
following table summarizes the employee warrant activity for the period from February&#160;6, 2024 (inception) through September 30,
2024:</ix:nonNumeric>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="orka_ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Warrants</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Exercise<br/> Price Per Share</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term (in&#160;Years)</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/> Intrinsic<br/> Value (in&#160;Thousands)</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance as of February&#160;6, 2024 (inception)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-131; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-132; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-133; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-134; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; width: 52%; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-23051">3,054,358</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-23052">7.80</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-135; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-136; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-137; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-138; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-23053">3,054,358</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-23054">7.80</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="orka:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" id="ixv-20381"><span style="font-family: Times New Roman, Times, Serif">9.8</span></ix:nonNumeric></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd" id="ixv-23055">51,038</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested and expected to vest, September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-23056">3,054,358</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-23057">7.80</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="orka:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest" id="ixv-20417"><span style="font-family: Times New Roman, Times, Serif">9.8</span></ix:nonNumeric></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" unitRef="usd" id="ixv-23058">51,038</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested and exercisable, September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-139; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-140; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-141; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-142; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
weighted average grant-date fair value per share of employee warrants granted during the period from February&#160;6, 2024 (inception)
to September 30, 2024 was $<ix:nonFraction contextRef="c171" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-23059">6.27</ix:nonFraction> per share. Aggregate intrinsic value represents the difference between the estimated fair value of the
underlying Company Common Stock and the exercise price of outstanding, in-the-money employee warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-20487"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the weighted-average assumptions used in calculating the fair value of the employee warrants for the three
months ended September 30, 2024 and for the period from February&#160;6, 2024 (inception) to September 30, 2024:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three&#160;Months Ended<br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period from<br/> February&#160;6,<br/> 2024<br/> (Inception) <br/> to<br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (in&#160;years)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonNumeric contextRef="c13" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-20530"><span style="font-family: Times New Roman, Times, Serif">6.1</span></ix:nonNumeric></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-20539"><span style="font-family: Times New Roman, Times, Serif">6.1</span></ix:nonNumeric></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-23060">99.0</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-23061">99.0</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-23062">4.2</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-23063">4.2</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-143; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-144; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock-Based
Compensation Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="ixv-20609"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the classification of the Company&#8217;s stock-based compensation expense in the condensed consolidated statement
of operations and comprehensive loss (in thousands):</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three&#8239;Months
                                            Ended<br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period
                                            from<br/> February&#160;6,<br/> 2024<br/> (Inception)<br/> to<br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research
    and development</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c181" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-23064">7,772</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c182" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-23065">8,310</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c183" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-23066">1,229</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c184" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-23067">1,459</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-23068">9,001</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-23069">9,769</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, total unrecognized compensation cost related to the unvested stock options was $<ix:nonFraction contextRef="c172" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd" id="ixv-23070">7.5</ix:nonFraction> million, which is expected
to be recognized over a weighted average period of approximately <ix:nonNumeric contextRef="c173" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-23071">3.4</ix:nonNumeric> years. As of September 30, 2024, total unrecognized compensation
cost related to the unvested RSAs was less than $<ix:nonFraction contextRef="c174" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd" id="ixv-23072">0.1</ix:nonFraction> million, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c167" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-23073">3.4</ix:nonNumeric>
years. As of September 30, 2024, the unrecognized compensation cost related to the employee warrants was $<ix:nonFraction contextRef="c175" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd" id="ixv-23074">17.8</ix:nonFraction> million, which is expected
to be recognized over a weighted average period of <ix:nonNumeric contextRef="c171" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-23075">3.6</ix:nonNumeric> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="ixv-23076">The
following table summarizes the award types of the Company&#8217;s stock-based compensation expense in the condensed consolidated statement
of operations and comprehensive loss (in thousands):</ix:nonNumeric>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three&#160;Months
                                            Ended <br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period
                                            from<br/> February&#160;6,<br/> 2024<br/> (Inception)<br/> to<br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paruka
    warrant obligation</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="orka:ParukaWarrantObligation" scale="3" unitRef="usd" id="ixv-23077">7,251</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:ParukaWarrantObligation" scale="3" unitRef="usd" id="ixv-23078">7,681</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Employee
    warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="orka:EmployeeWarrants" scale="3" unitRef="usd" id="ixv-23079">1,314</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:EmployeeWarrants" scale="3" unitRef="usd" id="ixv-23080">1,314</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock
    options</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" sign="-" unitRef="usd" id="ixv-23081">427</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" sign="-" unitRef="usd" id="ixv-23082">765</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Employee
    stock purchase plan</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd" id="ixv-23083">9</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd" id="ixv-23084">9</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-23085">9,001</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-23086">9,769</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-20841"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>9.
Income Taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c185" decimals="0" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-23087">No</ix:nonFraction>
provision for income taxes was recorded for the three months ended September 30, 2024 and for the period of February&#160;6, 2024 (inception)
through September 30, 2024. Deferred tax assets generated from the Company&#8217;s net operating losses have been fully reserved, as
the Company believes it is not more likely than not that the benefit will be realized due to the Company&#8217;s cumulative losses generated
to date.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="orka_OptionAgreementsTextBlock-c0_cont_1" escape="true" name="orka:OptionAgreementsTextBlock" id="ixv-20868"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>10.
Option Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
March&#160;2024, the Company entered into Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paragon
identifies, evaluates and develops antibodies directed against certain mutually agreed therapeutic targets of interest to the Company.
The Option Agreements include two selected targets, IL-23 (&#8220;ORKA-001&#8221;) and IL-17 A/F (&#8220;ORKA-002&#8221;). Under the
Option Agreements, the Company has the exclusive options to, on a research program-by-research program basis, be granted an exclusive,
worldwide license to all of Paragon&#8217;s right, title and interest in and to the intellectual property resulting from the applicable
research program to develop, manufacture and commercialize the antibodies and products directed to the selected targets (each, an &#8220;Option&#8221;),
with the exception of pursuing ORKA-001 for the treatment of inflammatory bowel disease. If the Company exercises its options, it will
be required to make non-refundable milestone payments to Paragon of up to $<ix:nonFraction contextRef="c186" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-23088">12.0</ix:nonFraction>&#160;million under each respective agreement upon the
achievement of certain clinical development milestones, up to $<ix:nonFraction contextRef="c187" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-23089">10.0</ix:nonFraction>&#160;million under each respective agreement upon the achievement
of certain regulatory milestones as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial
sale. From time to time, the Company can choose to add additional targets to the collaboration by mutual agreement with Paragon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s exclusive Option with respect to each research program for a particular target initiated by the parties (&#8220;Research
Program&#8221;) is exercisable at its sole discretion at any time during the period beginning on the initiation of activities under the
associated Research Program and ending a specified number of&#160;days following (i) with respect to any Research Program other than
ORKA-001, the delivery of the data package from Paragon related to the results of the Research Plan activities, or (ii) with respect
to ORKA-001, the completion of the IL-23 antibody selection process described in the agreement (the &#8220;Option Period&#8221;). There
is no payment due upon exercise of an Option pursuant to the Option Agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Unless
terminated earlier, the Option Agreements shall continue in force on a Research Program-by-Research Program basis until the earlier of:
(i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by the Company; (ii)&#160;the
expiration of the 30-day period after the Company exercises its Option with respect to such Research Program, subject to mutually agreed
extension, during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii) the expiration
of the applicable research term (the &#8220;Term&#8221;). Upon the expiration of the Term for all then-existing Research Programs, under
the Option Agreements, the Option Agreements will automatically expire in its entirety. The Company may terminate the Option Agreements
or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon, provided that the
Company must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred
by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate the Option Agreements or a
Research Program immediately upon written notice to the Company if, as a result of any action or failure to act by the Company or its
affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise
delayed for a certain consecutive number of months. Each party has the right to terminate the Option Agreements or any Research Program
upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the 30-day
period and (ii)&#160;the other party&#8217;s bankruptcy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Pursuant to the Option Agreements, on a research
program-by-research program basis following the finalization of the research plan for each respective research program, the Company was
required to pay Paragon a one-time, nonrefundable research initiation fee of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="6" unitRef="usd" id="ixv-23090">0.8</ix:nonFraction>&#160;million related to the ORKA-001 program. This amount
was recognized as a research and development expense during the period from February&#160;6, 2024 (inception) to September 30, 2024. In
June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process of its development candidate for
IL-23 antibody for ORKA-001 program. The Company was responsible for <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="orka:DevelopmentCostsPercentage" scale="-2" unitRef="pure" id="ixv-23091">50</ix:nonFraction>% of the development costs incurred through the completion of the
IL-23 selection process. The Company received the rights to at least one selected IL-23 antibody in June 2024. During the three months
ended September 30, 2024, the Company exercised its option for ORKA-001 and recorded a $<ix:nonFraction contextRef="c188" decimals="-5" format="ixt:num-dot-decimal" name="orka:MilestonePayment" scale="6" unitRef="usd" id="ixv-23092">1.5</ix:nonFraction> million milestone payment related to the achievement
of development candidate as research and development expense in the Company&#8217;s condensed consolidated statements of operations and
comprehensive loss for each of the three months ended September 30, 2024 and for the period from February 6, 2024 (inception) to September
30, 2024. The Company&#8217;s share of development costs incurred during the three months ended September 30, 3024 and for the period
from February 6, 2024 (inception) to September 30, 2024 was $<ix:nonFraction contextRef="c183" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" unitRef="usd" id="ixv-23093">0.8</ix:nonFraction> million and $<ix:nonFraction contextRef="c184" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" unitRef="usd" id="ixv-23094">13.2</ix:nonFraction> million, respectively, which were recorded as research
and development expenses during the respective periods. An amount of $<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="6" unitRef="usd" id="ixv-23095">2.3</ix:nonFraction> million is included in related party accounts payable and other
current liabilities as of September 30, 2024.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company was also required to reimburse Paragon
$<ix:nonFraction contextRef="c87" decimals="-5" format="ixt:num-dot-decimal" name="orka:OtherDevelopmentCost" scale="6" unitRef="usd" id="ixv-23096">3.3</ix:nonFraction>&#160;million for development costs related to ORKA-002 incurred by Paragon through December&#160;31, 2023 and certain other development
costs incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024 as stipulated by the Option Agreements. This amount was
recognized as a research and development expense during the period from February&#160;6, 2024 (inception) to September 30, 2024. The Company
is also responsible for the development costs incurred by Paragon from January&#160;1, 2024 through the completion of the IL-17 selection
process. The Company recognized an amount of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherNotesPayable" scale="6" unitRef="usd" id="ixv-23097">0.8</ix:nonFraction>&#160;million payable to Paragon for the research initiation fee related to ORKA-002
following the finalization of the ORKA-002 research plan. This was recognized as research and development expenses in the period from
February 6, 2024 (inception) to September 30, 2024. The Company accounted for development costs of $<ix:nonFraction contextRef="c181" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" unitRef="usd" id="ixv-23098">3.8</ix:nonFraction> million and $<ix:nonFraction contextRef="c182" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" unitRef="usd" id="ixv-23099">6.6</ix:nonFraction> million during
the three months ended September 30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively, as
research and development expenses during the respective periods. An amount of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="6" unitRef="usd" id="ixv-23100">3.8</ix:nonFraction> million is included in related party accounts payable
and other current liabilities as of September 30, 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="orka_OptionAgreementsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
part of the Option Agreements, on each of December 31, 2024 and December 31, 2025, the Company will grant warrants to purchase a number
of shares equal to <ix:nonFraction contextRef="c189" decimals="4" format="ixt:num-dot-decimal" name="orka:PercentageOfWarrantPurchare" scale="-2" unitRef="pure" id="ixv-23101"><ix:nonFraction contextRef="c190" decimals="4" format="ixt:num-dot-decimal" name="orka:PercentageOfWarrantPurchare" scale="-2" unitRef="pure" id="ixv-23102">1.00</ix:nonFraction></ix:nonFraction>% of outstanding shares as of the date of the grant on a fully diluted basis with an exercise price equal to the
fair market value of the underlying shares on the grant date. The warrants are liability-classified and after the initial recognition,
the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated
statement of operations and comprehensive loss (see Note&#160;8) as stock-based compensation expenses under research and development
expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified
within research and development expenses in the accompanying condensed consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise
in-process research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination
because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent
a group of similar identifiable assets. The research initiation fee represents a one-time cost on a research program-by-research program
basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts
paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of ongoing development cost,
monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior
to the effective date of the Option Agreements that is associated with services being rendered under the related Research Programs are
recognized as research and development expense when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">For
the three months ended September 30, 2024 and the period from February&#160;6, 2024 (inception) to September 30, 2024, the Company recognized
$<ix:nonFraction contextRef="c13" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="6" unitRef="usd" id="ixv-23103">13.4</ix:nonFraction> million and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="6" unitRef="usd" id="ixv-23104">33.8</ix:nonFraction> million of expenses, respectively, in connection with services provided by Paragon and Paruka under the Option
Agreements.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-20926"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>11.
Commitment and Contingencies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b>Leases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
April 2024, the Company entered into an operating lease agreement for the Company&#8217;s headquarters in Menlo Park, California, which
commenced on June 15, 2024 with an initial term of <ix:nonNumeric contextRef="c191" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-23105">39.5</ix:nonNumeric> months. The Company leases office space under this noncancelable operating lease
agreement. Lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining
the present value of lease payments, the Company used its incremental borrowing rate when measuring operating lease liabilities as discount
rates were not implicit or readily determinable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, the Company had $<ix:nonFraction contextRef="c192" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" unitRef="usd" id="ixv-23106">0.9</ix:nonFraction> million of operating lease right-of-use assets, operating lease liability, current of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" unitRef="usd" id="ixv-23107">0.1</ix:nonFraction>
million, and operating lease liability, noncurrent of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" unitRef="usd" id="ixv-23108">0.8</ix:nonFraction> million on its condensed consolidated balance sheets. As of September 30,
2024, the operating lease arrangement had a remaining lease term of <ix:nonNumeric contextRef="c3" format="ixt-sec:durmonth" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-23109">36.0</ix:nonNumeric> months and a discount rate of <ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" unitRef="pure" id="ixv-23110">17.95</ix:nonFraction>%. For the three months ended
September 30, 2024 and the period from February 6, 2024 (inception) to September 30, 2024, the Company recorded operating and variable
lease expense of $<ix:nonFraction contextRef="c13" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseVariableLeaseIncome" scale="6" unitRef="usd" id="ixv-23111">0.1</ix:nonFraction> and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseVariableLeaseIncome" scale="6" unitRef="usd" id="ixv-23112">0.2</ix:nonFraction> million, respectively, in general and administrative expenses in its condensed consolidated statements
of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="ixv-20946"><span style="font-family: Times New Roman, Times, Serif">The
following table presents the Company&#8217;s supplemental cash flow information related to leases (in thousands):</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p>

<ix:continuation id="_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">September
    30, <br/> 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    paid for amounts included in the measurement of lease liabilities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating
    cash flow from operating leases</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd" id="ixv-23113">74</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-23114">The
following table summarizes a maturity analysis of the Company&#8217;s operating lease liabilities showing the aggregate lease payments
as of September 30, 2024 (in thousands):</ix:nonNumeric>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Fiscal
    year ending December 31,</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%"><span style="font-family: Times New Roman, Times, Serif">2024
    (remainder)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" unitRef="usd" id="ixv-23115">63</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-23116">369</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd" id="ixv-23117">494</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitRef="usd" id="ixv-23118">380</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total
    undiscounted lease payments</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-23119">1,306</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    imputed interest</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-23120">318</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total
    discounted lease payments</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-23121">988</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    current portion of lease liability</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-23122">146</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Non-current
    portion of lease liability</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-23123">842</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:EarningsPerShareTextBlock" id="ixv-21131"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>12.
Net Loss per Share</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ixv-23124">Basic and diluted net loss per share attributable
to stockholders were calculated as follows (in thousands, except share and per share data):</ix:nonNumeric>&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_2" id="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three&#160;Months Ended<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period from<br/> February&#160;6,<br/> 2024<br/> (Inception)<br/> to<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Loss<br/>
 Allocation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/>
 Average<br/>
 Shares<br/>
 Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Loss Per<br/>
 Share &#8211;<br/>
 Basic and<br/>
 Diluted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Loss<br/>
 Allocation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Shares Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Loss Per<br/>
 Share &#8211;<br/>
 Basic and<br/>
 Diluted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Common Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="orka:CommonStockLossAllocation" scale="3" sign="-" unitRef="usd" id="ixv-23125">21,936</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-23126">15,013,655</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c13" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-23127">1.46</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:CommonStockLossAllocation" scale="3" sign="-" unitRef="usd" id="ixv-23128">47,192</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-23129">7,765,381</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-23130">6.08</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Company Series A Preferred Stock<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c193" decimals="-3" format="ixt:num-dot-decimal" name="orka:CommonStockLossAllocation" scale="3" sign="-" unitRef="usd" id="ixv-23131">697</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c193" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-23132">477</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c193" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-23133">1,460.62</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c120" decimals="-3" format="ixt:num-dot-decimal" name="orka:CommonStockLossAllocation" scale="3" sign="-" unitRef="usd" id="ixv-23134">1,121</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c120" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-23135">184</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c120" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-23136">6,077.13</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Company Series B Preferred Stock<sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c194" decimals="-3" format="ixt:num-dot-decimal" name="orka:CommonStockLossAllocation" scale="3" sign="-" unitRef="usd" id="ixv-23137">5,990</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c194" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-23138">49,191</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">(<ix:nonFraction contextRef="c194" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-23139">121.77</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c195" decimals="-3" format="ixt:num-dot-decimal" name="orka:CommonStockLossAllocation" scale="3" sign="-" unitRef="usd" id="ixv-23140">9,630</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c195" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-23141">19,015</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">(<ix:nonFraction contextRef="c195" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-23142">506.44</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-23143">28,623</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-23144">57,943</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_3" id="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The weighted-average number of
shares of as-converted Company Series A Preferred Stock used in the loss allocation was <ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable" scale="0" unitRef="shares" id="ixv-23145">477,196</ix:nonFraction> and <ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable" scale="0" unitRef="shares" id="ixv-23146">184,462</ix:nonFraction> for the three months ended
September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively.</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The weighted-average number of
shares of as-converted Company Series B Preferred Stock used in the loss allocation was <ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable" scale="0" unitRef="shares" id="ixv-23147">4,099,227</ix:nonFraction> and <ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable" scale="0" unitRef="shares" id="ixv-23148">1,584,575</ix:nonFraction> for the three months
ended September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively.</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">For the computation of basic net loss per share
attributable to stockholders, the amount of weighted-average shares outstanding excludes all shares of unvested restricted common stock
as such shares are not considered outstanding for accounting purposes until vested. The amount of weighted-average shares outstanding
includes the pre-funded warrants as the exercise price is negligible and these warrants are fully vested and exercisable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-23149">The potential shares of common stock that were excluded
from the computation of diluted net loss per share attributable to stockholders for the periods presented because including them would
have had an anti-dilutive effect were as follows:</ix:nonNumeric>&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three&#160;Months Ended<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period from<br/> February&#160;6,<br/> 2024<br/> (Inception)<br/> to<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Outstanding employee warrants to purchase common stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c196" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-23150">3,054,358</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c197" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-23151">3,054,358</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Outstanding unvested restricted stock awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c198" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-23152">2,207,553</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c199" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-23153">2,207,553</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Outstanding and issued common stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c200" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-23154">1,287,760</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c201" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-23155">1,287,760</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-23156">6,549,671</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-23157">6,549,671</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-21382"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>13.
Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Paragon
and Paruka each beneficially own less than <ix:nonFraction contextRef="c202" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" unitRef="pure" id="ixv-23158">5</ix:nonFraction>% of the Company&#8217;s capital stock through their respective holdings of Company Common
Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Fairmount beneficially owns more than <ix:nonFraction contextRef="c203" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" unitRef="pure" id="ixv-23159">5</ix:nonFraction>% of the
Company&#8217;s capital, currently has one representative appointed to the Board, and beneficially owns more than <ix:nonFraction contextRef="c204" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" unitRef="pure" id="ixv-23160">5</ix:nonFraction>% of Paragon. Fairmount
appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfCondensedFinancialStatementsTableTextBlock-c0_cont_1" escape="true" name="srt:ScheduleOfCondensedFinancialStatementsTableTextBlock" id="ixv-23161">The
following is a summary of related party accounts payable and other current liabilities (in thousands):</ix:nonNumeric>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfCondensedFinancialStatementsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September&#160;30,<br/>
                                            2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Paragon
    reimbursable Option Agreements&#8217; fees</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c205" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-23162">6,140</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paragon
    reimbursable other research expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c206" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-23163">146</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Paragon
    reimbursable patent expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c207" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-23164">71</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-23165">6,357</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>PART
II</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>INFORMATION
NOT REQUIRED IN PROSPECTUS </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#8201;13.
Other Expenses of Issuance and Distribution </b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The expenses
payable by us in connection with the issuance and distribution of the securities being registered hereunder on Form S-1 (other than underwriting
discounts and commissions, if any) are set forth below. The Selling Stockholders will not bear any portion of such expenses. Each item
listed is estimated, except for the SEC registration fee:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC
    registration fee</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,913</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"/></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printing
    and engraving</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    fees and expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"/></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting
    fees and expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous
    expenses</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,087</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">170,000</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#8201;14.
Indemnification of Officers and Directors </b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Section 145
of the DGCL authorizes a court to award, or a corporation&#8217;s board of directors to grant, indemnity to directors and officers under
certain circumstances and subject to certain limitations. The terms of Section 145 of the DGCL are sufficiently broad to permit indemnification
under certain circumstances for liabilities, including reimbursement of expenses incurred, arising under the Securities Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">As permitted
by the DGCL, the Registrant&#8217;s Certificate of Incorporation contains provisions that eliminate the personal liability of its directors
for monetary damages for any breach of fiduciary duties as a director, except liability for the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">any
                                            breach of the director&#8217;s duty of loyalty to the Registrant or its stockholders;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">acts
                                            or omissions not in good faith or that involve intentional misconduct or a knowing violation
                                            of law;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">under
                                            Section 174 of the DGCL (regarding unlawful dividends and stock purchases); or</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">any
                                            transaction from which the director derived an improper personal benefit.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">As permitted
by the DGCL, the Registrant&#8217;s Bylaws provide that:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            Registrant is required to indemnify its directors and executive officers to the fullest extent
                                            permitted by the DGCL, subject to very limited exceptions;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            Registrant may indemnify its other employees and agents as set forth in the DGCL;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            Registrant is required to advance expenses, as incurred, to its directors and executive officers
                                            in connection with a legal proceeding to the fullest extent permitted by the DGCL, subject
                                            to very limited exceptions; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            rights conferred in the Bylaws are not exclusive.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 155; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Registrant
has entered, and intends to continue to enter, into separate indemnification agreements with its directors and executive officers to
provide these directors and executive officers additional contractual assurances regarding the scope of the indemnification set forth
in the Registrant&#8217;s Certificate of Incorporation and Bylaws and to provide additional procedural protections. At present, there
is no pending litigation or proceeding involving a director or executive officer of the Registrant regarding which indemnification is
sought.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The indemnification
provisions in the Registrant&#8217;s Certificate of Incorporation, Bylaws and the indemnification agreements entered into or to be entered
into between the Registrant and each of its directors and executive officers may be sufficiently broad to permit indemnification of the
Registrant&#8217;s directors and executive officers for liabilities arising under the Securities Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Registrant
currently carries liability insurance for its directors and officers. One of the Registrant&#8217;s directors, Peter Harwin, is also
indemnified by his employer with regard to their service on the Registrant&#8217;s board of directors.</span></p><div>

</div><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#8201;15.
Recent Sales of Unregistered Securities </b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">On September
13, 2024, we completed the Private Placement of Private Placement Common Shares, Private Placement Conversion Shares and Pre-Funded Warrants
pursuant to the SPA with the Selling Stockholders in the September 2024 PIPE. We sold an aggregate of 5,600,000 shares of Common Stock,
2,439 shares of our Series A Preferred Stock and pre-funded warrants to purchase 680,000 shares of Common Stock in the September 2024
PIPE for an aggregate purchase price of approximately $200.5 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Subject to
stockholder approval and certain beneficial ownership limitations, each share of Series A Preferred Stock is convertible into 1,000 shares
of Common Stock. Shares of Series A Preferred Stock shall not be convertible if the conversion would result in a holder, together with
its affiliates, beneficially owning more than 9.99% of our outstanding shares of Common Stock as of the applicable conversion date, which
may be increased at the holders&#8217; option (not to exceed 19.99%), effective in accordance with the terms of our Series A Certificate
of Designation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The shares
issued pursuant to the September 2024 PIPE were offered and sold in transactions exempt from registration under the Securities Act, in
reliance on Section 4(a)(2) thereof and Rule 506 of Regulation D thereunder. Each of the investors represented that it was an &#8220;accredited
investor,&#8221; as defined in Regulation D, and acquired the securities for investment only and not with a view towards, or for resale
in connection with, the public sale or distribution thereof. The shares of Series A Preferred Stock issued pursuant to the September
2024 PIPE have not been registered under the Securities Act and such securities may not be offered or sold in the United States absent
registration or an exemption from registration under the Securities Act and any applicable state securities laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#8201;16.
Exhibits and Financial Statement Schedules </b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT<br/>
    NUMBER</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 90%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DESCRIPTION
    OF EXHIBIT</b></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1*&#8224;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex21.htm">Agreement
    and Plan of Merger and Reorganization, dated as of April 3, 2024, by and among ARCA biopharma, Inc., Atlas Merger Sub Corp., Atlas
    Merger Sub II, LLC and Oruka Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 of ARCA biopharma, Inc.&#8217;s Form 8-K
    filed on April 3, 2024, File No. 000-22873).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex3-5_oruka.htm">Amended
    and Restated Certificate of Incorporation of the Company, filed September 3, 2024 (incorporated by reference to Exhibit 3.5 to the
    Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 5, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex3-6_oruka.htm">Amended
    and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.6 to the Registrant&#8217;s Current Report on Form 8-K
    filed with the SEC on September 5, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024078549/ea021443901ex3-1_oruka.htm">Form
    of Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock (incorporated
    by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 13, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex3-9_oruka.htm">Form
    of Certificate of Designation of Preferences, Rights and Limitations of Series&#160;B Non-Voting Convertible Preferred Stock (incorporated
    by reference to Exhibit 3.9 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 5, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024078549/ea021443901ex10-2_oruka.htm">Form
    of Registration Rights Agreement, dated as of September 13, 2024 (incorporated by reference to Exhibit 10.2 to the
    Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 13, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024078549/ea021443901ex10-1_oruka.htm">Securities
    Purchase Agreement, dated September 11, 2024, by and between Oruka Therapeutics, Inc. and each purchaser identified on Annex A thereto
    (incorporated by reference to Exhibit 10.1 the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 13,
    2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024078549/ea021443901ex4-1_oruka.htm">Form
    of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the
    SEC on September 13, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="ea022056701ex5-1_oruka.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Gibson, Dunn &amp; Crutcher LLP.</span></a></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*
    &#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex101.htm">Form
    of Oruka Support Agreement (incorporated by reference to Exhibit 10.1 to ARCA biopharma, Inc&#8217;s Form&#160;8-K filed on April&#160;3,
    2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*&#8224;
    &#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex102.htm">Form
    of Oruka Subscription Agreement (incorporated by reference to Exhibit 10.2 to ARCA biopharma, Inc&#8217;s Form 8-K filed on April
    3, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3*&#8224;
    &#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024060156/ea020913401ex10-1_arcabio.htm">Form
    of Amendment to Oruka Subscription Agreement (incorporated by reference to Exhibit 10.1 to ARCA biopharma, Inc&#8217;s Form 8-K filed
    on July 9, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4*&#8224;
    &#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024060156/ea020913401ex10-2_arcabio.htm">Form
    of Amended &amp; Restated Oruka Subscription Agreement (incorporated by reference to Exhibit 10.2 to ARCA biopharma, Inc&#8217;s
    Form 8-K filed on July 9, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top">10.5*</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024097443/ea021692901ex10-4_oruka.htm">Form of Registration Rights Agreement, dated as of August 29, 2024 (incorporated by reference to Exhibit 10.4 to the Registrant's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024).</a></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6
    &#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex103.htm">Form
    of ACRA Support Agreement (incorporated by reference to Exhibit 10.3 to ARCA biopharma, Inc&#8217;s Form 8-K filed on April 3, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7*
    &#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex104.htm">Form
    of Lock-Up Agreement (incorporated by reference to Exhibit 10.4 to ARCA biopharma, Inc&#8217;s Form 8-K filed on April 3, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8*&#8224;&#8224;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024041846/abio-ex10_1.htm">Separation
    Agreement and Release, by and between ARCA biopharma, Inc. and Michael Bristow, dated as of April 3, 2024 (incorporated by reference
    to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form 8-K filed on April 4, 2024).</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9*&#8224;&#8224;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024041846/abio-ex10_2.htm">Consulting
    Agreement, by and between ARCA biopharma, Inc. and Michael Bristow, dated as of April 3, 2024 (incorporated by reference to Exhibit
    10.2 of ARCA biopharma, Inc.&#8217;s Form 8-K filed on April 4, 2024).</a></span></td></tr>
</table><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-45_arcabio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Indemnification Agreement between Oruka Therapeutics, Inc. and its directors and officers (incorporated by reference to Exhibit
    10.45 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</span></a></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex10-10_oruka.htm">Oruka
    Therapeutics, Inc. 2024 Stock Incentive Plan (incorporated by reference to Exhibit 10.10 to the Registrant&#8217;s Current Report
    on Form 8-K filed with the SEC on September 5, 2024).</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex10-11_oruka.htm">Oruka
    Therapeutics, Inc. 2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.11 to the Registrant&#8217;s Current
    Report on Form 8-K filed with the SEC on September 5, 2024).</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-40_arcabio.htm">Amended
    and Restated Oruka Therapeutics, Inc. 2024 Equity Incentive Plan, as amended by the First Amendment dated May 7, 2024 (incorporated
    by reference to Exhibit 10.40 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></span></td></tr>

<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14*#
    &#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex10-13_oruka.htm">Second Amendment to Amended and Restated Oruka Therapeutics, Inc. 2024 Equity Incentive Plan, effective as of May 7, 2024 (incorporated by reference to Exhibit 10.13 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 5, 2024).&#160;</a></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15*#
    &#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-41_arcabio.htm">Form
    of Restricted Stock Notice and Restricted Stock Purchase Agreement (incorporated by reference to Exhibit 10.41 to ARCA biopharma,
    Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></span></td></tr>

<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 91%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-42_arcabio.htm">Form
    of Stock Option Agreement under Oruka Therapeutics, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.42 to
    ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></span></td></tr>

<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 91%"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex10-16_oruka.htm">Form of Employee Warrant Agreement (incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 5, 2024).</a></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-43_arcabio.htm">Amended
    and Restated Director Offer Letter, dated March&#160;22, 2024, between Oruka Therapeutics, Inc. and Samarth Kulkarni (incorporated
    by reference to Exhibit 10.43 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-44_arcabio.htm">Director
    Offer Letter, dated April&#160;24, 2024, between Oruka Therapeutics, Inc. and Kristine Ball (incorporated by reference to Exhibit
    10.44 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024085543/ea021674601ex10-1_oruka.htm">Amended
    and Restated Employment Offer Letter by and between Oruka Therapeutics, Inc. and Lawrence Klein<span style="text-decoration: none">,
    dated as of October 3, 2024</span> (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K
    filed with the SEC on October 4, 2024<span style="text-decoration: none">, File No. 241354944</span>).</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024085543/ea021674601ex10-2_oruka.htm">Amended
    and Restated Employment Letter Agreement by and between the Company and Arjun Agarwal, dated as of October 3, 2024 (incorporated
    by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on October 4, 2024, File No.
    241354944).</a></span></td></tr>

<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-48_arcabio.htm">Employment
    Offer Letter, dated March 15, 2024, by and between Oruka Therapeutics, Inc. and Joana Goncalves (incorporated by reference to Exhibit
    10.48 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></span></td></tr>

<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-49_arcabio.htm">Employment
    Offer Letter, dated April&#160;12, 2024, by and between Oruka Therapeutics, Inc. and Paul Quinlan (incorporated by reference to Exhibit
    10.49 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24*&#8224;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024053881/ea020512202ex10-50_arcabio.htm">Amended
    and Restated Antibody Discovery and Option Agreement (IL-17), dated March&#160;28, 2024, by and among Paragon Therapeutics, Inc.,
    Paruka Holding LLC and Oruka Therapeutics, Inc. (incorporated by reference to Exhibit 10.50 to ARCA biopharma, Inc.&#8217;s Form
    S-4/A, filed on June 18, 2024, File No. 333-279387).</a></span></td></tr>
</table><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 158; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25*&#8224;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024053881/ea020512202ex10-51_arcabio.htm">Amended
    and Restated Antibody Discovery and Option Agreement (IL-23), dated March&#160;28, 2024, by and among Paragon Therapeutics, Inc.,
    Paruka Holding LLC and Oruka Therapeutics, Inc. (incorporated by reference to Exhibit 10.51 to ARCA biopharma, Inc.&#8217;s Form
    S-4/A, filed on June 18, 2024, File No. 333-279387).</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26*&#8224;#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex10-25_oruka.htm">Consulting
    Agreement, effective as of August 30, 2024, by and between Oruka Therapeutics, Inc. and Jeff Dekker (incorporated by reference to
    Exhibit 10.25 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 5, 2024).</a></span></td></tr>

<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1*</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 84%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex16-1_oruka.htm">Letter
    from KPMG LLP, dated September 5, 2024 (incorporated by reference to Exhibit 16.1 to the Registrant&#8217;s Current Report on Form
    8-K filed with the SEC on September 5, 2024).</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex21-1_oruka.htm">List
    of Subsidiaries of Oruka Therapeutics, Inc (incorporated by reference to Exhibit 21.1 to the Registrant&#8217;s Current Report on
    Form 8-K filed with the SEC on September 5, 2024).</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><a href="ea022056701ex23-1_oruka.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of PricewaterhouseCoopers LLP</span></a></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><a href="ea022056701ex5-1_oruka.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Gibson, Dunn &amp; Crutcher LLP (included in Exhibit 5.1) </span></a></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#d_001">Power of Attorney (included on the signature page to the registration statement)</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document.</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Labels Linkbase Document.</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><a href="ea022056701ex-fee_oruka.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing
    Fee Table. </span></a></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
                                            filed.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
                                            management contract or compensatory plan.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits
                                            and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant
                                            hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules
                                            upon request by the SEC; provided, however, that the registrant may request confidential
                                            treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so
                                            furnished. Certain portions of this exhibit (indicated by &#8220;[***]&#8221;) have been
                                            omitted because they are both (i) not material and (ii) is the type of information that the
                                            registrant both customarily and actually treats as private and confidential.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
                                            statement schedules</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 159; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#8201;17.
Undertakings </b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">(a) The undersigned
Registrant hereby undertakes:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">(1) To file,
during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">(i) to include
any prospectus required by Section 10(a)(3) of the Securities Act;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">(ii) to reflect
in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and
price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &#8220;Filing Fee Table&#8221;
in the effective registration statement; and</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">(iii) to
include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any
material change to such information in the registration statement;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">(2) That,
for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
be the initial <i>bona fide</i> offering thereof.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">(3) To remove
from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">(4) That,
for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as
part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses
filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used
after effectiveness. <i>Provided, however</i>, that no statement made in a registration statement or prospectus that is part of the registration
statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is
part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify
any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such
document immediately prior to such date of first use.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, and controlling
persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of
the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event
that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a
director, officer, or controlling person of the Registrant in the successful defense of any action, suit, or proceeding) is asserted
by such director, officer, or controlling person in connection with the securities being registered, the Registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question
whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication
of such issue. </span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 160; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="d_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SIGNATURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Act, the Registrant has duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Menlo Park, California, on November 13, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 4%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ORUKA
    THERAPEUTICS, INC.</b></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Lawrence Klein</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence
    Klein</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and
on the dates indicated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center; width: 17%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Lawrence Klein</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer &amp; Director</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    13, 2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence
    Klein</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Arjun Agarwal</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior
    Vice President, Finance and Treasurer </span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    13, 2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arjun
    Agarwal</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer and Principal Accounting Officer)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Samarth Kulkarni</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    13, 2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Samarth
    Kulkarni</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Kristine Ball</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    13, 2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kristine
    Ball</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Carl Dambkowski</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    13, 2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carl
    Dambkowski</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Peter Harwin</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    13, 2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Harwin</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Cameron Turtle</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    13, 2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cameron
    Turtle</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">II-7</span></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c1" id="hidden-fact-0" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-2" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-3" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-4" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-5" name="orka:SubscriptionReceivables" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-7" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-8" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-9" name="us-gaap:OtherAssetsNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-10" name="us-gaap:AccountsPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-11" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-12" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-13" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-14" name="us-gaap:OtherLiabilitiesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-15" name="us-gaap:LiabilitiesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-16" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-17" name="us-gaap:Liabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-18" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-19" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-20" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c8" id="hidden-fact-21" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-22" name="us-gaap:TemporaryEquitySharesIssued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c8" id="hidden-fact-23" name="us-gaap:TemporaryEquitySharesIssued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-24" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c8" id="hidden-fact-25" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-26" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-27" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-28" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-29" name="us-gaap:TemporaryEquitySharesIssued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-30" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-31" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-32" name="us-gaap:PreferredStockSharesAuthorized" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-33" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-34" name="us-gaap:CommonStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-35" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-36" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-37" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-38" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-39" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-40" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c26" id="hidden-fact-41" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c27" id="hidden-fact-42" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-43" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-44" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c26" id="hidden-fact-45" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c27" id="hidden-fact-46" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c28" id="hidden-fact-47" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-48" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-49" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-50" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-51" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c26" id="hidden-fact-52" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c27" id="hidden-fact-53" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c28" id="hidden-fact-54" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-55" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-56" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c26" id="hidden-fact-57" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c27" id="hidden-fact-58" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c28" id="hidden-fact-59" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-60" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c33" id="hidden-fact-61" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c34" id="hidden-fact-62" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-63" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-64" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-65" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-66" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-67" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-68" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-69" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-70" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-71" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-72" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c47" id="hidden-fact-73" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c48" id="hidden-fact-74" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-75" name="orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-76" name="orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-77" name="orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-78" name="orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-79" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-80" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-81" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-82" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-83" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-84" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-85" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-86" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-87" name="orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-88" name="orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-89" name="orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-90" name="orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-91" name="orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-92" name="orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-93" name="orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-94" name="orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-95" name="orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-96" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-97" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-98" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-99" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-100" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-101" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-102" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-103" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c59" id="hidden-fact-104" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-105" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c129" id="hidden-fact-106" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c130" id="hidden-fact-107" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c133" id="hidden-fact-108" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c134" id="hidden-fact-109" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" id="hidden-fact-110" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-111" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c149" id="hidden-fact-112" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c176" id="hidden-fact-113" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c177" id="hidden-fact-114" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-115" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-116" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" id="hidden-fact-117" name="orka:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-118" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-119" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-120" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-121" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-122" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-123" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-124" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" id="hidden-fact-125" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-126" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c178" id="hidden-fact-127" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c178" id="hidden-fact-128" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c179" id="hidden-fact-129" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c180" id="hidden-fact-130" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-131" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-132" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" id="hidden-fact-133" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-134" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-135" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-136" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-137" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-138" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-139" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-140" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" id="hidden-fact-141" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-142" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-143" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-144" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-23313">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-23314">0000907654</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="orka-20240930.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact ix_1_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_2_fact ix_3_fact" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_4_fact ix_5_fact" toRefs="ix_2_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-02-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">orka:ARCABIOPHARMAINCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-02-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">orka:ParagonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">orka:ParukaHoldingLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">orka:OrukaAdvisorsLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-22</xbrli:startDate>
    <xbrli:endDate>2024-03-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-07</xbrli:startDate>
    <xbrli:endDate>2024-03-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-06</xbrli:startDate>
    <xbrli:endDate>2024-03-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-31</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-31</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-30</xbrli:startDate>
    <xbrli:endDate>2024-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-02-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-02-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:CertainRegulatoryMilestonesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-02-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-02-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-06</xbrli:startDate>
    <xbrli:endDate>2024-03-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra9a2jfwGt44jro+lUyqzQL6/x1O9iJrf+dH3ymvrZRNb86/I06x7A9ljBSSeLHwUVO8zSU2wTDcbvo9VMwGaa9lLVYPe10sq6eTaiosvU//WQmETUn2YQF1MB+8Rrhxi9ypA8OCouD7AN9fcOhYxcJN+bW1vx4tZgDrEkxHw7OREH1QcuYc/HlxByK/E6Vd+/J9AmhwyCDseHEsE8kIbktayf3C+Snf9J5sz1W2sd2giB9Oo7QhM7subWFWiWJSPg=] CSR-->
  <xbrli:period>
    <xbrli:instant>2024-03-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNotesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNotesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-06</xbrli:startDate>
    <xbrli:endDate>2024-03-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNotesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ConvertibleNotePurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNotesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-12</xbrli:startDate>
    <xbrli:endDate>2024-04-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaPrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:ARCACommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaRestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:ReverseStockSplitMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:ReverseStockSplitMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:ReverseStockSplitMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">orka:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">orka:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:FairmountHealthcareFundIILPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-31</xbrli:startDate>
    <xbrli:endDate>2024-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-31</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-31</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-29</xbrli:startDate>
    <xbrli:endDate>2024-08-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:UnvestedStockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:UnvestedStockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:RestrictedStockActivityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:RestrictedStockActivityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:RestrictedStockActivityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-30</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:CertainRegulatoryMilestonesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-31</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-12-31</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:OutstandingEmployeeWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:OutstandingEmployeeWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:OutstandingUnvestedRestrictedStockAwardsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:OutstandingUnvestedRestrictedStockAwardsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:OutstandingAndIssuedCommonStockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:OutstandingAndIssuedCommonStockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:ParagonAndParukaMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:FairmountHealthcareFundIILPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:ParagonAndParukaMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:ParagonReimbursableOptionAgreementsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:ParagonReimbursableOtherResearchExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:ParagonReimbursablePatentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
[{"type": "S-1", "sequence": "1", "filename": "ea0220567-s1_orukatherap.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 2374162}]
{"company-data": {"conformed-name": "Oruka Therapeutics, Inc.", "cik": "0000907654", "assigned-sic": "2835", "organization-name": "03 Life Sciences", "irs-number": "363855489", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-1", "act": "33", "file-number": "333-283212", "film-number": "241456990"}, "business-address": {"street1": "855 OAK GROVE AVE.", "street2": "SUITE 100", "city": "MENLO PARK", "state": "CA", "zip": "94025", "phone": "650-606-7910"}, "mail-address": {"street1": "855 OAK GROVE AVE.", "street2": "SUITE 100", "city": "MENLO PARK", "state": "CA", "zip": "94025"}, "former-company": [{"former-conformed-name": "ARCA biopharma, Inc.", "date-changed": "20090128"}, {"former-conformed-name": "NUVELO INC", "date-changed": "20030203"}, {"former-conformed-name": "HYSEQ INC", "date-changed": "19970610"}]}
As
filed with the Securities and Exchange Commission on November 14, 2024
Registration
No. 333-
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
S-1
REGISTRATION
STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Oruka
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
36-3855489
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
855
Oak Grove Avenue
Suite
100
Menlo
Park, CA 94025
(650) 606-7910
(Address,
including zip code, and telephone number, including area code, of registrant's principal executive offices)
Paul
Quinlan
General
Counsel and Corporate Secretary
Oruka
Therapeutics, Inc.
855
Oak Grove Avenue
Suite
100
Menlo
Park, CA 94025
(650) 606-7910
(Name,
address, including zip code, and telephone number, including area code, of agent for service)
Copies
to:
Ryan
A. Murr
Branden
C. Berns
Gibson,
Dunn & Crutcher LLP
One
Embarcadero Center, Suite 2600
San
Francisco, CA 94111
(415)
393-8373
Approximate
date of commencement of proposed sale to the public
: From time to time after the effective date of this Registration Statement.
If any of
the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities
Act of 1933, check the following box. ☒
If this form
is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box
and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this form
is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this form
is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer,"
"smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
The Registrant
hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant
shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance
with Section 8(a) of the Securities Act of 1933, as amended, or until this registration statement shall become effective on such date
as the Commission, acting pursuant to said Section 8(a), may determine.
The
information in this prospectus is not complete and may be changed. The selling stockholders named in this prospectus may not sell these
securities until the registration statement filed with the Securities and Exchange Commission (the "SEC") is effective. This
prospectus is not an offer to sell these securities, and it is not soliciting an offer to buy these securities, in any jurisdiction where
the offer or sale is not permitted.
SUBJECT
TO COMPLETION, DATED NOVEMBER 13, 2024
PRELIMINARY
PROSPECTUS
Oruka
Therapeutics, Inc.
8,719,000
Shares
Common
Stock
Offered
by the Selling Stockholders
This prospectus
relates to the proposed resale or other disposition by the selling stockholders identified herein (the "Selling Stockholders")
of up to (i) 5,600,000 shares (the "Private Placement Common Shares") of our common stock, par value $0.001 per share ("Common
Stock"), (ii) 2,439,000 shares of Common Stock (the "Private Placement Conversion Shares") issuable upon the conversion
of 2,439 shares (the "Private Placement Preferred Shares") of Series A preferred stock, par value $0.001 (the "Series
A Preferred Stock") and (iii) 680,000 shares of Common Stock issuable upon the exercise of pre-funded warrants (the "Pre-Funded
Warrants"). Subject to receiving the requisite stockholder approval and certain beneficial ownership limitations set by each holder
of Series A Preferred Stock, each share of Series A Preferred Stock will automatically convert into an aggregate of 1,000 shares of Common
Stock. The shares of Common Stock registered by this prospectus are referred to herein as the "Resale Shares."
The Private
Placement Common Shares, Private Placement Preferred Shares and Pre-Funded Warrants were issued and sold to accredited investors in a
private placement (the "September 2024 PIPE"), which closed on September 13, 2024. We are not selling any Resale Shares under
this prospectus and will not receive any of the proceeds from the sale or other disposition of Resale Shares by the Selling Stockholders.
Upon any exercise of the Pre-Funded Warrants by payment of cash, however, we will receive the nominal cash exercise price paid by the
holders of the Pre-Funded Warrants. We intend to use those proceeds, if any, for general corporate purposes.
The Selling
Stockholders may sell the Resale Shares on any national securities exchange or quotation service on which the securities may be listed
or quoted at the time of sale, on the over-the-counter market, in one or more transactions otherwise than on these exchanges or systems,
such as privately negotiated transactions, or using a combination of these methods, and at fixed prices, at prevailing market prices
at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. See the disclosure under the heading
"Plan of Distribution" elsewhere in this prospectus for more information about how the Selling Stockholders may sell or otherwise
dispose of their Resale Shares hereunder.
The Selling
Stockholders may sell any, all or none of the securities offered by this prospectus and we do not know when or in what amount the Selling
Stockholders may sell their Resale Shares hereunder following the effective date of the registration statement of which this prospectus
forms a part. Discounts, concessions, commissions and similar selling expenses attributable to the sale of the Resale Shares will be
borne by the Selling Stockholder. We will pay certain fees and expenses (other than discounts, concessions, commissions and similar selling
expenses) incident to the registration of the Resale Shares with the U.S. Securities and Exchange Commission ("SEC").
You should
carefully read this prospectus and any applicable prospectus supplement before you invest in any of the securities being offered.
Our Common Stock is traded on The Nasdaq Global Market under the symbol
"ORKA." On November 12, 2024, the last reported sale price for our Common Stock was $26.10 per share.
An investment
in our securities involves a high degree of risk. You should carefully consider the information under the
heading
"
Risk Factors
" beginning on page 6 of this prospectus and any applicable
prospectus supplement.
We are
a "smaller reporting company" as defined by Rule 12b-2 of the Exchange Act and are subject to reduced public company reporting
requirements.
Neither
the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.
The
date of this prospectus is           , 2024
TABLE
OF CONTENTS
PAGE
ABOUT THIS PROSPECTUS
ii
CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
iii
PROSPECTUS SUMMARY
1
RISK FACTOR SUMMARY
4
RISK FACTORS
6
USE OF PROCEEDS
35
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
36
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
49
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
49
BUSINESS
50
MANAGEMENT
84
EXECUTIVE COMPENSATION
90
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
96
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
98
SELLING STOCKHOLDERS
102
PLAN OF DISTRIBUTION
111
DESCRIPTION OF CAPITAL STOCK
113
LEGAL MATTERS
117
EXPERTS
118
WHERE YOU CAN FIND MORE INFORMATION
119
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
F-1
i
ABOUT
THIS PROSPECTUS
This prospectus
is part of a registration statement that we filed with the SEC using a "shelf" registration process. Under this shelf registration
process, the Selling Stockholders may, from time to time, sell the securities described in this prospectus in one or more offerings.
This prospectus
contains information that you should consider when making your investment decision. Neither we, nor the Selling Stockholders, have authorized
anyone to give any information or to make any representation other than those contained in this prospectus. The Selling Stockholders
are offering to sell, and seeking offers to buy, our securities only in jurisdictions where it is lawful to do so. We have not authorized
anyone to provide you with different information. This prospectus and any accompanying prospectus supplement do not constitute an offer
to sell or the solicitation of an offer to buy any securities other than the securities described in any accompanying prospectus supplement
or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is
unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement and any related free writing
prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may
have changed materially since those dates.
In this prospectus,
unless the context otherwise requires, the terms "Oruka," the "Company," "we," "us,"
and "our" refer to Oruka Therapeutics, Inc., a Delaware corporation, and its consolidated subsidiaries.
This prospectus
contains trade names, trademarks and service marks of others, which are the property of their respective owners. Solely for convenience,
trademarks and trade names referred to in this prospectus may appear without the ® or TM symbols.
All references
to "our product candidates," "our programs," "our portfolio" and "our pipeline" in this
prospectus refer to the research programs with respect to which we have exercised the option to acquire intellectual property license
rights to or have the option to acquire intellectual property license rights to pursuant to those certain antibody discovery and option
agreements, each dated March 6, 2024 and subsequently amended and restated on March 28, 2024, by and among Oruka, Paragon Therapeutics,
Inc. ("Paragon") and Paruka Holding LLC ("Paruka") (the "Paragon Option Agreements").
ii
CAUTIONARY
STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
This prospectus
contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities
Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These forward-looking
statements involve a number of risks and uncertainties. We caution readers that any forward-looking statement is not a guarantee of future
performance and that actual results could differ materially from those contained in the forward-looking statement. These statements are
based on current expectations of future events.
All statements,
other than statements of historical facts contained in this prospectus, including, without limitation, statements regarding: stockholder
approval of the conversion rights of the Series A Preferred Stock; our ability to achieve the expected benefits or opportunities and
related timing with respect to the Merger (as defined below), our future results of operations and financial position, business strategy,
the length of time that we believe our existing cash resources will fund our operations, our market size, our potential growth opportunities,
our preclinical and future clinical development activities, the efficacy and safety profile of our product candidates, the potential
therapeutic benefits and economic value of our product candidates, the timing and results of preclinical studies and clinical trials,
the expected impact of macroeconomic conditions, including inflation, increasing interest rates and volatile market conditions, current
or potential bank failures, as well as global events, including ongoing military conflict between Russia and Ukraine, conflict in the
Middle East, and geopolitical tensions in China on our operations, and the receipt and timing of potential regulatory designations, approvals
and commercialization of product candidates. Forward-looking statements generally relate to future events or our future financial or
operating performance. Forward-looking statements generally relate to future events or our future financial or operating performance.
The words "believe," "may," "will," "potentially," "estimate," "continue,"
"anticipate," "predict," "target," "intend," "could," "would,"
"should," "project," "plan," "expect," and similar expressions that convey uncertainty
of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain
these identifying words.
These forward-looking
statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing
environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the
impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements we may make. Factors that might cause such a difference are disclosed
in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results
of Operations." You should evaluate all forward-looking statements made in this prospectus in the context of these risks and uncertainties.
We caution you that the risks, uncertainties and other factors referred to in this prospectus may not contain all of the risks, uncertainties
and other factors that may affect our future results and operations.
In addition,
statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements
are based on information available to us as of the date of this prospectus. While we believe that such information provides a reasonable
basis for these statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have
conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors
are cautioned not to unduly rely on these statements.
All subsequent
written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety
by the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly any revisions
to these forward-looking statements to reflect events or circumstances after the date of this prospectus or to reflect the occurrence
of unanticipated events, except as may be required under applicable U.S. securities laws. If we do update one or more forward-looking
statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
iii
PROSPECTUS
SUMMARY
This summary
may not contain all the information that you should consider before investing in securities. You should read the entire prospectus carefully,
including the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition
and Results of Operations," and our consolidated financial statements and the related notes included elsewhere in this prospectus,
before making an investment decision.
Company
Overview
We
are a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Our
mission is to offer patients suffering from chronic skin diseases like psoriasis ("PsO") the greatest possible freedom from
their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. We are advancing
a proprietary portfolio of antibodies that were engineered by Paragon and target the core mechanisms underlying PsO and other dermatologic
and inflammatory diseases.
Our
lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Our co-lead program,
ORKA-002, is designed to target interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis ("PsA"),
and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology
with the aim to increase exposure and decrease dosing frequency. We believe that our focused strategy, differentiated portfolio, and
deep expertise position us to set a new treatment standard in large inflammatory and immunology ("I&I") markets with
continued unmet need.
Our principal
executive offices are located at 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025, and our telephone number is (650) 606-7910. Our
website address is www.orukatx.com. Information contained on, or accessible through, our website is not incorporated by reference in
this prospectus. We make our periodic and current reports available on our website, free of charge, as soon as reasonably practicable
after such material is electronically filed with, or furnished to, the SEC. No portion of our website is incorporated by reference into
this prospectus. We file our annual, quarterly and special reports, proxy statements and other information with the SEC. Our filings
with the SEC are also available to the public on the SEC's website at http://www.sec.gov. Our Common Stock is traded on The Nasdaq
Global Market under the symbol "ORKA."
Business
Combination of ARCA and Pre-Merger Oruka and Pre-Closing Financing
On April 3, 2024, we (formerly known as ARCA biopharma, Inc.)
(prior to the Closing Date, unless context otherwise requires, "ARCA" and, after the Closing Date, the "Company"
or "Oruka") entered into the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), by and
among ARCA, Atlas Merger Sub Corp, a Delaware corporation and wholly owned subsidiary of ARCA ("First Merger Sub"), Atlas
Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of ARCA ("Second Merger Sub"), and Oruka
Therapeutics, a private Delaware corporation ("Pre-Merger Oruka") prior to the consummation of the Merger (as defined below).
On August
29, 2024 (the "Closing Date"), we consummated that previously announced business combination (the "Closing")
pursuant to the Merger Agreement to create a new public company focused on advancing Pre-Merger Oruka's pipeline of antibody therapies.
On the Closing Date, First Merger Sub merged with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the
surviving corporation of the merger (the "First Merger"), and Oruka merged with and into Second Merger Sub, with Second Merger
Sub being the surviving entity of the merger (the "Second Merger" and, together with the First Merger, the "Merger").
In connection with the completion of the Merger, we changed our name from "ARCA biopharma, Inc." to "Oruka Therapeutics,
Inc."
1
Immediately
prior to the execution and delivery of the Merger Agreement, certain new and existing investors of Oruka (the "Financing Investors")
entered into a subscription agreement with Oruka (the "Subscription Agreement"), pursuant to which, and on the terms and
subject to the conditions of which, immediately prior to the Closing, the Financing Investors purchased 39,873,706 shares of Pre-Merger
Oruka common stock and 9,664,208 Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $275.0 million (which includes
the issuance of 4,764,032 shares of Pre-Merger Oruka Common Stock on the conversion of Convertible Note, along with the accrued interest
through the conversion date), immediately prior to the Closing and before the effect of the Reverse Stock Split (as defined below) (the
"Pre-Closing Financing"). At the Closing, the shares of Pre-Merger Oruka common stock and Pre-Merger Oruka pre-funded warrants
issued in the Pre-Closing Financing were converted into shares of Common Stock in accordance with the Exchange Ratio (as defined herein).
In
connection with the consummation of the Merger, on the Closing Date (prior to the Reverse Stock Split (as defined below)):
●
Pre-Merger
Oruka issued to the Financing Investors an aggregate of 39,873,706 shares of Pre-Merger Oruka common stock and 9,664,208 Pre-Merger Oruka
pre-funded warrants for gross proceeds of approximately $275.0 million (which includes the issuance of 4,764,032 shares of Pre-Merger
Oruka Common Stock on the conversion of Convertible Note, along with the accrued interest through the conversion date); and
●
all
of the then-outstanding (i) 9,460,019 shares of Pre-Merger Oruka common stock, (ii) 20,000,000 shares of Series A convertible preferred
stock of Pre-Merger Oruka ("Pre-Merger Oruka Series A Preferred Stock"), (iii) 2,063,669 options exercisable for shares of
Pre-Merger Oruka common stock, (iv) 5,345,336 Pre-Merger Oruka employee warrants and (v) the Pre-Closing Financing Pre-Merger Oruka common
stock and pre-funded warrants were automatically converted into the right to receive the number of Common Stock, Series B Preferred Stock
or warrants in lieu thereof equal to the exchange ratio calculated in accordance with the Merger Agreement (the "Exchange Ratio"),
except for the preferred stock, which was converted at the Exchange Ratio divided by 1,000.
Following
the consummation of the Merger, we effected a 1-for-12 reverse stock split of our Common Stock (the "Reverse Stock Split"),
which became effective on September 3, 2024. Our Common Stock commenced trading on a post-Reverse Stock Split, post-Merger basis at the
open of trading on September 3, 2024.
Private
Placement of Common Stock, Preferred Stock and Pre-Funded Warrants
On
September 13, 2024, we completed the Private Placement of Private Placement Common Shares, Private Placement Conversion Shares and Pre-Funded
Warrants pursuant to the Securities Purchase Agreement dated September 11, 2024 (the "SPA") with the Selling Stockholders.
The Selling Stockholders purchased (i) an aggregate of 5,600,000 shares of the Common Stock, at a price per share of $23.00, (ii) an
aggregate of 2,439 shares of Series A Preferred Stock, at a price per share of $23,000.00, and (iii) Pre-Funded Warrants to purchase
an aggregate of 680,000 shares of Common Stock at a purchase price of $22.999 per Pre-Funded Warrant, which represents the per share
purchase price of the Private Placement Common Shares less the $0.001 per share exercise price for each Pre-Funded Warrant, for an aggregate
purchase price of approximately $200.5 million.
Subject
to stockholder approval and certain beneficial ownership limitations, each share of Series A Preferred Stock is convertible into 1,000
shares of Common Stock. Shares of Series A Preferred Stock shall not be convertible if the conversion would result in a holder, together
with its affiliates, beneficially owning more than 9.99% of our outstanding shares of Common Stock as of the applicable conversion date,
which may be increased at the holders' option (not to exceed 19.99%), effective in accordance with the terms of our Certificate
of Designation of Series A Convertible Preferred Stock ("Series A Certificate of Designation"). We filed a definitive proxy
statement with the SEC on October 18, 2024 to solicit such stockholder approval at a special meeting of stockholders to be held on November
14, 2024. Except as otherwise required by law (e.g., voting on a change to the authorized shares of Series A Preferred Stock or the rights
of such shares as required by the General Corporation Law of Delaware (the "DGCL")) and as specified in the Series A Certificate
of Designation, the Series A Preferred Stock does not have voting rights. The Pre-Funded Warrants will be exercisable at any time after
the date of issuance. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would
beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.
A holder of Pre-Funded Warrants may increase or decrease this percentage to a percentage not in excess of 19.99% by providing at least
61 days' prior notice to us.
The sale
of Private Placement Common Shares, Private Placement Conversion Shares and Pre-Funded Warrants was not registered under the Securities
Act, and such sale was intended to be exempt from registration pursuant to Section 4(a)(2) of the Securities Act as a transaction by
an issuer not involving a public offering.
Corporation
Information
On August
29, 2024, we completed the Merger, in connection with which Second Merger Sub changed its corporate name to "Oruka Therapeutics
Operating Company, LLC" and ARCA changed its name to "Oruka Therapeutics, Inc." Our principal executive offices are
located at 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025, and our telephone number is (650) 606-7910.
2
The
Offering
Shares
    Offered by the Selling Securityholders
Up
    to (i) 5,600,000 shares of Common Stock, (ii) 2,439,000 shares of Common Stock issuable upon the conversion of 2,439 shares of Series
    A Preferred Stock and (iii) 680,000 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants.
Terms
    of the Offering
The
    selling securityholders will determine when and how they will dispose of the shares of Common Stock, shares of Common Stock issuable
    upon conversion of Series A Preferred Stock and shares of Common Stock issuable upon the exercise of Pre-Funded Warrants registered
    under this prospectus for resale.
Shares
    Outstanding
As
    of September 30, 2024, there were 34,998,550 of our Common Stock, 2,439 shares of our Series A Preferred Stock and 137,138 shares
    of our Series B Non-Voting Convertible Preferred Stock, par value $0.001 per share ("Series B Preferred Stock"), outstanding.
Use
    of Proceeds
We
    will not receive any proceeds from the sale of the Resale Shares offered by the Selling Stockholders under this prospectus. The net
    proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders. Upon any exercise
    of the Pre-Funded Warrants by payment of cash, however, we will receive the nominal cash exercise price paid by the holders of the
    Pre-Funded Warrants. See the section titled "Use of Proceeds."
Risk
    Factors
See
    the section titled "Risk Factors" and other information included in this prospectus for a discussion of factors that
    you should consider carefully before deciding to invest in our securities.
Trading
    Markets and Ticker Symbols
Our
    Common Stock is listed on The Nasdaq Global Market under the symbol "ORKA."
The number
of issued and outstanding shares of Common Stock does not include the following, as of September 30, 2024:
●
2,439,000
shares of Common Stock issuable upon the conversion of 2,439 shares of Series A Preferred Stock;
●
11,428,149
shares of Common Stock issuable upon the conversion of 137,138 shares of Series B Preferred Stock;
●
5,522,207
shares of Common Stock issuable upon the exercise of 5,522,207 pre-funded warrants to acquire shares of Common Stock with an exercise
price of $0.01 per share;
●
680,000
shares of Common Stock issuable upon the exercise of 680,000 pre-funded warrants to acquire shares of Common Stock with an exercise price
of $0.001 per share;
●
1,287,760
shares of Common Stock issuable upon the exercise of stock options outstanding under the 2024 Equity Incentive Plan and the 2024 Stock
Incentive Plan with a weighted-average exercise price of 7.97 per share;
●
3,054,358
shares of Common Stock issuable upon the exercise of 3,054,358 warrants to acquire shares of Common Stock with a weighted-average exercise
price of $7.80 per share;
●
4,526,324
shares of Common Stock reserved for issuance under our 2024 Stock Incentive Plan; and
●
463,489
shares of Common Stock reserved for issuance under the ESPP.
For additional
information concerning the offering, see the section titled "
Plan of Distribution
."
3
RISK
FACTOR SUMMARY
The following
summarizes the principal factors that make an investment in the Company speculative or risky, all of which are more fully described in
the Risk Factors section below. This summary should be read in conjunction with the Risk Factors section and should not be relied upon
as an exhaustive summary of the material risks facing our business. The occurrence of any of these risks could harm our business, financial
condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking
statements we have made in this prospectus and those we may make from time to time. You should consider all the risk factors described
in our public filings when evaluating our business.
Risks
Related to Our Financial Condition and Capital Requirements
●
We
are a preclinical stage biopharmaceutical company with a limited operating history on which to assess our business; we have not initiated,
conducted or completed any clinical trials, and have no products approved for commercial sale.
●
We
have historically incurred losses and we anticipate that we will continue to incur losses for the foreseeable future.
●
We
have never generated revenue from product sales and may never be profitable.
●
We
may not be able to raise the capital that we need to support our business plans.
●
Raising
additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies
or product candidates.
Risks
Related to Clinical Development and Regulatory Approval
●
Drug
development and obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain.
●
We
are substantially dependent on the success of our two most advanced programs, ORKA-001 and ORKA-002, and our anticipated clinical trials
of such programs may not be successful.
●
We
may not be able to meet requirements for the chemistry, manufacturing and control of our programs.
●
We
face competition from entities that have developed or may develop programs for the diseases addressed by product candidates developed
by us.
●
The
United States Food and Drug Administration ("FDA") and comparable foreign regulatory approval processes are lengthy and time
consuming and we may not be able to obtain or may be delayed in obtaining regulatory approvals for our product candidates.
●
Even
if we obtain regulatory approval, we will be subject to ongoing regulatory obligations.
●
We
may fail to achieve our projected development goals in the time frames we announce and expect.
4
Risks
Related to Our Intellectual Property
●
Our
ability to obtain and protect our patents and other proprietary rights is uncertain.
●
We
may fail in obtaining or maintaining necessary rights to our programs.
●
We
may be subject to patent infringement claims or may need to file such claims.
●
Our
patents and our ability to protect our products may be impaired by changes to patent laws.
●
Our
patent protection could be reduced or eliminated for non-compliance with legal requirements.
●
We
may fail to identify or interpret relevant third-party patents.
●
We
may become subject to claims challenging the inventorship or ownership of our intellectual property.
●
Patent
terms may be inadequate to protect our competitive position of our programs.
●
Our
technology licensed from various third-parties may be subject to retained rights.
Risks
Related to Our Reliance on Third Parties
●
We
currently rely on agreements with third parties to develop our product candidates. If we are unable to maintain collaborations or licensing
arrangements, or if our collaborations or licensing arrangements are not successful, our business could be negatively impacted.
●
Third
parties we rely on for the execution of nonclinical studies and clinical trials may fail to carry out their contractual duties.
●
We
may be unable to use third-party manufacturing sites, our third-party manufacturers may encounter difficulties in production or we may
need to switch or create third-party manufacturer redundancies.
Other
Risk Factors - Risks Related to Employee Matters, Managing Growth, Other Risks Related to Our Business, and Owning Our Common Stock
●
Our
business is dependent on key personnel and we will be harmed if we cannot recruit and retain highly qualified personnel to successfully
implement our business strategy.
●
In
order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties
in managing this growth.
●
Our
estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete
achieve the forecasted growth, our business may not grow at similar rates, or at all.
●
Significant
disruptions of information technology systems or breaches of data security could adversely affect our business.
●
Changes
in and failures to comply with United States and foreign privacy and data protection laws, regulations and standards may adversely affect
our business, operations and consolidated financial performance.
●
We
may become exposed to costly and damaging liability claims and our insurance may not cover all damages from such claims.
●
Our
business could be adversely affected by macroeconomic conditions.
●
We
do not anticipate paying any dividends in the foreseeable future.
●
Future
sales of shares by existing stockholders could cause our stock price to decline.
●
Future
sales and issuances of equity and debt could result in additional dilution to our stockholders and could cause our stock price to decline.
5
RISK
FACTORS
Risks
Related to Our Financial Condition and Capital Requirements
We
are a preclinical stage biopharmaceutical company with a limited operating history on which to assess our business; we have not initiated,
conducted or completed any clinical trials, have no products approved for commercial sale, have historically incurred losses, and we
anticipate that we will continue to incur significant losses for the foreseeable future. Moreover, we have never generated revenue from
product sales and may never be profitable.
We
are a preclinical stage biopharmaceutical company with a limited operating history. We will need to raise substantial additional capital
to continue to fund our operations in the future. We have based our estimates on assumptions that may prove to be wrong, and could exhaust
our available financial resources sooner than it currently anticipates.
We
have devoted substantially all of our financial resources to identify, acquire, and develop our product candidates, organizing and staffing
our company, and providing general and administrative support for our operations.
Biopharmaceutical
product development is a highly speculative undertaking and involves a substantial degree of risk. We expect our losses to increase as
our product candidates enter advanced clinical trials. It may be several years, if ever, before we complete pivotal clinical trials
or have a product candidate approved for commercialization. We expect to invest significant funds into the research and development of
our current programs to determine the potential to advance product candidates to regulatory approval. If we obtain regulatory approval
to market a product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive
approval, and our ability to achieve sufficient market acceptance, pricing, coverage and adequate reimbursement from third-party payors,
and adequate market share for our product candidates in those markets. Even if we obtain adequate market share for our product candidates,
we may never become profitable despite obtaining such market share and acceptance of our products.
We
expect to continue to incur significant expenses and increasing operating losses for the foreseeable future and our expenses will increase
substantially if and as we:
●
continue
the preclinical development and initiate the clinical development of our product candidates;
●
continue
efforts to discover and develop new product candidates;
●
continue
the manufacturing of our product candidates or increase volumes manufactured by third parties;
●
advance
our product candidates into larger, more expensive clinical trials;
●
initiate
additional preclinical studies or clinical trials for our product candidates;
●
seek
regulatory and marketing approvals and reimbursement for our product candidates;
●
establish
a sales, marketing, and distribution infrastructure to commercialize any products for which it may obtain marketing approval and market
for ourselves;
●
make
milestone, royalty, or other payments under third-party license agreements;
●
seek
to maintain, protect, and expand our intellectual property portfolio; and
●
experience
any delays or encounter issues with the development and potential regulatory approval of our clinical and product candidates such as
safety issues, manufacturing delays, clinical trial accrual delays, longer follow-up for planned studies or trials, additional
major studies or trials, or supportive trials necessary to support marketing approval.
6
We
have no significant experience as a company in initiating, conducting or completing clinical trials. In part because of this lack of
experience, we cannot be certain that our planned clinical trials will begin or be completed on time, if at all. In addition, we have
not yet demonstrated an ability to obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party
to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently,
any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.
Further, the net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison
of our results of operations may not be a good indication of our future performance.
We
will need to continue to raise additional capital in order to fund our operations.
As
of September 30, 2024, we had $410.9 million of cash. We have incurred significant net losses since our inception. We anticipate that
we will continue to incur significant losses for the foreseeable future. Since February 6, 2024 (inception), we have incurred significant
operating losses. For the period from February 6, 2024 (inception) to September 30, 2024, we reported a net loss of $57.9 million
and net cash used from operating activities of $39.0 million. We will need to raise additional capital to continue to fund our operations
and service our debt obligations in the future. Until such time, if ever, as we can generate substantial revenue from the sale of our
product candidates, we expect to finance our cash needs through a combination of equity offerings, debt financings and licensing, development
or collaboration agreements. If we are unable to raise additional capital when needed, that may raise substantial doubt about our ability
to continue as a going concern. We expect that our existing cash as of $410.9 million as of September 30, 2024 will be sufficient to
fund our operating expenses and capital expenditure requirements for at least 12 months from the date these condensed consolidated financial
statements were issued.
Developing
our product candidates and operating our company requires a substantial amount of capital. We expect our research and development expenses
to increase in connection with our ongoing activities, particularly as we advance our product candidates through clinical trials. We
may need to raise additional capital to fund our operations and such funding may not be available to us on acceptable terms, or at all,
and such funding may become even more difficult to obtain. Competition for additional capital among biotechnology companies may be particularly
intense during this period of economic instability. We may be unable to raise capital through public offerings of our common stock and
may need to turn to alternative financing arrangements. Such arrangements, if we pursue them, could involve issuances of one or more
types of securities, including common stock, preferred stock, convertible debt, warrants to acquire common stock or other securities.
These securities could be issued at or below the then prevailing market price for our common stock. In addition, if we issue debt securities,
the holders of the debt would have a claim to our assets that would be superior to the rights of stockholders until the principal, accrued
and unpaid interest and any premium or make-whole has been paid. Interest on any newly-issued debt securities and/or newly-incurred borrowings
would increase our operating costs and reduce our net income (or increase our net loss), and these impacts may be material. If the issuance
of new securities results in diminished rights to holders of our common stock, the market price of our common stock could be materially
and adversely affected.
We
do not currently have any products approved for sale and do not generate any revenue from product sales. Accordingly, we expect to rely
primarily on equity and/or debt financings to fund our continued operations. Our ability to raise additional funds will depend, in part,
on the success of our preclinical studies and clinical trials and other product development activities, regulatory events, our ability
to identify and enter into licensing or other strategic arrangements, and other events or conditions that may affect our value or prospects,
as well as factors related to financial, economic and market conditions, many of which are beyond our control. There can be no assurances
that sufficient funds will be available to us when required or on acceptable terms, if at all.
7
If
we are unable to raise additional capital when required or on acceptable terms, we may be required to:
●
significantly
delay, scale back, or discontinue the development or commercialization of our product candidates;
●
seek
    strategic partnerships, or amend existing partnerships, for research and development programs at an earlier stage than otherwise
    would be desirable or that we otherwise would have sought to develop independently, or on terms that are less favorable than might
    otherwise be available in the future;
●
dispose
    of technology assets, or relinquish or license on unfavorable terms, our rights to technologies or any of our product candidates
    that we otherwise would seek to develop or commercialize ourselves;
●
pursue
    the sale of the company to a third party at a price that may result in a loss on investment for our stockholders; or
●
file
    for bankruptcy or cease operations altogether (and face any related legal proceedings).
Any
of these events could have a material adverse effect on our business, operating results, and prospects.
Even
if we are successful in raising new capital, we could be limited in the amount of capital we raise due to investor demand restrictions
placed on the amount of capital we raise, or other reasons.
Raising
additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights.
To
the extent that we raise additional capital through the sale of equity securities or convertible debt securities, the ownership interest
of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect
the rights of holders of our common stock. Debt financing and preferred equity financing, if available, may involve agreements that include
covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures,
or declaring dividends.
If
we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third
parties, we may be required to relinquish valuable rights to our research programs or product candidates or grant licenses on terms that
may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements with third
parties when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts
or grant rights to third parties to develop and market product candidates that we would otherwise prefer to develop and market ourselves.
To
the extent that we raise additional capital through the sale of equity, including pursuant to any sales under convertible debt or other
securities convertible into equity, the ownership interest of our stockholders will be diluted, and the terms of these new securities
may include liquidation or other preferences that adversely affect the rights of our stockholders.
In
September 2024, we entered into a Securities Purchase Agreement with certain new institutional and accredited investors, whereby the
investors purchased an aggregate of 5,600,000 shares of Company Common Stock, 2,439 shares of Company Series A Preferred Stock and pre-funded
warrants to purchase an aggregate of 680,000 shares of common stock for an aggregate purchase price of approximately $200.5 million.
Each share of Company Series A Preferred Stock is convertible into 1,000 shares of Company Common Stock.
Debt
financing, if available, would likely involve agreements that include covenants limiting or restricting our ability to take specific
actions, such as incurring additional debt, making capital expenditures, making additional product acquisitions, or declaring dividends.
If we raise additional funds through strategic collaborations or licensing arrangements with third parties, we may have to relinquish
valuable rights to our product candidates or future revenue streams or grant licenses on terms that are not favorable to us. We cannot
assure you that we will be able to obtain additional funding if and when necessary to fund our entire portfolio of product candidates
to meet our projected plans. If we are unable to obtain funding on a timely basis, we may be required to delay or discontinue one or
more of our development programs or be unable to expand our operations or otherwise capitalize on potential business opportunities, which
could materially harm our business, financial condition, and results of operations.
8
Risks
Related to Clinical Development, Regulatory Approval and Commercialization
We
face competition from entities that have developed or may develop programs for the diseases addressed by product candidates developed
by us.
The
development and commercialization of drugs is highly competitive. Product candidates developed by us, if approved, will face significant
competition and our failure to effectively compete may prevent us from achieving significant market penetration. We compete with a variety
of biopharmaceutical companies as well as academic institutions, governmental agencies, and public and private research institutions,
among others. Many of the companies with which we are currently competing or will compete against in the future have significantly greater
financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trials, regulatory approvals,
and marketing than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources
being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant
competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with
us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, recruiting participants
for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our product candidates.
Our
competitors have developed, are developing or will develop programs and processes competitive with our programs and processes. Competitive
therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments. Our
success will depend partially on our ability to develop and commercialize products that have a competitive safety, efficacy, dosing and/or
presentation profile. Our commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective,
have a more attractive dosing profile or presentation or are less expensive than the products we develop, or if our competitors develop
competing products or if biosimilars enter the market more quickly than we do and are able to gain market acceptance.
Our
programs are in preclinical stages of development and may fail in development or suffer delays. We depend on the successful initiation
and completion of clinical trials for our product candidates to advance our product development plans.
We
have no products on the market, and all of our programs are in preclinical stages of development and have not been tested in humans.
As a result, we expect it will be many years before we can obtain regulatory approval for and commercialize any product candidate,
if ever. We have not yet demonstrated our ability to initiate or complete any clinical trials, obtain regulatory approvals, manufacture
a clinical or commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities
necessary for successful product commercialization. We must initiate and complete clinical trials that demonstrate the safety and efficacy
of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, and can take years to complete
and is uncertain as to outcome. A failure of one or more of our clinical trials can occur at any stage of testing. The outcome of preclinical
testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial
do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and
analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical
trials have nonetheless failed to obtain marketing approval for their products.
We
may experience a number of unforeseen events during clinical trials, including the following:
●
our
product candidates may have undesirable side effects or unexpected characteristics, causing us or our investigators to suspend or terminate
the trials;
●
the
    supply of our clinical trial materials or other materials necessary to conduct clinical trials of our product candidates may be insufficient,
    delayed, does not meet agreed-upon specifications, or are otherwise inadequate for use in clinical trials;
●
regulators
    or institutional review boards ("IRBs"), the FDA or ethics committees may not authorize us or our investigators to commence
    a clinical trial or conduct a clinical trial at a prospective trial site; clinical trials of any product candidates may fail to show
    safety or efficacy, produce negative or inconclusive results, and we may decide, or regulators may require it, to conduct additional
    preclinical studies or clinical trials or we may decide to abandon product development programs;
●
we
    may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and/or contract research
    organizations ("CROs");
9
●
clinical
    trial sites deviating from trial protocol or dropping out of a trial; we may elect to, or regulators, IRBs or ethics committees may
    require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance
    with regulatory requirements or a finding that the participants in our trials are being exposed to unacceptable health risks;
●
the
    number of subjects required for clinical trials of any product candidates may be larger than we anticipate, especially if regulatory
    bodies require completion of non-inferiority or superiority trials; enrollment in these clinical trials may be slower than
    we anticipate or subjects may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher
    rate than we anticipate;
●
our
    third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely
    manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical
    trial sites or investigators;
●
the
    cost of clinical trials of any of our programs may be greater than we anticipate;
●
reports
    from clinical testing of other therapies may raise safety or efficacy concerns about our programs;
●
our
    failure to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product
    candidates as well as data emerging from other therapies in the same class as our product candidates; and
●
the
    FDA or other regulatory authorities may require us to submit additional data such as long-term toxicology studies, or impose
    other requirements before permitting us to initiate a clinical trial.
Commencing
clinical trials in the United States is subject to acceptance by the FDA of an investigational new drug application ("IND"),
biologics license application ("BLA") or similar application and finalizing the trial design based on discussions with the
FDA and other regulatory authorities. In the event that the FDA requires us to complete additional preclinical studies or it is required
to satisfy other FDA requests prior to commencing clinical trials, the start of our first clinical trials may be delayed. If our clinical
trials do not produce favorable results, our ability to obtain regulatory approval for our product candidates may be adversely impacted.
Moreover, the combined data from our trials maybe inconclusive or may not be sufficient to ultimately gain marketing approval from the
FDA or other regulatory authorities. There are equivalent processes and risks applicable to clinical trial applications in other countries,
including countries in the European Union ("EU").
In
addition, because of the competitive landscape for immunology and inflammation (commonly referred to as "I&I") indications,
we may also face competition for clinical trial enrollment. Clinical trial enrollment will depend on many factors, including if potential
clinical trial participants choose to undergo treatment with approved products or enroll in competitors' ongoing clinical trials
for programs that are under development for the same indications as our programs. An increase in the number of approved products for
the indications we are targeting with our programs may further exacerbate this competition. Our inability to enroll a sufficient number
of participants could, among other things, delay our development timeline, which may further harm our competitive position.
We
may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a product
candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, our product candidates.
Our inability to complete development of, or commercialize our product candidates, or significant delays in doing so, could have a material
and adverse effect on our business, financial condition, results of operations and prospects.
10
We
are substantially dependent on the success of our two most advanced programs, ORKA-001 and ORKA-002, and our anticipated clinical trials
of such programs may not be successful.
Our
future success is substantially dependent on our ability to develop and timely obtain marketing approval for, and then successfully commercialize,
our two most advanced programs, ORKA-001 and ORKA-002. We are investing a majority of our efforts and financial resources into the
research and development of these programs. We anticipate initiating a Phase 1 clinical trial in healthy volunteers of ORKA-001 in
the first quarter of 2025 and of ORKA-002 in the second half of 2025, each subject to the filing of an IND or foreign equivalent
and regulatory approval. The success of our programs is dependent on observing a longer half-life of our product candidates in humans
than other extended half-life monoclonal antibodies ("mAbs") currently marketed and in development as we believe this
longer half-life has the potential to result in a more favorable dosing schedule for our product candidates, assuming they successfully
complete clinical development and obtain marketing approval. This is based in part on the assumption that the longer half-life we
have observed in non-human primates ("NHPs") will translate into an extended half-life of our product candidates
in humans. To the extent we do not observe this extended half-life in humans, it would significantly and adversely affect the clinical
and commercial potential of our product candidates.
Our
programs will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, product development,
marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues
from product sales.
The
success of our product candidates will depend on a variety of factors. We do not have complete control over many of these factors, including
certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights
and the manufacturing, marketing, distribution and sales efforts of any current or future collaborator.
If
we do not achieve our projected development goals in the time frames we announce and expect, the development and potential commercialization
of our product candidates may be delayed and our expenses may increase and, as a result, our business may be materially harmed and our
stock price may decline.
From
time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product
development goals, which it sometimes refers to as milestones. These milestones may include the commencement or completion of scientific
studies and clinical trials, such as the expected timing for the anticipated commencement of our Phase 1 studies, clinical trials
in psoriasis ("PsO") and other target indications, as well as the submission of regulatory filings. From time to time, we
may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions.
The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control.
If we do not meet these milestones as publicly announced, or at all, the development and potential commercialization of our product candidates
may be delayed or never achieved and, as a result, our business may be materially harmed and our stock price may decline. Additionally,
delays relative to our projected timelines are likely to cause overall expenses to increase, which may require us to raise additional
capital sooner than expected and prior to achieving targeted development milestones.
Any
drug delivery device that we may use to deliver our product candidates may have its own regulatory, development, supply and other risks.
We
expect to deliver our product candidates via a drug delivery device, such as an injector or other delivery system. There may be unforeseen
technical complications related to the development activities required to bring such a product to market, including primary container
compatibility and/or dose volume requirements. Our product candidates may not be approved or may be substantially delayed in receiving
approval if the devices that we choose to develop do not gain and/or maintain their own regulatory approvals or clearances. Where approval
of the drug product and device is sought under a single application, the increased complexity of the review process may delay approval.
In addition, some drug delivery devices are provided by single-source unaffiliated third-party companies. We may be dependent
on the sustained cooperation and effort of those third-party companies both to supply the devices and, in some cases, to conduct
the studies required for approval or other regulatory clearance of the devices. Even if approval is obtained, we may also be dependent
on those third-party companies continuing to maintain such approvals or clearances once they have been received. Failure of third-party companies
to supply the devices on time and in accordance with the agreed-upon specifications, to successfully complete studies on the devices
in a timely manner, or to obtain or maintain required approvals or clearances of the devices could result in increased development costs,
delays in or failure to obtain regulatory approval and delays in product candidates reaching patients.
11
Our
approach to the discovery and development of our programs is unproven, and we may not be successful in our efforts to build a pipeline
of programs with commercial value.
Our
approach to the discovery and development of the research programs with respect to which we have the option to acquire intellectual property
license rights to pursuant to those certain antibody discovery and option agreements by and among the Company, Paragon Therapeutics,
Inc. and Paruka Holding, LLC (the "Option Agreements") and leverages clinically validated mechanisms of action and incorporates
advanced antibody engineering to optimize half-life and other properties designed to overcome limitations of existing therapies.
Our programs are purposefully designed to improve upon existing product candidates and products while maintaining the same, well-established mechanisms
of action. However, the scientific research that forms the basis of our efforts to develop programs using half-life extension technologies
is ongoing and may not result in viable programs. There is limited clinical data available on product candidates utilizing half-life extension
technologies, especially in I&I indications, demonstrating whether they are safe or effective for long-term treatment in
humans. The long-term safety and efficacy of these technologies and the extended half-life and exposure profile of our programs
compared to currently approved products is unknown.
We
may ultimately discover that utilizing half-life extension technologies for our specific targets and indications and any programs
resulting therefrom does not possess certain properties required for therapeutic effectiveness. We currently have only preclinical data
regarding the increased half-life properties of our programs and the same results may not be seen in humans. In addition, programs
using half-life extension technologies may demonstrate different chemical and pharmacological properties in participants than they
do in laboratory studies. This technology and any programs resulting therefrom may not demonstrate the same chemical and pharmacological
properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways.
In
addition, we may in the future seek to discover and develop programs that are based on novel targets and technologies that are unproven.
If our discovery activities fail to identify novel targets or technologies for drug discovery, or such targets prove to be unsuitable
for treating human disease, we may not be able to develop viable additional programs. We and our existing or future collaborators may
never receive approval to market and commercialize any product candidate. Even if we or an existing or future collaborator obtains regulatory
approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired
or may require labeling that includes significant use or distribution restrictions or safety warnings. If the products resulting from
the research programs with respect to which we have the option to acquire intellectual property license rights to pursuant to the Option
Agreements prove to be ineffective, unsafe or commercially unviable, such programs would have little, if any, value, which would have
a material and adverse effect on our business, financial condition, results of operations and prospects.
Preclinical
and clinical development involves a lengthy and expensive process that is subject to delays and uncertain outcomes, and results of earlier
studies and trials may not be predictive of future clinical trial results. If our preclinical studies and clinical trials are not sufficient
to support regulatory approval of any of our product candidates, we may incur additional costs or experience delays in completing, or
ultimately be unable to complete, the development of such product candidate.
Before
obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies
and then conduct extensive clinical trials to demonstrate the safety and efficacy of such product candidate in humans. Our clinical trials
may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or
clinical trial process.
Furthermore,
a failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early-stage clinical
trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to
varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical
studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. In addition, we expect
to rely on participants to provide feedback on measures such as measures of quality of life, which are subjective and inherently difficult
to evaluate. These measures can be influenced by factors outside of our control, and can vary widely from day-to-day for a
particular participant, and from participant to participant and from site to site within a clinical trial.
We
cannot be sure that the FDA will agree with our clinical development plan. We plan to use the data from our planned Phase 1 trials
of our ORKA-001 and ORKA-002 programs in healthy volunteers to support Phase 2 trials in PsO and potentially other I&I
indications. If the FDA requires us to conduct additional trials or enroll additional participants, our development timelines may be
delayed. We cannot be sure that submission of an IND, BLA or similar application will result in the FDA or comparable foreign regulatory
authorities, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues
may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Events that may prevent successful or
timely initiation or completion of clinical trials include: inability to generate sufficient preclinical, toxicology or other
in
vivo
or
in vitro
data to support the initiation or continuation of clinical trials; delays in reaching a consensus
with regulatory authorities on study design or implementation of the clinical trials; delays or failure in obtaining regulatory authorization
to commence a trial; delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which
can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; delays in identifying,
recruiting and training suitable clinical investigators; delays in obtaining required IRB approval at each clinical trial site; delays
in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our product candidates for use
in clinical trials or the inability to do any of the foregoing; failure by our CROs, other third parties or us to adhere to clinical
trial protocols; failure to perform in accordance with the FDA's or any other regulatory authority's current Good Clinical
Practice requirements ("GCPs") or applicable regulatory guidelines in other countries; changes to the clinical trial protocols;
clinical sites deviating from trial protocol or dropping out of a trial; changes in regulatory requirements and guidance that require
amending or submitting new clinical protocols; selection of clinical endpoints that require prolonged periods of observation or analyses
of resulting data; transfer of manufacturing processes to facilities operated by a contract manufacturing organization ("CMO")
and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; and third parties being unwilling
or unable to satisfy their contractual obligations to us.
12
We
could also encounter delays if a clinical trial is suspended or terminated by it, by the IRBs of the institutions in which such clinical
trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial or by the FDA or comparable foreign
regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct
the clinical trial in accordance with regulatory requirements or our clinical trial protocols, inspection of the clinical trial operations
or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety
issues or adverse side effects, failure to demonstrate a benefit from the programs, changes in governmental regulations or administrative
actions or lack of adequate funding to continue the clinical trial. If we are required to conduct additional clinical trials or other
testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials
of our product candidates, if the results of these trials are not positive or are only moderately positive or if there are safety concerns,
our business and results of operations may be adversely affected and we may need to adjust or abandon our business plans and we may incur
significant additional costs.
If
we encounter difficulties enrolling participants in our future clinical trials, our clinical development activities could be delayed
or otherwise adversely affected.
We
may experience difficulties in patient participant enrollment in our clinical trials for a variety of reasons. The timely completion
of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of participants
who remain in the trial until conclusion. The enrollment of participants in future trials for any of our programs will depend on many
factors, including if participants choose to enroll in clinical trials, rather than using approved products, or if our competitors have
ongoing clinical trials for programs that are under development for the same indications as our programs, and participants instead enroll
in such clinical trials. Even if we are able to enroll a sufficient number of participants for our clinical trials, it may have difficulty
maintaining participants in our clinical trials. Our inability to enroll or maintain a sufficient number of participants would result
in significant delays in completing clinical trials and increased development costs or may require us to abandon one or more clinical
trials altogether.
Preliminary,
"topline" or interim data from our clinical trials may change as more participant data becomes available and are subject
to audit and verification procedures.
From
time to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which are based
on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following
a more comprehensive review of the data. We also make assumptions, estimations, calculations and conclusions as part of our analyses
of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary or topline results
that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results,
once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures.
Any
preliminary or topline data should be viewed with caution until the final data are available. From time to time, we may also disclose
interim data from our preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical
outcomes may materially change as participant enrollment continues and more participant data become available or as participants from
our clinical trials continue other treatments. Further, others, including regulatory agencies, may not accept or agree with our assumptions,
estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the
value of the particular product candidate, the approvability or commercialization of the particular product candidate and our company
in general. In addition, the information we choose to publicly disclose regarding a particular preclinical study or clinical trial is
based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate
information to include in our disclosure. If the preliminary, topline or interim data that we report differ from actual results, or if
others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize,
our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.
13
Our
clinical trials may reveal significant adverse events or undesirable side effects not seen in our preclinical studies and may result
in a safety profile that could halt clinical development, inhibit regulatory approval or limit commercial potential or market acceptance
of any of our product candidates.
Results
of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects, adverse events or unexpected characteristics.
While preclinical studies in NHPs conducted with respect to our programs have not shown any such characteristics to date, we have not
yet initiated any clinical trials in humans. If significant adverse events or other side effects are observed in any of our future clinical
trials, we may have difficulty recruiting participants to such trials, participants may drop out of the trials, or we may be required
to abandon the trials or our development efforts of one or more programs altogether. We, the FDA or other applicable regulatory authorities,
or an IRB, may suspend any clinical trials of any program at any time for various reasons, including a belief that subjects or patients
in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential products developed in the biotechnology
industry that initially showed therapeutic promise in early-stage studies and trials have later been found to cause side effects
that prevented their further development. However, other potential products have shown side effects in preclinical studies, which side
effects do not present themselves in clinical trials in humans. Even if the side effects do not preclude the product candidate from obtaining
or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to their tolerability
versus other therapies. In addition, an extended half-life could prolong the duration of undesirable side effects, which could also
inhibit market acceptance. Treatment-emergent adverse events could also affect participant recruitment or the ability of enrolled
subjects to complete our clinical trials or could result in potential product liability claims. Potential side effects associated with
our product candidates may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from our
product candidates may not be normally encountered in the general patient population and by medical personnel. Any of these occurrences
could harm our business, financial condition, results of operations and prospects significantly.
In
addition, even if we successfully advance our product candidates or any future product candidates through clinical trials, such trials
will only include a limited number of participants and limited duration of exposure to our product candidates. As a result, we cannot
be assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of participants are
exposed to the product candidate after approval. Further, any clinical trials may not be sufficient to determine the effect and safety
consequences of using our product candidates over a multi-year period.
If
any of the foregoing events occur or if one or more of the research programs with respect to which we have the option to acquire intellectual
property license rights to pursuant to the Option Agreements prove to be unsafe, our entire pipeline could be affected, which would have
a material adverse effect on our business, financial condition, results of operations and prospects.
We
may expend our limited resources to pursue a particular program and fail to capitalize on programs that may be more profitable or for
which there is a greater likelihood of success.
Because
we have limited financial and managerial resources, we focus our research and development efforts on certain selected programs. For example,
we are initially focused on our most advanced programs, ORKA-001 and ORKA-002. As a result, we may forgo or delay pursuit of opportunities
with other programs that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to
capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development
programs for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial
potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration,
licensing or other royalty arrangements in cases in which we would have been more advantageous for us to retain sole development and
commercialization rights to such product candidate.
Any
approved products resulting from our current programs or any future program may not achieve adequate market acceptance among clinicians,
patients, healthcare third-party payors and others in the medical community necessary for commercial success and we may not generate
any future revenue from the sale or licensing of such products.
Even
if regulatory approval is obtained for a product candidate resulting from one of our current or future programs, they may not gain market
acceptance among physicians, patients, healthcare payors or the medical community. We may not generate or sustain revenue from sales
of the product due to factors such as whether the product can be sold at a competitive cost and whether it will otherwise be accepted
in the market. There are several approved products and product candidates in later stages of development for the treatment of PsO. However,
our programs incorporate advanced antibody engineering to optimize the half-life and formulation of antibodies; to date, no such
antibody has been approved by the FDA for the treatment of PsO. Market participants with significant influence over acceptance of
new treatments, such as clinicians and third-party payors, may not adopt a biologic that incorporates half-life extension for
our targeted indications, and we may not be able to convince the medical community and third-party payors to accept and use, or
to provide favorable reimbursement for, any programs developed by us or our existing or future collaborators. An extended half-life may
make it more difficult for patients to change treatments and there is a perception that half-life extension could exacerbate side
effects, each of which may adversely affect our ability to gain market acceptance. Market acceptance of our product candidates will depend
on many factors, including factors that are not within our control.
14
Sales
of medical products also depend on the willingness of clinicians to prescribe the treatment. We cannot predict whether clinicians, clinicians'
organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that our product is safe,
therapeutically effective, cost effective or less burdensome as compared with competing treatments. If any of our product candidates
is approved but does not achieve an adequate level of acceptance by such parties, we may not generate or derive sufficient revenue from
that product candidate and may not become or remain profitable.
Certain
of our programs may compete with our other programs, which could negatively impact our business and reduce our future revenue.
We
are developing product candidates for the same indication, PsO, and may in the future develop our programs for other I&I indications.
Each such program targets a different mechanism of action. However, developing multiple programs for a single indication may negatively
impact our business if the programs compete with each other. For example, if multiple programs are conducting clinical trials at the
same time, they could compete for the enrollment of participants. In addition, if multiple product candidates are approved for the same
indication, they may compete for market share, which could limit our future revenue.
We
may conduct clinical trials for programs at sites outside the United States, and the FDA may not accept data from trials conducted
in such locations.
We
may choose to conduct one or more of our future clinical trials outside the United States. Although the FDA may accept data from
clinical trials conducted outside the United States, acceptance of this data is subject to conditions imposed by the FDA. For
example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles.
The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population
and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject
to the applicable local laws, FDA acceptance of the data will depend upon the determination that the trials also complied with all applicable
U.S. laws and regulations. If the FDA does not accept the data from any trial that we conduct outside the United States, it
would likely result in the need for additional trials, which would be costly and time-consuming and would delay or permanently halt
our development of the applicable product candidates. Even if the FDA accepted such data, it could require us to modify our planned clinical
trials to receive clearance to initiate such trials in the United States or to continue such trials once initiated.
Further,
conducting clinical trials outside of the U.S. presents additional risks that may delay completion of our clinical trials. These risks
include the failure of enrolled participants in foreign countries to adhere to clinical protocol as a result of differences in healthcare
services or cultural customs that could restrict or limit our ability to conduct our clinical trials, the administrative burdens of conducting
clinical trials under multiple sets of foreign regulations, potential restrictions on data generated from the clinical trial, foreign
exchange fluctuations, diminished protection of intellectual property in some countries, as well as political and economic risks relevant
to foreign countries.
Risks
Related to Government Regulation
The
regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently
unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates,
we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue
will be materially impaired.
The
process of obtaining regulatory approvals, both in the United States and abroad, is unpredictable, expensive and typically takes
many years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety
of factors, including the type, complexity and novelty of the product candidates involved. Before obtaining regulatory approvals for
the commercial sale of our product candidates, including our most advanced programs, ORKA-001 and ORKA-002, we must demonstrate
through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective
for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process
to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, our product candidates may not be effective,
may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that
may preclude our obtaining marketing approval. The FDA and comparable foreign regulatory authorities have substantial discretion in the
approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional
preclinical, clinical or other data. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for
many reasons, including: the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical
trials; we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate
is safe and effective for our proposed indication; the results of clinical trials may not meet the level of statistical significance
required by the FDA or comparable foreign regulatory authorities for approval; serious and unexpected drug-related side effects
may be experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates; we may be
unable to demonstrate that a product candidate's clinical and other benefits outweigh our safety risks; the FDA or comparable foreign
regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; the data collected from
clinical trials of our product candidates may not be acceptable or sufficient to support the submission of a BLA or other submission
or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials;
the FDA or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of
our product candidates; the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities
of third-party manufacturers with which we contract for clinical and commercial supplies; and the approval policies or regulations
of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient
for approval.
15
Of
the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes
and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our
failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations
and prospects.
If
we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than
we request, including failing to approve the most commercially promising indications, may grant approval contingent on the performance
of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims
necessary or desirable for the successful commercialization of that product candidate. If we are not able to obtain, or if there are
delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed
in commercializing, our product candidates and our ability to generate revenue will be materially impaired.
We
may not be able to meet requirements for the chemistry, manufacturing and control of our programs.
In
order to receive approval of our products by the FDA and comparable foreign regulatory authorities, we must show that we and our CMO
partners are able to characterize, control and manufacture our drug products safely and in accordance with regulatory requirements. This
includes manufacturing the active ingredient, developing an acceptable formulation, manufacturing the drug product, performing tests
to adequately characterize the formulated product, documenting a repeatable manufacturing process, and demonstrating that our drug products
meet stability requirements. Meeting these chemistry, manufacturing and control requirements is a complex task that requires specialized
expertise. If we are not able to meet the chemistry, manufacturing and control requirements, we may not be successful in getting our
products approved.
Our
product candidates for which we intend to seek approval as biologics may face competition sooner than anticipated.
The
Patient Protection and Affordable Act, as amended by the Healthcare and Education Reconciliation Act (the "ACA"), includes
a subtitle called the Biologics Price Competition and Innovation Act of 2009 ("BPCIA"), which created an abbreviated
approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological
product. Under the BPCIA, an application for a highly similar or "biosimilar" product may not be submitted to the FDA until
four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar
product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During
this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA
approves a full BLA for the competing product containing the sponsor's own preclinical data and data from adequate and well-controlled clinical
trials to demonstrate the safety, purity and potency of their product.
We
believe that any of our product candidates approved as biologics under a BLA should qualify for the 12-year period of exclusivity.
However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not
consider our product candidates to be reference products for competing products, potentially creating the opportunity for competition
sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject
of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference products in a
way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a
number of marketplace and regulatory factors that are still developing.
Even
if we receive regulatory approval of our product candidates, we will be subject to extensive ongoing regulatory obligations and continued
regulatory review and may result in restrictions on the use of the product, which may result in significant additional expense and we
may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.
Any
regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities
and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions
for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management
requirements. For example, the FDA may require a risk evaluation and mitigation strategy ("REMS") in order to approve our
product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional
elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition,
if the FDA or comparable foreign regulatory authorities approve our product candidates, our product candidates and the activities associated
with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling,
storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the FDA
and other regulatory agencies in the United States and by comparable foreign regulatory authorities. These requirements include
submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with
current CGMPs and GCPs for any clinical trials that we conduct following approval. In addition, manufacturers of drug products and their
facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance
with CGMPs.
16
If
we or a regulatory authority discover previously unknown problems with a product, such as adverse events of unanticipated severity or
frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that
product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing,
restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials, restrictions
on the manufacturing process, warning or untitled letters, civil and criminal penalties, injunctions, product seizures, detentions or
import bans, voluntary or mandatory publicity requirements and imposition of restrictions on operations, including costly new manufacturing
requirements. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates
and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.
We
may face difficulties from healthcare legislative reform measures.
Existing
regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval
of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation
or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements
or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval
that we may have obtained and we may not achieve or sustain profitability.
Our
business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors,
patient organizations and customers will be subject to applicable healthcare regulatory laws, including conflicts of interest rules,
which could expose us to penalties.
Our
business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors,
patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These
laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we
research, market, sell and distribute our product candidates, if approved. Principal investigators for our clinical trials may serve
as scientific advisors or consultants to us or may be affiliated with our other service providers, including CROs or site management
organizations, and from time to time may receive cash compensation in connection with such services. If these relationships and any related
compensation result in perceived or actual conflicts of interest, the integrity of the data generated at the applicable clinical trial
site or in the applicable trial may be questioned or jeopardized.
Ensuring
that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations
will involve substantial costs. If our operations are found to be in violation of any of these laws or any other governmental laws and
regulations that may apply to it, we may be subject to significant penalties, including civil, criminal and administrative penalties,
damages, fines, exclusion from government-funded healthcare programs, integrity oversight and reporting obligations to resolve allegations
of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the
curtailment or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming and
may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought
against us, our business may be impaired.
Even
if we are able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement
policies, we may not be able to offer such product candidates at competitive prices which would seriously harm our business.
We
intend to seek approval to market our product candidates in the United States and in selected foreign jurisdictions. If we obtain
approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions.
Our ability to successfully commercialize any product candidates that we may develop will depend in part on the extent to which reimbursement
for these product candidates and related treatments will be available from government health administration authorities, private health
insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health
maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Government authorities and
other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications.
These entities may create preferential access policies for a competitor's product, including a branded or generic/biosimilar product,
over our products in an attempt to reduce their costs, which may reduce our commercial opportunity. Additionally, if any of our product
candidates are approved and we are found to have improperly promoted off-label uses of those product candidates, we may become subject
to significant liability, which would materially adversely affect our business and financial condition.
17
We
are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering
laws and regulations. We can face criminal liability and other serious consequences for violations, which can harm our business.
We
are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs
regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department's Office of Foreign
Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained
in 18 U.S.C. § 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering
laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their
employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly,
improper payments or anything else of value to or from recipients in the public or private sector. We may engage third parties to sell
our products outside the United States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations,
and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals,
universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors,
and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws
and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or
import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.
Governments
outside the United States tend to impose strict price controls, which may adversely affect our revenue, if any.
In
some countries, particularly member states of the EU ("EU Member States"), the pricing of prescription drugs is subject to
governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt
of marketing approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices
and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further
complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used
by various EU Member States and parallel distribution, or arbitrage between low-priced and high-priced EU Member States,
can further reduce prices. To obtain coverage and reimbursement or pricing approvals in some countries, we or current or future collaborators
may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other
available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors
or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries.
If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at
unsatisfactory levels, our business, financial condition, results of operations or prospects could be materially and adversely affected.
Brexit could lead to legal uncertainty and potentially divergent national laws and regulations, including those related to the pricing
of prescription pharmaceuticals, as the United Kingdom ("UK") determines which EU laws to replicate or replace. If the UK
were to significantly alter its regulations affecting the pricing of prescription pharmaceuticals, we could face significant new costs.
A
breakthrough therapy, fast track, or other expedited designation for our product candidates may not lead to a faster development or regulatory
review or approval process, and it does not increase the likelihood that those product candidates will receive marketing approval.
We
may seek a breakthrough therapy, fast track, or other designation for appropriate product candidates. Designations such as these are
within the discretion of the FDA, or other comparable regulatory authorities. The receipt of a designation for a product candidate may
not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures
and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualifies under one
of FDA's designation programs, the FDA may later decide that the products no longer meet the conditions for qualification or decide
that the time period for FDA review or approval will not be shortened.
18
Risks
Related to Our Intellectual Property
Our
ability to obtain and protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive
advantage.
We
rely upon a combination of patents, trademarks, trade secret protection, confidentiality agreements and the Option Agreements to protect
the intellectual property related to our programs and technologies and to prevent third parties from competing unfairly with it. Our
success depends in large part on our ability to obtain and maintain patent protection for our platform technologies, programs and their
uses, as well as our ability to operate without infringing on or violating the proprietary rights of others. Paragon has filed provisional
patent applications and intends to file one or more additional provisional patent applications directed to antibodies that target IL-23,
including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA-001.
In addition, Paragon has filed provisional patent applications and intends to file one or more additional provisional patent applications
directed to antibodies that target IL-17, including applications covering composition of matter, pharmaceutical formulations, and methods
of using such antibodies, including ORKA-002. However, we may not be able to protect our intellectual property rights throughout the
world and the legal systems in certain countries may not favor enforcement or protection of patents, trade secrets and other intellectual
property. Filing, prosecuting and defending patents on programs worldwide would be expensive and our intellectual property rights in
some foreign jurisdictions can be less extensive than those in the United States; the reverse may also occur. As such, we may not
have patents in all countries or all major markets and may not be able to obtain patents in all jurisdictions even if we apply for them.
Our competitors may operate in countries where we do not have patent protection and can freely use our technologies and discoveries in
such countries to the extent such technologies and discoveries are publicly known or disclosed in countries where we do have patent protection
or pending patent applications.
Our
pending and future patent applications may not result in patents being issued. Any issued patents may not afford sufficient protection
of our programs or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed,
designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products
or programs. Even if these patents are granted, they may be difficult to enforce. Further, any issued patents that we may license or
own covering our programs could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies
in the United States or abroad, including the United States Patent and Trademark Office ("USPTO"). Further, if
we encounter delays in our clinical trials or delays in obtaining regulatory approval, the period of time during which we could market
our product candidates under patent protection would be reduced. Thus, the patents that we may own and license may not afford us any
meaningful competitive advantage.
In
addition to seeking patents for some of our technology and programs, we may also rely on trade secrets, including unpatented know-how, technology
and other proprietary information, to maintain our competitive position. Any disclosure, either intentional or unintentional, by our
employees, the employees of third parties with whom we share our facilities or third-party consultants and vendors that we engage
to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity
breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements,
thus eroding our competitive position in our market. In order to protect our proprietary technology and processes, we rely in part on
confidentiality agreements with our collaborators, employees, consultants, outside scientific collaborators and sponsored researchers
and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate
remedy in the event of unauthorized disclosure of confidential information. We may need to share our proprietary information, including
trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft
of trade secrets, including through direct intrusion by private parties or state actors and those affiliated with or controlled by state
actors. In addition, while we undertake efforts to protect our trade secrets and other confidential information from disclosure, others
may independently discover trade secrets and proprietary information, and in such cases, we may not be able to assert any trade secret
rights against such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary
rights and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.
Lastly,
if our trademarks and trade names are not registered or adequately protected, then we may not be able to build name recognition in our
markets of interest and our business may be adversely affected.
19
We
may not be successful in obtaining or maintaining necessary rights to our programs through acquisitions and in-licenses.
Because
our development programs currently do and may in the future require the use of proprietary rights held by third parties, the growth of
our business may depend in part on our ability to acquire, in-license, or use these third-party proprietary rights. We
may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property
rights from third parties that we identify as necessary for our programs. The licensing and acquisition of third-party intellectual
property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual
property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due
to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive
us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual
property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully
obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we do obtain,
we may have to abandon development of the relevant program, which could have a material adverse effect on our business, financial condition,
results of operations, and prospects.
While
we plan to obtain the right to control prosecution, maintenance and enforcement of the patents relating to our programs, there may be
times when the filing and prosecution activities for patents and patent applications relating to our programs are controlled by our current
and future licensors or collaboration partners. If any of our current and future licensors or collaboration partners fail to prosecute,
maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by
payment of all applicable fees for patents covering our product candidates, we could lose our rights to the intellectual property or
our exclusivity with respect to those rights, our ability to develop and commercialize those product candidates may be adversely affected
and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the
right to control patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely
affected or prejudiced by actions or inactions of our licensees, our future licensors and our counsel that took place prior to the date
upon which we assumed control over patent prosecution.
Our
future licensors may rely on third-party consultants or collaborators or on funds from third parties such that our future licensors
are not the sole and exclusive owners of the patents we in-license. If other third parties have ownership rights to our future in-licensed patents,
they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This
could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.
It
is possible that we may be unable to obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain
a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that
event, we may be required to expend significant time and resources to redesign our technology, programs, or the methods for manufacturing
them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are
unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial
condition, results of operations, and prospects significantly. We cannot provide any assurances that third-party patents do not
exist which might be enforced against our current technology, manufacturing methods, programs, or future methods or products resulting
in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part
to pay royalties and/or other forms of compensation to third parties, which could be significant.
Disputes
may arise between us and our future licensors regarding intellectual property subject to a license agreement, including: the scope of
rights granted under the license agreement and other interpretation-related issues; whether and the extent to which our technology
and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; our right to sublicense
patents and other rights to third parties; our right to transfer or assign the license; the inventorship and ownership of inventions
and know-how resulting from the joint creation or use of intellectual property by our future licensors and us and our partners;
and the priority of invention of patented technology.
20
We
may be subject to patent infringement claims or may need to file claims to protect our intellectual property, which could result in substantial
costs and liability and prevent us from commercializing our potential products.
Because
the intellectual property landscape in the biotechnology industry is rapidly evolving and interdisciplinary, it is difficult to conclusively
assess our freedom to operate and guarantee that we can operate without infringing on or violating third-party rights. If certain
of our product candidates are ultimately granted regulatory approval, patent rights held by third parties, if found to be valid and enforceable,
could be alleged to render one or more of our product candidates infringing. If a third party successfully brings a claim against us,
we may be required to pay substantial damages, be forced to abandon any affected product candidate and/or seek a license from the patent
holder. In addition, any intellectual property claims (e.g., patent infringement or trade secret theft) brought against us, whether or
not successful, may cause us to incur significant legal expenses and divert the attention of our management and key personnel from other
business concerns. We cannot be certain that patents owned or licensed by us will not be challenged by others in the course of litigation.
Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because
they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation
could have a material adverse effect on our ability to raise funds.
Competitors
may infringe or otherwise violate our patents, trademarks, copyrights or other intellectual property. To counter infringement or other
violations, we may be required to file claims, which can be expensive and time-consuming. Any such claims could provoke these parties
to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights. In
addition, in a patent infringement proceeding, a court or administrative body may decide that one or more of the patents we assert is
invalid or unenforceable, in whole or in part, construe the patent's claims narrowly or refuse to prevent the other party from
using the technology at issue on the grounds that our patents do not cover the technology. Similarly, if we assert trademark infringement
claims, a court or administrative body may determine that the marks we have asserted are invalid or unenforceable or that the party against
whom we have asserted trademark infringement has superior rights to the marks in question. In such a case, we could ultimately be forced
to cease use of such marks. In any intellectual property litigation, even if we are successful, any award of monetary damages or other
remedy we receive may not be commercially valuable.
Further,
we may be required to protect our patents through procedures created to attack the validity of a patent at the USPTO. An adverse
determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which
could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary
standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO
proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim
if first presented in a district court action.
In
addition, if our programs are found to infringe the intellectual property rights of third parties, these third parties may assert infringement
claims against our future licensees and other parties with whom we have business relationships and we may be required to indemnify those
parties for any damages they suffer as a result of these claims, which may require us to initiate or defend protracted and costly litigation
on behalf of licensees and other parties regardless of the merits of such claims. If any of these claims succeed, we may be forced to
pay damages on behalf of those parties or may be required to obtain licenses for the products they use.
Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings
relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure
during this type of litigation or other proceedings.
We
may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent
contractors have wrongfully used or disclosed confidential information of third parties.
As
is common in the biotechnology industry, in addition to our employees, we engage the services of consultants to assist us in the development
of our programs. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or
may be currently providing consulting services to, other biotechnology or pharmaceutical companies including our competitors or potential
competitors. We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged
trade secrets or other confidential information of former employers or competitors. Although we try to ensure that our employees and
consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work
for us, we may become subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement,
or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information
of a former employer or competitor.
21
While
we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and
could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court
could prohibit us from using technologies or features that are essential to our programs, if such technologies or features are found
to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation
or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators,
engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results
of operations and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial
costs and be a distraction to management.
Changes
to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our
ability to protect our products.
Changes
in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the
Leahy-Smith America Invents Act (the "Leahy-Smith Act") could increase the uncertainties and costs surrounding
the prosecution of our owned and in-licensed patent applications and the maintenance, enforcement or defense of our owned and in-licensed issued
patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions
that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for
competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution
and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review,
inter partes review and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013,
in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States,
the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States
transitioned to a first-to-file system in which, assuming that the other statutory requirements for patentability are met,
the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was
the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties
and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could
have a material adverse effect on our business, financial condition, results of operations and prospects.
In
addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly
uncertain. U.S. Supreme Court and U.S. Court of Appeals for the Federal Circuit rulings have narrowed the scope of patent protection
available in certain circumstances and weakened the rights of patent owners in certain situations, including in the antibody arts. For
example, the United States Supreme Court in
Amgen, Inc. v. Sanofi
(
Amgen
) recently held that Amgen's
patent claims to a class of antibodies functionally defined by their ability to bind a particular antigen were invalid for lack of enablement
where the patent specification provided twenty-six exemplary antibodies, but the claimed class of antibodies covered a "vast
number" of additional antibodies not disclosed in the specification. The Court stated that if patent claims are directed to an
entire class of compositions of matter, then the patent specification must enable a person skilled in the art to make and use the entire
class of compositions. This decision makes it unlikely that we will be granted U.S. patents with composition of matter claims directed
to antibodies functionally defined by their ability to bind a particular antigen. Even if we are granted claims directed to functionally
defined antibodies, it is possible that a third party may challenge our patents, when issued, relying on the reasoning in
Amgen
or
other recent precedential court decisions. Additionally, there have been proposals for additional changes to the patent laws of the United States
and other countries that, if adopted, could impact our ability to enforce our proprietary technology. This combination of events has
created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress,
the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material
adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future.
Geopolitical
instability in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution
or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. For example, the United States'
and foreign governments' actions related to Russia's invasion of Ukraine may limit or prevent filing, prosecution and maintenance
of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result
in abandonment or lapse of patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such
an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government
in March 2022 allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality
in, are registered in, or have predominately primary place of business or profit-making activities in the United States and
other countries that Russia has deemed unfriendly without consent or compensation. Consequently, we would not be able to prevent third
parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia.
Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may
be adversely affected.
22
In
addition, a European Unified Patent Court ("UPC") entered into force on June 1, 2023. The UPC is a common patent court
that hears patent infringement and revocation proceedings effective for EU Member States. This could enable third parties to seek revocation
of a European patent in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which
the European patent is validated.
Although
we do not currently own any European patents or applications, if we obtain such patents and applications in the future, any such revocation
and loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology
and products. Moreover, the controlling laws and regulations of the UPC will develop over time, and may adversely affect our ability
to enforce or defend the validity of any European patents we may obtain. We may decide to opt out from the UPC any future European patent
applications that we may file and any patents we may obtain. If certain formalities and requirements are not met, however, such European
patents and patent applications could be challenged for non-compliance and brought under the jurisdiction of the UPC. We
cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, if we decide
to opt out of the UPC.
Obtaining
and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these
requirements.
Periodic
maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be
paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO
and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other
similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late
fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment
or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events
that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official
actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If
we fail to maintain the patents and patent applications covering our programs, our competitive position would be adversely affected.
We
may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent,
which might adversely affect our ability to develop and market our products.
We
cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims
or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent
and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product
candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in
a patent and the patent's prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application
may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party patent or may incorrectly
predict whether a third-party's pending application will issue with claims of relevant scope. Our determination of the expiration
date of any patent in the United States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly
interpret relevant patents may negatively impact our ability to develop and market our products.
In
addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent
applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing,
and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent
applications for technology covered by our issued patents or our pending applications, or that we were the first to invent the technology.
Our competitors may have filed, and may in the future file, patent applications covering products or technology similar to ours. Any
such patent application may have priority over our patent applications or patents, which could require us to obtain rights to issued
patents covering such technologies.
We
may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
We
may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual
property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the
patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different
individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter
of the patent, conflicting obligations of third parties involved in developing our programs or as a result of questions regarding co-ownership of
potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership.
Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we
fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as
exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our
business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees.
Our
future licensors may rely on third-party consultants or collaborators or on funds from third parties, such as the U.S. government,
such that our licensors would not be the sole and exclusive owners of any patents we in-license. If other third parties have
ownership rights or other rights to our in-licensed patents, they may be able to license such patents to our competitors, and
our competitors could market competing products and technology. This could have a material adverse effect on our competitive position,
business, financial conditions, results of operations, and prospects.
23
Patent
terms may be inadequate to protect the competitive position of our product candidates for an adequate amount of time.
Patents
have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
20 years from its earliest United States non-provisional filing date. Various extensions may be available, but the
life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent
life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time
required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might
expire before or shortly after such product candidates are commercialized. As a result, our owned and licensed patent portfolio may not
provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.
Our
technology licensed from various third parties may be subject to retained rights.
Our
future licensors may retain certain rights under the relevant agreements with us, including the right to use the underlying technology
for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make
customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors
limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology
in the event of misuse.
Risks
Related to Our Reliance on Third Parties
We
currently rely on licensing arrangements with Paragon through the Option Agreements. If we are unable to maintain collaborations or licensing
arrangements, or if our collaborations or licensing arrangements are not successful, our business could be negatively impacted.
We
currently rely on our licensing arrangements with Paragon through the Option Agreements for a substantial portion of our discovery capabilities
and in-licenses.
Collaborations
or licensing arrangements that we enter into may not be successful, and any success will depend heavily on the efforts and activities
of such collaborators or licensors. If any of our current or future collaborators or licensors experience delays in performance of, or
fails to perform our obligations under their agreement with us, disagrees with our interpretation of the terms of such agreement or terminates
their agreement with us, the research programs with respect to which we have the option to acquire intellectual property license rights
to pursuant to the Option Agreements and development timeline could be adversely affected. If we fail to comply with any of the obligations
under our collaborations or license agreements, including payment terms and diligence terms, our collaborators or licensors may have
the right to terminate such agreements, in which event we may lose intellectual property rights and may not be able to develop, manufacture,
market or sell the products covered by our agreements or may face other penalties under our agreements. Our collaborators and licensors
may also fail to properly maintain or defend the intellectual property we have licensed from them, if required by our agreement with
them, or even infringe upon, our intellectual property rights, leading to the potential invalidation of our intellectual property or
subjecting us to litigation or arbitration, any of which would be time-consuming and expensive and could harm our ability to commercialize
our product candidates. In addition, collaborators could independently develop, or develop with third parties, products that compete
directly or indirectly with our programs and products if the collaborators believe that the competitive products are more likely to be
successfully developed or can be commercialized under terms that are more economically attractive than ours.
As
part of our strategy, we plan to evaluate additional opportunities to enhance our capabilities and expand our development pipeline or
provide development or commercialization capabilities that complement ours. We may not realize the benefits of such collaborations, alliances
or licensing arrangements. Any of these relationships may require us to incur non-recurring and other charges, increase our
near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business.
We
may face significant competition in attracting appropriate collaborators, and more established companies may also be pursuing strategies
to license or acquire third-party intellectual property rights that we consider attractive. These companies may have a competitive
advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition,
companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a definitive agreement
for a collaboration will depend upon, among other things, our assessment of the collaborator's resources and expertise, the terms
and conditions of the proposed collaboration and the proposed collaborator's evaluation of a number of factors. Collaborations
are complex and time-consuming to negotiate, document and execute. In addition, consolidation among large pharmaceutical and biotechnology
companies has reduced the number of potential future collaborators. We may not be able to negotiate additional collaborations on a timely
basis, on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake
the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them
to market.
24
We
currently rely, and plan to rely in the future, on third parties to conduct and support our preclinical studies and clinical trials.
If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be
able to obtain regulatory approval of or commercialize our product candidates.
We
have utilized and plan to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions,
CROs, contract testing labs, CMOs and strategic partners, to supply, conduct and support our preclinical studies and clinical trials
under agreements with us. We will rely heavily on these third parties over the course of our preclinical studies and clinical trials,
and we control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion
of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials
than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our
studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance
on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required
to comply with GCP regulations, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities
for all of our programs in clinical development. If we or any of these third parties fail to comply with applicable GCP regulations,
the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities
may require us to perform additional clinical trials before approving our marketing applications or refuse to approve our marketing applications.
We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical
trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced under cGMP regulations.
Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.
Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws
and regulations or healthcare privacy and security laws.
Any
third parties conducting our clinical trials will not be our employees and, except for remedies available to us under our agreements
with such third parties, we cannot control whether they devote sufficient time and resources to our programs. These third parties may
be involved in mergers, acquisitions or similar transactions and may have relationships with other commercial entities, including our
competitors, for whom they may also be conducting clinical trials or other product development activities, which could negatively affect
their performance on our behalf and the timing thereof and could lead to products that compete directly or indirectly with our product
candidates. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines,
if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere
to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated
and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates.
In
addition, we currently rely on foreign CROs and CMOs, including WuXi Biologics (Hong Kong) Limited and its affiliates ("WuXi
Biologics") and will likely continue to rely on foreign CROs and CMOs in the future. WuXi is a subsidiary or affiliate of WuXi
Biologics, which is identified in the proposed U.S. legislation known as the BIOSECURE Act as a biotechnology "company of concern."
The current version of the BIOSECURE Act introduced in the House of Representatives would prohibit federal agencies from entering into
procurement contracts with, as well as providing grants and loans to, an entity that uses biotechnology equipment or services from a
biotechnology company of concern, and includes a grandfathering provision allowing biotechnology equipment and services provided or produced
by named "biotechnology companies of concern" under a contract or agreement entered into before the effective date until
January 1, 2032. The pathway and timing for the BIOSECURE Act or its provisions to become law are uncertain, although the bill was passed
in the House of Representatives on September 9, 2024. Depending on whether the BIOSECURE Act becomes law, what the final language of
the BIOSECURE Act includes, and how the law is interpreted by U.S. federal agencies, we could be potentially restricted from pursuing
U.S. federal government business or grants in the future if we continue to use WuXi or other parties identified as "biotechnology
companies of concern" beyond the grandfathering period. Foreign CMOs may be subject to U.S. legislation, including the proposed
BIOSECURE bill, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material
available to us, delay the procurement or supply of such material or have an adverse effect on our ability to secure significant commitments
from governments to purchase our potential therapies.
For
example, the biopharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government
policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on our collaborators in China
which could have an adverse effect on our business, financial condition, results of operations and prospects. Evolving changes in China's
public health, economic, political, and social conditions and the uncertainty around China's relationship with other governments,
such as the United States and the UK, could also negatively impact our ability to manufacture our product candidates for our planned
clinical trials or have an adverse effect on our ability to secure government funding, which could adversely affect our financial condition
and cause it to delay our clinical development programs. Furthermore, if the BIOSECURE bill is passed and one or more of our collaborators
in China, including WuXi Biologics, is deemed to be a biotechnology company of concern, our operations and financial condition may be
negatively impacted as a result of any delays or increased costs arising from the trade restrictions and other foreign regulatory requirements
affecting such collaborators. In addition, while we have established relationships with CROs and CMOs outside of China, moving to those
suppliers in the event of a geopolitical instability affecting our collaborators in China could introduce delays into the development
program.
25
We
currently rely and expect to rely in the future on the use of manufacturing suites in third-party facilities or on third parties to manufacture
our product candidates, and we may rely on third parties to produce and process our products, if approved. Our business could be adversely
affected if we are unable to use third-party manufacturing suites or if the third-party manufacturers encounter difficulties in production.
We
do not currently own any facility that may be used as our clinical or commercial manufacturing and processing facility and must currently
rely on CMOs to manufacture our product candidates. We have not yet caused any product candidates to be manufactured on a commercial
scale and may not be able to do so for any of our product candidates, if approved. We currently have a sole source relationship for our
supply of the ORKA-001 and ORKA-002 programs. If there should be any disruption in such supply arrangement, including any adverse
events affecting our sole supplier, it could have a negative effect on the clinical development of our programs and other operations
while we work to identify and qualify an alternate supply source. We may not control the manufacturing process of, and may be completely
dependent on, our contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the
FDA or comparable foreign regulatory authorities for the manufacture of our product candidates. Beyond periodic audits, we have limited
control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a
comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws
any approval in the future, we may need to find alternative manufacturing facilities, which would require the incurrence of significant
additional costs, delays, and materially adversely affect our ability to develop, obtain regulatory approval for or market our product
candidates, if approved. Similarly, our failure, or the failure of our CMOs, to comply with applicable regulations could result in sanctions
being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation,
seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly
and adversely affect supplies of our product candidates or drugs and harm our business and results of operations.
Moreover,
our CMOs may experience manufacturing difficulties due to resource constraints, supply chain issues, or as a result of labor disputes
or unstable political environments. If any CMOs on which we will rely fail to manufacture quantities of our product candidates at quality
levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows us to achieve
profitability, our business, financial condition and prospects could be materially and adversely affected. In addition, our CMOs are
responsible for transporting temperature-controlled materials that can be inadvertently degraded during transport due to several
factors, rendering certain batches unsuitable for trial use for failure to meet, among others, our integrity and purity specifications.
We and any of our CMOs may also face product seizure or detention or refusal to permit the import or export of products. Our business
could be materially adversely affected by business disruptions to our third-party providers that could materially adversely affect
our anticipated timelines, potential future revenue and financial condition and increase our costs and expenses. Each of these risks
could delay or prevent the completion of our preclinical studies and clinical trials or the approval of any of our product candidates
by the FDA, result in higher costs or adversely impact commercialization of our product candidates.
Risks
Related to Employee Matters, Managing Growth and Other Risks Related to Our Business
In
order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties
in managing this growth.
We
expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of
preclinical and clinical drug development, technical operations, clinical operations, regulatory affairs and, potentially, sales and
marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial
personnel and systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial
resources and the limited experience of our management team working together in managing a company with such anticipated growth, we may
not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel.
We
are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining
highly qualified personnel, we may not be able to successfully implement our business strategy.
We
are a preclinical stage biotechnology company with a limited operating history. We have been and will continue to be highly dependent
on the research and development, clinical and business development expertise of our executive officers, as well as the other principal
members of our management, scientific and clinical team. Any of our management team members may terminate their employment with us at
any time. We do not maintain "key person" insurance for any of our executives or other employees.
26
Attracting
and retaining qualified personnel will also be critical to our success, including with respect to any strategic transaction that we may
pursue. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development
and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing
executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals
in our industry with the breadth of skills and experience required to successfully develop, facilitate regulatory approval of and commercialize
product candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these
key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel.
We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions.
In
addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our discovery
and nonclinical and clinical development and commercialization strategy. Our consultants and advisors may be employed by employers other
than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.
If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.
Our
future growth may depend, in part, on our ability to operate in foreign markets, where it would be subject to additional regulatory burdens
and other risks and uncertainties.
Our
future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets for which we
may rely on collaboration with third parties. We are not permitted to market or promote any of our product candidates before we receive
regulatory approval from the applicable foreign regulatory authority, and may never receive such regulatory approval for any of our product
candidates. To obtain separate regulatory approval in many other countries, we must comply with numerous and varying regulatory requirements
of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and
distribution of our product candidates, and we cannot predict success in these jurisdictions. If we fail to comply with the regulatory
requirements in international markets and receive applicable marketing approvals, our target market will be reduced and our ability to
realize the full market potential of our product candidates will be harmed and our business will be adversely affected. Moreover, even
if we obtain approval of our product candidates and ultimately commercializes our product candidates in foreign markets, we would be
subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting
and legal requirements and reduced protection of intellectual property rights in some foreign countries.
Our
estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete
achieve the forecasted growth, our business may not grow at similar rates, or at all.
Our
market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which
may not prove to be accurate. Our estimates and forecasts relating to size and expected growth of our target market may prove to be inaccurate.
Even if the markets in which we compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or
at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many
risks and uncertainties.
Our
revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted
price for the product, the ability to obtain coverage and reimbursement and whether we own the commercial rights for that territory.
If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is
narrower than we expect or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not
generate significant revenue from sales of such products, even if approved.
27
Our
employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors
may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
We
are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators,
CROs, CMOs, suppliers and vendors acting for or on our behalf may engage in misconduct or other improper activities. We have adopted
a code of conduct and ethics, but it is not always possible to identify and deter misconduct by these parties and the precautions we
take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us
from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.
Our
internal information technology systems, or those of any of our CROs, manufacturers, other contractors or consultants, third-party service
providers, or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper
access to, use of, or destruction of our proprietary or confidential data, employee data or personal data, which could result in additional
costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations.
In
the ordinary course of our business, we and the third parties upon which we rely collect, receive, store, process, generate, use, transfer,
disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) proprietary, confidential, and sensitive
data, including personal data, intellectual property, trade secrets, and other sensitive data (collectively, sensitive information).
Despite
the implementation of security measures in an effort to protect systems that store our information, given their size and complexity and
the increasing amounts of information maintained on our internal information technology systems and those of our third-party CROs,
other contractors (including sites performing our clinical trials), third-party service providers and supply chain companies, and
consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system
malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent
or intentional actions by our employees, contractors, consultants, business partners and/or other third parties, or from cyber-attacks by
malicious third parties, which may compromise our system infrastructure or lead to the loss, destruction, alteration or dissemination
of, or damage to, our data.
Some
actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for
geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts,
we, and the third parties upon which we rely, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks,
that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services.
In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations,
ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion
payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for
example, applicable laws or regulations prohibiting such payments.
To
the extent that any disruption or security breach were to result in loss, destruction, unavailability, alteration or dissemination of,
or damage to, our data or applications, or for it to be believed or reported that any of these occurred, we could incur liability and
reputational damage and the development and commercialization of our product candidates could be delayed. Further, our insurance policies
may not be adequate to compensate us for the potential losses arising from any such disruption in, or failure or security breach of,
our systems or third-party systems where information important to our business operations or commercial development is stored.
Our
fully-remote workforce may create additional risks for our information technology systems and data because our employees work remotely
and utilize network connections, computers, and devices working at home, while in transit and in public locations. Additionally, business
transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems
could be negatively affected by vulnerabilities present in acquired or integrated entities' systems and technologies.
28
While
we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will
be effective. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and
techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred.
Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.
Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures
are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.
We
rely on third-party service providers and technologies to operate critical business systems to process sensitive information in
a variety of contexts. Our ability to monitor these third parties' information security practices is limited, and these third parties
may not have adequate information security measures in place. If our third-party service providers experience a security incident
or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service
providers fail to satisfy their privacy or security-related obligations to it, any award may be insufficient to cover our damages,
or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot
guarantee that third parties' infrastructure in our supply chain or our third-party partners' supply chains have not
been compromised.
If
we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may
experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections);
additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation
(including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions
in our operations (including availability of data); financial loss; management distraction; delays; and other similar harms. Security
incidents and attendant consequences may cause stakeholders (including investors and potential customers) to stop supporting our platform,
deter new customers from products, and negatively impact our ability to grow and operate our business.
Our
contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in
our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.
We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out
of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or
that such coverage will pay future claims.
We
are subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection,
and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which
could include civil or criminal penalties), fines and sanctions, private litigation and/or adverse publicity and could negatively affect
our operating results and business.
We
and third parties who we work with are or may become subject to numerous domestic and foreign laws, regulations, and standards relating
to privacy, data protection, and data security, the scope of which is changing, subject to differing applications and interpretations,
and may be inconsistent among countries, or conflict with other rules. We are or may become subject to the terms of contractual obligations
related to privacy, data protection and data security. Our obligations may also change or expand as our business grows. The actual or
perceived failure by us or third parties related to us to comply with such laws, regulations and obligations could increase our compliance
and operational costs, expose us to regulatory scrutiny, actions, fines and penalties, result in reputational harm, lead to a loss of
customers, result in litigation and liability, and otherwise cause a material adverse effect on our business, financial condition, and
results of operations.
If
we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur
costs that could have a material adverse effect on the success of our business.
We
are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the
handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations may involve the use of hazardous and
flammable materials, including chemicals and biological and radioactive materials. In addition, we may incur substantial costs in order
to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations
may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result
in substantial fines, penalties or other sanctions.
29
We
may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition.
The
rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative
process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which may have retroactive application)
could adversely affect our stockholders or us. We continue to assess the impact of various tax reform proposals and modifications to
existing tax treaties in all jurisdictions where we have operations or employees to determine the potential effect on our business and
any assumptions we make about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms
of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted. For example, the
United States enacted the Inflation Reduction Act of 2022, which implements, among other changes, a 1% excise tax on certain
stock buybacks. In addition, beginning in 2022, the Tax Cuts and Jobs Act eliminated the previously available option to deduct
research and development expenditures and requires taxpayers to amortize them generally over five years for research activities
conducted in the United States and over 15 years for research activities conducted outside the United States. The U.S. Congress
is considering legislation that would restore the current deductibility of research and development expenditures; however, there is no
assurance that the current provision will be repealed or otherwise modified. Such changes, among others, may adversely affect our effective
tax rate, results of operation and general business condition.
We
may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions.
We
may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that we believe
will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able
to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and
company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new product candidates or products
resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business.
There is no assurance that, following any such acquisition, we will achieve the synergies expected in order to justify the transaction,
which could result in a material adverse effect on our business and prospects.
We
maintain our cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions
could adversely affect our ability to pay our operational expenses or make other payments.
Our
cash held in non-interest-bearing and interest-bearing accounts exceeds the Federal Deposit Insurance Corporation ("FDIC")
insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance
limitations. For example, the FDIC took control of Silicon Valley Bank on March 10, 2023. The Federal Reserve subsequently announced
that account holders would be made whole. We currently hold a small portion of our cash and cash equivalents at Silicon Valley Bank.
However, the FDIC may not make all account holders whole in the event of future bank failures. In addition, even if account holders are
ultimately made whole with respect to a future bank failure, account holders' access to their accounts and assets held in their
accounts may be substantially delayed. Any material loss that we may experience in the future or inability for a material time period
to access our cash and cash equivalents could have an adverse effect on our ability to pay our operational expenses or make other payments,
which could adversely affect our business.
General
Risk Factors
Our
estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and
even if the markets in which we compete achieve the forecasted growth, our business may not grow at similar rates,
or at all.
Our
market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which
may not prove to be accurate. Our estimates and forecasts relating to size and expected growth of our target market may prove to be inaccurate.
Even if the markets in which we compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or
at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many
risks and uncertainties.
Our
revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted
price for the product, the ability to obtain coverage and reimbursement and whether we own the commercial rights for that territory.
If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is
narrower than we expect or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not
generate significant revenue from sales of such products, even if approved.
30
We
may become exposed to costly and damaging liability claims, either when testing a product candidate in the clinical or at the commercial
stage, and our product liability insurance may not cover all damages from such claims.
We
are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing,
marketing, and use of pharmaceutical products. While we currently have no products that have been approved for commercial sale, the future
use of a product candidate in clinical trials, and the sale of any approved products in the future, may expose us to liability claims.
These claims may be made by patients that use the product, healthcare providers, pharmaceutical companies, or others selling such product.
Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially and adversely affect the
market for our products or any prospects for commercialization of our products. Although we intend to obtain product liability insurance
for our future clinical trials, it is possible that any liabilities could exceed our insurance coverage or that in the future we may
not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability
that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess
of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.
Litigation
costs and the outcome of litigation could have a material adverse effect on our business.
From
time to time we may be subject to litigation claims through the ordinary course of our business operations
regarding, but not limited to, employment matters, security of patient and employee personal information, contractual relations with
collaborators and intellectual property rights. Litigation to defend ourselves against claims by third parties, or to enforce any rights
that we may have against third parties, may continue to be necessary, which could result in substantial costs and diversion of our resources,
causing a material adverse effect on our business, financial condition, results of operations or cash flows.
Our
business could be adversely affected by economic downturns, inflation, fluctuation in interest rates, natural disasters, public health
crises, political crises, geopolitical events, or other macroeconomic conditions, which could have a material and adverse effect on our
results of operations and financial condition.
The
global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things,
diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases
in inflation rates, fluctuation in interest rates, and uncertainty about economic stability. For example, the COVID-19 pandemic
resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. The Federal Reserve previously
raised interest rates multiple times in response to concerns about inflation and it may raise them again. Fluctuation in interest rates,
coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending.
Similarly, the ongoing military conflict between Russia and Ukraine and in the Middle East and rising tensions with China have created
extreme volatility in the global capital markets and may have further global economic consequences, including disruptions of the global
supply chain. Any such volatility and disruptions may adversely affect our business or the third parties on whom we rely. If the equity
and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing
more costly, more dilutive, or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates
can adversely affect us by increasing our costs, including materials, operational, labor and employee benefit costs.
We
may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating
or expanding clinical trials and manufacturing sufficient quantities of materials. Any one or a combination of these events could have
a material and adverse effect on our results of operations and financial condition.
31
Risks
Related to Owning Our Stock
The
market price of our common stock may continue to be volatile.
The
market price of our common stock may be subject to significant fluctuations. Some of the factors that may cause the market price of our
common stock to fluctuate include:
●
timing
and results of clinical trials and preclinical studies of our product candidates, or those of our competitors or our existing or future
collaborators;
●
failure
    to meet or exceed financial and development projections that we may provide to the public;
●
announcements
    of significant or potential equity or debt sales by us;
●
failure
    to meet or exceed the financial and development projections of the investment community;
●
failure
    to achieve the perceived benefits of our recent merger as rapidly or to the extent anticipated by financial or industry analysts;
●
announcements
    of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;
●
actions
    taken by regulatory agencies with respect to our product candidates, clinical studies, manufacturing process or sales and marketing
    terms;
●
disputes
    or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection
    for our technologies;
●
additions
    or departures of key personnel, including scientific or management personnel;
●
significant
    lawsuits, including patent or stockholder litigation;
●
if
    securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions
    regarding our business and stock;
●
changes
    in the market valuations of similar companies;
●
general
    market, macroeconomic or geopolitical conditions or market conditions in the pharmaceutical and biotechnology sectors;
●
sales
    of securities by us or our securityholders in the future;
●
if
    we fail to raise an adequate amount of capital to fund our operations or continued development of our product candidates;
●
trading
    volume of our common stock;
●
announcements
    by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or
    capital commitments;
●
adverse
    publicity relating to precision medicine product candidates, including with respect to other products in such markets;
●
the
    introduction of technological innovations or new therapies that compete with our products; and
●
period-to-period
    fluctuations in our financial results.
Moreover,
the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual
companies. These broad market fluctuations may also adversely affect the trading price of our common stock. In addition, a recession,
depression or other sustained adverse market event could materially and adversely affect our business and the value of our common stock.
In the past, following periods of volatility in the market price of a company's securities, stockholders have often instituted
class action securities litigation against such companies.
Furthermore,
market volatility may lead to increased shareholder activism if we experience a market valuation that activists believe is not reflective
of our intrinsic value. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of
our board of directors could have an adverse effect on our operating results, financial condition and cash flows.
32
Our
certificate of incorporation and bylaws, as well as provisions under Delaware law, could make an acquisition of the company more difficult
and may prevent attempts by our stockholders to replace or remove management.
Provisions
in our certificate of incorporation and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of the
company that stockholders may consider favorable, including transactions in which our common stockholders might otherwise receive a premium
price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of
our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible
for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace
or remove current management by making it more difficult for stockholders to replace members of our board of directors. Among other things,
these provisions:
●
establish
    a classified board of directors such that all members of the board are not elected at one time;
●
allow
    the authorized number of our directors to be changed only by resolution of our board of directors;
●
limit
    the manner in which stockholders can remove directors from the board;
●
establish
    advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on
    at stockholder meetings;
●
require
    that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written
    consent;
●
limit
    who may call a special meeting of stockholders;
●
authorize
    our board of directors to issue preferred stock without stockholder approval, which could be used to institute a "poison pill"
    that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not
    been approved by our board of directors; and
●
require
    the approval of the holders of at least 66 2/3% of the votes that all stockholders would be entitled to cast to amend or repeal certain
    provisions of our charter or bylaws.
Moreover,
because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law ("DGCL"),
which prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Although we believe
these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with
our board of directors, they would apply even if the offer may be considered beneficial by some stockholders.
Our
governing documents provide that, unless we consent in writing to the selection of an alternative forum, certain designated courts will
be the sole and exclusive forum for certain legal actions between us and our stockholders, which could limit our stockholders'
ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.
Our
governing documents provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware
is the sole and exclusive forum for state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action
asserting a claim of or based on a breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees
or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, the certificate of incorporation
or the bylaws, (iv) any action to interpret, apply, enforce or determine the validity of the certificate of incorporation or bylaws,
or (v) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery
having personal jurisdiction over the indispensable parties named as defendants therein, which for purposes of this risk factor refers
to herein as the "Delaware Forum Provision." Our governing documents further provide that, unless we consent in writing to
an alternative forum, the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting
a cause of action arising under the Securities Act, which for purposes of this risk factor refers to herein as the "Federal Forum
Provision." Neither the Delaware Forum Provision nor the Federal Forum Provision will apply to any causes of action arising under
the Exchange Act. In addition, any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will
be deemed to have notice of and consented to the foregoing Delaware Forum Provision and Federal Forum Provision; provided, however, that
stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations
thereunder.
The
Delaware Forum Provision and the Federal Forum Provision may impose additional litigation costs on our stockholders in pursuing any such
claims, particularly if such stockholders do not reside in or near the State of Delaware. Additionally, these forum selection clauses
may limit our stockholders' ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors,
officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action,
if successful, might benefit our stockholders.
33
Future
sales of shares by existing stockholders could cause our stock price to decline.
If
our stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after legal restrictions
on resale lapse, the trading price of our common stock could decline. In addition, shares of our common stock that are subject to our
outstanding options will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements
and Rules 144 and 701 under the Securities Act.
We
do not anticipate that we will pay any cash dividends in the foreseeable future
We
do not anticipate that we will pay any cash dividends in the foreseeable future. The current expectation is that we will retain our future
earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock
will be your sole source of gain, if any, for the foreseeable future.
Our
executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted
to our stockholders for approval.
Our
executive officers, directors and principal stockholders beneficially own a significant percentage of our outstanding common stock. As
a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters
submitted to our stockholders for approval, as well as our management and affairs. For example, these stockholders, if they choose to
act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of
all or substantially all of our assets. This concentration of voting power could delay or prevent our acquisition on terms that other
stockholders may desire.
If
equity research analysts do not publish research or reports, or publish unfavorable research or reports about us, our business or our
market, our stock price and trading volume could decline.
The
trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and
our business. Equity research analysts may elect to not provide research coverage of our common stock, and such lack of research coverage
may adversely affect the market price of our common stock. If we do have equity research analyst coverage, we will not have any control
over the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or more equity
research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases
coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our
stock price or trading volume to decline.
34
USE
OF PROCEEDS
We
are not selling any securities under this prospectus and we will not receive any proceeds from the sale of the Resale Shares covered
hereby. The net proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders.
Some of the shares of Common Stock offered hereby are issuable upon the exercise of the Pre-Funded Warrants. Upon exercise of such Pre-Funded
Warrants for cash, we will receive the nominal cash exercise price paid by the holders of the Pre-Funded Warrants. We intend to use those
proceeds, if any, for general corporate purposes.
Subject
to limited exceptions, the Selling Stockholders will pay any underwriting discounts and commissions and expenses incurred by the Selling
Stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Stockholders in disposing
of any of the Resale Shares. We will bear the costs, fees and expenses incurred in effecting the registration of the Resale Shares covered
by this prospectus, including all registration and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our independent
registered public accounting firm.
35
MANAGEMENT'S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You
should read the following discussion of our financial condition and results of operations in conjunction with the consolidated financial
statements and the related notes thereto and other financial information included elsewhere in this prospectus. This discussion contains
forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance
that involve risks, uncertainties and assumptions. Our actual results could differ materially from those discussed in these forward-looking
statements as a result of various factors. Factors that could cause or contribute to these differences include, but are not limited to,
those discussed below and elsewhere in this prospectus, particularly in the section titled "Risk Factors." Please also see
the section titled "Cautionary Statement Concerning Forward-Looking Statements." As used in this prospectus, unless the context
suggests otherwise, "we", "us", "our", "the Company", or "Oruka" refers to
Oruka Therapeutics, Inc. and its subsidiaries, including Oruka Therapeutics Operating Company, LLC.
Overview
We
are a biotechnology company focused on developing novel monoclonal antibody therapeutics for psoriasis ("PsO") and other
inflammatory and immunology ("I&I") indications. Our name is derived from
or
, for "skin," and
arukah
,
for "restoration" and reflects our mission to deliver therapies for chronic skin diseases that provide patients the
greatest possible freedom from their condition. Our strategy is to apply antibody engineering and format innovations to validated modes
of action, which we believe will enable us to improve meaningfully upon the efficacy and dosing regimens of standard-of-care medicines
while significantly intending to reduce technical and biological risk. Our programs aim to treat and potentially modify disease by targeting
mechanisms with proven efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells.
Our lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 ("IL-23p19") for the treatment of PsO.
Our co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F ("IL-17A/F") for the treatment of
PsO, psoriatic arthritis ("PsA"), and other conditions. These programs each bind their respective targets at high affinity
and incorporate half-life extension technology with the aim to increase exposure and decrease dosing frequency. We believe that our focused
strategy, differentiated portfolio, and deep expertise position us to set a new treatment standard in large I&I markets with
continued unmet need.
Since
our inception in February 2024, we have devoted substantially all of our resources to raising capital, organizing and staffing the
company, business and scientific planning, conducting discovery and research activities, establishing arrangements with third parties
for the manufacture of our programs and component materials, and providing general and administrative support for these operations. We
do not have any programs approved for sale and have not generated any revenue from product sales. To date, we have funded our operations
primarily with proceeds from the issuance of convertible preferred stock, common stock, convertible note, pre-funded warrants, and the
proceeds from the reverse recapitalization and merger with ARCA biopharma, Inc., our Pre-Closing Financing and subsequent PIPE Financing
(as defined and further described in "
Recent developments"
below).
Since
our inception, we have incurred significant losses and negative cash flows from our operations. Our ability to generate product revenue
sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of any programs
we may develop. We generated net losses of $28.6 million for the three months ended September 30, 2024 and $57.9 million for the period
from February 6, 2024 (inception) to September 30, 2024. For the period from February 6 (inception) to September 30, 2024,
we have used net cash of $39.0 million for our operating activities.
We
had cash and cash equivalents of $410.9 million as of September 30, 2024. We expect that our existing cash and cash equivalents will
be sufficient to fund our operating plans for at least twelve months from the date of filing of this prospectus. We expect to continue
to incur substantial losses for the foreseeable future, and our transition to profitability will depend upon successful development,
approval and commercialization of our product candidates and upon achievement of sufficient revenues to support our cost structure.
36
ORKA-001
ORKA-001
is a high affinity, extended half-life monoclonal antibody ("mAb") designed to target IL-23p19. IL-23 is a pro-inflammatory
cytokine that plays a critical role in the proliferation and development of T helper 17 ("Th17") cells, which are the primary
drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit that is
shared with IL-12 and a p19 subunit that is specific to IL-23. First-generation IL-23 antibodies bound p40 and inhibited both IL-12 and
IL-23 signaling, while more recent IL-23 antibodies targeting the p19 subunit have shown improved efficacy and safety. Based on preclinical
evidence, we believe that ORKA-001 could achieve higher response rates than established therapies in PsO while requiring less frequent
dosing and maintaining the favorable safety profile of therapies targeting IL-23p19.
ORKA-001
is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain to modify the pH-dependent
binding to the neonatal Fc receptor. As a result, it has a pharmacokinetic profile that has the potential to support a SQ injection as
infrequently as once or twice a year. In addition, emerging evidence suggests that IL-23 blockade can modify the disease biology of PsO,
possibly leading to durable remissions and preventing the development of PsA. We believe that the expected characteristics of ORKA-001
increase its potential to deliver these disease-modifying benefits.
We
plan to initiate a Phase 1 trial of ORKA-001 in the first quarter of 2025. We expect to share interim data from the first-in-human trial
in healthy volunteers, including initial pharmacokinetic data, in the second half of 2025 and initial efficacy data in PsO patients in
the second half of 2026.
ORKA-002
ORKA-002
is a high affinity, extended half-life mAb designed to target IL-17A and IL-17F ("IL-17A/F"). IL-17 inhibition has become
central to the treatment of psoriatic diseases, including PsO and PsA, and has also shown efficacy in other I&I indications,
such as hidradenitis suppurativa and axial spondyloarthritis. More recently, the importance of inhibiting the IL-17F isoform along
with IL-17A has become appreciated, and dual blockade with the recently approved therapy Bimzelx
®
(bimekizumab) has led
to higher response rates in patients than blockade of IL-17A alone. ORKA-002 is designed to bind IL-17A/F at similar epitopes, or binding
sites, and affinity ranges as bimekizumab, but incorporates half-life extension technology that could enable more convenient dosing intervals.
We plan to initiate a Phase 1 trial of ORKA-002 in the third quarter of 2025. We expect to share interim data from the first-in-human
trial in healthy volunteers, including initial pharmacokinetic data, in the first half of 2026.
We
view ORKA-002 and ORKA-001 as highly complementary. Patients with moderate-to-severe PsO that have purely skin manifestations are most
often treated with IL-23 inhibitors due to the high efficacy and tolerability of this mechanism. However, for patients who also have
joint involvement, or signs and symptoms of PsA, an IL-17 inhibitor is typically used due to its efficacy in addressing both skin and
joint symptoms. In addition, IL-17 inhibitors are often used in patients with highly resistant skin symptoms that do not adequately resolve
through treatment with an IL-23 inhibitor. Together, ORKA-001 and ORKA-002 provide the potential to offer a highly compelling product
profile for most patients with PsO and/or PsA, as well as the opportunity to address additional I&I indications.
Additional
Pipeline Program
We
have a third mAb program, ORKA-003, designed to target an undisclosed pathway. Our strategy as a company is to remain highly focused
on I&I diseases, and specifically on inflammatory dermatology conditions. Our third program provides the potential for indication
expansion beyond PsO and may create combination opportunities with our more advanced programs.
Recent
Developments
The
Merger
On
August 29, 2024, we consummated the previously announced business combination ("Closing") pursuant to that certain Agreement
and Plan of Merger and Reorganization, dated April 3, 2024 (the "Merger Agreement"), by and among ARCA, Atlas Merger Sub
Corp, a wholly owned subsidiary of ARCA ("First Merger Sub"), Atlas Merger Sub II, LLC, a wholly owned subsidiary of ARCA
("Second Merger Sub") and Oruka Therapeutics, Inc. ("Pre-Merger Oruka"), pursuant to which, among other matters,
Pre-Merger Oruka merged with and into First Merger Sub, with Pre-Merger Oruka continuing as a wholly owned subsidiary of ARCA and the
surviving corporation of the merger ("First Merger") and following that, Pre-Merger Oruka then merged with and into Second
Merger Sub, with Second Merger Sub being the surviving entity of the second merger (the "Second Merger" and together with
the First Merger, the "Merger"). Following consummation of the Merger, we effected a 1-for-12 reverse stock split (the "Reverse
Stock Split") of the common stock, par value $0.001 per share, of the Company ("Company Common Stock"), which became
effective on September 3, 2024. The Company Common Stock commenced trading on a post-Reverse Stock Split, post-Merger basis at the opening
of trading on September 3, 2024. Second Merger Sub changed its corporate name to "Oruka Therapeutics Operating Company, LLC"
and ARCA changed its name to "Oruka Therapeutics, Inc." We are led by the pre-reverse capitalization Pre-Merger Oruka management
team and remains focused on developing biologics to optimize the treatment of inflammatory skin diseases.
37
Pre-Closing
Financing
Immediately
prior to the execution and delivery of the Merger Agreement on April 3, 2024, certain new and existing investors of Pre-Merger Oruka
entered into a subscription agreement with Pre-Merger Oruka (the "Subscription Agreement"), pursuant to which, and on the
terms and subject to the conditions of which, immediately prior to the Closing, those investors purchased shares of common stock of Pre-Merger
Oruka ("Pre-Merger Oruka Common Stock") and Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $275.0
million (which includes $25.0 million of proceeds previously received from the issuance of the Convertible Note (refer to Note 6 in our
condensed consolidated financial statements included in this prospectus for additional details) and accrued interest on such note which
converted to shares of Pre-Merger Oruka Common Stock) (the "Pre-Closing Financing"). We incurred transaction costs of $20.5
million which was recorded as a reduction to additional paid-in capital in the unaudited condensed consolidated financial statements.
At the Closing, the shares of Pre-Merger Oruka Common Stock and Pre-Merger Oruka pre-funded warrants issued pursuant to the Subscription
Agreement were converted into shares of Company Common Stock and pre-funded warrants of Company Common Stock in accordance with the Exchange
Ratio (defined below).
In accordance with an Exchange Ratio determined
by terms of the Merger Agreement and upon the effective time of the First Merger (the "First Effective Time"), (i) each then-issued
and outstanding share of Pre-Merger Oruka Common Stock including outstanding and unvested Pre-Merger Oruka restricted stock and shares
of Pre-Merger Oruka Common Stock issued in connection with the Subscription Agreement, were converted into the right to receive a number
of shares of Company Common Stock, equal to the exchange ratio of 6.8569 shares of Company Common Stock (the "Exchange Ratio"),
which were subject to the same vesting provisions as those immediately prior to the Merger, (ii) each share of Pre-Merger Oruka Series
A convertible preferred stock, par value $0.0001 ("Pre-Merger Oruka Series A Preferred Stock"), outstanding immediately prior
to the First Effective Time was converted into the right to receive a number of shares of ARCA Series B non-voting convertible preferred
stock, par value $0.001 per share, which are convertible into shares of Company Common Stock at a conversion ratio of approximately 83.3332:1,
(iii) each outstanding option to purchase Pre-Merger Oruka Common Stock was converted into an option to purchase shares of Company Common
Stock, (iv) each outstanding warrant to purchase shares of Pre-Merger Oruka Common Stock was converted into a warrant to purchase shares
of Company Common Stock, and (v) each share of Company Common Stock issued and outstanding at the First Effective Time remain issued and
outstanding in accordance with its terms and such shares Subsequent to the close of the merger, the common stock shares were then, subject
to the reverse stock split of 1-for-12 effected on September 3, 2024.
As
part of the Pre-Closing Financing and the Closing, the investors in the Pre-Closing Financing received 22,784,139 shares of Company Common
Stock in exchange for 39,873,706 shares of Pre-Merger Oruka Common Stock (which includes the issuance of 2,722,207 shares of Company
Common Stock in exchange for 4,764,032 shares of Pre-Merger Oruka Common Stock on the conversion of Convertible Note along with the accrued
interest through the conversion date) and 5,522,207 Company pre-funded warrants in exchange for 9,664,208 Pre-Merger pre-funded warrants.
The
Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Pre-Merger Oruka
was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the fact that, immediately
following the Merger: (i) Pre-Merger Oruka stockholders own a substantial majority of the voting rights in the combined company; (ii)
Pre-Merger Oruka's largest stockholders retain the largest interest in the combined company; (iii) Pre-Merger Oruka designated
a majority of the initial members of the board of directors of the combined company; and (iv) Pre-Merger Oruka's executive management
team became the management team of the combined company. Accordingly, for accounting purposes: (i) the Merger was treated as the equivalent
of Pre-Merger Oruka issuing stock to acquire the net assets of ARCA; and (ii) the reported historical operating results of the combined
company prior to the Merger are those of Pre-Merger Oruka. Additional information regarding the Merger is included in Note 3 to the condensed
consolidated financial statements included in this prospectus.
38
Reverse
Stock Split
On
September 3, 2024, we effected the Reverse Stock Split, a 1-for-12 reverse stock split of Company Common Stock. The par value per share
and the number of authorized shares were not adjusted as a result of the Reverse Stock Split. The shares of Company Common Stock underlying
outstanding stock options, common stock warrants and other equity instruments were proportionately reduced and the respective exercise
prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. All references
to common stock, options to purchase common stock, outstanding common stock warrants, common stock share data, per share data, and related
information contained in the condensed consolidated financial statements have been retrospectively adjusted to reflect the effect of
the Reverse Stock Split for all periods presented, unless otherwise specifically indicated or the context otherwise requires.
PIPE
Financing
On September 11, 2024, we entered into a Securities
Purchase Agreement for a private placement (the "PIPE Financing") with certain institutional and accredited investors. The
closing of the PIPE Financing occurred on September 13, 2024.
Pursuant to the Securities Purchase Agreement,
the investors purchased an aggregate of 5,600,000 shares of Company Common Stock at a purchase price of $23.00 per share, an aggregate
of 2,439 shares of the Company's Series A non-voting convertible preferred stock, par value $0.001 per share ("Company Series
A Preferred Stock"), at a purchase price of $23,000.00 per share (each Company Series A Preferred Stock is convertible into 1,000
shares of Company Common Stock), and pre-funded warrants to purchase an aggregate of 680,000 shares of Company Common Stock at a purchase
price of $22.999 per pre-funded warrant, for aggregate net proceeds of approximately $188.7 million (net of issuance costs of $11.8 million).
Components
of Results of Operations
Revenue
To
date, we have not generated revenue from any sources, including product sales, and do not expect to generate any revenue from the sale
of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory
approval, we may generate revenue in the future from product sales or payments from future collaboration or license agreements that we
may enter into with third parties, or any combination thereof. We cannot predict if, when, or to what extent we will generate revenue
from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product
candidates.
Operating
Expenses
Research
and Development
Research
and development expenses consist primarily of costs incurred in connection with the development and research of our programs. These expenses
include costs of funding research performed by third parties, including Paragon Therapeutics, Inc. ("Paragon"), that conduct
research and development activities on our behalf, expenses incurred in connection with continuing our current research programs and
discovery-phase development of any programs we may identify, including under future agreements with third parties, such as consultants
and contractors, personnel-related expenses, including salaries, bonuses, employee benefits, stock-based compensation expense, and allocated
human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation
for our leased office space.
We
expense research and development costs as incurred. Our primary focus since inception has been the identification and development of
our pipeline programs. Our research and development expenses primarily consist of external costs, such as fees paid to Paragon under
the Option Agreements. We separately track the amount of costs incurred under the Option Agreements with Paragon between ORKA-001 and
ORKA-002. See "—
Contractual Obligations and Commitments
" below for further details on the Option Agreements.
We
expect our research and development expenses to increase substantially for the foreseeable future as we advance our product candidates
into and through preclinical studies and clinical trials, pursue regulatory approval of our product candidates and expand our pipeline
of product candidates.
39
General
and Administrative
General
and administrative expenses consist primarily of personnel-related expenses, including salaries, bonuses, employee benefits, and stock-based
compensation, for our executive and other administrative personnel. Other significant general and administrative expenses include legal
services, including intellectual property and corporate matters; professional fees for accounting, auditing, tax, insurance, and allocated
human resource costs, information technology costs, and facility-related costs, including rent, utilities, maintenance, and depreciation
for our leased office space.
We
expect our general and administrative expenses will increase substantially for the foreseeable future as we anticipate an increase in
our personnel headcount to support the expansion of research and development activities, as well as to support our operations generally.
We also expect to continue to incur significant expenses associated with being a public company, including costs related to accounting,
audit, legal, regulatory, and tax-related services associated with maintaining compliance with applicable Nasdaq and SEC requirements;
additional director and officer insurance costs; and investor and public relations costs. We also expect to incur additional intellectual
property-related expenses as we file patent applications to protect innovations arising from our research and development activities.
Other
Income (Expense), Net
Other
income (expense), net includes interest expense on the convertible note from a related party, interest income, and foreign currency transactions
gains and losses. Interest expense relates to a convertible note (the "Convertible Note") issued to Fairmount Healthcare
Fund II, L.P. ("Fairmount") in March 2024.
Income
Taxes
No
provision for income taxes was recorded for the three months ended September 30, 2024 and for the period from February 6, 2024 (inception)
through September 30, 2024. Deferred tax assets generated from our net operating losses have been fully reserved as we believe it
is not more likely than not that the benefit will be realized due to its cumulative losses generated to date.
Results
of Operations for the Three Months Ended September 30, 2024
The
following table summarizes our results of operations and comprehensive loss for the period presented (in thousands):
Three Months
Ended
September 30,
2024
Operating
    expenses
Research
    and development
(1)
$
25,691
General
    and administrative
(2)
3,758
Total
    operating expenses
29,449
Loss
    from operations
(29,449
)
Other
    income (expense)
Interest
    income
1,330
Interest
    expense
(3)
(504
)
Total
    other income, net
826
Net
    loss and comprehensive loss
$
(28,623
)
(1)
Includes
    related party amount of $13,537 for the three months ended September 30, 2024
(2)
Includes
    related party amount of $71 for the three months ended September 30, 2024
(3)
Includes
    related party amount of $504 for the three months ended September 30, 2024
40
Research
and Development Expenses
The
following table summarizes our research and development expenses for the period presented (in thousands):
Three
    Months Ended
September 30,
2024
External research
    and development costs by selected target:
ORKA-001
(1)
$
11,761
ORKA-002
(2)
4,147
Other
    research and development costs:
Personnel-related
    (including stock-based compensation)
(3)
9,076
Other
(4)
707
Total
    research and development expenses
$
25,691
(1)
Includes
    related party amount of $2,316 for the three months ended September 30, 2024
(2)
Includes
    related party amount of $3,824 for the three months ended September 30, 2024
(3)
Includes
    related party amount of $7,251 for the three months ended September 30, 2024
(4)
Includes
    related party amount of $146 for the three months ended September 30, 2024
Research
and development expenses were $25.7 million for the three months ended September 30, 2024 and consisted primarily of the following:
●
$2.3 million
    of research and development expense due to Paragon for services rendered under the Option Agreements for ORKA-001, including $1.5
    million of milestone payment due to Paragon upon exercise of option to enter into a license agreement and achievement of development
    candidate for IL-23;
●
$9.4
    million of research and development expenses on chemistry, manufacturing, and development costs for ORKA-001, including $3.2 million
    of toxicology testing for ORKA-001 with a third-party contract research organization;
●
$3.8 million
    of research and development expense due to Paragon for services rendered under the Option Agreements for ORKA-002;
●
$9.1
    million of personnel-related costs related to salaries, benefits and other compensation-related costs, and stock-based compensation
    expense of $7.8 million, including $7.3 million for stock-based compensation related to Paruka Holding LLC ("Paruka")
    warrants; and
●
$0.7
    million of other research expenses and allocated human resource costs, information technology costs, and facility-related costs,
    including rent, maintenance, utilities, and depreciation for our leased office space.
General
and Administrative Expenses
The
following table summarizes our general and administrative expenses for the period presented (in thousands):
Three
    Months Ended
September 30,
2024
Personnel-related
    (including stock-based compensation)
$
2,435
Professional
    and consulting fees
701
Legal
    fees related to patent
(1)
116
Other
506
Total
    general and administrative expenses
$
3,758
(1)
Includes
    related party amount of $71 for the three months ended September 30, 2024
41
General
and administrative expenses were $3.8 million for the three months ended September 30, 2024 and consisted primarily of the following:
●
$2.4 million
    of personnel-related costs related to salaries, benefits and other compensation-related costs, including stock-based compensation
    of $1.2 million;
●
$0.7 million
    of professional and consulting fees associated with accounting, audit, and legal fees to support our business activity and operations
    of a public company;
●
$0.1 million
of legal fees due to Paragon associated with patent related activities; and
●
$0.5
million of other business expense and allocated human resource costs, information technology costs, and facility-related costs, including
rent, maintenance, utilities, and depreciation for our leased office space.
Total
Other Income (Expense), Net
Interest
income from money market funds was $1.3 million for the three months ended September 30, 2024.
Interest
expense was $0.5 million for the three months ended September 30, 2024 relating to the Convertible Note from Fairmount.
Results
of Operations for the Period of February 6, 2024 (Inception) to September 30, 2024
The
following table summarizes our results of operations and comprehensive loss for the period presented (in thousands):
Period from
February 6,
2024
(Inception) to
September 30,
2024
Operating expenses
Research
    and development
(1)
$
49,557
General
    and administrative
(2)
8,248
Total
    operating expenses
57,805
Loss
    from operations
(57,805
)
Other
    income (expense)
Interest
    income
1,330
Interest
    expense
(3)
(1,468
)
Total
    other expense, net
(138
)
Net
    loss and comprehensive loss
$
(57,943
)
(1)
Includes
    related party amount of $33,967 for the period from February 6, 2024 (inception) to September 30, 2024
(2)
Includes
    related party amount of $1,339 for the period from February 6, 2024 (inception) to September 30, 2024
(3)
Includes
    related party amount of $1,468 for the period from February 6, 2024 (inception) to September 30, 2024
Research
                                            and Development Expenses
The
following table summarizes our research and development expenses for the period presented (in thousands):
Period from
February 6,
2024
(Inception) to
September 30,
2024
External research
    and development costs by selected target:
ORKA-001
(1)
$
26,939
ORKA-002
(2)
10,987
Other
    research and development costs:
Personnel-related
    (including stock-based compensation)
(3)
10,684
Other
(4)
947
Total
    research and development expenses
$
49,557
(1)
Includes
    related party amount of $15,478 for the period from February 6, 2024 (inception) to September 30, 2024
42
(2)
Includes
    related party amount of $10,662 for the period from February 6, 2024 (inception) to September 30, 2024
(3)
Includes
    related party amount of $7,681 for the period from February 6, 2024 (inception) to September 30, 2024
(4)
Includes
    related party amount of $146 for the period from February 6, 2024 (inception) to September 30, 2024
Research
and development expenses were $49.6 million for the period from February 6, 2024 (inception) to September 30, 2024 and consisted
primarily of the following:
●
$15.5 million
    of research and development expense due to Paragon for services rendered under the Option Agreements for ORKA-001, including $1.5
    million of milestone payment due to Paragon upon exercise of option to enter into a license agreement and achievement of development
    candidate for IL-23, and $5.9 million of research and development expense due to Paragon incurred through March 31, 2024 upon completion
    of IL-23 selection process;
●
$11.4
    million of research and development expense on chemistry, manufacturing, and development costs for ORKA-001, including $3.4 million
    in toxicology testing for ORKA-001 with a third-party contract research organization;
●
$11.0 million
    of research and development expense primarily due to Paragon for services rendered under the Option Agreements for ORKA-002;
●
$10.7 million
    of personnel-related costs related to salaries, benefits, and other compensation-related costs, and stock-based compensation expense
    of $8.3 million, including $7.7 million for stock-based compensation related to Paruka warrants; and
●
$0.9
    million of other research expense and allocated human resource costs, information technology costs, and facility-related costs, including
    rent, maintenance, utilities, and depreciation for our leased office space.
General
and Administrative Expenses
The
following table summarizes our general and administrative expenses for the period presented (in thousands):
Period from
February 6,
2024
(Inception) to
September 30,
2024
Personnel-related
    (including stock-based compensation)
(1)
$
4,590
Professional
    and consulting fees
2,330
Legal
    fees related to patent
(2)
606
Other
(3)
722
Total
    general and administrative expenses
$
8,248
(1)
Includes
    related party amount of $609 for the period from February 6, 2024 (inception) to September 30, 2024
(2)
Includes
    related party amount of $550 for the period from February 6, 2024 (inception) to September 30, 2024
(3)
Includes
    related party amount of $180 for the period from February 6, 2024 (inception) to September 30, 2024
43
General
and administrative expenses were $8.2 million for the period from February 6, 2024 (inception) to September 30, 2024 and consisted
primarily of the following:
●
$4.6 million
    of personnel-related costs related to recruiting costs, salaries, benefits and other compensation-related costs, including stock-based
    compensation of $1.5 million and $0.6 million of personnel-related costs are amounts due to Paragon related to recruiting costs
    for hiring our executive team, legal, and finance and accounting functions;
●
$2.3 million
    of professional and consulting fees associated with accounting, audit, and legal fees associated with becoming a public company;
●
$0.6 million
    of legal fees due to Paragon associated with patent related activities; and
●
$0.7
    million of other business expenses and allocated human resource costs, information technology costs, and facility-related costs,
    including rent, maintenance, utilities, and depreciation for our leased office space, including $0.2 million of other business
    expenses due to Paragon.
Total
Other Income (Expense), Net
Interest
income from money market funds was $1.3 million for the period from February 6, 2024 (inception) to September 30, 2024.
Interest
expense was $1.5 million for the period from February 6, 2024 (inception) to September 30, 2024 relating to the Convertible Note from
Fairmount.
Liquidity
and Capital Resources
As
of September 30, 2024, we had $410.9 million of cash and cash equivalents.
Since our inception, we have incurred significant
operating losses and negative cash flow from operations. We expect to incur significant expenses and operating losses for the foreseeable
future as we continue the pre-clinical and clinical development of our programs and continue our early-stage research activities. We have
not yet commercialized any products and we do not expect to generate revenue from sales of products for several years, if at all.
As of September 30, 2024, we had funded our operations primarily with proceeds from issuances of convertible preferred stock, common stock,
convertible note, and pre-funded warrants. In March 2024, we received $3.0 million in gross proceeds from the issuance of Pre-Merger
Oruka Series A Preferred Stock and $25.0 million in gross proceeds from the issuance of the Convertible Note, both of which
were related party transactions. In August 2024, we raised approximately $228.0 million in net proceeds from Pre-Closing Financing and
received $4.9 million in cash from ARCA upon consummation of the Merger. In September 2024, we received approximately $188.7 million in
net proceeds from the issuance of common stock, Company Series A Preferred Stock, and pre-funded warrants in connection with the PIPE
Financing.
Our
primary use of cash is to fund the development of our product candidates, and advance our pipeline. This includes both the research and
development costs and the general and administrative expenses required to support those operations. Since we are a clinical stage biotechnology
company, we have incurred significant operating losses since our inception and we anticipate such losses, in absolute dollar terms, to
increase as we continue to pursue clinical development of our product candidates, prepare for the potential commercialization of our
product candidates, and expand our development efforts in our pipeline of nonclinical candidates. We expect that our existing cash and
cash equivalents will be sufficient to fund our operating plans for at least twelve months from the date of filing of this prospectus.
We will need to secure additional financing in the future to fund additional research and development, and before a commercial drug can
be produced, marketed and sold. If we are unable to obtain additional financing or generate license or product revenue, the lack of liquidity
could have a material adverse effect on our company.
44
Cash
Flows
The
following table summarizes our cash flows for the period presented (in thousands):
Period from
February 6,
2024
(Inception) to September 30,
2024
Net
    cash used in operating activities
$
(39,019
)
Net
    cash used in investing activities
(171
)
Net
    cash provided by financing activities
450,065
Net
    increase in cash and cash equivalents
$
410,875
Operating
Activities
From
February 6, 2024 (inception) to September 30, 2024, net cash used in operating activities was $39.0 million, which was primarily
attributable to a net loss of $57.9 million, offset by non-cash charges of $11.3 million and net cash provided by changes in operating
activities of $7.6 million. Non-cash charges primarily consisted of a $9.8 million increase in stock-based compensation expense (primarily
from Paruka Warrant Obligation) and $1.5 million of non-cash interest expense. Net cash provided by changes in our operating activities
primarily consisted of a $1.6 million increase in accounts payable, $1.7 million increase in accrued expenses and other current liabilities,
$6.4 million increase in related parties accounts payable and other current liabilities, partially offset by a $2.0 million increase
in prepaid expenses and other current assets. The increase in amounts due to related parties, accounts payable, and accrued expenses
and other current liabilities was primarily due to an increase in our business activity, as well as vendor invoicing and payments. The
increase in prepaid expenses and other current assets was primarily due to prepaid research and development expenses with our contract
research organization.
Investing
Activities
From
February 6, 2024 (inception) to September 30, 2024, net cash used in investing activities was $0.2 million, which was attributable
to purchases of property and equipment.
Financing
Activities
From
February 6, 2024 (inception) to September 30, 2024, net cash provided by financing activities was $450.1 million, consisting
of $2.9 million of net proceeds from the issuance of Series B Preferred Stock, $25.0 million of net proceeds from
the issuance of the Convertible Note, $228.1 million of net proceeds from the Pre-Closing Financing, $189.1 million of net proceeds from
the PIPE Financing, and $4.9 million of cash acquired in connection with the reverse recapitalization.
Contractual
Obligations and Commitments
We
enter into contracts in the normal course of business with contract research organizations ("CROs") for clinical trials,
with contract manufacturing organizations ("CMOs") for clinical supplies manufacturing and with other vendors for preclinical
studies, supplies and other services and products for operating purposes. These contracts generally provide for termination on notice
or may have a potential termination fee if a purchase order is cancelled within a specified time, and therefore are cancelable contracts.
We do not expect any such contract terminations and did not have any non-cancellable obligations under these agreements as of September
30, 2024.
Option
Agreements
In
March 2024, we entered into antibody discovery and option agreements with Paragon and Paruka (the "Option Agreements").
Under the terms of the Option Agreements, Paragon identifies, evaluates and develops antibodies directed against certain mutually agreed
therapeutic targets of interest to us. The Option Agreements include two selected targets, IL-23 ("ORKA-001") and IL-17 A/F
("ORKA-002"). Under the Option Agreements, we have the exclusive options to, on a research program-by-research program basis,
be granted an exclusive, worldwide license to all of Paragon's right, title and interest in and to the intellectual property resulting
from the applicable research program to develop, manufacture and commercialize the antibodies and products directed to the selected targets
(each, an "Option"), with the exception of pursuing ORKA-001 for the treatment of inflammatory bowel disease. If we exercise
our options, we will be required to make non-refundable milestone payments to Paragon of up to $12.0 million under each respective
agreement upon the achievement of certain clinical development milestones, up to $10.0 million under each respective agreement upon
the achievement of certain regulatory milestones as well as tiered royalty payments in the low-to-mid single-digits beginning on the
first commercial sale. From time to time, we can choose to add additional targets to the collaboration by mutual agreement with Paragon.
During the three months ended September 30, 2024, we exercised our option for ORKA-001 and recorded a $1.5 million milestone payment
related to the achievement of development candidate as research and development expense in our condensed consolidated statements of operations
and comprehensive loss for the three months ended September 30, 2024. As of September 30, 2024, this amount is included under related
party accounts payable and other current liabilities on the condensed consolidated balance sheet.
45
Our
exclusive Option with respect to each research program for a particular target initiated by the parties ("Research Program")
is exercisable at our sole discretion at any time during the period beginning on the initiation of activities under the associated Research
Program and ending a specified number of days following (i) with respect to any Research Program other than ORKA-001, the delivery
of the data package from Paragon related to the results of the Research Plan activities, or (ii) with respect to ORKA-001, the completion
of the IL-23 antibody selection process described in the agreement (the "Option Period"). There is no payment due upon exercise
of an Option pursuant to the Option Agreements.
Unless
terminated earlier, the Option Agreements shall continue in force on a Research Program-by-Research Program basis until the earlier of:
(i) the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by us; (ii) the
expiration of the 30-day period after we exercise our Option with respect to such Research Program, subject to mutually agreed extension,
during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii) the expiration of the applicable
research term (the "Term"). Upon the expiration of the Term for all then-existing Research Programs, under the Option Agreements,
the Option Agreements will automatically expire in its entirety. We may terminate the Option Agreements or any Research Program at any
time for any or no reason upon 30 days' prior written notice to Paragon, provided that we must pay certain unpaid fees due
to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with its activities
under any terminated Research Program. Paragon may terminate the Option Agreements or a Research Program immediately upon written notice
to us if, as a result of any action or failure to act by us or our affiliates, such Research Program or all material activities under
the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of months. Each party
has the right to terminate the Option Agreements or any Research Program upon (i) 30 days' prior written notice of the
other party's material breach that remains uncured for the 30-day period and (ii) the other party's bankruptcy.
Pursuant to the Option Agreements, on a research
program-by-research program basis following the finalization of the research plan for each respective research program, we were required
to pay Paragon a one-time, nonrefundable research initiation fee of $0.8 million related to the ORKA-001 program. This amount was
recognized as a research and development expense during the period from February 6, 2024 (inception) to September 30, 2024. In June
2024, pursuant to the Option Agreements with Paragon, we completed the selection process of our development candidate for IL-23 antibody
for ORKA-001 program. We were responsible for 50% of the development costs incurred through the completion of the IL-23 selection process.
We received the rights to at least one selected IL-23 antibody in June 2024. During the three months ended September 30, 2024, we exercised
our option for ORKA-001 and recorded a $1.5 million milestone payment related to the achievement of development candidate as research
and development expense in our condensed consolidated statements of operations and comprehensive loss for each of the three months ended
September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024. Our share of development costs incurred
during the three months ended September 30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024 was $0.8 million
and $13.2 million, respectively, which were recorded as research and development expenses during the respective periods. An amount of
$2.3 million is included in related party accounts payable and other current liabilities as of September 30, 2024.
We were also required to reimburse Paragon $3.3 million
for development costs related to ORKA-002 incurred by Paragon through December 31, 2023 and certain other development costs incurred
by Paragon between January 1, 2024 and March 6, 2024 as stipulated by the Option Agreements. This amount was recognized as a
research and development expense during the period from February 6, 2024 (inception) to September 30, 2024. We are also responsible
for the development costs incurred by Paragon from January 1, 2024 through the completion of the IL-17 selection process. We recognized
an amount of $0.8 million payable to Paragon for the research initiation fee related to ORKA-002 following the finalization of the
ORKA-002 research plan. This was recognized as research and development expenses in the period from February 6, 2024 (inception) to September
30, 2024. We accounted for development costs of $3.8 million and $6.6 million during the three months ended September 30, 3024 and for
the period from February 6, 2024 (inception) to September 30, 2024, respectively, as research and development expenses during the respective
periods. An amount of $3.8 million is included in related party accounts payable and other current liabilities as of September 30, 2024.
As
part of the Option Agreements, on each of December 31, 2024 and December 31, 2025, we will grant warrants to purchase a number of shares
equal to 1.00% of outstanding shares as of the date of the grant on a fully diluted basis with an exercise price equal to the fair market
value of the underlying shares on the grant date. The warrants are liability-classified and after the initial recognition, the liability
is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated statement of operations
and comprehensive loss as stock-based compensation expenses under research and development expenses.
46
We
expense the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified
within research and development expenses in the accompanying condensed consolidated statement of operations and comprehensive loss.
We
concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise
in-process research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination
because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent
a group of similar identifiable assets. The research initiation fee represents a one-time cost on a research program-by-research program
basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts
paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of on-going development cost,
monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior
to the effective date of the Option Agreements that is associated with services being rendered under the related Research Programs are
recognized as research and development expense when incurred.
For
the three months ended September 30, 2024 and the period from February 6, 2024 (inception) to September 30, 2024, we recognized
$13.4 million and $33.8 million of expenses, respectively, in connection with services provided by Paragon and Paruka under the Option
Agreements.
Note Payable
with Related Party
In
March 2024, we entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the "Purchase Agreement")
with Fairmount, whereby we issued the Convertible Note, with an initial principal amount of $25.0 million that, at the time of issuance,
could be converted into Pre-Merger Oruka Series A Preferred Stock (or a series of preferred shares that is identical in respect
to the shares of preferred shares issued in its next equity financing) or shares of Pre-Merger Oruka Common Stock in exchange for aggregate
proceeds of $25.0 million. The Convertible Note accrued interest at a rate of 12.0% per annum. At issuance, the Convertible Note
required all unpaid interest and principal to mature on December 31, 2025 (the "Maturity Date") and prepayment was not
permitted without prior written consent of Fairmount. At issuance, the principal payment along with the accrued interest on the Convertible
Note was due in full on the Maturity Date. Pursuant to the Purchase Agreement, we had the right to sell and issue additional convertible
notes up to an aggregate principal amount equal to $30.0 million, in addition to the $25.0 million initial principal amount of the Convertible
Note.
Immediately
prior to the completion of the Merger, the Convertible Note was converted into shares of Pre-Merger Oruka Common Stock based on the aggregate
principal amount of $25.0 million, plus unpaid accrued interest of $1.5 million divided by the conversion price, which was determined
based upon the Company's fully-diluted capitalization immediately prior to the Merger. At the effective time of the Merger, the
Pre-Merger Oruka Common Stock issued upon the conversion of the Convertible Note (including accrued interest) automatically converted
into shares of Company Common Stock. 2,722,207 shares of Company Common Stock were issued on conversion of the Convertible Note and accrued
interest. As of September 30, 2024, there is no note payable to a related party.
Critical
Accounting Policies and Significant Judgments and Estimates
Our
management's discussion and analysis of its financial condition and results of operations is based on its financial statements,
which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires
us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets
and liabilities at the date of the financial statements, as well as the reported revenues recognized and expenses incurred during the
reporting periods. Our estimates are based on its historical experience and on various other factors that we believe are reasonable under
the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are
not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
While
our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements appearing elsewhere
in this prospectus, we believe the following accounting policies used in the preparation of our financial statements require the most
significant judgments and estimates.
47
Accrued
Research and Development Expenses
As
part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses.
This process involves estimating the level of service performed and the associated cost incurred for the services when we have not yet
been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed,
on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our
accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known to us at that time.
At each period end, we corroborate the accuracy of these estimates with the service providers and make adjustments, if necessary. Estimated
accrued research and development expenses include those related to fees paid to vendors in connection with discovery development activities
and any research organizations in connection with studies and testing. Although we do not expect our estimates to be materially different
from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing
of services performed may vary and may result in reporting amounts that are too high or too low in any particular period.
Stock-Based
Compensation
We
measure stock options granted to employees and non-employees based on the estimated fair values of the awards as of the grant date using
the Black-Scholes option-pricing model. The model requires management to make a number of assumptions, including common stock fair value,
expected volatility, expected term, risk-free interest rate and expected dividend yield. For restricted stock awards and restricted stock
units, the estimated fair value is the fair market value of the underlying stock on the grant date. We expense the fair value of our
equity-based compensation awards on a straight-line basis over the requisite service period, which is the period in which the related
services are received. We account for award forfeitures as they occur. The expense for stock-based awards with performance conditions
is recognized when it is probable that a performance condition is met during the vesting period.
Determination
of Fair Value of Common Stock
A
public trading market for Company Common Stock has been established in connection with the completion of this Merger. As such, it is
no longer necessary for our board of directors to estimate the fair value of our stock-based awards in connection with its accounting
for granted stock-based awards or other such awards we may grant, as the fair value of Company Common Stock and share-based awards is
determined based on the quoted market price of Company Common Stock.
Prior
to the merger, Pre-Merger Oruka's common stock valuations were prepared using a hybrid method, including an option pricing method
("OPM"). The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise
prices based on the value thresholds at which the allocation among the various holders of a company's securities changes. Under
this method, the common stock has value only if the funds available for distribution to stockholders exceed the value of the preferred
stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method is a probability-weighted
expected return method ("PWERM"), where the equity value in one or more of the scenarios is calculated using an OPM. The
PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of future values for the Company,
assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns
considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock
under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to
arrive at an indication of value for the common stock. A discount for lack of marketability of the common stock is then applied to arrive
at an indication of value for the common stock.
The
assumptions underlying these valuations represented management's best estimate, which involved inherent uncertainties and the application
of management's judgment. As a result, if Pre-Merger Oruka had used significantly different assumptions or estimates, the fair
value of Pre-Merger Oruka's incentive shares and its stock-based compensation expense could have been materially different.
Recently
Issued Accounting Pronouncements
See
Note 2 to the condensed consolidated financial statements included in this prospectus for more information regarding recently issued
accounting pronouncements.
Off-Balance
Sheet Arrangements
As
of September 30, 2024, we did not have any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.
48
CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
(a)
Dismissal
                                            of Independent Registered Public Accounting Firm
KPMG
LLP ("KPMG") served as the independent registered public accounting firm of ARCA prior to the consummation of the Merger.
On August 30, 2024, KPMG was dismissed as the independent registered public accounting firm of the Company. The decision to dismiss KPMG
was approved by the Audit Committee (the "Audit Committee") of the Board of Directors of the Company (the "Board").
The
reports of KPMG on the consolidated financial statements of the Company for the fiscal years ended December 31, 2023 and 2022 did
not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting
principles.
During
the Company's two most recent fiscal years and the subsequent period from January 1, 2024 to August 30, 2024, there were (i) no
disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto) with KPMG on any matter
of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement, if not resolved
to the satisfaction of KPMG, would have caused it to make reference to the subject matter of the disagreement in connection with its
report and (ii) no reportable events (as described in Item 304(a)(1)(v) of Regulation S-K).
The
Company provided KPMG with a copy of the disclosures made in this section and requested KPMG to furnish the Company with a letter addressed
to the SEC stating whether it agrees with the statements made by the Company and, if not, stating the respects in which it does not agree.
A copy of KPMG's letter to the SEC dated September 5, 2024 regarding these statements was filed as Exhibit 16.1 to the Company's
Current Report on Form 8-K filed on September 5, 2024.
(b)
Appointment
                                            of New Independent Registered Public Accounting Firm
PricewaterhouseCoopers
LLP ("PwC") served as the independent registered public accounting firm of Oruka prior to the consummation of the Merger.
On August 30, 2024, following the consummation of the Merger, the Audit Committee engaged PwC as the independent registered public accounting
firm of the Company.
During
ARCA's two most recent fiscal years and the subsequent period from January 1, 2024 to August 30, 2024, neither ARCA nor anyone
on its behalf consulted PwC regarding: (i) the application of accounting principles to a specified transaction, either completed or proposed,
or the type of audit opinion that might be rendered on ARCA's financial statements, and neither a written report nor oral advice
was provided to the ARCA that PwC concluded was an important factor considered by ARCA in reaching a decision as to any accounting, auditing
or financial reporting issue; or (ii) any matter that was the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation
S-K and the related instructions thereto) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).
QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We
are a smaller reporting company, as defined by Rule 12b-2 under the Exchange Act and in Item 10(f)(1) of Regulation S-K, and are not
required to provide the information under this item.
49
BUSINESS
Company
Overview
We
are a biotechnology company focused on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Our name
is derived from
or
, for "skin," and
arukah
, for "restoration" and reflects the company's
mission to deliver therapies for chronic skin diseases that provide patients the most possible freedom from their condition. Our strategy
is to apply antibody engineering and format innovations to validated modes of action, which we believe will enable us to improve meaningfully
upon the efficacy and dosing regimens of standard-of-care medicines while significantly reducing technical and biological risk. Our programs
aim to treat and potentially modify disease by targeting mechanisms with proven efficacy and safety involved in disease pathology and
the activity of pathogenic tissue-resident memory T cells ("TRMs"). Our lead program, ORKA-001, is designed to target the
p19 subunit of interleukin-23 ("IL-23p19") for the treatment of PsO. Our co-lead program, ORKA-002, is designed to target
interleukin-17A and interleukin-17F ("IL-17A/F") for the treatment of PsO, PsA, and other conditions. These programs each
bind their respective targets at high affinity and incorporate half-life extension technology with the aim to increase exposure and decrease
dosing frequency. We believe that our focused strategy, differentiated portfolio, and deep expertise position us to set a new treatment
standard in large I&I markets with continued unmet need.
Our Pipeline
ORKA-001
ORKA-001
is a high affinity, extended half-life monoclonal antibody ("mAb") designed to target IL-23p19. IL-23 is a pro-inflammatory
cytokine that plays a critical role in the proliferation and development of T helper 17 ("Th17") cells, which are the primary
drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit that is shared
with IL-12 and a p19 subunit that is specific to IL-23. First-generation IL-23 antibodies bound p40 and inhibited both IL-12 and IL-23
signaling, while more recent IL-23 antibodies targeting the p19 subunit have shown improved efficacy and safety. Based on preclinical
evidence, we believe that ORKA-001 could achieve higher response rates than established therapies in PsO while requiring less frequent
dosing and maintaining the favorable safety profile of therapies targeting IL-23p19. ORKA-001 is engineered with YTE half-life extension
technology, a specific three amino acid change in the fragment crystallizable ("Fc") domain to modify the pH-dependent binding
to the neonatal Fc receptor ("FcRn"). As a result, it has a pharmacokinetic profile designed to support a subcutaneous ("SQ")
injection as infrequently as once or twice a year. In addition, emerging evidence suggests that IL-23 blockade can modify the disease
biology of PsO, possibly leading to durable remissions and preventing the development of PsA. We believe that the expected characteristics
of ORKA-001 increase its potential to deliver these disease-modifying benefits.
We
plan to initiate a Phase 1 trial of ORKA-001 in the first quarter of 2025. We expect to share interim data from the first-in-human trial
in healthy volunteers, including initial pharmacokinetic data, in the second half of 2025 and initial efficacy on psoriasis patients
in the second half of 2026. Based on recent precedent for PsO, we anticipate that the entire development program from first-in-human
to biologics license application ("BLA") filing could take as little as six to seven years based on the averages for
recently approved medicines. However, we have no control over the length of time needed for FDA review, and this timeline could vary.
50
ORKA-002
ORKA-002
is a high affinity, extended half-life mAb designed to target IL-17A and IL-17F ("IL-17A/F"). IL-17 inhibition has become
central to the treatment of psoriatic diseases, including PsO and PsA, and has also shown efficacy in other I&I indications,
such as hidradenitis suppurativa ("HS") and axial spondyloarthritis ("axSpA"). More recently, the importance
of inhibiting the IL-17F isoform along with IL-17A has become appreciated, and dual blockade with the recently approved therapy Bimzelx
(bimekizumab) has led to higher response rates in patients than blockade of IL-17A alone. ORKA-002 is designed to bind IL-17A/F at similar
epitopes, or binding sites, and affinity ranges as bimekizumab, but incorporates half-life extension technology that could enable more
convenient dosing intervals. We plan to initiate a Phase 1 trial of ORKA-002 in the third quarter of 2025. We expect to share interim
data from the first-in-human trial in healthy volunteers, including initial pharmacokinetic data, in the first half of 2026.
We
view ORKA-002 and ORKA-001 as highly complementary. Patients with moderate-to-severe PsO that have purely skin manifestations are most
often treated with IL-23 inhibitors due to the high efficacy and tolerability of this mechanism. However, for patients who also have
joint involvement, or signs and symptoms of PsA, an IL-17 inhibitor is typically used due to its efficacy in addressing both skin and
joint symptoms. In addition, IL-17 inhibitors are often used in patients with highly resistant skin symptoms that do not adequately resolve
through treatment with an IL-23 inhibitor. Together, ORKA-001 and ORKA-002 provide the potential to offer a highly compelling product
profile for most patients with PsO and/or PsA, as well as the opportunity to address additional I&I indications.
Additional
Pipeline Programs
We
have a third mAb program, ORKA-003, designed to target an undisclosed pathway. Our strategy as a company is to remain highly focused
on I&I diseases, and specifically on inflammatory dermatology conditions. Our third program provides the potential for indication
expansion beyond PsO and may create combination opportunities with our more advanced programs.
Our Team,
Investors, and Paragon Collaboration
Pre-Merger
Oruka was founded in February 2024 by leading healthcare investor Fairmount Funds Management LLC ("Fairmount"). Fairmount
Funds Management has launched other successful biotechnology companies leveraging antibody technologies generated by Paragon, including
Apogee Therapeutics and Spyre Therapeutics. We are led by a management team with significant experience in developing novel treatments
for patients at biopharmaceutical companies such as CRISPR Therapeutics, Celgene, Novartis, CymaBay Therapeutics and Protagonist Therapeutics.
Together, our team has a proven track record of building successful biotech organizations in high-growth environments.
We
hold options to acquire intellectual property rights with respect to certain research programs, including ORKA-001 and ORKA-002, from
Paragon. Following the exercise of the Options (defined below) under the Paragon Option Agreements and execution of the respective license
agreements, we will have exclusive worldwide development and commercialization rights to our programs, with IL-23 rights for all indications
outside of inflammatory bowel disease ("IBD"), pursuant to such agreements, as applicable. Fairmount Funds Management founded
Paragon in 2021 as the firm's discovery engine for biologics that potentially overcome limitations of existing therapies. Paragon
leverages a dedicated in-house team of scientific experts in antibody development, as well as its partnership with FairJourney Biologics,
to generate unique therapeutic concepts and enable their rapid proof-of-concept validation. We consider Paragon to be a related party.
See the section titled "
Certain Relationships and Related Transactions
" for additional information.
51
Our Strategy
To
achieve our goal of developing leading therapeutic antibodies for patients with inflammatory skin diseases, we are applying antibody
engineering to validated modes of action. We believe this approach will enable us to improve meaningfully upon the efficacy and convenience
of standard-of-care medicines while significantly reducing technical and biological risk. The key elements of our strategy include:
●
Employ
                                            advanced antibody engineering to build biologics that could significantly improve upon existing
                                            therapies:
We and our collaborators at Paragon have optimized
                                            a variety of parameters using a suite of antibody technologies to develop candidates with
                                            the potential to improve upon existing therapies. These parameters include extending half-life
                                            to increase exposure and reduce dosing frequency, enhancing affinity and specificity to maximize
                                            potency and safety, and optimizing developability to ensure consistency and enable convenient,
                                            high-dose formulations. Together, we believe these features have the potential to translate
                                            into more efficacious and convenient medicines for patients.
●
Target
                                            validated mechanisms of action:
Our initial targets, IL-23p19
                                            and IL-17A/F, have established efficacy and safety for the treatment of PsO, PsA, and other
                                            indications. The FDA has approved four biologics in the IL-23 class, including three targeting
                                            IL-23p19, and four biologics in the IL-17 class, including one targeting IL-17A/F. While
                                            these therapies have advanced the standard of care in PsO and PsA, they have not addressed
                                            these diseases completely, and a significant fraction of patients do not achieve complete
                                            skin clearance. By applying our advanced antibody engineering to these validated targets,
                                            we believe we can maximize our chances of developing superior medicines for patients. In
                                            addition, the reduced technical and biological risk of these validated mechanisms may allow
                                            us to progress our programs more efficiently and rapidly.
●
Leverage
                                            insights from earlier entrants to optimize our approach:
We
                                            benefit from a large body of clinical evidence generated by prior therapies targeting IL-23
                                            and IL-17. We continue to extract and apply learnings from this precedent to our programs,
                                            including in development candidate selection, clinical trial design, dosing regimens, formulations
                                            and presentations, regulatory pathway, and indication prioritization. For instance, based
                                            on correlations between affinity and efficacy, we have designed ORKA-001 and ORKA-002 to
                                            bind to similar epitopes and at similar or greater affinities as the leading antibodies in
                                            each class: risankizumab and bimekizumab, respectively, with the aim of maximizing efficacy.
                                            Also, by understanding the exposure-response relationships for efficacy and safety for other
                                            therapies, we plan to select dose levels and regimens that could maximize efficacy and maintenance
                                            of response while maintaining safety.
●
Pursue
                                            opportunities with strong prospects of yielding meaningful new medicines as a "base
                                            case" and the potential to shift the treatment paradigm entirely as an "upside
                                            case":
Our strategy seeks to maximize the potential
                                            for our programs to reach a base case product profile that could meaningfully advance the
                                            standard of care — for instance, for ORKA-001, SQ dosing one or twice a year
                                            with equal or greater efficacy compared to today's standard of care. At the same time,
                                            we aim to deliver an upside case that dramatically improves outcomes for patients — for
                                            instance, significantly increasing rates of complete skin clearance via higher antibody exposures
                                            or offering patients durable remissions free from therapy by introducing patient-specific
                                            dosing intervals.
●
Build
                                            a preeminent biotechnology company focused on chronic skin disease and other I&I
                                            indications:
We are assembling a team of exceptional people
                                            and helping them reach their full potential and flourish so that together we can bring forward
                                            meaningful new medicines for patients.
We
believe that pursuing the focused strategy outlined above will help us to succeed in our mission of offering patients living with PsO,
PsA, and other dermatologic and inflammatory diseases the greatest possible freedom from their condition.
Targeting
IL-23 and IL-17 to Treat Multiple I&I Indications
Our
programs benefit from significant advances in the understanding of the biology of I&I diseases over the past four decades. ORKA-001
and ORKA-002 are designed to target two key cytokines that play a related role in multiple indications. IL-23 is an upstream regulator
of Th17 cells, a pro-inflammatory subset of T helper cells characterized by their production of IL-17. IL-23 has a critical role in maintaining
Th17 cells in the tissue as well as activating these cells to secrete IL-17, which acts downstream to trigger inflammation and other
disease symptoms. Th17 cells are involved in PsO, PsA, HS, axSpA, and many other diseases. They play a particularly central role in PsO
and PsA. The diagram below depicting the immunopathogenesis of PsO provides an example of how Th17 cells can mediate disease and how
blocking IL-23 or IL-17 can break the inflammatory cycle that drives disease.
52
Immunopathogenesis
of PsO and the role of IL-23 and IL-17
PsO
develops when environmental triggers and a genetic predisposition combine to cause activation of an inflammatory cycle in the skin that
leads to the formation of plaques and other disease manifestations. This process begins with the aberrant activation of the dendritic
cells ("DCs"), specifically those producing IL-23 and other cytokines like IL-1β, IL-21, TNF-α, and IL-12. These
cytokines induce the differentiation of Th17 cells, as well as other cell types, such as T helper type 1 ("Th1") cells that
produce IFNγ and TNF-α and T helper type 22 ("Th22") cells that produce IL-22. IL-23 plays a key role in the
differentiation and activation of Th17 cells to secrete IL-17, as well as Th22 cells to produce IL-22. IL-17 and these other cytokines
induce keratinocyte hyperproliferation leading to plaque formation and a feedforward inflammatory response, with changes in gene expression
in keratinocytes, the production of antimicrobial peptides, and neutrophil recruitment driving further inflammation. While many cytokines
and cell types contribute to the pathogenesis of PsO, the IL-23/IL-17 axis plays an important role, as supported by the success of therapies
targeting this axis.
While
the successful treatment of PsO — for instance, with mAbs targeting IL-23 or IL-17 — can result in lesional
skin returning to an apparently normal state, disease tends to recur at previously affected sites following cessation of therapy, suggesting
a mechanism of "immunological memory" that predisposes individuals to recurrence in the same locations. Evidence suggests
that pathogenic TRMs play a critical role in this memory. TRMs may arise from the Th17 cells and other cells that drove disease in the
first place and remain in their resident tissue, in this case the epidermis and dermis, for long periods of time. Upon a disease trigger,
these TRMs can actively produce proinflammatory cytokines, causing disease recurrence. IL-23 appears to play an important role in maintaining
and potentiating TRMs, as indicated by the depletion of TRMs following treatment with an IL-23 inhibitor but not an IL-17 inhibitor,
which may explain the longer remissions observed with IL-23 inhibitors following withdrawal of therapy. This type of data has raised
the prospect that efficient IL-23 blockade could modify the disease biology of PsO, possibly leading to durable remissions.
53
The
scientific discoveries that refined our understanding of the immunopathogenesis of PsO have led to waves of therapeutic advances, ultimately
leading to today's standard of care. Before the 1980s, PsO was not even thought of as an immunologic disease, but rather a disease
of keratinocyte dysfunction, leading to treatments such as phototherapy, methotrexate, and retinoids. The discovery in the 1980s that
PsO results from immune dysfunction led to the use of broad immunosuppressants like cyclosporine. From 1990 to 2008, it was believed
that Th1 cells were the predominant mediators of the disease, which led to the use of biologics targeting TNF-α such as Enbrel
(etanercept) and Humira (adalimumab). Finally, the revelation that PsO is driven principally by Th17 cells resulted in the development
of the primary therapies used today, which target IL-23 and IL-17. This increasingly refined understanding of the disease has narrowed
the standard of care from broad immunosuppressive agents (such as cyclosporine) to more specific immunomodulators (TNF-α inhibitors)
to precise biologic therapies targeting the key cytokines involved in disease pathology (IL-23 and IL-17 inhibitors), with each new therapeutic
class raising the bar on both safety and efficacy.
Biologic
therapies, especially mAbs, are now mainstays in the treatment of a wide variety of I&I diseases, including PsO and PsA. Therapies
that have improved upon efficacy and/or reduced dosing frequency have achieved the most commercial success, even when launching many years
after other biologics. Enbrel was first approved for PsO in 2004 with a weekly maintenance dosing schedule. Four years later, Humira
was approved for PsO with an every-other-week (Q2W) dosing schedule. Stelara (ustekinumab) was approved a year later with similar Phase 3
data to Humira, but with a significantly improved dosing schedule of every twelve weeks (Q12W). Several drugs for PsO have been
approved since 2009 that demonstrated higher efficacy in their pivotal studies compared to Stelara, but with more burdensome dosing schedules,
including Tremfya (guselkumab), which has a dosing schedule of every eight weeks (Q8W), and Cosentyx (secukinumab) and Taltz (ixekizumab),
which have dosing schedules of every four weeks (Q4W). While these therapies have all become generally successful products, the
most commercially successful drug in the PsO market today is Skyrizi (risankizumab), which combines Stelara's Q12W dosing schedule
with improvements in efficacy, as evidenced by a higher psoriasis area severity index (PASI) score of PASI 90 and PASI 100 rates in clinical
trials. In addition, Bimzelx (bimekizumab), approved by the FDA in 2023, has shown evidence of efficacy that exceeds even Skyrizi, though
with a less convenient Q8W dosing schedule. Although many biologics have entered the PsO market over the past two decades, new entrants
have had significant commercial success when they have improved upon efficacy and/or dosing frequency, and room remains to improve in
both areas to set a new standard for the treatment of PsO.
Biologics
have raised the bar on the standard of care in PsO, but leave room for improvement
The
biology driving PsO and PsA is well understood today, and the standard of care has progressed dramatically. We believe that it is unlikely
that a novel mechanism will emerge that is as safe and efficacious as targeting the IL-23/IL-17 axis. Therefore, we believe that innovation
now should be focused on optimizing the product profile that can be offered to patients. While much effort is being directed toward daily
oral formats to inhibit this axis, oral medicines have yet to match the efficacy of biologics. We believe that a better biologic with
a longer dosing interval and the potential for improved efficacy will present a more attractive product profile for most patients.
54
Overview
of Psoriasis (PsO)
PsO
is a chronic autoimmune skin disorder that affects an estimated 125 million people worldwide with steadily increasing prevalence,
estimated to be around 2 – 3% of the population currently, according to the World Psoriasis Day consortium. It is
the largest pharmaceutical market within dermatology, with annual sales of approximately $25 billion in 2022, which is estimated
to grow to $32 billion by 2028. The most common form of PsO is plaque psoriasis. Patients with chronic plaque psoriasis have well-demarcated,
erythematous plaques with overlying, coarse, silvery-scaled patches. These plaques can occur anywhere on the body, though are typically
found on the scalp, extensor areas of the knees and elbows, and gluteal cleft. Involvement of the palms, soles, or nails, and intertriginous
areas, including the genitals, can also occur and can be particularly difficult to treat. Between one-quarter and one-half of PsO patients
have moderate disease, defined as having 3% to 10% of the body surface area ("BSA") involved, or severe disease, defined
as having more than 10% BSA involvement. The chronic inflammation in PsO is associated with multiple comorbidities, including PsA, obesity,
metabolic syndrome, hypertension, diabetes, and atherosclerotic cardiovascular disease.
As
discussed earlier, PsO is a complex immune-mediated disease driven primarily by Th17 cells and the cytokines IL-23 and IL-17. The interplay
of environmental and behavioral risk factors and genetics is believed to trigger PsO. Multiple lines of evidence support a genetic
component to the disease, including the observation that approximately 40% of patients with PsO and PsA have a family history of the
disease and the identification of multiple susceptibility loci, many containing genes related to the regulation of the immune system,
in genome-wide association studies.
Current
PsO Treatments and Limitations
While
patients with mild PsO typically rely on topical corticosteroids or oral therapies like Otezla (apremilast), these agents often do not
provide an adequate response for patients with moderate-to-severe PsO. As a result, the American Academy of Dermatology-National
Psoriasis Foundation recommends biologics as first-line therapy for moderate-to-severe PsO.
Several
classes of biologic therapies have been approved for PsO over the past 20 years, resulting in progressively more complete symptom
relief. Efficacy in PsO is typically measured via the PASI scoring system. The first biologics approved for PsO were tumor necrosis alpha
("TNF-α") inhibitors such as Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab), which achieved a
90% improvement in PASI score ("PASI 90") at 16 weeks in around 25 – 50% of patients and a
100% improvement in PASI score ("PASI 100") in around 5 – 20% of patients. Stelara (ustekinumab), which
targets the p40 subunit of IL-23 that is shared with IL-12, was approved next and achieved efficacy on par with Humira. IL-17 inhibitors
Cosentyx (secukinumab), Taltz (ixekizumab), and Siliq (brodalumab) followed and achieved responses of PASI 90 in around 70% of patients
and PASI 100 in around 40% of patients with some risk of certain side effects such as oral candidiasis. Most recently, IL-23p19
inhibitors such as Ilumya (tildrakizumab), Tremfya (guselkumab), and Skyrizi (risankizumab) have achieved responses of PASI 90 in around
70 – 80% of patients and PASI 100 in around 30 – 50% of patients with highly tolerable profiles. Finally,
IL-17A/F inhibitors such as Bimzelx (bimekizumab) have recently shown even higher response rates than IL-23 inhibitors, but with slightly
less tolerable profiles.
Treatment
expectations in PsO have evolved progressively with this continued innovation. A 75% improvement in PASI score was previously thought
to be an adequate depth of response, and weekly SQ dosing was viewed as acceptable. With each subsequent generation of innovation, patient
and caregiver expectations have advanced. Today, Skyrizi (risankizumab) is widely viewed as the leader in PsO biologic therapy. In Phase 3
clinical trials, 43% and 58% of patients achieved PASI 100 at 16 and 52 weeks, respectively, with SQ maintenance dosing every three months.
Most recently, Bimzelx (bimekizumab) has shown evidence of efficacy that exceeds even Skyrizi, achieving a 64% PASI 100 rate at 16 weeks
in Phase 3 trials. However, the increased efficacy comes with a less convenient Q8W dosing schedule and an increased risk of certain
side effects, most notably oral candidiasis. While agents like Skyrizi and Bimzelx reflect the remarkable advancement in PsO treatment,
there remains significant unmet need. Approximately half of moderate-to-severe PsO patients do not achieve full skin clarity, and while
early signs are present, the promise of disease modifying therapy remains unrealized. In addition, a continued desire for more convenient
dosing options has driven significant interest in orally delivered medicines targeting these same pathways. However, oral therapies have
yet to match the efficacy and safety profile of biologics. We believe that ORKA-001 and ORKA-002 could represent the next step in biologic
innovation in PsO, with the potential for higher rates of complete skin clearance, more durable remissions, and markedly more convenient
dosing regimens.
55
Overview
of Psoriatic Arthritis (PsA)
PsA
is a chronic inflammatory condition that affects both the skin and joints, and often coexists with PsO. Around a quarter to a third
of patients with moderate-to-severe PsO also have PsA. Most individuals develop PsO before being diagnosed with PsA, with a median
gap of seven to eight years between the diagnosis of skin and joint disease, though in up to 30% of patients with PsA, joint symptoms
appear before or simultaneously with skin manifestations. Patients with PsA present with joint pain, stiffness, and swelling affecting
the peripheral joints, axial skeleton, or both. Enthesitis, dactylitis, nail lesions, fatigue, and ocular inflammation all occur commonly.
PsA can lead to irreversible joint damage, including bony fusion across a joint (ankylosis). The pathogenesis of PsA is likely to be
closely related to the mechanisms that underlie PsO. Like PsO, the exact cause of PsA remains unknown, but environmental triggers,
including infection and trauma, and genetic factors play a role.
Current
PsA Treatments and Limitations
Effective
treatment of PsA requires a coordinated approach to address the unique combination of disease manifestations each patient has, which
can include peripheral and axial arthritis, enthesitis, dactylitis, and skin and nail involvement. Many patients with milder disease
symptoms will start with nonsteroidal anti-inflammatory drugs ("NSAIDs") and/or local treatments to address specific disease
manifestations. However, those with more moderate or severe disease and/or multidomain involvement will typically receive a biologic
therapy targeting TNF-α or IL-17, or less commonly an oral Janus kinase ("JAK") inhibitor. Comorbid conditions can
also influence treatment selection. For example, an IL-17 inhibitor would be preferred for a patient with significant skin involvement,
but not for patients with IBD or ocular symptoms, where a TNF-α inhibitor would be preferred. The most common endpoint used to
measure the efficacy of TNF-α or IL-17 inhibitors in PsA is ACR response, or the proportion of patients achieving a specified percent
improvement in American College of Rheumatology ("ACR") score, which measures peripheral joint disease. Approved TNF-α
inhibitors, including Humira (adalimumab) and Cimzia (certolizumab), achieved a placebo-adjusted ACR50 response of around 30 – 35%
at 24 weeks with Q2W dosing. Approved IL-17 inhibitors, including Cosentyx (secukinumab) and Taltz (ixekizumab), achieved a slightly
lower placebo-adjusted ACR50 response of around 25 – 30% at 24 weeks, but with more convenient Q4W dosing.
Bimzelx (bimekizumab) which was recently approved in the United States for PsA achieved a placebo-adjusted ACR50 response of approximately
35% at 16 weeks with Q4W dosing. A significant fraction of patients with PsA still do not achieve a satisfactory response with available
therapies, and even the most convenient regimens require monthly SQ dosing.
Overview
of additional opportunities
In
addition to PsO and PsA, inhibition of IL-23 or IL-17 has demonstrated efficacy in a number of additional I&I indications, including
HS and axSpA.
HS
is a chronic inflammatory skin disease characterized by lesions that include deep-seated nodules and abscesses, draining tracts, and
fibrotic scars that occur most commonly in intertriginous areas, such as the armpits and groin. Due to the associated pain, sensitive
locations, drainage, odor, and scarring, this condition can have a particularly negative psychosocial impact on affected individuals.
HS is believed to be underdiagnosed and could have a prevalence well above 1% worldwide. Treatment varies depending on severity and can
include topical and systemic antibiotics, hormone therapy, immune modulators, and surgery. Humira (adalimumab) was the only FDA-approved
medication for the treatment of moderate-to-severe HS from its approval in 2015 until the approval of Cosentyx (secukinumab) in October 2023.
However, now multiple other biologics, including Bimzelx (bimekizumab), are advancing through development and have demonstrated encouraging
data in clinical trials, though a significant fraction of patients still do not achieve adequate responses.
56
axSpA
is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints that comprise the axial skeleton. The disease
causes severe pain, stiffness, and fatigue, and can have additional clinical manifestations like uveitis, enthesitis, peripheral arthritis,
and PsO. Patients with axSpA may develop further structural damage in their spine, which can lead to the fusion of vertebra (spinal
ankylosis), which has a massive negative impact on mobility, physical function, and quality of life. The overall prevalence of axSpA
is estimated to be around 1% in the United States. Treatment of axSpA starts with physical therapy and NSAIDs. If patients do not
have an adequate response to NSAIDs, a TNF-α inhibitor is typically used, followed by an IL-17 inhibitor, such as Cosentyx (secukinumab),
Taltz (ixekizumab), or Bimzelx (bimekizumab), or less frequently a JAK inhibitor. Patients often need to cycle through therapies over
time due to inadequate responses or loss of response.
Our Solution:
Half-Life Extension and Antibody Engineering Technologies
Our
antibody engineering campaigns are designed to optimize multiple attributes in parallel: binding affinity, potency in a variety of assays,
developability, and consistently extended serum half-life in non-human primates ("NHPs"). Half-life extension is possible
by modifying the pH-dependent binding affinity of the antibody Fc domain for FcRn. A primary mechanism of elimination of antibodies from
the serum is through pinocytosis and degradation in the lysosomes of cells. Throughout this process, antibodies can be recycled back
into the serum by binding to FcRn while they are in endosomes. The interior of the endosome is acidic, and therefore the efficiency of
this recycling process depends on the ability of the antibody Fc domain to bind to FcRn at low pH. If this low pH binding is efficient
enough, antibody recycling can be favored over degradation, potentially resulting in a much longer serum half-life.
Antibody
engineers have discovered methods of modifying the Fc domain to optimize the efficiency of recycling via FcRn binding. Several engineering
strategies have been identified over the past two decades, with the so-called "YTE" mutations (M252Y/S254T/T256E) and "LS"
mutations (M428L/N434S) being the most frequently used. Importantly, while these strategies have been known for some time, it was only
relatively recently that enough clinical precedent was established to provide confidence in how these mutations perform in humans. Two
products incorporating YTE modification were approved in 2023 by the FDA, Beyfortus (nirsevimab) and Evusheld (tixagevimab and cilgavimab),
and several more candidates are in clinical trials. Two products using LS mutations were approved in 2021 and 2022, Xevudy (sotrovima)
and Ultomiris (ravulizumab), respectively, and several more candidates are in clinical trials. Based on clinical data in humans, antibodies
with YTE mutations typically have a half-life that is two to four times longer than wildtype antibodies. In addition, preclinical data
in NHPs can be used to predict the approximate half-life in humans, with the human half-life equaling around two to four times the
NHP half-life.
Clinical
experience with YTE-modified mAbs predicts significant half-life extension over wildtype mAbs
While
this increasing body of clinical precedent serves to validate half-life extension, we do not yet have clinical data showing that the
introduction of these amino acid substitutions in our programs leads to a longer serum half-life. However, we aim to establish this favorable
pharmacokinetic profile early in the clinical development of our product candidates.
57
ORKA-001
Summary
ORKA-001
is a high affinity, extended half-life mAb designed to target the p19 subunit of IL-23. Based on preclinical data generated to date,
we believe ORKA-001 has the potential to become the leading IL-23 inhibitor and achieve an optimal product profile in PsO consisting
of the following:
●
One
to two maintenance doses per year.
Standard-of-care therapies targeting IL-23 require maintenance dosing
every eight to twelve weeks. We engineered the Fc portion of ORKA-001 to include YTE mutations to increase the half-life of ORKA-001
in circulation, which may enable dosing every six to twelve months — a dosing interval made feasible by half-life
extension technology. In preclinical studies, serum levels from NHPs indicated an elimination half-life of over 30 days following
SQ administration of ORKA-001. Based on published scientific literature on other antibodies incorporating YTE mutations and pharmacokinetic
modeling, we anticipate this half-life in NHPs to translate to a half-life in humans that could allow subcutaneous dosing every six to
twelve months while maintaining high antibody exposures.
●
Higher
PASI 100.
ORKA-001 benefits from the robust validation of IL-23 inhibition in PsO by multiple approved
therapies, such as Skyrizi (risankizumab) and Tremfya (guselkumab), while leveraging insights from these therapies to improve upon their
clinical profile. ORKA-001 is designed to bind a similar epitope to the market-leading anti-IL-23 antibody, Skyrizi, with similar or
greater affinity and could achieve much higher exposures in patients due to half-life extension and higher dosing. Skyrizi and Tremfya
both have a robust exposure-response relationship, with higher drug exposures leading to higher response rates. Published data indicates
that these therapies have not saturated this exposure-response relationship, and ORKA-001 could lead to higher response rates, including
higher rates of complete skin clearance, or PASI 100, through increased exposure, even while having more convenient dosing with as few
as one or two maintenance doses per year.
●
Validated
IL-23p19 safety profile.
Existing commercially approved antibodies targeting IL-23 provide a robust precedent
for the safety of IL-23 inhibition. Across thousands of patients dosed in dermatology and IBD indications, no correlations have been
observed at the patient level between exposure and safety. While we are not pursuing IBD, the approved Skyrizi regimens for Crohn's
disease and ulcerative colitis supports the safety of high peak exposures. Peak Skyrizi exposures during the IV induction phase
in Crohn's disease and ulcerative colitis are multiple times higher than the peak ORKA-001 exposures at dose levels we currently
plan to evaluate in PsO. In addition, an exposure-response analysis for Skyrizi in ulcerative colitis showed no relationship between
exposures and evaluated safety endpoints in the 12-week induction or 52-week maintenance periods. In this assessment, the top quartile
of average exposures were significantly higher than the highest anticipated exposures with ORKA-001 in the same periods.
●
Potential
to offer longer term remission to some patients.
Emerging evidence suggests that IL-23 blockade can modify
the disease biology of PsO, possibly leading to durable remissions and preventing the development of PsA. Dr. Andrew Blauvelt,
chair of our Scientific Advisory Board, pioneered some of this work by using two- and four-times the approved dose levels of risankizumab
to achieve best-in-indication response rates. This study, called KNOCKOUT, showed a robust depletion of TRMs following high dose IL-23
inhibition, which could lead to longer-lasting remissions in some patients. Additional evidence from a study of guselkumab, called GUIDE,
showed that intervention early in the disease course can lead to longer treatment-free remissions. In addition, retrospective claims
data suggests that treatment with an IL-23 inhibitor could help prevent progression to PsA, though this finding has yet to be confirmed
by a prospective clinical trial. Given the high antibody exposures expected with ORKA-001, we believe that ORKA-001 could lead to durable
remissions for some patients, especially those with short disease duration. We plan to pursue patient-specific dosing intervals to provide
each patient the greatest possible freedom from their disease.
We
believe that this target profile for ORKA-001 could offer improved freedom from disease to many patients affected by PsO and represent
a step forward in the standard of care.
58
Preclinical
Data
We
evaluated ORKA-001 in numerous preclinical studies for several key features:
Potency
that matches or exceeds Skyrizi (risankizumab) in vitro
We
have tested the potency of ORKA-001
in vitro
in multiple assays, including assays evaluating the inhibition of IL-17 release
from human peripheral mononuclear blood cells, in comparison to risankizumab generated recombinantly based on amino acid sequences from
patent filings. Based on the results of these experiments, we believe ORKA-001 binds a similar epitope as risankizumab with similar potency.
ORKA-001
binds to a similar epitope as risankizumab with similar potency
Significant
half-life extension in NHPs that could enable a maintenance dosing interval of once or twice a year in humans
We
assessed ORKA-001 in NHPs in comparison to risankizumab generated recombinantly based on amino acid sequences from patent filings. ORKA-001
had a significantly longer half-life, reaching over 30 days with SQ administration. Based on clinical experience with YTE-modified
mAbs and pharmacokinetic modeling, we believe that this half-life extension could enable dosing once or twice per year, as shown in the
figure below.
The incorporation
of YTE mutations significantly extends half-life in NHPs, which could enable once or twice yearly dosing
In
addition to enabling less frequent dosing, an extended half-life would increase the exposure of ORKA-001, which has the potential to
increase efficacy. Based on published literature, Skyrizi (risankizumab) demonstrates a clear relationship between antibody exposure
and efficacy, with higher average serum antibody concentration correlating with higher PASI 90 and PASI 100 rates short-term (at 16 weeks)
and long-term (at 52 weeks), as shown for PASI 100 in the figure below. In addition, the KNOCKOUT study, which evaluated two- and
four-times higher doses of Skyrizi than the approved regimen, yielded some of the highest PASI 100 rates observed to date, reaching 67%
at 16 weeks. Based on our pharmacokinetic modeling, ORKA-001 could achieve four-fold higher average exposures than the approved
Skyrizi regimen over the first 16 weeks and over two-fold higher average exposures at steady-state, exceeding even the exposures
in KNOCKOUT. Based on the exposure-response relationship observed with other IL-23 inhibiting antibodies, we believe that these
increased exposures could result in higher efficacy.
59
ORKA-001
is projected to extend the exposure-response relationship established by studies of Skyrizi
Safety
in vitro and in vivo
We
have evaluated ORKA-001 in several
in vitro
and
in vivo
preclinical studies to assess safety. In addition,
we have initiated a robust nonclinical program to characterize the toxicology, toxicokinetics, and anti-drug antibody profile of ORKA-001
in NHPs, including a single-dose non-GLP dose-range finding study and one-month and six-month GLP toxicology studies. Collectively, this
nonclinical program is designed to support the initiation of clinical trials. In addition, ORKA-001 benefits from the favorable safety
precedent for IL-23 inhibition provided by the existing commercially approved IL-23-targeted antibodies across several indications.
Characteristics
that support ease of manufacturing and potentially enable high-concentration formulations
Finally,
we have assessed a variety of attributes essential for manufacturability and high-concentration formulation, including viscosity, solubility,
and stability, among others. ORKA-001 shows evidence of desirable properties across these characteristics, which we believe will enhance
our ability to manufacture ORKA-001 successfully and consistently and to deliver high doses of ORKA-001 subcutaneously using convenient,
low-volume presentations.
Clinical
Development Plans
Based
on these potential advantages and preclinical data, we are advancing ORKA-001 towards a Phase 1 clinical trial in the first quarter
of 2025. This trial will encompass a Phase 1a single-ascending dose portion in healthy volunteers, followed by a Phase 1b,
multiple-dose portion in patients with moderate-to-severe PsO. Following completion of Phase 1b, patients will become eligible
for an open-label extension study. Initial data from the Phase 1a cohort has the potential to provide key validation of both early
safety and pharmacokinetics, including half-life, to support extended dosing intervals. Initial data from the Phase 1b cohort has
the potential to provide preliminary efficacy data in patients with PsO. Pending the results from the Phase 1 clinical trial,
we plan to initiate a Phase 2 clinical trial in PsO in 2026. Several aspects of PsO facilitate clinical development, including well-established,
reproducible endpoints based on PASI scores, low placebo rates, particularly with PASI 90 and PASI 100, a rapid efficacy readout at 16 weeks,
and potentially rapid enrollment due to the large patient population. We have not yet submitted an IND with the FDA for our Phase 1 clinical
trial for ORKA-001.
ORKA-002
Summary
ORKA-002
is a high affinity, extended half-life mAb designed to target IL-17A/F. Dual inhibition of both IL-17A and IL-17F has shown superior
efficacy compared to IL-17A inhibition alone in PsO and other indications, as shown by the performance of Bimzelx (bimekizumab) compared
to Cosentyx (secukinumab) and Taltz (ixekizumab) in Phase 3 trials. These therapies all utilize Q4W maintenance dosing in PsO and
PsA, except Bimzelx, where Q8W maintenance dosing in PsO patients <120 kg is recommended. By binding IL-17A/F at similar epitopes
and affinity ranges as Bimzelx while incorporating half-life extension technology to potentially enable dosing two to three times a year
in PsO and PsA, we believe that ORKA-002 could become the leading therapy in the IL-17 class.
60
Preclinical
Data
The
preclinical program we are conducting for ORKA-002 mirrors that for ORKA-001 and spans potency, pharmacokinetics, safety, and manufacturing
characteristics. Based on the results of these experiments, we believe ORKA-002 has the potential for comparable potency to bimekizumab,
but with a significantly longer half-life, which we believe could support dosing two or three times per year based on extrapolation from
clinical precedent and pharmacokinetic modeling.
Clinical
Development Plans
We
plan to initiate a Phase 1 trial of ORKA-002 in the third quarter of 2025. As with ORKA-001, initial data on ORKA-002 in healthy
volunteers has the potential to provide key validation of both early safety and pharmacokinetics to support extended dosing intervals.
Though clinical development of ORKA-002 will initially focus on one lead indication, we plan to evaluate ORKA-002 in a range of indications
over time. We see ORKA-002 as highly complementary to ORKA-001, with the potential to provide an optimal therapy for the approximately
one-quarter to one-third of moderate-to-severe PsO patients who have PsA, as well as for PsO patients with highly resistant skin symptoms
that do not respond adequately to an IL-23 inhibitor. Furthermore, ORKA-002 could address indications beyond PsO, including PsA with
limited skin involvement, HS, axSpA, and additional I&I diseases. We have not yet submitted an IND with the FDA for our Phase
1 clinical trial for ORKA-002.
Additional
Pipeline Programs
We
have a third mAb program, ORKA-003, that targets an undisclosed pathway. A core tenet of our strategy is to remain highly focused on I&I
diseases, and specifically on inflammatory dermatology conditions. ORKA-003 provides the potential for indication expansion beyond PsO
as well as combination opportunities with our more advanced programs. In the future, we may add additional programs to our portfolio
beyond ORKA-001, ORKA-002, and ORKA-003 that fit our strategic focus.
Intellectual
Property
We
strive to protect the proprietary programs and technologies that we believe are important to our business, including seeking and maintaining
patent protection intended to cover the composition of matter of our programs, their methods of use and manufacture, related technologies,
diagnostics, and other inventions.
Paragon
has filed provisional patent applications, and may file additional provisional patent applications directed to antibodies that target
IL-23, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including
ORKA-001. In addition, Paragon has filed provisional patent applications, and may file additional provisional patent applications directed
to antibodies that target IL-17, including applications covering composition of matter, pharmaceutical formulations, and methods of using
such antibodies, including ORKA-002. We have exercised our option to acquire exclusive rights to ORKA-001 and the corresponding IL-23
patent applications but have not yet entered into the corresponding license agreement. We have not yet exercised our option to acquire
exclusive rights to any IL-17 patent applications, but retain the right to do so. If the provisional patent applications are pursued
non-provisionally and mature into one or more issued patents covering ORKA-001 or ORKA-002, we would expect those patents to expire in
2045, absent any applicable patent term adjustments or extensions.
61
Commercial
Should
any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States
and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the full
commercial value of our programs. Given our stage of development, we have not yet established a commercial organization or distribution
capabilities. We have exercised our option to acquire exclusive worldwide rights to develop and commercialize ORKA-001 but have not entered
into the corresponding license agreement. We also currently hold an exclusive Option (as defined below) to acquire worldwide development
and commercialization rights to ORKA-002.
Manufacturing
We
do not currently own or operate facilities for product manufacturing, testing, storage, and distribution. We have contracted and expect
to continue to contract with third parties for the manufacture and distribution of our product candidates. Because we rely on contract
manufacturers, we employ personnel with extensive technical, manufacturing, analytical and quality experience. Our team has deep knowledge
and understanding of the regulations that govern manufacturing, documentation, quality assurance, and quality control of drug supply
that are required to support our regulatory filings.
Competition
The
biotechnology and biopharmaceutical industries are characterized by continuing technological advancement and significant competition.
While we believe that our programs, technology, development experience and scientific knowledge provide us with competitive advantages,
we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and
private research institutions, among others. Any product candidates that we successfully develop and commercialize will compete with
existing therapies and new therapies that may become available in the future. Many of the companies with which we are currently competing
or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing,
preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers
and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller
number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific
and management personnel, establishing clinical trial sites, patient enrollment for clinical trials as well as in acquiring technologies
complementary to, or necessary for, our programs.
Key
competitive factors affecting the success of all our product candidates that we develop, if approved, are likely to be efficacy, safety,
convenience, presentation, price, the level of generic competition, and the availability of reimbursement from government and other third-party
payors. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval
for our products, which could result in our competitors establishing a strong market position before we are able to enter the market.
Specifically,
there are several companies developing or marketing treatments that may be approved for the same indications and/or diseases as our two
most advanced programs, ORKA-001 and ORKA-002, including major pharmaceutical companies. We do not yet have clinical data for any of
our programs and there can be no assurance that our programs will have similar or comparable results.
There
are several approved biologic therapies for the treatment of moderate-to-severe PsO. These include mAbs targeting IL-23, such as
Skyrizi (risankizumab) from AbbVie, Tremfya (guselkumab) from Janssen, and Ilumya (tildrakizumab) from Sun Pharma, also marketed as Ilumetri
by Almirall in Europe, which all target the p19 subunit, and Stelara (ustekinumab) from Janssen, which targets the p40 subunit; mAbs
targeting IL-17, such as Bimzelx (bimekizumab) from UCB, which targets IL-17A/F, Cosentyx (secukinumab) from Novartis and Taltz (ixekizumab)
from Eli Lilly, which both target IL-17A, and Siliq (brodalumab) from Ortho Dermatologics, also marketed as Kyntheum by LEO Pharma in
Europe, which targets IL-17 receptor A; and biologics targeting TNF-α, such as Humira (adalimumab) from AbbVie, Enbrel (etanercept)
from Amgen, and Remicade (infliximab) from Janssen, and various biosimilar versions of each. In addition, there are several approved
oral medicines in these indications, including the phosphodiesterase-4 (PDE4) inhibitor Otezla (apremilast) from Amgen and the tyrosine
kinase 2 (TYK2) inhibitor Sotyktu (deucravacitinib) from Bristol-Myers Squibb. Many of these therapies also are approved or in development
for PsA, HS, axSpA, and other I&I indications.
62
In
addition, we are aware of several product candidates in clinical development for moderate-to-severe PsO, along with PsA, HS, axSpA, and
other indications. These include the biologics picankibart from Innovent Biologics targeting IL-23p19 and sonelokimab from MoonLake Immunotherapeutics
targeting IL-17A/F. Also, there are several oral agents in development, including JNJ-2113 from Janssen targeting the IL-23 receptor,
DC-806 and DC-853 from Eli Lilly targeting IL-17A, and TAK-279 from Takeda and ESK-001 from Alumis, both targeting TYK2.
License
Agreements
Paragon
Therapeutics
On
March 6, 2024, we entered into the Paragon Option Agreements. Under the terms of each agreement, Paragon identifies, evaluates,
and develops antibodies directed against certain mutually agreed therapeutic targets of interest to us. Each Paragon Option Agreement
initially included one of two selected targets: IL-23 and IL-17A/F. Under the Paragon Option Agreements, we have the exclusive option
to, on a research program-by-research program basis, be granted an exclusive, worldwide license to all of Paragon's right, title,
and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize
the antibodies and products directed to the selected target(s) (each, an "Option"). In the case of IL-23, our Option
excludes the therapeutic area of IBD. From time to time, we can choose to add additional targets to the collaboration by mutual
agreement with Paragon and Paruka. In September 2024 we exercised the Option to acquire the rights to ORKA-001 but have not yet entered
into the corresponding license agreement. As of the date hereof, we have not exercised the IL-17A/F Option.
Pursuant
to the terms of the Paragon Option Agreements, we initiated certain research programs with Paragon that generally focus on a particular
target (each, a "Research Program"). Each Research Program is aimed at discovering, generating, identifying, and/or characterizing
antibodies directed to the respective target. For each Research Program, we established or may establish in the future a research plan
with Paragon that sets forth the activities that will be conducted, and the associated research budget (each, a "Research Plan").
Our exclusive option with respect to each Research Program is exercisable at our sole discretion at any time during the period beginning
on the initiation of activities under the associated Research Program and ending a specified number of days following (i) with
respect to any Research Program other than ORKA-001, the delivery of the data package from Paragon related to the results of the Research
Plan activities or (ii) with respect to ORKA-001, the completion of the IL-23 antibody selection process described in the agreement
(the "Option Period"). There is no payment due upon exercise of an Option pursuant to the Paragon Option Agreements.
Unless
terminated earlier, each Paragon Option Agreement shall continue in force on a Research Program-by-Research Program basis until the earlier
of: (i) the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by us; (ii) the
expiration of the 30-day period after we exercise our Option with respect to a Research Program, subject to mutually agreed extension,
during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii) the expiration of the
applicable Research Term (as defined under each Paragon Option Agreement) (the "Term"). We may terminate any Paragon Option
Agreement or any Research Program at any time for any or no reason upon 30 days' prior written notice to Paragon, provided
that we must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred
by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate any Paragon Option Agreement
or a Research Program immediately upon written notice to us if, as a result of any action or failure to act by us or our affiliates,
such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed
for a certain consecutive number of months. Each party has the right to terminate the Paragon Option Agreements or any Research
Program upon (i) 30 days' prior written notice of the other party's material breach that remains uncured for the
30-day period and (ii) the other party's bankruptcy.
63
As
of the date of filing of this prospectus, we have exercised the Option with respect to ORKA-001 but have not yet entered into the corresponding
license agreement. We have not yet exercised the Option with respect to ORKA-002. For each of these agreements, once we enter into the
corresponding license agreements, we will be required to make non-refundable milestone payments to Paragon of up to $12.0 million
for each program upon the achievement of certain clinical development milestones, up to $10.0 million for each program upon the
achievement of certain regulatory milestones, as well as tiered royalty payments in the low-to-mid single-digits beginning on the first
commercial sale in each program.
Additionally,
as part of the Paragon Option Agreements, on each of December 31, 2024 and December 31, 2025, we will grant Paruka warrants
to purchase a number of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully-diluted basis, with an exercise
price equal to the fair market value of the underlying shares on the grant date.
Pursuant
to the Option Agreements, on a research program-by-research program basis following the finalization of the research plan for each respective
research program, the Company was required to pay Paragon a one-time, nonrefundable research initiation fee of $0.8 million related
to the ORKA-001 program. This amount was recognized as a research and development expense during the period from February 6 (inception)
to September 30, 2024. In June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process of its
development candidate for IL-23 antibody for ORKA-001 program. The Company was responsible for 50% of the development costs incurred
through the completion of the IL-23 selection process. The Company received the rights to at least one selected IL-23 antibody in June
2024. During the three months ended September 30, 2024, the Company exercised its option for ORKA-001 and recorded a $1.5 million milestone
payment related to the achievement of development candidate as research and development expense in the Company's condensed consolidated
statements of operations and comprehensive loss for each of the three months ended September 30, 2024 and for the period from February
6, 2024 (inception) to September 30, 2024. The Company's share of development costs incurred during the three months ended September
30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024 was $0.8 million and $13.2 million, respectively,
which were recorded as research and development expenses during the respective periods. An amount of $2.3 million is included in related
party accounts payable and other current liabilities as of September 30, 2024.
The
Company was also required to reimburse Paragon $3.3 million for development costs related to ORKA-002 incurred by Paragon through
December 31, 2023 and certain other development costs incurred by Paragon between January 1, 2024 and March 6, 2024 as
stipulated by the Option Agreements. This amount was recognized as a research and development expense during the period from February 6
(inception) to September 30, 2024. The Company is also responsible for the development costs incurred by Paragon from January 1,
2024 through the completion of the IL-17 selection process. The Company recognized an amount of $0.8 million payable to Paragon
for the research initiation fee related to ORKA-002 following the finalization of the ORKA-002 research plan. This was recognized as
research and development expenses in the period from February 6 (inception) to September 30, 2024. The Company accounted for development
costs of $3.8 million and $6.6 million during the three months ended September 30, 3024 and for the period from February 6, 2024 (inception)
to September 30, 2024, respectively, as research and development expenses during the respective periods. An amount of $3.8 million is
included in related party accounts payable and other current liabilities as of September 30, 2024.
For
the three months ended September 30, 2024 and the period from February 6, 2024 (inception) to September 30, 2024, we recognized
$13.4 million and $33.8 million of expenses, respectively in connection with services provided by Paragon and Paruka under the Paragon
Option Agreements.
Government
Regulation
The
FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among
other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging,
storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting
of biologics such as those we are developing. We, along with our third-party contractors, will be required to navigate the various preclinical,
clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies
or seek approval or licensure of our product candidates.
64
United
States Biologics Regulation
In
the United States, biological products are subject to regulation under the FDCA, the Public Health Service Act ("PHSA") and
other federal, state, local, and foreign statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance
with appropriate federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources.
Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or following
approval may subject an applicant to administrative action and judicial sanctions. The process required by the FDA before biologic product
candidates may be marketed in the United States generally involves the following:
●
completion
of preclinical laboratory tests and animal studies performed in accordance with the FDA's current Good Laboratory Practices ("GLP")
regulation;
●
submission
to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes
are made;
●
approval
by an independent IRB, or ethics committee at each clinical site before the trial is commenced;
●
manufacture
of the proposed biologic candidate in accordance with current Good Manufacturing Practices ("cGMPs");
●
performance
of adequate and well-controlled human clinical trials in accordance with current GCP requirements to establish the safety, purity and
potency of the proposed biologic product candidate for its intended purpose;
●
preparation
of and submission to the FDA of a BLA, after completion of all pivotal clinical trials;
●
satisfactory
completion of an FDA Advisory Committee review, if applicable;
●
a
determination by the FDA within 60 days of its receipt of a BLA to file the application for review;
●
satisfactory
completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to
assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological product's
continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; and
●
FDA
review and approval of a BLA to permit commercial marketing of the product for particular indications for use in the United States.
Preclinical
and Clinical Development
Prior
to beginning any clinical trial with a product candidate, in the United States, we must submit an IND to the FDA. An IND is a request
for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is
on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes
results of animal and
in vitro
studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics
of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the
investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective
30 days after receipt by the FDA, unless the FDA, within the 30-day period, raises safety concerns or questions about the proposed clinical
trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or
questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical
trial.
In
addition to the IND submission process, supervision of human gene transfer trials includes evaluation and assessment by an institutional
biosafety committee ("IBC"), a local institutional committee that reviews and oversees research utilizing recombinant or
synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to
public health or the environment and such review may result in some delay before initiation of a clinical trial.
65
Clinical
trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in
accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation
in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the
parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND
must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore,
an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and
its informed consent form before the clinical trial begins at that site, and must monitor the study until completed.
Regulatory
authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects
are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include
oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board,
which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from
the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such
as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials
and clinical study results to public registries.
For
purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.
●
Phase
1. The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition.
These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product
in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.
●
Phase
2. The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the
preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase
2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.
●
Phase
3. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically
significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial
sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an
adequate basis for product approval.
In
some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain
more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical
trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the
product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements.
The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things,
must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity
and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate
that the product candidate does not undergo unacceptable deterioration over its shelf life.
A
sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted
under an IND, all IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor
must ensure that the study complies with certain FDA regulatory requirements in order to use the study as support for an IND or application
for marketing approval or licensure, including that the study was conducted in accordance with GCP, including review and approval by
an independent ethics committee and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate
the data from the study through an onsite inspection if the FDA deems such inspection necessary. The GCP requirements encompass both
ethical and data integrity standards for clinical studies.
66
BLA Submission
and Review
Assuming
successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development,
nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or
more indications. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including
negative or ambiguous results as well as positive findings, together with detailed information relating to the product's chemistry,
manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to
test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored
by investigators. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption
applies.
In
addition, under the Pediatric Research Equity Act ("PREA"), a BLA or supplement to a BLA must contain data to assess the
safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and
to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Food and Drug
Administration Safety and Innovation Act requires that a sponsor who is planning to submit a marketing application for a biological product
that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial
pediatric study plan within sixty days after an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise
required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted.
Within
60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before
the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time
of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once
a BLA has been accepted for filing, the FDA's goal is to review standard applications within ten months after the filing date,
or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and
priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews
a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed,
packed or held meets standards designed to assure the product's continued safety, purity and potency. The FDA may convene an advisory
committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee,
but it considers such recommendations carefully when making decisions.
Before
approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve
an application unless it determines that the manufacturing processes and facilities are in compliance with GMP requirements and adequate
to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically
inspect one or more clinical sites to assure compliance with cGCPs. If the FDA determines that the application, manufacturing process
or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional
testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the
application does not satisfy the regulatory criteria for approval.
After
the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance
will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing
of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies
that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate
to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted
product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant
might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay
or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require
post-marketing testing and surveillance to monitor safety or efficacy of a product.
67
If
regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the
indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a REMS to ensure the benefits of
the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and
to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician
communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls
and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements
is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market
studies and surveillance to further assess and monitor the product's safety and effectiveness after commercialization, and may
limit further marketing of the product based on the results of these post-marketing studies.
Expedited
Development and Review Programs
The
FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended
to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible
for fast track designation if they are intended to treat a serious or life-threatening disease or condition and data demonstrate the
potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product
and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for more frequent interactions
with the review team during product development and, once a BLA is submitted, the product may be eligible for priority review. A fast
track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before
the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees
to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission
of the first section of the BLA.
A
product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation
to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates
that the product, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing
therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.
The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as
early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior
managers.
Any
marketing application for a biologic submitted to the FDA for approval, including a product with a fast track designation and/or breakthrough
therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as
priority review and accelerated approval. A product is eligible for priority review if there is evidence it has the potential to provide
a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition. For original BLAs, priority review
designation means the FDA's goal is to take action on the marketing application within six months of the 60-day filing date (as
compared to ten months under standard review).
Additionally,
products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated
approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit,
or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict
an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of
the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally
require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect
on irreversible morbidity or mortality or other clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022 the FDA may require,
as appropriate, that such studies be underway prior to approval or within a specific time period after the date of approval for a product
granted accelerated approval. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor
fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the
FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the
timing of the commercial launch of the product.
68
Fast
track designation, breakthrough therapy designation and priority review do not change the standards for approval but may expedite the
development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product
no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.
Post-Approval
Requirements
Any
products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including,
among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and
distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new
indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements,
under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors
are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections
by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon
us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance
of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of
any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly,
manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with
cGMPs and other aspects of regulatory compliance.
The
FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product
reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity
or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved
labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition
of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:
●
restrictions
on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;
●
fines,
warning letters or holds on post-approval clinical studies;
●
refusal
of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;
●
product
seizure or detention, or refusal of the FDA to permit the import or export of products;
●
consent
decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;
●
mandated
modification of promotional materials and labeling and the issuance of corrective information;
●
the
issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety
information about the product; or
●
injunctions
or the imposition of civil or criminal penalties.
The
FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating
to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label.
The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with
these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil
and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product's labeling
and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians
may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the
behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer's communications on the subject
of off-label use of their products.
69
Biosimilars
and Reference Product Exclusivity
The
ACA includes a subtitle called the BPCIA, which created an abbreviated approval pathway for biological products that are highly similar,
or "biosimilar," to or interchangeable with an FDA-approved reference biological product. The FDA has issued several guidance
documents outlining an approach to review and approval of biosimilars.
Biosimilarity,
which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of
safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability
requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the
same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual,
the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety
risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable
with an FDA-approved reference biological product may rely in part on the FDA's previous determination of safety and effectiveness
for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product.
Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which
such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked
out by the FDA. In September 2021, the FDA issued two guidance documents intended to inform prospective applicants and facilitate the
development of proposed biosimilars and interchangeable biosimilars, as well as to describe the FDA's interpretation of certain
statutory requirements added by the BPCIA.
Under
the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference
product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12
years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may
still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant's
own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its
product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it
is unclear whether products deemed "interchangeable" by the FDA will, in fact, be readily substituted by pharmacies, which
are governed by state pharmacy law.
A
reference biologic is granted twelve years of exclusivity from the time of first licensure of the reference product. The first biologic
product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity
against other biologics submitted under the abbreviated approval pathway for the lesser of (i) one year after the first commercial marketing,
(ii) 18 months after approval if there is no legal challenge, (iii) 18 months after the resolution in the applicant's favor of
a lawsuit challenging the biologics' patents if an application has been submitted, or (iv) 42 months after the application has
been approved if a lawsuit is ongoing within the 42-month period.
A
biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months
to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection
or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued "Written
Request" for such a study. The BPCIA is complex and continues to be interpreted and implemented by the FDA. In July 2018, the FDA
announced an action plan to encourage the development and efficient review of biosimilars, including the establishment of a new office
within the agency that will focus on therapeutic biologics and biosimilars. On December 20, 2020, Congress amended the PHSA as part of
the COVID-19 relief bill to further simplify the biosimilar review process by making it optional to show that conditions of use proposed
in labeling have been previously approved for the reference product, which used to be a requirement of the application. In addition,
government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which
may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation,
and impact of the BPCIA is subject to significant uncertainty.
As
discussed below, the IRA is a significant new law that intends to foster generic and biosimilar competition and to lower drug and biologic
costs.
70
Other
Healthcare Laws and Compliance Requirements
Pharmaceutical
companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states
and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the federal Anti-Kickback Statute
("AKS"); the federal False Claims Act ("FCA"); the Health Insurance Portability and Accountability Act of 1996
("HIPAA") and similar foreign, federal and state fraud, abuse and transparency laws.
The
AKS prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration,
to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which
payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value.
The
AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and purchasers on
the other. The government often takes the position that to violate the AKS, only one purpose of the remuneration need be to induce referrals,
even if there are other legitimate purposes for the remuneration. There are a number of statutory exceptions and regulatory safe harbors
protecting some common activities from AKS prosecution, but they are drawn narrowly and practices that involve remuneration, such as
consulting agreements, that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny
if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for protection under
a statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception
or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated
on a case-by-case basis based on a cumulative review of all of its facts and circumstances. A person or entity does not need to have
actual knowledge of the statute or specific intent to violate it in order to have committed a violation.
Civil
and criminal false claims laws, including the FCA, and civil monetary penalty laws, which can be enforced through civil whistleblower
or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims
for payment of federal government funds, including in federal healthcare programs, that are false or fraudulent. Pharmaceutical and other
healthcare companies have been prosecuted under these laws for engaging in a variety of different types of conduct that "caused"
the submission of false claims to federal healthcare programs. Under the AKS, for example, a claim resulting from a violation of the
AKS is deemed to be a false or fraudulent claim for purposes of the FCA.
HIPAA
created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit
program, including private third-party payors, and making false statements relating to healthcare matters. A person or entity does not
need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate the statute in order
to have committed a violation.
The
FDCA addresses, among other things, the design, production, labeling, promotion, manufacturing, and testing of drugs, biologics and medical
devices, and prohibits such acts as the introduction into interstate commerce of adulterated or misbranded drugs or devices. The PHSA
also prohibits the introduction into interstate commerce of unlicensed or mislabeled biological products.
The
U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which
payment is available under Medicare, Medicaid or the Children's Health Insurance Program, with specific exceptions, to annually
report to the Centers for Medicaid & Medicare Services ("CMS") information related to payments or other transfers of
value to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists,
certified nurse anesthetists, certified nurse-midwives, and teaching hospitals, as well as ownership and investment interests held by
physicians and their immediate family members. Beginning on January 1, 2023, California Assembly Bill 1278 requires California physicians
and surgeons to notify patients of the Open Payments database established under the federal Physician Payments Sunshine Act.
71
We
are also subject to additional similar U.S. state and foreign law equivalents of each of the above federal laws, which, in some cases,
differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If our operations
are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to penalties, including,
without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs,
such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations
to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits
and the curtailment or restructuring of our operations.
Data Privacy
and Security
Numerous
state, federal, and foreign laws govern the collection, dissemination, use, access to, confidentiality, and security of personal information,
including health-related information. In the United States, numerous federal and state laws and regulations, including state data breach
notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, govern the
collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations
of our partners. For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health ("HITECH"),
and their respective implementing regulations imposes data privacy, security, and breach notification obligations on certain health care
providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates and their covered
subcontractors that perform certain services that involve using, disclosing, creating, receiving, maintaining, or transmitting individually
identifiable protected health information ("PHI") for or on behalf of such covered entities. These requirements imposed by
HIPAA and the HITECH Act on covered entities and business associates include entering into agreements that require business associates
protect PHI provided by the covered entity against improper use or disclosure, among other things; following certain standards for the
privacy of PHI, which limit the disclosure of a patient's past, present, or future physical or mental health or condition or information
about a patient's receipt of health care if the information identifies, or could reasonably be used to identify, the individual;
ensuring the confidentiality, integrity, and availability of all PHI created, received, maintained, or transmitted in electronic form,
to identify and protect against reasonably anticipated threats or impermissible uses or disclosures to the security and integrity of
such PHI; and reporting of breaches of PHI to individuals and regulators. Entities that are found to be in violation of HIPAA may be
subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations
if required to enter into a resolution agreement and corrective action plan with the U.S. Department of Health and Human Services ("HHS")
to settle allegations of HIPAA non-compliance. A covered entity or business associate is also liable for civil money penalties for a
violation that is based on an act or omission of any of its agents, which may include a downstream business associate, as determined
according to the federal common law of agency. HITECH also increased the civil and criminal penalties applicable to covered entities
and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts
to enforce HIPAA and seek attorneys' fees and costs associated with pursuing federal civil actions. To the extent that we submit
electronic healthcare claims and payment transactions that do not comply with the electronic data transmission standards established
under HIPAA and HITECH, payments to us may be delayed or denied.
Even
when HIPAA does not apply, according to the FTC, violating consumers' privacy rights or failing to take appropriate steps to keep
consumers' personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section
5(a) of the Federal Trade Commission Act.
In
addition, certain state laws, such as the California Consumer Privacy Act of 2018 ("CCPA"), as amended by the California
Privacy Rights Act of 2020 ("CPRA"), govern the privacy and security of personal information, including health-related information
in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and
may not have the same effect, thus complicating compliance efforts. The CCPA/CPRA applies to personal data of consumers, business representatives,
and employees, and imposes obligations on certain businesses that do business in California, including to provide specific disclosures
in privacy notices, rights to California residents in relation to their personal information. Health information falls under the CCPA/CPRA's
definition of personal information where it identifies, relates to, describes, or is reasonably capable of being associated with or could
reasonably be linked with a particular consumer or household - unless it is subject to HIPAA - and is included under a new category of
personal information, "sensitive personal information," which is offered greater protection. Failure to comply with these
laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and
security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts,
and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on
data processing. Additionally, our use of artificial intelligence and machine learning may be subject to laws and evolving regulations
regarding the use of artificial intelligence/machine learning, controlling for data bias, and antidiscrimination.
72
In
addition, the CPRA expands the CCPA's requirements, including by adding a new right for individuals to correct their personal information
and establishing a new regulatory agency to implement and enforce the law. Other states, such as Virginia, Colorado, Connecticut and
Utah, have also passed comprehensive privacy laws, and similar laws are being considered in several other states, as well as at the federal
and local levels. While the laws in these states, like the CCPA, also exempt some data processed in the context of clinical trials, such
developments further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties upon whom
we rely.
Coverage
and Reimbursement
Significant
uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory
approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors,
such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the
level of reimbursement, if any, for such product by third-party payors. Decisions regarding whether to cover any of our product candidates,
if approved, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Further, no uniform
policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor
to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates,
but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process
is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product
candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained
in the first instance.
Third-party
payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing
the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety
and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with
existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement
for any product or a decision by a third-party not to cover a product could reduce physician usage and patient demand for the product.
For
products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult
because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment
or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic
tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or
biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products,
will apply to companion diagnostics.
In
addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including
price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. The IRA provides CMS
with significant new authorities intended to curb drug costs and to encourage market competition. For the first time, CMS will be able
to directly negotiate prescription drug prices and to cap out-of-pocket costs. Each year, CMS will select and negotiate a preset number
of high-spend drugs and biologics that are covered under Medicare Part B and Part D that do not have generic or biosimilar competition.
On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations. These price negotiations
will begin in 2023, although the Medicare drug price negotiation program is currently subject to legal challenges. The IRA also provides
a new "inflation rebate" covering Medicare patients that took effect in 2023 and is intended to counter certain price increases
in prescriptions drugs. The inflation rebate provision will require drug manufacturers to pay a rebate to the federal government if the
price for a drug or biologic under Medicare Part B and Part D increases faster than the rate of inflation. To support biosimilar competition,
beginning in October 2022, qualifying biosimilars may receive a Medicare Part B payment increase for a period of five years. Separately,
if a biologic drug for which no biosimilar exists delays a biosimilar's market entry beyond two years, CMS will be authorized to
subject the biologics manufacturer to price negotiations intended to ensure fair competition. Notwithstanding these provisions, the IRA's
impact on commercialization and competition remains largely uncertain.
73
Healthcare
Reform
The
United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system.
There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving
quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been
significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement
of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental
control of drug pricing.
The
ACA, which was enacted in March 2010, substantially changed the way healthcare is financed by both governmental and private insurers
in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import
to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs,
a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled,
infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies' share of sales to federal health
care programs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect
there will be additional challenges and amendments to the ACA in the future. For example, the IRA, among other things, extends enhanced
subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the
"donut hole" under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket
cost and creating a new manufacturer discount program.
Other
legislative changes have been proposed and adopted since the ACA was enacted, including automatic aggregate reductions of Medicare payments
to providers of on average 2% per fiscal year as part of the federal budget sequestration under the Budget Control Act of 2011. These
reductions went into effect in April 2013 and, due to subsequent legislative amendments, will remain in effect until 2032 unless additional
action is taken by Congress.
In
addition, the Bipartisan Budget Act of 2018, among other things, amended the Medicare Act (as amended by the ACA) to increase the point-of-sale
discounts that manufacturers must agree to offer under the Medicare Part D coverage discount program from 50% to 70% off negotiated prices
of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer's outpatient
drugs being covered under Medicare Part D.
Moreover,
there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products,
which has resulted in several Congressional inquiries and proposed and enacted federal and state measures designed to, among other things,
reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between pricing and manufacturer
patient programs, and reform government program reimbursement methodologies for drug products. For example, in May 2019, CMS adopted
a final rule allowing Medicare Advantage Plans the option to use step therapy for Part B drugs, permitting Medicare Part D plans to apply
certain utilization controls to new starts of five of the six protected class drugs, and requiring the Explanation of Benefits for Part
D beneficiaries to disclose drug price increases and lower cost therapeutic alternatives, which went into effect on January 1, 2021.
In response to the Biden administration's October 2022 executive order, on February 14, 2023, HHS released a report outlining three
new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility,
and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further,
on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in
rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft
Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product
as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised,
it is uncertain if that will continue under the new framework.
Notwithstanding
the IRA, continued legislative and enforcement interest exists in the United States with respect to specialty drug pricing practices.
Specifically, we expect regulators to continue pushing for transparency to drug pricing, reducing the cost of prescription drugs under
Medicare, reviewing the relationship between pricing and manufacturer patient programs, and reforming government program reimbursement
methodologies for drugs.
74
Other
Government Regulation Outside of the United States
In
addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other
things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage,
record keeping, distribution, reporting, export and import, advertising, marketing and other promotional practices involving biological
products as well as authorization, approval as well as post-approval monitoring and reporting of our products. Because biologically sourced
raw materials are subject to unique contamination risks, their use may be restricted in some countries.
Whether
or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries
prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United
States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement
of human clinical trials.
The
requirements and process governing the conduct of clinical trials, including requirements to conduct additional clinical trials, product
licensing, safety reporting, post-authorization requirements, marketing and promotion, interactions with healthcare professionals, pricing
and reimbursement may vary widely from country to country. No action can be taken to market any product in a country until an appropriate
approval application has been approved by the regulatory authorities in that country. The current approval process varies from country
to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price
of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved
by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially
unfeasible in such countries.
Regulation
in the European Union
European
Data Laws
The
collection and use of personal health data and other personal data in the EU is governed by the provisions of the European General Data
Protection Regulation (EU) 2016/679 ("GDPR"), which came into force in May 2018, and related data protection laws in individual
EU Member States. The GDPR imposes a number of strict obligations and restrictions on the ability to process, including collecting, analyzing
and transferring, personal data of individuals, in particular with respect to health data from clinical trials and adverse event reporting.
The GDPR includes requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal
data relates), the information provided to the individuals prior to processing their personal data, the notification obligations to the
national data protection authorities, and the security and confidentiality of the personal data. EU Member States may also impose additional
requirements in relation to health, genetic and biometric data through their national legislation.
In
addition, the GDPR imposes specific restrictions on the transfer of personal data to countries outside of the European Economic Area
("EEA") that are not considered by the European Commission ("EC") to provide an adequate level of data protection.
Appropriate safeguards are required to enable such transfers. Among the appropriate safeguards that can be used, the data exporter may
use the standard contractual clauses ("SCCs"). With regard to the transfer of data from the EEA to the United States, on
July 10, 2023, the EC adopted its adequacy decision for the EU-US Data Privacy Framework. On the basis of the new adequacy decision,
personal data can flow from the EEA to U.S. companies participating in the framework.
Failure
to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant
monetary fines for noncompliance of up to €20 million or 4% of the annual global revenues of the noncompliant company, whichever
is greater, other administrative penalties and a number of criminal offenses (punishable by uncapped fines) for organizations and, in
certain cases, their directors and officers, as well as civil liability claims from individuals whose personal data was processed. Data
protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data
protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing
personal data in the EU. Guidance developed at both the EU level and at the national level in individual EU Member States concerning
implementation and compliance practices are often updated or otherwise revised.
75
Furthermore,
there is a growing trend towards the required public disclosure of clinical trial data in the EU, which adds to the complexity of obligations
relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trials
Regulation No. 536/2014 ("CTR"), European Medical Agency ("EMA") disclosure initiatives and voluntary commitments
by industry. Failure to comply with these obligations could lead to government enforcement actions and significant penalties against
us, harm to our reputation, and adversely impact our business and operating results. The uncertainty regarding the interplay between
different regulatory frameworks, such as the CTR and the GDPR, further adds to the complexity that we face with regard to data protection
regulation.
With
regard to the transfer of personal data from the EEA to the UK, personal data may now freely flow from the EEA to the UK since the UK
is deemed to have an adequate data protection level.
However,
the adequacy decisions include a 'sunset clause' which entails that the decisions will automatically expire four years after
their entry into force. Additionally, following the UK's withdrawal from the EU and the EEA, companies also have to comply with
the UK's data protection laws (including the UK GDPR (as defined in section 3(10) (as supplemented by section 205(4)) of the Data
Protection Act 2018 (the "DPA 2018")), the DPA 2018, and related data protection laws in the UK). Separate from the fines
that can be imposed by the GDPR, the UK regime has the ability to fine up to the greater of £17.5 million or 4% of global turnover.
Following
the UK's withdrawal from the EU and the EEA, companies are subject to specific transfer rules under the UK regime; personal data
may flow freely from the UK to the EEA, since the EEA is deemed to have an adequate data protection level for purposes of the UK regime.
These UK international transfer rules broadly mirror the GDPR rules. On February 2, 2022, the UK Secretary of State laid before the UK
Parliament the international data transfer agreement ("IDTA") and the international data transfer addendum to the EC's
standard contractual clauses for international data transfers (Addendum) and a document setting out transitional provisions. The IDTA
and Addendum came into force on March 21, 2022 and replaced the old SCCs for the purposes of the UK regime. However, the transitional
provisions, adopted with the IDTA and the Addendum, provide that contracts concluded on or before September 21, 2022 on the basis of
any old SCCs continue to provide appropriate safeguards for the purpose of the UK regime until March 21, 2024, provided that the processing
operations that are the subject matter of the contract remain unchanged and reliance on those clauses ensures that the transfer of personal
data is subject to appropriate safeguards.
With
regard to the transfer of personal data from the UK to the United States, the UK government has adopted an adequacy decision for the
United States, the UK-US Data Bridge, which came into force on October 12, 2023. The UK-US Data Bridge recognizes the United States as
offering an adequate level of data protection where the transfer is to a U.S. company participating in the EU-US Data Privacy Framework
and the UK Extension.
Drug and
Biologic Development Process
Regardless
of where they are conducted, all clinical trials included in applications for marketing authorization ("MA") for human medicines
in the EU/EEA must have been carried out in accordance with EU regulations. This means that clinical trials conducted in the EU/EEA have
to comply with EU clinical trial legislation but also that clinical trials conducted outside the EU/EEA have to comply with ethical principles
equivalent to those set out in the EEA, including adhering to international good clinical practice and the Declaration of Helsinki. The
conduct of clinical trials in the EU is governed by the CTR, which entered into force on January 31, 2022. The CTR replaced the Clinical
Trials Directive 2001/20/EC, ("Clinical Trials Directive") and introduced a complete overhaul of the existing regulation
of clinical trials for medicinal products in the EU.
Under
the former regime, which will expire after a transition period of three years as outlined below in more detail, before a clinical trial
can be initiated it must be approved in each EU member state where there is a site at which the clinical trial is to be conducted. The
approval must be obtained from two separate entities: the National Competent Authority ("NCA") and one or more Ethics Committees.
NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent
Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU member state before
the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications
must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious
adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees
of the EU member state where they occur.
76
A
more unified procedure will apply under the new CTR. A sponsor will be able to submit a single application for approval of a clinical
trial through a centralized EU clinical trials portal (the "CTIS"). One national regulatory authority (the reporting EU member
state proposed by the applicant) will take the lead in validating and evaluating the application and consult and coordinate with the
other concerned EU Member States. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal.
If an approval is issued, the sponsor may start the clinical trial in all concerned EU Member States. However, a concerned EU member
state may in limited circumstances declare an "opt-out" from an approval and prevent the clinical trial from being conducted
in such member state. The CTR also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency
requirements such as mandatory submission of a summary of the clinical trial results to the EU Database. The CTR foresees a three-year
transition period. EU Member States will work in CTIS immediately after the system has gone live. Since January 31, 2023, submission
of initial clinical trial applications via CTIS is mandatory, and by January 31, 2025, all ongoing trials approved under the former Clinical
Trials Directive will need to comply with the CTR and have to be transitioned to CTIS. On July 19, 2023, the EC published guidance concerning
the steps to be taken in this transition. This guidance provides, among other things, that (i) documentation which was previously assessed
will not be reassessed, (ii) templates that were developed and endorsed by the EU Clinical Trials Expert Group to provide compliance
with the CTR do not need to be updated and (iii) there is no need to retrospectively create a site suitability form, which are only necessary
for new trial sites.
Under
both the former regime and the new CTR, national laws, regulations, and the applicable GCP and GLP standards must also be respected during
the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human
Use guidelines on Good Clinical Practice and the ethical principles that have their origin in the Declaration of Helsinki.
During
the development of a medicinal product, the EMA and national regulators within the EU provide the opportunity for dialogue and guidance
on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee
for Medicinal Products for Human Use ("CHMP") on the recommendation of the Scientific Advice Working Party. A fee is incurred
with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically
provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and
clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future Marketing
Authorization Application ("MAA") of the product concerned.
Drug Marketing
Authorization
In
the EEA, after completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining
a MA. To obtain a MA of a drug under European Union regulatory systems, an applicant can submit an MAA through, amongst others, a centralized
or decentralized procedure.
To
be used or sold in the UK, a drug must have an effective MA obtained by a centralized application through EMA or a national application.
National applications are governed by the Human Medicines Regulations (SI 2012/1916). Applications are made electronically through the
Medicines and Healthcare products Regulatory Agency ("MHRA") Submissions Portal. The process from application to authorizations
generally takes up to 210 days, excluding time taken to provide any additional information or data required by the MHRA.
On
August 30, 2023, the MHRA published detailed guidance on its recently announced new International Reliance Procedure ("IRP")
for MAAs. The IRP applies since January 1, 2024 and replaces existing EU reliance procedures to apply for authorizations from seven international
regulators (e.g. Health Canada, Swiss Medic, FDA, EMA, among others). The IRP allows medicinal products approved in other jurisdictions
that meet certain criteria to undergo a fast-tracked MHRA review to obtain and/or update a MA in the UK or Great Britain.
Applicants
can submit initial MAAs to the IRP but the procedure can also be used throughout the lifecycle of a product for post-authorization procedures
including line extensions, variations and renewals.
Centralized
Authorization Procedure
The
centralized procedure provides for the grant of a single MA that is issued by the EC following the scientific assessment of the application
by the EMA that is valid for all EU Member States as well as in the three additional member states of the EEA. The centralized procedure
is compulsory for certain types of medicinal products, including for medicines developed by means of certain biotechnological processes,
products designated as orphan medicinal products, advanced therapy medicinal products ("ATMP") and medicinal products with
a new active substance indicated for the treatment of certain diseases (AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune
and viral diseases). For medicinal products containing a new active substance not yet authorized in the EEA before May 20, 2004 and indicated
for the treatment of other diseases, medicinal products that constitute significant therapeutic, scientific or technical innovations
or for which the grant of a MA through the centralized procedure would be in the interest of public health at EU level, an applicant
may voluntarily submit an application for a MA through the centralized procedure.
77
Under
the centralized procedure, the CHMP established at the EMA, is responsible for conducting the initial assessment of a drug. The CHMP
is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions
to an existing MA. Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMA's CHMP is, in principle,
210 days from receipt of a valid MAA. However, this timeline excludes clock stops, when additional written or oral information is to
be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more, unless
the application is eligible for an accelerated assessment. Accelerated evaluation might be granted by the CHMP in exceptional cases,
when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation.
Upon request, the CHMP can reduce the time frame to 150 days if the applicant provides sufficient justification for an accelerated assessment.
The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements.
This opinion is then transmitted to the EC, which has the ultimate authority for granting MA within 67 days after receipt of the CHMP
opinion.
Decentralized
Authorization Procedure
Medicines
that fall outside the mandatory scope of the centralized procedure have three routes to authorization: (i) they can be authorized under
the centralized procedure if they concern a significant therapeutic, scientific or technical innovation, or if their authorization would
be in the interest of public health; (ii) they can be authorized under a decentralized procedure where an applicant applies for simultaneous
authorization in more than one EU member state; or (iii) they can be authorized in an EU member state in accordance with that state's
national procedures and then be authorized in other EU countries by a procedure whereby the countries concerned agree to recognize the
validity of the original, national MA (mutual recognition procedure).
The
decentralized procedure permits companies to file identical MA applications for a medicinal product to the competent authorities in various
EU Member States simultaneously if such medicinal product has not received marketing approval in any EU Member State before. This procedure
is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The competent authority
of a single EU Member State, the reference member state, is appointed to review the application and provide an assessment report. The
competent authorities of the other EU Member States, the concerned member states, are subsequently required to grant a MA for their territories
on the basis of this assessment. The only exception to this is where the competent authority of an EU Member State considers that there
are concerns of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually
be referred to the EC, whose decision is binding for all EU Member States.
Risk Management
Plan
All
new MAAs must include a Risk Management Plan ("RMP") describing the risk management system that the company will put in place
and documenting measures to prevent or minimize the risks associated with the product. RMPs are continually modified and updated throughout
the lifetime of the medicine as new information becomes available. An updated RMP must be submitted: (i) at the request of EMA or a national
competent authority, or (ii) whenever the risk-management system is modified, especially as the result of new information being received
that may lead to a significant change to the benefit-risk profile or as a result of an important pharmacovigilance or risk-minimization
milestone being reached. The regulatory authorities may also impose specific obligations as a condition of the MA. Since October 20,
2023, all RMPs for centrally authorized products are published by the EMA, subject only to limited redactions.
MA Validity
Period
MAs
have an initial duration of five years. After these five years, the authorization may subsequently be renewed on the basis of a reevaluation
of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority
decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five-year renewal. Applications for
renewal must be made to the EMA at least nine months before the five-year period expires.
78
Additionally,
the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw
materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing,
manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used.
Any
authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market
of the authorizing member state within three years after authorization ceases to be valid.
For
the UK, the period of three years during which the drug has not been marketed in Great Britain will be restarted from the date of conversion
to a Great Britain MA. Conversion refers to the procedure by which, as of January 1, 2021, MAs granted on the basis of a centralized
procedure in the EU are only valid in Northern Ireland but not in Great Britain, whereas, prior EU authorizations have all been automatically
converted into UK MAs effective in Great Britain only.
On
the other hand, for the EU, in the case the drug has been marketed in the UK, the placing on the UK market before the end of the period
starting when the UK left the EU on January 31, 2020 and ending on December 31, 2020 (the "Brexit Transition Period") will
be taken into account. If, after the end of the Brexit Transition Period, the drug is not placed on any other market of the remaining
EU Member States, the three-year period will start running from the last date the drug was placed on the UK market before the end of
the Brexit Transition Period.
Advanced
Therapy Medicinal Products
In
the EU, medicinal products, including ATMPs are subject to extensive pre- and post-market regulation by regulatory authorities at both
the EU and national levels. ATMPs comprise gene therapy products, somatic cell therapy products and tissue engineered products, which
are genes, cells or tissues that have undergone substantial manipulation and that are administered to human beings in order to cure,
diagnose or prevent diseases or regenerate, repair or replace a human tissue. Pursuant to the ATMP Regulation, the Committee on Advanced
Therapies ("CAT") is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CHMP and CAT are also responsible
for providing guidelines on ATMPs. These guidelines provide additional guidance on the factors that the EMA will consider in relation
to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs. Although
such guidelines are not legally binding, compliance with them is often necessary to gain and maintain approval for product candidates.
In
addition to the mandatory RMP, the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual
product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can
be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where
the product is used.
Exceptional
Circumstances/Conditional Approval
Similar
to accelerated approval regulations in the United States, conditional MAs can be granted in the EU in exceptional circumstances. A conditional
MA can be granted for medicinal products where, although comprehensive clinical data referring to the safety and efficacy of the medicinal
product have not been supplied, a number of criteria are fulfilled: (i) the benefit/risk balance of the product is positive, (ii) it
is likely that the applicant will be in a position to provide the comprehensive clinical data, (iii) unmet medical needs will be fulfilled
by the grant of the MA and (iv) the benefit to public health of the immediate availability on the market of the medicinal product concerned
outweighs the risk inherent in the fact that additional data are still required. A conditional MA must be renewed annually.
Data and
Market Exclusivity
As
in the United States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect
of postponing the entry into the marketplace of a competitor's generic, hybrid or biosimilar product (even if the pharmaceutical
product has already received a MA) and prohibiting another applicant from relying on the MA holder's pharmacological, toxicological
and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the
market. New Chemical Entities ("NCEs") approved in the EU qualify for eight years of data exclusivity and 10 years of marketing
exclusivity.
79
An
additional non-cumulative one-year period of marketing exclusivity is possible if during the data exclusivity period (the first eight
years of the 10-year marketing exclusivity period), the MA holder obtains an authorization for one or more new therapeutic indications
that are deemed to bring a significant clinical benefit compared to existing therapies.
The
data exclusivity period begins on the date of the product's first MA in the EU. After eight years, a generic product application
may be submitted and generic companies may rely on the MA holder's data. However, a generic product cannot launch until two years
later (or a total of 10 years after the first MA in the EU of the innovator product), or three years later (or a total of 11 years after
the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant clinical benefit within
the eight-year data exclusivity period. Additionally, another non-cumulative one-year period of data exclusivity can be added to the
eight years of data exclusivity where an application is made for a new indication for a well-established substance, provided that significant
pre-clinical or clinical studies were carried out in relation to the new indication.
Another
year of data exclusivity may be added to the eight years, where a change of classification of a pharmaceutical product has been authorized
on the basis of significant pre-trial tests or clinical trials (when examining an application by another applicant for or holder of MA
for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for
one year after the initial change was authorized).
Products
may not be granted data exclusivity since there is no guarantee that a product will be considered by the EU's regulatory authorities
to include an NCE. Even if a compound is considered to be an NCE and the MA applicant is able to gain the prescribed period of data exclusivity,
another company nevertheless could also market another version of the medicinal product if such company can complete a full MAA with
their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its product.
On
April 26, 2023, the EC submitted a proposal for the reform of the European pharmaceutical legislation. The current draft envisages e.g.,
a shortening of the periods of data exclusivity, however, there is currently neither a final version of this draft nor a date for its
entry into force.
Orphan
Designation and Exclusivity
The
criteria for designating an orphan medicinal product in the EU are similar in principle to those in the U.S. The EMA grants orphan drug
designation if the medicinal product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating
condition affecting no more than five in 10,000 persons in the EU (prevalence criterion). In addition, orphan drug designation can be
granted if, for economic reasons, the medicinal product would be unlikely to be developed without incentives and if there is no other
satisfactory method approved in the EU of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed
medicinal product is a significant benefit to patients affected by the condition. An application for orphan drug designation (which is
not a MA, as not all orphan-designated medicines reach the authorization application stage) must be submitted first before an application
for MA of the medicinal product is submitted. The applicant will receive a fee reduction for the MAA if the orphan drug designation has
been granted, but not if the designation is still pending at the time the MA is submitted, and sponsors must submit an annual report
to EMA summarizing the status of development of the medicine. Orphan drug designation does not convey any advantage in, or shorten the
duration of, the regulatory review and approval process. Designated orphan medicines are eligible for conditional MA.
The
EMA's Committee for Orphan Medicinal Products reassesses the orphan drug designation of a product in parallel with the review for
a MA; for a product to benefit from market exclusivity it must maintain its orphan drug designation at the time of MA review by the EMA
and approval by the EC. Additionally, any MA granted for an orphan medicinal product must only cover the therapeutic indication(s) that
are covered by the orphan drug designation. Upon the grant of a MA, orphan drug designation provides up to ten years of market exclusivity
in the orphan indication.
During
the 10-year period of market exclusivity, with a limited number of exceptions, the regulatory authorities of the EU Member States and
the EMA may not accept applications for MA, accept an application to extend an existing MA or grant a MA for other similar medicinal
products for the same therapeutic indication. A similar medicinal product is defined as a medicinal product containing a similar active
substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic
indication. An orphan medicinal product can also obtain an additional two years of market exclusivity for an orphan-designated condition
when the results of specific studies are reflected in the Summary of Product Characteristics ("SmPC") addressing the pediatric
population and completed in accordance with a fully compliant Pediatric Investigation Plan ("PIP"). No extension to any supplementary
protection certificate can be granted on the basis of pediatric studies for orphan indications.
80
The
10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer
meets the criteria for orphan designation, i.e. the condition prevalence or financial returns criteria under Article 3 of Regulation
(EC) No. 141/2000 on orphan medicinal products. When the period of orphan market exclusivity for an indication ends, the orphan drug
designation for that indication expires as well. Orphan exclusivity runs in parallel with normal rules on data exclusivity and market
protection. Additionally, a MA may be granted to a similar medicinal product (orphan or not) for the same or overlapping indication subject
to certain requirements.
In
the UK, following the post-Brexit transition period, a system for incentivizing the development of orphan medicines was introduced. Overall,
the requirements for orphan designation largely replicate the requirements in the EU and the benefit of market exclusivity has been retained.
Products with an orphan designation in the EU can be considered for an orphan MA in Great Britain, but a UK-wide orphan MA can only be
considered in the absence of an active EU orphan designation. The MHRA will review applications for orphan designation at the time of
a MA, and will offer incentives, such as market exclusivity and full or partial refunds for MA fees to encourage the development of medicines
in rare diseases.
Pediatric
Development
In
the EU, companies developing a new medicinal product are obligated to study their product in children and must therefore submit a PIP
together with a request for agreement to the EMA. The EMA issues a decision on the PIP based on an opinion of the EMA's Pediatric
Committee. Companies must conduct pediatric clinical trials in accordance with the PIP approved by the EMA, unless a deferral (e.g. until
enough information to demonstrate its effectiveness and safety in adults is available) or waiver (e.g. because the relevant disease or
condition occurs only in adults) has been granted by the EMA. The MAA for the medicinal product must include the results of all pediatric
clinical trials performed and details of all information collected in compliance with the approved PIP, unless a waiver or a deferral
has been granted, in which case the pediatric clinical trials may be completed at a later date. Medicinal products that are granted an
MA on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six-month extension
of the protection under a supplementary protection certificate (if any is in effect at the time of approval), or, in the case of orphan
medicinal products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and
is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required
when a MA holder wants to add a new indication, medicinal form or route of administration for a medicine that is already authorized and
covered by intellectual property rights.
In
the UK, the MHRA has published guidance on the procedures for UK PIPs which, where possible, mirror the submission format and requirements
of the EU system. EU PIPs remain applicable for Northern Ireland and EU PIPs agreed by the EMA prior to January 1, 2021 have been adopted
as UK PIPs.
PRIME
Designation
In
March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few
or no therapies currently exist. The Priority Medicines ("PRIME") scheme is intended to encourage drug development in areas
of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized
procedure. Products from small-and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies
on the basis of compelling non-clinical data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of
product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent
discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier
has been submitted. Importantly, once a candidate medicine has been selected for the PRIME scheme, a dedicated contact point and rapporteur
from the CHMP or CAT are appointed facilitating increased understanding of the product at EMA's Committee level. A kick-off meeting
with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts to provide guidance on the
overall development plan and regulatory strategy. PRIME eligibility does not change the standards for product approval, and there is
no assurance that any such designation or eligibility will result in expedited review or approval.
Post-Approval
Regulation
Similar
to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the
EMA, the EC and/or the competent regulatory authorities of the EU Member States. This oversight applies both before and after grant of
manufacturing licenses and MAs. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations,
pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting
of medicinal products.
Failure
by us or by any of our third-party partners, including suppliers, manufacturers and distributors to comply with EU laws and the related
national laws of individual EU Member States governing the conduct of clinical trials, manufacturing approval, MA of medicinal products
and marketing of such products, both before and after grant of MA, statutory health insurance, bribery and anti-corruption or other applicable
regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to
authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or
variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions,
injunctions, suspension of licenses, fines and criminal penalties.
81
The
holder of MA for a medicinal product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines,
which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products.
These
pharmacovigilance rules can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks
and benefits of marketed medicinal products and to engage in ongoing assessments of those risks and benefits, including the possible
requirement to conduct additional clinical studies or post-authorization safety studies to obtain further information on a medicine's
safety, or to measure the effectiveness of risk-management measures, which may be time consuming and expensive and could impact our profitability.
MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who
is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission
of Periodic Safety Update Reports ("PSURs") in relation to medicinal products for which they hold MAs. The EMA reviews PSURs
for medicinal products authorized through the centralized procedure. If the EMA has concerns that the risk benefit profile of a product
has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The agency can advise
that the MA holder be obliged to conduct post-authorization Phase 4 safety studies. If the EC agrees with the opinion, it can adopt a
decision varying the existing MA. Failure by the MA holder to fulfill the obligations for which the EC's decision provides can
undermine the ongoing validity of the MA.
More
generally, non-compliance with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the MA for the product
or imposition of financial penalties or other enforcement measures.
The
manufacturing process for pharmaceutical products in the EU is highly regulated and regulators may shut down manufacturing facilities
that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization
holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC,
Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice ("GMP").
These requirements include compliance with EU GMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients,
including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical
ingredients into the EU. Similarly, the distribution of pharmaceutical products into and within the EU is subject to compliance with
the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted
by the competent authorities of the EU Member States. The manufacturer or importer must have a qualified person who is responsible for
certifying that each batch of product has been manufactured in accordance with GMP, before releasing the product for commercial distribution
in the EU or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for
compliance with GMP.
Sales
and Marketing Regulations
The
advertising and promotion of our products is also subject to EU laws concerning promotion of medicinal products, interactions with physicians,
misleading and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU Member
States may apply to the advertising and promotion of medicinal products and may differ from one country to another. These laws require
that promotional materials and advertising in relation to medicinal products comply with the product's SmPC as approved by the
competent regulatory authorities. The SmPC is the document that provides information to physicians concerning the safe and effective
use of the medicinal product. It forms an intrinsic and integral part of the MA granted for the medicinal product. Promotion of a medicinal
product that does not comply with the SmPC is considered to constitute off-label promotion. All advertising and promotional activities
for the product must be consistent with the approved SmPC and therefore all off-label promotion is prohibited. Direct-to-consumer advertising
of prescription-only medicines is also prohibited in the EU. Violations of the rules governing the promotion of medicinal products in
the EU could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising
and promotion of our products to the general public and may also impose limitations on its promotional activities with healthcare professionals.
EU
regulation with regards to dispensing, sale and purchase of medicines has generally been preserved in the UK following Brexit, through
the Human Medicines Regulations 2012. However, organizations wishing to sell medicines online need to register with the MHRA. Following
Brexit, the requirements to display the common logo no longer apply to UK-based online sellers, except for those established in Northern
Ireland.
Anti-Corruption
Legislation
In
the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation
codes of conduct and physicians' codes of professional conduct both at EU level and in the individual EU Member States. The provision
of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order
or use of medicinal products is prohibited in the EU. The provision of benefits or advantages to physicians is also governed by the national
anti-bribery laws of the EU Member States. Violation of these laws could result in substantial fines and imprisonment.
82
Payments
made to physicians in certain EU Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the
subject of prior notification and approval by the physician's employer, his/her regulatory professional organization, and/or the
competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional
codes of conduct, applicable in the individual EU Member States. Failure to comply with these requirements could result in reputational
risk, public reprimands, administrative penalties, fines or imprisonment.
In
the UK, the pharmaceutical sector is recognized as being particularly vulnerable to corrupt practices, some of which fall within the
scope of the Bribery Act 2010. Due to the Bribery Act 2010's far-reaching territorial application, the potential penalized act
does not have to occur in the UK to become within its scope. If the act or omission does not take place in the UK, but the person's
act or omission would constitute an offense if carried out there and the person has a close connection with the UK, an offense will still
have been committed.
The
Bribery Act 2010 is comprised of four offenses that cover (i) individuals, companies and partnerships that give, promise or offer bribes,
(ii) individuals, companies and partnerships that request, agree to receive or accept bribes, (iii) individuals, companies and partnerships
that bribe foreign public officials, and (iv) companies and partnerships that fail to prevent persons acting on their behalf from paying
bribes. The penalties imposed under the Bribery Act 2010 depend on the offence committed, harm and culpability and penalties range from
unlimited fines to imprisonment for a maximum term of ten years and in some cases both.
Regulations
in the UK and Other Markets
The
UK formally left the EU on January 31, 2020 and EU laws now only apply to the UK in respect of Northern Ireland as laid out in the Protocol
on Ireland and Northern Ireland and as amended by the Windsor Framework sets out a long-term set of arrangements for the supply of medicines
into Northern Ireland. The EU and the UK agreed on a trade and cooperation agreement ("TCA"), which includes provisions affecting
the life sciences sector (including on customs and tariffs). There are some specific provisions concerning pharmaceuticals, including
the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP issued documents. The TCA does
not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards.
The
UK government has adopted the Medicines and Medical Devices Act 2021 (the "MMDA") to enable the UK's regulatory frameworks
to be updated following the UK's departure from the EU. The MMDA introduces regulation-making, delegated powers covering the fields
of human medicines, clinical trials of human medicines, veterinary medicines and medical devices. The MHRA has since been consulting
on future regulations for medicines and medical devices in the UK.
For
other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct
of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials
must be conducted in accordance with GCPs and the applicable regulatory requirements and the ethical principles that have their origin
in the Declaration of Helsinki.
If
we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical
trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.
Employees
and Human Capital Resources
As
of November 13, 2024, we had 27 full-time employees. We also engage temporary employees and consultants to augment our existing workforce.
None of our employees are represented by a labor union or covered under a collective bargaining agreement. We consider our relationship
with our employees to be good.
We
recognize that attracting, motivating, and retaining talent at all levels is vital to continuing our success. We invest in our employees
through high-quality benefits, professional development opportunities, and various health and wellness initiatives and offer competitive
compensation packages (base salary and incentive plans), ensuring fairness in internal compensation practices. The principal purposes
of our incentive plans (bonus and equity) are to align with the long-term interests of our stakeholders and stockholders.
Properties
and Facilities
We
maintain a corporate office at 855 Oak Grove Ave., Suite 100, Menlo Park, California. The lease for this office commenced on June 15,
2024 with an initial term of 39.5 months.
Legal
Proceedings
From
time to time, we may become involved in legal proceedings. We are not currently a party to or aware of any proceedings that we believe
will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.
Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources
and other factors.
83
MANAGEMENT
Executive
Officers and Directors
The
following table and discussion sets forth the names, ages as of November 13, 2024, positions and biographical and other information of
the individuals who currently serve as directors and executive officers of the Company.
Name
Age
Position
Executive
    Officers:
Lawrence
    Klein
42
President,
    Chief Executive Officer and Director
Arjun
    Agarwal
48
Senior
    Vice President, Finance and Treasurer
Joana
    Goncalves
51
Chief
    Medical Officer
Paul
    Quinlan
61
General
    Counsel and Corporate Secretary
Non-Employee
    Directors:
Samarth
    Kulkarni
(2)(3)
46
Chair
    and Director
Kristine
    Ball
(1)(3)
52
Director
Carl
    Dambkowski
(1)
40
Director
Peter
    Harwin
(2)(3)
38
Director
Cameron
    Turtle
(1)(2)
34
Director
(1)
Member
                                            of the Audit Committee.
(2)
Member
                                            of the Compensation Committee.
(3)
Member
                                            of the Nominating and Governance Committee (the "Governance Committee").
Each
executive officer serves at the discretion of the of the Board and holds office until their successor is duly appointed and qualified
or until their earlier resignation or removal.
Executive
Officers
Lawrence
Klein, Ph.D.
Dr. Klein has served as Chief Executive Officer and as a member of the board of directors of the Company since
the Closing and of Pre-Merger Oruka from February 2024 through the Closing. Prior to joining Pre-Merger Oruka, Dr. Klein was a Partner
at Versant Venture Management, LLC, a healthcare and biotechnology venture capital firm, from January 2023 to February 2024,
where he invested in and helped to grow early-stage biotechnology companies. Prior to Versant, Dr. Klein served in various
positions at CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, including Chief Operating Officer from January 2020
to October 2022, Chief Business Officer from January 2019 to January 2020, Senior Vice President, Business Development
and Strategy from November 2017 to December 2018 and as Vice President, Strategy from February 2016 to November 2017,
where he helped to initiate and execute on several transformative partnerships, establish the strategic direction of the company, oversee
important pipeline programs and led several functions, including program and portfolio management. Before joining CRISPR, Dr. Klein
was an Associate Partner at McKinsey & Company, a global management consulting firm, from October 2014 to February 2016.
Dr. Klein served as a member of the board of directors of Dyne Therapeutics, Inc. (Nasdaq: DYN) from September 2019 to May 2023
and of Jasper Therapeutics, Inc. (Nasdaq: JSPR) from September 2021 to June 2023. Dr. Klein received his B.S. in biochemistry
and physics from the University of Wisconsin-Madison and his Ph.D. in biophysics from Stanford University.
We
believe Dr. Klein is qualified to serve as a member of the Board because of his business development, operational and senior management
experience in the biotechnology industry and his academic expertise and accomplishments.
Arjun
Agarwal.
Mr. Agarwal has served as the Senior Vice President of Finance of the Company since the Closing and of Pre-Merger
Oruka from March 2024 through the Closing, where he is responsible for overseeing the company's finance and accounting functions.
Prior to joining Pre-Merger Oruka, Mr. Agarwal served as VP of Finance at Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology
company, from June 2021 to March 2024, including through multiple financings and the company's successful transition
to become a publicly traded entity. Before joining Jasper, Mr. Agarwal served as Vice President, Corporate Controller at Protagonist
Therapeutics, Inc. (Nasdaq: PTGX), a biotechnology company, from August 2019 to June 2021, where he was responsible for overseeing
the company's finance and accounting functions. Prior to joining Protagonist, Mr. Agarwal served in various roles of increasing
responsibility at McKesson Corporation (NYSE: MCK), an international healthcare services company, from 2009 to 2019. Prior
to McKesson, Mr. Agarwal worked at PricewaterhouseCoopers LLP, where he managed a portfolio of audit clients. He is a graduate of
Sydenham College of Commerce and Economics at Mumbai University, India. He is a Certified Public Accountant (CPA) and a Chartered Accountant
accredited by the Institute of Chartered Accountants of India.
84
Joana
Goncalves, MBChB.
Dr. Goncalves has served as the Chief Medical Officer of the Company since the Closing and of Pre-Merger
Oruka from April 2024 through the Closing. Prior to joining Pre-Merger Oruka, Dr. Goncalves served as Chief Medical Officer
of Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company, from October 2018 to April 2024, where she was responsible
for representing Cara Therapeutics in interactions with regulatory agencies, the investor and scientific communities and the board of
directors, building multifunctional terms and developing the clinical development strategy in dermatological conditions. Prior to Cara,
Dr. Goncalves held various positions at Celgene Corporation, a pharmaceutical company, which was later acquired by Bristol-Myers Squibb
Company, from April 2014 to October 2018, where she most recently served as Vice President, Medical Affairs for Dermatology
and Neurology and was instrumental in planning and executing medical support activities for a number of programs, including OTEZLA®
for psoriasis. Prior to Celgene, Dr. Goncalves served as Vice President, Medical Strategy and Scientific Affairs at LEO Pharma Inc.,
the U.S. subsidiary of LEO Pharma A/S, a global healthcare company specializing in dermatology and critical care, from February 2012
to April 2014. She began her pharmaceutical career at Novartis Pharmaceuticals, working on a range of products across various therapeutic
areas from 2001 to 2012. Dr. Goncalves received her MBChB from the University of Cape Town, South Africa.
Paul
Quinlan.
Mr. Quinlan has served as General Counsel and Corporate Secretary of the Company since the Closing and of Pre-Merger
Oruka since April 2024 through the Closing. Prior to joining Pre-Merger Oruka, Mr. Quinlan served as General Counsel, Chief
Compliance Officer and Corporate Secretary of CymaBay Therapeutics, Inc., a biopharmaceutical company, from October 2020 to March 2024,
where he was responsible for the general supervision of the company's legal affairs. From December 2017 to February 2020,
he served as General Counsel and Corporate Secretary of CymaBay, where he was responsible for the general supervision of the company's
legal affairs. Prior to CymaBay, Mr. Quinlan served as General Counsel and Secretary, from 2010 to January 2018, and Chief
Legal Officer from 2016 to January 2018, of TerraVia Holdings, Inc., a biotechnology company, where he was responsible for the general
supervision of the company's legal affairs. Prior to joining TerraVia, Mr. Quinlan served as General Counsel of Metabolex,
Inc., a biopharmaceutical company, from 2005 to 2010. Prior to joining Metabolex, Mr. Quinlan held various positions at Maxygen,
Inc., a biopharmaceutical company, from 2000 to 2005. Prior to Maxygen, Mr. Quinlan practiced law at Cooley LLP and Cravath, Swaine, &
Moore LLP. Mr. Quinlan received a law degree from Columbia Law School and an M.Sc. in Medical Biophysics from the University
of Toronto.
Non-Employee
Directors
Kristine
Ball.
Ms. Ball has served as a member of the board of directors of the Company since the Closing and of Pre-Merger Oruka since
May 2024 through the Closing. Ms. Ball has served as President and Chief Executive Officer of Antiva Biosciences, Inc., a private
biopharmaceutical company, since April 2023. Prior to Antiva, Ms. Ball served as Chief Executive Officer of Soteria Biotherapeutics,
Inc., a private biotechnology company, from September 2020 to August 2022. Prior to joining Soteria, Ms. Ball served as Senior
Vice President, Corporate Strategy and Chief Financial Officer of Menlo Therapeutics, Inc., a Nasdaq-listed biopharmaceutical company,
which later became VYNE Therapeutics Inc. (Nasdaq: VYNE), from September 2017 to March 2020, where she was responsible for
leading all non-R&D functions, including strategic planning, corporate development, commercial, human resources, legal, finance and
information technology. Prior to joining Menlo, Ms. Ball served as Chief Financial Officer and Senior Vice President of Relypsa, Inc.,
a Nasdaq-listed pharmaceutical company, which was later acquired by Galenica Group, from November 2012 to October 2016.
Prior to Relypsa, Ms. Ball held various other finance roles in the life sciences industry, including Senior Vice President of Finance &
Administration and Chief Financial Officer of KAI Pharmaceuticals, Inc., a biopharmaceutical company, and Vice President of Finance at
Exelixis, Inc. (Nasdaq: EXEL), a biotechnology company. Prior to that, Ms. Ball served as a senior manager in life sciences audit practice
of Ernst & Young LLP. Ms. Ball has previously served on the boards of directors of Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical
company, from 2020 to 2024, Soteria from 2020 to 2022 and Forty Seven, Inc., a Nasdaq-listed biotechnology company, which was later
acquired by Gilead Sciences, Inc., from 2018 to 2020. Ms. Ball received a B.S. from Babson College.
We
believe Ms. Ball is qualified to serve as a member of the Board because of her experience as an executive officer and director of life
sciences companies and her background in finance, corporate development and strategic planning.
85
Carl
Dambkowski, M.D.
Dr. Dambkowski has served as a member of the board of directors of the Company since the Closing and of
Pre-Merger Oruka from February 2024 through the Closing. Dr. Dambkowski has served as the Chief Medical Officer of Apogee Therapeutics,
Inc. (Nasdaq: APGE), a biotechnology company, since September 2022. Prior to joining Apogee, Dr. Dambkowski served as a strategic
and clinical leader for a variety of companies, including as Chief Medical Officer of QED Therapeutics, Inc., a private biotechnology
company, from July 2021 to September 2022; Chief Strategy Officer and EVP of Operations of Origin Biosciences, Inc., a private
bioecology company, from March 2018 to June 2021; and Chief Medical Officer of Navire Pharma, Inc., a private biotechnology
company, from January 2020 to September 2022, where he served as the clinical lead starting prior to IND for BBP-398 through
the out licensing of the compound to Bristol-Myers Squibb based on initial clinical data and for low-dose infigratinib in achondroplasia
through initial proof-of-concept data. He was part of the core team that brought TRUSELTIQ
®
(infigratinib) and
NULIBRY
®
(fosdenopterin) through regulatory review and FDA approval at QED Therapeutics and Origin Biosciences, respectively.
From July 2016 to March 2018, Dr. Dambkowski was an associate at McKinsey & Company, a global management consulting
firm, where he advised biotech and pharmaceutical companies across the world on a range of research and development activities. Dr. Dambkowski
co-founded Novonate, Inc., a private medical device company focused on building life-saving devices for neonates, in January 2015.
Dr. Dambkowski has coauthored numerous peer-reviewed publications and scientific abstracts and is a named inventor on multiple
published and granted patents. Dr. Dambkowski was trained as a physician at Stanford University, where he also received his M.D.
with a concentration in bioengineering. He also received a B.A. (with honors) from Stanford University and an M.A. from Columbia University.
We
believe Dr. Dambkowski is qualified to serve as a member of the Board because of his significant experience and innovations in the biotechnology
industry and his academic expertise and accomplishments.
Peter
Harwin.
Mr. Harwin has served as a member of the board of directors of the Company since the Closing and of Pre-Merger Oruka
from February 2024 through the Closing. Mr. Harwin is a Managing Member at Fairmount Funds Management, a healthcare investment
firm he co-founded in April 2016. Prior to Fairmount Funds Management, Mr. Harwin was a member of the investment team
at Boxer Capital, LLC, an investment fund that was part of the Tavistock Group, based in San Diego. Mr. Harwin also serves as chairman
of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT) and is a member of the board of directors of Apogee Therapeutics,
Inc. (Nasdaq: APGE), Viridian Therapeutics, Inc. (Nasdaq: VRDN) and Spyre Therapeutics, Inc. (Nasdaq: SYRE). Mr. Harwin received
a B.B.A. from Emory University.
We
believe Mr. Harwin is qualified to serve as a member of the Board because his experience serving as a director of biotechnology companies
and as a manager of funds specializing in the area of life sciences.
Samarth
Kulkarni, Ph.D.
Dr. Kulkarni has served as a member of the board of directors of the Company since the Closing and of Pre-Merger
Oruka from February 2024 through the Closing. Dr. Kulkarni has served as the Chief Executive Officer of CRISPR Therapeutics
AG (Nasdaq: CRSP), a biopharmaceutical company, since December 2017, where he has also served as a member and chair of the board
of directors since June 2018 and September 2023, respectively. Previously, Dr. Kulkarni served as CRISPR's President
and Chief Business Officer from May 2017 to November 2017 and as Chief Business Officer from August 2015. Prior to joining
CRISPR, Dr. Kulkarni was at McKinsey & Company, a global management consulting firm, from 2006 to 2015, with various titles,
his most recent being Partner within the Pharmaceuticals and Biotechnology practice. Dr. Kulkarni has also served as a member of
the boards of directors of Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology company, since 2019, including as lead
independent director since September 2023, Repare Therapeutics Inc. (Nasdaq: RPTX), a precision oncology company, since November 2019
and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a biotechnology company, since February 2021. Dr. Kulkarni received a Ph.D.
in Bioengineering and Nanotechnology from the University of Washington and a B. Tech. from the Indian Institute of Technology. Dr. Kulkarni
has authored several publications in leading scientific and business journals.
We
believe that Dr. Kulkarni is qualified to serve as a member of the Board because of his experience as a consultant and an executive in
the biopharmaceutical industry and his academic expertise and accomplishments.
86
Cameron
Turtle, D.Phil.
Dr. Turtle has served as a member of the board of directors of the Company since the Closing and of Pre-Merger
Oruka from February 2024 through the Closing. Dr. Turtle has served as Chief Executive Officer and a member of the board of
directors of Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) (Nasdaq: SYRE), a biotechnology company, since November 2023
and, before that, as Chief Operating Officer from June 2023 to November 2023. Prior to joining Spyre, Dr. Turtle was an
advisor to Spyre Therapeutics, Inc., a private biotechnology company, from May 2023 to June 2023. Previously, he served as
Venture Partner at Foresite Labs, a life sciences investment firm, from July 2022 to May 2023; Chief Strategy Officer of BridgeBio
Pharma (Nasdaq: BBIO), a biotechnology company, from January 2021 to April 2022; and Chief Business Officer of Eidos Therapeutics
(Nasdaq: EIDX), a biopharmaceutical company, from November 2018 to January 2021, where he led business development, investor
relations, and multiple operational functions as the company advanced an investigational medicine for a form of heart failure. Prior
to joining BridgeBio and Eidos, he was a consultant at McKinsey & Company, a global management consulting firm, where he worked
with pharmaceutical and medical device companies on topics including M&A, growth strategy, clinical trial strategy, and sales force
optimization. Dr. Turtle received his B.S. with honors in Bioengineering from the University of Washington and his D.Phil. in Cardiovascular
Medicine from the University of Oxford, St. John's College. He is the recipient of several awards, including a Rhodes Scholarship,
Goldwater Scholarship, Forbes 30 Under 30, San Francisco Business Times 40 Under 40, and the Biocom Life Sciences Catalyst
Award.
We
believe Dr. Turtle is qualified to serve as a member of the Board because of his experience as a leader in building, financing, and shaping
biopharmaceutical organizations from preclinical development to late-stage clinical trials and commercialization.
Family
Relationships
There
are no family relationships among any of our directors or executive officers.
Board
Structure and Related Matters
Board
Structure
Our
business and affairs are managed under the direction of our Board. Our Board currently consists of six members. Each of our current directors
will continue to serve until the election and qualification of their successor, or their earlier death, resignation or removal.
The
authorized number of directors is determined from time to time solely by resolution of the Board. Our certificate of incorporation and
bylaws provide that our directors may be removed only for cause by the affirmative vote of at least 66 2/3% of the voting power of the
common stock outstanding and entitled to vote thereon. In addition, only our Board is authorized to fill vacancies and any additional
directorships resulting from an increase in the authorized number of directors.
Our
certificate of incorporation establishes a classified Board consisting of three classes of directors with staggered three-year terms.
Only one class of directors is elected at each annual meeting of our stockholders to succeed the directors of the same class whose terms
are then expiring, with the other classes continuing for the remainder of their respective three-year terms. The terms of the directors
will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the years
2025 for Class I directors, 2026 for Class II directors, and 2027 for Class III directors.
●
Our
                                            Class I directors are Dr. Dambkowski and Mr. Harwin.
●
Our
                                            Class II directors are Dr. Klein and Dr. Turtle.
●
Our
                                            Class III directors are Ms. Ball and Dr. Kulkarni.
87
Director
Independence
Our
Board has reviewed the independence of all directors in light of each director's (or any family member's, if applicable)
affiliations with the Company and members of management, as well as significant holdings of our securities and all other facts and circumstances
that the Board has deemed relevant in determining the independence of each director. The Board has determined that each of the directors
other than Lawrence Klein, our current President and Chief Executive Officer, including Kristine Ball, Carl Dambkowski, Peter Harwin,
Samarth Kulkarni and Cameron Turtle, qualify as "independent directors" as defined by the Nasdaq listing rules.
Nasdaq
listing rules have objective tests and a subjective test for determining who is an "independent director." The subjective
test states that an independent director must be a person who lacks a relationship that, in the opinion of the Board, would interfere
with the exercise of independent judgment in carrying out the responsibilities of a director. The Board has not established categorical
standards or guidelines to make these subjective determinations but considers all relevant facts and circumstances.
Board
Leadership Structure
Our
Board has designated Dr. Kulkarni to serve as Chair of the Board. Although our bylaws do not require that we separate the Chief Executive
Officer and Chair positions, our Board believes that having the positions be separate is the appropriate leadership structure for us
at this time, as it helps facilitate independent Board oversight of management and allows the Chief Executive Officer to focus on strategy
execution and managing the business while the Chair focuses on corporate governance and managing the Board.
Our
Board recognizes that, depending on future circumstances, other leadership models, such as combining the roles of Chief Executive Officer
and Chair, might be appropriate. Accordingly, our Board may periodically review its leadership structure. At any time when a non-independent
director is serving as Chair, the independent directors will designate a lead independent director to preside at all meetings of the
Board at which the Chair is not present, preside over executive sessions of the independent directors (which occur regularly throughout
each year), serve as a liaison between the Chair and independent directors, and perform such additional duties as our Board may otherwise
determine and delegate.
Role
of Our Board in Risk Oversight
We
face a number of risks, including those described under the section titled "Risk Factors". Our Board believes that risk management
is an important part of establishing, updating and executing on our business strategy. Our Board, both as a whole and at the committee
level, has oversight responsibility relating to risks that could affect the strategy, business objectives, compliance, operations and
the financial condition and performance of the Company. Our Board focuses its oversight on the most significant risks facing the Company
and on its processes to identify, prioritize, assess, manage and mitigate those risks. Our Board and its committees receive regular reports
from members of our senior management on material risks to the Company, including strategic, operational, financial, legal and regulatory
risks. While our Board has an oversight role, management is principally tasked with direct responsibility for managing and assessing
risks and the implementation of processes and controls to mitigate their effects on the Company. Our Board believes its administration
of its risk oversight function has not significantly impacted its selection of the current leadership structure.
Board
Committees
We
currently have an Audit Committee, a Compensation Committee, and a Governance Committee. We believe that the functioning and composition
of these committees complies with the requirements of Nasdaq listing rules and SEC rules and regulations. Each committee has the responsibilities
described below.
88
Audit
Committee
The
Audit Committee currently comprises Ms. Ball, Dr. Dambkowski, and Dr. Turtle, each of whom qualifies as an independent director for Audit
Committee purposes, as defined under the rules of the SEC and the applicable Nasdaq listing rules and has sufficient knowledge in financial
and auditing matters to serve the Audit Committee. Ms. Ball chairs the Audit Committee and is an "audit committee financial expert"
as defined in Item 407(d)(5)(ii) of Regulation S-K promulgated under the Securities Act.
The
primary responsibilities of the Audit Committee are to oversee our accounting and financial reporting processes, including the audits
of the financial statements, and the internal and external audit processes. The Audit Committee also oversees the system of internal
controls established by management and our compliance with legal and regulatory requirements. The Audit Committee is also responsible
for the review, consideration and approval or ratification of related party transactions. The Audit Committee further oversees the independent
auditors, including their independence and objectivity. The Audit Committee is empowered to retain outside legal counsel and other advisors
as it deems necessary or appropriate to assist it in fulfilling its responsibilities and to approve the fees and other retention terms
of the advisors.
Compensation
Committee
The
Compensation Committee currently comprises Mr. Harwin, Dr. Kulkarni and Dr. Turtle, each of whom qualifies as an independent director
for Compensation Committee purposes, as defined under the rules of the SEC and the applicable Nasdaq listing rules. Dr. Turtle chairs
the Compensation Committee.
The
primary responsibility of the Compensation Committee is to periodically review and approve the compensation and other benefits of our
senior officers and directors. This includes reviewing and approving corporate goals and objectives relevant to the compensation of our
Chief Executive Officer and other executive officers, evaluating the performance of these officers in light of the goals and objectives
and setting or recommending to the Board the officers' compensation. The Compensation Committee also administers and makes recommendations
to the Board regarding equity incentive plans that are subject to the Board's approval, in addition to approving the grant of equity
awards under those plans.
Governance
Committee
The
Governance Committee currently comprises Ms. Ball, Dr. Kulkarni and Mr. Harwin, each of whom qualifies as an independent director, as
defined under applicable Nasdaq listing rules. Mr. Harwin chairs the Governance Committee.
The
Governance Committee is responsible for engaging in succession planning for our Board, developing and recommending to the Board criteria
for identifying and evaluating qualified director candidates and making recommendations to the Board regarding candidates for election
or reelection to the Board at each annual stockholders' meeting. In addition, the Governance Committee is responsible for overseeing
corporate governance matters. The Governance Committee is also responsible for overseeing the structure, composition and functioning
of the Board and its committees.
Compensation
Committee Interlocks and Insider Participation
None
of the members of our Compensation Committee has at any time been an officer or employee of the Company. None of our executive officers
currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity
that has one or more executive officers serving on our Board or Compensation Committee.
Code
of Conduct and Ethics
The
Board has adopted a Code of Conduct and Ethics that establishes the standards of ethical conduct applicable to all our directors, officers
and employees. The full text of our Code of Conduct and Ethics is posted on our website at https://ir.orukatx.com/corporate-governance.
It addresses, among other matters, compliance with laws and policies, conflicts of interest, corporate opportunities, regulatory reporting,
external communications, confidentiality requirements, insider trading, proper use of assets and how to report compliance concerns. Any
amendments to the Code of Conduct and Ethics, or any waivers of its requirements, will be posted on our website to the extent required
by applicable rules. The Audit Committee is responsible for applying and interpreting our Code of Conduct and Ethics in situations where
questions are presented to it. Information contained on, or that can be accessed through, our website is not incorporated by reference
into this prospectus, and you should not consider information on our website to be part of this prospectus.
89
EXECUTIVE
COMPENSATION
All
of the information contained in the sections below generally relates to ARCA compensation for fiscal years 2023 and 2022 and was included
in the definitive proxy statement/prospectus filed on Form S-4 with the SEC and declared effective on July 24, 2024 (the "Proxy
Statement/Prospectus"). Such information has not been adjusted to reflect the effects of the Reverse Stock Split. Since the date
of the Proxy Statement/Prospectus, there have been several changes to our senior management, including the following:
●
Thomas
                                            A. Keuer's resignation as our President and Chief Operating Officer, effective as of
                                            August 29, 2024, and termination of employment, effective as of September 1, 2024.
●
C.
                                            Jeffrey Dekker's resignation as our Chief Financial Officer, effective as of August
                                            29, 2024, and termination of employment, effective as of September 1, 2024. Mr. Dekker has
                                            entered into a consulting agreement with us, effective as of August 30, 2024, to provide
                                            transition services through August 30, 2025, unless terminated earlier in accordance with
                                            the agreement.
●
Lawrence
                                            Klein's appointment as our President and Chief Executive Officer, effective as of August
                                            29, 2024.
●
Arjun
                                            Agarwal's appointment as our Senior Vice President, Finance and Treasurer, effective
                                            as of August 29, 2024.
●
Joana
                                            Goncalves's appointment as our Chief Medical Officer, effective as of August 29, 2024.
●
Paul
                                            Quinlan's appointment as our General Counsel and Corporate Secretary, effective as
                                            of August 29, 2024.
ARCA Executive
Compensation
The
following table shows for the fiscal years ended December 31, 2023 and December 31, 2022, compensation awarded to, paid
to, or earned by ARCA's principal executive officer and its two most highly compensated executive officers as of December 31,
2023, collectively, the ARCA named executive officers:
Summary
Compensation Table
Name
    and Principal Position
Year
Salary
($)
(1)
Bonus
($)
(2)
Stock
Awards
($)
All Other
Compensation
($)
(3)
Total
($)
Michael
    R. Bristow
2023
345,000
—
—
13,800
358,800
Former
    President and
Chief Executive Officer
(4)
2022
345,000
—
—
13,800
358,800
Thomas
    A. Keuer
2023
340,000
35,000
—
25,802
400,802
President
    and Chief Operating Officer
2022
340,000
—
88,400
20,593
448,993
C. Jeffrey
    Dekker
2023
270,000
35,000
—
18,072
323,072
Chief
    Financial Officer
(1)
The
                                            amounts reported under "Salary" in the above table represent the actual amounts
                                            paid during the calendar year. Because ARCA's actual pay dates do not always coincide
                                            with the first and last days of the year, these amounts may differ from the base salary
                                            amounts authorized by ARCA's board of directors.
(2)
The
                                            amounts reported under "Bonus" in the above table represent retention bonuses
                                            paid to each of Thomas A. Keuer and C. Jeffrey Dekker in December 2023. These
                                            amounts were previously reported as "All Other Compensation" in ARCA's
                                            Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
(3)
Represents
                                            401(k) Company match in the amount of $13,800 for Michael R. Bristow in each of
                                            2023 and 2022, $15,000 and $13,600 for Thomas A. Keuer in 2023 and 2022, and $11,579
                                            for C. Jeffrey Dekker in 2023, Health Savings Account contributions by ARCA in the amount
                                            of $850 for Thomas A. Keuer in 2022, and $3,960 for C. Jeffrey Dekker in 2023,
                                            group term life premiums in the amount of $9,602 and $4,989 for Thomas A. Keuer in 2023
                                            and 2022, and $2,533 for C. Jeffrey Dekker in 2023, and cell phone reimbursements in
                                            the amount of $1,200 and $1,154 for Thomas A. Keuer in 2023 and 2022.
(4)
Dr. Bristow
                                            and ARCA mutually agreed to conclude Dr. Bristow's employment effective April 3,
                                            2024.
90
Narrative
Disclosure to Summary Compensation Table
Employment
Agreements or Arrangements
Michael
R. Bristow, M.D., Ph.D.
Dr. Bristow served as ARCA's President and Chief Executive Officer
under an Employment and Retention Agreement dated as of June 4, 2008, as amended. Pursuant to such employment agreement, Dr. Bristow
was permitted to continue his academic work for the University of Colorado Health Sciences Center and for the Cardiovascular Institute,
so long as it did not interfere with his duties as President and Chief Executive Officer of ARCA.
In
connection with Dr. Bristow's separation on April 3, 2024, ARCA and Dr. Bristow entered into a separation agreement
(the "Separation Agreement") pursuant to which ARCA paid Dr. Bristow a lump sum amount equal to $370,000, less applicable
tax withholding, which consisted of (i) 12 months of Dr. Bristow's base salary as of the last date of his employment
and (ii) a $25,000 cash payment. The separation payments were conditioned on Dr. Bristow not revoking the Separation Agreement.
ARCA
and Dr. Bristow also entered into a consulting agreement, effective April 3, 2024 (the "Consulting Agreement"),
pursuant to which Dr. Bristow provided certain consulting services to ARCA through the earlier of (i) the completion of services
under the Consulting Agreement, (ii) a termination in accordance with the terms of the Consulting Agreement, and (iii) a change
of control of ARCA (as defined in ARCA's 2020 Equity Incentive Plan (the "2020 Plan")). During the consulting term,
Dr. Bristow continued to vest in his outstanding equity awards.
Thomas
A. Keuer.
Mr. Keuer served as ARCA's President and Chief Operating Officer until August 29,
2024 under an Amended and Restated Employment Agreement that was effective as of January 1, 2015. The potential severance payments
and benefits available under Mr. Keuer's employment agreement as in effect on December 31, 2023 are set forth in Item 11 of ARCA's
Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
On
December 8, 2022, the Compensation Committee approved a retention bonus of $100,000 for Mr. Keuer, subject to continued employment
with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions. On November 29, 2023, the
Compensation Committee approved the amendment of the retention bonus letter between ARCA and Mr. Keuer to (i) increase the
aggregate amount of the retention bonus by 50%, to $150,000, and (ii) in order to assist with tax obligations associated with the
vesting of certain ARCA restricted stock unit awards, provided that $35,000 of Mr. Keuer's retention bonus was paid on
December 8, 2023. On April 20, 2024, the board of directors of ARCA approved the second amendment of the retention bonus letter
between ARCA and Mr. Keuer to increase the aggregate amount of the retention bonus by 33.33% to $200,000.
In
connection with Mr. Keuer's termination of employment, which was considered to be without "cause" related to a change
in control for purposes of his employment agreement, ARCA agreed to pay Mr. Keuer, in exchange for his execution of a legal release
of claims, a severance payment equivalent to (i) 12 months of his base salary, (ii) the unpaid portion of his retention
bonus noted above equal to $165,000, and (iii) reimbursement to cover out-of-pocket costs to continue group health insurance benefits
under COBRA for 12 months.
C. Jeffrey
Dekker.
Mr. Dekker served as ARCA's Chief Financial Officer until August 29, 2024 under an Employment
Agreement that was effective as of May 10, 2021. Mr. Dekker served as ARCA's Secretary since April 2023 until August
29, 2024.
Under
his employment agreement, Mr. Dekker was entitled to receive an annual base salary of $270,000, subject to annual increases if approved
by ARCA's board of directors or Compensation Committee and was eligible to receive an annual target bonus of 35% of his base salary
as determined by ARCA's board of directors or Compensation Committee in its sole discretion. The potential severance payments and
benefits available under Mr. Dekker's employment agreement as in effect on December 31, 2023 are set forth in Item 11 of ARCA's
Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
91
On
December 8, 2022, the Compensation Committee approved a retention bonus of $100,000 for Mr. Dekker, subject to continued employment
with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions. On November 29, 2023, the
Compensation Committee approved the amendment of the retention bonus letter between ARCA and Mr. Dekker to (i) increase the
aggregate amount of the retention bonus by 50%, to $150,000, and (ii) in order to assist with tax obligations associated with the
vesting of certain ARCA restricted stock unit awards, provided that $35,000 of Mr. Dekker's retention bonus was paid
on December 8, 2023. On April 20, 2024, the board of directors of ARCA approved the second amendment of the retention bonus
letter between ARCA and Mr. Dekker to increase the aggregate amount of the retention bonus by 33.33% to $200,000.
In
connection with Mr. Dekker's termination of employment, which was considered to be without "cause" related to a change
in control for purposes of his employment agreement, ARCA agreed to pay Mr. Dekker, in exchange for his execution of a legal release
of claims, a severance payment equivalent to (i) 12 months of his base salary, (ii) the unpaid portion of his retention
bonus noted above equal to $165,000, and (iii) reimbursement to cover out-of-pocket costs to continue group health insurance benefits
under COBRA for 12 months.
Outstanding
Equity Awards at Fiscal Year End
The
following table shows for the fiscal year ended December 31, 2023, certain information regarding outstanding equity awards at fiscal
year-end for ARCA named executive officers.
Option
    Awards
Name
Number of
Securities
Underlying
Unexercised
Options
(#)
Exercisable
Number of
Securities
Underlying
Unexercised
Options
(#)
Unexercisable
Option
Exercise
Price
($)
Option
Expiration
Date
Michael
    R. Bristow, Former President and Chief Executive Officer
408
—
245.70
2/26/2024
205
—
84.42
2/11/2025
1,511
—
59.40
6/8/2026
2,333
—
45.00
2/15/2027
142,500
47,500
(1)(4)
4.27
12/21/2030
63,334
31,666
(2)(4)
2.29
12/14/2031
Thomas
    A. Keuer, President and Chief Operating Officer
83
—
245.70
2/26/2024
108
—
84.42
2/11/2025
866
—
59.40
6/8/2026
1,400
—
45.00
2/15/2027
52,500
17,500
(1)(4)
4.27
12/21/2030
23,334
11,666
(2)(4)
2.29
12/14/2031
C. Jeffrey
    Dekker, Secretary, Chief Financial Officer
35,521
19,479
(3)(4)
3.06
5/10/2031
11,800
5,900
(2)(4)
2.29
12/14/2031
(1)
Options
                                            vest in 48 monthly installments measured from December 21, 2020.
(2)
Options
                                            vest in 36 monthly installments measured from December 14, 2021.
(3)
Options
                                            vested 25% after one year, then in 36 monthly installments measured from May 10, 2021.
(4)
In
                                            the event of a change in control of ARCA, 50% of the unvested shares subject to this award
                                            shall become fully and immediately vested upon the closing date of such change in control,
                                            provided, however, that on the earlier of (i) the one-year anniversary of the closing
                                            date or (ii) involuntary termination, any options that remain unvested on such earlier
                                            date shall become fully and immediately vested.
92
ARCA
Director Compensation
All
of the information contained in the sections below generally relates to compensation for our fiscal year 2023 and was included in the
Proxy Statement/Prospectus. Such information has not been adjusted to reflect the effects of the Reverse Stock Split. Since the date
of the Proxy Statement/Prospectus, there have been several changes to the composition of our Board, including the following:
●
Linda
                                            Grais, Anders Hove, Robert Conway, James Flynn and Jacob Ma-Weaver resigned from our Board,
                                            effective as of August 29, 2024.
●
Lawrence
                                            Klein, Kristine Ball, Carl Dambkowski, Peter Harwin, Samarth Kulkarni and Cameron Turtle
                                            were appointed to our Board, effective as of August 29, 2024.
The
following table shows for the fiscal year ended December 31, 2023, certain information with respect to the compensation of all non-employee
directors of ARCA:
Director
Compensation
(1)
Name
Fees Earned
or Paid in
Cash
($)
Option
Awards
($)
(2)
Total
($)
Linda
    Grais
(3)
162,500
—
162,500
Raymond
    L. Woosley
(4)(10)
55,000
—
55,000
Robert
    E. Conway
(5)
195,000
—
195,000
Dan
    J. Mitchell
(6)(10)
52,500
—
52,500
Anders
    Hove
(7)
150,000
—
150,000
Jacob
    Ma-Weaver
(8)
130,000
—
130,000
James
    Flynn
(9)
40,000
—
40,000
(1)
Dr. Bristow,
                                            ARCA's former President and Chief Executive Officer, was also a director during the
                                            year ended December 31, 2023, but did not receive any additional compensation for his
                                            service as a director. Dr. Bristow's compensation as an executive officer is set
                                            forth above under "Executive Compensation — Summary Compensation Table."
(2)
The
                                            amounts reported under "Option Awards" in the above table reflect the grant date
                                            fair value of these awards as determined in accordance with Financial Accounting Standards
                                            Board Accounting Standards Codification Topic 718, Compensation — Stock
                                            Compensation, excluding the effects of estimated forfeitures. The value of stock option awards
                                            was estimated using the Black-Scholes option-pricing model. The valuation assumptions used
                                            in the valuation of option grants may be found in Note 8 to ARCA's financial statements
                                            included in this annual report on Form 10-K for the year ended December 31, 2023.
(3)
The
                                            aggregate number of shares issuable upon exercise of option awards outstanding at December 31,
                                            2023, for Dr. Grais was 19,458, all of which were fully vested. Includes $52,500 for
                                            Special Committee compensation for 2022 approved and paid in 2023, as discussed below and
                                            $52,500 for 2023 approved and paid in 2024.
(4)
The
                                            aggregate number of shares issuable upon exercise of option awards outstanding at December 31,
                                            2023, for Dr. Woosley was 19,458, all of which were fully vested.
(5)
The
                                            aggregate number of shares issuable upon exercise of option awards outstanding at December 31,
                                            2023, for Mr. Conway, Chairman of ARCA's board of directors, was 19,458, all of
                                            which were fully vested. Includes $52,500 for Special Committee compensation for 2022 approved
                                            and paid in 2023, as discussed below and $52,500 for 2023 approved and paid in 2024.
(6)
The
                                            aggregate number of shares issuable upon exercise of option awards outstanding at December 31,
                                            2023, for Mr. Mitchell was 19,577, all of which were fully vested.
(7)
The
                                            aggregate number of shares issuable upon exercise of option awards outstanding at December 31,
                                            2023, for Dr. Hove was 18,999, all of which were fully vested. Includes $52,500 for
                                            Special Committee compensation for 2022 approved and paid in 2023, as discussed below and
                                            $52,500 for 2023 approved and paid in 2024.
(8)
The
                                            aggregate number of shares issuable upon exercise of option awards outstanding at December 31,
                                            2023, for Mr. Ma-Weaver was 18,000, of which 12,000 shares were fully vested. Includes
                                            $37,500 for Special Committee compensation for 2022 approved and paid in 2023, as discussed
                                            below and $52,500 for 2023 approved and paid in 2024.
(9)
The
                                            aggregate number of shares issuable upon exercise of option awards outstanding at December 31,
                                            2023, for Mr. Flynn was 12,000, of which 4,000 shares were vested.
(10)
These
                                            directors resigned from ARCA's board of directors effective February 2, 2024.
93
In
2021, ARCA revised its compensation plan for non-employee directors to provide that non-employee directors will be compensated for their
service on ARCA's board of directors, as follows:
●
Each
                                            non-employee director will receive an annual retainer fee of $40,000;
●
As
                                            additional compensation for their services, each non-employee director will receive (i),
                                            upon joining ARCA's board of directors, an initial option grant to purchase 12,000
                                            shares of ARCA's Common Stock under the 2020 Plan, (ii), in 2021 the members of the
                                            board of directors received a one-time retention option grant to purchase 12,000 shares of
                                            ARCA's Common Stock under the 2020 Plan, and (iii), on an annual basis as of the date
                                            of ARCA's annual stockholder meeting, an annual option grant to purchase 6,000 shares
                                            of ARCA's Common Stock under the 2020 Plan; provided that such non-employee director
                                            has served on ARCA's board of directors for at least six months prior to the date
                                            of grant (unless such six-month period is modified by recommendation of the Nominating and
                                            Corporate Governance Committee and approved by the Compensation Committee);
●
The
                                            Chairman of ARCA's board of directors will receive an additional annual retainer fee
                                            of $30,000;
●
ARCA's
                                            Audit Committee chair will receive an additional annual retainer fee of $15,000;
●
The
                                            chairs of ARCA's Compensation Committee and Nominating and Corporate Governance Committee
                                            will each receive an additional annual retainer fee of $10,000;
●
Each
                                            non-chair member of ARCA's Audit Committee will receive an additional annual retainer
                                            fee of $7,500; and
●
Each
                                            non-chair member of ARCA's Compensation Committee and Nominating and Corporate Governance
                                            Committees will receive an additional annual retainer fee of $5,000.
On
January 30, 2024, ARCA approved paying compensation to its existing non-employee directors, pursuant to ARCA's Director Compensation
Policy, by granting to Dr. Linda Grais, Dr. Anders Hove, Mr. Robert Conway, Mr. Daniel Mitchell, Dr. Raymond
Woosley, Mr. James Flynn and Mr. Jacob Ma-Weaver options to purchase 6,000 shares of common stock at an exercise price of $1.64
per share, the closing price of ARCA's common stock on January 30, 2024. The options are subject to the terms and conditions
of the 2020 Plan and ARCA's standard forms of Stock Option Agreement and Option Grant Notice for the 2020 Plan. The options vest
in 12 equal monthly installments beginning on January 30, 2024, assuming Dr. Grais', Dr. Hove's, Mr. Conway's,
Mr. Mitchell's, Dr. Woosley's, Mr. Flynn's and Mr. Ma-Weaver's continued service on the Board
for such periods.
In
2022, ARCA's board of directors established a Special Committee to evaluate strategic options for maximizing stockholder value.
The Special Committee includes ARCA board Chairman Robert E. Conway (chair), and board members Linda Grais, M.D., Anders Hove, M.D.
and Jacob Ma-Weaver. In December 2023, based on the recommendation of the Nominating and Corporate Governance Committee, the board
determined that each member of the Special Committee will be paid $7,500 per month for each month of substantive service on the Special
Committee. In December 2023, payments for 2022 service were made to the members of the Special Committee of $52,500 to each of Robert
E. Conway, Linda Grais, M.D., Anders Hove, M.D. and $37,500 to Jacob Ma-Weaver (joined the Committee in June 2022). Payments
for 2023 service were paid in 2024 to the members of the Special Committee consisting of $52,500 to each of Robert E. Conway, Linda
Grais, M.D., Anders Hove, M.D. and Jacob Ma-Weaver. Payments for 2024 service through April 2024 were paid in 2024 to the members
of the Special Committee consisting of $30,000 to each of Robert E. Conway, Linda Grais, M.D., Anders Hove, M.D. and Jacob Ma-Weaver.
2024
Director Compensation Program
On
September 17, 2024, our Board approved an updated director compensation program for non-employee members of our Board that provides for
the following annual cash retainers:
Annual
    Cash Retainer
$
40,000
Annual
    Board Chair Retainer
$
30,000
Audit
    Committee Retainers:
Chair
$
15,000
Non-Chair
    Member
$
7,500
Compensation
    Committee Retainers:
Chair
$
12,000
Non-Chair
    Member
$
6,000
Nominating
    and Corporate Governance Committee Retainers
Chair
$
10,000
Non-Chair
    Member
$
5,000
In
connection with the Company's annual meeting of stockholders, each member of the Board will receive an annual grant of stock options
to purchase 17,500 shares of common stock, which will vest in equal monthly installments over 12 months so long as such director joined
the Board prior to January 1 of the year in which such annual meeting occurs. In addition, in connection with a non-employee director's
initial appointment to the Board, they will receive an initial grant of stock options to purchase 35,000 shares of common stock, which
will vest in equal monthly installments over 36 months.
All
members of the Board are also reimbursed for reasonable and documented out-of-pocket travel and lodging expenses incurred in connection
with attending meetings and activities of the Board and its committees.
94
ARCA
EQUITY COMPENSATION PLAN INFORMATION
The
following table sets forth information as of December 31, 2023, for all of ARCA's equity compensation plans and has not been
adjusted to reflect the effects of the Reverse Stock Split:
Plan
    Category
Number of
Securities
to be Issued Upon
Exercise of
Outstanding
Options or Upon
Vesting of
Restricted Stock
Units
(a)
Weighted
Average
Exercise
Price of
Outstanding
Options
($)
(b)
Number of
Securities
Remaining
Available for
Future Issuance
Under Equity
Compensation
Plans (Excluding
Securities
Reflected in
Column(a))
(c)
Equity
    compensation plans approved by security holders
616,707
$
4.76
459,718
Equity
    compensation plans not approved by security holders
—
—
—
Total
616,707
$
4.76
459,718
On
December 10, 2020, ARCA stockholders approved the 2020 Plan at ARCA's 2020 annual meeting of stockholders. The 2020 Plan is
the successor to the Amended and Restated ARCA biopharma, Inc. 2013 Equity Incentive Plan (the "2013 Plan"). A description
of the 2020 Plan is set forth in Note 8 to ARCA's financial statements included in the Proxy Statement/Prospectus. The 2020
Plan only has options outstanding as of December 31, 2023; no warrants or rights are outstanding under this plan; therefore, all
values in the above table relate solely to the outstanding options.
On
September 17, 2013, ARCA stockholders approved the 2013 Plan at ARCA's 2013 annual meeting of stockholders. On June 9,
2016, ARCA stockholders approved an amendment to the 2013 Plan (as amended, the "Amended 2013 Plan"). A description of the
2013 Plan and the Amended 2013 Plan is set forth in Note 8 to ARCA's financial statements included in the Proxy Statement/Prospectus.
The Amended 2013 Plan only has options outstanding as of December 31, 2023; no warrants or rights are outstanding under this plan;
therefore, all values in the above table relate solely to the outstanding options.
Compensation
Risks
ARCA
believes its approach to goal setting, setting of targets with payouts at multiple levels of performance, and evaluation of performance
results assist in mitigating excessive risk-taking that could harm the value or reward poor judgment by its executives. ARCA believes
several features of its programs reflect sound risk management practices. ARCA believes it has allocated compensation among base salary
and short and long-term compensation target opportunities in such a way as to not encourage excessive risk-taking. The multi-year vesting
of equity awards properly accounts for the time horizon of risk. Furthermore, ARCA's Compensation Committee assesses and monitors
whether any of ARCA's compensation policies and programs has the potential to encourage excessive risk-taking on an annual basis.
95
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS
The following
table sets forth information, to the extent known by us or ascertainable from public filings, with respect to the beneficial ownership
of our Common Stock as of November 1, 2024.
●
each
person or group of affiliated persons, who is known by us to be the beneficial owner of more than 5% of Common Stock;
●
each
of our directors;
●
each
of our named executive officers; and
●
all
of our current directors and executive officers as a group.
The column
entitled "Percentage of Shares Outstanding Beneficially Owned" is based on a total of 34,998,550 shares of our Common Stock
outstanding as of November 1, 2024.
Beneficial
ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect
to the Common Stock. Shares of Common Stock subject to options that are currently exercisable or exercisable within 60 days of the date
of this table are considered outstanding and beneficially owned by the person holding the options for the purpose of calculating the
percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Due to the conversion
limitations on the Series A Preferred Stock, shares of underlying common stock have been excluded from beneficial ownership set forth
below. Except as otherwise noted, the persons and entities in this table have sole voting and investing power with respect to all of
the shares of Common Stock beneficially owned by them, subject to community property laws, where applicable. Except as otherwise indicated
in the table below, addresses of named beneficial owners are in care of Oruka Therapeutics, Inc., 855 Oak Grove Ave., Suite 100, Menlo
Park, CA 94025.
Name
    of Beneficial Owner
Number of
Shares
Beneficially
Owned
Percentage
of Shares
Outstanding
Beneficially
Owned
Entities
    affiliated with Fairmount Funds Management LLC
(1)
7,941,690
19.99
%
FMR
    LLC
(2)
4,682,300
13.38
%
Entities
    affiliated with Venrock Healthcare Capital Partners
(3)
3,541,941
9.99
%
Entities
    affiliated with RTW Investments, LP
(4)
1,963,147
5.61
%
Named
    Executive Officers and Directors:
Lawrence
    Klein
(5)
852,338
2.44
%
Arjun
    Agarwal
—
*
Joana
    Goncalves
—
*
Paul
    Quinlan
—
*
Michael
    R. Bristow
(6)
399
*
Thomas
    A. Keuer
(7)
3,394
*
C.
    Jeffrey Dekker
(8)
3,333
*
Cameron
    Turtle
(9)
85,233
*
Samarth
    Kulkarni
—
*
Peter
    Harwin
(1)
7,941,690
19.99
%
Carl
    Dambkowski
—
*
Kristine
    Ball
—
*
All
    executive officers and directors as a group (9 persons)
(10)
8,879,261
22.67
%
*
Less
                                            than 1%.
96
(1)
Consists
                                            of (i) (A) 638,614 shares of common stock, (B) 316,025 shares of common stock issuable upon
                                            the exercise of pre-funded warrants and (C) 4,413,743 shares of common stock issuable upon
                                            conversion of 52,965 shares of Series B Preferred Stock held by Fairmount Healthcare Fund
                                            II L.P. ("Fairmount Fund II") and (ii) 2,573,308 shares of common stock held
                                            by Fairmount Healthcare Co-Invest III L.P. ("Fairmount Fund III"). Excludes (i)
                                            4,981,639 shares of common stock issuable upon the exercise of the pre-funded warrants, (ii)
                                            7,014,406 shares of common stock issuable upon the conversion of 84,173 shares of Series
                                            B Preferred Stock and (iii) 160,000 shares of common stock issuable upon the conversion of
                                            160 shares of Series A Preferred Stock owned by Fairmount Fund II. The pre-funded warrants
                                            and Series A Preferred Stock are subject to a beneficial ownership limitation of 9.99% and
                                            the shares of Series B Preferred Stock are subject to a beneficial ownership limitation of
                                            19.99%, which such limitations restrict Fairmount Funds Management LLC ("Fairmount")
                                            and its affiliates from exercising that portion of the warrants and converting those shares
                                            of preferred stock that would result in Fairmount and its affiliates owning, after exercise
                                            or conversion, a number of shares of common stock in excess of the applicable ownership limitation.
                                            At such time as Fairmount and its affiliates beneficially own 9.0% or less of the shares
                                            of common stock, the beneficial ownership limitation applicable to the shares of Series B
                                            Preferred Stock will automatically reduce to 9.99%. Fairmount serves as investment manager
                                            for Fairmount Fund II and Fairmount Fund III. Fairmount Fund II and Fairmount Fund III have
                                            delegated to Fairmount the sole power to vote and the sole power to dispose of all securities
                                            held in Fairmount Fund II and Fairmount Fund III's portfolios. Because Fairmount Fund
                                            II and Fairmount Fund III have divested themselves of voting and investment power over the
                                            securities they hold and may not revoke that delegation on less than 61 days' notice,
                                            Fairmount Fund II and Fairmount Fund III disclaim beneficial ownership of the securities
                                            they hold. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount
                                            GP"). As managing members of Fairmount GP, Peter Harwin and Tomas Kiselak may be deemed
                                            to have voting and investment power over the shares held by Fairmount Fund II and Fairmount
                                            Fund III. Fairmount, Fairmount GP, Peter Harwin and Tomas Kiselak disclaim beneficial ownership
                                            of such shares, except to the extent of any pecuniary interest therein. The address of the
                                            entities and individuals listed is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA
                                            19428.
(2)
All
    of the shares listed in the table above are owned by funds or accounts managed by direct or indirect subsidiaries of FMR LLC, all
    of which shares are beneficially owned, or may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates,
    and other companies. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson
    family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of
    FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered
    into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority
    vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders'
    voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group
    with respect to FMR LLC. The address of FMR LLC is 245 Summer Street, Boston, MA 02210.
(3)
Consists
    of (i) 2,350,074 shares of common stock and 351,506 shares of common stock issuable upon the exercise of pre-funded warrants held
    by Venrock Healthcare Capital Partners EG, L.P. ("VHCPEG"), (ii) 668,656 shares of common stock and 95,284 shares of
    common stock issuable upon the exercise of pre-funded warrants held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"),
    and (iii) 66,890 shares of common stock and 9,531 shares of common stock issuable upon the exercise of pre-funded warrants held by
    VHCP Co-Investment Holdings III, LLC ("VHCPCo3"). Excludes (i) 54,474, 12,504 and 1,244 shares of common stock issuable
    upon the exercise of the pre-funded warrants held by VHCPEG, VHCP3 and VHCPCo3, respectively, and (ii) 157,000, 39,000 and 4,000
    shares of common stock issuable upon the conversion of Series A Preferred Stock held by VHCPEG, VHCP3 and VHCPCo3, respectively.
    The pre-funded warrants and Series A Preferred Stock are subject to a beneficial ownership limitation of 9.99%, which such limitations
    restrict Venrock Healthcare Capital Partners and its affiliates from exercising that portion of the warrants or Series A Preferred
    Stock that would result in Venrock Healthcare Capital Partners and its affiliates owning, after exercise, a number of shares of common
    stock in excess of the applicable ownership limitation. VHCP Management III, LLC ("VHCPM3") is the sole general partner
    of VHCP3 and the sole manager of VHCPCo3. VHCP Management EG, LLC ("VHCPM EG") is the sole general partner of VHCPEG.
    As voting members of VHCPM3 and VHCPM EG, Dr. Bong Koh and Nimish Shah may be deemed beneficial owners of any securities beneficially
    owned by VHCPM3 and VHCPM EG. The principal business address of each of these persons and entities is 7 Bryant Park, 23rd Floor,
    New York, NY 10018.
(4)
Consists
    of 1,963,147 shares of common stock held in the aggregate by RTW Master Fund, Ltd. ("RTW Master Fund"), RTW Innovation
    Master Fund, Ltd. ("RTW Innovation Master Fund"), and RTW Biotech Opportunities Operating Ltd. ("RTW Biotech"
    and together with RTW Master Fund and RTW Innovation Fund, the "RTW Funds"). Excludes 95,000 shares of common stock issuable
    upon the conversion of Series A Preferred Stock held in the aggregate by the RTW Funds. The Series A Preferred Stock is subject to
    a beneficial ownership limitation of 9.99%, which such limitations restrict the RTW Funds and its affiliates from exercising that
    portion of the Series A Preferred Stock that would result in the RTW Funds and its affiliates owning, after exercise, a number of
    shares of common stock in excess of the applicable ownership limitation. RTW Investments, LP ("RTW"), in its capacity
    as the investment manager of the RTW Funds, has the power to vote and the power to direct the disposition of the shares held by the
    RTW Funds. Accordingly, RTW may be deemed to be the beneficial owner of such securities. Roderick Wong, M.D., as the Managing Partner
    of RTW, has the power to direct the vote and disposition of the securities held by RTW. Dr. Wong disclaims beneficial ownership of
    the shares held by the RTW Funds, except to the extent of his pecuniary interest therein. The principal business address of RTW Investments,
    LP is 40 10th Avenue, Floor 7, New York, NY 10014, and the address of Dr. Wong and each of the RTW Funds is c/o RTW Investments,
    LP, 40 10th Avenue, Floor 7, New York, NY 10014.
(5)
Includes
    852,338 shares of restricted voting common stock.
(6)
Includes
    (i) 92 shares owned by Investocor Trust, of which Dr. Bristow is the sole trustee and (ii) 117 shares owned by NFS as Custodian for
    Michael Bristow's IRA. Dr. Bristow and ARCA mutually agreed to conclude Dr. Bristow's employment effective April 3, 2024.
(7)
Mr.
    Keuer resigned as named executive officer at the Closing and his last day of employment was September 1, 2024, which termination
    was considered to be without "cause" related to a change in control for purposes of his employment agreement with ARCA.
(8)
Mr.
    Dekker resigned as named executive officer at the Closing and his last day of employment was September 1, 2024, which termination
    was considered to be without "cause" related to a change in control for purposes of his employment agreement with ARCA.
(9)
Includes
                                            85,233 shares of restricted voting common stock held by the Turtle Family Trust, for which
                                            Mr. Turtle serves as Trustee.
(10)
See
                                            notes (1), (5) and (9) above.
97
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS
As discussed
in the "Certain Relationships and Related Party Transactions of the Combined Company" section of the Proxy Statement/Prospectus,
the following is a description of each transaction involving (1) the Company since the Closing, including proposed transactions, (2)
Pre-Merger Oruka since February 6, 2024 (its inception) through the Closing, and (3) ARCA, beginning on January 1, 2022, and in which:
●
the
Company, Pre-Merger Oruka, or ARCA has been, or is to be, a participant;
●
the
amount involved exceeded or will exceed the lesser of $120,000 and 1% of the average of either the Company's, Pre-Merger Oruka's,
or ARCA's assets (as the case may be); and
●
in
which the directors, executive officers, former directors, former executive officers, director nominees and holders of more than 5% of
capital stock of the Company, Pre-Merger Oruka, or ARCA (as the case may be), or other persons as may be required to be disclosed pursuant
to Item 404 of Regulation S-K, had or will have a direct or indirect material interest.
Other than
the compensation agreements and other arrangements disclosed above under the heading "Executive Compensation," and the transactions
described below, since the filing date of the Proxy Statement/Prospectus, there were no transactions or series of similar transactions
to which ARCA, Pre-Merger Oruka, or the Company were a party in which the amount involved exceed $120,000 (or, if less, 1% of the average
of ARCA, Pre-Merger Oruka, or the Company's total asset amounts (as the case may be)) and in which any director, executive officer,
holder of 5% or more of any class of ARCA's, Pre-Merger Oruka's or the Company's capital stock (as the case may be)
or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had a direct or indirect material
interest.
ARCA
Transactions
Transactions
With ARCA's Former President and Chief Executive Officer
ARCA
previously entered into unrestricted research grants with its former President and Chief Executive Officer's academic research
laboratory at the University of Colorado. Funding of any unrestricted research grants was contingent upon ARCA's financial condition,
and could be deferred or terminated at ARCA's discretion. There was no expense under these arrangements for the three months
ended March 31, 2024. Total expense under these arrangements for the three months ended March 31, 2023 was $108,000. Total
expense under these arrangements for the years ended December 31, 2023 and 2022 was $(91,000) and $432,000, respectively. In
December 2023, ARCA made a payment of $125,000 for the grant period July 2022 through December 2023 under these arrangements.
In April 2024, the President and Chief Executive Officer resigned.
Cooperation
Agreement
ARCA
was a party to a Cooperation Agreement (the "Cooperation Agreement") with Cable Car Capital LLC, The Funicular Fund, LP,
Funicular Funds, LP and Jacob Ma-Weaver (collectively, "Cable Car").
Pursuant
to the Cooperation Agreement, ARCA's board of directors appointed Mr. Ma-Weaver as a Class III director with a term
expiring at ARCA's 2024 annual meeting of stockholders, effective June 15, 2022 and appointed Mr. Ma-Weaver to the
Special Committee of ARCA's board of directors (the "First Director Appointment"). Mr. Ma-Weaver resigned from ARCA's
board of directors immediately prior to the Closing.
Additionally,
under the terms of the Cooperation Agreement, ARCA and Cable Car initiated a process and subsequently identified a mutually acceptable
second independent director, Mr. James Flynn, to join ARCA's board of directors. Mr. Flynn was elected as director at
the 2022 annual meeting of stockholders. Mr. Flynn resigned from ARCA's board of directors immediately prior to the Closing.
Under
the terms of the Cooperation Agreement, Cable Car agreed to abide by customary standstill restrictions from the date of the Cooperation
Agreement until the earlier to occur of (i) the 180
th
day after the First Director Appointment is no longer serving
as a director of ARCA and (ii) the 90
th
day prior to the 2023 Annual Meeting (such period, the "Cooperation
Period"), including that Cable Car would not, among other things, (i) seek additional representation, or the removal of an
existing director, on ARCA's board of directors, (ii) engage in any solicitation of proxies, or (iii) initiate, propose
or otherwise solicit, including any solicitations of the type contemplated by Rule 14a-2(b) promulgated under the Securities
Exchange Act of 1934 of ARCA's stockholders for the approval of, any stockholder proposal. The Cooperation Period
expired on November 1, 2023, the 90
th
day prior to the 2023 Annual Meeting.
ARCA
and Cable Car also agreed to customary mutual non-disparagement obligations.
98
Pre-Merger
Oruka Transactions
Private
Placements of Securities
Pre-Merger
Oruka Series A Preferred Stock and Convertible Note Financing
On March 6,
2024, Oruka entered into a Convertible Note Purchase Agreement with Fairmount Healthcare Fund II, L.P. ("Fairmount Fund II"),
whereby Oruka issued and sold to Fairmount Fund II (i) an aggregate of 20,000,000 shares of Pre-Merger Oruka Series A Preferred
Stock at a purchase price of $0.15 per share and (ii) a convertible note (the "Convertible Note") with an initial principal
amount of $25.0 million at an interest rate of 12% per annum, for aggregate gross proceeds of $28 million. Fairmount Fund II contributed
the aggregate principal amount of $25.0 million and all accrued interest under the Convertible Note (unpaid accrued interest of $1.5
million divided by the conversion price of $66.62 ($5.55 prior to the impact of the Reverse Stock Split) per share) in exchange for Pre-Merger
Oruka Common Stock and Pre-Merger Oruka pre-funded warrants in connection with the Pre-Closing Financing (as defined below), immediately
prior to the completion of the Merger. Fairmount Funds Management ("Fairmount") is the investment manager of Fairmount Fund
II. Peter Harwin, one of our directors, is a managing member of Fairmount.
Pre-Merger
Oruka Pre-Closing Financing
On
April 3, 2024, in connection with the execution of the Merger Agreement, Pre-Merger Oruka entered into the Subscription
Agreement to consummate the Pre-Closing Financing. Pursuant to the Subscription Agreement, the Financing Investors purchased
39,873,706 shares of Pre-Merger Oruka common stock and 9,664,208 Pre-Merger Oruka pre-funded warrants for gross proceeds of
approximately $275.0 million (which includes $25.0 million of proceeds previously received from the issuance of the Convertible Note
and accrued interest on such note which converted to 4,764,032 shares of Pre-Merger Oruka common stock), immediately prior to the
Closing and before the effect of the Reverse Stock Split. Three of the investors or their affiliates were beneficial
holders of more than 5% of Pre-Merger Oruka's capital stock, and the table below sets forth the number of shares of Pre-Merger
Oruka common stock and Pre-Merger Oruka pre-funded warrants purchased by such holders at the closing of the Pre-Closing
Financing.
Participant
Shares
    of
Pre-Merger Oruka
Common
Stock
Pre-funded
Warrants of
Pre-Merger Oruka
Total
Purchase
Price
Entities
    affiliated with Fairmount
5,139,797
9,271,241
$
79,907,282
(1)
Entities
    affiliated with Venrock Healthcare Capital Partners
5,011,172
392,967
$
29,996,067
Entities
    affiliated with FMR LLC
4,503,445
—
$
24,999,974
(1)
Includes
                                            $25.0 million of proceeds previously received by Pre-Merger Oruka from the issuance of the
                                            Convertible Note and accrued interest on such note, with the remainder of the purchase price
                                            paid in cash.
Company
Transactions
September
2024 Private Placement
On September 11, 2024, the Company entered into the SPA with the
Selling Stockholders to consummate the Private Placement. Pursuant to the SPA, the Selling Stockholders purchased (i) an aggregate of
5,600,000 shares of Common Stock, at a price per share of $23.00, (ii) an aggregate of 2,439 shares of Series A Preferred Stock (each
Series A Preferred Stock is convertible into 1,000 shares of Company Common Stock), at a price per share of $23,000.00, and (iii) pre-funded
warrants to purchase an aggregate of 680,000 shares of Common Stock at a purchase price of $22.999 per pre-funded warrant, which represents
the per share purchase price of the Private Placement Common Shares less the $0.001 per share exercise price for each pre-funded warrant,
for an aggregate purchase price of approximately $200.5 million. Subject to receiving the requisite stockholder approval and certain beneficial
ownership limitations set by each holder of Series A Preferred Stock, each share of Series A Preferred Stock will automatically convert
into an aggregate of 1,000 shares of Common Stock. Three of the Selling Stockholders or their affiliates were beneficial holders of more
than 5% of the Company's capital stock, and the table below sets forth the number of shares of Common Stock, Series A Preferred
Stock and pre-funded warrants purchased by such holders at the closing of the Private Placement.
Participant
Shares
    of
Common Stock
Series
    A Preferred Stock
Pre-Funded
    Warrants
Total
Purchase
Price
Entities
    affiliated with FMR LLC
2,105,000
830
—
$
67,505,000
Entities
    affiliated with Venrock Healthcare Capital Partners
150,000
200
300,000
$
14,949,700
Entities
    affiliated with Fairmount
275,000
160
—
$
10,005,000
99
Our Relationship
with Paragon and Paruka
We are party
to a number of agreements with Paragon and Paruka. Paragon and Paruka beneficially own more than 5% of our capital stock through their
joint holdings of our Common Stock. Fairmount beneficially owns more than 5% of our capital, one of Fairmount's employees serves
on our Board, and Fairmount beneficially owns more than 5% of Paragon. Fairmount appointed Paragon's board of directors and has
the contractual right to approve the appointment of any executive officers of Paragon, but is not the beneficial owner of Paragon's
securities. Paruka is an entity formed by Paragon as a vehicle to hold equity in our Company in order to share profits with certain employees
of Paragon.
In March 2024, Pre-Merger Oruka entered into
the Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paragon identifies, evaluates and develops antibodies
directed against certain mutually agreed therapeutic targets of interest to us. The Option Agreements include two selected targets, IL-23
(ORKA-001) and IL-17A/F (ORKA-002). Under the Option Agreements, we have the exclusive options to, on a research program-by-research program
basis, be granted an exclusive, worldwide license to all of Paragon's right, title and interest in and to the intellectual property
resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed to the
selected targets (each, an "Option"), with the exception of pursuing ORKA-001 for the treatment of inflammatory bowel disease.
If we exercise our options, we will be required to make non-refundable milestone payments to Paragon of up to $12.0 million under each
respective agreement upon the achievement of certain clinical development milestones, up to $10.0 million under each respective agreement
upon the achievement of certain regulatory milestones as well as tiered royalty payments in the low-to-mid single-digits beginning on
the first commercial sale. From time to time, we can choose to add additional targets to the collaboration by mutual agreement with Paragon.
During the three months ended September 30, 2024, we exercised our option for ORKA-001 and recorded a $1.5 million milestone payment related
to the achievement of development candidate as research and development expense in our condensed consolidated statements of operations
and comprehensive loss for the three months ended September 30, 2024. As of September 30, 2024, this amount is included under related
party accounts payable and other current liabilities on the condensed consolidated balance sheet.
Our exclusive Option with respect to each research
program for a particular target initiated by the parties ("Research Program") is exercisable at our sole discretion at any
time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of days
following (i) with respect to any Research Program other than ORKA-001, the delivery of the data package from Paragon related to the results
of the Research Plan activities, or (ii) with respect to ORKA-001, the completion of the IL-23 antibody selection process described in
the agreement (the "Option Period"). There is no payment due upon exercise of an Option pursuant to the Option Agreements.
Unless terminated earlier, the Option Agreements shall continue in
force on a Research Program-by-Research Program basis until the earlier of: (i) the end of the Option Period for such Research Program,
as applicable, if such Option is not exercised by us; (ii) the expiration of the 30-day period after we exercise our Option with
respect to such Research Program, subject to mutually agreed extension, during the Option Period and the parties are unable to finalize
and execute a license agreement, and (iii) the expiration of the applicable research term (the "Term"). Upon the expiration
of the Term for all then-existing Research Programs, under the Option Agreements, the Option Agreements will automatically expire in its
entirety. We may terminate the Option Agreements or any Research Program at any time for any or no reason upon 30 days' prior
written notice to Paragon, provided that we must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable
obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate
the Option Agreements or a Research Program immediately upon written notice to us if, as a result of any action or failure to act by us
or our affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or
otherwise delayed for a certain consecutive number of months. Each party has the right to terminate the Option Agreements or any Research
Program upon (i) 30 days' prior written notice of the other party's material breach that remains uncured for the
30-day period and (ii) the other party's bankruptcy.
Pursuant to the Option Agreements, on a research
program-by-research program basis following the finalization of the Research Plan for each respective research program, we were required
to pay Paragon a one-time nonrefundable research initiation fee of $0.8 million related to the ORKA-001 program. This amount was recognized
as a research and development expense during the period from February 6, 2024 (inception) to September 30, 2024. In June 2024, pursuant
to the Option Agreements with Paragon, we completed the selection process of our development candidate for IL-23 antibody for the ORKA-001
program. We were responsible for 50% of the development costs incurred through the completion of the IL-23 selection process. We received
the rights to at least one selected IL-23 antibody in June 2024. During the three months ended September 30, 2024, we exercised our option
for ORKA-001 and recorded a $1.5 million milestone payment related to the achievement of development candidate as research and development
expense in the Company's condensed consolidated statements of operations and comprehensive loss for each of the three months ended
September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024. Our share of development costs incurred
during the three months ended September 30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024 was $0.8 million
and $13.2 million, respectively, which were recorded as research and development expenses during the respective periods. An amount of
$2.3 million is included in related party accounts payable and other current liabilities as of September 30, 2024.
100
We were also required to reimburse Paragon $3.3
million for development costs related to ORKA-002 incurred by Paragon through December 31, 2023 and certain other development costs incurred
by Paragon between January 1, 2024 and March 6, 2024 as stipulated by the Option Agreements. This amount was recognized as a research
and development expense during the period from February 6, 2024 (inception) to September 30, 2024. We are also responsible for the development
costs incurred by Paragon from January 1, 2024 through the completion of the IL-17 selection process. We recognized an amount of $0.8
million payable to Paragon for the research initiation fee related to ORKA-002 following the finalization of the ORKA-002 research plan.
This was recognized as research and development expenses in the period from February 6, 2024 (inception) to September 30, 2024. We accounted
for development costs of $3.8 million and $6.6 million during the three months ended September 30, 3024 and for the period from February
6, 2024 (inception) to September 30, 2024, respectively, as research and development expenses during the respective periods. An amount
of $3.8 million is included in related party accounts payable and other current liabilities as of September 30, 2024.
As part of the Option Agreements, on each of December
31, 2024 and December 31, 2025, we will grant warrants to purchase a number of shares equal to 1.00% of outstanding shares as of the date
of the grant on a fully diluted basis with an exercise price equal to the fair market value of the underlying shares on the grant date.
The warrants are liability-classified and after the initial recognition, the liability is adjusted to fair value at the end of each reporting
period, with changes in fair value recorded in the consolidated statement of operations and comprehensive loss as stock-based compensation
expenses under research and development expenses.
Indemnification
Agreements and Insurance
We have entered
into an indemnification agreement with each of the directors and officers and purchased directors' and officers' liability
insurance. The indemnification agreements require us to indemnify our directors and officers to the fullest extent permitted under Delaware
law.
Review,
Approval or Ratification of Transactions with Related Parties
Prior to
the Closing, Pre-Merger Oruka did not have a formal policy regarding approval of transactions with related parties. All disclosable transactions
with related parties which occurred prior to the Closing were approved by the directors not interested in such transactions, pursuant
to Section 144(a)(1) of the DGCL.
The Company's
Board has adopted a written related person transactions policy. Under this policy, our executive officers, directors, nominees for election
as a director, beneficial owners of more than 5% of our Common Stock, and any members of the immediate family of and any entity affiliated
with any of the foregoing persons, are not permitted to enter into a material related person transaction with us without the review and
approval of our Audit Committee, or a committee composed solely of independent directors in the event it is inappropriate for our Audit
Committee to review such transaction due to a conflict of interest. The policy provides that, subject to limited exceptions, any transaction,
arrangement or relationship or series of similar transactions, arrangements or relationships in which (1) the aggregate amount involved
since the beginning of the Company's last completed fiscal year exceeds or is expected to exceed $120,000, (2) the Company or any
of our subsidiaries is a participant, and (3) any related person has or will have a direct or indirect interest, will be presented to
our Audit Committee for review, consideration and approval. In approving or rejecting any such proposal, our Audit Committee will consider
the material facts and other factors it deems appropriate, including, but not limited to, whether the transaction is on terms no less
favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the
related person's interest in the transaction.
101
SELLING
STOCKHOLDERS
This prospectus
covers the resale or other disposition from time to time by the Selling Stockholders identified in the table below of up to an aggregate
of 8,719,000 shares of our Common Stock. The Selling Stockholders may from time to time offer and sell any or all of the Resale Shares
set forth below pursuant to this prospectus and any accompanying prospectus supplement.
On September
11, 2024, we entered into the SPA, pursuant to which we sold an aggregate of (i) 5,600,000 shares of our Common Stock, (ii) 2,439 shares
of our Series A Preferred Stock, which will automatically convert into 1,000 shares of Common Stock, subject to stockholder approval
and certain beneficial ownership limitations set by each holder, pursuant to the Series A Certificate of Designation, and (iii) Pre-Funded
Warrants to purchase an aggregate of 680,000 shares of Common Stock at a purchase price of $22.999 per Pre-Funded Warrant, which represents
the per share purchase price of the Private Placement Common Shares less the $0.001 per share exercise price for each Pre-Funded Warrant,
for an aggregate purchase price of approximately $200.5 million. This prospectus covers the resale or other disposition by the Selling
Stockholders or their pledgees, donees, transferees or other successors-in-interest that receive their shares after the date of this
prospectus of up to the total number of shares of Common Stock, shares of Common Stock issuable upon the conversion of the Series A Preferred
Stock, and shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants sold to the Selling Stockholders pursuant to
the SPA. This prospectus covers the resale or other disposition by the Selling Stockholders or their transferees of up to the total number
of Private Placement Common Shares, Private Placement Preferred Shares and Pre-Funded Warrants issued to the Selling Stockholders upon
conversion of the Private Placement Preferred Shares and exercise of the Pre-Funded Warrants issued pursuant to the SPA. Throughout this
prospectus, when we refer to the "Selling Stockholders," we are referring to the purchasers under the SPA listed in the table
below.
We are registering
the Resale Shares to permit the Selling Stockholders and their pledgees, donees, transferees or other successors-in interest that receive
their shares after the date of this prospectus to resell or otherwise dispose of the shares in the manner contemplated under "Plan
of Distribution" herein.
Except as
otherwise disclosed herein, the Selling Stockholders do not have, and within the past three years have not had, any position, office
or other material relationship with us.
The following
table sets forth the names of the Selling Stockholders, the number of shares of our Common Stock owned by the Selling Stockholders, the
number of shares of our Common Stock that may be offered under this prospectus and the number of shares of our Common Stock that will
be owned after this offering by the Selling Stockholders assuming all of the shares registered for resale hereby are sold.
The Selling
Stockholders may sell some, all or none of their Resale Shares. We do not know how long the Selling Stockholders will hold the Resale
Shares before selling them, and we currently have no agreements, arrangements or understandings with the Selling Stockholders regarding
the sale or other disposition of any of the Resale Shares. The Resale Shares covered hereby may be offered from time to time by the Selling
Stockholders, provided that Resale Shares issued upon conversion of Series A Preferred Stock may only be offered after such shares of
Series A Preferred Stock are converted to Common Stock pursuant to the terms of the Series A Certificate of Designation.
The information
set forth below is based upon information obtained from the Selling Stockholders and upon information in our possession regarding the
issuance of the Private Placement Common Shares, Private Placement Preferred Shares and shares of Common Stock issuable upon the exercise
of the Pre-Funded Warrants in connection with the September 2024 PIPE. The percentages of Common Stock owned after the offering by each
Selling Stockholder below are based on 34,998,550 shares of Common Stock outstanding as of November 1, 2024, and, for each Selling Stockholder,
assumes the conversion of only the Series A Preferred Stock and exercise of only the Pre-Funded Warrants owned by such Selling Stockholder
but not the Series A Preferred Stock or Pre-Funded Warrants owned by any other Selling Stockholder. The numbers of shares of Common Stock
beneficially owned before and after the offering presented in the table below do not give effect to any Beneficial Ownership Limitations
with respect to the Series A Preferred Stock or Pre-Funded Warrants.
102
Name
    of Selling Stockholders(1)
Common
Stock
Beneficially
Owned
Before the
Offering (2)
Common
Stock that
May
Be Offered
Pursuant to
Prospectus
Common
    Stock
Beneficially
Owned After the
Offering (2)
Number
Percentage
(%)
Fidelity
    Securities Fund: Fidelity Small Cap Growth Fund (3)
555,043
179,838
375,205
1.07
%
Fidelity
    Securities Fund: Fidelity Small Cap Growth K6 Fund (3)
225,831
86,378
139,453
*
Fidelity
    Advisor Series VII:  Fidelity Advisor Biotechnology Fund (3)
609,300
197,572
411,728
1.18
%
Fidelity
    Select Portfolios:  Biotechnology Portfolio (3)
704,983
704,883
100
*
Fidelity
    Advisor Series VII:  Fidelity Advisor Health Care Fund (3)
629,688
67,978
561,710
*
Fidelity
    Select Portfolios:  Health Care Portfolio (3)
999,710
110,356
889,354
2.45
%
Variable
    Insurance Products Fund IV: VIP Health Care Portfolio (3)
159,859
25,109
134,750
*
Fidelity
    Mt. Vernon Street Trust: Fidelity Series Growth Company Fund (3)
78,239
78,239
—
—
Fidelity
    Mt. Vernon Street Trust: Fidelity Growth Company Fund (3)
297,445
297,445
—
—
Fidelity
    Growth Company Commingled Pool (3)
400,267
400,267
—
—
Fidelity
    Mt. Vernon Street Trust: Fidelity Growth Company K6 Fund (3)
92,707
92,707
—
—
Fidelity
    Capital Trust: Fidelity Stock Selector Small Cap Fund (3)
283,456
283,456
—
—
Fidelity
    Securities Fund: Fidelity Series Small Cap Opportunities Fund (3)
410,772
410,772
—
—
Braidwell
    Partners Master Fund LP (4)
1,777,426
1,630,000
147,426
*
Entities
    Associated with Venrock Healthcare Capital Partners (5)
3,541,941
650,000
2,891,941
7.50
%
Entities
                                            associated with Fairmount Funds Management LLC (6)
7,941,690
435,000
7,506,690
18.90
%
AI
    Biotechnology LLC (7)
1,791,052
350,000
1,441,052
4.12
%
Entities
    associated with Blackstone Alternative Asset Management Associates LLC (8)
590,174
350,000
240,174
*
Point72
    Associates, LLC (9)
618,671
340,000
278,671
*
Entities
    Associated with Frazier Life Sciences (10)
583,327
326,000
257,327
*
Entities
    Associated with Paradigm BioCapital Advisors LP (11)
819,660
305,000
514,660
1.47
%
Entities
    associated with RTW Investments, LP (12)
2,058,147
285,000
1,773,147
5.07
%
Entities
    Associated with T. Rowe Price Associates, Inc. (13)
1,244,191
215,000
1,029,191
2.94
%
SR
    One Capital Opportunities Fund I, LP (14)
430,330
173,000
257,330
*
Entities
    associated with Janus Henderson Investors US LLC (15)
335,456
150,000
185,456
*
Commodore
    Capital Master LP (16)
1,419,714
150,000
1,269,714
3.62
%
Kalehua
    Capital Partners LP (17)
150,000
150,000
—
—
Avidity
    Private Master Fund I LP (18)
701,363
110,000
591,363
1.69
%
Adage
    Capital Partners LP (19)
200,000
100,000
100,000
*
Affinity
    Healthcare Fund, LP (20)
284,836
45,000
239,836
*
Allostery
    Master Fund, LP (21)
20,000
20,000
—
—
*
Less
                                            than 1%
(1)
To
                                            our knowledge, unless otherwise indicated, all persons named in the table above have sole
                                            voting and investment power with respect to their shares of Common Stock. Unless an address
                                            is provided below, the address for the holder is 855 Oak Grove Ave., Suite 100, Menlo Park,
                                            CA 94025.
103
(2)
"Beneficial
                                                                                                                                                                                                                                                         ownership" is a term broadly defined by the SEC in Rule 13d-3 under the Exchange Act, and includes more than the typical form
                                                                                                                                                                                                                                                         of stock ownership, that is, stock held in the person's name. The term also includes what is referred to as "indirect
                                                                                                                                                                                                                                                         ownership," meaning ownership of shares as to which a person has or shares investment power. Notwithstanding the foregoing,
                                                                                                                                                                                                                                                         the beneficial ownership amounts assume the sale of all Common Stock that may be offered pursuant to this prospectus without taking
                                                                                                                                                                                                                                                         into account certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series
                                                                                                                                                                                                                                                         A Preferred Stock into shares of Common Stock (i) prior to the affirmative vote of the holders of a majority of the then outstanding
                                                                                                                                                                                                                                                         shares of the Series A Preferred Stock, or (ii) if, as a result of such conversion, such holder, together with its affiliates, would
                                                                                                                                                                                                                                                         beneficially own more than a specified percentage (established by the holder not to exceed 19.99%) (the "Beneficial Ownership
                                                                                                                                                                                                                                                         Limitation") of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such
                                                                                                                                                                                                                                                         conversion.
(3)
These
                                            funds and accounts are managed by direct or indirect subsidiaries of FMR LLC.  Abigail
                                            P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC.  Members
                                            of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly
                                            or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting
                                            power of FMR LLC. The Johnson family group and all other Series B shareholders have entered
                                            into a shareholders' voting agreement under which all Series B voting common shares
                                            will be voted in accordance with the majority vote of Series B voting common shares. Accordingly,
                                            through their ownership of voting common shares and the execution of the shareholders'
                                            voting agreement, members of the Johnson family may be deemed, under the Investment Company
                                            Act of 1940, to form a controlling group with respect to FMR LLC.  The address
                                            of these funds and accounts is 245 Summer Street, Boston, MA 02210.
(4)
Shares
                                            listed under "Common Stock Beneficially Owned Before the Offering" consist of
                                            (i) 250,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Braidwell Partners Master Fund LP ("Braidwell Partners"), (ii) 1,147,426
                                            shares of Common Stock held by Braidwell Partners and (iii) 380,000 shares of Common Stock
                                            issuable upon the exercise of the Pre-Funded Warrants held by Braidwell Partners. Braidwell
                                            LP (the "Braidwell Investment Manager") is the investment manager of Braidwell
                                            Partners. Braidwell GP LLC (the "Braidwell GP") is the general partner of Braidwell
                                            Partners. Braidwell Management LLC (the "Braidwell IM GP") is the general partner
                                            of the Braidwell Investment Manager and the managing member of the Braidwell GP. Messrs.
                                            Alexander T. Karnal and Brian J. Kreiter (together with Braidwell Partners, the Braidwell
                                            Investment Manager, the Braidwell GP and the Braidwell IM GP, the "Braidwell Parties")
                                            together own, directly or indirectly, the Braidwell Investment Manager, the Braidwell GP
                                            and the Braidwell IM GP. The address of Braidwell Partners is c/o Maples Corporate Services
                                            Limited, P.O Box 309, Ugland House, Grand Cayman, KY1-1104 Cayman Islands. The principal
                                            address of the Braidwell Investment Manager, the Braidwell GP and the Co-Founders is One
                                            Harbor Point, 2200 Atlantic Street, 4th Floor, Stamford, Connecticut 06902. The Braidwell
                                            Parties may be deemed to have shared voting and dispositive power with respect to the shares
                                            of Common Stock held by Braidwell Partners. Each of the Braidwell Parties disclaims beneficial
                                            ownership of such shares except to the extent of any pecuniary interest therein.
104
(5)
Shares
                                            listed under "Common Stock Beneficially Owned Before the Offering" consists of
                                            (i) 2,350,074 shares of common stock and 351,506 shares of common stock issuable upon the
                                            exercise of pre-funded warrants held by Venrock Healthcare Capital Partners EG, L.P. ("VHCPEG"),
                                            (ii) 668,656 shares of common stock and 95,284 shares of common stock issuable upon the exercise
                                            of pre-funded warrants held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"),
                                            and (iii) 66,890 shares of common stock and 9,531 shares of common stock issuable upon the
                                            exercise of pre-funded warrants held by VHCP Co-Investment Holdings III, LLC ("VHCPCo3").
                                            Excludes (i) 54,474, 12,504 and 1,244 shares of common stock issuable upon the exercise of
                                            the pre-funded warrants held by VHCPEG, VHCP3 and VHCPCo3, respectively, and (ii) 157,000,
                                            39,000 and 4,000 shares of common stock issuable upon the conversion of Series A Preferred
                                            Stock held by VHCPEG, VHCP3 and VHCPCo3, respectively. The pre-funded warrants and Series
                                            A Preferred Stock are subject to a beneficial ownership limitation of 9.99%, which such limitations
                                            restrict Venrock Healthcare Capital Partners and its affiliates from exercising that portion
                                            of the warrants or Series A Preferred Stock that would result in Venrock Healthcare Capital
                                            Partners and its affiliates owning, after exercise, a number of shares of common stock in
                                            excess of the applicable ownership limitation. VHCP Management III, LLC ("VHCPM3")
                                            is the sole general partner of VHCP3 and the sole manager of VHCPCo3. VHCP Management EG,
                                            LLC ("VHCPM EG") is the sole general partner of VHCPEG. As voting members of
                                            VHCPM3 and VHCPM EG, Dr. Bong Koh and Nimish Shah may be deemed beneficial owners of any
                                            securities beneficially owned by VHCPM3 and VHCPM EG. The principal business address of each
                                            of these persons and entities is 7 Bryant Park, 23rd Floor, New York, NY 10018.
(6)
Shares
                                            listed under "Common Stock Beneficially Owned Before the Offering" consists of
                                            (i) (A) 638,614 shares of common stock, (B) 316,025 shares of common stock issuable upon
                                            the exercise of pre-funded warrants and (C) 4,413,743 shares of common stock issuable upon
                                            conversion of 52,965 shares of Series B Preferred Stock held by Fairmount Healthcare Fund
                                            II L.P. ("Fairmount Fund II") and (ii) 2,573,308 shares of common stock held
                                            by Fairmount Healthcare Co-Invest III L.P. ("Fairmount Fund III"). Excludes (i)
                                            4,981,639 shares of common stock issuable upon the exercise of the pre-funded warrants, (ii)
                                            7,014,406 shares of common stock issuable upon the conversion of 84,173 shares of Series
                                            B Preferred Stock and (iii) 160,000 shares of common stock issuable upon the conversion of
                                            160 shares of Series A Preferred Stock owned by Fairmount Fund II. The pre-funded warrants
                                            and Series A Preferred Stock are subject to a beneficial ownership limitation of 9.99% and
                                            the shares of Series B Preferred Stock are subject to a beneficial ownership limitation of
                                            19.99%, which such limitations restrict Fairmount Funds Management LLC ("Fairmount")
                                            and its affiliates from exercising that portion of the warrants and converting those shares
                                            of preferred stock that would result in Fairmount and its affiliates owning, after exercise
                                            or conversion, a number of shares of common stock in excess of the applicable ownership limitation.
                                            At such time as Fairmount and its affiliates beneficially own 9.0% or less of the shares
                                            of common stock, the beneficial ownership limitation applicable to the shares of Series B
                                            Preferred Stock will automatically reduce to 9.99%. Fairmount serves as investment manager
                                            for Fairmount Fund II and Fairmount Fund III. Fairmount Fund II and Fairmount Fund III have
                                            delegated to Fairmount the sole power to vote and the sole power to dispose of all securities
                                            held in Fairmount Fund II and Fairmount Fund III's portfolios. Because Fairmount Fund
                                            II and Fairmount Fund III have divested themselves of voting and investment power over the
                                            securities they hold and may not revoke that delegation on less than 61 days' notice,
                                            Fairmount Fund II and Fairmount Fund III disclaim beneficial ownership of the securities
                                            they hold. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount
                                            GP"). As managing members of Fairmount GP, Peter Harwin and Tomas Kiselak may be deemed
                                            to have voting and investment power over the shares held by Fairmount Fund II and Fairmount
                                            Fund III. Fairmount, Fairmount GP, Peter Harwin and Tomas Kiselak disclaim beneficial ownership
                                            of such shares, except to the extent of any pecuniary interest therein. The address of the
                                            entities and individuals listed is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA
                                            19428.
105
(7)
Shares
                                            listed under "Common Stock Beneficially Owned Before the Offering" consist of
                                            (i) 1,441,052 shares of Common Stock purchased pursuant to a Subscription Agreement, dated
                                            August 3, 2024, among the Company and the purchasers thereto (including AI Biotechnology
                                            LLC) (ii) 125,000 shares of Common Stock issuable upon the conversion of Series A Preferred
                                            Stock held by AI Biotechnology LLC and (ii) 225,000 shares of Common Stock held by AI Biotechnology
                                            LLC. Access Industries Holdings LLC, or AIH, directly controls all of the outstanding voting
                                            interest in AI Biotechnology LLC. Access Industries Management, LLC, or AIM, controls AIH.
                                            Len Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH.
                                            Each of Len Blavatnik, AIM and AIH may be deemed to have voting and investment power over
                                            the shares held by AI Biotechnology LLC and disclaims beneficial ownership of such shares.
                                            The address of each of AI Biotechnology LLC, AIM, AIH and Len Blavatnik is c/o Access Industries,
                                            Inc., 40 West 57th Street, 28th Floor, New York, NY 10019.
(8)
Shares
                                            listed under "Common Stock Beneficially Owned Before the Offering" consist of
                                            (i) 72,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Spruce Street Aggregator L.P. ("Spruce Street Fund"), (ii) 130,078 shares
                                            of Common Stock held by Spruce Street Fund, (iii) 53,000 shares of Common Stock issuable
                                            upon the conversion of Series A Preferred Stock held by Blackstone Annex Master Fund L.P.
                                            ("Annex Fund"), and (iv) 335,096 shares of Common Stock held by Annex Fund. Blackstone
                                            Alternative Asset Management Associates LLC is the general partner of Annex Fund and Spruce
                                            Street Fund. Blackstone Holdings II L.P. is the sole member of Blackstone Alternative Asset
                                            Management Associates LLC. Blackstone Holdings I/II GP L.L.C. is the general partner of Blackstone
                                            Holdings II L.P. Blackstone Inc. is the sole member of Blackstone Holdings I/II GP L.L.C.
                                            Blackstone Group Management L.L.C. is the sole holder of the Series II preferred stock of
                                            Blackstone Inc. Blackstone Group Management L.L.C. is wholly owned by its senior managing
                                            directors and controlled by its founder, Stephen A. Schwarzman. Each of such Blackstone entities
                                            and Mr. Schwarzman may be deemed to beneficially own the securities beneficially owned by
                                            the Annex Fund and the Aggregator Fund directly or indirectly controlled by it or him, but
                                            each (other than each of the Annex Fund and the Aggregator Fund to the extent of their respective
                                            direct holdings) disclaims beneficial ownership of such securities. The address of each of
                                            the entities listed is c/o Blackstone Inc., 345 Park Avenue, New York, New York 10154.
(9)
Shares
                                            listed under "Common Stock Beneficially Owned Before the Offering" consist of
                                            (i) 115,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Point72 Associates, LLC ("Point72 Associates") and (ii) 503,671 shares
                                            of Common Stock held by Point72 Associates. Pursuant to an investment management agreement,
                                            Point72 Asset Management, L.P. maintains investment and voting power with respect to the
                                            securities held by certain investment funds it manages, including Point72 Associates. Point72
                                            Capital Advisors, Inc. is the general partner of Point72 Asset Management, L.P. Mr. Steven
                                            A. Cohen controls each of Point72 Asset Management, L.P. and Point72 Capital Advisors, Inc.
                                            By reason of the provisions of Rule 13d-3 of the Exchange Act, each of Point72 Asset Management,
                                            L.P., Point72 Capital Advisors, Inc., and Mr. Cohen may be deemed to beneficially own the
                                            securities held by Point72 Associates reflected herein. Each of Point72 Asset Management,
                                            L.P., Point72 Capital Advisors, Inc., and Mr. Cohen disclaims beneficial ownership of any
                                            such securities. The address for Point72 Associates is c/o Point72 Asset Management, L.P.,
                                            72 Cummings Point Road, Stamford, CT 06902.
106
(10)
Shares
                                            listed under "Common Stock Beneficially Owned Before the Offering" consist of
                                            (i) 1,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Frazier Life Sciences X, L.P. ("FLS X"), (ii) 23,785 shares of Common
                                            Stock held by FLS X, (iii) 1,000 shares of Common Stock issuable upon the conversion of Series
                                            A Preferred Stock held by Frazier Life Sciences XI, L.P. ("FLS XI"), (iv) 40,967
                                            shares of Common Stock held by FLS XI, (v) 81,000 shares of Common Stock issuable upon the
                                            conversion of Series A Preferred Stock held Frazier Life Sciences Public Fund, L.P. ("FLS
                                            Public Fund"), (vi) 297,560 shares of Common Stock held by FLS Public Fund, (vii) 23,000
                                            shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by Frazier
                                            Life Sciences Public Overage Fund, L.P. ("FLS Overage Fund") and (viii) 115,015
                                            shares of Common Stock held by FLS Overage Fund. FHMLSP, L.P. is the general partner of FLS
                                            Public Fund and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Albert Cha, James N.
                                            Topper, Patrick J. Heron and James Brush are the managing directors of FHMLSP, L.L.C. and
                                            therefore share voting and investment power over the shares held by FLS Public Fund. Dr.
                                            Cha, Dr. Topper, Mr. Heron and Dr. Brush disclaim beneficial ownership of the shares held
                                            by FLS Public Fund except to the extent of their pecuniary interests in such shares, if any.
                                            FHMLSP Overage, L.P., is the general partner of FLS Overage Fund and FHMLSP Overage, L.L.C.
                                            is the general partner of FHMLSP Overage, L.P. Dr. Cha, Dr. Topper, Mr. Heron and Dr. Brush
                                            are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power
                                            over the shares held by FLS Overage Fund. Dr. Cha, Dr. Topper, Mr. Heron and Dr. Brush disclaim
                                            beneficial ownership of the shares held by FLS Overage Fund except to the extent of their
                                            pecuniary interests in such shares, if any. FHMLS X, L.P. is the general partner of FLS X,
                                            and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Mr. Heron and Dr. Topper are
                                            the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares
                                            held by FLS X. Dr. Topper and Mr. Heron disclaim beneficial ownership of the shares held
                                            by FLS X except to the extent of their pecuniary interests in such shares, if any. FHMLS
                                            XI, L.P. is the general partner of FLS XI, and FHMLS XI, L.L.C. is the general partner of
                                            FHMLS XI, L.P. Mr. Heron, Dr. Topper and Daniel Estes are the members of FHMLS XI, L.L.C.
                                            and therefore share voting and investment power over the shares held by FLS XI. Dr. Topper,
                                            Mr. Heron and Mr. Estes disclaim beneficial ownership of the shares held by FLS XI except
                                            to the extent of their pecuniary interests in such shares, if any. The principal business
                                            address of the above referenced entities and persons is 1001 Page Mill Rd., Building 4, Ste.
                                            B, Palo Alto, CA 94304.
(11)
Shares
                                            listed under "Common Stock Beneficially Owned Before the Offering" consist of
                                            (i) 86,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Paradigm BioCapital International Fund Ltd. ("Paradigm Fund"), (ii) 617,323
                                            shares of Common Stock held by Paradigm Fund, (iii) 14,000 shares of Common Stock issuable
                                            upon the conversion of Series A Preferred Stock held by Paradigm BioCapital Advisors LP ("Paradigm
                                            Advisor"), as discretionary investment manager on behalf of a separate account client
                                            solely with respect to the assets for which Paradigm Advisor acts as its investment manager
                                            (the "Separate Account"), and (iv) 102,337 shares of Common Stock held by Paradigm
                                            Advisor, as discretionary investment manager on behalf of the Separate Account. The shares
                                            of Common Stock may be deemed to be indirectly beneficially owned by each of Paradigm Advisor,
                                            Paradigm BioCapital Advisors GP LLC ("Paradigm Advisor GP"), and Senai Asefaw,
                                            M.D. Paradigm Advisor GP is the general partner of Paradigm Advisor, and Senai Asefaw, M.D.
                                            is the managing member of Paradigm Advisor GP. Paradigm Advisor is the investment manager
                                            of Paradigm Fund. Paradigm Advisor, Paradigm Advisor GP, and Senai Asefaw, M.D. may be deemed
                                            to have full investment and voting discretion over the shares of Common Stock held by Paradigm
                                            Fund and the Separate Account. The business address for each person and entity named in this
                                            footnote is 767 Third Avenue, 17th Floor, New York, NY 10017.
107
(12)
Shares
                                            listed under "Common Stock Beneficially Owned Before the Offering" consist of
                                            (i) 95,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock  and
                                            (ii) 1,963,147 shares of Common Stock, in each case of (i) and (ii) as held in the aggregate
                                            by RTW Master Fund, Ltd. RTW Innovation Master Fund, Ltd., and RTW Biotech Opportunities
                                            Operating Ltd, (collectively, the "RTW Funds"). RTW Investments, LP ("RTW"),
                                            in its capacity as the investment manager of the RTW Funds, has the power to vote and the
                                            power to direct the disposition of the shares held by the RTW Funds. Accordingly, RTW may
                                            be deemed to be the beneficial owner of such securities. Roderick Wong, M.D., as the Managing
                                            Partner of RTW, has the power to direct the vote and disposition of the securities held by
                                            RTW. Dr. Wong disclaims beneficial ownership of the shares held by the RTW Funds, except
                                            to the extent of his pecuniary interest therein. The address and principal office of RTW
                                            Investments, LP is 40 10th Avenue, Floor 7, New York, NY 10014, and the address of Dr. Wong
                                            and each of the RTW Funds is c/o RTW Investments, LP, 40 10th Avenue, Floor 7, New York,
                                            NY 10014.  The shares of Common Stock issuable upon conversion of the shares of
                                            Series A Preferred Stock held by the RTW Funds are subject to a Beneficial Ownership Limitation
                                            of 9.99%.
(13)
Shares
                                            listed under "Common Stock Beneficially Owned Before the Offering" consist of
                                            (i) 62,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by T. Rowe Price Health Sciences Fund, Inc., (ii) 1,125,095 shares of Common Stock held
                                            by T. Rowe Price Health Sciences Fund, Inc., (iii) 3,000 shares of Common Stock issuable
                                            upon the conversion of Series A Preferred Stock held by T. Rowe Price Health Sciences Portfolio,
                                            and (iv) 54,096 shares of Common Stock held by T. Rowe Price Health Sciences Portfolio. T.
                                            Rowe Price Associates, Inc. ("TRPA"), as investment adviser, has dispositive
                                            and voting power with respect to the shares held by these funds and accounts. For purposes
                                            of the Securities Exchange Act of 1934, TRPA may be deemed to be the beneficial owner of
                                            these aforementioned shares; however, TRPA expressly disclaims that it is, in fact, the beneficial
                                            owner of such securities. TRPA is a wholly owned subsidiary of T. Rowe Price Group, Inc.,
                                            which is a publicly traded financial services holding company. The principal business address
                                            of TRPA is 100 East Pratt Street, Baltimore, MD 21202.
(14)
Shares
                                            listed under "Common Stock Beneficially Owned Before the Offering" consist of
                                            (i) 55,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by SR One Capital Opportunities Fund I, LP ("Opportunities Fund") and (ii)
                                            375,330 shares of Common Stock held by Opportunities Fund. SR One Capital Opportunities Partners
                                            I, LP ("SR One Partners") is the general partner of Opportunities Fund. SR One
                                            Capital Management, LLC ("SR One Management") is the general partner of SR One
                                            Partners. Simeon George, M.D. is the manager of SR One Management. SR One Partners, SR One
                                            Management, and Simeon George share voting and investment power with respect to the shares
                                            directly held by Opportunities Fund. All indirect holders of the above referenced shares
                                            disclaim beneficial ownership of all applicable shares except to the extent of their pecuniary
                                            interest therein. The address of these persons and funds is 985 Old Eagle School Road, Suite
                                            511, Wayne, Pennsylvania 19087.
(15)
Shares
                                            listed under "Common Stock Beneficially Owned Before the Offering" consist of
                                            (i) 30,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Janus Henderson Biotech Innovation Master Fund Limited, (ii) 258,149 shares of Common
                                            Stock held by Janus Henderson Biotech Innovation Master Fund Limited, (iii) 20,000 shares
                                            of Common Stock issuable upon the conversion of Series A Preferred Stock held by Janus Henderson
                                            Biotech Innovation Master Fund II Limited, and (iv) 27,307 shares of Common Stock held by
                                            Janus Henderson Biotech Innovation Master Fund II Limited. Such shares may be deemed to be
                                            beneficially owned by Janus Henderson Investors US LLC ("Janus"), an investment
                                            adviser registered under the Investment Advisers Act of 1940, who acts as investment adviser
                                            for Janus Henderson Biotech Innovation Master Fund Limited and Janus Henderson Biotech Innovation
                                            Master Fund II Limited (the "Janus Funds") and has the ability to make decisions
                                            with respect to the voting and deposition of the shares subject to the oversight of the board
                                            of directors of the Janus Funds. Under the terms of its management contract with the Janus
                                            Funds, Janus has overall responsibility for directing the investments of the Janus Funds
                                            in accordance with the Janus Funds' investment objective, policies and limitations.
                                            The Janus Funds have one or more portfolio managers appointed by and serving at the pleasure
                                            of Janus who make decisions with respect to the disposition of the shares of common stock
                                            offered hereby. The address for Janus is 151 Detroit Street, Denver, CO 80206.  The
                                            portfolio managers for the Janus Fund are Andrew Acker, Daniel S. Lyons and Agustin Mohedas.
108
(16)
Shares
                                            listed under "Common Stock Beneficially Owned Before the Offering" consist of
                                            (i) 50,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Commodore Capital Master LP and (ii) 1,369,714 shares of Common Stock held by Commodore
                                            Capital Master LP. Commodore Capital LP is the investment manager to Commodore Capital Master
                                            LP and may be deemed to beneficially own the shares held by Commodore Capital Master LP.
                                            Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital LP
                                            and exercise investment discretion with respect to these shares. Commodore Capital LP and
                                            Commodore Capital Master LP have shared voting and dispositive power with respect to these
                                            shares. The address of Commodore Capital LP and Commodore Capital Master LP is 444 Madison
                                            Avenue, 35th Floor, New York, NY 10022.
(17)
Shares
                                            listed under "Common Stock Beneficially Owned Before the Offering" consist of
                                            (i) 50,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Kalehua Capital Partners LP and (ii) 100,000 shares of Common Stock held by Kalehua
                                            Capital Partners LP. Kalehua Capital Partners LP is a buyout fund managed by Kalehua Capital
                                            Management LLC. Tai-Li Chang is the sole member of Kalehua Capital Management LLC. The address
                                            of these persons and funds is 3819 Maple Avenue, Dallas, Texas 75219.
(18)
Shares
                                            listed under "Common Stock Beneficially Owned Before the Offering" consist of
                                             (i) 20,000 shares of Common Stock issuable upon the conversion of Series A Preferred
                                            Stock held by Avidity Private Master Fund I LP and (ii) 681,363 shares of Common Stock held
                                            by Avidity Private Master Fund I LP, which is a Cayman exempted limited partnership. The
                                            general partner of Avidity Private Master Fund I LP is Avidity Capital Partners Fund (GP)
                                            LP, a Delaware limited partnership, whose general partner is Avidity Capital Partners (GP)
                                            LLC, a Delaware limited liability company. Avidity Partners Management LP is the investment
                                            manager of Avidity Private Master Fund I LP. Avidity Partners Management (GP) LLC is the
                                            general partner of Avidity Partners Management LP. David Witzke and Michael Gregory are the
                                            managing members of Avidity Capital Partners (GP) LLC and Avidity Partners Management (GP)
                                            LLC. Each of the entities and individuals referenced in this paragraph may be deemed to beneficially
                                            own the shares held by the Avidity entities. Certain affiliates of the Avidity entities,
                                            which are not selling stockholders, may also own shares. The address of Avidity Private Master
                                            Fund I LP is 2828 N. Harwood Street, Suite 1220, Dallas, Texas 75201.
(19)
Shares
                                            listed under "Common Stock Beneficially Owned Before the Offering" consist of
                                             (i) 25,000 shares of Common Stock issuable upon the conversion of Series A Preferred
                                            Stock held by Adage Capital Partners LP ("Adage") and (ii) 175,000 shares of
                                            Common Stock held by Adage. Bob Atchinson and Phillip Gross are the managing members of Adage
                                            Capital Advisors, L.L.C., which is the managing member of Adage Capital Partners GP, L.L.C.,
                                            which is the general partner of Adage, and each such person or entity, as the case may be,
                                            has shared voting and/or investment power over the securities held by Adage Capital Partners,
                                            LP and may be deemed the beneficial owner of such shares, and each such person or entity,
                                            as the case may be, disclaims beneficial ownership of such securities except to the extent
                                            of their respective pecuniary interest therein. The address of these funds and persons is
                                            200 Clarendon St., 52
nd
Floor, Boston, MA 02116.
(20)
Shares
                                            listed under "Common Stock Beneficially Owned Before the Offering" consist of
                                            (i) 10,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Affinity Healthcare Fund, LP ("Affinity Fund") and (ii) 274,836 shares
                                            of Common Stock held by Affinity Fund. Affinity Asset Advisors, LLC (the "Advisor")
                                            is the investment manager of Affinity Healthcare Fund, LP (the "Fund") and exercises
                                            investment discretion with regard to the shares of Common Stock owned by the Fund. The Fund
                                            and the Advisor have the shared power to vote or to direct the vote and to dispose or direct
                                            the disposition of such shares of Common Stock of the Issuer owned by the Fund.  The
                                            Advisor may be deemed to be the beneficial owner of such shares of Common Stock of the Issuer
                                            owned by the Fund by virtue of its position as investment manager of the Fund. The principal
                                            business address of each of the Fund and the Advisor is 767 Third Avenue, 15th Floor, New
                                            York, NY 10017.
109
(21)
Shares
                                            listed under "Common Stock Beneficially Owned Before the Offering" consist of
                                            (i) 8,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Allostery Master Fund, LP ("Allostry Master Fund") and (ii) 12,000 shares
                                            of Common Stock held by Allostry Master Fund. Allostery Funds GP LLC ("Allostery Funds
                                            GP") may be deemed the beneficial owner of the shares held by Allostery Master Fund
                                            because it is the general partner of Allostery Master Fund. Allostery Investments LP ("Allostery
                                            Investments") may be deemed the beneficial owner of the shares held by Allostery Master
                                            Fund because it is the investment manager of Allostery Master Fund. Allostery Investments
                                            GP LLC (the "Investments GP") may be deemed the beneficial owner of the shares
                                            beneficially held by Allostery Investments because it is the general partner of Allostery
                                            Investments. Christopher Staral and David Modest may be deemed the beneficial owners of the
                                            shares beneficially held by each of Investments GP and Allostery Funds GP by virtue of their
                                            positions as managing members of Investments GP and Allostery Funds GP. The address of Allostery
                                            Master Fund is c/o Maples Corporate Services Limited, Ugland House, South Church Street,
                                            Grand Cayman KY1-1104, Cayman Islands.
Relationship
with the Selling Stockholders
In addition
to the SPA, in connection with the Private Placement, we entered into the RRA (as defined below) on September 13, 2024 with the Selling
Stockholders. Certain of the September 2024 investors were, immediately prior to the closing of the September 2024 PIPE, or became holders
of more than 5% of our Common Stock and were parties to the Pre-Closing Financing. See "
Security Ownership of Certain Beneficial
Owners and Management and Related Stockholder Matters.
"
Registration
Rights Agreement
On September
13, 2024, we entered into a registration rights agreement (the "RRA") with the Private Placement investors. Pursuant to the
RRA, we agreed to file a resale registration statement to register the Registrable Securities (as defined in the RRA) (the "Registration
Statement"). This registration statement is being filed to satisfy our obligations under the RRA. We have agreed to use our commercially
reasonable efforts to cause this Registration Statement to be declared effective by the SEC as soon as practicable.
We have also
agreed, among other things, to indemnify the Selling Stockholders and each of their respective officers, directors, members, employees,
partners, managers, stockholders, affiliates, investment advisors and agents, each person who controls any such Selling Stockholder and
the officers, directors, members, employees, partners, managers, stockholders, affiliates, investment advisors and agents of each such
controlling person from certain liabilities and pay all fees and expenses (excluding any legal fees of the selling holder(s), and any
underwriting discounts and selling commissions) incident to our obligations under the RRA.
110
PLAN
OF DISTRIBUTION
We are registering
the Resale Shares issued to the Selling Stockholders to permit the sale, transfer or other disposition of these shares by the Selling
Stockholders or their donees, pledgees, transferees or other successors-in-interest from time to time after the date of this prospectus.
We will not receive any of the proceeds from the sale by the Selling Stockholders of the Resale Shares. We will, or will procure to,
bear all fees and expenses incident to our obligation to register the Resale Shares.
The Selling
Stockholders may sell all or a portion of the Resale Shares beneficially owned by them and offered hereby from time to time, and in the
case of the Private Placement Conversion Shares, may only be offered after such shares are converted to Common Stock pursuant to the
terms of the Series A Certificate of Designation, directly or through one or more underwriters, broker-dealers or agents. If the Resale
Shares are sold through underwriters or broker-dealers, the Selling Stockholders will be responsible for underwriting discounts (it being
understood that the Selling Stockholders shall not be deemed to be underwriters solely as a result of their participation in this offering)
or commissions or agent's commissions. The Resale Shares may be sold on any national securities exchange or quotation service on
which the securities may be listed or quoted at the time of sale, in the over-the-counter market or in transactions otherwise than on
these exchanges or systems or in the over-the-counter market and in one or more transactions at fixed prices, at prevailing market prices
at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions,
which may involve crosses or block transactions. The Selling Stockholders may use any one or more of the following methods when selling
Resale Shares:
●
ordinary
brokerage transactions and transactions in which the broker-dealer solicits purchasers;
●
block
trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal
to facilitate the transaction;
●
to
or through underwriters or purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
●
an
exchange distribution in accordance with the rules of the applicable exchange;
●
privately
negotiated transactions;
●
settlement
of short sales entered into after the effective date of the registration statement of which this prospectus is a part;
●
broker-dealers
may agree with the Selling Stockholders to sell a specified number of such shares at a stipulated price per share;
●
through
the writing or settlement of options or other hedging transactions, whether such options are listed on an options exchange or otherwise;
●
a
combination of any such methods of sale; and
●
any
other method permitted pursuant to applicable law.
The Selling
Stockholders also may resell all or a portion of the Resale Shares in open market transactions in reliance upon Rule 144, as permitted
by that rule, or Section 4(a)(1) under the Securities Act, if available, rather than under this prospectus, provided that they meet the
criteria and conform to the requirements of those provisions. The Selling Stockholders also may dispose of the Resales Shares through
distributions to members, partners, stockholders or other equityholders of the Selling Stockholders.
Broker-dealers
engaged by the Selling Stockholders may arrange for other broker-dealers to participate in sales. If the Selling Stockholders effect
such transactions by selling Resale Shares to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or
agents may receive commissions in the form of discounts, concessions or commissions from the Selling Stockholders or commissions from
purchasers of the Resale Shares for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts
to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction will not be in excess
of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown
in compliance with FINRA IM-2121.01.
In connection
with sales of the Resale Shares or otherwise, the Selling Stockholders may enter into hedging transactions with broker-dealers or other
financial institutions, which may in turn engage in short sales of the Resale Shares in the course of hedging in positions they assume.
The Selling Stockholders may also sell Resale Shares short and if such short sale takes place after the date that this registration statement
is declared effective by the SEC, the Selling Stockholders may deliver Resale Shares covered by this prospectus to close out short positions
and to return borrowed Resale Shares in connection with such short sales. The Selling Stockholders may also loan or pledge Resale Shares
to broker-dealers that in turn may sell such shares, to the extent permitted by applicable law. The Selling Stockholders may also enter
into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities
which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such
broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
Notwithstanding the foregoing, the Selling Stockholders have been advised that they may not use Resale Shares the resale of which has
been registered on this registration statement to cover short sales of our Common Stock made prior to the date the registration statement,
of which this prospectus forms a part, has been declared effective by the SEC.
111
The Selling
Stockholders may, from time to time, pledge or grant a security interest in some or all of the Resale Shares owned by them and, if they
default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the Resale Shares from time
to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities
Act, amending, if necessary, the list of Selling Stockholders to include the pledgee, transferee or other successors in interest as Selling
Stockholders under this prospectus. The Selling Stockholders also may transfer and donate the Resale Shares in other circumstances in
which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this
prospectus.
The Selling
Stockholders and any broker-dealer or agents participating in the distribution of the Resale Shares may be deemed to be "underwriters"
within the meaning of Section 2(11) of the Securities Act in connection with such sales. In such event, any commissions paid, or any
discounts or concessions allowed to, any such broker-dealer or agent and any profit on the resale of the shares purchased by them may
be deemed to be underwriting commissions or discounts under the Securities Act. Selling Stockholders who are "underwriters"
within the meaning of Section 2(11) of the Securities Act will be subject to the applicable prospectus delivery requirements of the Securities
Act including Rule 172 thereunder and may be subject to certain statutory liabilities of, including but not limited to, Sections 11,
12 and 17 of the Securities Act and Rule 10b-5 under the Exchange Act.
Each Selling
Stockholder has informed us that it is not a registered broker-dealer and does not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the Resale Shares. Upon us being notified in writing by a Selling Stockholder that
any material arrangement has been entered into with a broker-dealer for the sale of Common Stock through a block trade, special offering,
exchange distribution or secondary distribution or a purchase by a broker or dealer, a supplement to this prospectus will be filed, if
required, pursuant to Rule 424(b) under the Securities Act, disclosing (i) the name of each such Selling Stockholder and of the participating
broker-dealer(s), (ii) the number of Resale Shares involved, (iii) the price at which such the Resale Shares were sold, (iv) the commissions
paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not conduct any
investigation to verify the information set out in this prospectus, and (vi) other facts material to the transaction.
Under the
securities laws of some U.S. states, the Resale Shares may be sold in such states only through registered or licensed brokers or dealers.
In addition, in some U.S. states the Resale Shares may not be sold unless such shares have been registered or qualified for sale in such
state or an exemption from registration or qualification is available and is complied with.
There can
be no assurance that any Selling Stockholder will sell any or all of the Resale Shares registered pursuant to the shelf registration
statement, of which this prospectus forms a part.
Each Selling
Stockholder and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act and
the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which
may limit the timing of purchases and sales of any of the Resale Shares by the Selling Stockholder and any other participating person.
To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the Resale Shares to
engage in market-making activities with respect to the Resale Shares. All of the foregoing may affect the marketability of the Resale
Shares and the ability of any person or entity to engage in market-making activities with respect to the Resale Shares.
We will pay
all expenses of the registration of the Resale Shares pursuant to the September 2024 RRA, including, without limitation, SEC filing fees
and expenses of compliance with state securities or "blue sky" laws; provided, however, that each Selling Stockholder will
pay all underwriting discounts and selling commissions, if any and any related legal expenses incurred by it. We will indemnify the Selling
Stockholders against certain liabilities, including some liabilities under the Securities Act, in accordance with the September 2024
RRA, or the Selling Stockholders will be entitled to contribution. We may be indemnified by the Selling Stockholders against certain
civil liabilities set forth in the September 2024 RRA, including liabilities under the Securities Act, that may arise from any written
information furnished to us by the Selling Stockholders specifically for use in this prospectus, in accordance with the related registration
rights agreements, or we may be entitled to contribution.
112
DESCRIPTION
OF CAPITAL STOCK
General
The following
description summarizes the material terms of our capital stock, as well as other material terms of our amended and restated certificate
of incorporation ("Certificate of Incorporation") and amended and restated bylaws ("Bylaws") and certain provisions
of Delaware law. This summary does not purport to be complete and is qualified in its entirety by the provisions of our Certificate of
Incorporation and Bylaws, copies of which are filed as exhibits to our Current Report on Form 8-K filed on September 5, 2024.
Our authorized
capital stock consists of 545,000,000 shares of Common Stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001
par value per share ("Preferred Stock"), of which 2,439 shares have been designated as Series A Preferred Stock, $0.001 par
value per share, and 251,504 shares have been designated as Series B Preferred Stock, $0.001 par value per share.
As of November
1, 2024, there were 34,998,550 shares of our Common Stock, 2,439 shares of Series A Preferred Stock and 137,138 shares of Series B Preferred
Stock outstanding.
Common
Stock
Our Certificate
of Incorporation authorizes the issuance of up to 545,000,000 shares of Common Stock. All outstanding shares of Common Stock are validly
issued, fully paid and nonassessable.
Dividend
rights
Subject to
preferences that may apply to any shares of Preferred Stock outstanding at the time, the holders of our Common Stock are entitled to
receive dividends out of funds legally available if our Board, in its discretion, determines to issue dividends and then only at the
times and in the amounts that our Board may determine.
Voting
rights
Pursuant
to our Bylaws, holders of our Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders.
We have not provided for cumulative voting for the election of directors in our Certificate of Incorporation. Accordingly, pursuant to
our Certificate of Incorporation, holders of a majority of the shares of our Common Stock are able to elect all of our directors. Our
Certificate of Incorporation establishes a classified Board, divided into three classes with staggered three-year terms. Only one class
of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their
respective three-year terms.
No preemptive
or similar rights
Our Common
Stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions.
Right
to receive liquidation distributions
Upon our
liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably
among the holders of our Common Stock and any participating Preferred Stock outstanding at that time, subject to prior satisfaction of
all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding
shares of Preferred Stock.
Preferred
Stock
Under the
terms of our Certificate of Incorporation, our Board is authorized, subject to limitations prescribed by Delaware law, to issue up to
5,000,000 shares of Preferred Stock in one or more series, to establish from time to time the number of shares to be included in each
series and to fix the designation, powers, preferences and rights of the shares of each series and any of their qualifications, limitations
or restrictions, in each case without further vote or action by our stockholders. Subject to any certificates of designation, the Board
can also increase or decrease the number of shares of any series of Preferred Stock, but not below the number of shares of that series
then outstanding, without any further vote or action by our stockholders. Our Board may authorize the issuance of Preferred Stock with
voting or conversion rights that could adversely affect the voting power or other rights of the holders of our Common Stock. The issuance
of Preferred Stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other
things, have the effect of delaying, deferring or preventing a change in control of our company and might adversely affect the market
price of our Common Stock and the voting and other rights of the holders of our Common Stock. We issued shares of our Series A Preferred
Stock and shares of our Series B Preferred Stock in connection with the Private Placement and the Merger, respectively, and have no current
plan to issue any additional shares of Preferred Stock.
113
Series
A Preferred Stock
Holders of
Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal to, on an as-if-converted-to-common-stock
basis, and in the same form as dividends actually paid on shares of our Common Stock. Except as provided in the Series A Certificate
of Designation or as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares
of Series A Preferred Stock are outstanding, we will not, without the affirmative vote of the holders of a majority of the then outstanding
shares of the Series A Preferred Stock: (i) alter or change adversely the powers, preferences or rights given to the Series A Preferred
Stock, (ii) alter or amend the Series A Certificate of Designation, or (iii) amend or repeal any provision of, or add any provision to,
our Certificate of Incorporation or its Bylaws in any manner that adversely affects any rights of the holders of Series A Preferred Stock,
or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred
Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for
the benefit of the Series A Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the
Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise. The Series A Preferred
Stock shall rank on parity with the Common Stock and Series B Preferred Stock upon any liquidation, dissolution or winding-up of the
Company.
Series
B Preferred Stock
Certain holders
of our Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal to, on an as-if-converted-to-common-stock
basis, and in the same form as dividends actually paid on shares of our Common Stock. Except as provided in the Series B Certificate
of Designation or as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares
of Series B Preferred Stock are outstanding, we will not, without the affirmative vote of the holders of a majority of the then outstanding
shares of the Series B Preferred Stock: (a) (i) alter or change adversely the powers, preferences or rights given to the Series B Preferred
Stock, (ii) alter or amend the Series B Certificate of Designation, or (iii) amend or repeal any provision of, or add any provision to,
our Certificate of Incorporation or Bylaws in a manner that adversely affects any rights of the holders of the Series B Preferred Stock,
or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred
Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for
the benefit of the Series B Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the
Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (b) issue further
shares of Series B Preferred Stock beyond those contemplated for issuance in the Merger Agreement or increase or decrease (other than
by conversion) the number of authorized shares of Series B Preferred Stock, (c) at any time while at least 30% of the originally issued
Series B Preferred Stock remains issued and outstanding, consummate either: (x) any Fundamental Transaction (as defined in the Series
B Certificate of Designation) or (y) any merger or consolidation of the Company with or into another entity or any stock sale to, or
other business combination in which the stockholders of the Company immediately before such transaction do not hold at least a majority
of our capital stock immediately after such transaction, or (d) enter into any agreement with respect to any of the foregoing. The Series
B Preferred Stock shall rank on parity with the Common Stock as to the distribution of assets upon any liquidation, dissolution, or winding-up
of the Company. Each share of Series B Preferred Stock is convertible at the option of the holder, at any time, and without the payment
of additional consideration by the holder. As of September 30, 2024, each outstanding share of Series B Preferred Stock was convertible
into common stock at a ratio of approximately 83.3332:1.
114
Registration
Rights
Holders of
our Series A Preferred Stock are entitled to certain rights with respect to the registration of such securities as further provided under
the heading "
Selling Stockholders - Registration Rights Agreement
."
Anti-Takeover
Provisions
The provisions
of Delaware law, our Certificate of Incorporation and our Bylaws could have the effect of delaying, deferring or discouraging another
person from acquiring control of our company. These provisions, which are summarized below, may have the effect of discouraging takeover
bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our Board. We believe
that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the
disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their
terms.
Delaware
law
We are subject
to the provisions of Section 203 of the DGCL regulating corporate takeovers. In general, Section 203 prohibits a publicly-held Delaware
corporation from engaging in a business combination with an interested stockholder for a period of three years following the date on
which the person became an interested stockholder unless:
●
prior
to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction
which resulted in the stockholder becoming an interested stockholder;
●
upon
completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at
least 85% of the voting stock of the corporation outstanding upon consummation of the transaction, excluding for purposes of determining
the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (1) shares owned by persons who
are directors and also officers and (2) shares owned by employee stock plans in which employee participants do not have the right to
determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
●
at
or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized
at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding
voting stock which is not owned by the interested stockholder.
Section 203
defines a "business combination" to include:
●
any
merger or consolidation involving the corporation and the interested stockholder;
●
any
sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;
●
subject
to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested
stockholder;
●
any
transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of
the corporation beneficially owned by the interested stockholder; and
●
the
receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided
by or through the corporation.
In general,
Section 203 defines an "interested stockholder" as an entity or person who, together with the person's affiliates and
associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15%
or more of the outstanding voting stock of the corporation.
115
Certificate
of Incorporation and Bylaw Provisions
Our Certificate
of Incorporation and our Bylaws include a number of provisions that could deter hostile takeovers or delay or prevent changes in control
of our company, including the following:
●
Board
of Directors vacancies
. Our Certificate of Incorporation and Bylaws require that the Board, and not stockholders, fill any directorships
that become vacant or are created by an increase in the authorized number of directors by the affirmative vote of a majority of the remaining
directors or by the sole remaining director. In addition, pursuant to our bylaws, the number of directors constituting our Board is permitted
to be set only by a resolution adopted by a majority vote of the entire Board. These provisions prevent a stockholder from increasing
the size of our Board and then gaining control of the Board by filling the resulting vacancies with its own nominees. This makes it more
difficult to change the composition of the Board but promotes continuity of management.
●
Classified
board
. Our Certificate of Incorporation provides that our Board is classified into three classes of directors, each with staggered
three-year terms. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is
more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors.
●
Stockholder
action; special meetings of stockholders
. Our Certificate of Incorporation and Bylaws provide that our stockholders may not take
action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling
a majority of our capital stock would not be able to amend our Bylaws or remove directors without holding a meeting of our stockholders
called in accordance with our Bylaws. Further, our Bylaws provide that special meetings of stockholders may be called only by the Board,
thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force
consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal
of directors.
●
Advance
notice requirements for stockholder proposals and director nominations
. Our Bylaws provide advance notice procedures for stockholders
seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual
meeting of stockholders. Our Bylaws also specify certain requirements regarding the form and content of a stockholder's notice.
These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations
for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions might
also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer's own slate of directors
or otherwise attempting to obtain control of our company.
●
No
cumulative voting
. The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors
unless a corporation's certificate of incorporation provides otherwise. Our Certificate of Incorporation and Bylaws do not provide
for cumulative voting.
●
Directors
removed only for cause
. Our Bylaws provide that stockholders may remove directors only for cause, and only by the affirmative
vote of the holders of at least 66 2/3% of the voting power of the stock outstanding and entitled to vote generally in the election of
directors.
●
Amendment
of charter provisions
. Any amendment of the above provisions in our Certificate of Incorporation requires approval by holders
of at least two-thirds of our outstanding Common Stock.
●
Issuance
of Preferred Stock
. Our Board has the authority, without further action by the stockholders, to issue up to 5,000,000 shares
of Preferred Stock with rights and preferences, including voting rights, designated from time to time by our Board. The existence of
authorized but unissued shares of Preferred Stock enables our Board to render more difficult or to discourage an attempt to obtain control
of us by merger, tender offer, proxy contest or other means.
●
Choice
of forum
. Our Certificate of Incorporation and Bylaws provide that the Court of Chancery of the State of Delaware is the sole
and exclusive forum for any complaint asserting any internal corporate claims. In addition, our Bylaws also provide that the federal
district courts of the United States are the exclusive forum for the resolution of any complaint asserting a cause of action arising
under the Securities Act. These choice of forum provisions do not apply to claims brought to enforce a duty or liability created by the
Exchange Act.
Transfer
Agent and Registrar
The transfer
agent and registrar for our Common Stock, Class A Preferred Stock and Class B Preferred Stock is Computershare Trust Company, N.A. The
transfer agent's address is 150 Royall Street, Suite 101, Canton, MA 02021, and its telephone number is (800) 344-5128.
Exchange
Listing
Our Common
Stock is listed on The Nasdaq Global Market under the symbol "ORKA."
116
LEGAL
MATTERS
Certain legal
matters, including the legality of the securities offered, has been passed upon for us by Gibson, Dunn & Crutcher LLP, San Francisco,
California. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in
the applicable prospectus supplement.
117
EXPERTS
The
financial statement as of February 6, 2024 included in this Prospectus has been so included
in reliance on the report (which contains an explanatory paragraph relating to the Company's ability to continue as a going concern as
described in Note 1 to the financial statement) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given
on the authority of said firm as experts in auditing and accounting.
118
WHERE
YOU CAN FIND MORE INFORMATION
We are subject
to the informational requirements of the Exchange Act and are required to file annual, quarterly and other reports, proxy statements
and other information with the SEC. The SEC maintains an Internet website (http://www.sec.gov) that contains reports, proxy and information
statements, and various other information about us.
Information
about us is also available at our website at http://www.orukatx.com. You may access these materials free of charge as soon as reasonably
practicable after they are electronically filed with, or furnished to, the SEC. However, the information on our website is not a part
of this prospectus and is not incorporated by reference into this prospectus.
We have filed
a registration statement on Form S-1 with the SEC relating to the securities covered by this prospectus. This prospectus is a part of
the registration statement and does not contain all of the information in the registration statement. Whenever a reference is made in
this prospectus to a contract or other document of ours, please be aware that the reference is only a summary and that you should refer
to the exhibits that are part of the registration statement for a copy of the contract or other document. You may review a copy of the
registration statement through the SEC's website or our website.
119
ORUKA
THERAPEUTICS, INC.
INDEX
TO  FINANCIAL STATEMENT
As of February 6, 2024
Page
Report of Independent Registered Public Accounting Firm
F-2
Balance Sheet as of February 6, 2024
F-3
Notes to Financial Statement
F-4
INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
Page
Period from February 6, 2024 (Inception) to September 30, 2024
Condensed
    Consolidated Balance Sheets
F-10
Condensed
    Consolidated Statements of Operations and Comprehensive Loss
F-11
Condensed
    Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)
F-12
Condensed
    Consolidated Statement of Cash Flows
F-13
Notes
    to Condensed Consolidated Financial Statements
F-14
F-
1
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM
To the Board of Directors and Stockholders of Oruka Therapeutics, Inc.
Opinion on the Financial Statement — Balance Sheet
We have audited the accompanying balance sheet of Oruka Therapeutics,
Inc. (the "Company") as of February 6, 2024, including the related notes (collectively referred to as the "financial
statement"). In our opinion, the financial statement presents fairly, in all material respects, the financial position of the Company
as of February 6, 2024 in conformity with accounting principles generally accepted in the United States of America.
Substantial Doubt about the Company's Ability to Continue
as a Going Concern
The accompanying financial statement has been prepared assuming that
the Company will continue as a going concern. As discussed in Note 1 to the financial statement, the Company has not generated any revenue
from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception,
which raises substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are
also described in Note 1. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion
The financial statement is the responsibility of the Company's
management. Our responsibility is to express an opinion on the Company's financial statement based on our audit. We are a public
accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent
with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.
We conducted our audit of this financial statement in accordance with
the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement is free of material misstatement,
whether due to error or fraud.
Our audit included performing procedures to assess the risks of material
misstatement of the financial statement, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statement. Our audit also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation
of the financial statement. We believe that our audit provides a reasonable basis for our opinion.
Critical Audit Matters
Critical audit matters are matters arising from the current period
audit of the financial statement that were communicated or required to be communicated to the audit committee and that (i) relate to accounts
or disclosures that are material to the financial statement and (ii) involved our especially challenging, subjective, or complex judgments.
We determined there are no critical audit matters.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
May 13, 2024, except for the effects of the reverse stock split discussed
in Note 1 to the financial statement, as to which the date is September 5, 2024, and except for the effects of the reverse merger exchange
ratio discussed in Note 1 to the financial statement, as to which the date is November 13, 2024.
We have served as the Company's auditor since 2024.
F-
2
ORUKA THERAPEUTICS, INC.
BALANCE SHEET
(In thousands, except share amounts)
February 6,
2024
ASSETS
Current Assets
Subscription receivable
$
1
Total assets
$
1
Commitments and contingencies (Note 5)
STOCKHOLDERS' EQUITY
Series A convertible preferred stock, $
0.001
par value,
20,000,000
shares authorized,
no
shares issued and outstanding as of February 6, 2024
$
—
Common stock, $
0.001
par value,
65,000,000
shares authorized,
3,197,975
issued and outstanding as of February 6, 2024
3
Additional paid-in capital
(
2
)
Total stockholders' equity
$
1
The accompanying notes are an integral part of
this financial statement.
F-
3
ORUKA THERAPEUTICS, INC.
NOTES TO FINANCIAL STATEMENT
1. Nature of the Business and Basis of Presentation
Background and Basis of Presentation
Oruka Therapeutics, Inc. ("Oruka" or
the "Company") was established and incorporated under the laws of the state of Delaware on February 6, 2024. Oruka was founded
by Paragon Therapeutics, Inc. ("Paragon"). The Company currently operates as a virtual company, and thus, does not maintain
a corporate headquarters or other significant facilities. Oruka was formed to develop biologics to optimize the treatment of inflammatory
skin diseases.
The Company is subject to risks and uncertainties
common to early-stage companies in the biopharmaceutical industry, including, but not limited to, completing preclinical and clinical
trials, obtaining regulatory approval for product candidates, development by competitors of new technological innovations, dependence
on key personnel, the ability to attract and retain qualified employees, reliance on third-party organizations, protection of proprietary
technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the ability to
raise additional capital to fund operations.
The Company's potential products will require
approval from the U.S. Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales. There
can be no assurance that the Company's potential products will receive all the required approvals. In addition, there can be no
assurance that the Company's potential products, if approved, will be accepted in the marketplace, nor can there be any assurance
that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that
such products will be successfully marketed, if at all.
The financial statement and accompanying notes have
been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").
Liquidity
The accompanying financial statement has been prepared
on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of
liabilities in the normal course of business. As of February 6, 2024, the Company had no cash.
The Company will devote substantially all of its
resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning, raising capital,
and providing general and administrative support for these operations. Current and future programs will require significant research and
development efforts, including preclinical and clinical trials and regulatory approvals to commercialization. These efforts require significant
amounts of additional capital, adequate personnel, and infrastructure. Even if the Company's development efforts are successful,
it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company obtains regulatory approval
for any of its product candidates and starts to generate revenue, it expects to incur significant expenses related to developing its internal
commercialization capability to support product sales, marketing, and distribution.
As a result, the Company will need substantial additional
funding to support its operating activities as it advances its potential product candidates through development, seeks regulatory approval
and prepares for and, if any of its product candidates are approved, proceeds to commercialization. Until such time as the Company can
generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination
of equity offerings and debt financings. Adequate funding may not be available to the Company on acceptable terms, or at all.
F-
4
If the Company is unable to obtain additional funding,
the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its planned
operations, which may have a material adverse effect on the Company's business, financial condition, results of operations and ability
to operate as a going concern. The financial statement does not include any adjustments that may result if the Company is not able to
continue as a going concern.
The Company has not generated any revenue from product
sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception.
In March 2024, the Company received $
3.0
million
in proceeds from the sale of Series A convertible preferred stock and $
25.0
million in proceeds from the sale of an unsecured convertible
promissory note, both of which were related party transactions (see Note 7
Subsequent Events
).
ARCA biopharma, Inc., a Delaware corporation ("ARCA"),
and the Company entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") on April 3, 2024,
pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement,
Atlas Merger Sub Corp, a Delaware corporation ("First Merger Sub"), will merge with and into Oruka, with Oruka continuing
as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the "First Merger"), and Oruka will merge
with and into Atlas Merger Sub II, LLC, a Delaware limited liability company ("Second Merger Sub" and together with First
Merger Sub, "Merger Subs"), with Second Merger Sub being the surviving entity of the merger (the "Second Merger"
and, together with the First Merger, the "Merger"). In connection with the Merger, Second Merger Sub will change its corporate
name to "Oruka Therapeutics Operating Company, LLC" and ARCA will change its name to "Oruka Therapeutics, Inc."
ARCA following the Merger is referred to herein as the "combined company." The combined company will be led by Oruka's
management team and will remain focused on developing biologics to optimize the treatment of inflammatory skin diseases.
Concurrent with the execution of the Merger Agreement,
the Company entered into a subscription agreement with certain investors to which the Company agreed to issue and sell to investors in
a private placement financing (the "Private Placement") shares and pre-funded warrants of the Company's common stock
at an estimated purchase price of $
9.71
($
5.55
prior to impact of reverse stock split and reverse merger exchange ratio) per share of
common stock and estimated purchase price of $
9.70
($
5.54
prior to the impact of the reverse stock split and reverse merger exchange ratio)
per warrant for gross proceeds of approximately $
275.0
million, which will precede the closing of the Merger Agreement. Shares of the
Company's common stock and pre-funded warrants to purchase shares of the Company's common stock issued pursuant to the Private
Placement will be converted into the right to receive shares of ARCA common stock and pre-funded warrants to purchase ARCA common stock,
respectively, in accordance with the exchange ratio at the effective time of the close of the transaction. The proceeds from the Private
Placement are expected to advance the Company's pipeline, business development activities, working capital, and other general corporate
purposes.
However, the agreements are subject to the satisfaction
of customary closing conditions, and there are no assurances that such conditions will be achieved nor that such financing or other strategic
transactions will be available on acceptable terms, or at all. If the Merger Agreement is terminated under certain circumstances, ARCA
could be required to pay Oruka a termination fee of $
0.4
million or Oruka could be required to pay ARCA a termination fee of $
0.4
million.
Based on its expectation of continuing operating losses for the foreseeable future, as of May 13, 2024, the date the Company's financial
statement is available to be issued, the Company has concluded there is substantial doubt about its ability to continue as a going concern
for at least twelve months from the date the financial statement is available to be issued.
In connection with the Merger Agreement discussed
above, the Company effected a one-for-twelve reverse stock split of the Company's issued and outstanding shares of common stock
on September 3, 2024 without any change in the par value per share. Unless otherwise stated, all information related to the Company's
common stock, common stock warrants, restricted stock awards, and stock options, as well as the per share amounts, have been retroactively
adjusted to give effect for the one-for-twelve reverse stock split and reverse merger exchange ratio of
6.8569
as calculated in accordance
with the Merger Agreement for all periods presented.
F-
5
2. Summary of Significant Accounting Policies
Subscription receivable
The Company accounts for any notes received in exchange
for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement
is available to be issued.
3. Common Stock
As of February 6, 2024, the Company has the authority
to issue a total of
65,000,000
shares of common stock at a par value of $
0.001
. As of February 6, 2024,
3,197,975
shares of common stock
were issued and outstanding for a nominal consideration, which was received in March 2024, prior to the date the financial statement is
available to be issued. Each share of common stock entitles the holder to one vote for each share of common stock held of record by such
holder on all matters on which stockholders generally are entitled to vote. The holders of common stock are entitled to receive dividends,
if any, as declared by the Company's Board of Directors. Upon dissolution, liquidation or winding up of the Company, the holders
of shares of common stock, subject to the rights of the holders of any outstanding series of preferred stock, shall be entitled to receive
the assets of the Company available for distribution to its stockholders ratably in proportion to the number of shares held.
4. Related Party Transactions
The Company issued
3,197,975
shares of common stock,
through a series of contribution agreements, to Paragon, Paruka Holding, LLC ("Paruka"), an entity formed by Paragon as a
vehicle to hold equity in the Company, and Oruka Advisors LLC ("Oruka Advisors"), an entity formed by Paragon as a vehicle
to hold equity in the Company, as part of its common stock subscription agreement with such entities. As of February 6, 2024, Paragon,
Paruka and Oruka Advisors each beneficially own approximately
44.7
%,
44.7
% and
10.6
%, respectively, of the Company through their common
stock holdings.
5. Commitments and Contingencies
The Company may be subject to legal proceedings
that arise in the ordinary course of business. As of February 6, 2024, there were no material proceedings to which the Company was a party,
nor did the Company have knowledge of any proceedings threatened against it.
6. Stock-Based Compensation
On February 6, 2024, the Company's Board of
Directors approved the 2024 Equity Incentive Plan (the "2024 Plan"), under which the Company may grant stock options, restricted
stock awards, restricted stock units, or other stock-based awards to its employees, officers, directors, consultants, and advisors. The
Company reserved
213,085
shares of its common stock for issuance under the 2024 Plan. As of February 6, 2024, no awards had been issued
under the plan.
7. Subsequent Events
The Company evaluated all events subsequent to February
6, 2024, through May 13, 2024, the date on which the financial statement was available to be issued.
F-
6
Stock-Based Compensation
In February 2024, the Company's Board of Directors
authorized and granted
1,184,749
restricted stock awards at a price of $
0.0001
per share to employees of the Company.
In March 2024, the Company's Board of Directors
authorized and granted
1,022,804
restricted stock awards at a price of $
0.0001
per share to consultants and a director of the Company.
On March 5, 2024, the Company's Board of Directors
approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from
213,085
to
498,789
.
On March 22, 2024, the Company granted options for
the purchase of an aggregate
399,222
shares of common stock, at an exercise price of $5.16 per share.
On May 7, 2024, the Company's Board of Directors
approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from
498,789
to
1,179,193
.
On May 7, 2024, the Company granted options for
the purchase of an aggregate
779,971
shares of common stock, at an exercise price of $6.84 per share.
Antibody Discovery and Option Agreements
On March 6, 2024, the Company entered into an Antibody
Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March 28, 2024, whereby the Company
was granted an exclusive, worldwide option, on a research program-by-research program basis, to all of Paragon's right, title and
interest in and to the intellectual property ("ORKA-001") resulting from the applicable research program to develop, manufacture
and commercialize products directed at the selected target ("IL-23"), with the exception of pursuing ORKA-001 for the treatment
of inflammatory bowel disease. Upon signing of the Antibody Discovery and Option Agreement for ORKA-001, a one-time, non-refundable research
initiation fee of $
0.8
million was due to Paragon. This amount was recognized as a research and development expense during the period
ended March 31, 2024, and paid to Paragon in April 2024. The Company is also responsible for
50
% of the development costs incurred prior
to March 31, 2024, provided that the Company receives rights to at least one selected IL-23 antibody. As of the date this financial statement
is available to be issued, the Company has not received rights to a selected IL-23 antibody and has not paid or accrued the $
5.9
million
of development costs incurred prior to March 31, 2024. The Company will be responsible for
50
% of the ORKA-001 development costs incurred
from and after March 31, 2024, through the completion of the IL-23 selection process.
On March 6, 2024, the Company also entered into
an Antibody Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March 28, 2024, whereby
the Company was granted an exclusive, worldwide option, on a research program-by-research program basis, to all of Paragon's right,
title and interest in and to the intellectual property ("ORKA-002") resulting from the applicable research program to develop,
manufacture and commercialize products directed at the selected target ("IL-17"). The Company was also required to reimburse
Paragon $
3.3
million for development costs related to ORKA-002 incurred by Paragon through December 31, 2023 and certain other development
costs related to ORKA-002 incurred by Paragon between January 1, 2024 and March 6, 2024. This amount was recognized as a research and
development expenses during the period from February 6 (inception) to March 31, 2024 and accounts payable as of March 31, 2024. The Company
paid $
3.3
million to Paragon in April 2024. The Company is also responsible for the development costs incurred by Paragon from January
1, 2024 to March 31, 2024 of $
0.9
million, which was recognized as a research and development expense in the period from February 6 (inception)
to March 31, 2024. The Company will be required to pay Paragon $
0.8
million for the research initiation fee related to ORKA-002 within
30 days following finalization of the ORKA-002 research plan as well as for subsequent development costs related to ORKA-002.
As of the date of issuance of the Company's
financial statement, the Company has not exercised its options with respect to ORKA-001 or ORKA-002. For each of these agreements, if
the Company exercises its options, it will be required to make non-refundable milestone payments to Paragon of up to $
12.0
million upon
the achievement of certain clinical development milestones, up to $
10.0
million upon the achievement of certain regulatory milestones,
as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial sale.
F-
7
Additionally, as part of the Antibody Discovery
and Option Agreements, on each of December 31, 2024 and December 31, 2025, the Company will grant Paruka warrants to purchase a number
of shares equal to
1.00
% of the then outstanding shares of the Company's common stock as of the date of the grant on a fully-diluted
basis, with an exercise price equal to the fair market value of the underlying shares on the grant date.
Series A Preferred Stock
On March 6, 2024, the Company issued
20,000,000
shares of Series A convertible preferred stock to Fairmount Healthcare Fund II, L.P. ("Fairmount"), a related party of the
Company, at a purchase price of $
0.15
per share for gross proceeds of $
3.0
million. The Company incurred less than $
0.1
million of issuance
costs in connection with this transaction.
The holders of Series A convertible preferred stock
are entitled to vote, together with the holders of common stock, on all matters submitted to stockholders for a vote. Each holder of outstanding
shares of Series A convertible preferred stock is entitled to the number of votes equal to the number of shares of common stock into which
the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote
on such matter.
Each share of Series A convertible preferred stock
is convertible at the option of the holder, at any time, and without the payment of additional consideration by the holder. In addition,
each share of Series A convertible preferred stock will be automatically converted into shares of common stock at the applicable conversion
ratio then in effect upon either (i) the closing of a firm-commitment underwritten public offering of the Company's common stock
at a price of at least $
12.00
per share resulting in at least $
50.0
million of gross proceeds to the Company, or (ii) the vote or written
consent of the holders of a majority of the Preferred Stock, voting as a single class.
The conversion ratio of Series A convertible preferred
stock is determined by dividing the Original Issue Price by the Conversion Price in effect at the time of conversion. The Original Issue
Price is $
0.15
per share for Series A convertible preferred stock (in each case subject to appropriate adjustment in the event of any
stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company's certificate
of incorporation, as amended and restated). The Conversion Price is approximately $
0.26
per share for Series A convertible preferred stock
and each outstanding share of Series A Preferred Stock was convertible into common stock at a
0.5712
conversion ratio.
The Company may not declare, pay or set aside any
dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock) unless
the holders of the Series A convertible preferred stock then outstanding first receive, or simultaneously receive, a dividend on each
outstanding share of Series A convertible preferred stock in an amount at least equal to (i) in the case of a dividend being distributed
to common stock or any class or series that is convertible into common stock, the equivalent dividend on an as-converted basis or (ii)
in the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend rate on Series
A convertible preferred stock calculated based on the respective Original Issue Price of Series A convertible preferred stock.
In the event of any voluntary or involuntary liquidation,
dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares
of Series A convertible preferred stock then outstanding are entitled to be paid out of the assets or funds of the Company available for
distribution to stockholders before any payment is made to the holders of common stock. The holders of Series A convertible preferred
stock are entitled to an amount equal to the greater of (i) the applicable Original Issue Price per share of Series A convertible preferred
stock, plus any declared but unpaid dividends thereon, or (ii) the amount per share that would have been payable had all shares of Series
A convertible preferred stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed
Liquidation Event. If upon any such liquidation event, the assets or funds of the Company available for distribution to stockholders are
insufficient to pay the full amount to which they are entitled, then the holders of shares of Series A convertible preferred stock will
share ratably in any distribution of the assets or funds available for distribution in proportion to the respective amounts which would
otherwise be payable if it were paid in full.
F-
8
Unless the holders of a majority in voting power
of the then outstanding shares of Series A convertible preferred stock elect otherwise, a Deemed Liquidation Event shall include a merger
or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the
surviving or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all of the
Company's assets.
Series A convertible preferred stock does not have
redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event.
Convertible Notes
On March 6, 2024, the Company entered into a Series
A Preferred Stock and Convertible Note Purchase Agreement (the "Purchase Agreement") with Fairmount, whereby the Company issued
a convertible note (the "Convertible Note"), with an initial principal amount of $
25.0
million, that can be converted into
Series A preferred stock (or a Series of preferred shares that is identical in respect to the shares of preferred shares issued in its
next equity financing) or shares of the Company's common stock in exchange for proceeds of $
25.0
million. The Convertible Note will
automatically convert into shares of the Company's common stock upon the closing of a corporate transaction, including the reverse
recapitalization transaction, and is otherwise due and payable at the request of the holder at any time. The Convertible Note accrues
interest at a rate of
12.0
% per annum. All unpaid interest and principal are scheduled to mature on December 31, 2025. Prepayment is not
permitted without prior written consent of Fairmount. Pursuant to the Purchase Agreement, the Company has the right to sell and issue
additional convertible notes up to an aggregate principal amount equal to $
30.0
million, in addition to the $
25.0
million of initial principal
amount of the Convertible Note.
Oak Grove Lease
On April 12, 2024, the Company entered into a lease
agreement with Oak Grove LP ("Oak Grove Lease") for office space located in Menlo Park, California. The lease commencement
date is June 15, 2024 with an initial term of
39.5
months. The total lease payment is expected to be $
1.4
million over the initial lease
term.
8. Events subsequent to the reissuance of the financial statement
(unaudited)
In connection with the reissuance of the financial
statement, the Company has evaluated subsequent events through November 13, 2024, the date the financial statement was available to be
reissued.
F-
9
ORUKA
THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(In thousands, except share and per share data)
September 30,
2024
February 6,
2024
Assets
Current assets:
Cash and cash equivalents
$
410,875
$
—
Subscription receivable
—
1
Prepaid expenses and other current assets
2,074
—
Total current assets
412,949
1
Property and equipment, net
160
—
Operating lease right-of-use asset
938
—
Other non-current assets
43
—
Total assets
$
414,090
$
1
Liabilities, Convertible Preferred Stock and Stockholders' Equity
Current liabilities:
Accounts payable
$
2,145
$
—
Accrued expenses and other current liabilities
1,710
—
Operating lease liability, current
146
—
Related party common stock warrant liability
7,681
—
Related party accounts payable and other current liabilities
6,357
—
Total current liabilities
18,039
—
Operating lease liability, non-current
842
—
Total liabilities
18,881
—
Commitment and contingencies (Note 11)
Series A convertible preferred stock, $
0.0001
par value;
no
shares and
20,000,000
shares authorized as of September 30, 2024 and February 6, 2024, respectively;
no
shares issued and outstanding as of September 30, 2024 and February 6, 2024; liquidation preference of $
0
as of September 30, 2024 and February 6, 2024
—
—
Series A non-voting convertible preferred stock, $
0.001
par value;
2,439
and
no
shares authorized as of September 30, 2024 and February 6, 2024, respectively;
2,439
and
no
shares issued and outstanding as of September 30, 2024 and February 6, 2024, respectively
52,841
—
Stockholders' equity:
Series B non-voting convertible preferred stock, $
0.001
par value;
251,504
and
no
shares authorized as of September 30, 2024 and February 6, 2024, respectively;
137,138
and
no
shares issued and outstanding as of September 30, 2024 and February 6, 2024, respectively
2,931
—
Common stock, $
0.001
and $
0.001
par value as of September 30, 2024 and February 6, 2024, respectively;
545,000,000
and
65,000,000
shares authorized,
34,998,550
and
3,197,975
shares issued and outstanding as of September 30, 2024 and February 6, 2024, respectively
35
—
Additional paid-in capital
397,345
1
Accumulated deficit
(
57,943
)
—
Total stockholders' equity
342,368
1
Total liabilities, convertible preferred stock and stockholders' equity
$
414,090
$
1
The
accompanying notes are an integral part of these condensed consolidated financial statements.
F-
10
ORUKA
THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
(In thousands, except share and per share data)
Three Months Ended
September 30,
2024
Period from
February 6,
2024
(Inception) to
September 30,
2024
Operating expenses
Research and development
(1)
$
25,691
$
49,557
General and administrative
(2)
3,758
8,248
Total operating expenses
29,449
57,805
Loss from operations
(
29,449
)
(
57,805
)
Other income (expense)
Interest income
1,330
1,330
Interest expense
(3)
(
504
)
(
1,468
)
Total other income (expense), net
826
(
138
)
Net loss and comprehensive loss
$
(
28,623
)
$
(
57,943
)
Net loss per share attributable to common stockholders, basic and diluted
$
(
1.46
)
$
(
6.08
)
Net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted
$
(
1,461.10
)
$
(
6,077.25
)
Net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted
$
(
121.76
)
$
(
506.44
)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted
15,013,655
7,765,381
Weighted-average shares used in computing net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted
477
184
Weighted-average shares used in computing net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted
49,191
19,015
(1)
Includes related party amount of $13,537 for the three months ended September 30, 2024 and $33,967 for the period from February 6, 2024 (inception) to September 30, 2024
(2)
Includes related party amount of $71 for the three months ended September 30, 2024 and $1,339 for the period from February 6, 2024 (inception) to September 30, 2024
(3)
Includes related party amount of $504 for the three months ended September 30, 2024 and $1,468 for the period from February 6, 2024 (inception) to September 30, 2024
The
accompanying notes are an integral part of these condensed consolidated financial statements.
F-
11
ORUKA
THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)
(UNAUDITED)
(In thousands, except share data)
Series
    A
Convertible Preferred Stock
Series
    A
Non-Voting
Convertible Preferred Stock
Series
    B
Non-Voting
Convertible Preferred Stock
Common
    Stock
Additional
Paid-in
Accumulated
Total
Stockholders'
Equity
Shares
Amount
Shares
Amount
Shares
Amount
Shares
Amount
Capital
Deficit
(Deficit)
Balances
    as of February 6, 2024 (inception)
—
$
—
—
—
—
$
—
3,197,975
$
3
$
(
2
)
$
—
$
1
Issuance
    of common stock
—
—
—
—
—
—
2,207,553
2
(
2
)
—
—
Issuance of Series A convertible preferred stock, net of issuance costs of $
69
20,000,000
2,931
—
—
—
—
—
—
—
—
—
Stock-based
    compensation expense
—
—
—
—
—
—
—
—
17
—
17
Net loss
—
—
—
—
—
—
—
—
—
(
7,077
)
(
7,077
)
Balances
    as of March 31, 2024
20,000,000
$
2,931
—
—
—
—
5,405,528
$
5
$
13
$
(
7,077
)
$
(
7,059
)
Stock-based
    compensation expense
—
—
—
—
—
—
—
—
321
—
321
Net loss
—
—
—
—
—
—
—
—
—
(
22,243
)
(
22,243
)
Balances
    as of June 30, 2024
20,000,000
$
2,931
—
—
—
—
5,405,528
$
5
$
334
$
(
29,320
)
$
(
28,981
)
Exchange
    of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization
(
20,000,000
)
(
2,931
)
—
—
137,138
2,931
—
—
—
—
2,931
Conversion
    of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization
—
—
—
—
—
—
2,722,207
3
26,445
—
26,448
Issuance
    of common stock and pre-funded warrants in the Pre-Closing Financing,
—
—
—
—
—
—
20,061,932
20
248,437
—
248,457
Issuance
    costs of Pre-Closing Financing and reverse recapitalization
—
—
—
—
—
—
—
—
(
20,480
)
—
(
20,480
)
Issuance
    of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization
—
—
—
—
—
—
1,208,883
1
4,999
—
5,000
Issuance
    of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing
—
—
2,439
56,097
—
—
5,600,000
6
144,433
—
144,439
Issuance
    cost of PIPE Financing
(
3,256
)
(
8,573
)
(
8,573
)
Stock-based
    compensation expense
1,750
1,750
Net loss
—
—
—
—
—
—
—
—
—
(
28,623
)
(
28,623
)
Balances
    as of September 30, 2024
—
$
—
2,439
52,841
137,138
$
2,931
34,998,550
$
35
$
397,345
$
(
57,943
)
$
342,368
The
accompanying notes are an integral part of these condensed consolidated financial statements.
F-
12
ORUKA
THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(UNAUDITED)
(In thousands)
Period from
February 6,
2024
(Inception) to
September 30,
2024
Cash flows from operating activities:
Net loss
$
(
57,943
)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense
11
Stock-based compensation expense
9,769
Non-cash interest expense
1,468
Non-cash lease expense
65
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
(
1,980
)
Other non-current assets
(
43
)
Accounts payable
1,621
Accrued expenses and other current liabilities
1,650
Operating lease liability
6
Related party accounts payable and other current liabilities
6,357
Net cash used in operating activities
(
39,019
)
Cash flows from investing activities:
Purchases of property and equipment
(
171
)
Net cash used in investing activities
(
171
)
Cash flows from financing activities:
Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid
2,931
Proceeds from issuance of notes payable to related parties, net of issuance costs paid
24,980
Proceeds from the Pre-Closing Financing, net
228,127
Proceeds from the PIPE Financing, net
189,087
Cash acquired in connection with the reverse recapitalization
4,940
Net cash provided by financing activities
450,065
Net increase in cash and cash equivalents
410,875
Cash at beginning of period
-
Cash and cash equivalents at end of period
$
410,875
Supplemental disclosure of non-cash operating and financing activities:
Operating lease liability arising from obtaining operating right-of-use asset
$
982
Assets acquired in connection with the reverse recapitalization
$
114
Other liabilities assumed in connection with the reverse recapitalization
$
(
54
)
Pre-Closing Financing and reverse recapitalization issuance costs included in accounts payable
$
150
PIPE Financing issuance costs included in accounts payable
$
374
PIPE Financing issuance costs included in accrued expenses and other current liabilities
$
6
Non-cash accrued interest on convertible note converted to common stock
$
1,468
Non-cash exchange of Pre-Merger Oruka Series A Preferred Stock for Company Series B Convertible Preferred Stock
$
2,931
The
accompanying notes are an integral part of these condensed consolidated financial statements.
F-
13
ORUKA
THERAPEUTICS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
1.
Nature of the Business and Basis of Presentation
Background
and Basis of Presentation
Oruka
Therapeutics, Inc., together with its subsidiaries (collectively, the "Company"), formerly known as ARCA biopharma, Inc.
("ARCA"), is an early-stage biotechnology company that is the result of the reverse recapitalization discussed below. Prior
to the reverse recapitalization, the private company Oruka Therapeutics, Inc. ("Pre-Merger Oruka") was established and incorporated
under the laws of the state of Delaware on February 6, 2024 (referred to in the Notes as the inception of the Company). The Company
is headquartered in Menlo Park, California. The Company is focused on developing biologics to optimize the treatment of inflammatory
skin diseases.
These
condensed consolidated financial statements reflect, in the opinion of management, all adjustments of a normal and recurring nature that
are necessary for a fair statement of the Company's financial position as of September 30, 2024, and its results of operations
for the three months ended September 30, 2024 and from February 6, 2024 (inception) to September 30, 2024, and cash flows for the period
from February 6, 2024 (inception) to September 30, 2024. The condensed balance sheet as of February 6, 2024, included in the condensed
consolidated balance sheets was derived from the Company's audited financial statements. The condensed consolidated financial statements
and accompanying notes are prepared in accordance with United States ("U.S.") generally accepted accounting principles ("GAAP")
for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC")
and therefore do not include all information and disclosures normally included in the annual consolidated financial statements.
The
results for the three months ended September 30, 2024 and the period from February 6, 2024 (inception) to September 30, 2024 are not
necessarily indicative of results expected for the full fiscal year or any subsequent interim period. The condensed consolidated financial
statements include the financial statements of its wholly-owned subsidiaries. All significant intercompany balances and transactions
have been eliminated in consolidation.
Reverse
Recapitalization and Pre-Closing Financing
On
August 29, 2024, the Company consummated the previously announced business combination ("Closing") pursuant to that certain
Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the "Merger Agreement"), by and among ARCA, Atlas Merger
Sub Corp, a wholly owned subsidiary of ARCA ("First Merger Sub"), Atlas Merger Sub II, LLC, a wholly owned subsidiary of
ARCA ("Second Merger Sub") and Pre-Merger Oruka, pursuant to which, among other matters, Pre-Merger Oruka merged with and
into First Merger Sub, with Pre-Merger Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger
("First Merger") and following that, Pre-Merger Oruka then merged with and into Second Merger Sub, with Second Merger Sub
being the surviving entity of the second merger (the "Second Merger" and together with the First Merger, the "Merger").
Following consummation of the Merger, the Company effected a 1-for-12 reverse stock split (the "Reverse Stock Split") of
the common stock, par value $
0.001
per share, of the Company ("Company Common Stock"), which became effective on September
3, 2024. The Company Common Stock commenced trading on a post-Reverse Stock Split, post-Merger basis at the opening of trading on September
3, 2024. Second Merger Sub changed its corporate name to "Oruka Therapeutics Operating Company, LLC" and ARCA changed its
name to "Oruka Therapeutics, Inc." The Company is led by the Pre-Merger Oruka management team and remains focused on developing
biologics to optimize the treatment of inflammatory skin diseases.
Immediately
prior to the execution and delivery of the Merger Agreement on April 3, 2024, certain new and existing investors of Pre-Merger Oruka
entered into a subscription agreement with Pre-Merger Oruka (the "Subscription Agreement"), pursuant to which, and on the
terms and subject to the conditions of which, immediately prior to the Closing, those investors purchased shares of common stock of Pre-Merger
Oruka ("Pre-Merger Oruka Common Stock") and Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $
275.0
million (which includes $
25.0
million of proceeds previously received from the issuance of the Convertible Note (as defined in Note 6)
and accrued interest on such note which converted to shares of Pre-Merger Oruka Common Stock) (the "Pre-Closing Financing").
The Company incurred transaction costs of $
20.5
million which was recorded as a reduction to additional paid-in capital in the unaudited
condensed consolidated financial statements. At the Closing, the shares of Pre-Merger Oruka Common Stock and Pre-Merger Oruka pre-funded
warrants issued pursuant to the Subscription Agreement were converted into shares of Company Common Stock and pre-funded warrants of
Company Common Stock in accordance with the Exchange Ratio (defined below).
F-
14
In accordance with an Exchange Ratio determined
by terms of the Merger Agreement and upon the effective time of the First Merger (the "First Effective Time"), (i) each then-issued
and outstanding share of Pre-Merger Oruka Common Stock including outstanding and unvested Pre-Merger Oruka restricted stock and shares
of Pre-Merger Oruka Common Stock issued in connection with the Subscription Agreement, were converted into the right to receive a number
of shares of Company Common Stock, equal to the Exchange Ratio of
6.8569
shares of Company Common Stock, which were subject to the same
vesting provisions as those immediately prior to the Merger, (ii) each share of Pre-Merger Oruka Series A convertible preferred stock,
par value $
0.0001
("Pre-Merger Oruka Series A Preferred Stock"), outstanding immediately prior to the First Effective Time
was converted into the right to receive a number of shares of ARCA Series B non-voting convertible preferred stock, par value $
0.001
per
share ("Company Series B Preferred Stock"), which are convertible into shares of Company Common Stock, at a conversion ratio
of approximately 83:3332:1 (iii) each outstanding option to purchase Pre-Merger Oruka Common Stock was converted into an option to purchase
shares of Company Common Stock, (iv) each outstanding warrant to purchase shares of Pre-Merger Oruka Common Stock was converted into a
warrant to purchase shares of Company Common Stock, and (v) each share of Company Common Stock issued and outstanding at the First Effective
Time remain issued and outstanding in accordance with its terms and such shares. Subsequent to the close of the merger, the common stock
shares were then, subject to the reverse stock split of 1-for-12 effected on September 3, 2024. Net loss per share for periods prior to
the close of the reverse recapitalization has been revised to reflect the exchange ratio. After applying the exchange ratio and the reverse
stock split, net loss per share for the periods from February 6, 2024 (inception) to March 31, 2024 and for three months ended June 30,
2024 and from February 6, 2024 (inception) to June 30, 2024 are $(
2.21
), $(
6.96
), and $(
9.17
), respectively.
As
part of the Pre-Closing Financing and the Closing, investors in the Pre-Closing Financing received
22,784,139
shares of Company Common
Stock in exchange for
39,873,706
shares of Pre-Merger Oruka Common Stock (which includes the issuance of
2,722,207
shares of Company
Common Stock in exchange for
4,764,032
shares of Pre-Merger Oruka Common Stock on the conversion of Convertible Note along with the accrued
interest through the conversion date) and
5,522,207
Company pre-funded warrants in exchange for
9,664,208
Pre-Merger pre-funded warrants.
The Merger was accounted for as a reverse recapitalization
in accordance with U.S. GAAP. Under this method of accounting, Pre-Merger Oruka was deemed to be the accounting acquirer for financial
reporting purposes. This determination was primarily based on the fact that, immediately following the Merger: (i) Pre-Merger Oruka stockholders
own a substantial majority of the voting rights in the combined company; (ii) Pre-Merger Oruka's largest stockholders retain the
largest interest in the combined company; (iii) Pre-Merger Oruka designated a majority of the initial members of the board of directors
of the combined company; and (iv) Pre-Merger Oruka's executive management team became the management team of the combined company.
Accordingly, for accounting purposes: (i) the Merger was treated as the equivalent of Pre-Merger Oruka issuing stock to acquire the net
assets of ARCA, and (ii) the reported historical operating results of the combined company prior to the Merger are those of Pre-Merger
Oruka. Additional information regarding the Merger is included in Note 3.
Reverse
Stock Split
On
September 3, 2024, the Company effected the Reverse Stock Split, a 1-for-12 reverse stock split of Company Common Stock. The par value
per share and the number of authorized shares were not adjusted as a result of the Reverse Stock Split. The shares of Company Common
Stock underlying outstanding stock options, common stock warrants and other equity instruments were proportionately reduced and the respective
exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.
All references to common stock, options to purchase common stock, outstanding common stock warrants, common stock share data, per share
data, and related information contained in the condensed consolidated financial statements have been retrospectively adjusted to reflect
the effect of the Reverse Stock Split for all periods presented, unless otherwise specifically indicated or the context otherwise requires.
PIPE
Financing
On September 11, 2024, the Company entered into
a Securities Purchase Agreement for a private placement (the "PIPE Financing") with certain institutional and accredited investors.
The closing of the PIPE Financing occurred on September 13, 2024.
Pursuant to the Securities Purchase Agreement, the
investors purchased an aggregate of
5,600,000
shares of Company Common Stock at a purchase price of $
23.00
per share, an aggregate of
2,439
shares of the Company's Series A non-voting convertible preferred stock, par value $
0.001
per share ("Company Series
A Preferred Stock"), at a purchase price of $
23,000.00
per share (each Company Series A Preferred Stock is convertible into
1,000
shares of Company Common Stock), and pre-funded warrants to purchase an aggregate of
680,000
shares of Company Common Stock at a purchase
price of $
22.999
per pre-funded warrant, for aggregate net proceeds of approximately $
188.7
million (net of issuance costs of $
11.8
million).
F-
15
Liquidity
and Going Concern
Since
its inception, the Company has devoted substantially all of its resources to advancing the development of its portfolio of programs,
organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations.
Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and
regulatory approvals to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever,
the Company expects to finance its operating activities through a combination of equity offerings and debt financings.
The
Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative
cash flows from operations since inception. The Company has incurred a net loss of $
28.6
million for the three months ended September
30, 2024 and $
57.9
million during the period from February 6, 2024 (inception) to September 30, 2024. For the period from February
6, 2024 (inception) to September 30, 2024, the Company used net cash of $
39.0
million for its operating activities.
As
of September 30, 2024, the Company had cash and cash equivalents of $
410.9
million. The Company's management expects that the existing
cash and cash equivalents will be sufficient to fund the Company's operating plans for at least twelve months from the date these
condensed consolidated financial statements were issued. The Company expects that its research and development and general and administrative
costs will continue to increase significantly, including in connection with conducting future pre-clinical activities and clinical trials
and manufacturing for its existing product candidates and any future product candidates to support commercialization and providing general
and administrative support for its operations, including the costs associated with operating as a public company. The Company's
ability to access capital when needed is not assured and, if capital is not available to the Company when, and in the amounts needed,
the Company may be required to significantly curtail, delay or discontinue one or more of its research or development programs or the
commercialization of any product candidate, or be unable to expand its operations or otherwise capitalize on the Company's business
opportunities, as desired, which could materially harm the Company's business, financial condition and results of operations.
2.
Summary of Significant Accounting Policies
Use
of Estimates
The
preparation of the Company's condensed consolidated financial statements in conformity with U.S. GAAP requires management
to make estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent
liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the
reporting periods. Significant estimates and assumptions reflected within these condensed consolidated financial statements include but
are not limited to research and development expenses and related prepaid or accrued costs and the valuation of stock-based compensation
awards and related expenses. The Company bases its estimates on known trends and other market-specific or other relevant factors that
it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in
circumstances, facts, and experience. Actual results could differ materially from those estimates or assumptions.
Concentrations
of Credit Risk and Other Risks and Uncertainties
The
Company's cash and cash equivalents are maintained with financial institutions in the United States of America. Cash balances
are held at financial institutions and account balances may exceed federally insured limits. To date, the Company has not experienced
any losses on its cash and cash equivalents and periodically evaluates the creditworthiness of its financial institutions.
The
Company manages credit risk associated with its investment portfolio through its investment policy, which limits investments to high-quality
issuers and limits the amount of its portfolio that can be invested in a single issuer.
F-
16
The
Company is dependent on third-party organizations to research, develop, manufacture, and process its product candidates for its development
programs, including its two most advanced programs, ORKA-001 and ORKA-002. The Company expects to continue to be dependent on a small
number of manufacturers to supply it with its requirements for all products. The Company's research and development programs could
be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company's
research and development activities are performed under its agreements with Paragon Therapeutics, Inc. ("Paragon") (see Note 10).
Cash
and Cash Equivalents
The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The cash equivalents were comprised of investments in money market funds.
Debt
Issuance Costs
Debt
issuance costs incurred in connection with the Convertible Note (see Note 6) are recorded as a reduction of the carrying value of
the notes payable liability on the Company's balance sheet and are amortized to interest expense over the term of the loan using
the effective interest method.
Subscription
Receivable
The
Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable
is paid prior to the date the financial statement is available to be issued.
Fair
Value Measurements
Certain
assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be
received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are
to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered
observable and the last is considered unobservable:
●
Level 1
— Quoted prices in active markets that are identical assets or liabilities.
●
Level 2 — Observable
inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in
markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated
by observable market data.
●
Level 3 — Unobservable
inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities,
including pricing models, discounted cash flow methodologies, and similar techniques.
The
Company's cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note
4). The carrying values of the Company's prepaid expenses and other current assets, accounts payable and accrued expenses and other
current liabilities approximate their fair values due to their relatively short maturity period.
Property
and Equipment
Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:
Estimated
Useful Life
Furniture
    and fixtures
3
-
5
years
Computer
    and office equipment
3
-
5
years
F-
17
Classification
of Convertible Preferred Stock
Prior to the reverse recapitalization, the Company
had classified its Pre-Merger Oruka Series A Preferred Stock outside of stockholders' equity (deficit) on the Company's condensed
consolidated balance sheet because the holders of such stock have certain liquidation rights in the event of a deemed liquidation event
that, in certain situations, is not solely within the control of the Company and would require the redemption of the then-outstanding
convertible preferred stock.
Upon the closing of the Merger, the Company converted
its Pre-Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and has classified the Company Series B Preferred Stock
within stockholders' equity (deficit) on its condensed consolidated balance sheet because the Company Series B Preferred Stock is
not redeemable or puttable to the Company by the holder under any circumstances.
In connection with the PIPE Financing (see Note
1) the Company issued Company Series A Preferred Stock, and has classified the Company Series A Preferred Stock outside of stockholders'
equity (deficit) on the Company's condensed consolidated balance sheet because the holders of such stock have certain rights (see
Note 7) that, in certain situations, is not solely within the control of the Company and would require the redemption of the then-outstanding
convertible preferred stock.
Note Payable to Related Party
The Company accounted for the Convertible Note (as
defined in Note 6) at amortized cost. The Company considered if optional conversion features are required to be bifurcated and separately
accounted for as a derivative. Costs related to the issuance of the Convertible Note were recorded as a debt discount, amortized over
the term of the Convertible Note (see Note 6) and were accounted as interest expense in other income (expenses) within the condensed
consolidated statements of operations and comprehensive loss using the effective interest method. At the effective time of the Merger,
shares of Pre-Merger Oruka Common Stock issued pursuant to the conversion of the Convertible Note (including accrued interest) automatically
converted into shares of Company Common Stock (see Note 1).
Research and Development Contract Costs Accruals
The Company records the costs associated with research
studies and manufacturing development as incurred. These costs are a significant component of the Company's research and development
expenses, with a substantial portion of the Company's ongoing research and development activities conducted by third-party service
providers, including contract research organizations ("CROs") and contract manufacturing organizations ("CMOs"),
and the Company's related-party Paragon (see Note 10).
The Company accrues for expenses resulting from
obligations under its two antibody discovery and option agreements (the "Option Agreements") (see Note 10), by and among Paragon,
Paruka Holding LLC ("Paruka"), an entity formed by Paragon as a vehicle to hold equity in the Company, and the Company as
well as agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials
or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to
agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted
amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers
as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual
balance in each reporting period. If advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will
be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result
in material changes to the Company's accruals could materially affect the Company's results of operations. As of September
30, 2024, the Company has not experienced any material deviations between accrued and actual research and development expenses.
F-
18
Leases
At
the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies
a lease as either an operating or finance lease and recognizes a right-of-use ("ROU") asset and a current and non-current
lease liability, as applicable, in the balance sheet if the lease has a term greater than
one year
. Lease terms may include options to
extend or terminate the lease when it is reasonably certain that the Company will exercise its option.
At
the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future
minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit
rate, if it is readily determinable, or the risk-free discount rate for a period comparable with that of the lease term. For operating
leases, lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, lease expense
includes amortization expense of the ROU asset recognized on a straight-line basis over the lease term and interest expense recognized
on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments,
incentives received or initial direct costs. As of September 30, 2024, the Company has one operating lease and no finance leases.
The
Company accounts for lease and non-lease components related to operating leases as a single lease component. The Company has elected
that costs associated with leases having an initial term of 12 months or less are recognized in the condensed consolidated statement
of operations and comprehensive loss on a straight-line basis over the lease term and are not recorded on its condensed consolidated
balance sheets. Variable lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office
space related expenses.
Segment
Reporting
The
Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions.
The Company's chief executive officer, who is the chief operating decision maker (the "CODM"), reviews the Company's
financial information on an aggregated basis for purposes of evaluating financial performance and allocating resources.
Research
and Development Costs
Research
and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock-based compensation,
employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated
human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation.
Nonrefundable
advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid
expenses on the accompanying condensed consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered
or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable
advance payments represent a one-time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of
period end, the payment is expensed immediately.
General
and Administrative Expenses
General and administrative expenses consist primarily
of salaries and bonuses, stock-based compensation, employee benefits, finance and administration costs, patent and intellectual property
costs, professional fees, as well as allocated human resource costs, information technology costs, and facility-related costs, including
rent, maintenance, utilities and depreciation.
Commitments
and Contingencies
The
Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities.
The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the
loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the
balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but
not probable; however, it discloses the range of reasonably possible losses. As of September 30, 2024, no liabilities were recorded for
loss contingencies (see Note 11).
F-
19
Stock-Based
Compensation
The
Company measures all stock-based awards granted to employees, directors, and non-employees in the form of stock options to purchase shares
of its common stock, based on the fair value of the awards on the date of grant using the Black-Scholes option-pricing model. The Company
measures restricted common stock awards ("RSAs") using the difference, if any, between the purchase price per share of the
award and the fair value of the Company's common stock at the date of grant.
The
Company grants stock options, restricted stock awards, and warrants that are subject to service or performance-based vesting conditions.
Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line
method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards
to non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for
the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each
reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation
expense until it is probable that the performance-based vesting condition will be achieved.
The Company has issued stock options, warrants,
and RSAs with service-based and performance-based vesting conditions.
The
Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan ("ESPP"),
based on the fair value of the common stock estimated using the closing price of the Company's common stock as reported on the
date of offering, less the purchase discount percentage provided for in the plan.
The
Company classifies stock-based compensation expense in its condensed consolidated statement of operations and comprehensive loss in the
same manner in which the award recipient's payroll costs are classified or in which the award recipient's service payments
are classified.
Net Loss per Share Attributable to Stockholders
Basic and diluted net loss attributable to stockholders
per share is presented in conformity with the two-class method required for participating securities (Pre-Merger Oruka Series A Preferred
Stock). Basic earnings per share is computed by dividing net income available to each class of shares by the weighted-average number of
shares of common stock and participating securities outstanding during the period. Pre-funded warrants were included as the exercise price
is negligible and these warrants are fully vested and exercisable. Company Series A Preferred Stock and Company Series B Preferred Stock
share the same characteristics as Common Stock and have no substantive preference attributed to them and, accordingly, have been considered
as classes of Common Stock in the computation of net loss per share regardless of their legal form.
Net loss is allocated to common stock based on
its proportional ownership on an as-converted basis. Net loss is not allocated to participating securities as they do not have an obligation
to fund losses. The weighted-average number of shares outstanding of common stock reflects changes in ownership over the periods presented.
See Note 7— Convertible Preferred Stock and Stockholders' Equity.
Diluted net loss per share is computed by dividing
the net loss attributable to stockholders adjusted for income (expenses), net of tax, related to any diluted securities, by the weighted-average
number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of this calculation, stock
options to purchase common stock, employee warrants to purchase common stock, and unvested RSAs are considered potential dilutive common
shares.
The Company generated a net loss for the periods presented. Accordingly,
basic and diluted net loss per share is the same because the inclusion of the potentially dilutive securities would be anti-dilutive.
Income
Taxes
The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company's tax
returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis
of assets and liabilities using enacted tax rates in effect for the years in which the differences are expected to reverse. Changes
in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred
tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence,
that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established
through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies.
The
Company accounts for uncertainty in income taxes recognized in the condensed consolidated financial statements by applying a two-step
process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood
that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to
be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the condensed consolidated financial
statements. The amount of the benefit that may be recognized is the largest amount that has a greater than
50
% likelihood of being realized
upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits,
that are considered appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or
penalties related to uncertain tax positions as of September 30, 2024.
F-
20
Recently
Issued Accounting Pronouncements
In November 2023, the Financial Accounting
Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-07,
Segment Reporting
(
Topic 280
)
:
Improvements to Reportable Segment Disclosures
("ASU 2023-07"), which enhances the segment disclosure requirements
for public entities on an annual and interim basis. Under this proposal, public entities will be required to disclose significant segment
expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss. Additionally, current
annual disclosures about a reportable segment's profit or loss and assets will be required on an interim basis. Entities will also
be required to disclose information about the CODM's title and position at the Company along with an explanation of how the CODM
uses the reported measures of segment profit or loss in their assessment of segment performance and deciding how to allocate resources.
Finally, ASU 2023-07 requires all segment disclosures for public entities that have only a single reportable segment. The amendments
in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years
beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of
this ASU on its consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09,
Income Taxes (Topic 740): Improvements to Income Tax Disclosures
. This ASU expands disclosures in an entity's income
tax rate reconciliation table and disclosures regarding taxes paid both in the U.S. and foreign jurisdictions. This update is effective
beginning with the Company's 2025 fiscal year annual reporting period. The Company is currently evaluating the impact of the adoption
of this ASU on its consolidated financial statements.
In November 2024, the FASB issued ASU 2024-03,
Income
Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement
Expenses
. This ASU requires more detailed disclosures, on an annual and interim basis, about specified categories of expenses (including
employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement.
This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December
15, 2027. Early adoption is permitted. This ASU may be applied either prospectively or retrospectively. The Company is currently evaluating
the impact of the adoption of this ASU on its consolidated financial statements.
3. Reverse
Recapitalization and Pre-Closing Financing
As
described within the
Reverse Recapitalization and Pre-Closing Financing
section in Note 1, on August 29, 2024, the reverse recapitalization
between Pre-Merger Oruka and ARCA was consummated. The Merger was accounted for as a reverse recapitalization in accordance with U.S.
GAAP. At the effective time of the Merger, substantially all of the assets of ARCA consisted of cash and cash equivalents and other nominal
non-operating assets and liabilities. No goodwill or intangible assets were recognized.
As
part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands):
Amount
Cash and cash equivalents
$
4,940
Other current assets
114
Accrued liabilities
(
54
)
Net assets acquired
$
5,000
F-
21
4.
Fair Value Measurements
The
following tables present the Company's fair value hierarchy for financial assets measured as of September 30, 2024 (in thousands):
Fair Value Measurements as of September 30, 2024
Level 1
Level 2
Level 3
Total
Financial assets:
Money market funds
$
403,322
$
—
$
—
$
403,322
Total financial assets
$
403,322
$
—
$
—
$
403,322
There
were no transfers between Level 1, Level 2, or Level 3 during the period from February 6, 2024 (inception) to September
30, 2024.
5. Accrued
Expenses and Other Current Liabilities
Accrued
expenses and other current liabilities consisted of the following (in thousands):
September 30,
2024
Accrued
    employee compensation and benefits
$
933
Accrued
    professional and consulting
204
Accrued
    research and development
573
$
1,710
6.
Note Payable with Related Party
In
March 2024, the Company entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the "Purchase Agreement")
with Fairmount Healthcare Fund II, L.P. ("Fairmount"), whereby the Company issued a convertible note (the "Convertible
Note"), with an initial principal amount of $
25.0
million that, at the time of issuance, could be converted into Pre-Merger Oruka
Series A Preferred Stock (or a series of preferred shares that is identical in respect to the shares of preferred shares issued
in its next equity financing) or shares of Pre-Merger Oruka Common Stock in exchange for aggregate proceeds of $
25.0
million. The
Convertible Note accrued interest at a rate of
12.0
% per annum. At issuance, the Convertible Note required all unpaid interest and principal
to mature on
December 31, 2025
(the "Maturity Date") and prepayment was not permitted without prior written consent
of Fairmount. At issuance, the principal payment along with the accrued interest on the Convertible Note was due in full on the Maturity
Date.
The
Company assessed all terms and features of the Convertible Note in order to identify any potential embedded features that would require
bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the embedded features. The Company
determined that the share settled redemption feature was clearly and closely related to the debt host and did not require separate accounting.
The Company determined that the conversion options of the Convertible Note were not clearly and closely associated with a debt host.
However, these features did not meet the definition of a derivative under ASC 815,
Derivatives and Hedging
, and as a result,
did not require separate accounting as a derivative liability.
The
Company paid debt issuance costs of less than $
0.1
million in relation to the Convertible Note. The debt issuance costs were reflected
as a reduction of the carrying value of Convertible Note on the condensed consolidated balance sheet and were being amortized as interest
expense over the term of the Convertible Note using the effective interest method. For the three months ended September 30, 2024 and
the period from February 6, 2024 (inception) to September 30, 2024, the Company recognized interest expenses related to the Convertible
Note of $
0.5
million and $
1.5
million, respectively, which includes non-cash interest expense related to the amortization of debt issuance.
Immediately prior to the completion of the Merger
(see Note 1), the Convertible Note was converted into shares of Pre-Merger Oruka Common Stock based on the aggregate principal amount
of $
25.0
million, plus unpaid accrued interest of $
1.5
million divided by the conversion price which was determined based upon the Company's
fully-diluted capitalization immediately prior to the Merger. At the effective time of the Merger, the Pre-Merger Oruka Common Stock issued
upon the conversion of the Convertible Note (including accrued interest) automatically converted into
2,722,207
shares of Company Common
Stock. As of September 30, 2024, the Convertible Note is not outstanding.
F-
22
7.
Convertible Preferred Stock and Stockholders' Equity
Pre-Funded
Warrants
In
August 2024, pursuant to the Subscription Agreement and immediately prior to the Closing, certain new and current investors purchased
pre-funded warrants, which, at the effective time of the Merger, were exercisable for
5,522,207
shares of Company Common Stock at
a purchase price of approximately $
9.70
per warrant. After the Merger, there are
5,522,207
pre-funded warrants outstanding and are exercisable
for
5,522,207
shares of the Company Common Stock at an exercise price of $
0.01
per share.
In
September 2024, in connection with the PIPE Financing, the Company issued and sold
680,000
pre-funded warrants, at a purchase price of
$
22.999
per warrant, exercisable for
680,000
shares of Company Common Stock at an exercise price of $
0.001
per share.
The
pre-funded warrants were recorded as a component of stockholders' equity within additional paid-in-capital and have
no
expiration
date. As of September 30, 2024,
none
of the pre-funded warrants have been exercised and
6,202,207
pre-funded warrants remain outstanding.
Employee
Warrants
In
July 2024, Pre-Merger Oruka entered into a Subscription Agreement that provided for, among other things, the issuance of warrants to
certain of Pre-Merger Oruka's employees, directors, and service providers immediately prior to the closing of the Merger. During
the three months ended September 30, 2024,
3,054,358
employee warrants were issued at an exercise price of $
7.80
per warrant. These employee
warrants vest over a period of
four years
. Per the terms of the Employee Warrant Agreement, the holders of the Company's employee
warrants shall not have any of the rights or privileges of a stockholder of the Company in respect of any shares purchasable upon the
exercise of the warrant or any portion thereof unless and until a certificate or certificates representing such shares have been issued
or a book entry representing such shares has been made and such shares have been deposited with the appropriate registered book-entry
custodian. The Company recognizes compensation cost related to employee warrants on a straight-line basis over the requisite service
period, which is the period in which the related services are received. As of September 30, 2024,
none
of the employee warrants have
been exercised and
3,054,358
employee warrants remain outstanding.
Convertible
Preferred Stock
In March 2024, Pre-Merger Oruka issued and
sold an aggregate of
20,000,000
shares of Pre-Merger Oruka Series A Preferred Stock to Fairmount (see Note 13), at a purchase price
of approximately $
0.15
per share, for aggregate gross proceeds of $
3.0
million. Pre-Merger Oruka incurred less than $
0.1
million
of issuance costs in connection with this transaction. Upon the issuance of the Pre-Merger Oruka Series A Preferred Stock, the Company
assessed the embedded conversion and liquidation features of the securities as described below and determined that such features did not
require the Company to separately account for these features.
In
August 2024, upon the closing of the Merger, the Company converted the Pre-Merger Oruka Series A Preferred Stock to
137,138
shares of
Company Series B Preferred Stock.
In
September 2024, in connection with the PIPE Financing, the Company issued and sold an aggregate of
2,439
shares of the Company Series
A Preferred Stock at a purchase price of $
23,000.00
per share.
As
of September 30, 2024, convertible preferred stock consisted of the following (in thousands, except share data):
September 30, 2024
Preferred Stock
Authorized
Preferred Stock
Issued and
Outstanding
Carrying
Value
Common Stock
Issuable Upon
Conversion
Series A Non-Voting Preferred Stock
2,439
2,439
$
52,841
2,439,000
Series B Non-Voting Preferred Stock
251,504
137,138
$
2,931
11,428,149
F-
23
Pursuant to the Certificate of Designation of Preferences,
Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the "Series A Certificate of Designation")
filed in connection with the PIPE Financing, holders of Company Series A Preferred Stock are entitled to receive dividends on shares of
Company Series A Preferred Stock equal to, on an as-if-converted-to-Company Common Stock basis, and in the same form as, dividends actually
paid on shares of Company Common Stock. Except as provided in the Series A Certificate of Designation or as otherwise required by law,
the Company Series A Preferred Stock does not have voting rights. The Company Series A Preferred Stock shall rank on parity with the Company
Common Stock and Company Series B Preferred Stock upon any liquidation, dissolution or winding-up of the Company. Subject to the terms
and limitations contained in the Series A Certificate of Designation, the Company Series A Preferred Stock issued in the PIPE Financing
will not become convertible until the Company's stockholders approve the conversion of the Company Series A Preferred Stock into
shares of Company Common Stock in accordance with the listing rules of the Nasdaq Stock Market (the "Stockholder Approval"),
which resulted in the Company Series A Preferred Stock being classified outside of stockholders' equity (deficit) on the Company's
condensed consolidated balance sheet.. Following the Stockholder Approval, each share of Company Series A Preferred Stock will automatically
convert into 1,000 shares of Company Common Stock, subject to certain limitations, including that shares of Company Series A Preferred
Stock shall not be convertible if the conversion would result in a holder, together with its affiliates, beneficially owning more than
9.99
% of the Company's outstanding shares of Company Common Stock as of the applicable conversion date, which may be increased at
the holders' option (not to exceed
19.99
%), effective in accordance with the terms of the Series A Certificate of Designation. If,
at any time after the earlier of Stockholder Approval or six months after the initial issuance of the Series A non-voting preferred stock,
the Company fails to deliver to a holder such certificate or certificates, the Company shall, at the request of the holder, pay an amount
equal to the closing price of Company's common stock on the trading day immediately prior to the date on which notice to conversion
is received by the Company (the "Fair Value") of such undelivered shares, with such payment to be made within two business
days from the date of request by the holder, whereupon the Company's obligations to deliver such shares underlying the notice of
conversion shall be extinguished upon payment in full of the Fair Value of such undelivered shares; provided, however that such request
shall be presumed to have been made by such holder if Stockholder Approval shall not have been obtained prior to the date on which the
notice of conversion is delivered to the Company.
Pursuant
to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock (the
"Series B Certificate of Designation") filed in connection with the Merger, holders of Company Series B Preferred Stock are
entitled to receive dividends on shares of Company Series B Preferred Stock equal to, on an as-if-converted-to-Company Common Stock basis,
and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series B Certificate of
Designation or as otherwise required by law, the Company Series B Preferred Stock does not have voting rights. The Company Series B Preferred
Stock shall rank on parity with the Company Common Stock as to the distribution of assets upon any liquidation, dissolution, or winding-up
of the Company. Each share of Company Series B Preferred Stock is convertible at the option of the holder, at any time, and without the
payment of additional consideration by the holder. As of September 30, 2024, each outstanding share of Company Series B Preferred Stock
was convertible into common stock at a ratio of approximately 83.3332:1.
Common
Stock
As
of September 30, 2024, the Certificate of Incorporation provides for
545,000,000
authorized shares of Company Common Stock. As of September
30, 2024,
34,988,550
shares of Company Common Stock were issued and outstanding, including
2,207,553
shares of RSAs issued and outstanding.
As
of September 30, 2024, the Company had common stock reserved for future issuance as follows:
September 30,
2024
Shares
    issuable on conversion of Company Series A Preferred Stock
2,439,000
Shares
    issuable on conversion of Company Series B Preferred Stock
11,428,149
Shares issuable upon
    exercise of pre-funded warrants
6,202,207
Outstanding
    and issued stock options
1,287,760
Outstanding
    and issued employee warrants
3,054,358
Shares
    available for grant under 2024 Stock Incentive Plan
4,526,324
Shares
    available for grant under 2024 Employee Stock Purchase Plan
463,489
Total
    shares of common stock reserved
29,401,287
8.
Stock-Based Compensation
2024
Equity Incentive Plan
The
2024 Equity Incentive Plan ("2024 Plan") was adopted by the board of directors of Pre-Merger Oruka on February 6, 2024.
The 2024 Plan provided for Pre-Merger Oruka to grant stock options, restricted stock awards, restricted stock units, and other stock-based
awards to employees, officers, directors, consultants, and advisors. Equity Incentive Stock options granted under the 2024 Plan generally
vest over four years, subject to the participant's continued service, and expire after ten years, although stock options
have been granted with vesting terms less than four years. As of September 30, 2024, there are no shares of common stock available
for issuance.
F-
24
2024
Stock Incentive Plan
On
August 22, 2024, the 2024 Stock Incentive Plan ("2024 Stock Plan") was approved by the Company's stockholders and on
August 29, 2024, the board of directors of the Company (the "Board") ratified the 2024 Stock Plan. The 2024 Stock Plan allows
for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stockholder-based awards
and incentive bonuses. The 2024 Stock Plan is administered by the Compensation Committee of the Board (the "Compensation Committee")
or another committee designated by the Board to administer the Plan. The initial share pool under the 2024 Stock Plan is
4,634,891
shares
of Company Common Stock and as of September 30, 2024, there are
4,526,324
shares available in the pool. The shares that may be issued
under the 2024 Stock Plan will be automatically increased on January 1 of each year beginning in 2025 and ending with a final increase
on January 1, 2034 in an amount equal to
5
% of the diluted stock (including Company Common Stock, preferred stock and unexercised pre-funded
warrants) on the preceding December 31, unless a lower, or no, increase is determined by the Compensation Committee. Current or prospective
employees, officers, non-employee directors, and other independent service providers of the Company and its subsidiaries are eligible
to participate in the 2024 Stock Plan.
2024
Employee Stock Purchase Plan
The
2024 Employee Stock Purchase Plan (the "ESPP") was approved by the board of directors of ARCA on July 20, 2024, and by ARCA's
stockholders on August 22, 2024. The ESPP became effective on August 29, 2024, at which time
463,489
shares were reserved for issuance.
The shares that may be issued under the ESPP will be automatically increased on January 1 of each year beginning in 2025 and ending with
a final increase on January 1, 2034 in an amount equal to
1
% of the diluted stock (including Company Common Stock, preferred stock and
unexercised pre-funded warrants) on the preceding December 31, unless a lower, or no, increase is determined by the Compensation Committee.
As of September 30, 2024, no shares have been issued out of the ESPP.
Stock
Option Valuation
The
following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the three months ended
September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024:
Three
Months Ended
September 30,
2024
Period from
February 6,
2024
(Inception)
to
September 30,
2024
Expected term (in years)
6.1
6.1
Expected volatility
97.3
%
101.0
%
Risk-free interest rate
3.5
%
4.3
%
Expected dividend yield
—
%
—
%
Stock
Options
The
following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February 6, 2024
(inception) through September 30, 2024:
Number of
Stock Options
Weighted
Average
Exercise
Price Per
Share
Weighted
Average
Remaining
Contractual
Term (in Years)
Aggregate
Intrinsic
Value (in Thousands)
Balance as of February 6, 2024 (inception)
—
$
—
—
$
—
Granted
1,287,760
$
7.97
Exercised
—
$
—
Forfeited
—
$
—
Balance as of September 30, 2024
1,287,760
$
7.97
9.6
$
21,507
Vested and expected to vest, September 30, 2024
1,287,760
$
7.97
9.6
$
21,507
Exercisable, September 30, 2024
—
$
—
—
$
—
F-
25
The
weighted average grant-date fair value per share of stock options granted during the period from February 6, 2024 (inception) to
September 30, 2024 was $
6.44
per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying
Company Common Stock and the exercise price of outstanding, in-the-money employee stock options.
Restricted
Stock Awards
In
February 2024 and March 2024, the Company issued
2,207,553
shares of RSAs to certain employees, directors, and consultants at a
price of $
0.0001
per share, the then par value of Pre-Merger Oruka Common Stock. Such RSAs have service-based vesting conditions only
and vest over a four-year period, during which time all unvested shares are subject to forfeiture in the event the holder's service
with the Company voluntarily or involuntarily terminates.
The
following table summarizes the RSAs activity for the period from February 6, 2024 (inception) through September 30, 2024:
Number
                                            of
RSAs
Weighted
Average
Grant Date
Fair Value
Unvested balance
    as of February 6, 2024 (inception)
—
$
—
Granted
2,207,553
—
Unvested
    balance as of September 30, 2024
2,207,553
$
—
Option
Agreements and Paruka Warrant Obligation
In March 2024, the Company entered into antibody
discovery and option agreements with Paragon and Paruka (the "Option Agreements"). Under the terms of Option Agreements, Paragon
identifies, evaluates, and develops antibodies directed against certain mutually agreed therapeutic targets of interest to the Company,
and the Company has the exclusive option to, on a research program-by-research program basis, be granted an exclusive, worldwide license
to all of Paragon's right, title, and interest in and to the intellectual property resulting from the applicable research program
to develop, manufacture and commercialize the antibodies and products directed to the selected target(s). Paruka will be entitled to grants
of warrants to purchase a number of shares equal to
1.00
% of then outstanding shares of the Company's stock, on a fully diluted
basis, on December 31, 2024 and December 31, 2025, at the fair market value determined by the Board (the "Paruka Warrant
Obligation"). The grant dates for the issuance of warrants are expected to be December 31, 2024 and December 31, 2025
as all terms of the award, including number of shares and exercise price, will be known by all parties. The service inception period for
the grant precedes the grant date, with the full award being vested as of the grant date with no post-grant date service requirement.
Accordingly, the warrants expected to be granted to Paruka were accounted for as a liability on the condensed balance sheet and, after
the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded
in the statement of operations and comprehensive loss as stock-based compensation expenses under research and development expenses. As
of September 30, 2024, the estimated fair value of warrants to be granted on December 31, 2024 was $
11.0
million. For the three months
ended September 30, 2024 and the period from February 6, 2024 (inception) to September 30, 2024, $
7.3
million and $
7.7
million were recognized
as stock-based compensation expenses related to the Paruka Warrant Obligation, respectively.
Employee
Warrants
As stated above, on July 3, 2024, the Subscription
Agreement was amended and restated, among other things, for employee warrants to be issued to certain Pre-Merger Oruka's employees,
directors, and service providers, immediately prior to the closing of the Merger. Pursuant to this amendment, during the three months
ended September 30, 2024, the Company issued
3,054,358
employee warrants at an exercise price of $
7.80
per warrant, which are accounted
as equity in the condensed consolidated financial statements.
The
following table summarizes the employee warrant activity for the period from February 6, 2024 (inception) through September 30,
2024:
Number of
Warrants
Weighted
Average
Exercise
Price Per Share
Weighted
Average
Remaining
Contractual
Term (in Years)
Aggregate
Intrinsic
Value (in Thousands)
Balance as of February 6, 2024 (inception)
—
$
—
—
$
—
Granted
3,054,358
$
7.80
Exercised
—
$
—
Forfeited
—
$
—
Balance as of September 30, 2024
3,054,358
$
7.80
9.8
$
51,038
Vested and expected to vest, September 30, 2024
3,054,358
$
7.80
9.8
$
51,038
Vested and exercisable, September 30, 2024
—
$
—
—
$
—
The
weighted average grant-date fair value per share of employee warrants granted during the period from February 6, 2024 (inception)
to September 30, 2024 was $
6.27
per share. Aggregate intrinsic value represents the difference between the estimated fair value of the
underlying Company Common Stock and the exercise price of outstanding, in-the-money employee warrants.
F-
26
The
following table summarizes the weighted-average assumptions used in calculating the fair value of the employee warrants for the three
months ended September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024:
Three Months Ended
September 30,
2024
Period from
February 6,
2024
(Inception)
to
September 30,
2024
Expected term (in years)
6.1
6.1
Expected volatility
99.0
%
99.0
%
Risk-free interest rate
4.2
%
4.2
%
Expected dividend yield
—
%
—
%
Stock-Based
Compensation Expense
The
following table summarizes the classification of the Company's stock-based compensation expense in the condensed consolidated statement
of operations and comprehensive loss (in thousands):
Three Months
                                            Ended
September 30,
2024
Period
                                            from
February 6,
2024
(Inception)
to
September 30,
2024
Research
    and development
$
7,772
$
8,310
General
    and administrative
1,229
1,459
Total
$
9,001
$
9,769
As
of September 30, 2024, total unrecognized compensation cost related to the unvested stock options was $
7.5
million, which is expected
to be recognized over a weighted average period of approximately
3.4
years. As of September 30, 2024, total unrecognized compensation
cost related to the unvested RSAs was less than $
0.1
million, which is expected to be recognized over a weighted average period of
3.4
years. As of September 30, 2024, the unrecognized compensation cost related to the employee warrants was $
17.8
million, which is expected
to be recognized over a weighted average period of
3.6
years.
The
following table summarizes the award types of the Company's stock-based compensation expense in the condensed consolidated statement
of operations and comprehensive loss (in thousands):
Three Months
                                            Ended
September 30,
2024
Period
                                            from
February 6,
2024
(Inception)
to
September 30,
2024
Paruka
    warrant obligation
$
7,251
$
7,681
Employee
    warrants
1,314
1,314
Stock
    options
427
765
Employee
    stock purchase plan
9
9
Total
$
9,001
$
9,769
9.
Income Taxes
No
provision for income taxes was recorded for the three months ended September 30, 2024 and for the period of February 6, 2024 (inception)
through September 30, 2024. Deferred tax assets generated from the Company's net operating losses have been fully reserved, as
the Company believes it is not more likely than not that the benefit will be realized due to the Company's cumulative losses generated
to date.
F-
27
10.
Option Agreements
In
March 2024, the Company entered into Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paragon
identifies, evaluates and develops antibodies directed against certain mutually agreed therapeutic targets of interest to the Company.
The Option Agreements include two selected targets, IL-23 ("ORKA-001") and IL-17 A/F ("ORKA-002"). Under the
Option Agreements, the Company has the exclusive options to, on a research program-by-research program basis, be granted an exclusive,
worldwide license to all of Paragon's right, title and interest in and to the intellectual property resulting from the applicable
research program to develop, manufacture and commercialize the antibodies and products directed to the selected targets (each, an "Option"),
with the exception of pursuing ORKA-001 for the treatment of inflammatory bowel disease. If the Company exercises its options, it will
be required to make non-refundable milestone payments to Paragon of up to $
12.0
million under each respective agreement upon the
achievement of certain clinical development milestones, up to $
10.0
million under each respective agreement upon the achievement
of certain regulatory milestones as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial
sale. From time to time, the Company can choose to add additional targets to the collaboration by mutual agreement with Paragon.
The
Company's exclusive Option with respect to each research program for a particular target initiated by the parties ("Research
Program") is exercisable at its sole discretion at any time during the period beginning on the initiation of activities under the
associated Research Program and ending a specified number of days following (i) with respect to any Research Program other than
ORKA-001, the delivery of the data package from Paragon related to the results of the Research Plan activities, or (ii) with respect
to ORKA-001, the completion of the IL-23 antibody selection process described in the agreement (the "Option Period"). There
is no payment due upon exercise of an Option pursuant to the Option Agreements.
Unless
terminated earlier, the Option Agreements shall continue in force on a Research Program-by-Research Program basis until the earlier of:
(i) the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by the Company; (ii) the
expiration of the 30-day period after the Company exercises its Option with respect to such Research Program, subject to mutually agreed
extension, during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii) the expiration
of the applicable research term (the "Term"). Upon the expiration of the Term for all then-existing Research Programs, under
the Option Agreements, the Option Agreements will automatically expire in its entirety. The Company may terminate the Option Agreements
or any Research Program at any time for any or no reason upon 30 days' prior written notice to Paragon, provided that the
Company must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred
by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate the Option Agreements or a
Research Program immediately upon written notice to the Company if, as a result of any action or failure to act by the Company or its
affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise
delayed for a certain consecutive number of months. Each party has the right to terminate the Option Agreements or any Research Program
upon (i) 30 days' prior written notice of the other party's material breach that remains uncured for the 30-day
period and (ii) the other party's bankruptcy.
Pursuant to the Option Agreements, on a research
program-by-research program basis following the finalization of the research plan for each respective research program, the Company was
required to pay Paragon a one-time, nonrefundable research initiation fee of $
0.8
million related to the ORKA-001 program. This amount
was recognized as a research and development expense during the period from February 6, 2024 (inception) to September 30, 2024. In
June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process of its development candidate for
IL-23 antibody for ORKA-001 program. The Company was responsible for
50
% of the development costs incurred through the completion of the
IL-23 selection process. The Company received the rights to at least one selected IL-23 antibody in June 2024. During the three months
ended September 30, 2024, the Company exercised its option for ORKA-001 and recorded a $
1.5
million milestone payment related to the achievement
of development candidate as research and development expense in the Company's condensed consolidated statements of operations and
comprehensive loss for each of the three months ended September 30, 2024 and for the period from February 6, 2024 (inception) to September
30, 2024. The Company's share of development costs incurred during the three months ended September 30, 3024 and for the period
from February 6, 2024 (inception) to September 30, 2024 was $
0.8
million and $
13.2
million, respectively, which were recorded as research
and development expenses during the respective periods. An amount of $
2.3
million is included in related party accounts payable and other
current liabilities as of September 30, 2024.
The Company was also required to reimburse Paragon
$
3.3
million for development costs related to ORKA-002 incurred by Paragon through December 31, 2023 and certain other development
costs incurred by Paragon between January 1, 2024 and March 6, 2024 as stipulated by the Option Agreements. This amount was
recognized as a research and development expense during the period from February 6, 2024 (inception) to September 30, 2024. The Company
is also responsible for the development costs incurred by Paragon from January 1, 2024 through the completion of the IL-17 selection
process. The Company recognized an amount of $
0.8
million payable to Paragon for the research initiation fee related to ORKA-002
following the finalization of the ORKA-002 research plan. This was recognized as research and development expenses in the period from
February 6, 2024 (inception) to September 30, 2024. The Company accounted for development costs of $
3.8
million and $
6.6
million during
the three months ended September 30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively, as
research and development expenses during the respective periods. An amount of $
3.8
million is included in related party accounts payable
and other current liabilities as of September 30, 2024.
F-
28
As
part of the Option Agreements, on each of December 31, 2024 and December 31, 2025, the Company will grant warrants to purchase a number
of shares equal to
1.00
% of outstanding shares as of the date of the grant on a fully diluted basis with an exercise price equal to the
fair market value of the underlying shares on the grant date. The warrants are liability-classified and after the initial recognition,
the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated
statement of operations and comprehensive loss (see Note 8) as stock-based compensation expenses under research and development
expenses.
The
Company expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified
within research and development expenses in the accompanying condensed consolidated statement of operations and comprehensive loss.
The
Company concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise
in-process research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination
because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent
a group of similar identifiable assets. The research initiation fee represents a one-time cost on a research program-by-research program
basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts
paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of ongoing development cost,
monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior
to the effective date of the Option Agreements that is associated with services being rendered under the related Research Programs are
recognized as research and development expense when incurred.
For
the three months ended September 30, 2024 and the period from February 6, 2024 (inception) to September 30, 2024, the Company recognized
$
13.4
million and $
33.8
million of expenses, respectively, in connection with services provided by Paragon and Paruka under the Option
Agreements.
11.
Commitment and Contingencies
Leases
In
April 2024, the Company entered into an operating lease agreement for the Company's headquarters in Menlo Park, California, which
commenced on June 15, 2024 with an initial term of
39.5
months. The Company leases office space under this noncancelable operating lease
agreement. Lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining
the present value of lease payments, the Company used its incremental borrowing rate when measuring operating lease liabilities as discount
rates were not implicit or readily determinable.
As
of September 30, 2024, the Company had $
0.9
million of operating lease right-of-use assets, operating lease liability, current of $
0.1
million, and operating lease liability, noncurrent of $
0.8
million on its condensed consolidated balance sheets. As of September 30,
2024, the operating lease arrangement had a remaining lease term of
36.0
months and a discount rate of
17.95
%. For the three months ended
September 30, 2024 and the period from February 6, 2024 (inception) to September 30, 2024, the Company recorded operating and variable
lease expense of $
0.1
and $
0.2
million, respectively, in general and administrative expenses in its condensed consolidated statements
of operations and comprehensive loss.
The
following table presents the Company's supplemental cash flow information related to leases (in thousands):
September
    30,
2024
Cash
    paid for amounts included in the measurement of lease liabilities
Operating
    cash flow from operating leases
$
74
The
following table summarizes a maturity analysis of the Company's operating lease liabilities showing the aggregate lease payments
as of September 30, 2024 (in thousands):
Amount
Fiscal
    year ending December 31,
2024
    (remainder)
$
63
2025
369
2026
494
2027
380
Total
    undiscounted lease payments
1,306
Less:
    imputed interest
(
318
)
Total
    discounted lease payments
988
Less:
    current portion of lease liability
(
146
)
Non-current
    portion of lease liability
$
842
F-
29
12.
Net Loss per Share
Basic and diluted net loss per share attributable
to stockholders were calculated as follows (in thousands, except share and per share data):
Three Months Ended
September 30,
2024
Period from
February 6,
2024
(Inception)
to
September 30,
2024
Loss
Allocation
Weighted
Average
Shares
Outstanding
Loss Per
Share –
Basic and
Diluted
Loss
Allocation
Weighted Average Shares Outstanding
Loss Per
Share –
Basic and
Diluted
Common Stock
$
(
21,936
)
15,013,655
$
(
1.46
)
$
(
47,192
)
7,765,381
$
(
6.08
)
Company Series A Preferred Stock
(1)
(
697
)
477
$
(
1,460.62
)
(
1,121
)
184
$
(
6,077.13
)
Company Series B Preferred Stock
(2)
(
5,990
)
49,191
$
(
121.77
)
(
9,630
)
19,015
$
(
506.44
)
Net loss
$
(
28,623
)
$
(
57,943
)
(1)
The weighted-average number of
shares of as-converted Company Series A Preferred Stock used in the loss allocation was
477,196
and
184,462
for the three months ended
September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively.
(2)
The weighted-average number of
shares of as-converted Company Series B Preferred Stock used in the loss allocation was
4,099,227
and
1,584,575
for the three months
ended September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively.
For the computation of basic net loss per share
attributable to stockholders, the amount of weighted-average shares outstanding excludes all shares of unvested restricted common stock
as such shares are not considered outstanding for accounting purposes until vested. The amount of weighted-average shares outstanding
includes the pre-funded warrants as the exercise price is negligible and these warrants are fully vested and exercisable.
The potential shares of common stock that were excluded
from the computation of diluted net loss per share attributable to stockholders for the periods presented because including them would
have had an anti-dilutive effect were as follows:
Three Months Ended
September 30,
2024
Period from
February 6,
2024
(Inception)
to
September 30,
2024
Outstanding employee warrants to purchase common stock
3,054,358
3,054,358
Outstanding unvested restricted stock awards
2,207,553
2,207,553
Outstanding and issued common stock options
1,287,760
1,287,760
Total
6,549,671
6,549,671
13.
Related Party Transactions
Paragon
and Paruka each beneficially own less than
5
% of the Company's capital stock through their respective holdings of Company Common
Stock.
Fairmount beneficially owns more than
5
% of the
Company's capital, currently has one representative appointed to the Board, and beneficially owns more than
5
% of Paragon. Fairmount
appointed Paragon's board of directors and has the contractual right to approve the appointment of any executive officers of Paragon.
The
following is a summary of related party accounts payable and other current liabilities (in thousands):
September 30,
2024
Paragon
    reimbursable Option Agreements' fees
$
6,140
Paragon
    reimbursable other research expenses
146
Paragon
    reimbursable patent expenses
71
$
6,357
F-
30
PART
II
INFORMATION
NOT REQUIRED IN PROSPECTUS
Item 13.
Other Expenses of Issuance and Distribution
The expenses
payable by us in connection with the issuance and distribution of the securities being registered hereunder on Form S-1 (other than underwriting
discounts and commissions, if any) are set forth below. The Selling Stockholders will not bear any portion of such expenses. Each item
listed is estimated, except for the SEC registration fee:
SEC
    registration fee
$
33,913
Printing
    and engraving
5,000
Legal
    fees and expenses
75,000
Accounting
    fees and expenses
50,000
Miscellaneous
    expenses
6,087
Total
$
170,000
Item 14.
Indemnification of Officers and Directors
Section 145
of the DGCL authorizes a court to award, or a corporation's board of directors to grant, indemnity to directors and officers under
certain circumstances and subject to certain limitations. The terms of Section 145 of the DGCL are sufficiently broad to permit indemnification
under certain circumstances for liabilities, including reimbursement of expenses incurred, arising under the Securities Act.
As permitted
by the DGCL, the Registrant's Certificate of Incorporation contains provisions that eliminate the personal liability of its directors
for monetary damages for any breach of fiduciary duties as a director, except liability for the following:
●
any
                                            breach of the director's duty of loyalty to the Registrant or its stockholders;
●
acts
                                            or omissions not in good faith or that involve intentional misconduct or a knowing violation
                                            of law;
●
under
                                            Section 174 of the DGCL (regarding unlawful dividends and stock purchases); or
●
any
                                            transaction from which the director derived an improper personal benefit.
As permitted
by the DGCL, the Registrant's Bylaws provide that:
●
the
                                            Registrant is required to indemnify its directors and executive officers to the fullest extent
                                            permitted by the DGCL, subject to very limited exceptions;
●
the
                                            Registrant may indemnify its other employees and agents as set forth in the DGCL;
●
the
                                            Registrant is required to advance expenses, as incurred, to its directors and executive officers
                                            in connection with a legal proceeding to the fullest extent permitted by the DGCL, subject
                                            to very limited exceptions; and
●
the
                                            rights conferred in the Bylaws are not exclusive.
II-
1
The Registrant
has entered, and intends to continue to enter, into separate indemnification agreements with its directors and executive officers to
provide these directors and executive officers additional contractual assurances regarding the scope of the indemnification set forth
in the Registrant's Certificate of Incorporation and Bylaws and to provide additional procedural protections. At present, there
is no pending litigation or proceeding involving a director or executive officer of the Registrant regarding which indemnification is
sought.
The indemnification
provisions in the Registrant's Certificate of Incorporation, Bylaws and the indemnification agreements entered into or to be entered
into between the Registrant and each of its directors and executive officers may be sufficiently broad to permit indemnification of the
Registrant's directors and executive officers for liabilities arising under the Securities Act.
The Registrant
currently carries liability insurance for its directors and officers. One of the Registrant's directors, Peter Harwin, is also
indemnified by his employer with regard to their service on the Registrant's board of directors.
Item 15.
Recent Sales of Unregistered Securities
On September
13, 2024, we completed the Private Placement of Private Placement Common Shares, Private Placement Conversion Shares and Pre-Funded Warrants
pursuant to the SPA with the Selling Stockholders in the September 2024 PIPE. We sold an aggregate of 5,600,000 shares of Common Stock,
2,439 shares of our Series A Preferred Stock and pre-funded warrants to purchase 680,000 shares of Common Stock in the September 2024
PIPE for an aggregate purchase price of approximately $200.5 million.
Subject to
stockholder approval and certain beneficial ownership limitations, each share of Series A Preferred Stock is convertible into 1,000 shares
of Common Stock. Shares of Series A Preferred Stock shall not be convertible if the conversion would result in a holder, together with
its affiliates, beneficially owning more than 9.99% of our outstanding shares of Common Stock as of the applicable conversion date, which
may be increased at the holders' option (not to exceed 19.99%), effective in accordance with the terms of our Series A Certificate
of Designation.
The shares
issued pursuant to the September 2024 PIPE were offered and sold in transactions exempt from registration under the Securities Act, in
reliance on Section 4(a)(2) thereof and Rule 506 of Regulation D thereunder. Each of the investors represented that it was an "accredited
investor," as defined in Regulation D, and acquired the securities for investment only and not with a view towards, or for resale
in connection with, the public sale or distribution thereof. The shares of Series A Preferred Stock issued pursuant to the September
2024 PIPE have not been registered under the Securities Act and such securities may not be offered or sold in the United States absent
registration or an exemption from registration under the Securities Act and any applicable state securities laws.
II-
2
Item 16.
Exhibits and Financial Statement Schedules
(a)
Exhibits
EXHIBIT
NUMBER
DESCRIPTION
    OF EXHIBIT
2.1*†
Agreement
    and Plan of Merger and Reorganization, dated as of April 3, 2024, by and among ARCA biopharma, Inc., Atlas Merger Sub Corp., Atlas
    Merger Sub II, LLC and Oruka Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 of ARCA biopharma, Inc.'s Form 8-K
    filed on April 3, 2024, File No. 000-22873).
3.1*
Amended
    and Restated Certificate of Incorporation of the Company, filed September 3, 2024 (incorporated by reference to Exhibit 3.5 to the
    Registrant's Current Report on Form 8-K filed with the SEC on September 5, 2024).
3.2*
Amended
    and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.6 to the Registrant's Current Report on Form 8-K
    filed with the SEC on September 5, 2024).
3.3*
Form
    of Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock (incorporated
    by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed with the SEC on September 13, 2024).
3.4*
Form
    of Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock (incorporated
    by reference to Exhibit 3.9 to the Registrant's Current Report on Form 8-K filed with the SEC on September 5, 2024).
4.1*
Form
    of Registration Rights Agreement, dated as of September 13, 2024 (incorporated by reference to Exhibit 10.2 to the
    Registrant's Current Report on Form 8-K filed with the SEC on September 13, 2024).
4.2*
Securities
    Purchase Agreement, dated September 11, 2024, by and between Oruka Therapeutics, Inc. and each purchaser identified on Annex A thereto
    (incorporated by reference to Exhibit 10.1 the Registrant's Current Report on Form 8-K filed with the SEC on September 13,
    2024).
4.3*
Form
    of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K filed with the
    SEC on September 13, 2024).
5.1
Opinion
    of Gibson, Dunn & Crutcher LLP.
10.1*
Form
    of Oruka Support Agreement (incorporated by reference to Exhibit 10.1 to ARCA biopharma, Inc's Form 8-K filed on April 3,
    2024).
10.2*†
Form
    of Oruka Subscription Agreement (incorporated by reference to Exhibit 10.2 to ARCA biopharma, Inc's Form 8-K filed on April
    3, 2024).
10.3*†
Form
    of Amendment to Oruka Subscription Agreement (incorporated by reference to Exhibit 10.1 to ARCA biopharma, Inc's Form 8-K filed
    on July 9, 2024).
10.4*†
Form
    of Amended & Restated Oruka Subscription Agreement (incorporated by reference to Exhibit 10.2 to ARCA biopharma, Inc's
    Form 8-K filed on July 9, 2024).
10.5*
Form of Registration Rights Agreement, dated as of August 29, 2024 (incorporated by reference to Exhibit 10.4 to the Registrant's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024).
10.6
Form
    of ACRA Support Agreement (incorporated by reference to Exhibit 10.3 to ARCA biopharma, Inc's Form 8-K filed on April 3, 2024).
10.7*
Form
    of Lock-Up Agreement (incorporated by reference to Exhibit 10.4 to ARCA biopharma, Inc's Form 8-K filed on April 3, 2024).
10.8*††
Separation
    Agreement and Release, by and between ARCA biopharma, Inc. and Michael Bristow, dated as of April 3, 2024 (incorporated by reference
    to Exhibit 10.1 of ARCA biopharma, Inc.'s Form 8-K filed on April 4, 2024).
10.9*††
Consulting
    Agreement, by and between ARCA biopharma, Inc. and Michael Bristow, dated as of April 3, 2024 (incorporated by reference to Exhibit
    10.2 of ARCA biopharma, Inc.'s Form 8-K filed on April 4, 2024).
II-
3
10.10*#
Form
    of Indemnification Agreement between Oruka Therapeutics, Inc. and its directors and officers (incorporated by reference to Exhibit
    10.45 to ARCA biopharma, Inc.'s Form S-4, filed on May 14, 2024, File No. 333-279387).
10.11*#
Oruka
    Therapeutics, Inc. 2024 Stock Incentive Plan (incorporated by reference to Exhibit 10.10 to the Registrant's Current Report
    on Form 8-K filed with the SEC on September 5, 2024).
10.12*#
Oruka
    Therapeutics, Inc. 2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.11 to the Registrant's Current
    Report on Form 8-K filed with the SEC on September 5, 2024).
10.13*#
Amended
    and Restated Oruka Therapeutics, Inc. 2024 Equity Incentive Plan, as amended by the First Amendment dated May 7, 2024 (incorporated
    by reference to Exhibit 10.40 to ARCA biopharma, Inc.'s Form S-4, filed on May 14, 2024, File No. 333-279387).
10.14*#
Second Amendment to Amended and Restated Oruka Therapeutics, Inc. 2024 Equity Incentive Plan, effective as of May 7, 2024 (incorporated by reference to Exhibit 10.13 to the Registrant's Current Report on Form 8-K filed with the SEC on September 5, 2024).
10.15*#
Form
    of Restricted Stock Notice and Restricted Stock Purchase Agreement (incorporated by reference to Exhibit 10.41 to ARCA biopharma,
    Inc.'s Form S-4, filed on May 14, 2024, File No. 333-279387).
10.16*#
Form
    of Stock Option Agreement under Oruka Therapeutics, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.42 to
    ARCA biopharma, Inc.'s Form S-4, filed on May 14, 2024, File No. 333-279387).
10.17*#
Form of Employee Warrant Agreement (incorporated by reference to Exhibit 10.16 to the Registrant's Current Report on Form 8-K filed with the SEC on September 5, 2024).
10.18*#
Amended
    and Restated Director Offer Letter, dated March 22, 2024, between Oruka Therapeutics, Inc. and Samarth Kulkarni (incorporated
    by reference to Exhibit 10.43 to ARCA biopharma, Inc.'s Form S-4, filed on May 14, 2024, File No. 333-279387).
10.19*#
Director
    Offer Letter, dated April 24, 2024, between Oruka Therapeutics, Inc. and Kristine Ball (incorporated by reference to Exhibit
    10.44 to ARCA biopharma, Inc.'s Form S-4, filed on May 14, 2024, File No. 333-279387).
10.20*#
Amended
    and Restated Employment Offer Letter by and between Oruka Therapeutics, Inc. and Lawrence Klein
,
    dated as of October 3, 2024
(incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K
    filed with the SEC on October 4, 2024
, File No. 241354944
).
10.21*#
Amended
    and Restated Employment Letter Agreement by and between the Company and Arjun Agarwal, dated as of October 3, 2024 (incorporated
    by reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K filed with the SEC on October 4, 2024, File No.
    241354944).
10.22*#
Employment
    Offer Letter, dated March 15, 2024, by and between Oruka Therapeutics, Inc. and Joana Goncalves (incorporated by reference to Exhibit
    10.48 to ARCA biopharma, Inc.'s Form S-4, filed on May 14, 2024, File No. 333-279387).
10.23*#
Employment
    Offer Letter, dated April 12, 2024, by and between Oruka Therapeutics, Inc. and Paul Quinlan (incorporated by reference to Exhibit
    10.49 to ARCA biopharma, Inc.'s Form S-4, filed on May 14, 2024, File No. 333-279387).
10.24*†
Amended
    and Restated Antibody Discovery and Option Agreement (IL-17), dated March 28, 2024, by and among Paragon Therapeutics, Inc.,
    Paruka Holding LLC and Oruka Therapeutics, Inc. (incorporated by reference to Exhibit 10.50 to ARCA biopharma, Inc.'s Form
    S-4/A, filed on June 18, 2024, File No. 333-279387).
II-
4
10.25*†
Amended
    and Restated Antibody Discovery and Option Agreement (IL-23), dated March 28, 2024, by and among Paragon Therapeutics, Inc.,
    Paruka Holding LLC and Oruka Therapeutics, Inc. (incorporated by reference to Exhibit 10.51 to ARCA biopharma, Inc.'s Form
    S-4/A, filed on June 18, 2024, File No. 333-279387).
10.26*†#
Consulting
    Agreement, effective as of August 30, 2024, by and between Oruka Therapeutics, Inc. and Jeff Dekker (incorporated by reference to
    Exhibit 10.25 to the Registrant's Current Report on Form 8-K filed with the SEC on September 5, 2024).
16.1*
Letter
    from KPMG LLP, dated September 5, 2024 (incorporated by reference to Exhibit 16.1 to the Registrant's Current Report on Form
    8-K filed with the SEC on September 5, 2024).
21.1*
List
    of Subsidiaries of Oruka Therapeutics, Inc (incorporated by reference to Exhibit 21.1 to the Registrant's Current Report on
    Form 8-K filed with the SEC on September 5, 2024).
23.1
Consent of PricewaterhouseCoopers LLP
23.2
Consent
    of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1)
24.1
Power of Attorney (included on the signature page to the registration statement)
101.INS
Inline
    XBRL Instance Document.
101.SCH
Inline
    XBRL Taxonomy Extension Schema Document.
101.CAL
Inline
    XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF
Inline
    XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB
Inline
    XBRL Taxonomy Extension Labels Linkbase Document.
101.PRE
Inline
    XBRL Taxonomy Extension Presentation Linkbase Document.
104
Cover
    Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
107
Filing
    Fee Table.
*
Previously
                                            filed.
#
Indicates
                                            management contract or compensatory plan.
†
Exhibits
                                            and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant
                                            hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules
                                            upon request by the SEC; provided, however, that the registrant may request confidential
                                            treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so
                                            furnished. Certain portions of this exhibit (indicated by "[***]") have been
                                            omitted because they are both (i) not material and (ii) is the type of information that the
                                            registrant both customarily and actually treats as private and confidential.
(b)
Financial
                                            statement schedules
None.
II-
5
Item 17.
Undertakings
(a) The undersigned
Registrant hereby undertakes:
(1) To file,
during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i) to include
any prospectus required by Section 10(a)(3) of the Securities Act;
(ii) to reflect
in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and
price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Filing Fee Table"
in the effective registration statement; and
(iii) to
include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any
material change to such information in the registration statement;
(2) That,
for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
be the initial
bona fide
offering thereof.
(3) To remove
from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering.
(4) That,
for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as
part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses
filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used
after effectiveness.
Provided, however
, that no statement made in a registration statement or prospectus that is part of the registration
statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is
part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify
any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such
document immediately prior to such date of first use.
(5)
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, and controlling
persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of
the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event
that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a
director, officer, or controlling person of the Registrant in the successful defense of any action, suit, or proceeding) is asserted
by such director, officer, or controlling person in connection with the securities being registered, the Registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question
whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication
of such issue.
II-
6
SIGNATURES
Pursuant
to the requirements of the Securities Act, the Registrant has duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Menlo Park, California, on November 13, 2024.
ORUKA
    THERAPEUTICS, INC.
By:
/s/
    Lawrence Klein
Lawrence
    Klein
Chief
    Executive Officer
Pursuant
to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and
on the dates indicated.
Signature
Title
Date
/s/
    Lawrence Klein
Chief
    Executive Officer & Director
November
    13, 2024
Lawrence
    Klein
(Principal
    Executive Officer)
/s/
    Arjun Agarwal
Senior
    Vice President, Finance and Treasurer
November
    13, 2024
Arjun
    Agarwal
(Principal
    Financial Officer and Principal Accounting Officer)
/s/
    Samarth Kulkarni
Chairman
    of the Board
November
    13, 2024
Samarth
    Kulkarni
/s/
    Kristine Ball
Director
November
    13, 2024
Kristine
    Ball
/s/
    Carl Dambkowski
Director
November
    13, 2024
Carl
    Dambkowski
/s/
    Peter Harwin
Director
November
    13, 2024
Peter
    Harwin
/s/
    Cameron Turtle
Director
November
    13, 2024
Cameron
    Turtle
II-7